<SEC-DOCUMENT>0001558370-21-014338.txt : 20211103
<SEC-HEADER>0001558370-21-014338.hdr.sgml : 20211103
<ACCEPTANCE-DATETIME>20211103170929
ACCESSION NUMBER:		0001558370-21-014338
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211103
DATE AS OF CHANGE:		20211103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		211376488

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptgx-20210930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/3/2021 9:04:42 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 1ddd2d19-068b-4f0a-902a-6a46d332b269 -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptgx="http://www.protagonist-inc.com/20210930" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_WI9K15k_20GZnOd8VNG8IQ">usgaap:LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_ZbKry8j0sUCaJBlX4me6bA">usgaap:LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_x34gDY71902u0Osenos8WA">usgaap:LicenseAndServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_W6anfsYeE0emhqkDRNQTkw">usgaap:LicenseAndServiceMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Iw4yYFTj806qmla4EB7gTQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Ug3l-MxwREOmKYIwED51ZQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:PreferredStockValue" id="Hidden_mgvgdq6FiEyJOe8QmZFQqQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:PreferredStockValue" id="Hidden_1KAK1AR2YkOh-f0KOSdQPw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:CommonStockValue" id="Hidden_DprURJf_sUCs9NbETOeebA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" xs:nil="true" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:CommonStockValue" id="Hidden_P9F1pxSCpEGbW6iv8r1a5g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_ISrdM4PW902gdSwI2P7geg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_cKlt8s2Pyk2lMzvXw3U3UQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_iwPIj70IREOqVhapJq4v9A">47671654</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_qms1Q3i8VEe1Czi4YEu9FA">43745465</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_segment_ulf2uGevlEWfB2AwE0yW3g" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_u4SjkEALd06OJORFVCaVuQ">1</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityCentralIndexKey" id="Tc_ucGo2JKJ50qPq7diRg0E2A_2_1">0001377121</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:CurrentFiscalYearEndDate" id="Tc_f1xXwSkjS0i9OBSmE8EKDA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentFiscalYearFocus" id="Tc_cNhuSROELUiGIYomMqRvRA_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentFiscalPeriodFocus" id="Tc_Y82Fma2h0EycDWln1zw5Hw_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:AmendmentFlag" id="Tc_UDa3bh5WiUe7gBzE4HYJnQ_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_If59OPpEK02lxvyiRk3sOQ">us-gaap:OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_GABQ-ji7AkWiSoCyPdZ-iA">us-gaap:OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_VdeOmiqn-EmGbvHLuN1aAA">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_LH77hsw29EuHMm-jjFeFDQ">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_K67XINXtckW2yeWVvsxsDQ">us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_CT0nErfOFkCb97eo7Czw9g">us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_b6WSSFcN8kyrZANs0pC1gg">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_Td8JIgKxPEyJEBQXFFlrvQ">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA" decimals="-5" name="us-gaap:OperatingLeaseLiability" id="Hidden_W9bIUIMLtUuXqk-5ssyS9Q">1400000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptgx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_9Z964QKwJE2qr29wKQspDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_zKmsy6v6FUaz1H9GRlgxZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_UN3M56DNcEqfJFsFQtlo7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_34DT_TXcJ0G9oeklOaHaWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_eu303YctzUm4oyVCdG6opQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ffkr2mgme0Kc83elbZL7aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8X-9N-uxzEWLV5_AkyjFPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAo-gksv90emgd8j5zQ9WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T3JUh_bQFUWzNCgqWLw-SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ScZrHzQctkadsqBzu4TDGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_URkiGm8zuEaVvS65J30DTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4dru7UabbEO8vq8Kk60BLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_07-nJWm-n0OlxE7BAmCSvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o9SfVFUv-UWAdi0N3P_IpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cofzvfw-4UGemNVWygkS8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dmfd75drp0Sl92sRinfLjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_hze2TlFsxEWN43owngJkXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iXBhd1us706tUU2Z6TGdoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A4ngj4JfEEud5h_rZa61rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wDJZBP8oWkmr1-cnJEWO_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_15NQ36sPLUyBE0gs8_H_zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qLCgYz5FGUGJWujpfLA26w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EyCHRvQf9UG7GDeEg-B-bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_NpkY5Or850q-_7gddnu5kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6k8OGpvpa0CnTaIinonZ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ShsA1tWpGUmhQJqfvR21Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pjYolJb8NUSZoqWWvsTjEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2VW_uzB5fkeRI3qxZyicNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_sPnFRiazY0WPCIV18TjFyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ZWhhGQPBKUuEzunwWJ1GhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8zEeV8gTA0OQG69UlVTpzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_ChADps65pUSE5xPbZYa91Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_MLttZWHz2UiEm3p_zIvcnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_RdllORFsOUWkT56_8WgrPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NQqJPEuYYU24niCb9tj5og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEkXG0l4dU-MPpEChb8m2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MdN54EnQNUy4goQYips2hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rFCznfZHPUidpHv3XziwjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OQZenvrZlk6VJmwZFGIrag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_HO9dXCVgUUKyFTdCLwfdHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3v_HJaV_TEawCCjJ-8U_bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8bkYSfa3AECmsmdja2QoLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2018_To_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_tOd2A-ZoskaNnweabNr7Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_VXWpZKcTTkKp8eVZQhziGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_F2fAANpPG0qxaN1I2cAc1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_StatementGeographicalAxis_stpr_CA_Ujq4sL4CxEW0D5YwkaKV3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9KOXTrTqMUiTDI99y3z_ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__vWz_fmTEUCSA1s4LTbr_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_ZNKaf1RmykO0-f7B2C1WOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_9rUNAqUsGU-Kz_BLZ_8PsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k2WesrzFCUWJheqmlJkQMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-pvHJ7QJ90yW1k3Cfl4qtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ESv4u0HBt0CnfQx4AKYNAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_picUoPu6YU6hAp4STfCryA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I6LDpOFLME2hRdBnUQSKZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T6A4i7LXhkGkWOztGamCHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_D-unIeqFvkKbPDLT1e3qMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vnFLoq50b0y_n6K8gPk8yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_IcQjRh5fKEOqMWWM3N6bgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_O2mng1-tskSGO5KBeSuZsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_NLWK1h6eUUCL1SCn1CQ7wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_82q0nTVsSUC8bXZMRz6aLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_lvaVnROBNEGcQD3RONq0EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_K7Od3CM6-kOKjqWB7rXSfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MZM0ma8qsUmURiga3ySKXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_mjNjDSCfZ0OjAafvNYLJ9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_HREnfaqhhk6qERJYnhneIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_562smoZuLkS9KsBvdrpLtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_potMVrgeoEGalpEJm2UCjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_9QJowPauUk-gaWt5sFT-HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M3p7YmD9vkCTXzn0pO5cbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_NvuFc-sXQUC2i1aTvziUiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yX6TYuMbYEicxZwbaMBgVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_EXzMSWZYJkq4Gd12kF9Hhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_lZeL8hdzf028kJ3_rDwFag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yFhWkhHuuEaQKk7rwr082w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jxODNBy8nUGGb5t1661FYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VRhvgs9oa0mTUaqYjRO3ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EnjUd2zZYk6vz2-cHlqtXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:JanssenLicenseAndCollaborationAgreement26May2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_YTpXeQgJJUeKa5oZr8AiAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_M6ZuWy-_Aky-LJndvpy4bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_DkFNZeRNm0ydJRjGjJnj3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_gec9OfdVA0-QavCdRuU7ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_b77QUVVp-EabKEv4WpeA6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_quwzsXAt80GJsdttydqn8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_xC4RqMR0Q0KyABMRO1X4UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_RyDegFl_A06Zzlx5SUabIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_gJztAK_pJkSEMdZvVKmVEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_Jby6BCZwZEmx5lkgaQcFoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_Yd94PRDSaEyHbItBmTnC2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember__UavJt8cZ0e-l_KQU4eymg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6QBcAGRDREGf4rn_KPZpcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-jIggHYH1UmbKLFheHzbgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZdtE_xThKkSdI-Vaaceeog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_8Myl1B2k-kSOnAjEMsdY-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_R2T0FeSCkU-4AuqwK_udIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_GTf2MVxlEEGBedzfKpF1Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_qZvf9xKSG0OZSn-Pah-mXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_7TCHAu-iM0K20R1_6ZSBeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_W-JTrmc1iUqyssBi9jfgmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_0Hh9M4XK4UiFA8GLjbeoAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OKk9lwDz4EGN0BwH0atvlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fUK5OnhlFU66Xq1kj7KKrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_mBhTXxceV02MtGdxdWbrGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:FacilityLeaseAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_r1RtIdBqNkaMdBGIaOjSHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_1dBmY6pAUU6RcuwSZPcgtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbxkG_gzsk-x_bM6qbI8_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_YzrwOrK_Z0OF0-Mj3NtBLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_nTdQkTXU-0S6ergKcYz3vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptgx:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_n0Ta9bA0r0Kq2dDdfjjplg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SpzSmd-Mk2osYBgelFKpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GzDm5mfuBEe6F8PeGg2E1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_tLWEwGzi6E-KqzZmPdOOrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptgx:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T0H8ABLR8UW5UTiO70X3Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AcXFvIPtgkyUmawuHCqSow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2I_k75JCq0eeHRkxbMxQXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_t-wbdQnITUaC7MfBqxrb9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_a0FuumrKYUO7tJOSkOvu3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9O0ysWYJAk2T3ppTE9BJ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l6HbK0TvKE283tUIhVWh1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RLO4WIMRGkC7XbCfwot3cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_M8yFhIOS4UWfLn0-racdCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseTwoClinicalTrialSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_k7-5iEviVkaUoyPynKb8ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseTwoClinicalTrialSecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_zpwdW8FrMU2yPOUewuio1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_E3q_5X1xx0W9IH0IDoVYIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_27_2019_To_11_27_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_xRIStPOlqkO3ZRkjqtTj2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-27</xbrli:startDate><xbrli:endDate>2019-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_3MZvEqMKLkqJJimay3c3Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_uyHNYHVIIUOFt7eISFZ0iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_RUQmYM3F3ku4NzFw_8JxVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_OrLsItNoVUWmXfX_oVcZTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_fHticHz3nEOKl7dkY7LJ5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_W5_EmxclnkqveI5CjIX6wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_aGR3Nn_0oUCmeAgOesXdXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_5wmoKVR2DU2fW1JWG3YE4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_DR8YsZ1k4EKWFSFZzgo99w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseThreeClinicalTrialForAnyIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_QqjayIBfTU2Zb8ZXHEhcpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_AHS1J3rNPkunnKl_uozAJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseThreeClinicalTrialMember_PxpJvRYYhEWj49AtdxBe5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseThreeClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_T5go7T86jkGHW8Ogcd55BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_ebVRPtOngkuKafR-yF0DZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_sxi-lVVXP0eAqntyNRA1rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_e1g49FhL7kmfXyQdu4N9Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_HNZLcuNLlkC4l1XQ9mRg5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__XGvkKYt2kq50PQcaNBpsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_6kgROCjubEaK_kfQMy3jkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_EKO4dc3A9kW58GT-34PVkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_htTtbMn45UOqoFQw4o06MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:Ptg200PhaseAndSecondGenerationCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-07</xbrli:startDate><xbrli:endDate>2020-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JyX857Du9kCccikwVOJK1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_nJ2YdyBimE6P9t5VGQxkZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_GjbbJITBaUG01OT1oWNJlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_5LG8Bd8oPkGEzWl62U-nbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_f6vGdpv7dkiDKg1sBRHOoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_y3q_xyeqpEq7Mcn87B_l1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_df9Ci-g-EECi012fGqcB-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_8VDg-9H-LkmeiUYsHBLxHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_CXrEby6GiEaljTlG3GLsBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_PIZR72h8sUiUXP2iC_lkKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_ml2M2iwfc0KpJiIzGxvCug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_r2A-BxT7r0GiRUZodoE_Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_xBi47oQ55EWzPVnVxo6vOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_vlCXpQQLhUe0YkX2S-ZJvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_eY73vDQa7U23JqhEa2BFLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_rRvBtxUPXUy-HfoqhGT3wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_s96udydX3kChOKXdoymkjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:FacilityLeaseAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_29_2021_AWZjUpWCCEa46ziiy36xdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_ulf2uGevlEWfB2AwE0yW3g"><xbrli:measure>ptgx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA"><xbrli:measure>ptgx:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w"><xbrli:measure>ptgx:payment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg"><xbrli:measure>ptgx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_l-KtIo8rkUevq1Vg6RPLug"><xbrli:measure>ptgx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-indent:0pt;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ab2dbce1_a635_4afb_858f_546278917b1e"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;text-align:center;margin:4pt 0pt 4pt 0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentType" id="Narr_or1jKlXV7U2GvOwWu5hvCA">10-Q</ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9c73ccc8_1c21_4de1_abde_d67e528384c2"></a><a id="Tc_jno58qndzkG6kwUoBdBc5g_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentQuarterlyReport" id="Tc_gtete85zQU2rdwA4y-bokA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><b style="font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentPeriodEndDate" id="Narr_I0ExGzF9sUa5HgVO-Bjc0g"><b style="font-weight:bold;">September 30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">or</b></p><a id="_034736cb_9c53_4f05_baba_117e7f6efb31"></a><a id="Tc_efyeLwhMBUmZvt6l9ChxcQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.85%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.14%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:5.85%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:DocumentTransitionReport" id="Tc_jqEfzZZUR0ut4PKsdWmtlg_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.14%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityFileNumber" id="Narr_Tmiigh4AyUaX7CeNHxa1Pw"><b style="font-weight:bold;">001-37852</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityRegistrantName" id="Narr_YlNy9RWTOE-D8tY_g3H1mg">PROTAGONIST THERAPEUTICS,&#160;INC.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_46d797aa_fc7b_43ac_a779_4822b652c374"></a><a id="Tc_lmEwGBnDJUCABc4nubtuXw_1_0"></a><a id="Tc_ZpZ7PnWCnkSctMOs7rA0WA_1_2"></a><a id="Tc_zdzT5FfPykeS6SV13bQDAw_3_0"></a><a id="Tc___JZmjD2NkKl27Td5W1QdQ_3_2"></a><a id="Tc_zJf4UQuxUkOs7mtPoi98EQ_4_0"></a><a id="Tc_6pOpy0k3v0SY7AchV5gG0w_4_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:48.26%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityIncorporationStateCountryCode" id="Tc__0WwrSiew0OvaUPcszI2Kw_0_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.81%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityTaxIdentificationNumber" id="Tc_KDVRiXON2kGphjDi37T8Zg_0_2"><b style="font-size:8pt;font-weight:bold;">98-0505495</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.26%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S.&#160;Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.26%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.26%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityAddressAddressLine1" id="Narr_gtETPZkzNkyGsJkP-34JJA"><b style="font-size:8pt;font-weight:bold;">7707 Gateway Boulevard, Suite&#160;140</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityAddressCityOrTown" id="Narr_h6qf2hOnekqdf4FgZqUFqg"><b style="font-size:8pt;font-weight:bold;">Newark</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityAddressStateOrProvince" id="Narr_b0Na5aFEQECGdVok-e07Kg"><b style="font-size:8pt;font-weight:bold;">California</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityAddressPostalZipCode" id="Narr_gokBQWmiqUSk-h2sHkXUjQ"><b style="font-size:8pt;font-weight:bold;">94560-1160</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:CityAreaCode" id="Narr_vcDwbyNliESQnhQWCawBAA"><b style="font-size:8pt;font-weight:bold;">510</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:LocalPhoneNumber" id="Narr_QBD4MTvFP0OM40NBsritdg"><b style="font-size:8pt;font-weight:bold;">474-0170</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.26%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address, including zip code, of registrant&#8217;s principal executive offices)</b></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.81%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Telephone number, including area code, of registrant&#8217;s principal executive offices)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:4pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_46f73342_28c0_432f_b1b7_e03209677621"></a><a id="Tc_z-rnxc93hU63mz4Z9tHPQA_1_0"></a><a id="Tc_9gGhshkDVkSdj5hwuXMheQ_1_1"></a><a id="Tc_Bsr357Rh_EC3byfDK_okwA_1_2"></a><a id="Tc_rpBJkP-boEqdiwItd2yuzQ_2_0"></a><a id="Tc_q0cJmPVabkCTljyYc9rXxw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.08%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:8.15pt;"><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:33.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:6.35pt;"><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:Security12bTitle" id="Narr_f3Zfyv_DfUmjiT7-4SGHog"><span style="font-size:6pt;">Common Stock</span></ix:nonNumeric><span style="font-size:6pt;">, par value $0.00001</span></p></td><td style="vertical-align:top;width:33.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:TradingSymbol" id="Tc_s1UYzmzGbU-pHYT8loDOGg_2_1"><span style="font-size:6pt;">PTGX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:SecurityExchangeName" id="Narr_cPuy3vXGYEiSUzg79MuTgg"><span style="font-size:6pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:6pt;"> Stock Market, LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityCurrentReportingStatus" id="Narr_1VjeC-WWzEOp0Ed5QRMFhg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityInteractiveDataCurrent" id="Narr_s_SCVLk9ekKt_JVkpXADPw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &quot;emerging growth company&quot; in Rule&#160;12b-2 of the Exchange Act</p><a id="_8cd7cd14_32f4_4349_9c85_e9ab5803a807"></a><a id="Tc_jqUiXCS06UyboOlHxtyfhw_2_0"></a><a id="Tc_UENGEfl13E25BXtWzKXaqg_2_1"></a><a id="Tc_eer8odKFr0ShPOS-NoirkA_2_2"></a><a id="Tc_z7YfvrFfm0WCw042hYQKMw_2_3"></a><a id="Tc_c9CdIiEIukSUgt4erHwzPQ_3_2"></a><a id="Tc_aSN8iNgmEEasBxMWn_uMZA_4_1"></a><a id="Tc_bpIkZVXdXUaieuyWd-K5mw_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:16.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:33.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:16.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntitySmallBusiness" id="Tc_-Q9tfckU60ar6x9F8pEMMQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:16.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityFilerCategory" id="Tc_-D9AwjZ6qki_MiGZNBkmJw_4_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityEmergingGrowthCompany" id="Tc_fLshVKg0-kaAJIT7nvyABA_4_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#160;&#160;&#160; </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityExTransitionPeriod" id="Narr_fZmtoIYjZU2aGXTC5r1qhA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-</span><span style="font-size:9pt;white-space:pre-wrap;">2 of the Exchange Act of 1934).    &#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="dei:EntityShellCompany" id="Narr_mD7-ONolDk6X7CDzjVkegQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">As of October 29, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_10_29_2021_AWZjUpWCCEa46ziiy36xdQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_mcpYVBdeuEuWAcvI6JEE4w">47,728,227</ix:nonFraction> shares of the registrant&#8217;s Common Stock, par value $0.00001 per share, outstanding.</p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_76ad5b23_419e_42e0_93b6_4903b4ba21f5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FORM 10-Q</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I</p></div></div></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_720470"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_720470"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1_875098"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1_875098"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_23436"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCompreh"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofSOE"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCashFlo"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoCondensedConsolidatedFinancialSta"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Unaudited Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_256354"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_256354"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_664238"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_664238"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_914493"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_914493"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_924131"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_924131"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_778794"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_778794"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosure</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_390923"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_390923"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_645051"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_645051"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:81.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_754707"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:8.6%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_de169232_1903_4b58_a39a_0a7288109237"></a><a id="PARTIFINANCIALINFORMATION_720470"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I.&#160;&#8211; FINANCIAL INFORMATION</p><a id="ITEM1_875098"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;1.</b></span>FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="CondensedConsolidatedBalanceSheets_23436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_febe1038_8bae_49b4_9044_1959d2ff9acc"></a><a id="Tc_sPvOPgmS10qmvImnTPqTWg_1_2"></a><a id="Tc_FI7XD240E0OkNHcmiREBZQ_1_5"></a><a id="Tc_rDw9Mpgs_UKIkFuwASqEOw_2_2"></a><a id="Tc_5pfPiOPKs0ms5NfoqA2iXg_2_5"></a><a id="Tc_lDhm5tdWp0STXfzFUfg3fg_3_0"></a><a id="Tc_FujB_WioykySqYScthSQ-g_4_0"></a><a id="Tc_6Q1zpA4WUkCLEvoS8wW4gA_5_0"></a><a id="Tc_izt4Nk09M0-ysJNQWhP99w_5_2"></a><a id="Tc_dcTqiudg5EeU7ULONAPh3w_5_5"></a><a id="Tc_f0rANbLzukKqpGFhnA36lw_6_0"></a><a id="Tc_2_SW_aNx6UObplf-Tw3HMw_7_0"></a><a id="Tc_stXUH_WpOEa6FW3V0qn16A_7_3"></a><a id="Tc_DXWJyLcefkyYQeCJRV8UhA_8_0"></a><a id="Tc_TZAx6xAcP0Kif4nr9BnPUw_9_0"></a><a id="Tc_ygiapoXdXk6qmsNOTYaWUQ_10_0"></a><a id="Tc_cSWgY-U5DUSSwwS5M4vCNA_11_0"></a><a id="Tc_C64u6l5LeUWrsPbfW7D6Kw_12_0"></a><a id="Tc_xS8Aq12v60O7SydvGZy_cA_13_0"></a><a id="Tc_3xt9921UvkCwYufotOV_-A_14_0"></a><a id="Tc_6fyYQvbEhkG8rHSHgjh37w_15_0"></a><a id="Tc_whp59zchnkGX0f_waYCkLA_16_0"></a><a id="Tc_0L_pZrA8E0Oo4ELFMCIGgg_16_2"></a><a id="Tc_F1zry-HgbEWm5pHizZ0sog_16_5"></a><a id="Tc_59HeUEqay0yJOQEwyVlqXw_17_0"></a><a id="Tc__EHsQ_KiwEy5ejga4S_DpA_18_0"></a><a id="Tc_uWS636hd1EyWfiCqKUZlpg_19_0"></a><a id="Tc_nrz3IHRCXUKEf2jCKUEKOQ_19_2"></a><a id="Tc_wbrxIvuKzkuOZzQZlBlZUQ_19_5"></a><a id="Tc_4u-mKnA0ikyp6Ah7O6UhGA_20_0"></a><a id="Tc_ErGGxAxmeE6xSRRjSV5ueg_21_0"></a><a id="Tc_mSGW8y1JQUGGHTkB8-cixg_22_0"></a><a id="Tc_GiMsHY1S5U-n2Ry8hxAe7g_23_0"></a><a id="Tc_WgdTSGkFjEWjw31XjPY9Yw_24_0"></a><a id="Tc_7jA3tp-eYEu-sc3wxGxrXA_25_0"></a><a id="Tc_-5xwkrFFrECLfL_CpiGp3A_26_0"></a><a id="Tc_BZHgFFVA1EmScGgu4P2DyA_27_0"></a><a id="Tc_fIgxorM-0ka8gRJV8UHcOA_28_0"></a><a id="Tc_NGaEWvmi9kyQZETvo-qDHA_29_0"></a><a id="Tc_BuaheeowLUqmqdPL5_GTuw_30_0"></a><a id="_23a0f114_aad5_4967_84b0_c7b5f941bd94"></a><a id="_23a0f114_aad5_4967_84b0_c7b5f941bd94_2"></a><a id="_23a0f114_aad5_4967_84b0_c7b5f941bd94_3"></a><a id="Tc_WHshW_GyvUC9dqewvjWMFg_31_0"></a><a id="Tc_h73QqKPjwUOm_5cRCDK66w_32_0"></a><a id="Tc_UqjgnTd0ZU6T1wGup28XMw_33_0"></a><a id="Tc_xzPLYeCVSEu7NCjWTyuqjA_34_0"></a><a id="Tc_6posZeIzk0uQhQFsDUiIAQ_35_0"></a><a id="Tc_il_ETCXvb020Jdzz-PU-pA_36_0"></a><a id="Tc_fQ7nmItN_UGjcaG89B04Pg_36_2"></a><a id="Tc_0as8VFat8kavKV7O8vyPlA_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LRYGB8jYOUShM-zpBCONlw_5_3">120,542</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_s_YSSqhdOEq7cn6ay5yhhw_5_6">117,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_hEIS-8L6Jk-KbCGhDoTHKQ_6_3">193,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_GSzBCHT6uk29UlVlARzr5g_6_6">188,451</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_GE4EntS7b06jfACZk9g30A_7_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Receivable from collaboration partner and contract asset - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="Tc_ZK_q_VX6aES84aNy4rIoDg_8_3">2,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="Tc_VXAKzbKaMEy3oYIIzNG84Q_8_6">2,426</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax incentive receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="Tc_mj_R4yOWGk-RCvASlHOjHQ_9_3">1,871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="Tc_yn68QtIt0E6YIcWrRrLUGA_9_6">1,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Odnsr24F9E-Cxu4RNz3hcA_10_3">8,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_3jTi0PCkrkOoZcszQmTaTQ_10_6">6,277</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_GvAJhHreZ0SGcpd-4zMpIQ_11_3">327,687</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_jJ_HyPcbH0C7_ul1VQsppg_11_6">315,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_wcytnh2xb0egdx3Hi9AJUg_12_3">38,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_qzKfujUPSkWpoDWEuEpujw_12_6">2,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_BG7Bn_Zh6ECNNnpbHyImpQ_13_3">1,723</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ft-DVJibY0-s2juN15cPww_13_6">1,462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_t-ZWQ5TpREy66Y5yFtmFWg_14_3">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_CUbF0dSxBEuJuZmh2I0f6A_14_6">450</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_uqXsYmOtCEiNGCQCVqGg7w_15_3">5,371</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_DYkWlaxvGEmfr_rip9l4BA_15_6">4,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_FDkMnK5iVUuV1Eyi6lEZjQ_16_3">373,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Qn7Cg8cO1kuZzbGknYeddw_16_6">324,468</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_YFJnnDEiWkK6Tn5sbBRXiQ_19_3">706</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_4ZdqQ50SFEGsdfQgfoSkjQ_19_6">3,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payable to collaboration partner - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_FcbrgcO2yk68RJTzxIlcww_20_3">1,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_kGp7lra9kUy9-oEgBaUfnw_20_6">2,732</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other payables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_EinRtL9Jr0W8FgOp2yGL6w_21_3">33,061</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_gY6j1a_lJ02em99t1WvjFQ_21_6">18,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue - related party </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_vwv2ZQBc3UOphwHsnxGQCg_22_3">2,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_xT9mxtk870OnoBwHfrb_Uw_22_6">14,477</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_XZmcaCAu3UaIMMYpUY5IqA_23_3">2,027</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_7MKV_vSBqEeb8uNuyvkqHA_23_6">1,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_rhiMlymBCkuWfVFow1P3cw_24_3">39,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_5Tu4bkPsBEeHO7kv1exx6g_24_6">40,241</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_D3Rp8u3s8kq1_2Y0I9cb2A_25_3">4,238</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_AaTDubJV0E6KuTEv78FbdA_25_6">4,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_BhZCMe5En0WkENkfHjYjrA_26_3">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_MnQ4ygkC50WRk_D0mse0Mg_26_6">121</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_SFkaKQJIRkGbq1sUV7iu7A_27_3">43,515</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_1DGJ1hfIYEmlTAU8dJ7-DA_27_6">44,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_gOG9tBxhUUm2c7C0djkMxA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_jcjgb1aai0K4l3MpxR_Qvw">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SQwKrAAXSkOVCHHactB3KQ"><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_IUntXhUyrkiNse5o1XoYDA">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_PgzmZV9FWkGwDX4JkcIbXw"><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_cuskBHInYEWkVqI7fTz33w">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_mgvgdq6FiEyJOe8QmZFQqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1KAK1AR2YkOh-f0KOSdQPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_AxAE0n3h_0WugbY_Kj_TQw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_qdH-Elrh5EO70f5uJp9Bdg">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Pl03hwHoSkOEguTd-5XhgQ"><ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3F8X2wdjzUiuezg0iydCHA">90,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_hqFn4zJQ8U2y2kk3SwUy2g">47,671,654</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_bCJGXo6KM0eO0DBd5KXdPw">43,745,465</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_iwPIj70IREOqVhapJq4v9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_qms1Q3i8VEe1Czi4YEu9FA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of September&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_DprURJf_sUCs9NbETOeebA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P9F1pxSCpEGbW6iv8r1a5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_BEhenKxB5EeQZRJs9Gbedg_32_3">702,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_54nTOhdDtE2lDH57PiDy2A_32_6">563,389</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive (loss) gain</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_9zI4QsUFSk-zdGn-QyTDgQ_33_3">204</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_gZ7qEbK_tkKfk0IpjHGTGg_33_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_7HtNCEHXA0GAzd4ISjhjEQ_34_3">372,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_X32aIRrshkKq_EEgheoo2g_34_6">283,811</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; equity </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wZOb5By_bUeUDFQU0S63Jw_35_3">329,660</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1kBfzvzwIEGG3cmk1jcfsA_35_6">279,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_hMiAltOlCU6q6pELxINYqw_36_3">373,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_b9Lx7b1J3EW3ELp5KsFOUg_36_6">324,468</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f954481a_891f_46d9_ac5a_2a20d218615c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_ba5b5023_cd70_40f3_acec_66ab6d9efda2"></a><a id="Tc_b8500nA2sk2L6plC_cvL4g_2_2"></a><a id="Tc_jbW1SE8-aEa9DGdXn9A2yA_2_8"></a><a id="Tc_93knQ30m5kmgCFLdbUsV9Q_3_2"></a><a id="Tc_xF_EpzvgZEWtiR_LiP4uUg_3_8"></a><a id="Tc_-QkVBtkLN0KMPHvCBc8t3Q_4_2"></a><a id="Tc_r96r8bHkJ0qHZGHS6iEDVw_4_5"></a><a id="Tc_ftkFID9oOUunsPB33hCTeA_4_8"></a><a id="Tc_9vUqTiAZFk6M0_Anffja1g_4_11"></a><a id="Tc_dXwtQrSffk2UyNnslg3jgg_5_2"></a><a id="Tc_2rlN6E3-fEKFbK0pPClvwA_5_5"></a><a id="Tc_6xcNIbHpEE6isEl6IoUZQA_5_8"></a><a id="Tc_MZ4UECiHLUOifq3aha02YQ_5_11"></a><a id="Tc_2NrcZVr43E2x_nCCw_dG9A_6_0"></a><a id="Tc_KkYLJa67NkC8UVsb6-Q3kg_7_0"></a><a id="Tc_oPdGkaJFWUCwu2iIrstx4Q_8_0"></a><a id="Tc_YqDMaiquDU-WedVXaUZ7Gg_9_0"></a><a id="Tc_qiIj_KGjQEqE3rukpfL08g_10_0"></a><a id="Tc_Zmi3ImUpdUqSPnPv6tee0w_11_0"></a><a id="Tc_MRFx6AZaiE-KKOvGB1Qsug_12_0"></a><a id="Tc_48Tgo55NEEuZEqn0JRBRlg_12_3"></a><a id="Tc_05mA_jwfD0CzCLR4Mdg5zw_12_9"></a><a id="Tc_DxakpNVG5kOOWjftgrQ6Dg_13_0"></a><a id="Tc_YXlFjR8mkUGVl-tIKbDMaw_13_3"></a><a id="Tc_BTCephQwa0u5SGlk1JCX3w_13_6"></a><a id="Tc_8SnsKoFjNk-haJDNUBwyyw_13_9"></a><a id="Tc_M86IpfuB9Uub73Ldr9e4TA_14_0"></a><a id="Tc_7VGj-l2LCUWdIBHq5T5Ujw_14_3"></a><a id="Tc_YTO8XeYiikWbWIB5VO5K8Q_15_0"></a><a id="Tc_2H8FLsVU80m30PdCPolt_w_16_0"></a><a id="Tc_jQ9Guv7yBU22mL3IjdHN7Q_16_3"></a><a id="Tc_RQPv7PYV5kyH-1j6nAlKug_16_6"></a><a id="Tc_B8kd4T-BCESsrcQwTynWnQ_16_9"></a><a id="Tc_56Jgk-6QMU2ff5kVTaPzOg_17_0"></a><a id="Tc_3t0jnQ6t3USd4qPPfEjmbg_17_2"></a><a id="Tc_pvvzTkybY0WP59X-TK1Y5A_17_5"></a><a id="Tc_Uu3Lb8qSaU-z6PzGqxnFIw_17_8"></a><a id="Tc_lwCcJDROr0ScUBbOAqnV7g_17_11"></a><a id="Tc_NS1r_urt0E2cnsaA_09rLQ_18_0"></a><a id="Tc_13FjqH3wJEaVtgRJ6ryMZw_18_2"></a><a id="Tc_TxHKnP8mq0aocvmb85to5g_18_5"></a><a id="Tc_KX-kMQBz1EmShrucsVy45g_18_8"></a><a id="Tc_MWXu_MoGkkOlhDijX2O05g_18_11"></a><a id="Tc_GEz95PIifUOoIm4WpVSxNg_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_WI9K15k_20GZnOd8VNG8IQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">License and collaboration revenue - related party</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_yjITiuozsEya1gywAWfGvA_5_3">10,286</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_Wacz94UvwEqNF4iuylv_ww_5_6">13,114</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_kTC1jl3d6Emt8W_tnPpwOA_5_9">18,740</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_KMgclmLVFkyX-kibL3U1GQ_5_12">22,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_CYQL2SE8g0-gATzn5Dfs1g_7_3">36,956</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_-pWp5p9fEU2kTIZ-NrTIVQ_7_6">15,995</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_JpWtmLu5xEaplhHmZetF8w_7_9">87,633</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_CJZomGf7K0WgqmYKuralGw_7_12">55,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_T9qF-bnv0UG96F_4SzbM9Q_8_3">7,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_M5z4jBoSZEyDLgJryWO6Xg_8_6">4,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ohMnsx9O2kK9YwlxZFGg0A_8_9">19,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_d_EiezEzk0mNGczRYxaw0Q_8_12">13,644</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_fHcuEwrs0kWSd4N3gaeIUQ_9_3">44,212</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_HNNwnzDvKEyGbPgTahE3CQ_9_6">20,886</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_88rMvS1PV0G6o-foc70T7Q_9_9">107,569</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_jOijU6t-CkGkRP1LnEhrpQ_9_12">68,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_EFhG6oMprkOjwYhlXs2n-w_10_3">33,926</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tdofUpxOT0yn99yr84eA6Q_10_6">7,772</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_HkrZuhUnLki2sTKusNUTcg_10_9">88,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tLp-Z0Rp2U28PuPw45sOKQ_10_12">45,686</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_oIiJQAoh7EOrArvfnQ8SXg_11_3">122</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_tlhIzMzqzkCAosDk5LbiCA_11_6">87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_6owtcce2o0eEFfG27XX-og_11_9">321</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_cfJ-Glr2nEqmFR_mjRvMjA_11_12">820</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_scbokXVWTkeWoyJimhRdNQ_12_6">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_23AtYMNci0qCS2Rq1MDlJw_12_12">471</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on early repayment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_fSn2ds7XoEa7URs0da6vkA_13_12">585</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_edYgQ0G0lE-u2aLSk3J3bA_14_6">59</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Ztpu2ZzXjUKNqyyH8GKZhg_14_9">136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_NWGU-5OVWE6GIa7zGb9euw_14_12">37</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_x9Him8dRFkqqA6s2R1usPw_15_3">33,804</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_v53Od1zm2EKHsV_patgTbQ_15_6">7,763</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_irbTE339oUep-0nGsPKJLA_15_9">88,644</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_xTUez_dPtE-n95SbipR2Og_15_12">45,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ggayimcUNUScmw7prKb9cw_16_12">1,305</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_QWrSfZPsW0W-O1RJu81iMA_17_3">33,804</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mY11Ph9KT0aJ1dz8LnsG5w_17_6">7,763</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zVF-Tz-k2UGegsQQP7MK7Q_17_9">88,644</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8tofxM5fvEqZv9P8uca37g_17_12">47,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_jND37E3PUEKFmORDc4MRcQ_18_3">0.70</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_B1aLYjE6oU6nTUJ48alIzw_18_6">0.21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_SVVlstFZnk2Nc2R75W3ubw_18_9">1.94</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_autMS-LEuU2B-4M7srR38g_18_12">1.45</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares used to compute net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_X7lx4W_tbkivnSisVjb3IA_19_3">47,987,184</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_57OgTEwEtk-CWZDwfdLNZg_19_6">37,386,881</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_vSIGRKSlqUW7R1FZRtGTJw_19_9">45,705,782</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_-wyfAM4LoEqbW14oS1LAew_19_12">32,647,524</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8a65c40_95cb_49fb_9b75_197974451889"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="CondensedConsolidatedStatementsofCompreh"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_99b28e53_5993_48e6_a254_7f2861295174"></a><a id="Tc_XpzoH2924kybRJNVY9cZuw_1_2"></a><a id="Tc_iC_UqZ_wZkS9lW2xfLZS1w_1_8"></a><a id="Tc_F-EFpmakbkKbiHtkybdE7w_2_2"></a><a id="Tc_EoWkBYF1z0KtHZRuwRGobA_2_8"></a><a id="Tc_Q8imCF9EvEiog6z2iG-N4g_3_2"></a><a id="Tc_CTB-tcLsikGMZf7BnD62Fw_3_5"></a><a id="Tc_J30fe5sLZ0ee7NQoqPt08g_3_8"></a><a id="Tc_H9e-ure3w0G-X4JMe-UQ_Q_3_11"></a><a id="Tc_JONlvaCjWEqxDCF7noq2OA_4_0"></a><a id="Tc_CyRI3F9M4UinAcLLq39YPA_4_2"></a><a id="Tc_yEQy7386XEOGaqdVgxejmw_4_5"></a><a id="Tc_zWL2aHV8VUSp2WIZZd139w_4_8"></a><a id="Tc_ll7PMo5rFEa4KLe9OtC2rQ_4_11"></a><a id="Tc_2xrwkMfckEe8YsEHfr90ug_5_0"></a><a id="Tc_qR-IObpR90C3AQPYJCV_Gw_6_0"></a><a id="Tc_83tYrZUhj0SSjS7018LUPw_7_0"></a><a id="Tc_Xh7bKnsUfkaJADdu5f2HZQ_8_0"></a><a id="Tc_Gz0FBNJ69k64oQT6wWr5Bg_8_2"></a><a id="Tc_BA4KcbBUcEihSKS2j5-aKw_8_5"></a><a id="Tc_XPIaFJBFAkaLw0RmBr0_Sw_8_8"></a><a id="Tc_RurY3OcxKU65ulQ9JIjYGw_8_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pwB5nhjT90a41KgiRP1-Qg_4_3">33,804</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__lCNrGUNdUCPqBfJbSflzw_4_6">7,763</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NoV67kZEKUWUOrQYcH-dcg_4_9">88,644</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RL89nlvEBEyipS7UTH1l4Q_4_12">47,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Loss) gain on translation of foreign operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_m-BwgUEYxEac0agWrMDB9Q_6_3">140</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_d7cAuBoTBUSR4gWEc0Udow_6_6">129</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_w-bYJLWqZE2CXcsPwNpBng_6_9">207</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_NH2OmmhgKECdPT7HEoaLzg_6_12">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_Sgw5fdtMFkqYBdjd1EUk_g_7_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_ywPkWeZ300-ssO3NGx88Lg_7_6">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_ouoFY9Irb0qeu4o18VfGcg_7_9">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_s_dhVWZjd0-ndsy6SJz9gw_7_12">10</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_k0tvlkdIUE2UmWUeXeB1UQ_8_3">33,949</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_eOPNr5tYRkiDMmxSmFBC8w_8_6">7,643</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_GW_Ne8kq8kua4TGPffnQzw_8_9">88,876</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_pyu9fDV3R0e4QsiZD4nEWg_8_12">47,131</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5bfc7fed_4a0b_4b17_b430_58f3a2b4d31f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></p><a id="CondensedConsolidatedStatementsofSOE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e608385a_0630_4ffd_ab00_3901f1ef2ce1"></a><a id="Tc_qIFG_4ra0EmDowUFpJVCTA_1_10"></a><a id="Tc_G2TvYoJZ-UqBUu3pMgDlLg_2_7"></a><a id="Tc_KW-YR8AQlEWv3IXPDKW0MA_2_10"></a><a id="Tc_3Xjp_AAKb0yQA2YTHty4Ew_2_16"></a><a id="Tc_mCc-ctDXUEun-e6gbKaBJQ_3_2"></a><a id="Tc_ZiHVcejEgkiCXp0rQpWkqg_3_7"></a><a id="Tc__qlD-hdbIEaD8eKolzp7Dg_3_10"></a><a id="Tc_pOcuVl_690q_E86KdDLbxg_3_13"></a><a id="Tc_01NMDWxfD0uj-DHStconCw_3_16"></a><a id="Tc_NBoYJEFA6kujHKI2hgoN7A_4_2"></a><a id="Tc_DOJTgrxUzEGke6lNxMsV5g_4_7"></a><a id="Tc_HyCm3mtQmEWkh3g5f25G_g_4_10"></a><a id="Tc_11wSPJbFlk2a5YBNBM0bpA_4_13"></a><a id="Tc_tZXV80C1vUajIMeVxs8yHg_4_16"></a><a id="Tc_l7DAovPJaEWxc7Vl3meqZA_5_0"></a><a id="Tc_Sgiuilp3skiHnIktu3I_gg_5_2"></a><a id="Tc_D6Ew5Tnqok2MbN9_1wKw3g_5_4"></a><a id="Tc_qJKptkSYWkW2fBvhRM3uWQ_6_0"></a><a id="Tc_4WRBbttrzEu8jwLRrf-H1g_6_4"></a><a id="Tc_pbrxIbq4iUe5EvCWEgZhWQ_6_5"></a><a id="Tc_9S3HZpZriU2bfisfPAKblw_6_7"></a><a id="Tc_YOb5es18Q0u1SpObhpiy2Q_6_10"></a><a id="Tc_MZ52nccND0-jLk6Yp-wR1A_6_13"></a><a id="Tc_KC13UiwtA0CwvE81DELkog_6_16"></a><a id="Tc_e7FuEKTokU6MBZkMdfpkzw_7_0"></a><a id="Tc_Pi0EHjuv3EmY8IOJvoOWEw_7_5"></a><a id="Tc_eKT6YOM7iU63lppTjhPROA_7_11"></a><a id="Tc_jioz44QPm0SYNURX67cSyA_7_14"></a><a id="Tc_Ko2wnDzfhUiaUcX3E2K_WQ_8_0"></a><a id="Tc_wXHDAT3M20Cc-h4zc8W6fQ_8_5"></a><a id="Tc_JvMOw1GMYkS-E_JyyX9m1A_8_11"></a><a id="Tc_qeqkkz-4QE-ktT3X9bYGIg_8_14"></a><a id="Tc_CAKhFZ2_5kWnhBsFMK85dA_9_0"></a><a id="Tc_TOvPuG5eHkeAAtq63jgwog_9_2"></a><a id="Tc_7mCjr0kJqkCNIsxFEvAYyA_9_5"></a><a id="Tc_2GYTrMSzvkOA2rld0F1B7w_9_11"></a><a id="Tc_zRBvsyZTc0ykNzeRaKG78g_9_14"></a><a id="Tc_-LD4f9GXy0aVNdip9Coh1A_10_0"></a><a id="Tc_41b4RNqSNEeCF_SPA-zyig_10_2"></a><a id="Tc_fkrFt-ZCk0-g3L_NjfGpSw_10_5"></a><a id="Tc_wu7BLSFIXk2sK3nqZRAeEQ_10_8"></a><a id="Tc_pF203yVjqkWXmetJHFp-LA_10_14"></a><a id="Tc__j0sjnjmB0-1SfP1dWk5oQ_11_0"></a><a id="Tc_S_tkldALC0SLYozIoeCvrA_11_2"></a><a id="Tc_6fyOy5pwkUC8qEz0xx9oFw_11_5"></a><a id="Tc_q-EV5rUHykGYtU1LteMlXA_11_8"></a><a id="Tc_s5KUeYmJAk6iDrlw5LFvYw_11_11"></a><a id="Tc_RrZ6FRDNMUuNeQSVqy60ZQ_12_0"></a><a id="Tc_b7xbXRjmL0CEpf8rM83B8w_12_4"></a><a id="Tc_csq3m77H1kueGTENJWjB_w_12_5"></a><a id="Tc_w6qJI-YB0k60KhgPVtTvhA_12_7"></a><a id="Tc_B3hXWBuSfUqZCuDQ9wFyIg_12_10"></a><a id="Tc_KEQNd6J6Bkutl_6T3hm_qg_12_13"></a><a id="Tc_4C8_QKa97U-OWn1afdOjLA_12_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three months ended September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at June 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jxODNBy8nUGGb5t1661FYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_lYs4JvpVZkWveY3bKpkcPA_6_2">47,525,560</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cofzvfw-4UGemNVWygkS8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8UQB76iYxU-crzfzT6EwCQ_6_8">696,157</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dmfd75drp0Sl92sRinfLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YIRTor-m8Ee86kZFLG8xCQ_6_11">59</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o9SfVFUv-UWAdi0N3P_IpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_A--bMrZuO02YsvSwzzPkmA_6_14">338,651</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2021_hze2TlFsxEWN43owngJkXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hRS_QjgmEUacJWT8GTuG4Q_6_17">357,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_M2krQ_WjQkiNrLewQwJ06w_7_8">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_x803EC56uU-Onfn95lJr5A_7_17">6</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8X-9N-uxzEWLV5_AkyjFPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_teUwdMyXyU-8tT82bIqG7w_8_2">146,094</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_9RjF8wH6kES0uEoCfc7RpQ_8_8">1,381</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_ph3viNlDzE6H1SwZPF65YQ_8_17">1,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_9jyOKDei-UOLQf61NSDV6Q_9_8">4,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0gXvrgmZrEiYRQP9y1n2cA_9_17">4,775</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k2WesrzFCUWJheqmlJkQMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_cFc8mEtBKUqx1_crlUJbyw_10_11">145</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_h1rQdHBnF0CPfmWAY-iK0g_10_17">145</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I6LDpOFLME2hRdBnUQSKZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xbJJ3JcT5kWUY8bF-2BndQ_11_14">33,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ShgOTFjDrk6G2h3kd-AyxA_11_17">33,804</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_nJWFytjhqk-6jDmpJH89xA_12_2">47,671,654</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vx8zqhba0kSzEeLGrhw-iQ_12_8">702,319</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GqRu2g0eMU61hvw1Th5Jhw_12_11">204</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LUwide3JiUGcHhf7bE7dLQ_12_14">372,455</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XCw4_Nh-sUqi1I-Gi7qosA_12_17">329,660</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cb8a5a43_cd0c_409e_85f8_49d1d96fdb08"></a><a id="Tc_MnM5lUZZ6UuRuPjheLqSkw_1_10"></a><a id="Tc_Fo70DHiNTk2CDS2yo1nePg_2_7"></a><a id="Tc_0AH6HNEBBUGbqaYndybc7w_2_10"></a><a id="Tc_SOZzOh1n9kOzBT9psrhqvA_2_16"></a><a id="Tc_xgCednY9eEK-najf48I_Gw_3_2"></a><a id="Tc_xOy9bvn3f0qhz-0D1TTURA_3_7"></a><a id="Tc_47gVRh-680GlznAxdbkQXQ_3_10"></a><a id="Tc_4s6xlU1lS0K7eoXOGNqyGQ_3_13"></a><a id="Tc_Yx63Wh1Jek2CPstrXBU79g_3_16"></a><a id="Tc_-mhOegQN7kODNUmwvFGHhQ_4_2"></a><a id="Tc_JXCoZSh1F0aXHxsSrJ7apg_4_7"></a><a id="Tc_d3BE66HtJ0uV7qOX4HUPWw_4_10"></a><a id="Tc_4uyHfpam8ESIfJo3z1e12w_4_13"></a><a id="Tc_4Lpcx0u3VkqfGj8bkU38Hg_4_16"></a><a id="Tc_6MZvaeT--kKnUCvg38U_xw_5_0"></a><a id="Tc_gqcdapzIokidvd5w7EHS-A_5_2"></a><a id="Tc_C3Xa5oeyGUSmn_Ny1kQUaw_5_4"></a><a id="Tc_V3tcpfHHqkOIZ12dzzspKg_6_0"></a><a id="Tc_bDvN4GfSbk-SpKMrOaN5CA_6_4"></a><a id="Tc_dwOs1G-NA0q65X74Y2pD6g_6_5"></a><a id="Tc_CZHWMBmZuUuJpfAUFBBJsQ_6_7"></a><a id="Tc_HoB1Ps4SAkG_lZrTY3t4Xg_6_10"></a><a id="Tc_3dhuMgdGwUSNuuOtzdMi7g_6_13"></a><a id="Tc_xdPN-C2dEkSl8Eqqjni2xg_6_16"></a><a id="Tc_1pU_yDKQAUyJyBbmkXKfVQ_7_0"></a><a id="Tc_GomSjMCXi0e1rDWNq6LCtw_7_2"></a><a id="Tc_7O0V3K3rr0uJqurSXNBaxw_7_5"></a><a id="Tc_8wY-Tzaf0E-3xB8z4hvQ2g_7_11"></a><a id="Tc_EFh1MBN0tEujINFrVqJ_GQ_7_14"></a><a id="Tc_ABJxOydOmECj7cFniQ26jQ_8_0"></a><a id="Tc_iDtH6iUj5EKGdv2dvlcXVg_8_5"></a><a id="Tc_jgBUZuw2qkSKlu9QxuX-Zw_8_11"></a><a id="Tc_rIG816EZh0K47GRTlJlGSg_8_14"></a><a id="Tc_cFvKCRHotE-2qDtrRz4lpw_9_0"></a><a id="Tc__q5bXaNmf0C12_FCJe8usQ_9_5"></a><a id="Tc_5E0AB0xsE0KX-W4u-5dthg_9_11"></a><a id="Tc_udeLRdFE_0ijunfGDx0DRQ_9_14"></a><a id="Tc_NozpVYEQM0uy_opy3qs9MQ_10_0"></a><a id="Tc_DQvKLO_3yUmuNKO56N-1TQ_10_2"></a><a id="Tc_2UmCbDy0K0KftxbjfHn7ww_10_5"></a><a id="Tc_XumnaNGp6kGR7TFIAx1Pcw_10_11"></a><a id="Tc_fT_h9sgPgkCpNxRAbua3gw_10_14"></a><a id="Tc_ezFn45wZbkmkSovVsJQoYQ_11_0"></a><a id="Tc_bDOXcJj9jkWuRgjg4sYb5A_11_2"></a><a id="Tc_tuKMX972VEa0BI6fNTBJdw_11_5"></a><a id="Tc_KzzxYRYrdU6npLmONT_Ncg_11_8"></a><a id="Tc__W1qqUkkiUWNZlOXPvewtw_11_14"></a><a id="Tc_y8jTOAQxiUCv1BrADsjjMg_12_0"></a><a id="Tc_l96ieXi3r0ikcC38BIBe0g_12_2"></a><a id="Tc_AtHZsJbyNk-ZT2fTIxfDEQ_12_5"></a><a id="Tc_etXem76n2kuPiKQRiNNqjw_12_8"></a><a id="Tc_JfjqO6Hir0OZ6H_cIm5VVA_12_11"></a><a id="Tc_XT6oANdDjEmfYWd4D5HZFw_13_0"></a><a id="Tc_w8OKfwwrAkGrkyQCTWib8Q_13_4"></a><a id="Tc_ihxtFR5X0EWg7zhIigK2yg_13_5"></a><a id="Tc_jytJS6STB0G3Pck72wuzjA_13_7"></a><a id="Tc_Je8Jb9qO8ECmNlmAUeTVYw_13_10"></a><a id="Tc_zfHKWHTVBEm4iLDxX7COfg_13_13"></a><a id="Tc_VWLCcE3ESEKk92dG-uAW8g_13_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Three months ended September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at June 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VRhvgs9oa0mTUaqYjRO3ng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_TQvbE7et90OHz-hgm2NkpQ_6_2">36,802,139</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qLCgYz5FGUGJWujpfLA26w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Zchm2ifmrEaOkA4HqMui1A_6_8">424,855</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EyCHRvQf9UG7GDeEg-B-bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_45rg6CzG2U2wG2al3m9_yA_6_11">208</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_15NQ36sPLUyBE0gs8_H_zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mQuUPz9SukmE01c2P8KQVQ_6_14">257,162</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2020_NpkY5Or850q-_7gddnu5kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2AYTgAKcY0GMDG8CwSfdhQ_6_17">167,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc_91K_2ELtnEOtwaUZo3KVeg_7_8">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc_wcSVooANzEqR-RKPFm-cpA_7_17">3</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ScZrHzQctkadsqBzu4TDGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_n0y6P9hAVE61QZv93tlx1A_8_2">333,047</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_UN3M56DNcEqfJFsFQtlo7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_IMg9BpNyo02Lqgf03vxbNg_8_8">6,368</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_34DT_TXcJ0G9oeklOaHaWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ftggLD1VdUqKqYxV_-MDQw_8_17">6,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAo-gksv90emgd8j5zQ9WA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_TPfDnE8W6E6_dGlYK2zvrQ_9_2">179,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_ZGPlhxXHFkSSSX9bQqnwuA_9_8">1,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_EnSYfV_OP0yMiriXObhUXw_9_17">1,495</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_P1_G7xgadki7WeEfJ0JuwA_10_8">1,888</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_IoV75eM1XkK2rdAFxMs8ZQ_10_17">1,888</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ESv4u0HBt0CnfQx4AKYNAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_rSRNYnQZwEqCL0QksgvEXg_11_11">120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_E6alF6NfU0WZOWYt8Aaftg_11_17">120</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_D-unIeqFvkKbPDLT1e3qMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_M0aNzuw26kyjnYUDe_HuWA_12_14">7,763</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PfXl0rrwG06GyaqbGyRIOw_12_17">7,763</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_k1hvRxrVskGOQj7Q6RSOsQ_13_2">37,314,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8zX-Qwkf3EWpe4qY-ZjSZw_13_8">434,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XMwRDBRu8Ei39Lw9JBpIBg_13_11">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uEv_1AwrqE6tpR5p3n3M0A_13_14">264,925</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vzZ7qPCULEu6Au43DY3jtg_13_17">169,590</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d9c690f5_0c84_4716_bad3_08e739b6d189"></a><a id="Tc_FKdoXMScdkSBACHrLUD9_Q_1_10"></a><a id="Tc_VQYW7vZTFUK9NgYhV8tofg_2_7"></a><a id="Tc_Sjx90kLLjkOIQN8hguvOpw_2_10"></a><a id="Tc_PCeDXQ-fw0iFhMQmy3JYJA_2_16"></a><a id="Tc_EeVKgcK2K06YiRqyzvGG1g_3_2"></a><a id="Tc_mB-IXqnfBkCQ4XiKA9Xv5g_3_7"></a><a id="Tc_0wuqkpdQbU2EGubGQRJwoA_3_10"></a><a id="Tc_5H9AIy23u0a2dzk0E87raA_3_13"></a><a id="Tc_QE5d5_KucE-F130s1Gn-Iw_3_16"></a><a id="Tc_sOXW23-T3UG66kLidRy6KA_4_2"></a><a id="Tc_HqdmPRFxV0KOCgGqSb_JjQ_4_7"></a><a id="Tc_abxdJIW3IUGP1xzfibXzXA_4_10"></a><a id="Tc_BxW0-ZJv_kmXgNDHd0hQTw_4_13"></a><a id="Tc_2wLTraSMk02MGivm_N3RcA_4_16"></a><a id="Tc_6zOuYoKQyUOv6Pu90V66pQ_5_0"></a><a id="Tc_lV5ARUvhtEeoTP57320B6g_5_2"></a><a id="Tc_RirM1n2yt0KLa04vQn0tBQ_5_4"></a><a id="Tc_VX-povmjZkObhO6B0tSUGQ_6_0"></a><a id="Tc_QwBJroEFFUuHViw2oeJwdQ_6_4"></a><a id="Tc_p-AA65fnmUirFZfCTNtb6A_6_5"></a><a id="Tc_OuvvwGU6d0iuwZcPk_JAQg_6_7"></a><a id="Tc_nBfrYmA1KkuEbnAm1Ugs5Q_6_10"></a><a id="Tc_MLKs-vdPG0ioQTkjgyw9LQ_6_13"></a><a id="Tc_tUwWxXuoMkmGmWGt4CUZKw_6_16"></a><a id="Tc_rXVrchy0vk2huDQuP6yNPA_7_0"></a><a id="Tc_kXjraZeOe0appbOMyC0Ogw_7_5"></a><a id="Tc_2e1b0hj6k0eh1_19OztDOA_7_11"></a><a id="Tc_mFpzR5N57EePhijzICTCLQ_7_14"></a><a id="Tc_FDD19OSS-EqPAG-IYlRLrg_8_0"></a><a id="Tc_81VXVB7060a6HxJKjOz87A_8_5"></a><a id="Tc_gZ3NttPzb024jlM8iHjPGQ_8_11"></a><a id="Tc__UlIQtqRAkS8hX81WuSiug_8_14"></a><a id="Tc_tTSyDrIfG06kuYxw6k8g5w_9_0"></a><a id="Tc_4EcUPYru606ydBii311yrQ_9_5"></a><a id="Tc_7FWcmeWv50y7xF5851yXNg_9_11"></a><a id="Tc_qs_cJPqR1kuV7cslFR3ujg_9_14"></a><a id="Tc_puHcGXGXt0Gozb0pMvIT1w_10_0"></a><a id="Tc_et02cjQM_UOeB3tIUMQaRg_10_2"></a><a id="Tc_FPOLi_j74Ee2DF6kVWeatw_10_5"></a><a id="Tc_OLLdeIoRZ0afGIpEif90VQ_10_11"></a><a id="Tc_bt-_uCvO4E-X0fkRS8Cglw_10_14"></a><a id="Tc_qKzzHWfg_0uUqa4PWMEaOA_11_0"></a><a id="Tc_achbdGlfCEObTd6fun_fpw_11_2"></a><a id="Tc_HE3ESRvn5kScvBSESuwKLw_11_5"></a><a id="Tc_-vuxCJATdEqPXjZHP97_Kw_11_8"></a><a id="Tc_97-9nvfTeEGxYkoMrefUEQ_11_14"></a><a id="Tc_qRtvNHkcAU-MzB4NKh_6WA_12_0"></a><a id="Tc_VEl4jsRGikaimqWNTev1mQ_12_2"></a><a id="Tc_XmSAqOGXuk6LS2X5TpDJrA_12_5"></a><a id="Tc_1ZlIGsk5tEuVQICJSAfEdA_12_8"></a><a id="Tc__N5HLCNRhUqVTJYFRu8_Qg_12_11"></a><a id="Tc_RBBTGgoIskG4YnwmgSBaPg_13_0"></a><a id="Tc_IIUO_seRdE-2C-_MZ_PgnA_13_4"></a><a id="Tc_vwUnuEdSXkCt5QTO8qnuUQ_13_5"></a><a id="Tc_1E_qeSYBmkqDMNbNs1shIQ_13_7"></a><a id="Tc_RiGj_Lqq9Ui48BJcvMH9hQ_13_10"></a><a id="Tc_zNOht4QF3kSH2IA7G_EvLw_13_13"></a><a id="Tc_f5aRVt0VuEazJCzy2P079g_13_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nine months ended September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_JpojdPPBcEKVKqdHAkFqVw_6_2">43,745,465</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A4ngj4JfEEud5h_rZa61rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NL9ti-eLV0GdyMncvs9rvg_6_8">563,389</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wDJZBP8oWkmr1-cnJEWO_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uwep9awLqUKgovLQwfvm0Q_6_11">28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iXBhd1us706tUU2Z6TGdoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AnGE8YQwVkShayT4EEWE0A_6_14">283,811</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-rXRAda1b0qfiCXWBS54yw_6_17">279,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_Ce49V8LrpUKA30rspUIk8w_7_2">3,503,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Ut0HLu1GOE2N7v4nWFE4dQ_7_8">123,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_GOf54niwbEqRkApkaEKvOQ_7_17">123,804</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_Vi3q53g7JEK7-k__ioZ8OQ_8_2">429,938</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_UJr9WlJ4LUWlpNgJDPeAWg_8_8">3,944</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_ZO04PjJ0wUCtOnQbgPfycA_8_17">3,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shares withheld for net settlement of tax withholding upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw" decimals="INF" format="ixt:numdotdecimal" name="ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" sign="-" scale="0" id="Tc_SUJzi8Dr10-7rEQqTG2pKQ_9_2">7,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" scale="3" id="Tc_u8polFbSXku1Est06zoWQA_9_8">189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" scale="3" id="Tc_4xtAMszJ10aFdWcaPB2R3Q_9_17">189</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ZByrsBpQP0WBNJFBXjKHuQ_10_8">11,371</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UrV-A9OoHUmD9JNLjFsnvA_10_17">11,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-pvHJ7QJ90yW1k3Cfl4qtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_KWxPFD8slEyQFCNiAbNTFg_11_11">232</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_SbNoyJfdVUGugf8hTy_0Mw_11_17">232</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T6A4i7LXhkGkWOztGamCHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1oeAZB-URkOMdM0P48dOKw_12_14">88,644</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZMwdHRIxGE-tDtR_F_KyLA_12_17">88,644</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_8cmpS1AZF0Si9dL0vWa6NQ_13_2">47,671,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0sLiuoTESkOnwgM5TQnmIA_13_8">702,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_d7STEdoTIEyhcltpv3IG0g_13_11">204</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BSosxA54OUiwFSKJFnGCrg_13_14">372,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kk9LWOUG20-AeHdnsB8FLQ_13_17">329,660</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_822c1399_1d05_4379_8a94_9665d1f34033"></a><a id="Tc_eukFMZXKBU-cOUvNSS870g_1_10"></a><a id="Tc_hTYOyVmdUUGOiKmb3gPk8A_2_7"></a><a id="Tc_ezKJlwkOqkymSoGBrqg8cA_2_10"></a><a id="Tc_aFf2Vji_CUWhImBGbay_Qw_2_16"></a><a id="Tc_5wtSTBIdJU6La9WXKYz5FQ_3_2"></a><a id="Tc_BnKUIqV6GkefOsaUePlQcQ_3_7"></a><a id="Tc_jBzvWhDYCUOLg5WEJhKauA_3_10"></a><a id="Tc_BuMaGvkaRUecU0e4rDJ6UQ_3_13"></a><a id="Tc_CkKjhdp_Mkay9qWn_N-6EA_3_16"></a><a id="Tc_a7nh3pUKqEGZ4bQiuucAow_4_2"></a><a id="Tc_Pg9HzIDYUEqdSa7NDRyK3Q_4_7"></a><a id="Tc_vnYBWeqJ10C6_oiMkyNX0w_4_10"></a><a id="Tc_n1OwMbS6pEKnHwIZNvVC8A_4_13"></a><a id="Tc_12tWH4SBbkCNHknIgX6n0g_4_16"></a><a id="Tc__asCKDUwm0S-3o0uIEXt4A_5_0"></a><a id="Tc_EPHXbleK1UyA68kmuYwhcg_5_2"></a><a id="Tc_5mzqf1vfQ02oWkneLzJ95g_5_4"></a><a id="Tc_IP8DM3VYqUigplklWpTBMw_6_0"></a><a id="Tc_keORXtwpR0Cyfyj-5rfFaw_6_4"></a><a id="Tc_9oLo-_sn6kiYc_q_cLChOg_6_5"></a><a id="Tc_ZIxqS9maeUCZtgicUnoHaw_6_7"></a><a id="Tc_sp_0vefaBEaoFKeTtWoNkQ_6_10"></a><a id="Tc_oIN7dNSjDEel6nagZ5XDvA_6_13"></a><a id="Tc_PmbhGvUay06Tqcnw5tEz9Q_6_16"></a><a id="Tc_FGiTZs71NU-YGBgda1nwGg_7_0"></a><a id="Tc_-XulxarIs0ukgMVGNxxB4Q_7_5"></a><a id="Tc_sEaZBLUF20ONKPKX23pGxQ_7_11"></a><a id="Tc_Aqm4nSwOv0K-T6f3BpJ4rA_7_14"></a><a id="Tc_TBEUnkkojUSXA6Ey4MEffg_8_0"></a><a id="Tc_Y1LeDwtGEUyaiwOHs6MdXg_8_5"></a><a id="Tc_OrInhRqHXkq5eMgBp6sQzg_8_11"></a><a id="Tc_2_s3clmDOUmHfE-K_i804A_8_14"></a><a id="Tc_VhVyVx18pUiCrNXr78NyhQ_9_0"></a><a id="Tc_V4a5f2ThtkaPhhk6N66oPw_9_5"></a><a id="Tc_5UMdx8urF0eQHFcVbmyG7g_9_11"></a><a id="Tc_wmFax33RnEKIh7iKhq6NTw_9_14"></a><a id="Tc_gfXCLprGVUmP1qnOUNHX-g_10_0"></a><a id="Tc_8Gqec3Djx0m_nHndk6fGuQ_10_2"></a><a id="Tc_JqGafP-o6kiradbFCN7ckQ_10_5"></a><a id="Tc_1k3_D_edlEmFWR7sqFb29g_10_11"></a><a id="Tc_EwlNH7x3jk2hFRUuYwv12w_10_14"></a><a id="Tc_uJzzD5_0jUy1Ox4PSVuFuQ_11_0"></a><a id="Tc_nySJ0yjhUEmrAM9ozA3kTw_11_2"></a><a id="Tc_gfjzPw1EIUeOQxSSyNk6gQ_11_5"></a><a id="Tc_gJxi7sYVJkSBuN1RTzqMBw_11_8"></a><a id="Tc_K-otkagMikm3dkk4eN_SyQ_11_14"></a><a id="Tc_9541EtL1kkWqHo6erKwJVg_12_0"></a><a id="Tc_ZnkW_oWtJkO-Qut_5DAdnQ_12_2"></a><a id="Tc_yLXFMETqL0KsDMFA196Sng_12_5"></a><a id="Tc_dKndkgDG8UyauGG9hsjvfQ_12_8"></a><a id="Tc_pDk07vlpEUqJpjMhwYqbIA_12_11"></a><a id="Tc_ch116Io9lU-uuTDdO1mXPQ_13_0"></a><a id="Tc_fHS6JZImkECt2aOGEn0hBA_13_4"></a><a id="Tc_jukQx-sKsUmBEtxUhGu91w_13_5"></a><a id="Tc_c00NgVUrKkC2-zZlsI5Yhg_13_7"></a><a id="Tc_HHTgyaLuQE6GuJ47THiFrA_13_10"></a><a id="Tc_EuTJ8NdSJ0u9WCEXHXFbug_13_13"></a><a id="Tc_Kt9QH4uAikWa_E4ua8Kh9g_13_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nine months ended September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EnjUd2zZYk6vz2-cHlqtXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_ff79DFH5hES6ae0_KVl1Fg_6_2">27,217,649</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ShsA1tWpGUmhQJqfvR21Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OBqGqprkGUu250Wt8RBYbA_6_8">297,846</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pjYolJb8NUSZoqWWvsTjEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KzX4RV0T10KlLyaeV88rtg_6_11">221</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6k8OGpvpa0CnTaIinonZ3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pRfCZ1L0DEqK_GKt-oVhyw_6_14">217,661</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZBf-i5XHGkG7DkHdMsxy8A_6_17">79,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_gnvpeX4krkinNj_Wu2dYZg_7_2">8,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_wqbf_psxD0yk5n_MrH7ZKw_7_8">105,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_d89gJv5sV0GRMxUDV3R8QQ_7_17">105,328</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_07-nJWm-n0OlxE7BAmCSvQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_d7SsSk6RakCDyLHYC79gXw_8_2">1,565,840</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_eu303YctzUm4oyVCdG6opQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_fXML86g8e0uG2XyjIl19lA_8_8">23,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ffkr2mgme0Kc83elbZL7aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JscEZ-CfYEmizMfM2iEVAQ_8_17">23,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_3uqao9Gh5k-1nYPI6Z3qzQ_9_2">481,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_2PzhyjQ24kiGHt5y03KtNQ_9_8">2,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_1TmSrkQY-E-sBmwJCbGiyg_9_17">2,486</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zxBODRL-IkWqTUgXVhJS0A_10_8">5,932</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_COn8ApiYUU-e69lCFrE0lA_10_17">5,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_picUoPu6YU6hAp4STfCryA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_Jepq_osRMEOUm6GJ1m7_pQ_11_11">133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_xPZJWjtE-E6UbGFJ8K9vVQ_11_17">133</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vnFLoq50b0y_n6K8gPk8yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DSDFxp0Q4k6AGQwn9Fqo1Q_12_14">47,264</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6b5s73e7aU-lcwexL2w_Zg_12_17">47,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_o6u_W_PMkUKyXjCNdur-3w_13_2">37,314,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LsUIxTLRQUSNqg4ttrB56A_13_8">434,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ljv3iBLB50qnZn5DJH_zMg_13_11">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8KKmFDE9vkGfEWCazGl11Q_13_14">264,925</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2dY-SRCZyEm1HBK1U0olzw_13_17">169,590</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk75175978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b0bd4b9a_5d58_4501_b93a_42be546a554d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="CondensedConsolidatedStatementsofCashFlo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Unaudited) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55c002ee_834e_46e5_9f17_0a70d25eee00"></a><a id="Tc_Ja8lmUm_FEONLJzqV5lwng_1_2"></a><a id="Tc_DICJ5lzq-kuJvVELf8qwsw_2_2"></a><a id="Tc_24St1pdxcU6o7LQPVzB5SA_3_2"></a><a id="Tc_14uHiu0JXESn_JCGRDnGhg_3_5"></a><a id="Tc_ALDkUPxBa0u4od5NHJ0S0w_4_0"></a><a id="Tc_a6jGgVkWZUydLgV1IT0PPA_5_0"></a><a id="Tc_S5VDnND2yUKE2Y_vKF3OmQ_5_2"></a><a id="Tc_3KLJNs25q0-ZgTfKXy6odA_5_5"></a><a id="Tc_0g3k1iD1sEurvXyiZ9PSNg_6_0"></a><a id="Tc_anSE4Ntv00ayL4gN4fxjCA_7_0"></a><a id="Tc_ZT0I0V2ib0OpS4fsY3dCsg_8_0"></a><a id="Tc_SW2cAeGWIUC_hlXoJJaIIg_9_0"></a><a id="Tc_Y7kBIGzYnEW9aB-hMRectg_10_0"></a><a id="Tc_26QJ8lrJsUiPproZCuM_8Q_11_0"></a><a id="Tc_OHZ_AVs0_kOP380-Dq0CKQ_11_3"></a><a id="Tc_dHKgfv2NhkmRp4FqnKoaEw_12_0"></a><a id="Tc_iuBk3rw9M0CUzusTMFCh3A_12_3"></a><a id="Tc_pZjr-wiRf0eLsza67O4X_g_13_0"></a><a id="Tc_d67FHtPpB0CdNybDHTU_SA_13_3"></a><a id="Tc_rB6GACZCg0S9894aMGAFIA_14_0"></a><a id="Tc_EITX57lrsUSOpZ_Nn12uLg_15_0"></a><a id="Tc_4j67AK19tEa4oXXtz2YZgQ_16_0"></a><a id="Tc_kb59pdwUdUaTVvUtOodIcw_17_0"></a><a id="Tc_XfXUOfdvik2NkC_Hz2vmOg_18_0"></a><a id="Tc_gOisdDd-aUmO8TyMZDfnOg_19_0"></a><a id="Tc_96L4nErYAESdF7jiZVnluA_20_0"></a><a id="Tc_vLuqK-2MxkCfzi-g0hFdfg_21_0"></a><a id="Tc_RvkAN8pohU2fVozI_h5dIQ_22_0"></a><a id="Tc_MjE3W8ZVlUi6OnRTCjNTjg_23_0"></a><a id="Tc__9218RukKkm7lif3SugXwA_23_3"></a><a id="Tc_wHmm_NS8rk6dwSZ9Vu4uqQ_24_0"></a><a id="Tc_OfwXMybsWEmlUUFIMuzEsw_25_0"></a><a id="Tc_bR4eRufBnE2SysFp9sNt3A_26_0"></a><a id="Tc_j8tj-Qo4PkyHpFTpIwApQA_27_0"></a><a id="Tc_IFqcucNNq0Kjb-egPL9AhA_28_0"></a><a id="Tc_UujH9lWJx0yf5R5HFETfhg_29_0"></a><a id="Tc_VyMRkyIGTEKTfdE_Qwkv_A_30_0"></a><a id="Tc_b395eTdMGkaaI5hjzkxkxg_31_0"></a><a id="Tc_bVryAUjZiUGe46MWhvciiQ_32_0"></a><a id="Tc_aLz6lGgXe0Wcj49aeB6leA_33_0"></a><a id="Tc_5Fg3iH9VwEC1vpkOsO9eLg_33_6"></a><a id="Tc_IDt2L4qv-EKrMaFJ3s_U4w_34_0"></a><a id="Tc_1iKwHBYO1kCm3mQRkAIEcg_34_3"></a><a id="Tc_5_6D372cZ0qNMVBFwq1Feg_35_0"></a><a id="Tc_t0PCAaXxjkqk96niUFpH_Q_35_3"></a><a id="Tc_mLckqhyQlkSBzXRHIBHN2w_36_0"></a><a id="Tc_xYvSxHWfTEi5thF3HMiKMQ_36_3"></a><a id="Tc_LzR0v7DkY0K2kNUsi3kGfg_37_0"></a><a id="Tc_IX9n-qnssEelvAzKDd3vnQ_38_0"></a><a id="Tc_EmVy8SMx-U2hnMsRo9knRg_39_0"></a><a id="Tc_EA6FpJsD8EWOXRZK9LyftA_40_0"></a><a id="Tc_Fvc6d0Xk7kmvNKXOKHh3fQ_41_0"></a><a id="Tc_FxYAx4wkzUqsnt9hmvCq0Q_41_2"></a><a id="Tc_SpCm76oPuEW6ahTGl8tVgw_41_5"></a><a id="Tc_LsQifDRkzUelGT3IE76XTA_42_0"></a><a id="Tc_iL0yNbAQkE-J-eDu51WgFw_43_0"></a><a id="Tc_PE6SI594uUCAtAN8pcFi1g_43_2"></a><a id="Tc_AMdV-4sbKkCdh_1WOKbOLg_43_5"></a><a id="Tc_Yd389Ubjt0iMNrriYJ1aPw_44_0"></a><a id="Tc_lSJcylXqnES4AglW4rFjeA_44_2"></a><a id="Tc_OuwNlBdiY06Ts16excxdVA_44_5"></a><a id="Tc_6PT-2cYcAU2juRlB-Ll1sw_45_0"></a><a id="Tc_ZvVAgRX2IU6S59Sr5T_6vQ_45_2"></a><a id="Tc_DZAezZ-cqkKiKfH0nqTF9A_45_3"></a><a id="Tc_ajRVAJf2J0mjHHEMZOJZaw_45_5"></a><a id="Tc_2WSxZRj7vE-mqjLjFpoLkw_46_0"></a><a id="Tc_HBELGIkjwUyBgoJlt36vMA_46_2"></a><a id="Tc_yzjtKGfTgkSjxtHCwVmhqQ_46_3"></a><a id="Tc_-QI1PjSeEkyY0Jw0bOaVLQ_46_5"></a><a id="Tc__8b3F7nzuUWKztV2the8fw_47_0"></a><a id="Tc_tOHTm251zkqCZhhfkov-EA_47_2"></a><a id="Tc_kc4aEAPeW0OQzlqpy3NlVA_47_3"></a><a id="Tc_23h4839PmkupkbXyiTTqdg_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_M_CsAYooq0WBjQVACV_pVQ_5_3">88,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_B7OkbC-hyk-1oRZsBuP5gA_5_6">47,264</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_IuZhMflpC0Spa4zPcJDLHQ_7_3">11,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_s3mYNa180k-A1kMHuRSzhw_7_6">5,932</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use asset amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="Tc_XDUcHxVfJ0avpEF8SpYeWg_8_3">1,378</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="Tc_MxF0P45jp0qPWPKq7mvzDA_8_6">1,331</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_o88B4u40UEGcF8dg6YGvWg_9_3">578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_q1JsYzW2hk6tDXKLUurCdg_9_6">601</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net amortization of premium (accretion of discount) on marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_h57uriS8RUq9nhpTCdkjLg_10_3">1,321</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_vOZqyZEDeEybS_CiCaJ5dg_10_6">155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Loss on early repayment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_bIUoPTM_FEaRIKXwtzxXTQ_11_6">585</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Amortization of debt issuance costs and accretion of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" scale="3" id="Tc_VWQldjsE_kyDTAQiO8KghQ_12_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Change in deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" id="Tc_ZuS7qp0vrUWD6jaRrJ8szg_13_6">1,404</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Research and development tax incentive receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_DoCRj5GOC0i7FCgKLPlyuw_15_3">854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_UuVsE1FptE61nh_lJh_-1Q_15_6">517</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Receivable from collaboration partner - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="Tc_Whi7tEq-60ynpwYnn5IxUg_16_3">212</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" sign="-" scale="3" id="Tc_b3-gQ5pK-0q8nOL0CI--0Q_16_6">3,966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_oL9U57BbM0Oq2FvZhEr-tA_17_3">2,632</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_kG1RSvqCyEq8ZY8TGf52nA_17_6">1,566</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_A072urdPCkitmYn47Tl_tA_18_3">2,285</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_GeMkHZrX6EGmGCayZFbz2w_18_6">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payable to collaboration partner - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" sign="-" scale="3" id="Tc_xT1BPXdeekWTdhc8O9_-5Q_19_3">1,611</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" id="Tc_7ozcJUysJk6A2sskqGXG8g_19_6">815</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other payables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_O0OKEFFNE0uZTl0-outqQA_20_3">14,393</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_ezgr6zgIg0C3gpr-yjmyrg_20_6">3,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Deferred revenue - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_qhDDWPu7KEOHn2RVCNv70A_21_3">12,236</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_2DjXk-V6eEiA9Q_OF8hFDQ_21_6">20,653</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Operating lease liability </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_L9Mo84oygEG2MSd4hrAxKA_22_3">1,493</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_xqT_WSbdvUeZRS6nL7jXrw_22_6">1,450</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_SiZM2zvClkKiXwu9crsQMQ_23_6">170</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_tjM8jZHqHk61_c7oAfHiUQ_24_3">80,926</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc__FLSCiE_bke3BLKWWFJdkA_24_6">53,617</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Purchase of marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_rpEuCbrjKUONoQaYxqPurg_26_3">255,902</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_oFZQF9jdZUKPlt-R5WCalQ_26_6">147,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_a_T54AUgqU6jesdu7DTHtg_27_3">213,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_BfS1vTYRI0a5hDfhf-z3Nw_27_6">131,383</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Purchases of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ar-f8iNWiU2iB8hREIVD4Q_28_3">905</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_4OIfLiqx-0GCRa2CUbvbtQ_28_6">346</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_RTWO22ChWUO5EfzmsIYl_A_29_3">43,727</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ee2r16slWE6699MoD-W4vg_29_6">16,563</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from public offering of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_FmbCFjR71EiWNIgASNX_zA_31_3">123,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_rkSbpl9NsEC64qN7JsD6zw_31_6">105,478</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_Ku0vogj5_0mcBOrcMZRlZA_32_3">3,944</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_r8HGcXLclEOaVE7r4wDB8w_32_6">2,486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Tax withholding payments related to net settlement of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" scale="3" id="Tc_4_ke0WxkHUO4ytO5WHtO9g_33_3">189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="Tc_kSmyLHeyAkC4R2D5Xwe6Rg_34_6">23,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance costs related to long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_tZdwQDbtsU60yjI6lYcNdg_35_6">14</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Early repayment of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_JJbOnIcO_kKh43dTnrBnjA_36_6">10,524</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_EJU8HMJGF0e5Jy0_6EeBRg_37_3">127,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_XFE1mkcQ8EOrHlPfuOnVkA_37_6">120,645</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_N370q8sFDUKHB2HnYm1U8Q_38_3">148</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_LXROJqlEXkSADV-Y4T7rzQ_38_6">154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_10nbfLIvNE6X4_9Q2NvB8A_39_3">2,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_QR4CyHD7p0SIQ8Ywg2Gm-A_39_6">50,619</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_OC62nECye0SBBYefXBnauw_40_3">117,818</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ykTHWEOrXEmYtTETaJHieg_40_6">33,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_pEQ-xNGK6ki6UAyyyb_1dQ_41_3">120,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_PEycGniOqEeL50-h7lRhFQ_41_6">84,085</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Disclosure of Non-Cash Financing and Investing Information:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Purchases of property and equipment in accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_DtOFqRINUkiMK9uNQtRPcw_43_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_DiQDT3UWA0az39cPxnbJAg_43_6">27</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance costs related to common stock offering included in accrued liabilities and other payables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_lvaVnROBNEGcQD3RONq0EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_9AYEXrWbeEq1lLZf60susw_44_3">191</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MZM0ma8qsUmURiga3ySKXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_IOAfLq5nbkGMltJFRCpjxg_44_6">25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance costs related to common stock offering included in prepaid expenses and other assets at the end of the previous year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_HREnfaqhhk6qERJYnhneIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_21ua8SU2gEuo0QhlhuFsUg_45_6">125</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance costs related to at-the-market offering of common stock included in prepaid expenses and other assets at the end of the previous year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_K7Od3CM6-kOKjqWB7rXSfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_SJSVFXIoOUuHgS8M1VkKNQ_46_6">191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Issuance costs related to at-the-market offering of common stock included in accrued liabilities and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_mjNjDSCfZ0OjAafvNYLJ9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_0zENxB4j8Eap9iArfGUupQ_47_6">17</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d809ebf4_5a72_4677_843f_30182cb08576"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS, INC.</p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes to Unaudited Condensed Consolidated Financial Statements</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_FrKCjKV9mESwkuNnEunxYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;1.</b></span>Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Protagonist Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) is headquartered in Newark, California. The Company <span style="background-color:#ffffff;">is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company&#39;s proprietary technology platform. </span>Protagonist Pty Limited (&#8220;Protagonist Australia&#8221;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. The Company manages its operations as a <span style="-sec-ix-hidden:Hidden_u4SjkEALd06OJORFVCaVuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">single</span></span> operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue" scale="6" id="Narr_A4KfBT-PvE6hcE1privaXg">352.5</ix:nonFraction> million. The Company has incurred net losses from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_TFp1JJlLlkCTLgjRaP_Lig">372.5</ix:nonFraction> million as of September&#160;30,&#160;2021. The Company&#8217;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#8217;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the&#160;ongoing COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company&#39;s activities remains uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#8217;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company&#39;s activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#8217;s clinical trial sites are located; the development and spread of COVID-19 variants, the timing, extent, effectiveness and durability of COVID-19 vaccine programs or other treatments; and new or continuing travel and other restrictions and public health measures,&#160;such as social distancing, business closures or disruptions. Accordingly, the extent and severity of the impact on the Company&#39;s existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company&#39;s future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these condensed consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company&#39;s future financial condition, liquidity or results of operations remains uncertain.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_cXlgIFK6yk-WdQwGV39GaA" continuedAt="Tb_cXlgIFK6yk-WdQwGV39GaA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;2. </b></span>Summary of Significant Accounting Policies </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_fmRiHL3PyEW9Y4DcaC4Drw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) and applicable rules&#160;and regulations of the SEC regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the condensed consolidated balance sheet as of&#160;December 31, 2020&#160;has been derived from the Company&#8217;s audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair presentation of the Company&#8217;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2021&#160;are not necessarily indicative of the results to be expected for the&#160;year ending&#160;December 31, 2021&#160;or for any other interim period or for any other future&#160;year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the&#160;year ended&#160;December&#160;31, 2020&#160;included in the Company&#8217;s Annual Report on Form&#160;10-K, filed with the SEC on March&#160;10, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_gXWe2bF7rk2k4J-Im37qBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:UseOfEstimates" id="Tb_ejlO4bavsEiQ4zpFFwewyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_o7oq46GWxkS4nmDiDVFqBw" continuedAt="Tb_o7oq46GWxkS4nmDiDVFqBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by <ix:nonFraction unitRef="Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:CashNumberOfFinancialInstitutions" scale="0" id="Narr_WVz0xNt2X0mjIkK10xGQOA">two</ix:nonFraction> financial institutions </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09d28485_8ab2_4ef1_bea4_3927f7e8e3fa"></a><a id="Tc_NwdK-k_N002ybLMMM7XuPg_1_2"></a><a id="Tc_u-_SU5w6OEq_hlycxjHrvg_2_2"></a><a id="Tc_q68GUt2YIkaqTudIpJzB2A_2_5"></a><a id="Tc_pZGlxFKXt0KH-L1ulwpNzA_3_0"></a><a id="Tc_E-TF52wXkU-saGNALEarOw_3_2"></a><a id="Tc_0Q-NkTv_GkmfeT1l0Uk44w_3_5"></a><a id="Tc_d_QJ6wDm_0aF2wGSqvAMWg_4_0"></a><a id="Tc_TEf3brCFe0ujgY0Ixfz9Xw_4_3"></a><a id="Tc_EYenZ6Q440qoMRqp0PB5BQ_5_0"></a><a id="Tc_PGPWBUA2uke9C_ILn-KLcQ_6_0"></a><a id="Tc_a3w6Q3XWKUW0kRmyYiaFyA_6_2"></a><a id="Tc_KkMeO3oo50C2llmxCpkX7Q_6_5"></a><ix:continuation id="Tb_cXlgIFK6yk-WdQwGV39GaA_cont1" continuedAt="Tb_cXlgIFK6yk-WdQwGV39GaA_cont2"><ix:continuation id="Tb_o7oq46GWxkS4nmDiDVFqBw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that management believes are of high credit quality. Such financial instruments regularly exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="Tb_NCjBZ4-IzUy67mkRgnkaCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_u0Cl5k74aESbgVGabcNSTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March&#160;2017. The letter of credit balance decreased from $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_9rUNAqUsGU-Kz_BLZ_8PsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_gfpFsaJ33EaLN3EsEa1V0Q">0.5</ix:nonFraction> million at December 31, 2020 to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_ZNKaf1RmykO0-f7B2C1WOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_myyjsA30jU2v-2hpNmQRRg">0.2</ix:nonFraction> million at September 30, 2021 pursuant to the terms of the Company&#8217;s May 2017 facility lease. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_20eRDPXjpUur3tCW8MjALQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Condensed Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the condensed consolidated balance sheets.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_vVkI8FbNTEiSzzGOtVI9Cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_f_fgHk_BaEusybSEryd_Ng_3_3">120,542</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gDdfmaIzY0KxznxJVdJUJQ_3_6">83,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_KwGD88gqBUylTpyWHiLHGQ_4_6">10</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_6mHl8IW9VkKQffMIVOJnlg_5_3">225</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_IaFr67ZprU-Aym5G3zuDGw_5_6">450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash reported on condensed consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6PhkmQCx-EKcBfFx2u9kOQ_6_3">120,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__SuzZlWTe0qp5mZVjnuylA_6_6">84,085</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_-8TU5KQl30WaOmiU86FvLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three&#160;months but no longer than 365&#160;days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive gain or loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_LM--ATrW0E2cHQ69vNPqaQ" continuedAt="Tb_LM--ATrW0E2cHQ69vNPqaQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cXlgIFK6yk-WdQwGV39GaA_cont2" continuedAt="Tb_cXlgIFK6yk-WdQwGV39GaA_cont3"><ix:continuation id="Tb_LM--ATrW0E2cHQ69vNPqaQ_cont1" continuedAt="Tb_LM--ATrW0E2cHQ69vNPqaQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than <ix:nonFraction unitRef="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" scale="0" id="Narr_YdsewHt_jU25FqPFsSYpPQ">one</ix:nonFraction> performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cXlgIFK6yk-WdQwGV39GaA_cont3" continuedAt="Tb_cXlgIFK6yk-WdQwGV39GaA_cont4"><ix:continuation id="Tb_LM--ATrW0E2cHQ69vNPqaQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, and that expectation is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt:booleantrue" name="us-gaap:RevenuePracticalExpedientFinancingComponent" id="Narr_cTFywX8oEUSAe5TFh72i-w"><span style="background-color:#ffffff;">financing component</span></ix:nonNumeric><span style="background-color:#ffffff;">. </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_Hq4gh3AB0kOMN7rt6Bln9A" continuedAt="Tb_Hq4gh3AB0kOMN7rt6Bln9A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the condensed consolidated balance sheets and within research and development expense in the condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number of locations of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="0" format="ixt:numdotdecimal" name="ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit" scale="0" id="Narr_NAcZj3J5GUepTD3MdVehgg">25</ix:nonFraction>% U.S. federal income tax credit on qualifying clinical study expenditures.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cXlgIFK6yk-WdQwGV39GaA_cont4" continuedAt="Tb_cXlgIFK6yk-WdQwGV39GaA_cont5"><ix:continuation id="Tb_Hq4gh3AB0kOMN7rt6Bln9A_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" id="Tb_M9jaB3H0j0KosDfzsECjsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Tax Incentive</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_RUQmYM3F3ku4NzFw_8JxVA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria" scale="6" id="Narr_-jNxEr__6UWKzwxEiKHIZA">20.0</ix:nonFraction> million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available.<span style="white-space:pre-wrap;"> </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_qGLOtMd9uEuA1-xDUmxb6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company granted performance share units (&#8220;PSUs&#8221;) to certain executives of the Company. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes compensation expense over the vesting periods of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_U2HSJ8pYWkC0EhasQrk47w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260,<i style="font-style:italic;"> Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible, and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholder&#8217;s Equity for additional information regarding the Exchange Warrants. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_gQ1GL-B0FkuOHb_ky3SLew" continuedAt="Tb_gQ1GL-B0FkuOHb_ky3SLew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company adopted this guidance effective January 1, 2021 and there was no impact on its condensed consolidated financial statements and disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cXlgIFK6yk-WdQwGV39GaA_cont5"><ix:continuation id="Tb_gQ1GL-B0FkuOHb_ky3SLew_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its condensed consolidated financial statements and disclosures.</p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_RlpdSpR8TUWltelwVMnn6g" continuedAt="Tb_RlpdSpR8TUWltelwVMnn6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Note&#160;3. License and Collaboration Agreement</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Agreement Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 27, 2021, the Company entered into an amended and restated License and Collaboration Agreement (&#8220;Restated Agreement&#8221;) with Janssen Biotech, Inc., a Pennsylvania corporation (&#8220;Janssen&#8221;). The Restated Agreement amends and restates the License and Collaboration Agreement, dated May 26, 2017, by and between the Company and Janssen (as amended by the First Amendment thereto, effective May 7, 2019, the &#8220;Original Agreement&#8221;). Janssen is a related party to the Company as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp; Johnson. The Original Agreement became effective on July 13, 2017. Upon the effectiveness of the Original Agreement, the Company received a non-refundable, upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_s96udydX3kChOKXdoymkjg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeAgreementUpfrontPayment" scale="6" id="Narr__o2j4-DZG0O_nGHjeLywVg">50.0</ix:nonFraction> million from Janssen. Upon the effectiveness of the First Amendment, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_rRvBtxUPXUy-HfoqhGT3wg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementEligibleAmountReceived" scale="6" id="Narr_1YHyQcBi_EuJwuvp4WnLSA">25.0</ix:nonFraction> million payment from Janssen in 2019. The Company also received a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_3_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_eY73vDQa7U23JqhEa2BFLA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementEligibleAmountReceived" scale="6" id="Narr_GrK73bypKES6U6ezbM1I1w">5.0</ix:nonFraction> million payment triggered by the successful nomination of a second-generation oral Interleukin (&#8220;IL&#8221;)-23 receptor antagonist development compound (&#8220;second-generation compounds&#8221;) during the first quarter of 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement relates to the development, manufacture and commercialization of oral IL-23 receptor antagonist drug candidates. The candidates currently in development as of the balance sheet date pursuant to the Restated Agreement include PTG-200, PN-232 and PN-235. PTG-200 is an oral IL-23 receptor antagonist in that was in Phase 2a development for the treatment of Crohn&#8217;s disease (&#8220;CD&#8221;). PN-232 and PN-235 are second-generation products currently in Phase 1 studies. Janssen is primarily responsible for the conduct of the PTG-200 Phase 2a trial and the Company is primarily responsible for the conduct of the PN-232 and PN-235 Phase 1 studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restated Agreement, the parties have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">amended development milestones to reflect Janssen&#8217;s expected development of collaboration compounds for multiple indications in the IL-23 pathway;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limited the Company&#8217;s further development and related expense obligations under the Restated Agreement to the PTG-200 Phase 2a study, and the ongoing Phase 1 studies in PN-232 and PN-235; Janssen is responsible for all other future development and related expenses under the Restated Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">concluded the parties&#8217; </span><ix:nonNumeric contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_GjbbJITBaUG01OT1oWNJlw" format="ixt-sec:durwordsen" name="ptgx:DurationOfResearchCollaborationAgreement" id="Narr_2PJ0oInR1EaS51osyZHA7A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> research collaboration, while enabling Janssen to continue conducting additional research through July 2024 on compounds developed pursuant to the Original Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement enables Janssen to develop collaboration compounds for multiple indications. Under the Restated Agreement, Janssen is required to use commercially reasonable efforts to develop at least one collaboration compound for at least two indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s development cost obligations in the Original Agreement for the period following the effective date of the Original Agreement were as follows: (a) up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_6kgROCjubEaK_kfQMy3jkg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_-LQKtp3V4EOPV5DcUX68QA">20.0</ix:nonFraction> million of costs related to up to three Phase 1 studies of second-generation compounds; (b) up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_EKO4dc3A9kW58GT-34PVkA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_i9RJ04OetkWLbiytoWpq1A">20.0</ix:nonFraction> million of costs related to Phase 2a and 2b costs for PTG-200 (i.e., <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_xBi47oQ55EWzPVnVxo6vOg" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_an8aTN2eLEmh9V-URlfwdA">20</ix:nonFraction>% of the first $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__XGvkKYt2kq50PQcaNBpsA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_MfD5FmLFN0aLrOqEvVvOgQ">100.0</ix:nonFraction> million in costs); (c) up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_sxi-lVVXP0eAqntyNRA1rg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_EJqVYKC29EerO7__8haK3A">25.0</ix:nonFraction> million in costs related to up to two Phase 2 studies evaluating second-generation compounds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s continuing development expense obligations under the Restated Agreement are as follows: (a) the Company will continue to fund <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_r2A-BxT7r0GiRUZodoE_Qg" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_6pHbbvdwTEOZ0ManXT25Bw">20</ix:nonFraction>% of the costs related to the Phase 2a study evaluating PTG-200 for the treatment of CD (subject to a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_e1g49FhL7kmfXyQdu4N9Bw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_bbSK_Nc8KkmzyKZBypBSmw">20.0</ix:nonFraction> million cap); (b) the Company is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_vlCXpQQLhUe0YkX2S-ZJvg" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_5vLSmm2EfkuPdYZIiHFWIg">50</ix:nonFraction>% of agreed-upon costs related to the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RlpdSpR8TUWltelwVMnn6g_cont1" continuedAt="Tb_RlpdSpR8TUWltelwVMnn6g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ongoing Phase 1 study evaluating PN-235 incurred through January 4, 2021; (c) the Company is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_ml2M2iwfc0KpJiIzGxvCug" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" scale="-2" id="Narr_qLcOMSVP0UavRERn93T9Gg">100</ix:nonFraction>% of agreed-upon costs related to the ongoing Phase 1 study evaluating PN-232. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s previous development expense obligations under the Original Agreement have been limited or eliminated as follows: (a) the Company&#8217;s previous $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_5LG8Bd8oPkGEzWl62U-nbw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DevelopmentCostsEliminated" scale="6" id="Narr_-0_eytr2uk-bNCz-l2rWkQ">25.0</ix:nonFraction> million obligation for <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_PIZR72h8sUiUXP2iC_lkKw" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" scale="-2" id="Narr_NtRgC3JKckO-WyYOW_8CxA">20</ix:nonFraction>% of costs related to Phase 2 studies for second-generation products has been eliminated; (b) the Company&#8217;s previous $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_f6vGdpv7dkiDKg1sBRHOoA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DevelopmentCostsEliminated" scale="6" id="Narr_q9zfnIbREka4X20aKiP1qg">5.0</ix:nonFraction> million obligation for <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_CXrEby6GiEaljTlG3GLsBA" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" scale="-2" id="Narr_TPSb87H2M0aZMUwSjoQ3sw">50</ix:nonFraction>% of the costs of a potential third Phase 1 study evaluating a second-generation compound has been eliminated; and (c) the Company has no obligation to fund any portion of any Phase 2b or other study evaluating PTG-200 beyond the Phase 2a study in CD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One milestone for second-generation Phase 2 development was reduced from $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_ebVRPtOngkuKafR-yF0DZg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_3tAscp4dp0yBtuH-mGqR_A">50.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_T5go7T86jkGHW8Ogcd55BQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_jMhtwWQ0oUu3M76w6-5siQ">25.0</ix:nonFraction> million in the Restated Agreement; otherwise, t<span style="white-space:pre-wrap;">he various milestone payment amounts in the Restated Agreement remain substantially the same as in the Original Agreement. To reflect parallel development of multiple indications in the IL-23 pathway, milestone payments under the Restated Agreement generally now correspond to the achievement of specified milestones in: (a) any initial indication (rather than CD, as in the Original Agreement); (b) any second indication (rather than ulcerative colitis (&#8220;UC&#8221;), as in the Original Agreement); and (c) any third indication. With respect to second-generation compounds, milestone payments for second and third indications may be triggered by any second-generation compound (i.e., not necessarily the second-generation compound that triggered the initial payment for any indication, or the payment for a second indication).  In addition, the opt-in payments contemplated by the Original Agreement related to the scope of Janssen&#8217;s license rights have been converted into development milestones in the Restated Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upcoming potential development milestones for second-generation compounds include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_zpwdW8FrMU2yPOUewuio1A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:UpcomingPotentialDevelopmentMilestonesPayment" scale="6" id="Narr_OHN1IjEhskesBMCRjLXEnw">7.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for completion of the first Phase 1 clinical trial of a second-generation compound; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_M8yFhIOS4UWfLn0-racdCw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:UpcomingPotentialDevelopmentMilestonesPayment" scale="6" id="Narr_dSAm2-0j_0SrotguI-hNdQ">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseTwoClinicalTrialSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_k7-5iEviVkaUoyPynKb8ag" decimals="-5" format="ixt:numdotdecimal" name="ptgx:UpcomingPotentialDevelopmentMilestonesPayment" scale="6" id="Narr_gUeaTRUuw0OINytgVaROzQ">10.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication (i.e., an indication different than the indication which triggered the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_HNZLcuNLlkC4l1XQ9mRg5Q" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_ro_dzCZpoU6w_QHDUhV-2g">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million milestone described above); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_E3q_5X1xx0W9IH0IDoVYIA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:UpcomingPotentialDevelopmentMilestonesPayment" scale="6" id="Narr_WDXxKezFLk-Gsrhb221aKA">50.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_5wmoKVR2DU2fW1JWG3YE4w" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_1QgjIRnMMUGAZX4k2hC2Vg">15.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for a second indication; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_DR8YsZ1k4EKWFSFZzgo99w" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_76cYwbNhzkWi9H_hGfHrFg">115.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for a Phase 3 clinical trial for a second-generation compound for any indication meeting its primary clinical endpoint.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Development milestones for PTG-200 were unchanged under the Restated Amendment, except that milestone achievement is generally no longer indication-specific. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restated Agreement, the Company remains eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA" decimals="2" format="ixt-sec:numwordsen" name="ptgx:PercentagesRoyaltiesOnNetProductSales" scale="-2" id="Narr_suNkRJTouUamJPvGD-iEhg">ten</ix:nonFraction> percent. The sales milestone payments in the Original Agreement also remain the same in the Restated Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to both the Original and Restated Agreements, payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RlpdSpR8TUWltelwVMnn6g_cont2" continuedAt="Tb_RlpdSpR8TUWltelwVMnn6g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Janssen retains exclusive, worldwide rights to develop and commercialize IL-23 receptor antagonist compounds derived from the research collaboration conducted under the Original Agreement, or Janssen&#8217;s further research under the Restated Agreement. Any further research and development will be conducted by Janssen. The Company will have the right to co-detail (for CD and UC indications) up to two of the IL-23 receptor antagonist compounds under the collaboration in the U.S. market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Restated Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Revenue Recognition</b><span style="font-style:normal;font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement contains a single performance obligation for the development license; Phase 1 development services for PTG-200, PN-232 and PN-235; the Company&#8217;s services associated with Phase 2a development for PTG-200 in CD; the initial year of second-generation compound research services; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200 through Phase 2a and PN-232 and PN-235 through Phase 1. Under the Restated Agreement, development services performed by the Company for PTG-200 beyond Phase 2a and PN-232 and PN-235 beyond Phase 1 are no longer required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the license was not distinct from the revised development services within the context of the agreement because the revised development services did not change the utility of the intellectual property. The Company also concluded that the remaining development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the Restated Agreement of the development license and PTG-200, PN-232 and PN-235 services, including compound supply and other services. Therefore, the Restated Agreement is treated as if it were part of the Original Agreement. The Restated Agreement will be accounted for as if it were a modification of services under the Original Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the Restated Agreement, the Company calculated the adjusted cumulative revenue under the Restated Agreement with primary updates to the transaction price, including the release of and update of prior constraints and fewer remaining services to be provided, resulting in a cumulative adjustment that increased revenue by $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="Narr_Vgq30GA-ukarshgbZ9MDfQ">8.0</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the duration of the Restated Agreement began on the Original Agreement effective date of July 13, 2017 and ends upon the later of the end of Phase 2a for PTG-200 in CD or the completion of a Phase 1 clinical trial for either PN-232 or PN-235.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the effective date of the Restated Agreement consists of future milestone payments and cost sharing payments for agreed upon services offset by development costs reimbursable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract are included in the transaction price at the Company&#8217;s share of the estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen related to agreed-upon services for activities that Janssen performs within the duration of the contract are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The transaction price of the initial performance obligation under the Restated Agreement was $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_H_G4HDOLo0qcDZdPrMyNAA">105.7</ix:nonFraction> million as of September 30, 2021, an increase of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yFhWkhHuuEaQKk7rwr082w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="Narr_eN5lqHXgTEy4h4P1Z0y_iw">9.9</ix:nonFraction> million from the transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__vWz_fmTEUCSA1s4LTbr_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_PyVwCiExo0eDfjRL17IZ9A">95.8</ix:nonFraction> million as of June 30, 2021, under the Original Agreement. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. The transaction price as of September 30, 2021 includes the $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeAgreementUpfrontPayment" scale="6" id="Narr_hJnFcTg430yd8gs88cXCXg">80.0</ix:nonFraction> million of nonrefundable payments received to date, $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_htTtbMn45UOqoFQw4o06MQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ReimbursementForServicesPerformed" scale="6" id="Narr_G5Mk5pcX6kyUM5TX8vcv4A">17.9</ix:nonFraction> million of reimbursement from Janssen for services performed for IL-23 receptor antagonist compound research costs and other services, and estimated variable consideration consisting of a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_QqjayIBfTU2Zb8ZXHEhcpA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_zAEI7g1hQEaqP-arv28xNQ">7.5</ix:nonFraction> million milestone payment subject to </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_RlpdSpR8TUWltelwVMnn6g_cont3" continuedAt="Tb_RlpdSpR8TUWltelwVMnn6g_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">completion of the clinical data collection for Phase 1 activities for PN-235 and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ReimbursementForServicesPerformed" scale="6" id="Narr_fkfm_bk54EOwUk8gVq5nuw">8.4</ix:nonFraction> million of development cost reimbursement receivable from Janssen, partially offset by $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable" scale="6" id="Narr_Y7wyWB0BDEOqaFLr-Zl9fg">8.1</ix:nonFraction> million of net cost reimbursement due to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of September 30, 2021 is not probable. The Company concluded that the variable consideration constraint is appropriately reflected in the estimated transaction price as of September 30, 2021. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation, revenue is recognized as these services are performed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input methods of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_lZeL8hdzf028kJ3_rDwFag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="Narr_-x82PhruRE2cZGG8ke93Xw">8.0</ix:nonFraction> million, and also recorded $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yX6TYuMbYEicxZwbaMBgVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="Narr_Ko0mKjbkyEO9IHaIKAzeBA">2.3</ix:nonFraction> million of license and collaboration revenue following the contract modification for the Restated Agreement. For the three months ended September 30, 2020, the Company recognized license and collaboration revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M3p7YmD9vkCTXzn0pO5cbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_tB1XWuSou0yXv0xkpHvrTQ">12.6</ix:nonFraction> million. In addition, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_562smoZuLkS9KsBvdrpLtw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_j6e5xK5sEEiNtrlz2T4Khw">zero</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_9QJowPauUk-gaWt5sFT-HA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_2In6wRUYqEGkk0zF0ZYl2Q">0.5</ix:nonFraction> million in revenue for the three months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="Narr_HzC5ZcUZE0OGtglpgsVLaw">8.0</ix:nonFraction> million, and also recorded $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_EXzMSWZYJkq4Gd12kF9Hhw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="Narr_eXIzeH5mnUO8_nh3dWeLnQ">9.9</ix:nonFraction> million of license and collaboration revenue following the contract modification for the Restated Agreement. For the nine months ended September 30, 2020, the Company recognized license and collaboration revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_pUE74Zua4EKsvZdbcBx8ZQ">22.0</ix:nonFraction> million. In addition, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_potMVrgeoEGalpEJm2UCjQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr__z1t8dHuF0WYYSSZn24uyA">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_NvuFc-sXQUC2i1aTvziUiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_vbOxLbP0DU2S5OCVtYZ1TQ">1.0</ix:nonFraction> million in revenue for the nine months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d479b914_af87_4ad8_abee_6961fb34ba56"></a><a id="Tc_VedtcK9UEk-teszoaRUm0g_1_2"></a><a id="Tc_CQQGY3dZzUek87M6OjEkEw_1_11"></a><a id="Tc_POVCpY1vRkuibHyupwpw3Q_2_2"></a><a id="Tc_vv5ALRE96Ui_r5lgyTMlgA_2_11"></a><a id="Tc_ZJw-opV6LU-rMwBl7VsRHQ_3_0"></a><a id="Tc_wNMJ1KU_qk27zsd641xqxg_3_2"></a><a id="Tc_DpzN37KX9Uuhh87SeIlV2Q_3_5"></a><a id="Tc_M2-nRZwY7keyUIY4LNXz-Q_3_8"></a><a id="Tc_GpeO2z5ZvkiJqcxHWg6YcA_3_11"></a><a id="Tc_xqHPn_xLgEyQc-jzHvDiag_4_0"></a><a id="Tc_pOFzygaptUipMAPX6FvIYw_5_0"></a><a id="Tc_fAbfj1uARUmmRnKzseee7w_5_2"></a><a id="Tc_cTX6fxiSRkOSSE8gVD7e_A_5_5"></a><a id="Tc_cUmkdbePVk6T7zBxqO9hJw_5_8"></a><a id="Tc_XtlLuHjCIkyA_8F5RuP58g_5_11"></a><a id="Tc_UnwVtkxqCUKshad-f-xFVQ_6_0"></a><a id="Tc_GSniYHQgfEGK7U1ByJVPMg_7_0"></a><a id="Tc_0UGWZN-lYkCPpWdx1x-LOg_7_2"></a><a id="Tc_7D06NIsY20mMIFOgfXzKTA_7_5"></a><a id="Tc_VOfiDdRuZE6Zr7ZLXMf0eQ_7_8"></a><a id="Tc_4QwfZRdqX0m10U-aYZbc6Q_7_11"></a><a id="Tc_57bK_WiEAkKXvEmjPPEusw_8_0"></a><a id="Tc_BkRyFEEvp0aUO9rPPZsocQ_8_2"></a><a id="Tc_VyV7RGXdoUKrvWQlKS77kQ_8_5"></a><a id="Tc_y9VG0_2BK0u0_bdcf5sjfQ_8_8"></a><a id="Tc_dWeih2iRJkaeyA5N-UvYJQ_8_11"></a><a id="Tc_ucKk26Uy4ku7aKom7oUZ6A_11_2"></a><a id="Tc_WmGQlAqmCUS5gAfkef0yFQ_11_11"></a><a id="Tc_ZJTHYNFoBkSTuQ9tUO_Nog_12_2"></a><a id="Tc_LEehYfIn80ucfdWUGiQ4kQ_12_11"></a><a id="Tc_i1vXB0o4OUW8Q8Ytc2-p-g_13_0"></a><a id="Tc_YBtR9GKCUUOoVAFjkVOdtw_13_2"></a><a id="Tc_AECSGTvT2EW8SqBzUCFgbQ_13_5"></a><a id="Tc_-c3nRHZUuUyPMIm6H2HE6A_13_8"></a><a id="Tc_c36AZsIKRkKgBSVJQm_7Jg_13_11"></a><a id="Tc_a6zty26DlEWaGBrHqfZhUg_14_0"></a><a id="Tc_XgCP_VoW4EGlDfM4lLm-PA_15_0"></a><a id="Tc_y4PSWVuCIUC35GmVr-Omdw_15_2"></a><a id="Tc_2yM3PZKn90CHRgpvgIKdUg_15_5"></a><a id="Tc_Dzak-yIWA0Wkso7YaOyrgg_15_8"></a><a id="Tc_rJNbpPcNz0-nHhAUT7DbtA_15_11"></a><a id="Tc_fBp6ZbriSEylqsoOQCrABw_16_0"></a><a id="Tc_nIzDwVwz_kSfMBKEf5rAXw_16_2"></a><a id="Tc_6HaI8pg18Ue69aZbp8TjTA_16_5"></a><a id="Tc_pJeVxw8NK0KACIyCZwgDYQ_16_8"></a><a id="Tc_AGY4jkUJoUWQK41N4Cag7Q_16_11"></a><a id="Tc_STfCkNlGy0agq-oWGpgbuA_16_12"></a><a id="Tc_6OQwnQEGhESxYGRIXYgq7g_17_0"></a><a id="Tc_Mmc3vVno10-QLKWojDb8cg_18_0"></a><a id="Tc_0_yDyo53vkqbqaR7qiEDrA_18_2"></a><a id="Tc_IwdIKwqxn0O8EB-4CSs4iQ_18_5"></a><a id="Tc_2YsgVVxHrEm5OCHs7yE-CA_18_8"></a><a id="Tc_uWCyuq73E0-Duw6Tbz0QSA_18_11"></a><a id="Tc_2JDyJMZ2iE6ATR3lWvw3_g_19_0"></a><a id="Tc_1bNG9ah4-E29GTmUp0sG9A_19_2"></a><a id="Tc_eligiGinNkuURiwWcwgj6w_19_5"></a><a id="Tc_qry5BwK-g0yJtcT5d5tHRw_19_8"></a><a id="Tc_x7lEbK70aUWahzp0RSkFLQ_19_11"></a><ix:continuation id="Tb_RlpdSpR8TUWltelwVMnn6g_cont4"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_F3RFb5HA60OJd6f2l94Plw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables present changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_NvYWA_ruNkqosH-Y8odMWA_5_3">2,426</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetAdditions" scale="3" id="Tc_yrvtl3fX7kGoLX3E-UZ40A_5_6">5,732</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetDeduction" scale="3" id="Tc_vgfyi8kA1UinkQeStlHUeg_5_9">5,520</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_QyKbm0omFU-SGqlLsjygbA_5_12">2,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Im1rUCZcTkqSssDVJ5eaRg_7_3">14,477</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_s4dl53S8iEqg3UQvg1ekhA_7_6">16,715</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityDeduction" scale="3" id="Tc_vpOQsTB3ckuUYnpsLj0uKw_7_9">28,951</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_LAiwT-Me4UqURkpmX5NlZw_7_12">2,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_3a8xYtYCtkW1s79SgjVdMw_8_3">2,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyAdditions" scale="3" id="Tc_r1gYehCDCU-nR5mS9tu1hA_8_6">9,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyDeductions" scale="3" id="Tc_P8RrVn6mDk6eTQFLDENB2A_8_9">11,396</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_3SOJ6Wxov0yr4YwCgVZ4hQ_8_12">1,121</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_WZF4AMPE_k2R5fN89glORQ_15_3">5,955</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetAdditions" scale="3" id="Tc_5he34gmLckW4jVSOwYaVbg_15_6">5,284</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetDeduction" scale="3" id="Tc_VZBNmpiyHUq_L3Odupwbww_15_9">8,450</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_Ex5s1OXZ40yae-Xopc0qDg_15_12">2,789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_sgE9lqDduU6bh81NC5BPww_16_3">800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyAdditions" scale="3" id="Tc_3cxIr_SStUeu3Y7a3o5flg_16_6">342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyDeduction" sign="-" scale="3" id="Tc_dhg-Yds0lEmvBxzJ8tAxBg_16_9">1,142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_H52jvVJRSEiQY_am8-RySg_18_3">41,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_nrRUJmRlRU-CCET2ClnTjQ_18_6">3,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityDeduction" scale="3" id="Tc_nfR_2i41p0miA_TX9VXb_g_18_9">24,153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc__sFh1wyuJE2Hzhw-3nN5OA_18_12">20,877</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_mM8S24zP3USv2y5HRTG05g_19_3">1,262</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyAdditions" scale="3" id="Tc_OiBD93jnoE6In-fQZ6xLIg_19_6">2,114</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyDeductions" scale="3" id="Tc_9stYQxVuLkakQ7S1gofk-g_19_9">1,299</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_Dcto2LKN1UWBvCRGiZ8FQw_19_12">2,077</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="Narr_lwRTe7RU6EO9rN8iKlinog">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="Narr_qkNmOc33_0azBdQ6KrflWg">1.7</ix:nonFraction> million, respectively, from amounts included in the deferred revenue contract liability balance at the beginning of each period. During the three and nine months ended September 30, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="Narr__lLKjKsCX0Kawnq5iZ_3ZQ">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="Narr_pTYf0RWxTkaVOQ_4IhXnCw">11.8</ix:nonFraction> million, respectively, for each period from amounts included in the deferred revenue contract liability balance at the beginning of each period. None of the costs to obtain or fulfill the contract were capitalized.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Rdb5ePYt60GFAvmRiG9zZw" continuedAt="Tb_Rdb5ePYt60GFAvmRiG9zZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;4. Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 1</i>&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 2&#8212;</i>Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 3</i>&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_722d4a56_7ee2_4ad4_b96a_c0308c21b7ab"></a><a id="Tc_ZKPh7D6XJ0SwyP-Q22nusQ_1_2"></a><a id="Tc_TEh8GCP3DESwhpgVGrWQgA_2_2"></a><a id="Tc_15JN5gaTjU6CBvsuYhQdtg_2_5"></a><a id="Tc_RCu_FI_YAEqipiyOE1Rgqw_2_8"></a><a id="Tc_4YjQN6hqYkOHy86dhzkCKA_2_11"></a><a id="Tc_Q4AzTyLmb0-upEKr-G18Nw_3_0"></a><a id="Tc_npfs_ikgSUuyBgh2tm9vwA_4_0"></a><a id="Tc_iDAW_3wapEShs4wL2F7TFA_4_2"></a><a id="Tc_7d1QvW0ALEq7PAYBqv0dUQ_4_5"></a><a id="Tc_VCmEk11Sc024p1N_WFu6YQ_4_6"></a><a id="Tc_WJTo-2-2pUy4Zb1boW90mg_4_8"></a><a id="Tc_DW2se40LmEibMC2BMZhmWQ_4_9"></a><a id="Tc_8DiNRpZ2dUe4_5Kj3MEpxA_4_11"></a><a id="Tc_Ws93s9EkrkC6HkAdvCO3Ag_5_0"></a><a id="Tc_U5wO1xFmXUiAXY9189jVHg_5_3"></a><a id="Tc_huu9YeQii0-uEeujabYlkA_5_9"></a><a id="Tc_HfdgO1DT-UehhQIW6SftTw_6_0"></a><a id="Tc_wjEx0qSSmka6qmX--1QDKg_6_3"></a><a id="Tc_XA9SNSS5lU-KdessBb_aLQ_6_9"></a><a id="Tc_es-PdQmj-Um8UamqJ1lKQQ_7_0"></a><a id="Tc_Rf6a1Sx6lk2nw0UaDM12SA_7_3"></a><a id="Tc_2iD2c0EKWUqUyOHk-GrgSw_7_9"></a><a id="Tc_U14qgeOAN0eyq3isTxrMIg_8_0"></a><a id="Tc_qfMSIo_F7kmOVAgBEt_iBA_8_3"></a><a id="Tc_PWu-ogKWpkWFkrb57AIt_Q_8_9"></a><a id="Tc_hcT6o9YN_02k36yA8v9nTg_9_0"></a><a id="Tc_MIjoU-XFY0-jKvUAPuMlsQ_9_2"></a><a id="Tc_09QmFNhqe0ip6FXSy17fuQ_9_5"></a><a id="Tc_hc7Z7LC2AUSNBmB90pko8g_9_8"></a><a id="Tc_ZUGUrXyuQUaj3hTtASx7dg_9_9"></a><a id="Tc_UewmPr0Z4kqnVsvLzqKmyQ_9_11"></a><a id="_35a8c75e_a0a8_4f84_a843_a443de9efe58"></a><a id="Tc_jLAi9w4PMkaXuQzh6nIWVw_1_2"></a><a id="Tc_040pPDrnX0SEP9TWuvt6SA_2_2"></a><a id="Tc_YiqSl0j0iESE4c9IpeYLYg_2_5"></a><a id="Tc_t_Npfbxnykqccc_HHR0Ydw_2_8"></a><a id="Tc_266XaYMiQEOfbDWSvc8jCg_2_11"></a><a id="Tc_FUuE3zMk1k6hfY1NMVE09Q_3_0"></a><a id="Tc_A06pCE75y0m1fpl14gpjwQ_4_0"></a><a id="Tc_Tg1hlSxxG06Vy_bubr_u-A_4_2"></a><a id="Tc_WZo08OLfUEmApRp497-CqA_4_5"></a><a id="Tc_JUA_S4FE6UmizXMyEqXVdw_4_6"></a><a id="Tc_Sk6C9I7V7kejc5ss32wgCg_4_8"></a><a id="Tc_Sf4M3v8kKEWuspgPr_zfcg_4_9"></a><a id="Tc_KJf15hHNBEGL2uQTxXXE-A_4_11"></a><a id="Tc_h3aUyDPz8kaKawUcex6ATA_5_0"></a><a id="Tc_9dM1jUeeO0u1YIhotYTV2w_5_3"></a><a id="Tc_7RbgzLzwL0OfBTlB4VX4gA_5_9"></a><a id="Tc_k-w51LP8DE-xEs_H1eytBA_6_0"></a><a id="Tc_MQW00Gt9MkGrnDFiw5aeTg_6_3"></a><a id="Tc_MqztYLieVE6IBKmTsif-ew_6_9"></a><a id="Tc_jJ4945FMTUyz78K_pFGREg_7_0"></a><a id="Tc_00cNcWDt20qDbQlsb900jg_7_3"></a><a id="Tc_ItOLBOhfB066R1bDwtLImQ_7_9"></a><a id="Tc_rt5_JhvI6Uup44dHml2-Iw_8_0"></a><a id="Tc_g_Ic9cxILUC2Gq3k9X2tpA_8_2"></a><a id="Tc_x9-HKtwvE0qbY3_kCVRtXQ_8_5"></a><a id="Tc_QWZCL9LR5UWeB9QUXZ5XIA_8_8"></a><a id="Tc_IPPEhfg2yECKv4RaC19SMA_8_9"></a><a id="Tc_a16RdhET90mIKPmvtHCcew_8_11"></a><ix:continuation id="Tb_Rdb5ePYt60GFAvmRiG9zZw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_g8pKDMSodkOa7mntJuGjsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_xC4RqMR0Q0KyABMRO1X4UA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_YhlC6OtEY0iAjRZlSKi_jg_4_3">57,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_RyDegFl_A06Zzlx5SUabIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ibMOpVE3cEqcfvwopPnxrw_4_12">57,077</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_gec9OfdVA0-QavCdRuU7ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4rv_Kg5pYku0WkSF7031CQ_5_6">161,312</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_Jby6BCZwZEmx5lkgaQcFoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_KfQhJGdOL0iVu-yUJJevEg_5_12">161,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_DkFNZeRNm0ydJRjGjJnj3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_l7Cd_m_jXEi0qj4X4ny4Zg_6_6">81,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_gJztAK_pJkSEMdZvVKmVEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc__-xKdlvTl0yzMsIRQTO2eA_6_12">81,392</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_b77QUVVp-EabKEv4WpeA6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_luD1ot8Er0Caid8fcRuvuw_7_6">42,187</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_Yd94PRDSaEyHbItBmTnC2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ZOeexGnq1EK9o5tIkPP6dA_7_12">42,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_quwzsXAt80GJsdttydqn8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_HpHqikTxE0qR9cLwSy_iGQ_8_6">6,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember__UavJt8cZ0e-l_KQU4eymg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_bAsP3U3Yjkqdwge7qhYjYA_8_12">6,028</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-jIggHYH1UmbKLFheHzbgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_9W3j1GRgUU-hds78VO4HYA_9_3">57,077</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6QBcAGRDREGf4rn_KPZpcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-hSYeRXDtUmu0l8VPlfT4A_9_6">290,919</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_2qloWJvvrki-oGWKTu7mdQ_9_12">347,996</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_GTf2MVxlEEGBedzfKpF1Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_trr4E79dD02wTj0fyTFizw_4_3">27,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_qZvf9xKSG0OZSn-Pah-mXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_SDfFN6fscES_wNaPIWpKwg_4_12">27,481</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_8Myl1B2k-kSOnAjEMsdY-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_AIAEVAFA1EaUXeBSXo26fg_5_6">65,863</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_W-JTrmc1iUqyssBi9jfgmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ZCGFffV6P0683QquPNHG-g_5_12">65,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZdtE_xThKkSdI-Vaaceeog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_C1Z4PM8Aa0SS-xVrTQxnBg_6_6">27,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_7TCHAu-iM0K20R1_6ZSBeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_cckGQoGLpkqbExr2XmxUnw_6_12">27,590</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_R2T0FeSCkU-4AuqwK_udIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_CKhGzjG9wUGMUdHbv0Ht8Q_7_6">183,210</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_0Hh9M4XK4UiFA8GLjbeoAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_4MBMpAg7J0qdToz4lCIw-g_7_12">183,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fUK5OnhlFU66Xq1kj7KKrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_C7z2OXOwTUyI20sHyzHjhQ_8_3">27,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OKk9lwDz4EGN0BwH0atvlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Cs4ei-zr4U2ebbMwTi_t8Q_8_6">276,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_mBhTXxceV02MtGdxdWbrGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_tAP-qgdCZEyjzKiNagYLkA_8_12">304,144</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s commercial paper, U.S. Treasury and agency securities, corporate debt securities, U.S. Treasury and agency securities, including U.S. Treasury bills, and supranational and sovereign government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </p></ix:continuation><a id="_786bf314_c708_4682_bf10_82594d792afe"></a><a id="Tc_cTB1d2UHfEmp5B8PuBVGPw_1_2"></a><a id="Tc_ObbHH99XGES621yTjGkpzw_2_2"></a><a id="Tc_ID30BR8O10entYbTTVFFmA_2_5"></a><a id="Tc_Zp3UsHszHk6CrFWG5m9AZw_3_2"></a><a id="Tc_i8ivlTlMX0qxj2NuMY5OHw_3_5"></a><a id="Tc_GXwJpA7W2ESPLYbtV1aRlQ_3_8"></a><a id="Tc_bmWVcNguY0awV1HPhClHmg_3_11"></a><a id="Tc_DbsJV_hXOkCIs3uV7le-VA_4_0"></a><a id="Tc__nnGSn4aikirAO16DPCoMw_4_2"></a><a id="Tc_b5s7vAJ3Y0qoEA052ZpeyA_4_5"></a><a id="Tc_k9E9piANi0qCjvSVFoxNdg_4_6"></a><a id="Tc_2b6tIKpoL0iNpF_67Qg65w_4_8"></a><a id="Tc_GbiIcR6l-UCglA3xA2v0xw_4_9"></a><a id="Tc_kYCYF_Vuv0qVZT_Hs4BsuQ_4_11"></a><a id="Tc_V01LNrDh6EK5qQRgVJw1JQ_5_0"></a><a id="Tc_mcUNe3ZHX0ai_Ou6SiahlQ_6_0"></a><a id="Tc_Ha56FNSlS0e0juxwP2aS5w_7_0"></a><a id="Tc_ceMoOJSpW0imLi2ivkX0fQ_8_0"></a><a id="Tc_2_6ZoBo5mkW947wcYvlF7A_8_6"></a><a id="Tc_mbL7oVJfIUuxHQEpOkmm_g_8_9"></a><a id="Tc_TxEU5aIVQEWpGN-aJKWD8A_9_0"></a><a id="Tc_2_Slvg8QB0OJ5FzN9X-hLQ_9_2"></a><a id="Tc_kQ-FKlxtz02cN5XFwEWWag_9_5"></a><a id="Tc_LCfRtchjzU-XAB22Ogxvzg_9_8"></a><a id="Tc_u9QjF8nTfEqp7VzDhDsFlQ_9_11"></a><a id="Tc_Mx6LgxPxKUa8DJl_jyQzmg_10_0"></a><a id="Tc_8RlmFrxHE0utWvgQtufglA_11_0"></a><a id="Tc_M1ODwCOmfUOUv7JDa6S4Tw_11_11"></a><a id="Tc_kSMPGgwUZ0-QzZgAV5iJBQ_12_0"></a><a id="Tc_L5fOHiOzVUCiuMTfgRPvLg_13_0"></a><a id="Tc_zBDqkK9dUUOxyCDHUKFufw_14_0"></a><a id="Tc_iOPYXqkZ3E2wG_aTrRiz_g_14_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_jdE8I8YgC0634dC19iboZw" continuedAt="Tb_jdE8I8YgC0634dC19iboZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 5. Cash Equivalents and Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:MarketableSecuritiesTextBlock" id="Tb_RPcUBFwLYkCLp4tbKpLBow" continuedAt="Tb_RPcUBFwLYkCLp4tbKpLBow_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_VD9UQ_OiCE6_WRK8A7mLLg_4_3">57,077</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_0ezqK4upIkGBLJEfwaopCQ_4_12">57,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_4n-VPyhvF0CF48BSB5Oy2Q_5_3">161,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_3F5lg37slEWGbwjavskCUg_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_ts856BjxfU6re4yWtUBSVg_5_9">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_AKzpqLJ2P02arAoG2xim2A_5_12">161,312</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_qjbcNCBk3Uu7VoRuBBLrSQ_6_3">81,413</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_YFRoXpiOG0O54l_lYFjQWA_6_6">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_1RQ-VxoiTUGFVW64sud23w_6_9">22</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_mzUF8u8jREuNOAlEEa9M0w_6_12">81,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_AGHzcjYih0uj1014pOZ7sg_7_3">42,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_pwyjyYPwQEObvMBHPN0qcA_7_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_wQ7HKLkjnUq5otVTkyJaoA_7_9">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_Pw6OeXA0Ek-ooULTgJ_YXQ_7_12">42,187</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_pM4Wx3ORi0mu0i6RKYEpKg_8_3">6,028</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_BG8c373S9kSpjt-2CSHFXA_8_12">6,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_Pijo4i4zPkyGwmdFy4tWCw_9_3">348,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_GHabeJpEv0ajjwhlgKy-sQ_9_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_KfasBluXDkyE0i1fhR2Bdw_9_9">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_FcEcI2T1wkqm_OhQN6zVMg_9_12">347,996</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_Ofu0oIliiEW34aeJIRaDlA_11_12">116,068</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_ehT_oElk7kmVkfqDPXjyGg_12_12">193,759</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_RDL0vwiKwEuG6o48lLN7Hg_13_12">38,169</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_ugm6GrC3F0C24zbvEHBASw_14_12">347,996</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d87d11e8_2f12_4e1b_ad50_e374d9cece72"></a><a id="Tc_6sAZWS-0kU2zg9Cc9CRG2Q_1_2"></a><a id="Tc_9tuXu6PEtEyTVUAgnOFxmw_2_2"></a><a id="Tc_8BN1KiOt5UeHjgDq6FwZRA_2_5"></a><a id="Tc_QjZO2xGwqUivoCrKAd1bew_3_2"></a><a id="Tc_wicdPKhvmkmdjHWc3NDqVg_3_5"></a><a id="Tc_tVKLdsYQPEGU8WYBOvdBiw_3_8"></a><a id="Tc_PW9h48Zxkku5U1_7oJsrrA_3_11"></a><a id="Tc_p3K63tAfQEShKBdU8uxNnw_4_0"></a><a id="Tc_SCaP7Cs_SU-rGgVjR3CLew_4_2"></a><a id="Tc_18angW027kWywX6da7TI0g_4_5"></a><a id="Tc_WWq958jtVkiqW2STvFLLCQ_4_6"></a><a id="Tc_ZXC2YvEz5ECDGUb6txn4uQ_4_8"></a><a id="Tc_GdR2wGLkzUSAm8BEbAdPiw_4_9"></a><a id="Tc_QxbP5vFv9kOZBRP08I_BCw_4_11"></a><a id="Tc_gBTuPgbzi0-r85JLUNO5qQ_5_0"></a><a id="Tc_WX16ERM2PUSvSFjeTVfnDw_5_6"></a><a id="Tc_RsTfSOFWRUWvbUKPY8Gz_w_6_0"></a><a id="Tc_XdPVFwmmaEmjWtT2Llk-sA_7_0"></a><a id="Tc_fPOq8viYlEGDZ0UTzoZhxQ_8_0"></a><a id="Tc_9UWn4WCfmE25dSKohWIkmQ_8_2"></a><a id="Tc__3BN0Zd6lEyb3fFaBAF5UQ_8_5"></a><a id="Tc_d39Ju4Rb_k2996JSjM_g9A_8_8"></a><a id="Tc_3EvuuxRFK0OIk-Ljwhke3A_8_11"></a><a id="Tc_WW7KlqD7HE6o632fQP9luQ_9_0"></a><a id="Tc_rRAYvPgJIEuYgcX9Xg1PBA_10_0"></a><a id="Tc_rM0yAVBiv0WjZ4Ufhe-9_g_10_11"></a><a id="Tc_oLbPIdts0UyarCV-IjaRXA_11_0"></a><a id="Tc_kw_03azJdUqoz-81LL4SHA_12_0"></a><a id="Tc_RedR8UoaZEOSc9KuPjyYQg_13_0"></a><a id="Tc_OdSUIhnvpEik1tUT91e2vw_13_11"></a><ix:continuation id="Tb_jdE8I8YgC0634dC19iboZw_cont1"><ix:continuation id="Tb_RPcUBFwLYkCLp4tbKpLBow_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_js-E9DgxEk6mIidCRo9wrw_4_3">27,481</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_Y76P8gf74kerg6hRweq7pw_4_12">27,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_ZMUG0RmyiU2BJK22lRaWzA_5_3">65,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_yqoh8_1vQEeiMCRLaxdiQg_5_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_DWrtu37snECueM5tESufOA_5_12">65,863</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_zCBDtEJAsUibZdraX51acA_6_3">27,592</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_Y3UR7mpyqUm0H86QfBEv8Q_6_6">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_7_XwefbnfUy13b2yQpWQoA_6_9">4</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_tNgGRNWcUEuHJ7IHWH7Cig_6_12">27,590</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_O3RH-oUn8E-tNZ8fUBvGUQ_7_3">183,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_ScMIvEHpCkare4r6K3hduA_7_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_d2mBs6ebbEuG3_9Z4U9Pvg_7_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_OM0XrzneEUiYiy_sGzQ1Xg_7_12">183,210</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_WZ4bwMmqTkCzkpGU_T1dcw_8_3">304,142</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_OxCKUsAAhE-s_DH-GnXl2Q_8_6">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_oWevcwERvEeVfCRKy3hZrA_8_9">10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_SKuyCVh2T0KJds6f8olkrg_8_12">304,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_YwWHMFcCuU6hO2_F0_n_fQ_10_12">113,693</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_yqEE_EiBtESsdbOx4k0jDw_11_12">188,451</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_XwPIp6gvZkqwFkmtNYKoKA_12_12">2,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_0vugfEuFoEatWoZZDf_zFA_13_12">304,144</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Marketable securities &#8211; current of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="Narr_9lVein4g1EeJva4jyi7XTg">193.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="Narr_iREWWlwer0qBVTF08994IA">188.5</ix:nonFraction> million held at September 30, 2021 and December&#160;31, 2020, respectively, had contractual maturities of less than <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:durwordsen" name="ptgx:CurrentContractualMaturitiesMaximumPeriod" id="Narr_ilfoLTzRtkexvS9m67khZg"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" format="ixt-sec:durwordsen" name="ptgx:CurrentContractualMaturitiesMaximumPeriod" id="Narr_ngduljyBR0Gdmcq_vYjUeQ"><span style="white-space:pre-wrap;">one&#160;year</span></ix:nonNumeric></ix:nonNumeric><span style="white-space:pre-wrap;">. Marketable securities &#8211; noncurrent of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="Narr_1GijMXh6NkyHXntolPawHA">38.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="Narr_wwtCBwW13k6Rnl4NsIgaTg">2.0</ix:nonFraction> million held at September 30, 2021 and December 31, 2020 had contractual maturities of at least </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMinimumPeriod" id="Narr_MymoDp1qAkag2Jl6OPoZ_g"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMinimumPeriod" id="Narr__jpVzh6WDUGeeOpye67duA"><span style="white-space:pre-wrap;">one year</span></ix:nonNumeric></ix:nonNumeric><span style="white-space:pre-wrap;"> but less than </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMaximumPeriod" id="Narr_B_KVQMctHE-B3-iks0761A"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMaximumPeriod" id="Narr_ndo2WzZmY0ChqQIU8UXuRg"><span style="white-space:pre-wrap;">two years</span></ix:nonNumeric></ix:nonNumeric><span style="white-space:pre-wrap;">. The Company does not intend to sell its securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell its securities before recovery of their amortized cost basis, which may be at maturity. There were no realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_6c369269_c84e_4a0a_b8a2_f6aad96004e4"></a><a id="Tc_kF0suBFZe0qVKsF8c7Ry3A_1_2"></a><a id="Tc_7DuTzX1ov0WXq9A-z4Xmtw_1_5"></a><a id="Tc_SteDMPz9d0-DsVis0dhrlg_2_2"></a><a id="Tc_KmXCzwiJ2Eeg_rIb43EAbg_2_5"></a><a id="Tc_rQ4nk40IF0WRFrYfmNY5TA_3_0"></a><a id="Tc_DY3lQY2BqkyX3ALj-CnNNA_3_2"></a><a id="Tc_kq_2NgWDkEOzW8linWMlTg_3_5"></a><a id="Tc_SY0vaFq_aUeDvf0bGYIi9A_4_0"></a><a id="Tc_wWR3qTuIIUSaUNctG8YoKg_5_0"></a><a id="Tc_2krd8kkUmEKHPci9nyMvfw_6_0"></a><a id="Tc_jDwezL-11U6Wksu7dCPfig_6_6"></a><a id="Tc_-__37um0dkKVFR4uk4gdJg_7_0"></a><a id="Tc_ksv1PwnTVUm28Xt2ilmuoQ_8_0"></a><a id="Tc_gDABmZJBdECLITNqeKGLAg_8_2"></a><a id="Tc_x0ZwS1k-Ik6eoOHtFHIc6A_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" id="Tb_5X1MlmgcGkKPHdPXw6mjgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;6. </b></span>Accrued Expenses and Other Payables</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_SJwOZ5S3bkya93MhN3skhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent" scale="3" id="Tc_PFfMM4xWG0yz64Jkc_zIYQ_3_3">24,482</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent" scale="3" id="Tc_8u6Nj-zU5ESAdWieTtzc0w_3_6">11,335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_pHZ80JZMdEqdsIeAP-2a7A_4_3">4,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_g6089Ohd3E-0tnoH0qVm9Q_4_6">6,413</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_hV6WYAUZtke_a6ksX1PSkQ_5_3">1,566</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_MjbSc7mfG0GcysrsLFX6kQ_5_6">668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued collaboration payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AccruedMilestonePaymentToFormerCollaborationPartner" scale="3" id="Tc_3uFdkK3740O1ftfJx1Wm5Q_6_3">1,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_E5SJac7Uc0GdqsH-0Zx7Ew_7_3">791</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_4Ye1YLRhpUeF7p2FhN3z_g_7_6">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_3q8ord31zUCKvvJAsQEqfg_8_3">33,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_pxxkHp5DJUCcgGoqnIVsTA_8_6">18,498</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_hXcVH0xyAkOh2e0PxEA0bA" continuedAt="Tb_hXcVH0xyAkOh2e0PxEA0bA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and Zealand Pharma A/S (&#8220;Zealand&#8221;) entered into a collaboration agreement in June 2012. In October 2013, Zealand abandoned the collaboration, and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#8217;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company previously determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made <ix:nonFraction unitRef="Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w" contextRef="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw" decimals="0" format="ixt-sec:numwordsen" name="ptgx:NumberOfDevelopmentMilestonePayments" scale="0" id="Narr_v3G_CQQNwUaSYMzcvepNoA">three</ix:nonFraction> development milestone payments for an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr_gjhOPfdlSUGaQ8exq6jG2A">1.0</ix:nonFraction> million under the agreement. However, upon reevaluation, the Company concluded in 2019 that rusfertide is not a compound requiring post-termination payments under the agreement and initiated an </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hXcVH0xyAkOh2e0PxEA0bA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">arbitration proceeding in January 2020. On August 4, 2021, the Company and Zealand agreed to resolve the dispute and entered into an Arbitration Resolution Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 11. Commitments and Contingencies &#8211; Legal Proceedings for additional information on the results of arbitration proceedings related to this research and collaboration agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr__mK4c4pVG0-XaXKZM_4sSA"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr_poQAIBlfWEqoSqKH5tonig">4.0</ix:nonFraction></ix:nonFraction> million in research and development expense was recorded under the agreement for the three and nine months ended September 30, 2021. <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-5" format="ixt-sec:numwordsen" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr_lU4m-STxWk-396EV7zAhRg"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-5" format="ixt-sec:numwordsen" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr_uyrKPBy1Uk6Jguqn8Gtfdw">No</ix:nonFraction></ix:nonFraction> research and development expense was recorded under the Zealand collaboration agreement for the three and nine months ended September 2020. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="ptgx:GovernmentProgramsDisclosureTextBlock" id="Tb_b2f98-sC902tbhLH7M8AjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8. Government Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Tax Incentive</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2021, the Company recognized AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_idl2biIFfkKt8Igq3UiAMQ">0.6</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_FKCSrWytdEa262v1X46TSQ">0.5</ix:nonFraction> million) and AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_BpRQs8x6YkCCSSg0oz--EA">2.9</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_s3nBFRKafUOvuOns33cxlQ">2.2</ix:nonFraction> million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the three and nine months ended September 30, 2020, the Company recognized AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_COB_IPiB-US8U8_cvNzsNw">0.4</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_2tMAZ07W60W61AMsXkv96A">0.3</ix:nonFraction> million) and AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_GZAA8KjmaE29xIPWFXlUiw">0.8</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_0Wq-2G1ePUyrLjB3Hal2lw">0.5</ix:nonFraction> million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. As of September 30, 2021 and December 31, 2020, the research and development cash tax incentive receivable was AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_X0RhiD3AwEOo9O-0DmPtbQ">2.6</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_dyYdTCq_gkS3U2y7e0IFqw">1.9</ix:nonFraction> million) and AUD <ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_40U4NDySeEGB5uKOgNBnUA">1.4</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_gJ-Q8C6FAEWrJYn4YYcnCw">1.1</ix:nonFraction> million), respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received SBIR grants from the National Institutes of Health (&#8220;NIH&#8221;) in support of research aimed at its product candidates. The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_fHticHz3nEOKl7dkY7LJ5A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_qZaZgsN23kSmouoJqLzt3g">0.1</ix:nonFraction> million as a reduction of research and development expenses for the nine months ended September 30, 2021. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_aGR3Nn_0oUCmeAgOesXdXA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_Hvrkl6qUj0q1IGpy4EzDmw">0.3</ix:nonFraction> million as a reduction of research and development expenses for the nine months ended September 30, 2020. <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_W5_EmxclnkqveI5CjIX6wQ" decimals="-5" format="ixt-sec:numwordsen" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_uLZtdj_Tj0yYoYX5fZwknw"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_OrLsItNoVUWmXfX_oVcZTA" decimals="-5" format="ixt-sec:numwordsen" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_ZtpJFpB5oUqSmo-763PAMQ">No</ix:nonFraction></ix:nonFraction> such amounts were recorded during the three months ended September 30, 2021 and 2020. The Company records a receivable to reflect the eligible costs incurred under the grants that are contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the condensed consolidated balance sheets. There was <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_NLWK1h6eUUCL1SCn1CQ7wg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GrantsReceivable" scale="6" id="Narr_CKAte0wUlEiE8co6dZP7Ew"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_82q0nTVsSUC8bXZMRz6aLA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GrantsReceivable" scale="6" id="Narr___mAcEHxk0qBeUa7IuEw4g">no</ix:nonFraction></ix:nonFraction> such receivable as of September 30, 2021 or December 31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_jN3h5rGTo0-7CCQ1qKC71Q" continuedAt="Tb_jN3h5rGTo0-7CCQ1qKC71Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 9.   Term Loan Facility </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#8220;Closing Date&#8221;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#8220;Agent&#8221;) (such agreement, the &#8220;Term Loan Credit Agreement&#8221;), which provided for a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_b65_5Ylza0ihVIeuPpG-fQ">50.0</ix:nonFraction> million term loan facility. The Term Loan Credit Agreement provided for (i) on the Closing Date, $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_fibjtOdW0U-xqYczxkBtgw">10.0</ix:nonFraction> million aggregate principal amount of term loans, (ii) at the Company&#8217;s option, until December 31, 2020, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentTrancheInstallmentAmount" scale="6" id="Narr_68HeQQ-jaEqpoPfuFZn2gA">20.0</ix:nonFraction> million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#8217;s option, until September 30, 2021, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentTrancheInstallmentAmount" scale="6" id="Narr_CO1KBosHwE-uH2kRDaBYQw">20.0</ix:nonFraction> million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#8220;Term Loans&#8221;). The Company used proceeds from drawdowns on the Term Loans for general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Term Loans were subject to an origination fee of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentLoanOriginationFeePercentage" scale="-2" id="Narr_mwVXfzm0P0OvvplhTNz5Ww">0.25</ix:nonFraction>% for each funded tranche under the Term Loan Credit Agreement and bore interest at an annual rate based on prime rate plus <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_zhExiO0jPk60lu-YQkVFRg">2.91</ix:nonFraction>%, subject to a prime rate floor of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentFloorRate" scale="-2" id="Narr_k1zrrl0QcUqUuwyMXcna2g">4.94</ix:nonFraction>%. At the Company&#8217;s option, the Company could prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_y3q_xyeqpEq7Mcn87B_l1w" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_Lqm8EYzlC0qPzhtwo3wk9Q">3.0</ix:nonFraction>% of any amount prepaid if the prepayment occurred through and including the first anniversary of the Closing Date, <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_df9Ci-g-EECi012fGqcB-A" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_9HA-xZGZnUadqleb0Io9Wg">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurred after the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jN3h5rGTo0-7CCQ1qKC71Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">first anniversary of the closing date through and including the second anniversary of the closing date, and <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_8VDg-9H-LkmeiUYsHBLxHQ" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_gcX-C30mF0uUBMuHkjcQwA">1.0</ix:nonFraction>% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" scale="-2" id="Narr_Ka_Eu01j-UuuUQvZWjgPDQ">2.85</ix:nonFraction>% of the amount of Term Loans advanced by the Lenders was due upon prepayment or repayment of the Term Loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Term Loan Credit Agreement required the Company to maintain cash and cash equivalents of at least <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw" decimals="2" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" scale="-2" id="Narr_ZB1aH9fyHE-lB5qPYTHLkQ">35</ix:nonFraction>% of the outstanding Term Loans at all times and was secured by a perfected security interest in all of the Company&#39;s assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contained other covenants that limit the Company&#8217;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balance above a certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants would result in default for the Company. The Term Loan Credit Agreement included a clause which allowed lenders to accelerate repayment upon the occurrence of certain events of default. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company prepaid the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_ClpTux2il0Ccz2NiV5wrtA">10.0</ix:nonFraction> million balance on the term loan as well as $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="Narr_zqpIb6znwUyXAs9CVKNcDA">0.6</ix:nonFraction> million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $<ix:nonFraction unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="Narr_4UoObvMOQ0qCPLwc0UjSXA">0.1</ix:nonFraction> million related to capitalized and unamortized debt issuance costs, which is included as part of the $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_oOcvu1HZSEWu0eprAr7nEQ">0.6</ix:nonFraction> million loss on early repayment of debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company executed a payoff letter to release all obligations under the Term Loan Credit Agreement. As a result, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_O2mng1-tskSGO5KBeSuZsw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="Narr_OsvwrJPuWUW0E5Rq3MGpDg">no</ix:nonFraction> outstanding balance and no obligations related to the Term Loan Credit Agreement as of September 30, 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_-UnjUVwmXEac2BPjFIC_wA" continuedAt="Tb_-UnjUVwmXEac2BPjFIC_wA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 842, to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company has elected to account for each separate lease component and non-lease components as one single component for all lease assets. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_lease_l-KtIo8rkUevq1Vg6RPLug" contextRef="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_nJ2YdyBimE6P9t5VGQxkZA" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfOperatingLeaseAgreement" scale="0" id="Narr_moBfgBhRK0WoYR3opo4dqA">one</ix:nonFraction> operating lease agreement entered into in March 2017 for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A" contextRef="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_nCt9QlWrikuA6Q7uB9hZSg">42,900</ix:nonFraction> square feet of laboratory and office space located in Newark, California. The Company provided the landlord with a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_Ju9kWTVDMUqHTTnNsSW0UA">450,000</ix:nonFraction> letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. The security deposit for the lease was later reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_3_31_2021_srt_StatementGeographicalAxis_stpr_CA_Ujq4sL4CxEW0D5YwkaKV3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_jkccl0IKOECLwxF5O7Z8fA">225,000</ix:nonFraction> in March 2021. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 2, 2021, the Company entered into an amendment (the &#8220;Second Amendment&#8221;) to its facility lease agreement dated as of March 2017, as amended, to lease approximately <ix:nonFraction unitRef="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A" contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_VUa-HqF78UuLY1H22wJtbw">15,000</ix:nonFraction> square feet of additional office space in Newark, California. The Company commenced operations in the additional space in September 2021. Under the Second Amendment, the Company will pay additional base rent of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_HCY5n-DdJUmr8db9V7rBYA">1.5</ix:nonFraction> million over the lease term, which expires in May 2024. As a result of this amendment, the Company recorded an additional right-of-use asset and the related <span style="-sec-ix-hidden:Hidden_W9bIUIMLtUuXqk-5ssyS9Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">liability</span></span><span style="white-space:pre-wrap;"> of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_C8raKfwT7ECsix3Muf5CyQ">1.4</ix:nonFraction> million as of September 30, 2021. The Company will be responsible for its proportional share of operating expenses and tax obligations. <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA" decimals="-5" format="ixt-sec:numwordsen" name="ptgx:AdditionalSecurityDeposit" scale="6" id="Narr_cTwXinh98Umu_JUA75hVXw">No</ix:nonFraction> additional security deposit was required pursuant to the Second Amendment.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Y48ogRYK1UuGKaWpSBQOsQ_1_2"></a><a id="Tc_ooltrks6lkmhTFpDplae4w_1_5"></a><a id="Tc_PynUiELRYECxoSlhbpCjjQ_2_0"></a><a id="Tc_MbsKccdAEUOsQq0TlCknkw_2_2"></a><a id="Tc_tYw3Pg1HXUOlKqe8BNSI8g_2_5"></a><a id="Tc_0wzZUak7e0e3CMcLeBrZQA_3_2"></a><a id="Tc_XmAodps9Hk-RlW7vzkoWgw_3_5"></a><a id="Tc_F6EhZAxCTEWIQ883ANvOCw_5_2"></a><a id="Tc_l4riDi4nPk2zSAIjkZ6Y5A_5_5"></a><a id="Tc_ouiv9FOiHUmS_oSBRFrSKA_7_2"></a><a id="Tc_J2ZpTL4j90qyH6eUeKKsOQ_7_5"></a><a id="Tc_0wSNgbe7s0G5x3szY30N_Q_9_0"></a><a id="Tc_6CebCBq78kGn3zaBIrHDZQ_10_0"></a><a id="Tc_9CT8R3Vg3k60-qSS74_rEw_1_2"></a><a id="Tc_ODDRtWJUkEWh-EMx-Fw5QA_2_2"></a><a id="Tc_dl12fRcMo0qBamSZ8eM2pg_2_5"></a><a id="Tc_DcOWzw-nEEuAoPl4A_Myww_3_0"></a><a id="Tc_a4dMFpdomkKMURB3CPdHng_3_2"></a><a id="Tc_dCP39ghoZU28QWKY3vULJQ_3_5"></a><a id="Tc_iWoOFJNGIE-L1U8kspkNEA_4_0"></a><a id="Tc_nz7TSC0m6k6kB_mTXvCqVA_5_0"></a><a id="Tc_9nLCHgIqvkWX5fmy7H_BEA_5_2"></a><a id="Tc_OEpS43tELUqiYmLqbolSTg_5_5"></a><a id="Tc_ARclCNVwS0OnoA7PyltR3Q_1_2"></a><a id="Tc_hhTej30fPECUj7z5bmISyQ_2_2"></a><a id="Tc_oqpiAO9xJkCu_fjghMhrqw_2_5"></a><a id="Tc_t9iPQvtz90CUWE5cTXOxrQ_4_0"></a><a id="Tc_OR7L0sL-lEy4b2QrncihPQ_4_2"></a><a id="Tc_YiPceDqfNk-_i-jfb6sjIg_4_5"></a><a id="Tc_nqJBVoJ0zUSlxtdBe4BzTw_5_0"></a><a id="Tc_RFcZ390v8kqhCDLVapPLsg_5_2"></a><a id="Tc_KeK4Baezbk6gSwLdMBTVuQ_5_5"></a><a id="Tc_cBRb8KE0g0eyzIIyS3Toyg_5_6"></a><a id="Tc_J7ZW0x9jlkaGOQ9yHp9N7A_1_0"></a><a id="Tc_sUsiZTKqtEWfDWABIUBGUg_1_2"></a><a id="Tc_bRtKx7JeJk-AzT77_0CD_g_2_0"></a><a id="Tc_sZ8QgBC7M0CyT54JJPZbsw_2_2"></a><a id="Tc_FNljrj6t8UCsv1wsxvMTnA_3_0"></a><a id="Tc_1tGKxpsjp0yiqBnBJhAD6A_4_0"></a><a id="Tc_ZH-t7NaqW0SI4eNU5MdgRg_5_0"></a><a id="Tc_yzSFiZard0K75SJkmgl9uQ_6_0"></a><a id="Tc_MdumqHTKYkiZQpsyBv3NTw_6_3"></a><a id="Tc_5944HZH51kiDSoPHq-lJpw_7_0"></a><a id="Tc_7bKZX6N-9kGpQpvCGj6zSA_7_3"></a><a id="Tc_0k89-ndBgUGS7_uGeJmwDg_8_0"></a><a id="Tc_qKVgOtil_UiAwoCbutXabQ_9_0"></a><a id="Tc_v_fqmuwvAkG_qMprGIsnfw_10_0"></a><a id="Tc_659iLUwqJkq8hw-ovIQsZg_10_2"></a><ix:continuation id="Tb_-UnjUVwmXEac2BPjFIC_wA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides balance sheet information related to operating leases is as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="ptgx:LeaseBalanceSheetDisclosureTableTextBlock" id="Tb_yYjQgigMfUuG-Fa3wsWT8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_If59OPpEK02lxvyiRk3sOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_oHNXLhD2mEOWChFQaei_zQ_3_3">5,371</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_nDiACAvtr0a5_iF46_D5WA_3_6">4,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VdeOmiqn-EmGbvHLuN1aAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_jzPvgv-ZckC8BiYpZi-vrA_5_3">2,027</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_SqXTTKX23E28Iq_dJqdUCg_5_6">1,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_K67XINXtckW2yeWVvsxsDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ddrERsoL9kOd-P_sGX_-hw_6_3">4,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Qz1NU_ora0eqKpc4wjMmwA_6_6">4,500</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b6WSSFcN8kyrZANs0pC1gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_sm3VenmD0UeFG4osxtEcCQ_7_3">6,265</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_MWzvVibD-06CcyTif7OFnA_7_6">5,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_jGJkY5y9tky5Cy_54bEv2w_9_3">2.7</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_1nP5USJs7kK51sUuBnbMjA_9_6"> 3.4</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_SJqbWpMDMUC1LPMRbiQV2Q_10_3">9.6</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_GifiPv0HpEyEp_lheXw_ig_10_6">11.0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Other information related to the Company&#8217;s operating leases is as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:LeaseCostTableTextBlock" id="Tb_LhztC8oTxECON7MAqQMIRQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_5qKGxVmzrUu4mBviXcHskA_3_3">1,378</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_YB-vixteRE2MlpWNsbjYGg_3_6">1,331</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_VDM1d-V2Pk-xynfve2j0Rg_4_3">68</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_VKoxcPaoc06733MKUGFTVw_4_6">22</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_FjTHOFIahEeugqdSQyM6sA_5_3">1,310</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_zvAPeMhSr0GqBGnl9Tp3_A_5_6">1,309</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental cash flow information is as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="ptgx:LeaseCashFlowInformationDisclosureTableTextBlock" id="Tb_LAnnaICZ_k6alVHP9U-U6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_3jVXvoREF0y0eXpHfXq4Qw_4_3">1,493</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_PhpnMqBUYUi4vuo4ekVExQ_4_6">1,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New operating lease asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_G6oSq_H3B0a5WOhyR2oeXQ_5_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> -</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Future lease payments required under lease obligations as of September&#160;30, 2021 are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_Q8CoNzYnDUm7GV3VgH-K-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_iGX_K45N_EeaeOGnY3vWSg_2_3">556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_RBc8qmtmgkC7ixLk1NQ5Uw_3_3">2,660</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_su2FVZQRfkG8cX6N4RCfpg_4_3">2,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_dMk1belQlUuVdWTKEIuBWw_5_3">1,160</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_7tNbNx-qn0i-V4ZEvBReGg_8_3">7,120</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_DCWfuA_Bw0qfE22gLU67OA_9_3">855</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_0bl7xS5a4UahMBpr7klktw_10_3">6,265</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_EpfqmBUfJUWTVwbR09E4WA" continuedAt="Tb_EpfqmBUfJUWTVwbR09E4WA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accruals for legal actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand related to a collaboration agreement the Company and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_EpfqmBUfJUWTVwbR09E4WA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 4, 2021, the Company and Zealand agreed to resolve the dispute and reached an Arbitration Resolution Agreement. Under the Arbitration Resolution Agreement, (1) the Company is required to make an additional payment of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" scale="6" id="Narr_1BelnrDrB0WOPIIBMp8lxA">1.5</ix:nonFraction> million to Zealand in August 2022 with respect to rusfertide, (2) all development milestones with respect of rusfertide have been reduced by <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw" decimals="2" format="ixt:numdotdecimal" name="ptgx:LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" scale="-2" id="Narr_72JKOdXUekOpRWJBkxCTaA">50</ix:nonFraction>%, except that the Company agreed to pay in full within <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfBusinessDays" scale="0" id="Narr_PAK1Ee93XUytMNIxdvzQRA">two</ix:nonFraction> (2) business days after the effective date of the Agreement (and timely paid): (i) a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_AHS1J3rNPkunnKl_uozAJw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_dgbO-btnd0ybeBpE4HlD-g">1.0</ix:nonFraction> million milestone for initiation of a Phase 2b clinical trial; and (ii) a $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseThreeClinicalTrialMember_PxpJvRYYhEWj49AtdxBe5A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable" scale="6" id="Narr_Mt2yN-ruK0COTZKL9PE15Q">1.5</ix:nonFraction> million milestone for initiation of a Phase 3 clinical trial; (3) the royalty rate payable by the Company on net sales of rusfertide has been reduced by <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg" decimals="2" format="ixt:numdotdecimal" name="ptgx:RoyaltiesOnNetProductSalesPercentagesReduction" scale="-2" id="Narr_ud3cIrnqjEWL5pmgGo_q3Q">50</ix:nonFraction>%; (4) all sales milestone payments on net sales of rusfertide have been reduced by <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg" decimals="2" format="ixt:numdotdecimal" name="ptgx:LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" scale="-2" id="Narr_9RwpMa6lUEewf9LytC6Vdw">50</ix:nonFraction>%; (5) the parties agreed that each party will retain all payments previously made by the other party in connection with the original collaboration agreement; and (6) the parties have released claims related to the original collaboration agreement, the abandonment agreement and the arbitration. In addition to the payments specified in items (1) and (2) above, the Company may also be required to pay Zealand up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg" decimals="-4" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementFutureDevelopmentMilestonePayable" scale="6" id="Narr_pnHWwR-U8E-FbDqQP01oDg">2.75</ix:nonFraction> million in future development milestone payments relating to rusfertide. Those payments include up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementRegistrationProposalExpensesPayable" scale="6" id="Narr_Wa8dQWm3Xkubah5Te221gw">1.0</ix:nonFraction> million in the aggregate for registrational proposals and up to $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg" decimals="-4" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementCommercialLaunchExpensesPayable" scale="6" id="Narr_ilhTxGcpS0-EWgRyO6Dqmw">1.75</ix:nonFraction> million in the aggregate for commercial launch in the <ix:nonFraction unitRef="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg" contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfGeographicTerritories" scale="0" id="Narr__4ecKI8wdUudRTrM5OPlxg">three</ix:nonFraction> geographic territories specified in the original collaboration agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company considered the outcome of these arbitration proceedings as being related to its research and development project; therefore, payments or milestone payments were recorded as research and development expenses. As a result, <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_IcQjRh5fKEOqMWWM3N6bgQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="Narr_76HSXIOHBU6NqaPxZXAYFg">no</ix:nonFraction> related legal accruals were recognized as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_rRA2mK-u5Uq5DnNZo5BC7g" continuedAt="Tb_rRA2mK-u5Uq5DnNZo5BC7g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_8p4IY5txmkqga8vJ3P2Zkg">2,750,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9KOXTrTqMUiTDI99y3z_ig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_3lWadvsahke6nmb48iLqbA">8.00</ix:nonFraction> per share, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_QKnBIEfHH0SAjcPVE9tDTA">21.7</ix:nonFraction> million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_M6ZuWy-_Aky-LJndvpy4bA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_VSnChRrS30iU0rwHvoaXYQ">2,750,000</ix:nonFraction> shares of its common stock (each, a &#8220;Warrant&#8221; and, collectively, the &#8220;Warrants&#8221;). Each Warrant is exercisable from August 8, 2018 through <ix:nonNumeric contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_wVRnXKW3vkq4XxkBdnmPBw">August 8, 2023</ix:nonNumeric>. Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_fcKYxkGVlEGlX-uyDbMWug">1,375,000</ix:nonFraction> shares of the Company&#8217;s common stock have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_uxZ9VeLU80C2mEWJW4qmaw">10.00</ix:nonFraction> per share and Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_ZzHekoC5p0C6GhCu9OH2HA">1,375,000</ix:nonFraction> shares of the Company&#8217;s common stock have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_uO8beZgCr0avgT5A18AOYg">15.00</ix:nonFraction> per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480<i style="font-style:italic;">, </i>Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JyX857Du9kCccikwVOJK1A" decimals="-3" format="ixt-sec:numwordsen" name="ptgx:NumberOfWarrantsExercised" scale="3" id="Narr_sdy3SpuLX0iQK51IR2cQwA">none</ix:nonFraction> of the Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2018, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with an Investor and its affiliates (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_m17xHVihGU2-hPeBfc6csQ">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_3TWsI55cOU6BQHtue_29hQ">0.00001</ix:nonFraction> per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA" decimals="INF" format="ixt:numdotdecimal" name="ptgx:StockExchangedForPreFundedWarrants" scale="0" id="Narr_7BhUSK2wXkSzqbzYD9LEfg">1,000,000</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_UHGI_KO6dUOg3WhLM2gzVg">0.00001</ix:nonFraction> per share. The Exchange Warrants will expire <ix:nonNumeric contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA" format="ixt-sec:durwordsen" name="ptgx:ClassOfWarrantOrRightTermOfWarrants" id="Narr_JyJ0ojtW5UihwdCDMPq9gw">ten years</ix:nonNumeric> from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_8xDA2VQi1EWNKwkVgZePOw">9.99</ix:nonFraction>% of the Company&#8217;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,<i style="font-style:italic;"> Equity</i>, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rRA2mK-u5Uq5DnNZo5BC7g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480<i style="font-style:italic;">,</i> and fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_YTpXeQgJJUeKa5oZr8AiAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_GoMlPkRGGEO52bNtLHYOUQ">400,000</ix:nonFraction> of the Exchange Warrants remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company filed a registration statement on Form S-3 (File No. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_uyHNYHVIIUOFt7eISFZ0iA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_nyS-tZTR20uJkphSeZk53w">250.0</ix:nonFraction> million of its common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_3MZvEqMKLkqJJimay3c3Rg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_oMgs9-oveEmjEmWVAGkzKw">75.0</ix:nonFraction> million of the maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_11_27_2019_To_11_27_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_xRIStPOlqkO3ZRkjqtTj2g" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_lFGPYkqRHE-qNfSR5-yDOA">250.0</ix:nonFraction> million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, 2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_mpMIa_s68kCkGIQq4ZMeRA">7,000,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_ChADps65pUSE5xPbZYa91Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_jPUPcPkzx0aM-DvuF_CKxQ">14.00</ix:nonFraction> per share and issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_URkiGm8zuEaVvS65J30DTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_KSujYu6tK0O3VhELyM81Ng">1,050,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8zEeV8gTA0OQG69UlVTpzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_h-PpZtoXJUKDEkcJNByiDA">14.00</ix:nonFraction> per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_Br5LFMTTFEWueNxEL4-jrQ">105.3</ix:nonFraction> million. As of September 30, 2021, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_zKmsy6v6FUaz1H9GRlgxZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_LD2y1VwFd0Cgni3iozrJSg">94.2</ix:nonFraction> million of common stock remained available for sale under the 2019 Form S-3, $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_9Z964QKwJE2qr29wKQspDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_RjmeMTMJS0u-aA-opReJxw">31.9</ix:nonFraction> million of which remained available for sale under the ATM financing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;">In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which it completed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_s9h4ANeN-EWT5OZrqM39mg">4,761,904</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ac6mZRjQgEeMtjEB_i6UOA">21.00</ix:nonFraction> per share and issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4dru7UabbEO8vq8Kk60BLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TehSuQznWkuK--IYlosbrg">714,285</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ZWhhGQPBKUuEzunwWJ1GhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_V5DKjoBBK0-ZSZJVlzQQCA">21.00</ix:nonFraction> per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_jOeM5D1Y8UudLVfSrpwpOA">107.6</ix:nonFraction> million. In June 2021, pursuant to Registration Statement No. 33-251254, the Company completed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_EoboCxcPXUaHRPb_kL9d5Q">3,046,358</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_sPnFRiazY0WPCIV18TjFyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_CjCaA3v-3ESxnwqzGsEw_g">37.75</ix:nonFraction> per share and issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T3JUh_bQFUWzNCgqWLw-SA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Pp_xPPHMakSsFSJ-DllAzQ">456,953</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2VW_uzB5fkeRI3qxZyicNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_G0sfsuJsLEKCW5-QJ6_qxg">37.75</ix:nonFraction> per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_9_Rqj5ctUES5Q-LwTen4jw">123.8</ix:nonFraction> million. The Form S-3ASR expires in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_AEIOULastRenderedPageBreakAEIOU73"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_jDM9HwKEM0mcm45Sz-iJ2g" continuedAt="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;13. Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) to replace the 2007 Stock Option Plan. The 2016 Plan is administered by the board of directors, or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2016 Plan expire no later than <ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_VXWpZKcTTkKp8eVZQhziGw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_xl6r0NZgQUGOY5eYuVVHzQ">ten&#160;years</ix:nonNumeric> from the date of grant. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_RdllORFsOUWkT56_8WgrPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_0VcYX_iFwEik_PZ2RylqYQ">524,762</ix:nonFraction> shares were available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2018, the Company&#8217;s board of directors approved the 2018 Inducement Plan, as subsequently amended. The 2018 Inducement Plan is a non-stockholder approved stock plan, under which the Company awards options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than <ix:nonNumeric contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_tOd2A-ZoskaNnweabNr7Ig" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_dx8u4exlTEmMWg89N1KcDA">ten years</ix:nonNumeric> from the date of grant. As of September 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_MLttZWHz2UiEm3p_zIvcnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_pHSsGEivlUuZeGTe-8drtA">243,125</ix:nonFraction> shares were available for issuance under the Amended and Restated 2018 Inducement Plan. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_494a0c0d_a9c9_453c_9e06_4c1d28ae6f00"></a><a id="Tc_F4XIHWSkEkmPsoYNrf-TtA_2_4"></a><a id="Tc_6t6dBSccikS5u3UlKBBd1w_2_7"></a><a id="Tc_hI9gQ9EIm0SssXhTT9a-dA_3_4"></a><a id="Tc_iOdstY_N9E21Z0H43KrqQQ_3_7"></a><a id="Tc_xdLv9eV--0SfSwloJlXpjw_4_4"></a><a id="Tc_8-TGBw1UbkaRMMiaxzSQKw_4_7"></a><a id="Tc_3LXYfV0tmUaY4ZyyULxrxw_4_9"></a><a id="Tc_QhO9TqPJY0ugSl6L_EDCUA_5_2"></a><a id="Tc_etAKNXc71kC1jNs_6j2Wtw_5_4"></a><a id="Tc_ksp0lqHWGUGa6Q0kZGdzPQ_5_7"></a><a id="Tc_AtHtmR_DFE-r88poKJFfEg_5_9"></a><a id="Tc_3AKNydspIES-UvC_Jy9sxw_6_2"></a><a id="Tc_8hgZd3zk1Ei9ZU1SOJeLzQ_6_4"></a><a id="Tc_H68GJ_HvLUWnyIHzuuGoxQ_6_7"></a><a id="Tc_xLQkl8c4akeRQQg0rNUQ2Q_6_9"></a><a id="Tc_WqGA-D_6AE2DeMIrSWI6QA_7_9"></a><a id="Tc_6wtfAmN9TEW88RNT7E5SnQ_8_0"></a><a id="Tc_Rud8V9hWN0Koese9HfSplw_8_4"></a><a id="Tc_xymTsfQzhE63hWf9OWPJzQ_8_9"></a><a id="Tc_RjjIdrNOREaukPMy1LDWQg_9_0"></a><a id="Tc_TkxPYHZoBUS1G8vWOlK1eg_10_0"></a><a id="Tc_QfhcLQ2jK0aKPlXBzsN89Q_11_0"></a><a id="Tc_YQIleT0x_kOKPdbKj6y-7Q_12_0"></a><a id="Tc_PUXgtrOykU2pry-5-_rJYA_12_4"></a><a id="Tc_4vee3__sbEmQBU0NseS5GA_12_9"></a><a id="Tc_p6WpPpsDIkOHkxpjV-n_Tg_13_0"></a><a id="Tc_Xfx2c9nF2EOQS7kfXe6Blg_13_4"></a><a id="Tc_B4MckQ032kquZCe9b12J9w_13_9"></a><a id="Tc_lGSjdXnDQUioQC5lbn0QXg_14_0"></a><a id="Tc_SYOUrnpSTkG3Eakg8UWLkw_14_4"></a><a id="Tc_jSU30dyV9kCTgqrIESKP5Q_14_9"></a><a id="Tc_XZxBF8z2PU2cVDHMztZZaA_1_2"></a><a id="Tc_vnuXXfcBE06nHSdl4j6Ttw_1_6"></a><a id="Tc_cmG0xigO3kS5UzCzEx7s9g_2_2"></a><a id="Tc_DmPo8XbDrU2fn6fqoFnkWg_2_6"></a><a id="Tc_EWP8aiG2IEm1VepyaW6Lnw_3_2"></a><a id="Tc_4b2F1jMLwkinh-yCERcpkA_3_4"></a><a id="Tc_gzrie79tDES3fovnTe0j_w_3_6"></a><a id="Tc_-RH9GZ0n00KSsdWh8_K9RQ_3_8"></a><a id="Tc_SlbIuD5yWEeQAhgKLeyEAQ_4_0"></a><a id="Tc_c6vpyC0aB0enZvhQrpF9Gg_4_2"></a><a id="Tc_hWiWMLo7okGOMNX7r1LeHw_4_4"></a><a id="Tc_-FRdQ47qoUiO9t1p3KpnDA_4_6"></a><a id="Tc_pBimr2yRfEaFFvKW9TSBqQ_4_8"></a><a id="Tc_YvJYnzpPkUmSj4RCNt7wgw_5_0"></a><a id="Tc_qHgWvDk8T06yc-omY-a0TQ_5_2"></a><a id="Tc_1T7s5Dr40Ui1Ffy1vdV5Qg_5_4"></a><a id="Tc_niUUav_LA0u2RzayM_0aFA_5_6"></a><a id="Tc_cKTBgwfpJkeZWUt-uW4bcw_5_8"></a><a id="Tc_AN8ca59r_kaizAgDDhFz5w_6_0"></a><a id="Tc_LLpPqa71skSY75QWTiupjw_6_2"></a><a id="Tc_jJWiwhdtqkSmtLgNv64-aA_6_4"></a><a id="Tc_LlxfKaigukCDyPWxtisMWw_6_6"></a><a id="Tc_VnKRCLFp90W33DTrxQxolg_6_8"></a><a id="Tc_r2GsclDWYE6HQ4p77FVWBA_7_0"></a><ix:continuation id="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont1" continuedAt="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option activity under the Company&#8217;s equity incentive and inducement plans is set forth below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_w0JcREucJUSTKNE1QVbszw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AAlMzepgEEauKJ9L_Sa8dQ_8_2">4,648,120</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_nxKsMPlDp0uVcLjMXqHCGQ_8_5">11.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_C1zAudG900ugOvd1DcyFrg_8_7"> 7.61</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_SZA_HdFcBk6tmPWs9oohOw_8_10">40.0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_NFHZzN79akKcrEtlJQGZbg_9_2">1,920,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7-iK8ffqKUSJtnWztJ8Vnw_9_5">29.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Al8z0pdx2U2BwVUAlfRGow_10_2">308,125</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_2hXWMsXgkEuDSUEEqCQaYw_10_5">9.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_pErEPlZ11UKuRBps72FsKg_11_2">176,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_LxrT3laa7UCiwM_gBxlbCQ_11_5">16.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dmiGqPvfGEyNBjWzdV9NOQ_12_2">6,083,955</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_wC-m7Ed2f0OMuUhiD6agcg_12_5">17.54</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_NrcbkYWX00i08WopzHVxSg_12_7"> 7.58</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_kEzDuPiAvES2-ixVAEcwsw_12_10">27.6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable &#8211; September&#160;30,&#160;2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_eIZ6DGj0vkqvz20shK4VNw_13_2">3,121,045</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_bTnojJ1U6EarXnXF63s7JA_13_5">12.89</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_T03xXGs05kW9l0Psqk8XsQ_13_7"> 6.29</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Tc_mW9pwDsrnkuASjaZh8KtrQ_13_10">18.7</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest &#8211; September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_e2JIXmDTmUWJjIYzkD9t5A_14_2">6,083,955</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_jvvR9SeBPk62z1TALZrXzQ_14_5">17.54</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_NmUatdeAtEG9rtYaxE2Qnw_14_7"> 7.58</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="Tc_4u3BGa6HeEGQLQO12DmOpg_14_10">27.6</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on September 30, 2021. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on September 30, 2021.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated weighted-average grant-date fair value of common stock underlying options granted to employees during the nine months ended September 30, 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_QmeCdPBnLUqI2tg9JykJsw">21.92</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options Valuation Assumptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of employee stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_yUvznez_Xkif5hSUDvrFhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NQqJPEuYYU24niCb9tj5og" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_qJ4Xip228kG2uWcPfvpG8g">6.02</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEkXG0l4dU-MPpEChb8m2Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_LcuHDHnm4km3et_SU65mKA">6.08</ix:nonNumeric> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OQZenvrZlk6VJmwZFGIrag" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_1RgZvknKwkSwfdeP_9ziPg">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_HO9dXCVgUUKyFTdCLwfdHQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_zhIbV8UBskS4_SDx7e_JPA">6.08</ix:nonNumeric> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MdN54EnQNUy4goQYips2hQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_306hDEZ4j0Oo4Ucd6m_Afg">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rFCznfZHPUidpHv3XziwjA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_YZZj7UIK6ECENQjacfMgWw">6.08</ix:nonNumeric> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3v_HJaV_TEawCCjJ-8U_bg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_73x_z9mg50ib2kXCLDqlJw">5.27</ix:nonNumeric>- <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8bkYSfa3AECmsmdja2QoLA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_W175tND6AUyqn5RBnQgOkQ">6.08</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_vQC4uhSdzkSix-FucAtqVw">87.4</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_l34TQ83BUkyw4ZddacWamA">88.4</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_LxK6IO4ezU-owLO4_KY7Mw">84.5</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_1ElR5kulkkicWmpIWJMyMA">85.1</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_mGYtTFC3aUmMHdBpcTl8YQ">87.4</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_2i490yxFQUO4xPheOmw_gg">90.2</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_1DTtHP1_RkiITYLcr1_Zrw">72.1</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_T1IYapYnrk2_Tsu0cIr-OA">85.1</ix:nonFraction>%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_YnK00bNQJ06O0Vv4XPTznw">0.85</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_FA_OJmCMbUmeZX--00ernw">1.16</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_uTIDPFtgTUWUkAWwZ79mJw">0.23</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_HpTz4Ial-U-rI3rYxgSCxQ">0.40</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_pbCIZZKVNECyaKsABlw_eQ">0.11</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_tIvRjKFOckKgcowANKTO2w">1.16</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_aAl333qx9USU6FP9-JXiGQ">0.23</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_eEw-DQLsZUiIMDuta5nGKg">1.44</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Z-6yXHmVkkCSSKxBc4Ecaw_7_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_VPvdmohqAE-STU7VOr_gBQ_7_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_wHopSw9FIU20kWgp22k7_w_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_LLtErILH-kqV9v8yzl6I0A_7_8">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8212;For the year ended December 31, 2020, the Company&#8217;s expected volatility was estimated based upon a mix of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" scale="-2" id="Narr_Ciuw1SgWd0u-Q7V0Q9G9-A">75</ix:nonFraction>% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" scale="-2" id="Narr_L7vjfN4lvka6oZ4yhdLVIw">25</ix:nonFraction>% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016. Beginning January 1, 2021, the Company&#8217;s expected volatility is estimated based upon a mix of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" scale="-2" id="Narr_Egi-wMvp3Ee-bx6H6qKCIw">50</ix:nonFraction>% of the average volatility for comparable publicly traded biopharmaceutical </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ZV5RNneY8k6yW8jN96lQYQ_1_4"></a><a id="Tc_mb06zsT1XUWfbiFq27W8HA_2_4"></a><a id="Tc_Y4inem4BWUq5INs1SCTo8g_3_2"></a><a id="Tc_GH9dA4V9XEec9agG-VrcLA_3_4"></a><a id="Tc_haNlCJCK5E-JiLzZQRID0w_4_2"></a><a id="Tc_mRanMPSmeUC1i2yPtGNi6A_4_4"></a><a id="Tc_kchs-t8_jUGo8U2XgWx64Q_5_0"></a><a id="Tc_lvTlFqGb4UWq8Kio7KmU0g_5_4"></a><a id="Tc_U_TXJ2jJcEyFcHoFf22vYQ_6_0"></a><a id="Tc_I7pcK-3_oECC232AFzrUxw_7_0"></a><a id="Tc_6pai47KG90as7222U6Tqyw_8_0"></a><a id="Tc_ojVarOoVtUyEoPeztROX5w_9_0"></a><a id="Tc_Wfcz8lnHYEuR8bb7NXsMfQ_9_4"></a><a id="Tc_thzJZnOcS06FgtjcBBJJcQ_1_4"></a><a id="Tc_WmEBDaMfWEu6Euw2uqinFw_2_4"></a><a id="Tc_ICF_0zRvBUux8zOLNoB90A_3_2"></a><a id="Tc_cZDYInqvF0ONx32o81ndCQ_3_4"></a><a id="Tc_IWrq1HzfykWNvMPFhrnHqA_4_2"></a><a id="Tc_cv1bQ-H4AUehZPbJkQisuw_4_4"></a><a id="Tc_yNxefkdC00Gu-QAAk9HyiA_5_0"></a><a id="Tc_WklfrIG3nEikXTfI01Ek2w_5_2"></a><a id="Tc_K00dgfLSvkGzn3QiEoaaAw_5_5"></a><a id="Tc_28MelXyOxEWP7j8yQoQCxg_6_0"></a><a id="Tc_5Jd_98d1ykKLCfPzJwIPbA_6_4"></a><a id="Tc_pRqAcEUpS0aL5SPNtJbUMg_7_0"></a><a id="Tc_SQ8SO4zAkEiY7SWm5sOZzw_7_2"></a><a id="Tc_yyW4lO713UWtibkiHhXvEg_7_5"></a><a id="Tc_sx8PZM-7B0ixBj1rbfM0pQ_8_0"></a><a id="Tc_CVSKgHdeeEmZTWMtxL_p1w_8_5"></a><a id="Tc_mkqTkK1ETU21HCChlkADYQ_9_0"></a><a id="Tc_1dh8_JQXzkKSSLKG9rmmYg_9_4"></a><ix:continuation id="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont2" continuedAt="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">companies over a period equal to the expected term of the stock option grants and <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" scale="-2" id="Narr_-B44rNlWo02qw5S8im7JNA">50</ix:nonFraction>% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans is set forth below: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_y8B4shYqG0KDDCa-cxtLoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_-Lj96MGmiU-xIJUPNaa1Ng_5_2">244,545</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_H2Cjelg8HUabGBL8DHaNvg_5_5">9.31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_CuGElhMTK0uVAgRoCK5Hzg_6_2">302,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_oXyt2yv59kqbtW1t7PfSYA_6_5">24.40</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_GRIBE5ltKkudQSIU_Rcj3Q_7_2">78,165</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_QzbAL3ENFU-cVcK1JWtv2g_7_5">10.13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_995Nl2esa0uh1_NRXLWqhQ_8_2">49,970</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_vQijrE02Z0y3VF4liAtvpA_8_5">18.86</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_voN695BjME6BvBOKH2rRfQ_9_2">418,660</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_8f8wayk88kub4oH3C0_B1Q_9_5">20.07</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Performance Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:6pt 0pt 6pt 0pt;">Performance stock unit activity under the Company&#8217;s equity incentive plans is set forth below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="Tb_e9x5b02NX0ON6Zwv-e34kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">                 &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_WVcHtbyv7UerN80ORwOdfQ_6_2">110,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_8oTF9gEv1UiZkZ7sa1KM3w_6_5">23.57</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_kqF4Z8Z2gEioyNRv2-TNzQ_8_2">5,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Z9S9lSPkp0aOsLFcFVY6NQ_9_2">105,500</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_sTJZn5R64UCThtfe-GZMjg_9_5">23.57</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt;">During the first quarter of 2021, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_3V3wGGeatE6hQ_xIesPIQg">110,500</ix:nonFraction> PSUs to certain executives of the Company pursuant to the terms of the 2016 Plan. The grant date fair value of the PSUs was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="Narr_3EoQwVF0hUqUNPEsfOkSXg">23.57</ix:nonFraction> per share. The terms of the PSUs provide for <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_4y7lpIYSJkCxrKL17xCOFw">100</ix:nonFraction>% of shares to be earned based on the achievement of certain pre-determined performance objectives, subject to the participant&#8217;s continued employment. The PSUs will expire <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_oiYadHMCIE-rGEdrnhjYAw">five years</ix:nonNumeric> from the grant date if the performance objectives are not achieved. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company&#8217;s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest when the achievement of the related performance objective becomes probable. The total fair value of the PSUs granted in February 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_F2fAANpPG0qxaN1I2cAc1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_AGj38ifyvkSMxbyv_7BIPA">2.6</ix:nonFraction> million. As of September 30, 2021, the achievement of the related performance objective was deemed not probable and, accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensation" scale="0" id="Narr_wg5kzDrW9USA4m2p9Huavg">no</ix:nonFraction> stock-based compensation for the PSUs has been recognized as expense as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="Narr_w72ijA7Uck6KCJ9L-6oKGA">15</ix:nonFraction>% of their eligible compensation. At the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_961512fb_b7e8_4f35_a485_e62b4c6c8e55"></a><a id="Tc_AEWJAtKxcUybusV1GnhI_w_1_2"></a><a id="Tc_IgEYF0E-TEaJ-IIJiZF8pw_1_8"></a><a id="Tc_4A6PLbgHI0Gd6Q-rP9d91g_2_2"></a><a id="Tc_F3ZqWprkXEajR56iqRnV_g_2_8"></a><a id="Tc_TjDrDcyXjUaMxcShQccubQ_3_2"></a><a id="Tc_HqGADRBMpk2bDVhN2i5TaA_3_5"></a><a id="Tc_0dj6bke6AEaFlHFyTWRoZw_3_8"></a><a id="Tc_MujLhXpEBE-f7epOlrhBzg_3_11"></a><a id="Tc_ESPryX4ph0Sr9VKlJVkGKQ_4_0"></a><a id="Tc_gwzEzB-SMEez5iunRNqimQ_4_2"></a><a id="Tc_0po90XBxLEKdptGFbsaIyQ_4_5"></a><a id="Tc_uZfKh94qO0KLbNDqTCeEBg_4_8"></a><a id="Tc_968M4iDEy06iW9gL14pf6Q_4_11"></a><a id="Tc_Z0UWfraEVkufAgeqTtS-RA_5_0"></a><a id="Tc_DQ8-N3aKqUafcyptqARLXw_6_0"></a><a id="Tc_uX7ZH8HsSE2XW76FNRLEJQ_6_2"></a><a id="Tc_7tT1HtYIhEqwDQ5PLBOoeA_6_5"></a><a id="Tc_pcQfw9l8skeFl1snsnuKZw_6_8"></a><a id="Tc_FBgwVyfwvUOGzTyOn_ueAQ_6_11"></a><ix:continuation id="Tb_jDM9HwKEM0mcm45Sz-iJ2g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">end of each offering period, eligible employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_jtOYGLBf0UOrXV1bFgtMow">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the nine months ended September 30, 2021, a total of <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_sbWSMS82p0elvDScXk6TqQ">43,648</ix:nonFraction> shares of common stock were issued under the 2016 ESPP, and <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_5Ot0oGHC8EqfxenMzse-SA">1,013,999</ix:nonFraction> shares remain available for issuance as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_rPxn-Ro7YUKA-vRgstK-XQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total stock-based compensation expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T0H8ABLR8UW5UTiO70X3Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TI4EFht7Ok-qSajA6nuEDA_4_3">2,611</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_a0FuumrKYUO7tJOSkOvu3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_W6GmQbQsZkOa8hreanHOyw_4_6">1,006</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2I_k75JCq0eeHRkxbMxQXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4CgX2xRsbEew5WXyuOu6Fg_4_9">6,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l6HbK0TvKE283tUIhVWh1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_UiuCpXROBEu8SyU2PubttA_4_12">3,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AcXFvIPtgkyUmawuHCqSow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_OgM8RCHW_UyAKPbM8myJtA_5_3">2,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9O0ysWYJAk2T3ppTE9BJ4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2QiirjP2NE2r5sRENAIzXw_5_6">882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_t-wbdQnITUaC7MfBqxrb9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6CRLFCaE-0SwWLZ8BCX3jw_5_9">5,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RLO4WIMRGkC7XbCfwot3cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wqIsmyqJVUeF0HiNHx-d1Q_5_12">2,834</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0DEyI0365kOcalzxntSEhw_6_3">4,775</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4cs9hb1RWUKY8pOxdsa57g_6_6">1,888</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yhEXqGttOkC9hlDz-2wOgw_6_9">11,371</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XBGYafnWRk--XMXGTunCog_6_12">5,932</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, total unrecognized stock-based compensation expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_7RBcB1neEUqjmL0enMODEg">51.5</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Og_mOMmH8kqhs8DSVS0ruw"><span style="white-space:pre-wrap;">2.9</span></ix:nonNumeric><span style="white-space:pre-wrap;"> years.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_iksScfRBi0WG8QXUtx-Dow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14. 401(k) Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (&#8220;401(k)&#160;Plan&#8221;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company may make contributions to this plan at its discretion. For the three and nine months ended September 30, 2021, the Company plans to match <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_qtj4OoArD0ulZQ1GueuQ3w"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_CZ2sZxPaQUe4rbGW3ksFiA">50</ix:nonFraction></ix:nonFraction>%<span style="white-space:pre-wrap;"> of each employee&#8217;s contribution up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_wF67uOoOB0qN6yNxuUyVpQ"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_KJDfr17BnU2_yxDurTp7SQ">3,500</ix:nonFraction></ix:nonFraction>, and recognized expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_8a_jXlTjjkK5e62uKhqaUg">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_XKoXZmXUgEKJCsJ629V55A">0.3</ix:nonFraction> million, respectively, relating to these contributions. <ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_EdfAsY0se02URu5SO3p36g"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_qqsOflBaPk6larXbJfKiHA">No</ix:nonFraction></ix:nonFraction> contributions were made to the plan by the Company for the three and nine months ended September 30, 2020.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_IYHVyED28UyJDlMX6gFz4w" continuedAt="Tb_IYHVyED28UyJDlMX6gFz4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;15. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_Ljtwvi0EDUSuJj_Coo3sKw"><ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_3h4Dahl2zUWjT_IxiD-45w">No</ix:nonFraction></ix:nonFraction> income tax expense was recorded by the Company during the three and nine months ended September 30, 2021. The Company recorded income tax expense of $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_HVz670uwlUOtg1lRIP07Lg">1.3</ix:nonFraction> million for the nine months ended September 30, 2020, representing an effective income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_pKokhmkwqEunbZi-7ePg7g">2.8</ix:nonFraction>%. During the second quarter of 2020, the Company&#8217;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a valuation allowance is necessary for its Australia subsidiary. Income tax expense for the nine months ended September 30, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain tax position liabilities. The Company&#8217;s effective income tax rate differed from the Company&#8217;s federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_HN41UxW970-KZBLdYjLgYQ"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_5oCoMYL7Ak2e55M2rknuHQ"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_0y2_Uc07qkWl7AOJBicZkw"><ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_qrxB8KSKC0CYVPAP_pMxPg">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>%, primarily because its U.S. loss cannot be benefited due to the full valuation allowance position and reduced by foreign taxes. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IYHVyED28UyJDlMX6gFz4w_cont1"></ix:continuation><a id="_4e281541_13a1_4688_8352_a0a45a6df6d1"></a><a id="Tc_gALs30fYOEOndmSA-u0FsQ_1_2"></a><a id="Tc_OGOIWxvoq0adFJIYeqNfTg_1_8"></a><a id="Tc_xOoecXfiekGOr3ALw_YCHQ_2_2"></a><a id="Tc_6NObrty3OE2-GjhCuN14KQ_2_8"></a><a id="Tc_Je9eZlqm5Ue67yqOVbxUww_3_2"></a><a id="Tc_fSBf7iOEw0i5XyElgnwFOQ_3_5"></a><a id="Tc_j1PXO201i0i5cQck89dDzg_3_8"></a><a id="Tc_OmpLN_5XlkmSoTRKEtU0Sw_3_11"></a><a id="Tc__1f0V7ves0Kfmcj1B1LkMQ_4_0"></a><a id="Tc_2k1vlWxIIk-IjVF3Mn8n-A_5_0"></a><a id="Tc_K3v8vgOGWU-_kY9d12lGtQ_5_2"></a><a id="Tc_UYsAeodZVEqXLRDs3his3A_5_5"></a><a id="Tc_iA4yQVWsJUO54b1aW6qqJQ_5_8"></a><a id="Tc_oa336FY8fkyMAUU7RpHREA_5_11"></a><a id="Tc_ncklU5HoAEyIqa0q4CqExg_6_0"></a><a id="Tc_ulOSUuxdUEenHTat1wLLZg_7_0"></a><a id="Tc_ltZZU0Bhvky39hmh4eqLng_8_0"></a><a id="Tc_0f1xNm9i_Eqti-5cV7YO0w_8_2"></a><a id="Tc_iBjwicRGRUWMR9XHpEEQUA_8_5"></a><a id="Tc_yuZq7siQ-EmODehnSObfVw_8_8"></a><a id="Tc_1bk44MRVmkW7tmvOg1Q6JQ_8_11"></a><a id="Tc_MBVpRLLYjkiPtIUwEY1iNw_1_2"></a><a id="Tc_w35uMrAtfUi7b2m9gZM4GQ_2_2"></a><a id="Tc_jEFoeXAQskud74DrmEgQYA_3_2"></a><a id="Tc_K2cgLS9360mCAUjOArUkxA_3_4"></a><a id="Tc_lVrrqbIe-k2UOhDd13TPOg_4_0"></a><a id="Tc__GmhqRWoAEum7UaGFWELNQ_5_0"></a><a id="Tc_ui5eAvmy6UOr_TN-0_19gg_6_0"></a><a id="Tc_8m6QxQtzOECRcg5TAgOv3g_7_0"></a><a id="Tc_qKG2wjAwZEWPP7DYiUX3PQ_7_4"></a><a id="Tc_p20nU62bHkygjdwXeRyQSg_8_0"></a><a id="Tc_Y_rZrvNYJ0Cgkw8jDRFfWA_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_x_nrzoE22ECZiUrUDrfVZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;16. Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As the Company had net losses for the three and nine months ended September 30, 2021 and 2020, all potential dilutive common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_vNXqncqtU0Gl39OG6C6daw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_h5Kw961_X0S7SfTJRwyfMg_5_3">33,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gLhAegJzy0COO95MoZBrRw_5_6">7,763</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Np7e__s3g06ocw-ZgCf-6Q_5_9">88,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sk4NRceG9k63NHbxWTCWJw_5_12">47,264</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_qUJqw9u_tkGhxuK_PH-ikg_7_3">47,987,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_5mETal8IHESrce0yY_NY1A_7_6">37,386,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_Dg5fVpomLUuA0ea-tTQ7CQ_7_9">45,705,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_rC_60f88u06qbbEjIdcLiw_7_12">32,647,524</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_W73O8A8d9EKB3NijtoY-7w_8_3">0.70</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_J0mldnjxnEO_vV2xZjDAOw_8_6">0.21</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_X_1vKbYXHUSAOYdqIdFGVQ_8_9">1.94</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_D-ySwlo2YEOhvNDDgTDjcQ_8_12">1.45</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share computations for the periods presented because their inclusion would be anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_zZUFD2o3rEOO6LpLMwaVvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbxkG_gzsk-x_bM6qbI8_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_AG5xZmpMREiBXNWCdUvoxg_4_2">6,083,955</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SpzSmd-Mk2osYBgelFKpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KGMQc-lKU0eWUTTP3QBvOw_4_4">4,596,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_nTdQkTXU-0S6ergKcYz3vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sB2GCAQe-UGOCMb5OLkeXA_5_2">2,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_tLWEwGzi6E-KqzZmPdOOrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_g-to4f8XPE-FC1ezqOX-dQ_5_4">2,750,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_r1RtIdBqNkaMdBGIaOjSHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L4_aNlFFtEC856hisNKIlA_6_2">418,660</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_n0Ta9bA0r0Kq2dDdfjjplg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vu6nOPP9d0yoN9U-8hKl0w_6_4">262,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_1dBmY6pAUU6RcuwSZPcgtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gC4EgAXO8U6yp9k5DDNpKg_7_2">105,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESPP shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_YzrwOrK_Z0OF0-Mj3NtBLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WLlLjucglUmCeA6MYXb_6Q_8_2">18,660</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GzDm5mfuBEe6F8PeGg2E1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_y_XU-L0e6E-85UwER7DKxA_8_4">28,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Q2qG5Z_Wm0ChjxvVoxWLzA_9_2">9,376,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ" contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_67OOgxBEckerjm132I8gCQ_9_4">7,638,045</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_DYMDRy1U20mVKnU7jnDodA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17. Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately <ix:nonFraction unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw" contextRef="Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ" decimals="2" format="ixt:numdotdecimal" name="ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan" scale="-2" id="Narr_Mazj4_1jOEK5wFgY_celEA">12</ix:nonFraction>% of the Company&#8217;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $<ix:nonFraction unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw" contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_CSF1bGw2MEiBGwGgwGRf1Q">0.3</ix:nonFraction> million, substantially all of which were related to employee severance and benefits costs.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3602db5_8c72_4f1e_b245_c4809b398a1c"></a><a id="ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;2.</b></span>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our Unaudited Condensed Consolidated Financial Statements and related notes included in Part&#160;I, Item&#160;1 of this quarterly report (this &#8220;Quarterly Report&#8221;) on Form&#160;10-Q and with our Audited Consolidated Financial Statements and related notes thereto for the&#160;year ended December&#160;31, 2020, included in our Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;10, 2021.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward-Looking Statements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Quarterly Report contains certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecasts,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;targets,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks, uncertainties and other important factors. In particular, statements, whether expressed or implied, concerning, among other things, the potential for our programs, the timing of our clinical trials, the potential for eventual regulatory approval and commercialization of our product candidates and our potential receipt of milestone payments and royalties under our collaboration agreements, the timing and amount of potential payments that we may be required to make to collaboration partners; future operating results or the ability to generate sales, income or cash flow, and the impact of the ongoing COVID-19 pandemic are forward-looking statements. They involve risks, uncertainties and assumptions that are beyond our ability to control or predict, including those discussed in Part&#160;II, Item&#160;1A, of this Quarterly Report. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Given these risks, uncertainties and other important factors, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future. &#8220;Protagonist,&#8221; the Protagonist logo and other trademarks, service marks and trade names of Protagonist are registered and unregistered marks of Protagonist Therapeutics,&#160;Inc. in the United States and other jurisdictions.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:213pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">We are a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company&#39;s proprietary discovery technology platform.</span> Our clinical programs fall into two broad categories of diseases; (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our Product Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ptgx-20210930x10q007.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:213pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:480.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our most advanced clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability. We initiated Phase&#160;2 proof of concept (&#8220;POC&#8221;) studies in the blood disorders polycythemia vera (&#8220;PV&#8221;) in the third quarter of 2019 and hereditary hemochromatosis (&#8220;HH&#8221;) in January&#160;2020. In December 2020, we presented four posters and one oral presentation relating to rusfertide at the American Society for Hematology&#8217;s virtual annual meeting, including updated interim Phase&#160;2 results for rusfertide in PV. In June 2021, we presented updated Phase 2 data supporting the long-term efficacy of rusfertide in PV during an oral presentation at the European Hematology Association (&#8220;EHA&#8221;) 2021 Virtual Congress. We believe these interim results provide evidence regarding the potential of rusfertide for managing hematocrit, reducing thrombotic risk and improving iron deficiency symptoms. Rusfertide has a unique mechanism of action in the potential treatment of PV, which may enable it to decrease and maintain hematocrit levels within the range of recommended clinical guidelines without causing the iron deficiency that may occur with frequent phlebotomy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 16, 2021, the FDA orally informed us that a clinical hold would be placed on our rusfertide clinical studies. We received formal written notice of the clinical hold on September 17, 2021.&#160; In October 2021, we submitted a Complete Response to the FDA related to the clinical hold, and the FDA removed the clinical hold on October 8, 2021. The clinical hold was imposed following our submission to the FDA of findings in a 26-week rasH2 transgenic mouse carcinogenicity study.&#160; In the rasH2 study, benign squamous cell papilloma were observed in six of 75 male mice and six of 75 female mice treated with doses of rusfertide ranging from 6.25 mg/kg to 25 mg/kg.&#160; Malignant squamous cell carcinoma was also observed in one male mouse and one female mouse.&#160; There were no findings in either the male or female control group.&#160; The rasH2 finding prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials (involving 160 patients) through the date of the submission of the Complete Response. All cases were initially assessed as unrelated to rusfertide treatment.&#160; Upon re-examination in light of the rasH2 finding, two of the cases were re-classified as possibly related to rusfertide. No additional cancer cases, and no other unexpected safety signals, surfaced in this process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In our Complete Response, we provided the individual patient clinical safety reports the FDA requested for human cancers observed in rusfertide clinical trials, updated the investigator brochure and patient informed consent forms for ongoing rusfertide trials, proposed new safety and stopping rules in clinical study protocols of our ongoing rusfertide clinical trials, and performed a comprehensive review of our rusfertide safety database. Dosing of patients in ongoing clinical trials with rusfertide is expected to resume in the fourth quarter of 2021.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We completed enrollment of 63 patients in the ongoing Phase 2 clinical trial of rusfertide in PV during the second quarter of 2021. Based on ongoing end of Phase 2 feedback provided by the FDA&#8217;s Division of Nonmalignant Hematology and written comments from the European Medicines Agency (&#8220;EMA&#8221;), we expect to initiate a global Phase 3 clinical trial of rusfertide in PV in the first quarter of 2022. During the first quarter of 2021, we initiated another Phase 2 study for rusfertide in up to 20 patients diagnosed with PV and with routinely elevated hematocrit levels (&gt;48%). In addition, we completed enrollment for our Phase 2 POC study in HH, our second indication, in April 2021. A<span style="background-color:#ffffff;">n abstract highlighting preliminary data our Phase 2 study of rusfertide in HH has been selected for oral presentation at The Liver Meeting&#174; 2021, hosted by the&#160;</span>American Association for the Study of Liver Diseases<span style="background-color:#ffffff;">&#160;(AASLD), taking place virtually&#160;in November 2021. </span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To date we have received the following designations for rusfertide in PV:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The FDA granted orphan drug designation for rusfertide for the treatment of PV in June 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The European Medicines Agency granted orphan drug designation for rusfertide for the treatment of PV in October 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The FDA granted Fast Track designation for rusfertide for the treatment of PV in December 2020; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The FDA granted Breakthrough Therapy Designation for rusfertide for the treatment of PV in June 2021.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 58.5pt;"><span style="background-color:#ffff00;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our alpha-4-beta-7 (&#8220;&#945;4&#946;7&#8221;) antagonist PN-943 and our Interleukin-23 receptor (&#8220;IL-23R&#8221;) antagonist compounds, including PN-232 and PN-235, are orally delivered investigational drugs that are designed to block biological pathways currently targeted by marketed injectable antibody drugs. Our orally stable peptide approach may offer targeted delivery to the GI tissue compartment. We believe that, compared to antibody drugs, these product candidates have the potential to provide improved safety due to minimal exposure in the blood, increased convenience and compliance due to oral delivery, and the opportunity for the earlier introduction of targeted oral therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PN-943 is an investigational, orally delivered, gut-restricted &#945;4&#946;7 specific integrin antagonist for inflammatory bowel disease (&#8220;IBD&#8221;). We submitted a U.S. Investigational New Drug application with the FDA for PN-943 in December&#160;2019, which took effect in January&#160;2020. During the second quarter of 2020 we initiated a 150-patient Phase&#160;2 study evaluating the safety, tolerability and efficacy of PN-943 in patients with moderate to severe UC. This study includes a 12-week induction period and a 40-week open label extension. Topline data from the 12-week induction period is expected in the second quarter of 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">In May&#160;2017, we entered into a worldwide license and collaboration agreement with Janssen Biotech, Inc. (&#8220;Janssen&#8221;), a Johnson &amp; Johnson company, to co-develop and co-detail our IL-23R antagonist compounds, including PTG-200 and certain related compounds for all indications, including IBD. PTG-200 was an investigational, orally delivered, IL-23R antagonist for the treatment of IBD. The agreement with Janssen was amended in May&#160;2019 to expand the collaboration by supporting efforts towards second-generation IL-23R antagonists; and in July 2021 to, among other things, enable Janssen to develop collaboration compounds for multiple indications and further align our financial interests around potential multiple compound development for multiple indications in the IL-23 pathway. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#201f1e;">Following a pre-specified interim analysis criteria, a portfolio decision was made to stop further development of first generation IL-23R antagonist candidate PTG-200 (JNJ-67864238), in favor of continued development of two second-generation candidates PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186) with superior product profiles. In particular:</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#201f1e;">&#160;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="background-color:#ffffff;color:#201f1e;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#201f1e;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The Phase 1 study of&#160;PN-235 is completed, and a Phase 2 study in psoriasis is anticipated to initiate in early 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="background-color:#ffffff;color:#201f1e;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#201f1e;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The Phase 1 study with PN-232 is under progress with study completion expected by mid-2022.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="background-color:#ffffff;color:#201f1e;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#201f1e;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Additional development in IBD is expected to initiate in 2022.</span></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we became eligible to receive a $7.5 million milestone payment from Janssen triggered by the completion of data collection for PN-235 Phase 1 activities. We<span style="background-color:#ffffff;"> will earn a $25.0 million milestone in connection with the initiation of the first Phase 2 study of a second-generation candidate, and a $10.0 million milestone in connection with the initiation of the second Phase 2 study of a second-generation candidate.&#160;We remain eligible for up to approximately $900.0 million&#160;in development-related milestone payments, in addition to the $87.5M in milestones already earned.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our clinical assets are all derived from our proprietary discovery platform. Our platform enables us to engineer novel, structurally constrained peptides that are designed to retain key advantages of both orally delivered small molecules and injectable antibody drugs in an effort to overcome many of their limitations as therapeutic agents. Importantly, constrained peptides can be designed to potentially alleviate the fundamental instability inherent in traditional peptides to allow different delivery forms, such as oral, subcutaneous, intravenous, and rectal. We continue to use our peptide technology platform to discover product candidates against targets in disease areas with significant unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Business Impact </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to risks and uncertainties as a result of the&#160;ongoing COVID-19&#160;pandemic. We are continuing to closely monitor the impact of the COVID-19 pandemic on our business and have taken and continue to take proactive efforts to protect the health and safety of our patients, study investigators, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on our activities is uncertain and difficult to predict, as the pandemic and the response to the pandemic continue to evolve. Capital markets and economies worldwide have been significantly impacted by the&#160;COVID-19&#160;pandemic, and the pandemic has contributed to a global economic recession. Such economic disruption could have a material adverse effect on our business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on our activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas we, our suppliers and our manufacturers operate and areas where our clinical trial sites are located; the development and spread of COVID-19 variants; the timing, extent, effectiveness and durability of vaccine programs or other treatments; and new or continuing travel and other restrictions and public health measures,&#160;such as social distancing, business closures or disruptions. Accordingly, the extent and severity of the impact on our existing and planned clinical trials, manufacturing, collaboration activities and operations is uncertain and cannot be fully predicted. We have experienced delays in our existing and planned clinical trials due to the worldwide impacts of the pandemic. Our future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials and collaboration activities, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on operating activities and employees, and the ongoing impact of any initiatives or programs that we may undertake to address financial and operational challenges. As of the date of issuance of this Quarterly Report on Form 10-Q, the extent to which the&#160;COVID-19&#160;pandemic may materially impact our future financial condition, liquidity or results of operations is uncertain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have incurred net losses in each year since inception and we do not anticipate achieving sustained profitability in the foreseeable future. Our net loss was $33.8 million and $88.6 million for the three and nine months ended September 30, 2021, respectively. Our net loss was $7.8 million and $47.3 million for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021, we had an accumulated deficit of $372.5 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant research, development, commercialization and other expenses related to our ongoing operations and product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development, including clinical development activities under our worldwide license and collaboration agreement with Janssen, and, as a result, we expect to continue to incur losses in the future as we continue our development of, and seek regulatory approval for, our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Janssen License and Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 27, 2021, we entered into an amended and restated License and Collaboration Agreement (&#8220;Restated Agreement&#8221;) with Janssen. The Restated Agreement amends and restates the License and Collaboration Agreement, dated May 26, 2017, by and between us and Janssen (as amended by the First Amendment thereto, effective May 7, 2019, the &#8220;Original Agreement&#8221;). Janssen is a related party to us as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of ours, and Janssen are both subsidiaries of Johnson &amp; Johnson. The Original Agreement became effective on July 13, 2017. Upon the effectiveness of the Original Agreement, we received a non-refundable, upfront cash payment of $50.0 million from Janssen. Upon the effectiveness of the First Amendment, we received a $25.0 million payment from Janssen in 2019. We also received a $5.0 million payment triggered by the successful nomination of a second-generation IL-23R antagonist development compound during the first quarter of 2020. In October 2021, we became eligible to receive a $7.5 million milestone payment from Janssen triggered by completion of the data collection for PN-235 Phase 1 activities. <span style="color:#201f1e;">Following a pre-established interim analysis criteria, a portfolio decision was made to discontinue further development of first generation candidate PTG-200, in favor of further development of two second-generation candidates PN-235 and PN-232 with superior product profiles.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 3 to the condensed consolidated financial statements included elsewhere in this report for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Polices and Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We have taken into consideration any known COVID-19 impacts in our accounting estimates to date and are not aware of any additional specific events or circumstances that would require any additional updates to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize compensation costs related to stock options accounted for under Accounting Standards Codification Topic 718 &#8211; &#8220;<i style="font-style:italic;">Stock Compensation&#8221;</i> based on the estimated fair value of the awards on the date of grant. We estimate the fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The estimated fair value of the stock-based awards is generally recognized over the requisite service period, which is generally the vesting period of the respective awards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. Expected volatility generally requires significant judgement to determine. For the year ended December 31, 2020, our expected volatility was estimated based upon a mix of 75% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and 25% of the volatility of our own stock price since our initial public offering in August 2016. Beginning January 1, 2021, our expected volatility is estimated based upon a mix of 50% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and 50% of the volatility of our own stock price since our initial public offering in August 2016. These comparable companies are chosen based on their similar size, stage in the life cycle, or area of specialty. We will continue to apply this process until a longer period of historical information regarding the volatility of our own stock price becomes available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, we granted performance share units (&#8220;PSUs) to certain of our executives. <span style="white-space:pre-wrap;">Stock-based compensation expense associated with PSUs is based on the fair value of our common stock on the grant date, which equals the closing price of our common stock on the grant date. We recognize compensation expense over the vesting period of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable. The total fair value of the PSUs granted in February 2021 was $2.6 million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no other material changes in our critical accounting policies during the&#160;three and nine months ended September 30, 2021, as compared to those disclosed in&#160;<i style="font-style:italic;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8221;</i>&#160;in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 10, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our license and collaboration revenue is derived from payments we receive under the Janssen License and Collaboration Agreement. See Note 3 to the condensed consolidated financial statements included elsewhere in this report for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred, unless there is an alternative future use in other research and development projects or otherwise. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when payment has been made. In instances where we enter into agreements with third parties to provide research and development services to us, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service and may include upfront payments,&#160;monthly payments, and payments upon the completion of milestones or the receipt of deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">expenses incurred under agreements with clinical study sites that conduct research and development activities on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">employee-related expenses, which include salaries, benefits and stock-based compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">laboratory vendor expenses related to the preparation and conduct of pre-clinical, non-clinical, and clinical studies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs related to production of clinical supplies and non-clinical materials, including fees paid to contract manufacturers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">license fees and milestone payments under license and collaboration agreements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">facilities and other allocated expenses, which include expenses for rent and maintenance of facilities, information technology, depreciation and amortization expense and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize the funds from grants under government programs as a reduction of research and development expenses when the related research costs are incurred. In addition, we recognize the funds related to our Australian research and development refundable cash tax incentive that are not subject to refund provisions as a reduction of research and development expenses. The research and development tax incentives are recognized when there is reasonable assurance that the incentives will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. We evaluate our eligibility under the tax incentive program as of each balance sheet date and make accruals and related adjustments based on the most current and relevant data available. We may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We allocate direct costs and indirect costs incurred to product candidates when they enter clinical development. For product candidates in clinical development, direct costs consist primarily of clinical, pre-clinical, and drug discovery costs, costs of supplying drug substance and drug product for use in clinical and pre-clinical studies, including clinical manufacturing costs, contract research organization fees, and other contracted services pertaining to specific clinical and pre-clinical studies. Indirect costs allocated to our product candidates on a program specific basis include research and development employee salaries, benefits, and stock-based compensation, and indirect overhead and other administrative support costs. Program-specific costs are unallocated when the clinical expenses are incurred for our early-stage research and drug discovery projects, our internal resources, employees and infrastructure are not tied to any one research or drug discovery project and are typically deployed across multiple projects. As such, we do not provide financial information regarding the costs incurred for early-stage pre-clinical and drug discovery programs on a program-specific basis prior to the clinical development stage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses incurred during the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;white-space:nowrap;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,881</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,322</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,128</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,881</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,919</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,847</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,394</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,867</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PN-235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 567</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,799</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PN-232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 183</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,108</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 338</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 307</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical and drug discovery research expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,126</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,779</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,371</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,695</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Milestone payment obligation to former collaboration partner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants and tax incentives expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (467)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (250)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,280)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (838)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,020</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">        </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect our research and development expenses will increase as we progress our product candidates into later stage clinical trials, expand the number of ongoing clinical trials, advance development activities under the Janssen License and Collaboration Agreement, advance our discovery research projects into the pre-clinical stage and continue our early-stage research. The process of conducting research, identifying potential product candidates and conducting pre-clinical and clinical trials necessary to obtain regulatory approval is costly and time intensive. We may never succeed in achieving marketing approval for our product candidates regardless of our costs and efforts. The probability of success of our product candidates may be affected by numerous factors, including pre-clinical data, clinical data, competition, manufacturing capability, our ability to receive, and the timing of, regulatory approvals, market </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conditions, and our ability to successfully commercialize our products if they are approved for marketing. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. Our research and development programs are subject to change from time to time as we evaluate our priorities and available resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist of personnel costs, allocated facilities costs and other expenses for outside professional services, including legal, human resources, audit and accounting services, and pre-commercial selling and marketing costs. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of expenses for rent and maintenance of facilities, information technology, depreciation and amortization expense and other supplies. We expect to continue to incur expenses to support our continued operations, including expenses related to existing and future compliance with rules&#160;and regulations of the SEC and those of the national securities exchange on which our securities are traded, insurance expenses, investor relations, professional services and general overhead and administrative costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of interest earned on our cash, cash equivalents and marketable securities, which is comprised of contractual interest, premium amortization and discount accretion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists of interest recognized on borrowings under our term loan facility, which is comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss on Early Repayment of Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Loss on early repayment of debt consists of prepayment and final payment fees paid upon the early repayment of our long-term debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other expense, net consists primarily of amounts related to foreign exchange gains and losses and related items.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Three&#160;Months Ended September 30, 2021 and 2020 </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:nowrap;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License and collaboration revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,286</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,114</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,828)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (22)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,956</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,995</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,961</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 131</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,256</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,891</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,365</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,212</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,886</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,326</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 112</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,926)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,772)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26,154)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 337</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 122</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (19)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (59)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,804)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,763)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26,041)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 335</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,804)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,763)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26,041)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 335</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Includes $2.6 million and $1.0 million of non-cash stock-based compensation expense for the three&#160;months ended September 30, 2021 and 2020, respectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Includes $2.2 million and $0.9 million of non-cash stock-based compensation expense for the three&#160;months ended September 30, 2021 and 2020, respectively.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">License and collaboration revenue decreased $2.8 million, or 22%, from $13.1 million for the three months ended September 30, 2020 to $10.3 million for the three months ended September 30, 2021. We recognized $8.0 million as a cumulative catch-up amount during the three months ended September 30, 2021, following the amendment of our collaboration agreement for the development of IL23R assets with Janssen. This cumulative catch-up was primarily the result of an acceleration of our cumulative performance completed under our obligation, following the amendment to the collaboration which reduced the remaining services that we are responsible to provide  We are nearing completion of our remaining services to be provided to Janssen under the collaboration, in particular, both the Phase 1 trials in PN-235 &amp; PN-232, which are expected to be completed in the fourth quarter of 2021 and second quarter 2022, respectively.  Revenue for the prior year&#8217;s third quarter of 2020 also included an estimate update for services completed versus remaining services to be performed under the Janssen collaboration agreement which accelerated revenue recognition.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have determined that the transaction price of the initial performance obligation under the Restated Janssen License and Collaboration Agreement was $105.7 million as of September 30, 2021, an increase of $9.9 million from the transaction price of $95.8 million as of June 30, 2021 under the Original Agreement. In order to determine the transaction price, we evaluated all payments expected to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. We determined that the transaction price includes  $80.0 million of nonrefundable payments received to date, $17.9 million of reimbursement from Janssen for services performed for IL-23R antagonist compound research costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to the completion of the clinical data collection Phase 1 activities for PN-235 and $8.4 million of development cost reimbursement receivable from Janssen, partially offset by $8.1 million of net cost reimbursement due to Janssen for services performed. The increase in transaction price from June 30, 2021 to September 30, 2021 was primarily due to changes related to the Second Amendment to the Janssen License and Collaboration Agreement. We re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,881</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,322</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,559</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 79</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,919</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,847</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,072</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 184</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 567</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 567</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 183</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (172)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (94)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (23)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical and drug discovery research expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,126</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,779</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,347</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Milestone payment obligation to former collaboration partner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants and tax incentives expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (467)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (250)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (217)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,961</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 131</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*Percentage not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Research and development expenses increased $21.0 million, or 131%, from $16.0 million for the three&#160;months ended September 30, 2020 to $37.0 million for the three&#160;months ended September 30, 2021. The increase was primarily due to an increase of $7.1 million in PN-943 clinical trial and development costs following the initiation of the Phase 2 trial in UC in 2020; an increase of $6.6 million in rusfertide clinical trial and development costs, including the ongoing Phase 2 trials in PV, which began in December 2019 and the first quarter of 2021, respectively, and HH, which began in early 2020, and clinical and contract manufacturing activities in preparation for a planned global Phase 3 clinical trial of rusfertide in PV; $4.0 million of expenses related to milestone payments and obligations under the Zealand Agreement for rusfertide pursuant to the resolution of related arbitration; an increase of $2.3 million in preclinical and drug discovery research expenses; $0.8 million of Phase 1 clinical trial and development costs for PN-232; and $0.6 million of Phase 1 clinical trial and development costs for PN-235. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We had 92 and 57 full-time equivalent research and development employees as of September 30, 2021 and 2020, respectively. Research and development expenses for the three months ended September 30, 2021 included increases $1.6 million in stock-based compensation expense and $1.6 million of other personnel related expenses compared to the three months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">General and administrative expenses increased $2.4 million, or 48%, from $4.9 million for the three&#160;months ended September 30, 2020 to $7.3 million for the three&#160;months ended September 30, 2021 primarily due to an increase of $1.6 million in personnel expenses, a $1.0 million increase in consulting fees to support the growth of our business, and a $0.2 million increase in insurance costs, partially offset by a $0.4 million decrease in legal fees. The increase in personnel expenses was primarily due to increases of $1.3 million in stock-based compensation expense and $0.2 million in wages and benefits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We had 24 and 19 full-time equivalent general and administrative employees as of September 30, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Nine&#160;Months Ended September 30, 2021 and 2020 </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:top;white-space:nowrap;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License and collaboration revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,740</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,978</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,238)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,633</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55,020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,613</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,644</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,292</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 107,569</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 68,664</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38,905</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (88,829)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (45,686)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,143)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 94</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 321</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 820</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (499)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (61)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (471)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 471</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on early repayment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (585)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 585</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (136)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (99)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 268</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (88,644)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (45,959)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (42,685)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 93</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,305)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,305</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (88,644)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (47,264)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (41,380)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Includes $6.3 million and $3.1 million of non-cash stock-based compensation expense for the nine&#160;months ended September 30, 2021 and 2020, respectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Includes $5.1 million and $2.8 million of non-cash stock-based compensation expense for the nine&#160;months ended September 30, 2021 and 2020, respectively.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">License and collaboration revenue decreased $4.2 million, or 18%, from $23.0 million for the nine months ended September 30, 2020 to $18.7 million for the nine months ended September 30, 2021, which was primarily related to a decrease in services provided under the Janssen License and Collaboration Agreement recognized based on proportional performance partially offset by an $8.0 million cumulative catch-up amount recognized during the nine months ended September 30, 2021, following the amendment of our collaboration agreement for the development of IL23R assets with Janssen. This cumulative catch-up was primarily the result of an acceleration of our cumulative performance completed under our obligation, following the amendment to the collaboration which reduced the remaining services that we are responsible to provide  Revenue for the nine months ended September 30, 2020 included  an update in the amounts forecast for future services remaining to be performed under the Janssen License and Collaboration Agreement, which correspondingly increased our overall cumulative percentage of completion of our performance obligation during the third quarter of 2020, coupled with continued performance and delivery of services under the ongoing Janssen License and Collaboration Agreement. We are nearing completion of our remaining services to be provided to Janssen under the collaboration, in particular, both the Phase 1 trials in PN-235 &amp; PN-232, which are expected to be completed in the fourth quarter of 2021 and second quarter 2022, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We have determined that the transaction price of the initial performance obligation under the Restated Janssen License and Collaboration Agreement was $105.7 million as of September 30, 2021, an increase of $7.1 million from the transaction price of $98.6 million as of December 31, 2020 under the Original Agreement. In order to determine the transaction price, we evaluated all payments expected to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. We determined that the transaction price includes  $80.0 million of nonrefundable payments received to date, $17.9 million of reimbursement from Janssen for services performed for IL-23R antagonist compound research costs and other services, and estimated variable consideration consisting of a $7.5 million milestone  payment subject to the completion of the clinical data collection Phase 1 activities for PN-235 and $8.4 million of development cost reimbursement receivable from Janssen, partially offset by $8.1 million of net cost reimbursement due to Janssen for services performed. The increase in transaction price from December 30, 2020 to September 30, 2021 was due primarily to changes related to the Second Amendment to the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Janssen License and Collaboration Agreement. We re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37,128</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,881</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,247</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,394</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,867</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,527</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,799</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,799</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,108</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,095)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (99)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 338</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical and discovery research expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,371</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,695</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,676</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Milestone payment obligation to former collaboration partner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants and tax incentives expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,280)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (838)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,442)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 172</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,613</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*Percentage not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Research and development expenses increased $32.6 million, or 59%, from $55.0 million for the nine&#160;months ended September 30, 2020 to $87.6 million for the nine&#160;months ended September 30, 2021. The increase was primarily due to an increase of $14.2 million in rusfertide clinical trial and development costs as the clinical trials have enrolled and progressed, including the ongoing Phase 2 trials in PV, which began in December 2019 and the first quarter of 2021, respectively, and HH, which began in early 2020, and clinical and contract manufacturing activities incurred in 2021 in preparation for the ongoing Phase 2 trials and a planned global Phase 3 clinical trial of rusfertide in PV; $8.5 million in PN-943 clinical trial and development costs following the initiation of the Phase 2 trial in UC during the second quarter of 2020 and related contract manufacturing activities incurred in 2021; $4.0 million of expenses related to milestone payments and obligations under the Zealand Agreement for rusfertide pursuant to the resolution of related arbitration; $3.8 million of Phase 1 clinical trial and development costs for PN-235 beginning in December 2020, an increase of $3.7 million in preclinical and drug discovery research expenses, and $0.9 million of Phase 1 clinical trial and development costs for PN-232 initiated in May 2021. These increases were partially offset by a $1.4 million increase in grant and accrued refundable cash tax incentives and a decrease of $1.1 million in PTG-200 clinical trial and development expenses under the Janssen License and Collaboration Agreement due to our delivery of substantially all agreed-upon services for the PTG-200 Phase 2 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We had 92 and 57 full-time equivalent research and development employees as of September 30, 2021 and 2020, respectively. Research and development expenses for the nine months ended September 30, 2021 included increases of $3.1 million in stock-based compensation expense and $3.1 million of other personnel-related expenses compared to the nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">General and administrative expenses increased $6.3 million, or 46%, from $13.6 million for the nine&#160;months ended September 30, 2020 to $19.9 million for the nine&#160;months ended September 30, 2021 primarily due to an increase of $3.5 million in personnel expenses, $1.4 million in consulting expenses, $0.7 million in market research expenses, and $0.5 million in recruiting expenses to support the growth of our operations, and a $0.2 million increase in legal fees. The increase in personnel expenses was primarily due to increases of $2.3 million in stock-based compensation expense and $1.2 million in wages and salaries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We had 24 and 19 full-time equivalent general and administrative employees as of September 30, 2021 and 2020, respectively. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Interest income decreased $0.5 million, or 61%, from $0.8 million for the nine months ended September 30, 2020 to $0.3 million for the nine months ended September 30, 2021. This decrease was due primarily to the recent record low interest rate environment and a change in the mix of marketable securities compared to the prior year period, despite higher interest-earning asset balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Interest Expense  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>Interest expense of $0.5 million for the nine months ended September 30, 2020 reflects interest expense on our long-term debt under our term credit facility. We prepaid our outstanding long-term debt under our term credit facility during the second quarter of 2020. We executed a payoff letter to release all obligations under the term credit facility during the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss on Early Repayment of Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Loss on early repayment of debt of $0.6 million for the nine months ended September 30, 2020 reflects prepayment and final payment fees paid in connection with the early repayment of our term loan in June 2020. We had no debt outstanding as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other expense, net was $0.1 million for the nine months ended September 30, 2021 compared to zero for the nine months ended September 30, 2020. The change was due primarily to an increase in foreign exchange losses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax expense decreased $1.3 million, or 100%, from $1.3 million for the nine months ended September 30, 2020 to zero for the nine months ended September 30, 2021. Our effective income tax rate was 0% for the nine months ended September 30, 2021 as compared to 2.8% for the nine months ended September 30, 2020. During the second quarter of 2020, our Australia subsidiary sold beneficial rights to discovery intellectual property to our U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, we analyzed tax planning strategies and future income and concluded that a valuation allowance is necessary for our Australia subsidiary. Income tax expense for the nine months ended September 30, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain tax position liabilities. We maintained a full valuation allowance on our tax position as of September 30, 2021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, we have funded our operations primarily from net proceeds from the sale of shares of our common stock and payments under collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2020, we filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which we completed an underwritten public offering of 4,761,904 shares of common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of our common stock at a price of $21.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by us, were $107.6 million. In June 2021, pursuant to Registration Statement No. 333-251254, we completed an underwritten public offering of 3,046,358 shares of common stock at a public offering price of $37.75 per share and issued an additional 456,953 shares of common stock at a public offering price of $37.75 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commission and offering costs paid by us, were $123.8 million. This Form S-3ASR expires in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2019, we filed a registration statement on Form S-3 (File no. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement we entered into on November 27, 2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, we completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share, and we issued an additional 1,050,000 shares of our common stock at a price of $14.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by us, were $105.3 million. During the year ended December 31, 2020, we issued 2,483,719 shares under our ATM facility for net proceeds of $41.9 million. No shares were issued under the ATM facility during the three and nine months ended September 30, 2021. As of September 30, 2021, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility. This Form S-3 expires in October 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have received $80.0 million in non-refundable payments from Janssen since the inception of the Janssen License and Collaboration Agreement in 2017 through September 30, 2021, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Upon effectiveness of the agreement, we received a non-refundable, upfront cash payment of $50.0 million from Janssen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Upon effectiveness of the First Amendment, we became eligible to receive a $25.0 million payment from Janssen, which was received during the second quarter of 2019; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">In December 2019, we became eligible to receive a $5.0 million payment triggered by the successful nomination of a second-generation development compound, which was received during the first quarter of 2020.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we became eligible to receive a $7.5 million milestone payment from Janssen triggered by completion of the data collection for PN-235 Phase 1 activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also receive payments for services provided under the collaboration agreement and in-kind reimburses Janssen for certain costs they have incurred based on the cost sharing terms of the agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Pursuant to the amended and restated License and Collaboration Agreement with Janssen executed July 27, 2021 (the &#8220;Restated Agreement&#8221;), we will be eligible to receive clinical development, regulatory and sales milestones, if and as achieved. Upcoming potential development milestones for second-generation products include:  </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0 million for dosing of the third patient in the first Phase 2 clinical trial for any second-generation product for any indication; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$10.0 million for dosing of the third patient in the first Phase 2 clinical trial for any second-generation product for a second indication (i.e. an indication different than the indication which triggered the $25.0 million milestone described directly above).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Capital Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of September 30, 2021, we had $352.5 million of cash, cash equivalents and marketable securities and an accumulated deficit of $372.5 million. Our capital expenditures for nine months ended September 30, 2021 were $0.9 million. Our capital expenditures for the years ended December 31, 2020 and 2019 were $0.5 million and $1.0 million, respectively. Our primary uses of cash are to fund operating expenses, primarily our research and development expenditures, general and administrative costs and pre-commercialization costs. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses. We believe, based on our current operating plan and expected expenditures, that our existing cash, cash equivalents and marketable securities will be sufficient to meet our anticipated operating and capital expenditure requirements for at least the next 12&#160;months from the date of this filing. We have based this estimate on assumptions that may prove to be wrong. We could utilize our available capital resources sooner than we currently expect if our planned pre-clinical and clinical trials are successful or expanded, our product candidates enter new and more advanced stages of clinical development or our newer product clinical trials or advance beyond the discovery stage. We expect to require additional financing to advance our product candidates through clinical development and toward potential regulatory approval and to develop, acquire or in-license other potential product candidates. Such additional funding may come from raising additional capital, seeking access to additional debt, and additional collaborative or other arrangements with corporate sources, but such funding may not be available at terms acceptable to us, if at all. We anticipate that we will need to raise substantial additional funding, the requirements of which will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress, timing, scope, results and costs of advancing our clinical trials and pre-clinical studies for our product candidates, including the ability to enroll patients in a timely manner for our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of and ability to obtain clinical and commercial supplies and any other product candidates we may identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to successfully commercialize the product candidates we may identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the selling and marketing costs associated with our current product candidates and any other product candidates we may identify and develop, including the cost and timing of expanding our sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the achievement of development, regulatory and sales milestones resulting in payments to us from Janssen under the Janssen License and Collaboration Agreement or other such arrangements that we may enter into, and the timing of receipt of such payments, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing, receipt and amount of royalties under the Janssen License and Collaboration Agreement on worldwide net sales of IL-23 receptor antagonist compounds, upon regulatory approval or clearance, if any;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the amount and timing of sales and other revenues from our current product candidates and any other product candidates we may identify and develop, including the sales price and the availability of adequate third-party reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing, payment and amount of potential milestones and royalties due under our collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the cash requirements of any future acquisitions or discovery of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the time and cost necessary to respond to technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the extent to which we may acquire or in-license other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs necessary to attract, hire and retain qualified personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of maintaining, expanding and protecting our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of ongoing general and administrative activities to support the growth or our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials, other research and development activities and pre-commercialization costs. If we do raise additional capital through public or private equity offerings or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to fully estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the periods indicated (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (80,926)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (53,617)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,727)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,563)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 127,750</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 120,645</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Cash Flows from Operating Activities<b style="font-style:normal;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities for the nine months ended September 30, 2021 was $80.9 million, consisting of our net loss of $88.6 million and a net change of $6.9 million in net operating assets and liabilities, partially offset by $14.6 million in non-cash charges. Non-cash charges were primarily comprised of $11.4 million of stock-based compensation, $1.4 million of operating lease right-of-use asset amortization, $1.3 million of net amortization of discount on marketable securities, and $0.6 million of depreciation. The change in net operating assets and liabilities was primarily due to a decrease of $12.2 million in deferred revenue related to the Janssen License and Collaboration Agreement, an increase of $0.2 million in receivable from collaboration partner, an increase of $0.9 million in research and development tax incentive receivable, an increase in prepaid expenses and other assets of $2.6 million, a decrease of $1.5 million in operating lease liability, a decrease of $1.6 million in payable to collaboration partner, a decrease of $2.3 million in accounts payable and partially offset by an increase of $14.4 million in accrued expenses and other payables.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities for the nine months ended September 30, 2020 was $53.6 million, consisting of our net loss of $47.3 million and a net change of $16.0 million in net operating assets, partially offset by $9.7 million in non-cash charges. Non-cash charges were primarily comprised of $5.9 million of stock-based compensation, a $1.4 million change in net deferred tax asset, $1.3 million of operating lease right-of-use asset amortization, a $0.6 million loss on early prepayment of long-term debt and $0.6 million of depreciation and amortization, partially offset by $0.2 million of net accretion of discount on marketable securities. The change in net operating assets and liabilities was primarily due to a decrease of $20.7 million in deferred revenue related to the Janssen License and Collaboration Agreement, a $1.6 million decrease in prepaid expenses and other assets, a $1.5 million decrease in operating lease liability, and a $0.5 million increase in Australia research and development incentive receivable, partially offset by a decrease of $4.0 million in receivable from collaboration partner, an increase of $3.1 million in accrued expenses and other payables, an increase of $0.8 million in payable to collaboration partner, and an increase of $0.2 million in other liability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows from Investing Activities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities for the nine months ended September 30, 2021 was $43.7 million, consisting of proceeds from maturities of marketable securities of $213.1 million, offset by purchases of marketable securities of $255.9 million and purchases of property and equipment of $0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities for the nine months ended September 30, 2020 was $16.6 million, consisting of proceeds from maturities of marketable securities of $131.4 million, partially offset by purchases of marketable securities of $147.6 million and purchases of property and equipment of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows from Financing Activities<span style="font-style:normal;font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the nine months ended September 30, 2021 was $127.8 million, consisting of $124.0 million of cash proceeds from our public offering of common stock and $3.9 million from the issuance of common stock upon exercise of stock options and purchases of common stock under our employee stock purchase plan, partially offset by $0.2 million of tax withholding payments related to net settlement of restricted stock units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the nine months ended September 30, 2020 was $120.6 million, consisting primarily of cash proceeds from our public offering of common stock of $105.5 million, cash proceeds from ATM sales of $23.2 million, and proceeds from the issuance of common stock upon exercise of stock options and purchases of common stock under our employee stock purchase plan of $2.5 million, partially offset by early repayment of long-term debt of $10.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Other Commitments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our contractual obligations include minimum lease payments under our operating lease obligations. On July 2, 2021, we entered into an amendment to our facility lease agreement dated as of March 2017, as amended, to lease approximately 15,000 square feet of additional office space in Newark, California. See Note 10 to the condensed consolidated financial statements elsewhere in this Quarterly Report on Form 10-Q for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Janssen License and Collaboration Agreement, we share with Janssen certain development, regulatory and compound supply costs. The actual amounts that we pay Janssen or that Janssen pays us will depend on numerous factors, some of which are outside of our control and some of which are contingent upon the success of certain development and regulatory activities. On July 27, 2021, we entered into an amended and restated License and Collaboration Agreement (&#8220;Restated Agreement&#8221;) with Janssen Biotech, Inc., a Pennsylvania corporation (&#8220;Janssen&#8221;). The Restated Agreement amends and restates the License and Collaboration Agreement, dated May 26, 2017, by and between the Company and Janssen (as amended by the First Amendment thereto, effective May 7, 2019, the &#8220;Original Agreement&#8221;). See Note 3 to the condensed consolidated financial statements elsewhere in the Quarterly Report on Form 10-Q for additional information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 23, 2020, we initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand Pharma related to a collaboration agreement we and Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that we elect to further develop and meet specified conditions. On August 4, 2021, we and Zealand agreed to resolve the dispute and reached an Arbitration Resolution Agreement. See Note 11 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2021, there were no other material changes to our contractual obligations and commitments described under <i style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i> in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2020 filed with the SEC on March&#160;10, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_dedc6f6f_62c9_48ac_a54d_548e91e6a903"></a><a id="ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;3.</b></span>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks have primarily include interest rate sensitivities related to our borrowings and investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had $352.5 million and $307.8 million in cash, cash equivalents and marketable securities at September 30, 2021 and December&#160;31, 2020, respectively. Cash and cash equivalents consist of cash, money market funds, commercial paper and government bonds. Marketable securities consist of corporate bonds, commercial paper and government bonds. A portion of our investments may be subject to interest rate risk and could fall in value if market interest rates increase. Based on our interest rate sensitivity analysis, an immediate 100 basis point increase in interest rates would increase our interest income by approximately $2.2 million, while an immediate 100 basis point decrease in interest rates would decrease our interest income by approximately $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approximately $1.8 million and $1.0 million of our cash balance was located in Australia at September 30, 2021 and December 31, 2020, respectively. Our expenses, except those related to our Australian operations, are generally denominated in U.S. dollars. For our operations in Australia, the majority of the expenses are denominated in Australian dollars. To date, we have not had a formal hedging program with respect to foreign currency, but we may do so in the future if our exposure to foreign currency becomes more significant. A 10% increase or decrease in current exchange rates would not have a material effect on our results of operations.</p><a id="_e20f9ee4_c4ad_4f53_ad9f_356f6c4afabd"></a><a id="ITEM4CONTROLSANDPROCEDURES_256354"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;4.</b></span>CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As required by Rule&#160;13a-15(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this Quarterly Report. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7237c6ad_01c8_4efe_a57e_a0bcb44caa77"></a><a id="PARTIIOTHERINFORMATION_664238"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">PART&#160;II&#160;&#8211;&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="ITEM1LEGALPROCEEDINGS_914493"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;1.</b></span>LEGAL PROCEEDINGS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition. We were a party in the arbitration proceeding that was resolved during the third quarter of 2021, described in Note 11 to the condensed consolidated financial statements elsewhere in this Quarterly Report on Form 10-Q.</p><a id="_870db173_7f40_4c26_aea5_75d9959a1b25"></a><a id="ITEM1ARISKFACTORS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;1A.</b></span>RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. Investors should carefully consider the risks described below before making an investment decision. Our business faces significant risks and the risks described below may not be the only risks we face. If any of these risks occur, our business, results of operations or financial condition could suffer, and the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The following is a summary of the principal risks that could adversely affect our business, operations, and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to the COVID-19 Pandemic</b>&#8221; we describe risks to our business arising from the COVID-19 pandemic. The pandemic has and could continue to adversely impact our business, including our ongoing and planned clinical trials and preclinical and discovery research. The impacts on our business include, among others, delays to some of our ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Clinical Development</b>&#8221; we describe risks related to on our ongoing clinical development efforts. They include, among others, the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have no approved products and no historical product revenue, which makes it difficult to assess our future prospects and financial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are heavily dependent on the success of our product candidates in clinical development. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can occur at any stage of clinical development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity, including being</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> required by an independent data monitoring committee or regulatory authorities to, delay or halt our clinical trials, or if such side effects or adverse events are sufficiently severe or prevalent, order us to suspend or cease altogether further development of our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Financial Position and Capital Requirements</b>&#8221; we describe risks associated with our financial position and future capital requirements. They include, among others, the following: <span style="font-style:italic;font-weight:bold;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have never generated any revenue from product sales and may never be profitable.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We expect to require substantial additional funding. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Raising additional capital may cause dilution to our existing stockholders. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b>&#8221;<b style="font-weight:bold;"> </b><span style="white-space:pre-wrap;">we describe risks related to our reliance on third parties.  They include, among others, the following:</span><b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on Janssen Biotech, Inc. (&#8220;Janssen&#8221;) to continue the development of product candidates subject to our license and collaboration with Janssen, and to successfully commercialize any resulting products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our existing or future collaborations with third parties may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third parties to conduct our pre-clinical studies and clinical trials and are subject to risks associated with their businesses and performance of their obligations to us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third party contract manufacturers to manufacture our drug substance and clinical drug product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Regulatory Approval</b>&#8221; we describe risks related to the potential regulatory approval required to market our product candidates in the United States or other jurisdictions. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Commercialization of our Product Candidates</b>&#8221; we describe risks related to the commercialization of any our product candidates that are eventually approved for marketing. We have no marketing and sales organization and may not be able to effectively market and sell any products or generate product revenue if any of our product candidates are approved for marketing. Also, if we commercialize our product candidates abroad, we will be subject to the risks of doing business outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Business and Industry</b><span style="white-space:pre-wrap;">&#8221; we describe risks related to our business in general, and to our company in the biotechnology and pharmaceutical industry.  They include, among others, the following: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">face significant competition from other biotechnology and pharmaceutical companies. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our success depends on our ability to attract, retain and motivate qualified executives and other personnel.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may experience difficulties in managing the growth of our organization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are subject to risks associated with information technology systems or breaches of data security.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any misconduct by our employees, independent contractors, principal investigators, consultants and vendors could have a material adverse effect on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our headquarters is located near known earthquake fault zones. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Intellectual Property</b>&#8221;<b style="font-weight:bold;"> </b>we describe risks related to the intellectual property that is critical to the success of our business. They include, among others, the following:<b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are unable to obtain or protect intellectual property rights related to our product candidates and technologies, we may not be able to compete effectively in our markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Patents covering our product candidates could be found invalid or unenforceable.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Ownership of our Common Stock</b><span style="white-space:pre-wrap;">&#8221; we describe risks associated with owning our common stock.  They include, among others, the following:</span><b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our stock price has been and will likely continue to be volatile and may decline, regardless of our operating performance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any failure to maintain the adequacy of internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, or make it difficult </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">for stockholders to replace members of our board of directors</span><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the COVID-19 Pandemic </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic has and could continue to adversely impact our business, including our ongoing and planned clinical trials and preclinical and discovery research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The extent to which the ongoing COVID-19 pandemic will continue to impact our business is uncertain and cannot be predicted.  The pandemic&#8217;s impact on our business will depend on a variety of factors, including the timing, extent, effectiveness and durability of vaccine programs or other treatments, new or continuing travel and other restrictions and public health measures,&#160;such as social distancing, business closures or disruptions, and the development and spread of COVID-19 variants. The effectiveness of actions taken in the United States and other countries to contain, ameliorate the impact of and treat the disease and to address its impact, is not yet known. A number of jurisdictions, including California and other jurisdictions in the United States, have at various times begun re-opening only to return to restrictions in the face of increases in new COVID-19 cases. As the COVID-19 pandemic continues, we could experience additional disruptions or increased expenses that may adversely impact our business, including: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays or difficulties in enrolling patients in our ongoing clinical trials and our future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, or maintaining ongoing operations at such sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limitations in resources, including our employees, that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people or restrictions on movement or access to our facility as a result of government-imposed &#8220;shelter-in-place&#8221; or similar working restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">interruptions or delays in the operations of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in manufacturing, receiving the supplies, materials and services needed to conduct clinical trials and preclinical research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or require us to discontinue the clinical trial altogether; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or furloughs of government or contractor personnel. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, since March 2020, Alameda County, California, where our headquarters are located, has been subject to various &#8220;shelter-in-place&#8221; regulations and guidance related to the pandemic. While the &#8220;shelter-in-place&#8221; orders have terminated or been phased out along with the reopening of businesses in Alameda County, California, we may continue to be subject to capacity restrictions and health and safety recommendations that encourage continued social distancing and remote work, limiting or ability to return to pre-pandemic levels of activity. Our laboratory facilities currently remain open for research activities that cannot be conducted remotely, with heightened safety measures designed to minimize occupational exposure and reduce transmission of COVID-19 within our workplace. Our non-laboratory employees telecommute at least part-time, which may impact certain of our operations over the near term and long term. In addition, we may in the future resume a more restrictive remote work model due to the pandemic. These disruptions in our operations could negatively impact our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we may be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of patients and clinical sites, shipping drug product directly to patients rather than clinical sites, and measures to ensure that clinical data are collected pursuant to the study protocol and consistent with good clinical practices (&#8220;GCPs&#8221;). Patients who miss scheduled appointments, any interruption in study drug supply, or other consequence that may result in incomplete data being generated during a study as a result of the pandemic must be adequately documented and justified in accordance with FDA guidance. These additional requirements may be difficult to fulfill and may result in an incomplete data set, which could negatively impact the study results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition, and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Clinical Development </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a clinical-stage biopharmaceutical company with no approved products and no historical product revenue, which makes it difficult to assess our future prospects and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history as a publicly traded company. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. Our operations to date have been limited to developing our technology, undertaking pre-clinical studies and Phase 1 and Phase 2 clinical trials of our pipeline candidates and conducting research to identify additional product candidates. We have not yet successfully developed an approved product or generated revenue from product sales or successfully conducted a pivotal registration trial for one of our product candidates. Consequently, the ability to accurately assess our future operating results or business prospects is significantly more limited than if we had a longer operating history or approved products on the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect that our financial condition and operating results will fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control, including the success of our programs, decisions by regulatory bodies, actions taken by competitors and other factors identified in these risk factors. Accordingly, the likelihood of our success must be evaluated in light of many potential challenges and variables associated with a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical-stage biopharmaceutical company, many of which are outside of our control, and past results, including operating or financial results, should not be relied on as an indication of future results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are heavily dependent on the success of our product candidates in clinical development, and if any of these products fail to receive regulatory approval or are not successfully commercialized, our business would be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no product candidates that are in registrational or pivotal clinical trials or are approved for commercial sale, and we may never develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to our current product candidates and the development of other product candidates. We cannot be certain that our product candidates will receive regulatory approval or, if approved, be successfully commercialized. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of our product candidates will be subject to extensive regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other regulatory authorities in the United States and other countries. In addition, even if approved, our pricing and reimbursement will be subject to further review and discussions with payors. We are not permitted to market any product candidate in the United States until after approval of a new drug application (&#8220;NDA&#8221;) from the FDA, or in any foreign countries until approval by corresponding regulatory authorities. We will need to conduct larger, more extensive clinical trials in the target patient populations to support a potential application for regulatory approval by the FDA or corresponding regulatory authorities. Those trials, for rusfertide for PV or subsequent late-stage product candidates, may not demonstrate the safety and efficacy of our product candidates to support a marketing approval in the United States or other jurisdictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates require additional clinical development, regulatory approval and secure sources of commercial manufacturing supply. We cannot assure you that our clinical trials for our product candidates will be initiated or completed in a timely manner or successfully, or at all. Further we cannot be certain that we plan to advance any other product candidates into clinical trials. Moreover, any delay or setback in the development of any product candidate would be expected to adversely affect our business and cause our stock price to fall. For example, the announcement of the premature discontinuation of the global Phase 2 clinical trial of PTG-100 for the treatment of moderate-to-severe ulcerative colitis (&#8220;UC&#8221;) in March 2018 due to the interim analysis meeting futility criteria on the primary endpoint of clinical remission (that was subsequently confirmed to be due to human error in endoscopy reads by the original vendor) significantly depressed our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. The results of pre-clinical studies and early clinical trials of our product candidates and studies and trials of other products may not be predictive of the results of later-stage clinical trials. Any hypothesis formed from pre-clinical or early clinical observations for any of our product candidates may prove to be incorrect, and the data generated in animal models or observed in limited patient populations may be of limited value and may not be applicable in clinical trials conducted under the controlled conditions required by applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our planned pre-clinical studies and clinical trials, we expect to have to complete one or more large scale, well-controlled clinical trials to demonstrate substantial evidence of efficacy and safety for each product candidate we intend to commercialize. Further, given the patient populations for which we are developing therapeutics, we expect to have to evaluate long-term exposure to establish the safety of our therapeutics in a chronic-dose setting. We have never conducted a Phase 3 clinical trial or submitted an NDA. As a result, we have no history or track record to rely on when entering these phases of the development cycle. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Clinical trial failures may result from a multitude of factors including, but not limited to, flaws in trial design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety and/or efficacy traits of the product candidate. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including if a clinical trial is modified, suspended or terminated by us, by the institutional review boards or ethics committees of the institutions in which such clinical trials are being conducted, by a Data Safety Monitoring Board, for such trial or by the FDA or other regulatory authorities. Such authorities may impose a modification, suspension or termination due to a number of factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, on September 16, 2021, a full clinical hold by the FDA for the rusfertide clinical studies was triggered by a non-clinical finding in a 26-week rasH2 transgenic mouse model indicating benign and malignant subcutaneous skin tumors. On October 8, 2021, the FDA removed the full clinical hold on our rusfertide clinical studies and dosing in all clinical studies of rusfertide could be resumed. For additional information, see Risk Factor &#8211; &#8220;Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In addition, there are a significant number of global clinical trials in inflammatory bowel disease and in hematologic disorders that are currently ongoing, especially in Phases 2 and 3, making it highly competitive and challenging to recruit subjects. Furthermore, any negative results we may report in clinical trials of our product candidates, such as the premature termination of our Phase 2 clinical trial of PTG-100 for the treatment of moderate-to-severe UC, may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience material delays in the completion of any clinical trial, the reduction in remaining patent term would harm the commercial prospects for that product candidate and our ability to generate product revenue from any of these product candidates will be delayed. Any of these occurrences may harm our business, financial condition and prospects significantly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">All of our product candidates other than rusfertide, PTG-232, PN-235, PN-943 and PTG-100 are in research or pre-clinical development and have not entered into clinical trials. If we are unable to develop, test and commercialize our product candidates, our business will be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our strategy, we seek to discover, develop and commercialize new product candidates in addition to rusfertide, PTG-232, PN-235, PN-943 and PTG-100. Research programs to identify appropriate biological targets, pathways and product candidates require substantial scientific, technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our proprietary peptide platform may not result in any products of commercial value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have developed a proprietary peptide technology platform to enable the identification, testing, design and development of new product candidates. Our peptide platform may not yield additional product candidates that enter clinical development and, ultimately, become commercially valuable. Although we expect to continue to enhance the capabilities of our platform by developing and integrating existing and new research technologies, our enhancement and development efforts may not succeed.  As a result, we may not be able to advance our drug discovery capabilities as quickly as we expect or identify as many potential drug candidates as we desire.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If undesirable side effects or adverse events are caused by our product candidates or by other companies&#8217; similar approved drugs or product candidates, then we may elect to, or be required by an independent data monitoring committee or regulatory authorities to, delay or halt our clinical trials. If such side effects or adverse events are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sufficiently severe or prevalent, the FDA or comparable foreign regulatory authorities could order us to suspend or cease altogether further development of our product candidates. Even if our product candidates are approved, side effects or adverse events could result in significant delay in or denial of, regulatory approval, restrictive labeling, or potential product liability claims. Moreover, since our product candidate PN-943 and the product candidates under development in our collaboration with Janssen are in development for indications for which injectable antibody drugs have been approved, clinical trials for those product candidates may need to show a risk/benefit profile that is competitive with those existing products in order to obtain regulatory approval or, if approved, a product label that is favorable for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, on September 16, 2021 the Company&#8217;s clinical studies for rusfertide placed on a full clinical hold by the FDA. On October 8, 2021, per the FDA, the full clinical hold was lifted and dosing in all clinical studies of rusfertide could be resumed. We provided the FDA with all requested information as the basis for a Complete Response and subsequent removal of the clinical hold. In particular, we provided the requested individual patient clinical safety reports, updated the investigator brochure and patient informed consent forms, performed a comprehensive review of the most recent safety database, and included new safety and stopping rules in the study protocols. We are working closely with study investigators and clinical trial sites to resume dosing of patients in ongoing clinical trials with rusfertide after patients have been reconsented. The clinical hold was initially triggered by a recent non-clinical finding in a 26-week rasH2 transgenic mouse model indicating benign and malignant subcutaneous skin tumors. The rasH2 signal also prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials involving over 160 patients, and a comprehensive review of the safety database, including cases of suspected unexpected serious adverse reactions. No additional cancer cases, and no other unexpected safety signals, surfaced in this process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have focused our limited resources to pursue particular product candidates and indications, and consequently, we may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we have focused on research programs and product candidates mainly on the development of rusfertide, PN-943 and the product candidates developed in our Janssen collaboration. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration partnerships, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have incurred significant operating losses every year since inception and expect to continue to incur operating losses for the foreseeable future. As of September 30, 2021, we had an accumulated deficit of $372.5 million.  We expect to continue to incur significant research, development and other expenses related to our ongoing operations and product development. As a result, we expect to continue to incur losses in the future as we continue our development of, and seek regulatory approvals for, our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate generating revenue from sales of products for at least several years, if ever, and we do not yet have any product candidates in registration or pivotal clinical trials. If any of our product candidates fail in clinical trials or do not gain regulatory approval or fail to achieve market acceptance, we may never become profitable. Revenue we generate from our collaboration with Janssen, and any future collaboration arrangements may not be sufficient to sustain our operations. Failure to become and remain profitable may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed substantial amounts of cash since inception. Developing pharmaceutical product candidates, including conducting pre-clinical studies and clinical trials, is expensive. We expect to require substantial additional future capital in order to complete clinical development and, if we are successful, to commercialize any of our current product candidates. Further, in the event our Janssen License and Collaboration Agreement is terminated, we may not receive any additional fees or milestone payments under that agreement. Absent the funding support from this agreement, our further development of the collaboration product candidates would require significant additional capital from us, or the establishment of alternative collaborations with third parties, which may not be possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, we had cash, cash equivalents and marketable securities of $352.5 million. Based upon our current operating plan and expected expenditures, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next 12 months. However, we expect that we will need to have access to substantial additional funds in the future in order to complete clinical development or commercialize our product candidates to a point where our operations generate net cash inflows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates or technologies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek additional funding through a combination of equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. Our ability to raise additional capital may be adversely impacted by adverse economic conditions and market volatility. The incurrence of indebtedness and/or the issuance of certain equity securities could result in fixed payment obligations and could also result in certain additional restrictive covenants, such as limitations on our ability to incur debt and/or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations and/or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to our proprietary technology platform or product candidates. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Janssen does not elect to continue the development of product candidates subject to our Janssen collaboration, our business and business prospects would be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The product candidates in development pursuant to our Janssen collaboration may prove to have undesirable or unintended side effects or other characteristics adversely affecting their safety, efficacy or cost effectiveness that could prevent or limit their approval for marketing and successful commercial use, or that could delay or prevent the commencement and/or completion of clinical trials. Under the terms of the Janssen License and Collaboration Agreement, Janssen may terminate the agreement for convenience and without cause on written notice of a certain period. In addition, prior to any termination of the agreement, Janssen will generally have control over the further clinical development of PN-232, PN-235, PTG-200 and any other second-generation compounds. Janssen&#8217;s decisions with respect to such development will affect the timing and availability of potential future payments under the agreement, if any. If the research program or the Janssen License and Collaboration Agreement are terminated early, or if Janssen&#8217;s development activities are terminated early or suspended for an extended period of time, or are otherwise unsuccessful, our business and business prospects would be materially adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may have disagreements with Janssen during the term of the Janssen License and Collaboration Agreement, and if they are not settled amicably or in the favor of Protagonist, the result may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the risk of possible disagreements with Janssen regarding the development of our Janssen collaboration compounds or other matters under the Janssen License and Collaboration Agreement, such as interpretation of the agreement or ownership of proprietary rights. Also, after the period of collaborative development ends under the agreement, Janssen will have sole decision-making authority for product candidates resulting from the collaboration, which could lead to disputes with Janssen. Disagreements with Janssen could lead to litigation or arbitration, which would be expensive and would be time-consuming for our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining development and commercialization collaborations, any collaboration arrangements we enter into in the future may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other than our Janssen License and Collaboration Agreement, we have no active collaborations for any of our product candidates. Even if we establish other collaboration arrangements, any such collaboration may not ultimately be successful, which could have a negative impact on our business, results of operations, financial condition and growth prospects. If we enter into collaborations limited to certain territories, we may not maintain significant rights or control of future development and commercialization of any product candidate subject to the collaboration and potential disputes could develop in the future over the terms of the collaboration and the respective rights of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual obligations or do not meet regulatory requirements or expected deadlines, we may not be able to obtain timely regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon third party contract research organizations (&#8220;CROs&#8221;) to execute, monitor and manage clinical trials and collect data for our pre-clinical studies and clinical programs. We control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that their conduct meets regulatory requirements and that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. We and our CROs are required to comply with GCPs, which are regulations and guidelines promulgated by the FDA, the European Medicines Agency (&#8220;EMA&#8221;) and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may not accept the data or require us to perform additional clinical trials before considering our filing for regulatory approval or approving our marketing application. In addition, significant portions of the clinical studies for our product candidates are expected to be conducted outside of the United States, which will make it more difficult for us to monitor CROs and perform visits of our clinical trial sites (particularly during the ongoing pandemic) and will force us to rely heavily on CROs to ensure the proper and timely conduct of our clinical trials and compliance with applicable regulations, including GCPs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance and clinical drug product and we intend to rely on third parties to produce commercial supplies of any approved product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We rely on contract manufacturers to manufacture and provide product for us that meets applicable regulatory requirements. We do not currently have, nor do we plan to develop, the infrastructure or capability internally to manufacture our drug supplies and we expect to continue to depend on contract manufacturers for the foreseeable future. As we proceed with the development and potential commercialization of our product candidates, we will need to increase the scale at which the drug is manufactured which will require the development of new manufacturing processes to potentially reduce the cost of goods. We will rely on our internal process research and development efforts and those of contract manufacturers to develop the good manufacturing processes (&#8220;GMPs&#8221;) required for cost-effective, large-scale production. If we and our contract manufacturers are not successful in converting to commercial-scale manufacturing, then our product costs may not be competitive and the development and/or commercialization of our product candidates would be materially adversely affected. Moreover, our contract manufacturers are the sole source of supply for our clinical product candidates. If we were to experience an unexpected loss of supply for any reason, whether as a result of manufacturing, supply or storage issues, natural disasters, the ongoing COVID-19 pandemic or otherwise, we could experience delays, disruptions, suspensions or termination of our clinical study and planned development program, or be required to restart or repeat, any ongoing clinical trials.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely on our contract manufacturers to purchase from third party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that our vendors use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, for commercial sale. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a contract manufacturer or other third party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy and time consuming, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is substantially dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, the EMA or any other foreign regulatory authority, and we may never receive such regulatory approval for any of our product candidates. The time required to obtain approval by the FDA and comparable foreign authorities is difficult to predict, typically takes many years following the commencement of clinical trials and depends upon numerous factors. Approval policies, regulations and the types and amount of clinical and manufacturing data necessary to gain approval may change during the course of clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we have in development or may seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the results of clinical trials may fail to achieve the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data submitted in support of regulatory approval;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the data collected from pre-clinical studies and clinical trials of our product candidates may not be sufficient to support the submission of an NDA, supplemental NDA, or other regulatory submissions necessary to obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we or our contractors may not meet the GMP and other applicable requirements for manufacturing processes, procedures, documentation and facilities necessary for approval by the FDA or comparable foreign regulatory authorities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes to the approval policies or regulations of the FDA or comparable foreign regulatory authorities with respect to our product candidates may result in our clinical data becoming insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we were to obtain regulatory approval, regulatory authorities may approve our product candidates for fewer or more limited indications than what we requested approval for, may include safety warnings or other restrictions that may negatively impact the commercial viability of our product candidates, including the potential for a favorable price or reimbursement at a level that we would otherwise intend to charge for our products. Likewise, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or the conduct of an expensive risk-evaluation and mitigation system, which could significantly reduce the potential for commercial success or viability of our product candidates. Any of the foregoing possibilities could materially harm the prospects for our product candidates and business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to obtain orphan drug designations from the FDA and/or EU for our product candidates, as applicable, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy includes filing for orphan drug designation where available for our product candidates. Rusfertide has received orphan drug designation for the treatment of patients with PV from the FDA and the European Union (&#8220;EU&#8221;). Despite this designation, we may be unable to maintain the benefits associated with orphan drug status, including market exclusivity. We may not be the first to obtain regulatory approval of a product candidate for a given orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet patient needs. Further, even if we obtain orphan drug designation exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval for a given active ingredient will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no marketing and sales organization. To the extent any of our product candidates for which we maintain commercial rights is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell any products or generate product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to commercialize any of our product candidates that receive marketing approval, we will have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of any of our product candidates, we may elect to build a targeted specialty sales force which will be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. With respect to our product candidates, we may choose to partner with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, and in the case of the Janssen License and Collaboration Agreement, we may elect to exercise our Co-Detailing Option (allows us to elect to provide up to 30% of the selling effort in the United States for any IL-23R antagonist compounds approved for commercial sale), which would require us to establish a U.S. sales team. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, in the United States in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, (collectively, the &#8220;ACA&#8221;) was enacted to increase access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and the health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The law has continued the downward pressure on pharmaceutical pricing, especially under the Medicare program, and increased the industry&#8217;s regulatory burdens and operating costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, former President Trump signed Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been enacted. The Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and the medical device tax and, effective January 1, 2021, also eliminated the health insurance tax. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;) among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221;  On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">as well. The U.S. Supreme Court is currently reviewing this case, but it is unclear when a decision will be made. On February 10, 2021, the Biden administration withdrew the federal government&#8217;s support for overturning the ACA. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and will remain open until August 15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional action is taken by Congress. COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2021. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period in which the government may recover overpayments to providers from three to five years. </p><a id="_Hlk63689237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently conduct, and intend to continue to conduct, a substantial portion of the clinical trials for our product candidates outside of the United States. If approved, we may commercialize our product candidates abroad. We will thus be subject to the risks of doing business outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently conduct, and intend to continue to conduct, a substantial portion of our clinical trials outside of the United States and, if approved, we intend to also market our product candidates outside of the United States. We are thus subject to risks associated with doing business outside of the United States. Our business and financial results in the future could be adversely affected due to a variety of factors associated with conducting development and marketing of our product candidates, if approved, outside of the United States, including varying medical standards and practices, geopolitical risks, uncertainty around intellectual property protection, and regulatory risks, such as compliance with the Foreign Corrupt Practices Act. If we are unable to anticipate and address these risks properly, our business and financial results will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business and Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors worldwide, including major multinational pharmaceutical companies, biotechnology companies, specialty pharmaceutical and generic pharmaceutical companies as well as universities and other research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, and experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of newer technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, pharmaceutical products that are easier to develop, more effective or less costly than any product candidates that we are currently developing or that we may develop. If approved, our product candidates are expected to face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate advantages in efficacy, convenience, tolerability or safety in order to overcome price competition and to be commercially successful. If our competitors succeed in obtaining FDA, EMA or other regulatory approval or discovering, developing and commercializing drugs before we do, there would be a material adverse impact on the future prospects for our product candidates and business. For example, in June <span style="background-color:#ffffff;color:#121212;white-space:pre-wrap;">2020, the FDA accepted a Biologics License Application for ropeginterferon alfa-2b for use in treatment for patients with PV in the absence of symptomatic splenomegaly from PharmaEssentia Corporation, the manufacturer of the novel pegylated interferon. A decision from the FDA on this application is expected in early 2021.  We also face competition in certain instances from the existing standards of care, which may be significantly less expensive than our expected drug prices. For example, one widely used treatment for PV and hereditary hemochromatosis (&#8220;HH&#8221;) patients is phlebotomy and/or chelation therapy. While patients may not like therapies that involve frequent blood draws, these </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#121212;white-space:pre-wrap;">therapies are inexpensive and may present pricing challenges for us if our drug candidates are successfully developed and approved. </span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with state and federal healthcare regulatory laws, we could face substantial penalties, damages, fines, disgorgement, integrity oversight and reporting obligations, exclusion from participation in governmental healthcare programs, and the curtailment of our operations, any of which could adversely affect our business, operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any future product candidates we may develop or any product candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Anti-Kickback Statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal false claims laws, including the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which also imposes obligations, including mandatory contractual terms, on HIPAA-covered entities, their business associates as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal civil monetary penalties statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Physician Payments Sunshine Act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the ACA, among other things, amended the intent requirements of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. While we have worked to structure our arrangements to comply with applicable laws, because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use our product candidates, if approved, to be in violation of applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued to increase their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of significant investigations, prosecutions, convictions and settlements in the healthcare industry. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could significantly increase our costs or otherwise have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, exclusion from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If, and to the extent that, Janssen or we are unable to comply with these regulations, our ability to earn potential royalties from worldwide net sales of Janssen collaboration product candidates would be materially and adversely impacted. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. The imposition of any of these penalties or other commercial limitations could negatively impact our collaboration with Janssen or cause Janssen to terminate the Janssen License and Collaboration Agreement, either of which would materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical and regulatory personnel. We are highly dependent on our existing senior management team. The loss of the services of any of our executive officers or other key employees and our inability to find suitable replacements would harm our research and development efforts, our collaboration efforts, as well as our business, financial condition and prospects. Our success also depends on our ability to continue to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing, marketing, sales, general and administrative and management training and skills.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other biopharmaceutical and pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Many are located in areas of the country with lower costs of living. Any or all of these factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize product candidates and to grow our business and operations as currently contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to expand the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, we had 116 full-time equivalent employees, including 92 full-time equivalent employees engaged in research and development. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, scientific, sales, marketing, research, development, regulatory, manufacturing, financial and other resources. In addition, as our operations expand, we expect that we will need to manage relationships with strategic collaborators, CROs, contract manufacturers, suppliers, vendors and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. We may not be successful in accomplishing these tasks in growing our company, and our failure to accomplish any of them could adversely affect our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">communications. The size and complexity of our internal computer systems and those of our CROs, contract manufacturers, collaboration partner, and other third parties on which we rely may make them potentially vulnerable to breakdown, telecommunications and electrical failures, malicious intrusion such as ransomware and computer viruses that may result in the impairment of key business processes. Those systems and processes require appropriate training and adherence to security protocols by our personnel and third-party personnel. In addition, our systems are potentially vulnerable to data security breaches, by employees or others, that may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property or could lead to the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others. A malicious intrusion, data security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, consultants or vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations established and enforced by comparable foreign regulatory authorities, or (iv) laws that require the true, complete and accurate reporting of financial information or data. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if approved, limit commercialization of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our product candidates. We currently carry clinical trial liability insurance for our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our headquarters is located near known earthquake fault zones. The occurrence of an earthquake, fire or any other catastrophic event could disrupt our operations or the operations of third parties who provide vital support functions to us, which could have a material adverse effect on our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and some of the third-party service providers on which we depend for various support functions are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism, pandemics and similar unforeseen events beyond our control. Our corporate headquarters, including our laboratory facilities, are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford medications and therapies. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain adequate pricing that will allow us to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree, but also have their own methods and approval process. Therefore, coverage and reimbursement can differ significantly from payor to payor. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours since there is no body of established practices and precedents for these new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries may cause us to price our product candidates on less favorable terms than we currently anticipate. In many countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain or protect intellectual property rights related to our product candidates and technologies, we may not be able to compete effectively in our markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely upon a combination of patent protection, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and technologies. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. We may or may not file or prosecute all necessary or desirable patent applications. The patent applications that we own or license may fail to result in issued patents in the United States or in other foreign countries, or they may fail to result in issued patents with claims that cover our product candidates or technologies in the United States or in other foreign countries. Any failure to identify relevant prior art relating to a patent or patent applications can invalidate a patent or prevent a patent from issuing. Even if patents have been issued, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patent and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates and technologies, or prevent others from designing around our claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the breadth or strength of protection provided by our patents is challenged, or if they fail to provide meaningful exclusivity for our product candidates, it could prevent us from asserting exclusivity over the covered product and allow generic competition. We cannot offer any assurances about which, if any, of our patent applications will issue, the breadth of any such issued patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition or other challenge to our patents or patent applications could significantly diminish the commercial prospects of any products that we develop. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, patents have a limited lifespan. In the United States and in many other countries, the natural expiration of a patent is generally 20 years after it is filed, and once any patents covering a product expire, generic competitors may enter the market. Our granted U.S. patents covering PN-943 and PTG-200 expire in 2035, and our granted U.S. patent covering rusfertide expires in 2034. Although the life of a patent can be increased based on certain delays caused by the U.S. Patent and Trademark Office (the &#8220;PTO&#8221;), this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we encounter delays in our clinical trials or in gaining regulatory approval, the period of time during which we could market any of our product candidates under patent protection, if approved, would be reduced. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States and many countries limit the enforceability of patents against third parties, including government agencies or government contractors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be effective or sufficient to prevent them from so competing. Also, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and applications. Non-compliance could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. For example, we primarily rely on trade secrets and confidentiality agreements to protect our peptide therapeutics technology platform. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. If we are unable to protect the confidentiality of our trade secrets and proprietary know-how or if competitors independently develop viable competing products, our business and competitive position may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we require all of our employees to assign their inventions to us, and endeavor to execute confidentiality agreements with all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how and other confidential information related to such technology, we cannot be certain that we have executed such agreements with all third parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can be we certain that our agreements will not be breached. If any of the parties to these confidentiality agreements breaches or violates the terms of such agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to adequately protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently discovered by our competitors. Competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, in the absence of patent protection, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, others may be able to exploit our proprietary peptide product candidate discovery technologies to identify and develop competing product candidates, and thus our competitive position could be adversely affected, as could our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits and other legal proceedings to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our issued patents or any patents issued as a result of our pending or future patent applications. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party in such infringement proceeding from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put any of our patent applications at risk of not yielding an issued patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and in the patent office in the United States and abroad. For example, our patent applications, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings, and our patents may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our patent rights, result in the loss of exclusivity, or limit our ability to stop others from using or commercializing our platform technology and products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us, the PTO or any foreign patent authority may be necessary to determine the priority or ownership of inventions with respect to our patent or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any issued patents covering our product candidates, including any patent that may issue as a result of our pending or future patent applications, could be found invalid or unenforceable if challenged in court in the United States or abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As more groups become engaged in scientific research and product development in fields related to our product candidates, such as IL-23R, &#945;4&#946;7integrin or hepcidin mimetics, the risk of our patents, or patents that we have in-licensed, being challenged through patent interferences, derivation proceedings, oppositions, re-examinations, litigation or other means will likely increase. An adverse outcome in a patent dispute could have a material adverse effect on our business by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">causing us to lose patent rights in the relevant jurisdiction(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">subjecting Janssen or us to litigation, or otherwise preventing the commercialization of product candidates in the relevant jurisdiction(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">requiring Janssen or us to obtain licenses to the disputed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">forcing Janssen or us to cease using the disputed technology; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">requiring Janssen or us to develop or obtain alternative technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An adverse outcome in a patent dispute could severely harm our collaboration with Janssen or cause Janssen to terminate the Janssen License and Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and, even if resolved in our favor, are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing or otherwise violating the patents and proprietary rights of third parties. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates, and there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates and technologies. Third parties may initiate legal proceedings against us alleging that we are infringing or otherwise violating their patent or other intellectual property rights. Given the vast number of patents in our field of technology, marketing of our product candidates or practice of our technologies could infringe existing patents or patents granted in the future. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending of which we are unaware that may later result in issued patents that may be infringed by the practice of our peptide therapeutics technology platform or the manufacture, use or sale of our product candidates. In addition, third parties may obtain patents in the future and claim that our product candidates or technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product or formulation itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. As our industry expands and more patents are issued, the risk increases that our product candidates or technologies may give rise to claims of infringement of the patent rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Even if we are successful in defending against any infringement claims, litigation is expensive and time-consuming and is likely to divert management&#8217;s attention and substantial resources from our core business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We may choose to seek, or may be required to seek, a license from the third-party patent holder and would most likely be required to pay license fees or royalties or both, each of which could be substantial. These licenses may not be available on commercially reasonable terms, however, or at all. Even if we were able to obtain a license, the rights we obtain may be nonexclusive, which would provide our competitors access to the same intellectual property rights upon which we are forced to rely. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In such an event, we would be unable to further practice our technologies or develop and commercialize any of our product candidates at issue, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant third party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect our ability to develop and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to protect our product candidates through acquisitions and in-licenses. We may find that our programs require the use of proprietary rights held by third parties or the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third party intellectual property rights from third parties we identify as necessary for our product candidates. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of former or other employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our employees and consultants, including our senior management and our scientific founders, have been employed or retained at universities or by other biotechnology or pharmaceutical companies, including potential competitors. Some of our employees and consultants, including each member of our senior management and each of our scientific founders, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or retention. We may be subject to claims that we or these employees, consultants or independent contractors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s or consultant&#8217;s former or other employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our issued patents, any patents issued as a result of our pending or future patent applications and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our issued patents, any patents issued as a result of our pending or future applications or other intellectual property. We have had in the past, and we may also have in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates and technologies. Litigation may be necessary to defend against these and other claims. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some of our intellectual property was generated through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our intellectual property rights were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations.&#160; These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party in certain circumstances (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States, subject to a potential waiver. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not obtain registered trademarks for commercial trade names for our product candidates. Any trademarks or trade names that we do obtain may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may be able to make compounds or formulations that are similar to our product candidates, but that are not covered by the claims of any patents that we own, license or control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may independently develop the same, similar, or alternative technologies without infringing, misappropriating or violating our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued patents may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse impact on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of our Common Stock </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our stock price has fluctuated in the past and is likely to be volatile in the future. <span style="background-color:#ffffff;">From January 1, 2020 through September 30, 2021, the reported sale price of our common stock has fluctuated between $5.30 and $50.54 per share. </span>The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock, including due to the factors discussed in these &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Volatility in our share price could subject us to securities class action litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities class action litigations have often been brought against companies following a decline in the market price of their securities. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act (Section 404), to furnish a report by management on the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Our public float on June 30, 2021 was greater than $700.0 million, and our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting beginning with our Annual Report required to be filed with the SEC for the fiscal year ending December 31, 2021. At that time, if we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and continue the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. We may not complete our continued evaluation, testing and any required remediation in a timely fashion. During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting or fail to remediate any material weaknesses, we will be unable to assert that our internal control over financial reporting is effective. Any material weakness or other failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) provides that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings. Furthermore, Section 22 of the Securities Act of 1933, as amended, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage such lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">There are provisions in our Certificate of Incorporation and Bylaws, such as the existence of a classified board and the authorization of &#8220;blank-check&#8221; preferred stock, that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by our stockholders.  These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibit a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Any provision in our Certificate of Incorporation, our Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating loss carryforwards to offset future taxable income, and our ability to use tax credit carryforwards, may be subject to certain limitations.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:27.8pt;margin:0pt;">Our ability to use our federal and state net operating losses (&#8220;NOLs&#8221;) to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use our NOLs. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:27.8pt;margin:0pt;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than fifty percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income or tax liability may be limited. We have experienced ownership changes in the past and in the current year, resulting in annual limitations in our ability to use our NOLs and credits. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our financial statements could be limited and may expire unused. Any such material limitation or expiration of our NOLs may harm our future operating results by effectively increasing our future tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:75.8pt;text-indent:-75.8pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may have additional tax liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are regularly subject to audits by tax authorities in the jurisdictions in which we conduct business. Although we believe our tax positions are reasonable, the final outcome of tax audits and related litigation could be materially different than that reflected in our historical income tax provisions and accruals, and we could be subject to assessments of additional taxes and/or substantial fines or penalties. The resolution of any audits or litigation could have an adverse effect on our financial position and results of operations. We and our subsidiary are engaged in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_AEIOULastRenderedPageBreakAEIOU48"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">intercompany transactions, the terms and conditions of which may be scrutinized by tax authorities, which could result in additional tax and/or penalties becoming due.</p><a id="_459f0d1b_32fd_47b0_a776_20c3800c5224"></a><a id="ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;2.</b></span>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Repurchases of Shares or of Company Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_52cb6336_2f5a_4d72_8a13_d7f53a1426ca"></a><a id="ITEM3DEFAULTSUPONSENIORSECURITIES_924131"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;3.</b></span>DEFAULTS UPON SENIOR SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_6206504f_7f14_4e96_8378_36d8d84be401"></a><a id="ITEM4MINESAFETYDISCLOSURES_778794"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;4.</b></span>MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_ad2132bf_1657_4a87_bedc_4cb415246d33"></a><a id="ITEM5OTHERINFORMATION_390923"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;5.</b></span>OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_796f6c6f_14d9_4fb8_bd5d_fb386003998b"></a><a id="ITEM6EXHIBITS_645051"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ITEM&#160;6.</b></span>EXHIBITS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_2fa66848_cc58_4781_818a_22571aaa20ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC File No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516683189/d237730dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Certificate of Incorporation</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37852</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/16/2016</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex32b.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Bylaws</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-212476</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/1/2016</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">10.1+&#8224;  </span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">10.2+&#8224;  </span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Arbitration Resolution Agreement, dated August 4</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, 2021, by and among Protagonist Therapeutics, Inc. and Zealand Pharma, A/S.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3+</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1+*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document <span style="background-color:#ffffff;">- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">+&#160;&#160;&#160;&#160;&#160;Filed herewith</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:10pt;white-space:pre-wrap;">&#8224;    </span>Confidential treatment has been granted for a portion of this exhibit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160; This certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form&#160;10-Q is not deemed filed<span style="font-size:10pt;"> </span>with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of<span style="font-size:10pt;"> </span>Protagonist Therapeutics,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of<span style="font-size:10pt;"> </span>1934, as amended, whether made before or after the date of the Form&#160;10-Q, irrespective of any general<span style="font-size:10pt;"> </span>incorporation language contained in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:36.7pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ee47854d_0c1e_4160_9987_b71706ba671d"></a><a id="SIGNATURES_754707"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:46.72%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:bottom;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">`</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: &#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Don Kalkofen</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Don Kalkofen</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:53.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:11.03%;margin-top:30pt;page-break-after:avoid;width:78.62%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ptgx-20210930xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">EXECUTION COPY</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">LICENSE AND COLLABORATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">BY AND BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">JANSSEN BIOTECH, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 1</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DEFINITIONS</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">1</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 2</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">GOVERNANCE</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">22</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 3</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ACTIVITIES DURING DEVELOPMENT TERM</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">24</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 4</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">RESEARCH ACTIVITIES</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">38</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 5</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ACTIVITIES DURING LICENSE TERM</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">41</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 6</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">LICENSE GRANTS</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">48</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 7</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">FINANCIAL TERMS</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">51</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 8</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">INTELLECTUAL PROPERTY</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">65</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 9</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CONFIDENTIALITY; PUBLICITY</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">77</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 10</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">REPRESENTATIONS AND WARRANTIES</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">82</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 11</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">INDEMNIFICATION AND INSURANCE</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">88</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 12</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">TERM AND TERMINATION</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">90</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 13</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DISPUTE RESOLUTION</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">97</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 14</font></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">MISCELLANEOUS</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">100</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:90pt;text-indent:-90pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">i</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">LICENSE AND COLLABORATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this &#8220;</font><b style="font-size:12pt;font-weight:bold;">Agreement</b><font style="font-size:12pt;">&#8221;) is made and effective as of July 27, 2021 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Restatement Effective Date</b><font style="font-size:12pt;">&#8221;), by and between Janssen Biotech, Inc., a Pennsylvania corporation (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen</b><font style="font-size:12pt;">&#8221;) and Protagonist Therapeutics, Inc., a Delaware corporation (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist</b><font style="font-size:12pt;">&#8221;). &#160;Each of Janssen and Protagonist is sometimes referred to herein individually as a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Party</b><font style="font-size:12pt;">&#8221; and collectively as the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Parties</b><font style="font-size:12pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, Protagonist has developed certain technology and owns certain intellectual property rights relating to the Licensed Compounds (as defined below) and Licensed Products (as defined below);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, Janssen and Protagonist previously entered into that certain License and Collaboration Agreement (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Original Agreement</b><font style="font-size:12pt;">&#8221;), with an execution date of May 26, 2017 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Original Execution Date</b><font style="font-size:12pt;">&#8221;) and an effective date of July 13, 2017 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Original Effective Date</b><font style="font-size:12pt;">&#8221;), as amended by the First Amendment dated May 7, 2019 (the Original Agreement as so amended, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Existing Agreement</b><font style="font-size:12pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Parties desire to amend and restate the Existing Agreement in its entirety on the Restatement Effective Date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the various promises and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree that the Existing Agreement is hereby amended and restated in its entirety as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, will have the meaning set forth below or, if not listed below, the meaning designated where first used in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.1.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;"> Generation Compound</b><font style="font-size:12pt;">&#8221; means any cyclic (including bicyclic, tricyclic or other multi-cyclic) peptide other than the Initial Compound that (i) is disclosed by any Protagonist IL23 Receptor Inhibitor Patent Right, (ii) was discovered and/or developed by either or both of the Parties pursuant to the Prior 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Plan or in the course of conducting the Research Activities during the Research Term or (iii) is discovered and/or developed by or on behalf of Janssen or its Affiliates in the performance of the Janssen Independent Research Activities during the Janssen Independent Research Term and, in each of cases (i), (ii) and (iii), meets one of the following criteria:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">has an IC50 value of less than or equal to [ * ] nanomolar (i.e., [ * ]), as determined in the [ * ] ([ * ]) described in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;">; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">has an affinity for IL23R less than or equal to [ * ] pM (i.e., [ * ]), as determined by [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.2.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;"> Generation Product</b><font style="font-size:12pt;">&#8221; means a Licensed Product containing a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.3.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Acceptance</b><font style="font-size:12pt;">&#8221; means, in reference to a Drug Approval Application, receipt of a written communication from the applicable Regulatory Authority acknowledging that it has received the Drug Approval Application and that the Drug Approval Application is sufficiently complete to permit a substantive review for approval purposes. &#160;For illustrative purposes, Acceptance of an NDA by the FDA may be provided in an FDA filing communication letter pursuant to 21 CFR &#167;&#160;314.101(a)(2). &#160;Where the NDA is submitted on a rolling basis, Acceptance will not occur until all parts or modules forming the NDA have been completed and submitted to the FDA and the FDA has acknowledged that the NDA is sufficiently complete to permit such substantive review. The Acceptance of a marketing approval application by the EMA may be provided in the form of written confirmation from the EMA that the marketing approval application submission is validated (with respect to eligibility for review via the centralized procedure) and considered to be sufficiently complete to permit such substantive review.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.4.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Acquirer</b><font style="font-size:12pt;">&#8221; means any Third Party that is a party to any Change of Control transaction and any of such Third Party&#8217;s Affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.5.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Affiliate</b><font style="font-size:12pt;">&#8221; means, with respect to any Party, any corporation or other business entity that directly or indirectly controls, is controlled by, or is under common control with such Party at the time at which the determination of affiliation is being made. &#160;For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) as used with respect to any Party, means the possession of at least 50% of the voting stock or other ownership interest of the other corporation or entity, or the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint at least 50% of the members of the governing body of the corporation or other entity through the ownership of the outstanding voting securities or by contract or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.6.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Applicable Law</b><font style="font-size:12pt;">&#8221; means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority, including, as applicable, the FFDCA, Public Health Service Act, Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167;331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335(a) et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), Federal False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.7.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Business Day</b><font style="font-size:12pt;">&#8221; means a day other than Saturday, Sunday or any other day on which banking institutions in New York, New York are closed for business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.8.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Calendar Quarter</b><font style="font-size:12pt;">&#8221; means a financial quarter based on the Johnson &amp; Johnson Universal Calendar; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that the first Calendar Quarter for the first Calendar Year extends from the Original Effective Date to the end of the then-current Calendar Quarter and the last</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Calendar Quarter extends from the first day of such Calendar Quarter until the effective date of the termination or expiration of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.9.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Calendar Year</b><font style="font-size:12pt;">&#8221; means a year based on the Johnson &amp; Johnson Universal Calendar for that year. &#160;The last Calendar Year of the Term begins on the first day of the Johnson &amp; Johnson Universal Calendar Year for the year during which termination or expiration of this Agreement occurs, and the last day of such Calendar Year will be the effective date of such termination or expiration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.10.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">CD</b><font style="font-size:12pt;">&#8221; means the treatment of Crohn&#8217;s disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.11.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Change of Control</b><font style="font-size:12pt;">&#8221; means, with respect to a Party: (a) that any Third Party acquires directly or indirectly the beneficial ownership of any voting securities of such Party, or if the percentage ownership of such Person in the voting securities of such Party is increased through stock redemption, cancellation or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of outstanding voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of such Party; (b)&#160;a merger, consolidation, recapitalization or reorganization of such Party is consummated, other than any such transaction in which stockholders or equity holders of such Party immediately prior to such transaction beneficially own, directly or indirectly, at least fifty percent (50%) of the voting securities of the surviving entity (or its parent entity) immediately following such transaction; (c)&#160;that the stockholders or equity holders of such Party approve a plan of complete liquidation of such Party; (d)&#160;that individuals who, as of the Original Execution Date, constitute the Board of Directors of such Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Incumbent Board</b><font style="font-size:12pt;">&#8221;) cease for any reason to constitute at least a majority of the Board of Directors of such Party (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that any individual becoming a director subsequent to the Original Execution Date whose election, or nomination for election by such Party&#8217;s stockholders, was recommended or approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board of Directors of such Party); or (e)&#160;the sale or disposition to a Third Party of all or substantially all of such Party&#8217;s assets taken as a whole. &#160;For purposes of this definition, &#8220;beneficial ownership&#8221; shall have the meaning accorded in the U.S. Securities Exchange Act of 1934 and the rules of the U.S. SEC thereunder in effect as of the Original Execution Date. Notwithstanding the foregoing, a transaction solely to change the domicile of a Party shall not constitute a Change of Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.12.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Clinical Manufacturing Cost</b><font style="font-size:12pt;">&#8221; means a Party&#8217;s reasonable, attributable and necessary internal costs and reasonable, documented Third Party costs incurred in clinical manufacturing or acquisition and supply of Licensed Compound or Licensed Product, determined in accordance with such Party&#8217;s accounting policies that are in accordance with U.S. generally accepted accounting principles and consistently applied across such Party&#8217;s clinical manufacturing supply network to other products that such Party or one of its Affiliates manufactures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.13.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Clinical Trial</b><font style="font-size:12pt;">&#8221; means any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial or any other clinical trial of a Licensed Compound or Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.14.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">CMC Development</b><font style="font-size:12pt;">&#8221; means Development activities related to the composition, manufacture and specification of drug substance and drug product intended to assure the proper identification, quality, purity and strength of the drug, including: test method development and stability testing, process development, drug substance development, process validation, process scale-up, formulation development, quality assurance and quality control development.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.15.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">CMC Development Costs</b><font style="font-size:12pt;">&#8221; means, with respect to any CMC Development activities that are not Phase 1A Activities or PTG-200 Phase 2A Activities, the reasonable, attributable and required internal costs and reasonable, documented Third Party costs incurred by a Party or its Affiliates in performing such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.16.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Activities</b><font style="font-size:12pt;">&#8221; means, collectively, the PTG-200 Phase 2A Activities, PN-232 Phase 1A Activities, PN-235 Phase 1A Activities, Research Activities and, to the extent they are conducted during the Development Term, any other Development or CMC Development activities with respect to the PTG-200 Product or any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product that are set forth in the PTG-200 Clinical Development Plan or the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan. &#160;For clarity, Collaboration Activities do not include the Janssen Independent Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.17.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Information</b><font style="font-size:12pt;">&#8221; means: (a) the PTG-200 Clinical Development Plan, the Prior CMC Development Plan, the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, the Prior Clinical Development Plan, and the Research Plan (as defined in the Existing Agreement); (b) the JSC minutes prepared in accordance with Section 2.1.4(b) and the Collaboration Records; (c) the reports delivered by the Parties pursuant to Sections 3.4.1(c), 3.4.2(d) and 3.4.3(c); (d) all data, results and reports delivered by the Parties pursuant to Sections 4.1.2 and 4.4; (e) the Phase 1A Data Packages, Phase 2A Results and the final clinical study reports for the PN-232 Phase 1A Clinical Trial and the PN-235 Phase 1A Clinical Trial; (f) any data, data packages, results or reports relating to the Licensed Compounds or Licensed Products delivered by the Parties prior to the Restatement Effective Date; and (g) non-public Collaboration Know-How (other than Included Research Know-How) and non-public Collaboration Patent Rights (other than Collaboration Patent Rights that claim Included Research Know-How).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.18.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Invention</b><font style="font-size:12pt;">&#8221; means any Collaboration Know-How that is an invention. &#160;For clarity, Collaboration Inventions do not include any Excluded Research Know-How that is an invention.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.19.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Know-How</b><font style="font-size:12pt;">&#8221; means any Know-How that is generated (or, in the case of an invention, conceived of or reduced to practice) by a Party&#8217;s, or its Affiliates&#8217; or Third Party Subcontractors&#8217;, employees or agents in Developing, Manufacturing or Commercializing the Licensed Compounds or Licensed Products pursuant to this Agreement, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that Collaboration Know-How includes any Know-How directed to 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds or 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products or modifications, uses or manufacture thereof arising from the Janssen Independent Research Activities (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Included Research Know-How</b><font style="font-size:12pt;">&#8221;), but does not include any other Know-How arising from the Janssen Independent Research Activities (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Excluded Research Know-How</b><font style="font-size:12pt;">&#8221;). &#160;If any Excluded Research Know-How is actually incorporated into or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">used to Develop, Manufacture or Commercialize a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound or 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product after completion of the Janssen Independent Research Activities, such Know-How shall be Collaboration Know-How to the extent that it is incorporated into or used to Develop, Manufacture or Commercialize such 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound or 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.20.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Combination Product</b><font style="font-size:12pt;">&#8221; means any product containing: (a) as a single formulation, two or more active pharmaceutical ingredients as components including (i) a Licensed Compound and (ii) one or more other active pharmaceutical ingredients; or (b) in a single package or container and intended for coordinated use, two or more products as components including (i) a Licensed Product containing a Licensed Compound as its sole active pharmaceutical ingredient, and (ii) one or more other products for therapeutic administration or diagnostic use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.21.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercialization</b><font style="font-size:12pt;">&#8221; means any activities directed to marketing, promoting, educating, informing, distributing, importing, offering to sell and/or selling a pharmaceutical or biologic product. &#160;When used as a verb, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercialize</b><font style="font-size:12pt;">&#8221; means to engage in Commercialization activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.22.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</b><font style="font-size:12pt;">&#8221; means: (a) with respect to the Development, seeking and obtaining Marketing Approval, Manufacture or Commercialization of a Licensed Product in a country by or on behalf of Janssen, those reasonable, good faith efforts normally used [ * ] under similar circumstances for similar products or product candidates owned or controlled by Janssen and its Affiliates, or to which Janssen or any of its Affiliates has similar rights, which product or product candidate is of similar market potential in such country ([ * ] ) and is at a similar stage in its development or product life, taking into account all Relevant Factors; or (b) with respect to the efforts to be expended by either Party with respect to any objective or activity other than those described in clause (a) of this Section 1.22, those reasonable, good faith efforts to accomplish such objective or perform such activity as [ * ] would normally use to accomplish a similar objective under similar circumstances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.23.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Compound API</b><font style="font-size:12pt;">&#8221; means the active pharmaceutical ingredient for a Licensed Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.24.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Confidential Information</b><font style="font-size:12pt;">&#8221; means: (a) all non-public or proprietary information (including Know-How) that is disclosed by or on behalf of a Party (or any of its Affiliates) to the other Party, any of its Affiliates or any of their respective employees, agents or contractors pursuant to or in connection with this Agreement; and (b) all other non-public or proprietary information (including Know-How) that is expressly deemed in this Agreement to be Confidential Information, whether or not disclosed by or on behalf of a Party (or any of its Affiliates) to the other Party, any of its Affiliates or any of their respective employees, agents or contractors, in each case ((a) or (b)), without regard as to whether any of the foregoing is marked &#8220;confidential&#8221; or &#8220;proprietary,&#8221; or in oral, written, graphic or electronic form.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.25.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Control</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">Controlled</b><font style="font-size:12pt;">&#8221; means, with respect to any Know-How, Patent Right or other intellectual property right, subject to Section 8.10.3, possession by a Party (whether by ownership or license or otherwise, but without taking into account any rights granted pursuant to this Agreement), directly or through an Affiliate of such Party, of the ability to transfer, or grant a license or sublicense under, such right as provided for herein without violating the terms of any agreement or binding arrangement with any Third Party; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that any Know-How,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Patent Right or other intellectual property right that is owned or licensed by an Acquirer of Protagonist or any Affiliate of such Acquirer (excluding any Affiliate that was an Affiliate of Protagonist prior to a Change of Control and became an Affiliate of such Acquirer as a result of such Change of Control) shall not be deemed to be Controlled by Protagonist for purposes of this Agreement, except to the extent, and only to the extent that, such Know-How, Patent Right or other intellectual property right is either (a) actually used by Protagonist, the Acquirer or any of their respective Affiliates in the performance of Development, Manufacturing or Commercialization activities with respect to any Licensed Compound or Licensed Product following the consummation of the Change of Control of Protagonist, or (b)&#160;made, conceived or reduced to practice by the Acquirer or any such Affiliates through the use of the Protagonist Intellectual Property (to the extent such Protagonist Intellectual Property Covers the manufacture, use or sale of, or is necessary to manufacture, use or sell, a Licensed Compound or Licensed Product), Collaboration Know-How or Collaboration Patent Rights following the consummation of the Change of Control of Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.26.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Cover</b><font style="font-size:12pt;">&#8221;, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Covering</b><font style="font-size:12pt;">&#8221; and &#8220;</font><b style="font-size:12pt;font-weight:bold;">Covered</b><font style="font-size:12pt;">&#8221; means, with respect to a Patent Right and an invention, that, in the absence of ownership of or a license under such Patent Right, the practice of such invention (e.g., with respect to a Patent Right in the U.S., the manufacture, use, sale, offer for sale or importation of such invention) would infringe a Valid Claim of such Patent Right (or in the case of a pending patent application, if the claims of such patent application as then existing were issued).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.27.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">CTA</b><font style="font-size:12pt;">&#8221; means (a) a clinical trial authorization application filed with a Regulatory Authority in any regulatory jurisdiction outside the U.S., the filing of which is necessary to commence or conduct clinical testing of a pharmaceutical or biologic product in humans in such jurisdiction; or (b) documentation issued by a Regulatory Authority that permits the conduct of clinical testing of a product in humans in a regulatory jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.28.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Data</b><font style="font-size:12pt;">&#8221; means any data or information used or developed to commence a Clinical Trial, any data or information developed as a result of a Clinical Trial, and all data and information resulting from CMC Development of a Licensed Compound or Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.29.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development</b><font style="font-size:12pt;">&#8221; means all research and non-clinical and clinical drug development activities and processes, including toxicology, pharmacology, project management and other non-clinical efforts, formulation development, delivery system development, statistical analysis, Manufacturing development, the performance of Clinical Trials (including the Manufacturing of products for use in clinical trials), or other activities reasonably necessary in order to obtain and maintain Marketing Approval of a pharmaceutical or biologic product. &#160;When used as a verb, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Develop</b><font style="font-size:12pt;">&#8221; means to engage in Development activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.30.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development Budget</b><font style="font-size:12pt;">&#8221; means the PTG-200 Development Budget or 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Budget, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.31.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development Plan</b><font style="font-size:12pt;">&#8221; means the PTG-200 Clinical Development Plan or the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.32.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development Term</b><font style="font-size:12pt;">&#8221; means the period beginning on the Original Effective Date and ending on the first date on which Janssen has paid Protagonist both of the following: (a) the Milestone Payment for either Milestone Event B-1 or Milestone Event C; and (b) the Milestone Payment for Milestone Event C-1. &#160;Upon the request of either Party, the Parties shall memorialize the last day of the Development Term, as defined in the immediately preceding sentence, in a written document for the records.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.33.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Diligent Efforts</b><font style="font-size:12pt;">&#8221; means, with respect to any Party&#8217;s performance of the Research Activities during the Research Term or the Collaboration Activities during the Development Term, the carrying out of such activities in a prompt and timely manner using reasonable, good faith efforts and adequate and appropriate resources.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.34.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Drug Approval Application</b><font style="font-size:12pt;">&#8221; means: (a) a new drug application submitted to the FDA pursuant to Section 505(b) of the FFDCA, 21 U.S.C. &#167; 355(b) (an &#8220;</font><b style="font-size:12pt;font-weight:bold;">NDA</b><font style="font-size:12pt;">&#8221;); (b) a Biologics License Application submitted to the FDA pursuant to the Public Health Service Act, 42 U.S.C. &#167;&#167; 262 - 263 (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">BLA</b><font style="font-size:12pt;">&#8221;); or (c) an application for authorization to market and/or sell a drug product submitted to a Regulatory Authority in any country or jurisdiction other than the U.S., in each case ((a), (b) or (c)), including all amendments and supplements thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.35.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Drug Product</b><font style="font-size:12pt;">&#8221; means any formulation of Compound API or Licensed Product in final finished form, including packaging and labeling.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.36.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">EMA</b><font style="font-size:12pt;">&#8221; means the European Medicines Agency or any successor agency for the EU with responsibilities comparable to those of the European Medicines Agency.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.37.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">EU</b><font style="font-size:12pt;">&#8221; means the countries of the European Economic Area, as it is constituted on the Original Execution Date and as it may be modified from time to time after the Original Execution Date, and the United Kingdom.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.38.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Executive Officers</b><font style="font-size:12pt;">&#8221; means the [ * ] of Protagonist and the [ * ] of Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.39.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FDA</b><font style="font-size:12pt;">&#8221; means the United States Food and Drug Administration or any successor agency in the United States with responsibilities comparable to those of the United States Food and Drug Administration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.40.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FFDCA</b><font style="font-size:12pt;">&#8221; means the U.S. Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;301 et seq.), as amended from time to time, and any regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.41.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Field</b><font style="font-size:12pt;">&#8221; means all therapeutic, prophylactic and diagnostic uses in humans and animals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.42.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">First Commercial Sale</b><font style="font-size:12pt;">&#8221; means, with respect to a given Licensed Product and a given country, the first arm&#8217;s-length commercial sale of such Licensed Product to a Third Party in the Field in such country after the receipt of Marketing Approval for such Licensed Product in such country. &#160;Sales for Clinical Trial purposes, early access or compassionate use programs, or similar uses, shall not constitute a First Commercial Sale. &#160;In addition, sales of a Licensed Product by and between Janssen and its Affiliates, distributors and (sub)licensees, or between the Parties (or their respective Affiliates, distributors or (sub)licensees), shall not constitute a First Commercial Sale.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.43.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FTE Rate</b><font style="font-size:12pt;">&#8221; means a rate of [ * ] &#160;per [ * ] FTE per Calendar Year (pro-rated for the period beginning on the Original Effective Date and ending on the last day of the first Calendar Year of the Term); </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that such rate shall be increased or decreased annually beginning on [ * ] by the percentage increase or decrease in the CPI between the last day of the most recently completed Calendar Year and December 31, 2020, plus [ * ] &#160;percent ([ * ]%). &#160;The FTE Rate is &#8220;fully burdened&#8221; and will cover employee salaries and such facilities and equipment and other materials and services, including ordinary laboratory consumables procured from distributors of relevant products as they may use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.44.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Generic Product</b><font style="font-size:12pt;">&#8221; means, with respect to a Licensed Product in a country in the Territory, any product sold by a Third Party (including a &#8220;generic product&#8221;, &#8220;biogeneric&#8221;, &#8220;follow-on biologic&#8221;, &#8220;follow-on biological product&#8221;, &#8220;follow-on protein product&#8221;, &#8220;similar biological medicinal product&#8221; or &#8220;biosimilar product&#8221;) approved in such country by way of an abbreviated regulatory mechanism by the Regulatory Authority in such country that, in each case, meets the equivalency determination by the applicable Regulatory Authority (including a determination that the product is &#8220;comparable&#8221;, &#8220;interchangeable&#8221;, &#8220;bioequivalent&#8221;, &#8220;biosimilar&#8221; or other term of similar meaning, with respect to such Licensed Product), in each case, as is necessary to permit substitution of one product for another product under Applicable Law. &#160;A product shall not be considered to be a Generic Product if (a) Janssen or any of its Affiliates or sublicensees was involved in the Development of such product, or (b) such product is Commercialized by any Person who obtained such product in a chain of distribution that included Janssen or any of its Affiliates or sublicensees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.45.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Good Clinical Practice</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">GCP</b><font style="font-size:12pt;">&#8221; means the current standards for clinical trials for pharmaceuticals, as set forth in the ICH guidelines and applicable regulations promulgated thereunder, as amended from time to time, and such standards of good clinical practice as are required by the European Union and other organizations and Governmental Authorities in countries in which a pharmaceutical product is intended to be sold to the extent such standards are not less stringent than United States Good Clinical Practice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.46.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Good Laboratory Practice</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">GLP</b><font style="font-size:12pt;">&#8221; means the current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development, as amended from time to time, and such standards of good laboratory practice as are required by the European Union and other organizations and Governmental Authorities in countries in which a pharmaceutical product is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.47.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Good Manufacturing Practice</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">GMP</b><font style="font-size:12pt;">&#8221; means the current quality assurance standards that ensure that pharmaceutical products are consistently produced and controlled in accordance with the quality standards appropriate to their intended use as defined in 21 C.F.R. &#167; 210 and 211, European Directive 2003/94/EC, Eudralex 4, Annex 16, and applicable United States, European Union, Canadian and ICH guidance or equivalent laws in other jurisdictions to the extent no less stringent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.48.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Governmental Authority</b><font style="font-size:12pt;">&#8221; means any applicable government authority, court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational body.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.49.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">HSR Act</b><font style="font-size:12pt;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time, and any comparable Applicable Law in jurisdictions outside the U.S. related to the approval of transactions similar to those contemplated under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.50.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">IND</b><font style="font-size:12pt;">&#8221; means an Investigational New Drug application as defined in the FFDCA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.51.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Indication</b><font style="font-size:12pt;">&#8221; means treatment of a discrete clinically recognized form of a disease. &#160;For purposes of this Agreement, treatment of different subpopulations within a population of patients having a disease shall not be treated as separate Indications, and treatment of different signs or symptoms of the same disease shall not be treated as separate Indications. &#160;For example, treatment of mild to moderate Crohn&#8217;s disease is not a different Indication from treatment of moderate to severe Crohn&#8217;s disease. &#160;For clarity, Psoriasis and Psoriatic Arthritis are separate Indications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.52.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Compound API Cost</b><font style="font-size:12pt;">&#8221; means Janssen&#8217;s reasonable, attributable and necessary internal costs and reasonable, documented Third Party costs incurred in manufacturing or acquisition and supply of Compound API for the Initial Compound for commercial purposes, determined in accordance with Janssen&#8217;s accounting policies that are in accordance with U.S. generally accepted accounting principles and consistently applied across such Janssen&#8217;s commercial manufacturing supply network to other products that Janssen or one of its Affiliates manufactures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.53.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initiation</b><font style="font-size:12pt;">&#8221; means, with respect to a Clinical Trial, the dosing of the [ * ] subject in such Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.54.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Product</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200 Product</b><font style="font-size:12pt;">&#8221; means the Licensed Product containing the Initial Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.55.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Parent</b><font style="font-size:12pt;">&#8221; means Johnson &amp; Johnson.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.56.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Johnson &amp; Johnson Universal Calendar</b><font style="font-size:12pt;">&#8221; means the universal calendar system used by Janssen Parent and its Affiliates for internal and external reporting purposes (a copy of which for the year 2021 is attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.56</u><font style="font-size:12pt;"> and a copy of which prior to the beginning of each such year for succeeding years shall be provided to Protagonist upon request).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.57.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Know-How</b><font style="font-size:12pt;">&#8221; means any non-public or proprietary information, inventions, discoveries, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, trade secrets, technology, techniques, designs, drawings, correspondence, computer programs, documents, apparatus, results, strategies, Regulatory Documentation, information and submissions pertaining to, or made in association with, filings with any Regulatory Authority or patent office, data (including pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market data, financial data or descriptions), devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">like, in written, electronic, oral or other tangible or intangible form, now known or hereafter developed, whether or not patentable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.58.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">License Term</b><font style="font-size:12pt;">&#8221; means the period beginning immediately after the end of the Development Term and ending on the last day of the Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.59.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Licensed Compound</b><font style="font-size:12pt;">&#8221; means (a) PTG-200, a GI-targeted peptide with local IL23 receptor antagonist effect, as further described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.59</u><font style="font-size:12pt;"> (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Compound</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> or </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">); or (b) PN-232, PN-235 or any other 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.60.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Licensed Product</b><font style="font-size:12pt;">&#8221; means any pharmaceutical product or formulation containing the Initial Compound or a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.61.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Major European Countries</b><font style="font-size:12pt;">&#8221; means [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.62.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Major Market Countries</b><font style="font-size:12pt;">&#8221; means [ * ] .</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.63.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Manufacturing</b><font style="font-size:12pt;">&#8221; means any activities directed to producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping and storage of a pharmaceutical or biologic product directly or through one or more Third Parties. &#160;When used as a verb, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Manufacture</b><font style="font-size:12pt;">&#8221; means to engage in Manufacturing activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.64.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Marketing Approval</b><font style="font-size:12pt;">&#8221; means any and all approvals (including supplements, amendments, pre- and post-approvals), licenses, registrations or authorizations of any Regulatory Authority that are necessary to market and/or sell a pharmaceutical or biologic product in a country or jurisdiction for one or more uses, including any pricing and reimbursement approvals that are necessary to conduct a launch of such product in such country or jurisdiction (even if such pricing and reimbursement approvals are not legally required to launch such product in such country or jurisdiction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.65.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Material Safety Issue</b><font style="font-size:12pt;">&#8221; means the occurrence of any significant safety-related event, incident or circumstance with respect to a Licensed Compound or Licensed Product that leads a Party to reasonably determine that the continued use of such Licensed Compound or Licensed Product by patients may result in patients being exposed to a product for which the risks outweigh the benefits. &#160;Examples of Material Safety Issues include the issuance of a clinical hold order (or similar requirement or recommendation) by a Regulatory Authority, where the clinical hold is not resolvable in the ordinary course, or an IRB requirement or recommendation to terminate or suspend a Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.66.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Net Sales</b><font style="font-size:12pt;">&#8221; means the gross amounts invoiced on sales of a Licensed Product by Janssen, or any of its Affiliates or sublicensees, to a Third Party purchaser in an arm&#8217;s-length transaction, less the following customary and commercially reasonable deductions, determined in accordance with U.S. generally accepted accounting principles and internal policies and actually taken, paid, accrued, allocated, or allowed based on good faith estimates:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">trade, cash and/or quantity discounts, allowances, deductions, fees and credits, excluding commissions for commercialization;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">excise taxes, use taxes, tariffs, sales taxes and customs duties and/or other government charges or fees imposed on the sale of Licensed Product (including VAT, but only to the extent that such VAT taxes are not reimbursable or refundable), specifically excluding, for clarity, any income taxes assessed against the income arising from such sale;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">compulsory or negotiated payments and cash rebates or other expenditures to governmental authorities (or designated beneficiaries thereof) in the context of any national or local health insurance programs or similar programs, including, but not limited to, pay-for-performance agreements, risk sharing agreements and government-levied fees as a result of the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 or any other successor program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">rebates, chargebacks, administrative fees and discounts (or equivalent thereof) to managed health care organizations, group purchasing organizations, insurers, pharmacy benefit managers (or equivalent thereof), specialty pharmacy providers, governmental authorities, or their agencies or purchasers, reimbursers, or trade customers, as well as amounts owed to patients through co-pay assistance cards or similar forms of rebate to the extent the latter are directly related to the prescribing of Licensed Product;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">outbound freight, shipment, insurance and other distribution costs to the extent included in the invoiced price and separately itemized on the invoice;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:12pt;">retroactive price reductions, credits or allowances actually granted upon claims, rejections or returns of Licensed Product, including for recalls or damaged or expired goods, billing errors and reserves for returns;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:12pt;">any invoiced amounts that are not collected by Janssen or its Affiliates, including bad debts; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:12pt;">any deductions in the context of payments that are due or collected significantly after invoice issuance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">All the aforementioned deductions shall only be allowable to the extent they are commercially reasonable and shall be determined, on a country-by-country basis, as incurred in the ordinary course of business in type and amount verifiable based on Janssen&#8217;s and its Affiliates&#8217; reporting system. &#160;All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to Licensed Product and other products of Janssen and its Affiliates and sublicensees such that Licensed Product does not bear a disproportionate portion of such deductions. &#160;</font><font style="font-size:12pt;">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">For clarity, (x) sales of a Licensed Product by and between Janssen and any of its Affiliates or (sub)licensees shall not be considered sales to unaffiliated Third Parties and shall be excluded from Net Sales calculations for all purposes and (y) only a single sales transaction with respect to a particular unit of Licensed Product, made at the time Janssen or any of its Affiliates or (sub)licensees sells such unit of Licensed Product to an unaffiliated Third Party purchaser in arms-</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">length transaction, will qualify as the basis for determining the Net Sales amount for such unit of Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, the following sales of a Licensed Product shall be excluded from Net Sales calculations for all purposes: (i) transfer or dispositions of reasonable quantities of samples of such Licensed Product at no cost for promotional or educational purposes; (ii) transfers or dispositions of reasonable and customary quantities of such Licensed Product as free samples or donations, or for patient assistance, testing marketing programs or other similar programs at no cost; and (iii) use or sale of such Licensed Product for Clinical Trial or other scientific testing purposes, early access programs (such as to provide patients with such Licensed Product prior to Marketing Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event a Licensed Product is sold as part of a Combination Product in a country, the Net Sales with respect to the Combination Product in such country (for all financial terms pursuant to Article 7) shall be determined by multiplying the Net Sales amount for the Combination Product during the applicable reporting period, calculated as set forth above, by the fraction A/(A+B), where A is the weighted average sale price (by sales volume) of the Licensed Product in such country when sold separately, and B is the weighted average sales price of the other active ingredient(s) or product(s) in the Combination Product in such country when sold separately, in each case in the same dosage and dosage form and in the same country as the Combination Product during the applicable reporting period. If the other active ingredient(s) or product(s) in the Combination Product is not sold separately in such country during the applicable reporting period, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by a fraction A/C where A is the weighted average sale price (by sales volume) of the Licensed Product in such country when sold separately, and C is the weighted average sale price (by sales volume) of the Combination Product in such country. &#160;If neither the Licensed Product nor the other active ingredient(s) or product(s) were sold separately in such country during the applicable reporting period, then the respective average sales prices during the most recent reporting period in which sales of both occurred in the same country as the Combination Product shall be used. &#160;In the event that the weighted average sale price (by sales volume) of the Licensed Product is not available in a given country for any reporting period, then the average sales prices (weighted by sales volume) of the respective products described above (in the same dosage and dosage form as the Combination Product) in a proxy country to be agreed upon by both Parties will be used (such agreement not be unreasonably withheld, delayed or conditioned), and if the Parties cannot agree upon such proxy country, or no such comparable sales figures are available in an appropriate proxy country, Net Sales for the applicable Combination Product shall be allocated based on the relative value contributed by each component (such relative value to be agreed upon by the Parties or, if the Parties cannot agree, to be determined by the dispute resolution procedures set forth in Article 13).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.67.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Nondisclosure Agreement</b><font style="font-size:12pt;">&#8221; means the Confidential Disclosure Agreement between the Parties dated March 24, 2017.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.68.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Patent Costs</b><font style="font-size:12pt;">&#8221; means any out-of-pocket costs and expenses incurred by a Party or its Affiliates in prosecuting and maintaining any Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.69.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Patent Proceeding</b><font style="font-size:12pt;">&#8221; means any opposition, re-issue, and re-examination, and any contested case, including inter-partes review, post-grant review, interference, derivation or similar proceedings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.70.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Patent Rights</b><font style="font-size:12pt;">&#8221; means any and all (a) patents, (b)&#160;pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates or the equivalent thereof, (d) inventor&#8217;s certificates, (e) any other form of government-issued right substantially similar to any of the foregoing, and (f) all United States and foreign counterparts of any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.71.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Person</b><font style="font-size:12pt;">&#8221; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.72.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1A Activities</b><font style="font-size:12pt;">&#8221; means (i) the PN-232 Phase 1A Activities and (ii) the PN-235 Phase 1A Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.73.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1 Clinical Trial</b><font style="font-size:12pt;">&#8221; means, in reference to a clinical trial of a Licensed Product, (a) a trial that would satisfy the requirements for a Phase&#160;1 study as defined in 21&#160;C.F.R. &#167;&#160;312.21(a) or (b) a Phase 1 study as defined in the ICH E8 Guideline (or, in either case, any amended or successor regulation or guideline).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.74.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1 Development Costs</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means (a) Phase 1 Out-of-Pocket Costs and Expenses, (b) Phase 1 FTE Costs, (c) with respect to the Manufacturing of clinical supplies of Compound API or Drug Product for Phase 1A Activities, the Clinical Manufacturing Costs incurred by either Party or any of its Affiliates in performing such activities and (d) with respect to CMC Development activities that are Phase 1A Activities, the reasonable, attributable and required internal costs and reasonable, documented Third Party costs incurred by a Party or its Affiliates in performing such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.75.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1 Development FTE</b><font style="font-size:12pt;">&#8221; means [ * ] hours of work devoted to or in direct support of the Phase 1A Activities under this Agreement by one or more qualified scientific, medical, manufacturing, technical and other employees, contractors or consultants of a Party or its Affiliates, as measured in accordance with such Party&#8217;s normal time allocation practices, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such employees, contractors or consultants shall not include personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.76.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1 FTE Costs</b><font style="font-size:12pt;">&#8221; means, with respect to any period, the FTE Rate multiplied by the number of Phase 1 Development FTEs expended by a Party or any of its Affiliates during such period in the performance of Phase 1A Activities under this Agreement or the </font><font style="font-size:12pt;">preparing, filing and maintaining of Regulatory Documentation (such as INDs and CTAs) for Licensed Products in support of such </font><font style="font-size:12pt;">Phase 1A Activities under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.77.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1 Out-of-Pocket Costs and Expenses</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means amounts paid by either Party or any of its Affiliates (a) to Third Party vendors or contractors for services or materials provided by them directly in the performance of Phase 1A Activities under this Agreement, to the extent such services or materials apply directly to such Phase 1A Activities, or the preparing, filing and maintaining of Regulatory Documentation (such as INDs and CTAs) for Licensed Products in support of such Phase 1A Activities under this Agreement or (b) to the FDA or other Regulatory Authorities for filing fees for such Regulatory Documentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.78.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1/2 Clinical Trial</b><font style="font-size:12pt;">&#8221; means, in reference to a clinical trial of a Licensed Product, that such trial combines both a Phase 1 Clinical Trial and a Phase 2 Clinical Trial of such Licensed Product into a single protocol, where the Phase 1 Clinical Trial portion is performed first to (a) establish initial safety, tolerability, pharmacokinetic and pharmacodynamic information for the Licensed Product as a monotherapy or in combination with another agent or (b) determine the maximum tolerable dose of such Licensed Product in subjects, and the Phase 2 Clinical Trial portion is performed second to further evaluate safety and/or efficacy of such Licensed Product as a monotherapy or in combination with another agent in subjects treated with a selected dose.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.79.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2 Clinical Trial</b><font style="font-size:12pt;">&#8221; means, in reference to a clinical trial of a Licensed Product, (a) a trial that would satisfy the requirements for a Phase&#160;2 study as defined in 21 C.F.R. &#167; 312.21(b) or (b) a Phase 2 study as defined in the ICH E8 Guideline (or, in either case, any amended or successor regulation or guideline). &#160; For purposes of Section 7.3.1, a Phase 1/2 Clinical Trial shall be deemed to be a Phase 2 Clinical Trial upon Initiation of the Phase 2 Clinical Trial portion of such Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.80.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2 Development Costs</b><font style="font-size:12pt;">&#8221; means (a) Phase 2 Out-of-Pocket Costs and Expenses, (b) Phase 2 FTE Costs, (c) with respect to the Manufacturing of clinical supplies of Compound API or Drug Product for the PTG-200 Phase 2A Activities, the Clinical Manufacturing Costs incurred by either Party or any of its Affiliates in performing such activities, and (d) with respect to CMC Development activities that are PTG-200 Phase 2A Activities, the reasonable, attributable and required internal costs and reasonable, documented Third Party costs incurred by a Party or its Affiliates in performing such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.81.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2 Development FTE</b><font style="font-size:12pt;">&#8221; means [ * ] hours of work devoted to or in direct support of the PTG-200 Phase 2A Activities under this Agreement by one or more qualified scientific, medical, manufacturing, technical and other employees, contractors or consultants of a Party or its Affiliates, as measured in accordance with such Party&#8217;s normal time allocation practices, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such employees, contractors or consultants shall not include personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.82.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2 FTE Costs</b><font style="font-size:12pt;">&#8221; means, with respect to any period, the FTE Rate multiplied by the number of Phase 2 Development FTEs expended by a Party or any of its Affiliates during such period in the performance of PTG-200 Phase 2A Activities under this Agreement or the </font><font style="font-size:12pt;">preparing, filing and maintaining of Regulatory Documentation (such as INDs and CTAs) for Licensed Products in support of such </font><font style="font-size:12pt;">PTG-200 Phase 2A Activities under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.83.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2 Out-of-Pocket Costs and Expenses</b><font style="font-size:12pt;">&#8221; means amounts paid by either Party or any of its Affiliates (a) to Third Party vendors or contractors for services or materials provided by them directly in the performance of PTG-200 Phase 2A Activities under this Agreement, to the extent such services or materials apply directly to such PTG-200 Phase 2A Activities under this Agreement, or the </font><font style="font-size:12pt;">preparing, filing and maintaining of Regulatory Documentation (such as INDs and CTAs) for Licensed Products in support of such </font><font style="font-size:12pt;">PTG-200 Phase 2A Activities under this Agreement or (b) to the FDA or other Regulatory Authorities for filing fees for such </font><font style="font-size:12pt;">Regulatory Documentation</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.84.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2/3 Clinical Trial</b><font style="font-size:12pt;">&#8221; means, in reference to a clinical trial of a Licensed Product, a Phase 2 Clinical Trial involving a sufficient number of subjects that, prior to commencement of the trial or at any other defined point in the trial, satisfies both of the following ((a) and (b)):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">such trial is designed to (i) establish that the applicable Licensed Product is safe and efficacious for its intended use, and (ii) define and determine warnings, precautions, and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed, which trial is intended to support Marketing Approval of such Licensed Product or a similar clinical study prescribed by the FDA, with respect to the U.S., or other Regulatory Authority with respect to any other country in the Territory; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">such trial is or becomes a registration trial sufficient for filing a Drug Approval Application for such Licensed Product, as evidenced by (i) an agreement with or statement from the FDA, with respect to the U.S., or other Regulatory Authority with respect to any other country in the Territory on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA or such other Regulatory Authority for such registration trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.85.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 3 Clinical Trial</b><font style="font-size:12pt;">&#8221; means, in reference to a clinical trial of a Licensed Product, (a) a trial that would satisfy the requirements for a Phase&#160;3 study as defined in 21 C.F.R. &#167; 312.21(c) or (b) a Phase 3 study as defined in the ICH E8 Guideline (or, in either case, any amended or successor regulation or guideline). &#160;For purposes of Section 7.3.1, a Phase 2/3 Clinical Trial shall be deemed to be a Phase 3 Clinical Trial upon the date that such Phase 2/3 Clinical Trial first satisfies the criteria set forth in clause (b) of Section 1.85.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.86.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-232</b><font style="font-size:12pt;">&#8221; means the peptide known as &#8220;PN-232,&#8221; a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound discovered and selected for pre-clinical and clinical development prior to the Restatement Effective Date, as further described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.86.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.87.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-232 Phase 1A Activities</b><font style="font-size:12pt;">&#8221; means (a) the PN-232 Phase 1A Clinical Trial and (b) any related Development activities (including pre-clinical and IND-enabling studies and CMC Development and Manufacturing activities) set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.88.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-232 Phase 1A Clinical Trial</b><font style="font-size:12pt;">&#8221; means the Phase 1 Clinical Trial of a Licensed Product containing PN-232 with protocol number PN-232-01, as it may be amended from time to time under Section 3.4.2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">15</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.89.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-235</b><font style="font-size:12pt;">&#8221; means the peptide known as &#8220;PN-235,&#8221; a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound discovered and selected for pre-clinical and clinical development prior to the Restatement Effective Date, as further described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.89.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.90.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-235 Phase 1A Activities</b><font style="font-size:12pt;">&#8221; means (a) the PN-235 Phase 1A Clinical Trial and (b) any related Development activities (including pre-clinical and IND-enabling studies and CMC Development and Manufacturing activities) set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.91.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-235 Phase 1A Clinical Trial</b><font style="font-size:12pt;">&#8221; means the Phase 1 Clinical Trial of a Licensed Product containing PN-235 with protocol number PN-235-01 as it may be amended from time to time under Section 3.4.2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.92.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist-Controlled Patent Rights</b><font style="font-size:12pt;">&#8221; means (a) the Retained Patent Rights and (b) any Protagonist Patent Rights that Cover Protagonist Platform Know-How and do not Cover a Licensed Compound or Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.93.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist IL23 Receptor Inhibitor Patent Rights</b><font style="font-size:12pt;">&#8221; means the Patent Rights listed in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.93</u><font style="font-size:12pt;">, and any Patent Rights that are counterparts to or that have a valid priority claim to any of the patents and applications listed in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.93</u><font style="font-size:12pt;">, excluding the Retained Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.94.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Intellectual Property</b><font style="font-size:12pt;">&#8221; means Protagonist Know-How and Protagonist Patent Rights, collectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.95.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Know-How</b><font style="font-size:12pt;">&#8221; means any Know-How used in or otherwise relating to a Licensed Compound or Licensed Product or the Development, Manufacture and Commercialization of a Licensed Compound or Licensed Product that either (a) is Controlled by Protagonist or any of its Affiliates on the Original Execution Date or (b) comes into the Control of Protagonist or any of its Affiliates during the Term. &#160;For clarity, Protagonist Know-How shall include the Protagonist Collaboration Know-How, but excludes Know-How that relates solely to any Retained Compounds.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.96.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Platform Know-How</b><font style="font-size:12pt;">&#8221; means any Know-How owned by or licensed to Protagonist that primarily relates to Protagonist&#8217;s core peptide technology platform which comprises the following: &#160;molecular design tools and structure of peptide scaffolds, computational screening and rank ordering of scaffolds, virtual libraries of constrained scaffolds and peptides, collectively known as Vectrix, random libraries and phage-display techniques, medicinal chemistry know-how, peptide and peptidomimetic chemistry know-how, oral stability assays and know-how, formulation know-how, and in vivo pharmacology tools, techniques and know-how pertaining to peptide oral stability, transport, and GI-restriction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.97.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Patent Right</b><font style="font-size:12pt;">&#8221; means (a) the Protagonist IL23 Receptor Inhibitor Patent Rights; (b) the Protagonist Collaboration Patent Rights; (c) Protagonist&#8217;s and its Affiliates&#8217; interests in the Joint Collaboration Patent Rights; and (d) any Patent Right other than those described in clauses (a) through (c) that: (i) either (A) is Controlled by Protagonist or any of its Affiliates on the Original Execution Date or (B) comes into the Control of Protagonist or any of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">16</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">its Affiliates during the Term; and (ii) Covers any Licensed Compound, Licensed Product or Protagonist Know-How.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.98.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Research Compound</b><font style="font-size:12pt;">&#8221; means any compound arising from Protagonist&#8217;s performance of the Research Activities that is not a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.99.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Research FTE</b><font style="font-size:12pt;">&#8221; means [ * ] of work devoted to or in direct support of Research Activities under this Agreement by one or more qualified scientific, medical, manufacturing, technical and other employees, contractors or consultants of Protagonist or its Affiliates, as measured in accordance with Protagonist&#8217;s normal time allocation practices, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such employees, contractors or consultants shall not include personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.100.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Research </b><b style="font-size:12pt;font-weight:bold;">FTE Rate</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means a rate of [ * ] FTE per Calendar Year for Research Activities; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that such rate shall be increased or decreased annually beginning on [ * ] by the percentage increase or decrease in the CPI between the last day of the most recently completed Calendar Year and December 31, 2020, plus [ * ] &#160;percent ([ * ]%). The FTE Rate is </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">fully burdened</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> and will cover employee salaries and such facilities and equipment and other materials and services, including ordinary laboratory consumables procured from distributors of relevant products as they may use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.101.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200 Phase 2A Activities</b><font style="font-size:12pt;">&#8221; means (a) the PTG-200 Phase 2A Clinical Trial and (b) any related Development activities (including pre-clinical and IND-enabling studies and CMC Development and Manufacturing activities) set forth in the PTG-200 Clinical Development Plan. &#160;The PTG-200 Phase 2A Activities do not include any Development activities relating to a Phase 2B Clinical Trial (as defined in Section 7.3.3).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.102.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200 Phase 2A Clinical Trial</b><font style="font-size:12pt;">&#8221; means the Phase 2 Clinical Trial with protocol number 67864238PACRD2001. &#160;The PTG-200 Phase 2A Clinical Trial is ongoing as of the Restatement Effective Date. &#160;</font><font style="font-size:12pt;">The PTG-200 Phase 2A Clinical Trial is not a Phase 2B Clinical Trial (as defined in Section 7.3.3).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.103.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Public Health Service Act</b><font style="font-size:12pt;">&#8221; means the U.S. Public Health Service Act (42 U.S.C. &#167;201 et seq.), as amended from time to time, and any regulations promulgated thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.104.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Approval</b><font style="font-size:12pt;">&#8221; means any and all approvals (including Marketing Approvals), licenses (including import licenses), registrations or authorizations of any national, regional, state or local Regulatory Authority, department, bureau, commission, council or other governmental entity, that are necessary or useful to Development, Manufacture or Commercialize a Licensed Compound or Licensed Product in any country or jurisdiction in the Territory for one or more uses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.105.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Authority</b><font style="font-size:12pt;">&#8221; means any Governmental Authority with authority over the Development, marketing and sale of a pharmaceutical or biologic product in a country, such as the FDA in the United States or EMA in the EU. &#160;Regulatory Authority also includes any non-governmental group licensed by an entity described in the preceding sentence to perform inspections, audits and/or reviews.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">17</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.106.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Documentation</b><font style="font-size:12pt;">&#8221; means: (a) all applications for Regulatory Approval (including Drug Approval Applications); (b) all Regulatory Approvals, including INDs, CTAs and Marketing Approvals; (c) all supporting documents created for, referenced in, submitted to or received from an applicable Regulatory Authority relating to any of the applications or Regulatory Approvals described in clauses (a) or (b), including drug master files (or any equivalent thereof outside the U.S.), annual reports, regulatory drug lists, advertising and promotion documents shared with Regulatory Authorities, adverse event files, complaint files and Manufacturing records; and (d) all correspondence made to, made with or received from any Regulatory Authority (including written and electronic mail correspondence and minutes from meetings, discussions or conferences (whether in person or by audio conference or videoconference)).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.107.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Exclusivity Period</b><font style="font-size:12pt;">&#8221; means, with respect to a Licensed Product and a country, a period of exclusivity (other than patent exclusivity), granted or afforded by Applicable Laws or by a Regulatory Authority in such country, that confers exclusive marketing rights with respect to such Licensed Product in such country and prevents the initial market entry of a Generic Product with respect to such Licensed Product. &#160;If such exclusivity is not available with respect to a Licensed Product in a country, the Regulatory Exclusivity Period for such Licensed Product in such country shall be deemed to expire upon the First Commercial Sale of such Licensed Product in such country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.108.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Relevant Factors</b><font style="font-size:12pt;">&#8221; means all relevant scientific, technical, operational, commercial, economic and other factors that may affect the Development, Marketing Approval, Manufacturing or Commercialization of a product, including (as applicable): [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.109.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Retained Compound</b><font style="font-size:12pt;">&#8221; means any peptide that is disclosed by any Protagonist IL23 Receptor Inhibitor Patent Rights and that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">has an IC50 value of greater than [ * ] nanomolar (nM), as determined in the [ * ] described in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;">; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">has an affinity for IL23R greater than [ * ]nM, as determined in the [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.110.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Term</b><font style="font-size:12pt;">&#8221; means: (i) with respect to a Licensed Product containing PTG-200, PN-232 or PN-235 (each such compound, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Existing Compound</b><font style="font-size:12pt;">&#8221;) and a country, the period beginning on the date of First Commercial Sale of such Licensed Product in such country and ending on the later of: (a) ten (10) years after the date of First Commercial Sale of such Licensed Product in such country; (b) the expiration of the last to expire Valid Claim of any Protagonist Patent Right that Covers the composition of matter of such Licensed Product in such country; or (c) the expiration or termination of the Regulatory Exclusivity Period with respect to such Licensed Product in such country; and (ii) with respect to any Licensed Product that does not contain an Existing Compound and a country, the period beginning on the date of First Commercial Sale of such Licensed Product in such country and ending on the later of: (a) twelve (12) years after the date of First Commercial Sale of such Licensed Product in such country; (b) the expiration of the last to expire Valid Claim of any Protagonist Patent Right that Covers the composition of matter of such Licensed Product in such country; or (c) the expiration or termination of the Regulatory Exclusivity Period with respect to such Licensed Product in such country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">18</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.111.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Tax</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">Taxes</b><font style="font-size:12pt;">&#8221; means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including any penalties or interest thereon).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.112.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Territory</b><font style="font-size:12pt;">&#8221; means worldwide.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.113.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party</b><font style="font-size:12pt;">&#8221; means any Person other than a Party or any of its Affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.114.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party Blocking Intellectual Property Rights</b><font style="font-size:12pt;">&#8221; means intellectual property rights of a Third Party that Cover the manufacture, use or sale of, or are necessary to manufacture, use or sell, a Licensed Compound or a Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.115.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Trademark</b><font style="font-size:12pt;">&#8221; means any word, name, symbol, color, designation, or device or any combination thereof, whether registered or unregistered, including any trademark, trade dress, service mark, service name, brand mark, trade name, brand name, logo or business symbol.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">1.116.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">UC</b><font style="font-size:12pt;">&#8221; means treatment of ulcerative colitis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.117.</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Valid Claim</b><font style="font-size:12pt;">&#8221; means: (a) a claim of any issued and unexpired patent that (i) has not been dedicated to the public, disclaimed, revoked or held unenforceable or invalid by a decision of a Governmental Authority of competent jurisdiction from which no appeal can be taken, or a decision of a Governmental Authority of competent jurisdiction that can be appealed, but with respect to which an appeal has not taken within the time allowed for appeal, and (ii) has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b) a claim of any pending patent application that (i) has not been cancelled, withdrawn or abandoned, without being re-filed in another application in the applicable jurisdiction, (ii) has not been finally rejected by an administrative agency or other governmental action from which no appeal can be taken and (iii) has not been pending or filed more than [ * ] from the earliest possible priority date for such patent application; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that if such claim is later issued, it shall from the issuance date forward be deemed to be a Valid Claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.118.</font></font><b style="font-size:12pt;font-weight:bold;">Additional Definitions. &#160;</b><font style="font-size:12pt;">Each of the following definitions are found in the body of this Agreement as indicated:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:54.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Defined Term</b></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:42.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Section</b></p></td></tr><tr><td style="vertical-align:top;width:54.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2nd Generation Clinical Development Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2nd Generation Development Budget</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.3(b)(1)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Agreement</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Alliance Manager</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2.1.5</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Anti-Corruption Laws</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10.5.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Anti-Kickback Laws</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10.5.2(a)(1)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Audited Site</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.1(i)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Bankruptcy Code</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.4.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">BLA</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.34</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Breaching Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">CAPA</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.1(g)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Co-Detailing Agreement</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(e)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Co-Detailing Option</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(b)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">19</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Co-Detailing Option Exercise Notice</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Collaboration Patent Right</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Collaboration Records</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.3(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Competing Product</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">6.7.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Conducting Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.1(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Cost Records</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.7.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">CPR Mediation Procedure</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">13.2.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">CPR Rules</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">13.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">CREATE Act</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.3.7</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Cure Period</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Detail</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(a)(1)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Development Costs</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.2.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Directed to IL23R</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">6.7.2(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Disclosing Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">9.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Dispute</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">13.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Excess Development Costs</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.2.6(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Excluded Research Know-How</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.19</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Exclusivity Period</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">6.7.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Existing Agreement</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Recitals</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Existing Compound</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.110</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Existing Protagonist Know-How</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10.3.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Existing Protagonist License Agreement</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10.3.2</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Existing Protagonist Patents</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">10.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">IBD Indication</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(a)(2)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Included Research Know-How</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.19</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Incumbent Board</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.11</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Indemnified Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.2</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Indemnifying Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.2</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Initial Co-Detailing Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(d)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Initial Compound</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.59 </font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Insolvency Event</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.4.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">IRB</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.1(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Collaboration Know-How</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Collaboration Patent Right</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.1(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Elected Protagonist Patent Rights</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.3.3(d)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Indemnified Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.1.2</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Independent Research Activities</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">4.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Janssen Independent Research Term</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">4.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">JMC</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2.1.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Joint Collaboration Patent Right</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.1(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">JRC</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2.1.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">JSC</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2.1.1(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Losses</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Manufacturing Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.1(h)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Milestone Event</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.3.1</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">20</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Milestone Payment </font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">NDA</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.34</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Ongoing Clinical Trials</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.4.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Ongoing PTG-200 Phase 2 Activities</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.5.1(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Original Agreement</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Recitals</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Original Effective Date</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Recitals</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Original Execution Date</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Recitals</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Party/Parties</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Patent Representative</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Patent Term Restoration</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.6</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Phase 1A Data Package</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.4.2(e)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Phase 2A Results</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.4.1(d)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Phase 2B Clinical Trial</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.3.3</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PN-232 Phase 2 Activities</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.3(b)(2)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PN-235 Phase 2 Activities</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.3(b)(2)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Primary Call</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(a)(3)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Prior 2nd Generation Development Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Prior Clinical Development Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.2(c)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Prior CMC Development Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.2(d)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Protagonist</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Protagonist Collaboration Know-How</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Protagonist Collaboration Patent Right</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.2.1(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Protagonist Indemnified Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PTG-200</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.59 </font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PTG-200 Clinical Development Plan</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.2(e)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PTG-200 Development Budget</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.2.3(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PTG-200 Product</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">1.54</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Receiving Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">9.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Research Activities</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">4.2.1(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Research Compound IP</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">4.5</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Research Term</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">4.2.1(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Restatement Effective Date</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Restricted Change of Control</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(a)(4)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Retained Patent Rights</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">8.3.5(a)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Royalty Records</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.7.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Sales Milestone Event</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Sales Milestone Payment</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Second Indication</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.3.4</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Secondary Call</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">5.6.2(a)(5)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Segregate</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">6.7.2(d)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Specified Percentage</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.2.6(a)</font></p></td></tr><tr style="height:3.7pt;"><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Specified Phase 1 Percentage</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.2.1(e)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Specified Phase 2 Percentage</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.2.2</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Subcommittees</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">2.1.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Subcontracting Party</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Term</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.1</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">21</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Terminating Party </font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">12.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Third Indication</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.3.5</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Third Party Claim</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">11.1.1</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Third Party Subcontractor</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">3.5.2(b)</font></p></td></tr><tr><td style="vertical-align:top;width:54.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Transfer Taxes</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">7.8.2</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">2.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Joint Steering Committee</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.1.</font></font><b style="font-size:12pt;font-weight:bold;">Formation, Composition and Term of JSC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Prior to the Restatement Effective Date, the Parties established a joint steering committee (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">JSC</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) to oversee and coordinate the Parties</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;"> activities under Article 3. &#160;On and after the Restatement Effective Date, the JSC shall no longer have any oversight or decision-making authority and instead shall serve solely as an information sharing body in accordance with the provisions of Article 3 and Section 5.3.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">The JSC shall continue to be composed of [ * ] members, [ * ] of whom are representatives appointed by Protagonist and [ * ] of whom are representatives appointed by Janssen, each with the requisite experience and seniority with respect to the issues to be discussed by the JSC. Neither Party shall appoint any representative to the JSC that is not an employee of such Party or one of its Affiliates without the prior written consent of the other Party, which consent shall not be unreasonably withheld. Each Party has appointed one (1) of its representatives as co-chairperson of the JSC. The size of the JSC may be changed from time to time by written agreement of the Parties, </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that the JSC shall at all times include an equal number of representatives of each Party. Each Party may replace its JSC representatives at any time upon written notice to the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">The JSC shall automatically dissolve when Janssen has no further reporting obligations under Section 5.3.2 (or such later time as agreed by the Parties).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">22</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.2.</font></font><b style="font-size:12pt;font-weight:bold;">Subcommittees.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">The Joint Manufacturing Committee (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">JMC</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) is dissolved as of the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">The Parties established a Joint Research Committee (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">JRC</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> and, together with the JMC, the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Subcommittees</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) prior to the Restatement Effective Date, with each Party designating [ * ] representatives to serve on the JRC. &#160;On and after the Restatement Effective Date, the purpose of the JRC is to oversee and coordinate the Parties</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;"> conduct and completion of the ongoing Research Activities in accordance with Section 4.2. &#160;The JRC shall automatically dissolve on the last day of the Research Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.3.</font></font><b style="font-size:12pt;font-weight:bold;">Responsibilities of the JSC. &#160;</b><font style="font-size:12pt;">The JSC shall perform such functions as expressly set forth in this Agreement or as mutually agreed upon by the Parties in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">2.1.4.</font></font><b style="font-size:12pt;font-weight:bold;">JSC Operations</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Meetings</i><font style="font-size:12pt;">. During the Development Term, the JSC shall hold meetings at least [ * ] or as often as its members may determine. &#160;Thereafter, the JSC shall hold meetings at least [ * ]. &#160;JSC meetings may be held in person or by any means of telecommunications as the members deem necessary or appropriate, including telephone, video conference or similar means in which each participant can hear what is said, and be heard, by the other participants, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that, unless otherwise agreed by the Parties, the location of any in-person meetings shall alternate between a location chosen by Protagonist and a location chosen by Janssen. &#160;A quorum of the JSC shall exist whenever there is present at a meeting at least one (1) representative appointed by each Party. &#160;Employees or consultants of either Party who are performing Collaboration Activities hereunder but are not members of JSC may attend meetings of the JSC relating to such activities, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that (i) such attendees shall be bound in writing by obligations of confidentiality and non-use equivalent to those set forth in Article 9 and (ii) a consultant of a Party may attend a meeting only with prior notice to and consent of the other Party, which shall not be unreasonably withheld. &#160;Except as provided in the prior sentence, individuals who are not members of the JSC may not attend a meeting of the JSC without the prior consent of both Parties, except that each Party&#8217;s Alliance Manager may attend without such consent. &#160;Each Party shall be responsible for its own expenses of participating in the JSC and in any Subcommittee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Agenda and Minutes</i><font style="font-size:12pt;">. &#160;Each Party shall have the right to propose agenda items and shall provide all appropriate information with respect to such proposed agenda items in advance of each JSC meeting. &#160;Each co-chairperson of the JSC, on an alternating basis, shall prepare and circulate to all members of the JSC for review draft minutes of each JSC meeting within [ * ] after such meeting. &#160;The Parties shall agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JSC, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that, if the Parties cannot agree as to the content of the minutes by the time of the next JSC meeting, such minutes shall be finalized to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">23</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">reflect any areas of disagreement. &#160;The minutes of each meeting of the JSC shall be Collaboration Information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.5.</font></font><b style="font-size:12pt;font-weight:bold;">Alliance Managers</b><font style="font-size:12pt;">. &#160;Each Party has designated a single alliance manager for all of the Development Term activities contemplated under this Agreement (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Alliance Manager</b><font style="font-size:12pt;">&#8221;). &#160;Such Alliance Managers are responsible for the day-to-day worldwide coordination of the collaboration contemplated by this Agreement and will serve to facilitate communication between the Parties. &#160;Such Alliance Managers have experience and knowledge appropriate for managers with such project management responsibilities. &#160;Each Party may change its designated Alliance Manager from time to time upon notice to the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.1.6.</font></font><b style="font-size:12pt;font-weight:bold;">Discontinuation of the JSC. &#160;</b><font style="font-size:12pt;">The JSC and the JRC shall continue to exist as provided in Section 2.1.1(c) or Section 2.1.2, as applicable, unless before such time the Parties mutually agree to disband such committee or Protagonist provides written notice to Janssen of its intention to disband and no longer participate in such committee. Once the Parties mutually agree to disband a committee or Protagonist has provided written notice to disband a committee, such committee shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement or such exchange of information shall be made through the Alliance Managers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ACTIVITIES DURING DEVELOPMENT TERM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Overview</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.1.1.</font></font><font style="font-size:12pt;">Prior to the Restatement Effective Date, Protagonist conducted and completed a Phase 1 Clinical Trial of the PTG-200 Product. &#160;Janssen commenced the PTG-200 Phase 2A Clinical Trial, and Protagonist commenced the PN-235 Phase 1A Clinical Trial and the PN-232 Phase 1A Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.1.2.</font></font><font style="font-size:12pt;">After the Restatement Effective Date and for the remainder of the Development Term, the Parties shall conduct Development of the PTG-200 Product and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in accordance with this Article 3. &#160;Unless expressly stated otherwise, the provisions of this Article 3 shall apply only during the Development Term. &#160;Notwithstanding the foregoing, this Article 3 shall apply to all PTG-200 Phase 2A Activities and Phase 1A Activities to the extent they are performed after the end of the Development Term but before the end of the Term, including all Phase 1 Development Costs and Phase 2 Development Costs incurred during such period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PTG-200 Clinical Development Plan; 2</b><sup style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"> Generation Clinical Development Plan</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.1.</font></font><b style="font-size:12pt;font-weight:bold;">General</b><font style="font-size:12pt;">. &#160;Except as set forth in Article 4, during the Development Term, the Development of the PTG-200 Product shall be conducted in accordance with the PTG-200 Clinical Development Plan and the Development of the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products shall be conducted in accordance with the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">24</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.2.</font></font><b style="font-size:12pt;font-weight:bold;">Definitions</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;"> Generation Clinical Development Plan</b><font style="font-size:12pt;">&#8221; means the Parties&#8217; written plan for the clinical Development of PN-232, PN-235 and any other 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products on and after the Restatement Effective Date, including the budgets and timelines described below in Section 3.2.3(b), as such plan may be updated and amended in accordance with Section 3.2.4. &#160;The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan shall not include descriptions of or budgets for the ongoing Research Activities or Janssen Independent Research Activities, which instead are subject to the terms set forth in Article 4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Prior 2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd </sup><b style="font-size:12pt;font-weight:bold;">Generation Development Plan</b><font style="font-size:12pt;">&#8221; means the Parties&#8217; written plan for the discovery, research and pre-clinical and clinical Development of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products prior to the Restatement Effective Date (which was referred to as the &#8220;2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Plan&#8221; in the Existing Agreement), including the budget that was in effect immediately prior to the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Prior Clinical Development Plan</b><font style="font-size:12pt;">&#8221; means the Parties&#8217; written plan for the clinical Development of the PTG-200 Product prior to the Restatement Effective Date (which was referred to as the &#8220;Clinical Development Plan&#8221; in the Existing Agreement), including the budget that was in effect immediately prior to the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Prior CMC Development Plan</b><font style="font-size:12pt;">&#8221; means the Parties&#8217; written plan for CMC Development and Manufacturing of PTG-200 and PTG-200 Product and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound(s) and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product(s) prior to the Restatement Effective Date, including the budget that was in effect immediately prior to the Restatement Effective Date (such budget, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">CMC Development Budget</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200 Clinical Development Plan</b><font style="font-size:12pt;">&#8221; means the Parties&#8217; written plan for the clinical Development of the PTG-200 Product on and after the Restatement Effective Date, including the budget and timelines described below in Section 3.2.3(a), as such plan may be updated and amended in accordance with Section 3.2.4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.3.</font></font><b style="font-size:12pt;font-weight:bold;">Contents</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">PTG-200 Clinical Development Plan</i><font style="font-size:12pt;">. &#160;As of the Restatement Effective Date, the Prior Clinical Development Plan is superseded by the PTG-200 Clinical Development Plan attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:12pt;">. &#160;The PTG-200 Clinical Development Plan contains all Development activities (including CMC Development and Manufacturing activities) necessary to complete the PTG-200 Phase 2A Clinical Trial. The PTG-200 Clinical Development Plan includes a reasonably detailed description of such activities, a timeline for completion of such activities and the deliverables for such activities. The PTG-200 Clinical Development Plan includes a budget for the PTG-200 Phase 2A Activities broken down by activity and by Calendar Year (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">PTG-200 Development Budget</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">). &#160;If Janssen amends the PTG-200 Clinical Development Plan to include any other</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">25</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Clinical Trials for the PTG-200 Product in accordance with Section 3.2.4(b), the plan shall include a reasonably detailed description of such Clinical Trials, but is not required to include a budget for such Clinical Trials.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">2</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">nd</sup><i style="font-size:12pt;font-style:italic;"> Generation Clinical Development Plan</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">As of the Restatement Effective Date, the Prior 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Plan is superseded by the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:12pt;">. &#160;The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan contains all Development activities (including CMC Development and Manufacturing activities) necessary to complete (i) the PN-232 Phase 1A Clinical Trial and (ii) the PN-235 Phase 1A Clinical Trial. The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan includes a reasonably detailed description of such activities, timelines for achievement of certain milestone events and completion of each of the PN-232 Phase 1A Clinical Trial and PN-235 Phase 1A Clinical Trial by target dates (taking into account previous and expected delays caused by the COVID-19 pandemic) and the deliverables for such activities. The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan includes a budget for the PN-232 Phase 1A Activities and PN-235 Phase 1A Activities broken down by activity and by Calendar Year (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;"> Generation Development Budget</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">). &#160;The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Budget will include reimbursement by Janssen of all costs incurred by Protagonist for any accelerated or non-standard analyses requested by Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">As of the Restatement Effective Date, the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan also contains all other Development activities through the end of Phase 2 for PN-232 and PN-235 that are necessary for advancement to a Phase 3 Clinical Trial (such activities with respect to PN-232, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-232 Phase 2 Activities</b><font style="font-size:12pt;">&#8221; and such activities with respect to PN-235, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">PN-235 Phase 2 Activities</b><font style="font-size:12pt;">&#8221;) as well as all additional Development activities that Janssen plans as of the Restatement Effective Date to conduct with respect to any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound. &#160;The 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan includes a reasonably detailed description of such activities, but does not include a budget for such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Janssen amends the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan to include any other Clinical Trials for any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product in accordance with Section 3.2.4(b), the plan shall include a reasonably detailed description of such Clinical Trials, but is not required to include a budget for such Clinical Trials.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Prior CMC Development Plan</i><font style="font-size:12pt;">. &#160;As of the Restatement Effective Date, the Prior CMC Development Plan is no longer in effect. &#160;The PTG-200 Clinical Development Plan and the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan include CMC Development and Manufacturing activities and budgets for such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">26</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2.4.</font></font><b style="font-size:12pt;font-weight:bold;">Amendments</b><font style="font-size:12pt;">. &#160;Janssen shall have sole authority to amend the Development Plans in its sole discretion, subject to Sections 3.2.4(a), 3.2.4(b), 3.4.2(h) and 5.3.1. &#160;For clarity, such amendments shall not be subject to JSC or Protagonist&#8217;s approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Ongoing Clinical Trials</i><font style="font-size:12pt;">. &#160;From time to time during the Development Term, Janssen may amend the applicable Development Plan to make changes to the PTG-200 Phase 2A Clinical Trial, the PN-232 Phase 1A Clinical Trial or the PN-235 Phase 1A Clinical Trial (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Ongoing Clinical Trials</b><font style="font-size:12pt;">&#8221;) or any of their related Development activities. &#160;Where reasonably practicable, Janssen shall discuss any such amendments with Protagonist at a JSC meeting prior to implementation and shall consider in good faith any comments provided by Protagonist with respect thereto. &#160;Such amendments to the Development Plans shall not require the consent or approval of the JSC or Protagonist, except that the following amendments shall require Protagonist&#8217;s written consent before taking effect:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">any amendment relating to an Ongoing Clinical Trial or its related Development activities that would [ * ]; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">any amendment that would result [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Other Amendments</i><font style="font-size:12pt;">. &#160;During the Development Term, Janssen may decide to conduct new Clinical Trials of the PTG-200 Product or any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product (in addition to those set forth in the then-current Development Plans). &#160;If Janssen decides to conduct a new Clinical Trial, Janssen shall amend the PTG-200 Clinical Development Plan and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan to add such Clinical Trial. &#160;In addition, subject to Section 3.4.3(b), Janssen may amend the PTG-200 Clinical Development Plan and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan to change or remove any activities in such plans in its sole discretion (other than amendments to the Ongoing Clinical Trials and their related Development activities, which are subject to Section 3.2.4(a)). &#160;Janssen shall provide such amendments to the JSC for informational purposes (including for purposes of enabling Protagonist to monitor and assess Janssen&#8217;s compliance with its obligations under Sections 3.4.2(h) and 5.3.1).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Updates after Development Term</i><font style="font-size:12pt;">. &#160;After the Development Term, Janssen will no longer have any obligation to amend the Development Plans or to provide any amended Development Plans to Protagonist, but, instead, shall be obligated to provide reports to Protagonist in accordance with Section 5.3.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">3.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Regulatory Matters during the Development Term</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Janssen Regulatory Responsibility</b><font style="font-size:12pt;">. &#160;Except as set forth in Section 3.3.2, Janssen shall have the sole right and authority, at its sole cost and expense, to conduct all regulatory matters relating to Licensed Compounds and Licensed Products during the Development Term, including preparing and submitting INDs and CTAs and communicating with Regulatory Authorities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">27</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">Protagonist Regulatory Responsibility</b><font style="font-size:12pt;">. &#160;Prior to the Restatement Effective Date, Protagonist prepared and submitted to the appropriate Regulatory Authorities the INDs and CTAs necessary to conduct the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities. &#160;During the Development Term:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Protagonist shall take all actions reasonably necessary to maintain such INDs and CTAs during the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Protagonist shall be responsible for all regulatory responsibilities relating to the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities as required by Applicable Laws, including safety reporting obligations to Regulatory Authorities, ethics committees and investigators, submission of the final clinical study report to a Regulatory Authority, and all other reporting and publication requirements under Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Protagonist shall have the sole responsibility for, and sole authority with respect to, communications with any Regulatory Authority regarding the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that Janssen shall have the right to participate as a silent observer in all material meetings, conferences and discussions between Protagonist and any Regulatory Authorities pertaining to the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities, unless the Parties have agreed otherwise in advance of such meeting, conference or discussion. &#160;Protagonist shall provide Janssen with reasonable advance notice of all such meetings, conferences and discussions and advance copies of all related documents and other relevant information relating to such meetings, conferences and discussions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Protagonist shall provide Janssen with copies of any material Regulatory Documentation with respect to the Licensed Compounds and Licensed Products that Protagonist submits to any Regulatory Authority in connection with the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities. &#160;In addition, in the event that Protagonist is notified of any material regulatory or other inquiries that relate to a Licensed Compound or Licensed Product during the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities, Protagonist shall promptly notify Janssen of such inquiries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Development Activities during the Development Term</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.4.1.</font></font><b style="font-size:12pt;font-weight:bold;">PTG-200 Phase 2A Activities</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Responsibility; Diligence</i><font style="font-size:12pt;">. &#160;During the Development Term, Janssen shall be solely responsible for conducting the PTG-200 Phase 2A Activities. &#160;The costs and expenses of the PTG-200 Phase 2A Activities shall be shared by the Parties in accordance with Section 7.2.2. &#160;Janssen shall conduct and complete the PTG-200 Phase 2A Activities in accordance with the PTG-200 Clinical Development Plan, and shall use Diligent Efforts to meet the timeline set forth in the PTG-200 Clinical</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">28</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Development Plan. &#160;Janssen shall have day-to-day operational control over the conduct of the PTG-200 Phase 2A Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Conduct</i><font style="font-size:12pt;">. &#160;Janssen shall conduct the PTG-200 Phase 2A Activities in accordance with the terms and conditions of this Agreement, in good scientific manner and in compliance with Applicable Law, including, as applicable, those relating to GLP, GCP, GMP, pharmacovigilance and safety reporting, and requirements for the protection of human subjects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Reports &amp; Notices</i><font style="font-size:12pt;">. &#160;Janssen shall provide updates on its progress with respect to the conduct of the PTG-200 Phase 2A Activities, and a summary of the data and results from such activities, at each meeting of the JSC. &#160;In addition to any such reports made to the JSC, Janssen shall make its employees and consultants available for an in-person or telephonic meeting with Protagonist at least [ * ] to discuss its progress with respect to the conduct of the PTG-200 Phase 2A Activities. &#160;Janssen shall provide Protagonist with access to the data and results from the PTG-200 Phase 2A Activities upon Protagonist&#8217;s reasonable request. &#160;Janssen shall notify Protagonist promptly following (i) the database lock for the PTG-200 Phase 2A Clinical Trial after the last patient in such Clinical Trial completes the last visit as described in the protocol for such Clinical Trial or (ii) if earlier, the termination or completion of such Clinical Trial; such notice shall specify date of such database lock, termination or completion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">Results</i><font style="font-size:12pt;">. &#160;Janssen shall deliver to Protagonist the top-line results from the PTG-200 Phase 2A Clinical Trial within [ * ] after they become available to Janssen, which results shall include the primary and secondary endpoints, as well as available safety and exposure data, from the analysis cohort (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 2A Results</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">[Reserved</font><i style="font-size:12pt;font-style:italic;">.</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><i style="font-size:12pt;font-style:italic;">Other Development Activities for PTG-200</i><font style="font-size:12pt;">. &#160;Except for the PTG-200 Phase 2A Activities, Janssen shall have the sole authority to decide whether and how to conduct any Clinical Trials, CMC Development and other Development activities for the PTG-200 Product in its sole discretion and at its sole expense, subject only to Section 5.3.1. &#160;Without limiting the foregoing, Janssen has no obligation to conduct a Phase 2B Clinical Trial (as defined in Section 7.3.3) for the PTG-200 Product. &#160;If Janssen decides to conduct any Clinical Trials or other Development activities for the PTG-200 Product, it shall do so in accordance with Section 3.4.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.4.2.</font></font><b style="font-size:12pt;font-weight:bold;">PN-232 Phase 1A Activities and PN-235 Phase 1A Activities</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Responsibility; Diligence</i><font style="font-size:12pt;">. &#160;During the Development Term, Protagonist shall be solely responsible for conducting the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities, except that Janssen shall be responsible for conducting any CMC Development activities allocated to Janssen in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan. &#160; The costs and expenses of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities shall be shared by the Parties in accordance with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">29</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Section 7.2.1. &#160;Protagonist shall commence such activities as soon as possible (if not commenced prior to the Restatement Effective Date), shall conduct the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities in accordance with the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, and shall use Diligent Efforts to meet the timelines set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan. &#160;Janssen shall conduct the CMC Development activities allocated to it in accordance with the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, and shall use Diligent Efforts to meet the timelines set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan with respect to such activities. &#160;Protagonist shall have day-to-day operational control over the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities, except that Janssen shall have day-to-day operational control over the CMC Development activities it is responsible for conducting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Protocols</i><font style="font-size:12pt;">. &#160;The PN-232 Phase 1A Clinical Trial and the PN-235 Phase 1A Clinical Trial shall be conducted by Protagonist in accordance with the protocols mutually agreed upon by the Parties prior to the Restatement Effective Date. &#160;Protagonist shall not make any changes to the protocols without the prior written consent of Janssen. &#160;Janssen may require Protagonist to make changes to the protocols from time to time. &#160;If any such change would result in a material increase to the Phase 1 Development FTEs of Protagonist required to conduct the applicable trial, such change shall require the prior written consent of Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Conduct</i><font style="font-size:12pt;">. &#160;Each Party shall conduct the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities in accordance with the terms and conditions of this Agreement, in good scientific manner and in compliance with Applicable Law, including, as applicable, those relating to GLP, GCP, GMP, pharmacovigilance and safety reporting, and requirements for the protection of human subjects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">Reports</i><font style="font-size:12pt;">. &#160;Protagonist shall provide Janssen with access to the data and results from the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities upon Janssen&#8217;s reasonable request. &#160;In addition, the Parties&#8217; clinical development teams shall meet [ * ] (or on another schedule agreed upon by the teams) to discuss the progress of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities. &#160;Protagonist shall provide updates on its progress with respect to the conduct of the PN-232 Phase 1A Activities and the PN-235 Phase 1A Activities compared to the timelines set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, and a summary of the data and results from such activities, at each such meeting. &#160;In addition, if Protagonist at any time becomes aware of an expected or actual delay in the PN-232 Phase 1A Activities or the PN-235 Phase 1A Activities, or any issue that may reasonably be expected to give rise to a delay, Protagonist shall notify Janssen as soon as possible. The Parties shall then promptly meet to develop an action plan to remedy (where possible) the issue and/or mitigate the delay risk. The action plan may include Janssen agreeing to assist Protagonist with the relevant activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><i style="font-size:12pt;font-style:italic;">Phase 1A Data Packages</i><font style="font-size:12pt;">. &#160;Following the date of database lock for each of the PN-232 Phase 1A Clinical Trial or the PN-235 Phase 1A Clinical Trial, Protagonist shall prepare and deliver to Janssen a data package with respect to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">30</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">PN-232 Phase 1A Activities or the PN-235 Phase 1A Activities, as applicable, that contains: (a) [ * ] from such activities; (b) all [ * ] with respect to the Data relating to the Licensed Compounds and Licensed Products generated by or on behalf of Protagonist pursuant to the conduct of such activities; and (c) the other documents and information described on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 3.4.2(e)</u><font style="font-size:12pt;"> (each such data package, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1A Data Package</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><i style="font-size:12pt;font-style:italic;">Clinical Study Reports</i><font style="font-size:12pt;">. &#160;Protagonist shall use Diligent Efforts to complete the clinical study report for each of the PN-232 Phase 1A Clinical Trial and the PN-235 Phase 1A Clinical Trial as promptly as is practicable following the delivery of the Phase 1A Data Package therefor, and shall deliver such clinical study report to Janssen promptly following its completion (and, in any event, no later than [ * ] after the date of database lock for the applicable trial).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><i style="font-size:12pt;font-style:italic;">Technology Transfer</i><font style="font-size:12pt;">. &#160;Promptly following the date that Janssen determines pursuant to Section 3.4.2(h) to proceed with PN-232 Phase 2 Activities or PN-235 Phase 2 Activities, Protagonist shall transfer or make available to Janssen copies of (i) all Protagonist Know-How that is necessary and (ii) all Protagonist Know-How (other than Protagonist Platform Know-How or Know-How that originates from any other Protagonist programs that are not targeting the IL23 receptor) that is specifically useful, for Janssen to conduct the PN-232 Phase 2 Activities or PN-235 Phase 2 Activities, as applicable, to the extent not previously provided under this Agreement. &#160;In addition, upon Janssen&#8217;s reasonable request, Protagonist shall promptly provide to Janssen (x) [ * ], as applicable (including [ * ], as applicable) and (y) [ * ] with respect to the data described in clause (x), in each case ((x) and (y)), to the extent that such information was not previously provided by Protagonist to Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><i style="font-size:12pt;font-style:italic;">PN-232 Phase 2 Activities and PN-235 Phase 2 Activities</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Following delivery of a Phase 1A Data Package for PN-232 or PN-235 under Section 3.4.2(e), Janssen shall determine whether to proceed with the PN-232 Phase 2 Activities or PN-235 Phase 2 Activities, as applicable, in its sole discretion, subject to Sections 3.4.3(b) and 5.3.1. Janssen shall notify Protagonist of its determination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Janssen determines to proceed with the PN-232 Phase 2 Activities or PN-235 Phase 2 Activities, Protagonist shall use Diligent Efforts to provide to Janssen all data and information relating to the applicable 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product necessary to prepare the INDs and CTAs for such activities as soon as practicable after Janssen&#8217;s determination. &#160;Janssen shall use Diligent Efforts to prepare and submit such INDs and CTAs to the applicable Regulatory Authorities after Protagonist provides such necessary data and information. &#160;The Parties will use Diligent Efforts to complete the activities described in this Section 3.4.2(h)(2) as soon as reasonably practicable after the date on which Janssen makes its determination, and in any event Janssen shall submit the INDs/CTAs within</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">31</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">[ * ] after Janssen makes its determination, it being understood that any delay in Protagonist&#8217;s delivery to Janssen of the necessary data and information as required above will result in a day for day increase to such time period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Janssen shall use Diligent Efforts to initiate study site recruitment for the next Clinical Trial for the applicable Licensed Product set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan within [ * ] after submission of the applicable IND/CTA, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that there are no delays caused by the action of a Regulatory Authority. &#160;Thereafter, Janssen shall use Diligent Efforts to continue such recruitment and conduct and complete the applicable Clinical Trial in accordance with the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan. &#160;Notwithstanding the foregoing, if a Regulatory Authority requests or requires any changes to the PN-232 Phase 2 Activities or PN-235 Phase 2 Activities following submission of an IND or CTA in accordance with Section 3.4.2(h)(2), Janssen shall update the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan to address such request or requirement in accordance with Section 3.2.4(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><i style="font-size:12pt;font-style:italic;">Other Development Activities for PN-232 and PN-235</i><font style="font-size:12pt;">. &#160;Except for the PN-232 Phase 1A Activities, the PN-235 Phase 1A Activities and as set forth in Section 3.4.2(h), Janssen shall have the sole authority to decide whether and how to conduct any Clinical Trials, CMC Development and other Development activities for PN-232 and PN-235 in its sole discretion and at its sole expense, subject only to Sections 3.4.3(b) and 5.3.1. &#160;If Janssen decides to conduct any Clinical Trials or other Development activities for PN-232 or PN-235, it shall do so in accordance with Section 3.4.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.4.3.</font></font><b style="font-size:12pt;font-weight:bold;">Other Development Activities</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Right to Conduct</i><font style="font-size:12pt;">. &#160;During the Development Term, Janssen shall have the sole right and authority to conduct Clinical Trials, CMC Development and other Development activities for the PTG-200 Product and any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in its sole discretion and at its sole expense, subject to Sections 3.2.4(b), 3.4.1, 3.4.2, 3.4.3(b) and 5.3.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Conduct</i><font style="font-size:12pt;">. &#160;Janssen shall use Diligent Efforts to conduct such Clinical Trials and other Development activities in accordance with the applicable Development Plan (including the timeline set forth therein); </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that Janssen shall at all times during the Development Term ensure that the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan contemplates the advancement of [ * ] 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product into a Phase 3 Clinical Trial (including the dosing of [ * ] patients in such Phase 3 Clinical Trial) within [ * ] that is consistent with Janssen&#8217;s development timelines for other product candidates at similar stages of development. &#160;Janssen shall have day-to-day operational control over the conduct of such Development activities. &#160;Janssen shall conduct such activities for the PTG-200 Product and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in accordance with the terms and conditions of this Agreement, in good</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">32</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">scientific manner and in compliance with Applicable Law, including, as applicable, those relating to GLP, GCP, GMP, pharmacovigilance and safety reporting, and requirements for the protection of human subjects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Plan Updates and Reports</i><font style="font-size:12pt;">. &#160;During the Development Term, if Janssen elects to conduct any Clinical Trial of the PTG-200 Product or any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product that is not included in the then-current PTG-200 Clinical Development Plan or 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan, Janssen shall update the applicable Development Plan to include such Clinical Trial in accordance with Section 3.2.4(b). &#160;In addition, Janssen shall provide Protagonist, through the JSC, with an update (in the form of a report or presentation at a meeting of the JSC) of its progress and high-level summaries of its plans with respect to any Clinical Trials other than the Ongoing Clinical Trials. &#160;Upon request, Janssen shall provide Protagonist with a copy of all materials presented at such JSC meetings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">Regulatory Documentation</i><font style="font-size:12pt;">. &#160;Upon Janssen&#8217;s request, Protagonist shall transfer to Janssen sufficient rights in, to or under, all INDs, CTAs, safety databases and other Regulatory Documentation with respect to the applicable Licensed Product then held by Protagonist, its Affiliates and Third Party Subcontractors as reasonably necessary or useful to conduct Clinical Trials and other Development activities for the Licensed Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conduct of Activities during Development Term</b><font style="font-size:12pt;">. &#160;The following provisions of this Section 3.5 shall apply during the Development Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.5.1.</font></font><b style="font-size:12pt;font-weight:bold;">Development Compliance Matters</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Sponsorship</i><font style="font-size:12pt;">. &#160;The Party responsible for conducting an Ongoing Clinical Trial of a Licensed Product in accordance with this Article 3 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Conducting Party</b><font style="font-size:12pt;">&#8221;) shall be the sponsor of such Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Notifications. &#160;</i><font style="font-size:12pt;">Without limiting Protagonist&#8217;s obligations under Section 3.4.2(d), the Conducting Party shall notify the other Party as soon as reasonably practicable in the event that the Conducting Party becomes aware of any of the following with respect to the applicable Clinical Trial:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">changes proposed to be made by the Conducting Party and/or that may be required by any Regulatory Authority;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">safety or technical issue;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">expected or actual delay, or any issue that may reasonably be expected to give rise to a delay; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">other substantive issue.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">33</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">Following receipt of notice of any such event, the Parties shall promptly meet to discuss the circumstance and the Conducting Party shall inform the other Party of its intended action plan to remedy (where possible) the issue and/or mitigate the delay risk to successful completion of the applicable Clinical Trial. &#160;In determining an action plan, the Conducting Party shall take the other Party&#8217;s comments into consideration in good faith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">IRB</i><font style="font-size:12pt;">. &#160;The Conducting Party shall be responsible for obtaining any necessary approvals from institutional review boards (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">IRB</b><font style="font-size:12pt;">&#8221;) including, where applicable, obtaining approval of all Clinical Trial protocols, informed consents, investigator brochures, subject recruitment materials or plans, authorization of disclosure of confidential subject information, and any alterations to or waivers of the same, prior to commencement of any study. &#160;The Conducting Party shall not modify the protocol or the informed consent without the prior written agreement of the IRB.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">Informed Consent and Patient Authorization</i><font style="font-size:12pt;">. &#160;The Conducting Party shall be responsible for obtaining (i) an informed consent document, which shall have been approved by the IRB, signed by or on behalf of each human study subject prior to the subject&#8217;s participation in the Clinical Trial; and (ii) a HIPAA patient authorization signed by or on behalf of each human study subject, as described in 45 C.F.R. Part 164 (or for sites outside of the United States, the foreign equivalent), which authorization shall contain such provisions as are necessary for the other Party to have access to patient data to the extent reasonably necessary to exercise its rights and fulfill its obligations hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><i style="font-size:12pt;font-style:italic;">Clinical Study Registration and Results Reporting</i><font style="font-size:12pt;">. &#160;The Conducting Party shall be responsible for registering such Clinical Trial in the appropriate clinical study registry and reporting Clinical Trial results as may be required under Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><i style="font-size:12pt;font-style:italic;">Samples</i><font style="font-size:12pt;">. &#160;The Conducting Party shall accept, to the extent permitted by Applicable Law, responsibility for the retention of documentation and storage of samples of Licensed Products according to Applicable Law (provided, with respect to Janssen as the Conducting Party, the necessary documentation and samples have been transferred by Protagonist pursuant to this Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><i style="font-size:12pt;font-style:italic;">Audits</i><font style="font-size:12pt;">. &#160;With respect to any facility or site at which a Party conducts any PTG-200 Phase 2A Activities, PN-232 Phase 1A Activities or PN-235 Phase 1A Activities, and subject to the terms of any agreement between such Party and any applicable Third Party Subcontractor with respect to any facility or site of such Third Party Subcontractor, the other Party shall have the right, at its own expense, upon reasonable written notice to such Party, and during normal business hours, to inspect such site and facility of such Party or to accompany such Party to inspect any Third Party Subcontractor site and any records relating thereto [ * ], to verify such Party&#8217;s compliance with Applicable Law in carrying out its obligations under this Agreement, including those relating to GLP, GCP, GMP, pharmacovigilance and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">34</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">safety reporting, and requirements for the protection of human subjects. &#160;In the event that any such facility or site is found to be non-compliant with GLP, GCP, GMP, pharmacovigilance and safety reporting, or requirements for the protection of human subjects during such an audit, and such non-compliance relates to or impacts any PTG-200 Phase 2A Activities, PN-232 Phase 1A Activities or PN-235 Phase 1A Activities, the audited Party shall submit to the auditing Party proposed Corrective and Preventative Actions (&#8220;</font><b style="font-size:12pt;font-weight:bold;">CAPA</b><font style="font-size:12pt;">&#8221;) within [ * ] after the auditing Party provides notice of such non-compliance. &#160;The auditing Party shall have the right to review and comment on such CAPA, which comments the audited Party shall consider in good faith. &#160;The audited Party shall use Diligent Efforts to implement such CAPA promptly after review and comment by the auditing Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><i style="font-size:12pt;font-style:italic;">Manufacturing Site Audits</i><font style="font-size:12pt;">. &#160;In addition to its rights under Section 3.5.1(g), each Party shall have the right to conduct an audit of the manufacturing sites where any CMC Development activities are conducted by the other Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Manufacturing Party</b><font style="font-size:12pt;">&#8221;) or its Third Party Subcontractors, and subject to the terms of any agreement between the Manufacturing Party and the applicable Third Party Subcontractors. &#160;The Manufacturing Party shall facilitate the accommodation of such request with its Third Party Subcontractors. &#160;Following the completion of any such audit, the auditing Party may request the remediation of deficiencies that are not in compliance with GMP and identified during such audit. &#160;In the case of any critical observation relating to any CMC Development activities that the Manufacturing Party or its Third Party Subcontractor cannot or do not remediate in a timely manner, the auditing Party shall have the right to require the use of a different manufacturer for such CMC Development activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><i style="font-size:12pt;font-style:italic;">Audits by Regulatory Authorities</i><font style="font-size:12pt;">. &#160;Each Party shall cooperate in good faith with respect to Regulatory Authority inspections of any site or facility where Collaboration Activities are conducted pursuant to this Agreement by or on behalf of such Party, whether such site or facility is such Party&#8217;s, an Affiliate&#8217;s, or a subcontractor&#8217;s (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Audited Site</b><font style="font-size:12pt;">&#8221;). &#160;Such Party shall inform the other Party as promptly as practicable and in any event within [ * ] of receiving notice of such a Regulatory Authority audit and shall provide daily updates to the other Party regarding the audit status. &#160;In the event that any Audited Site is found to be non-compliant with one or more of GLP, GCP, GMP, current standards for pharmacovigilance and safety reporting, or requirements related to the protection of human subjects, and such non-compliance relates to or impacts any Collaboration Activities, the audited Party shall submit to the other Party proposed CAPA within [ * ] after the audited Party, its Affiliate, or its subcontractor receives notification of such non-compliance from the relevant Regulatory Authority. &#160;The other Party shall have the right to review and comment on such CAPA, which comments the audited Party shall consider in good faith. &#160;The audited Party shall use Diligent Efforts to implement such CAPA promptly after review and comment by the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.5.2.</font></font><b style="font-size:12pt;font-weight:bold;">Subcontracting</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">35</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Each Party may subcontract the performance of any Collaboration Activities &#160;to any of its Affiliates or any Third Party without prior written notice to the other Party (except as required pursuant to JSC sharing of information), </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that such Party shall oversee the performance by its Affiliates and Third Party Subcontractors in a manner that would be reasonably expected to result in their timely completion and shall remain responsible for the performance of such activities in accordance with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">With respect to any Collaboration Activities to be subcontracted to a Third Party in accordance with Section 3.5.2(a) (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party Subcontractor</b><font style="font-size:12pt;">&#8221;) by Protagonist or by Janssen pursuant to a subcontracting agreement with a Third Party that is first entered into after the Original Effective Date: (A) each such arrangement will be set forth in a written contract with such Third Party Subcontractor; and (B) each such contract shall be consistent with &#160;the terms and conditions of this Agreement and shall include (i)&#160;restrictions on the use and disclosure of Confidential Information of the other Party and (ii)&#160;an assignment to the applicable Party entering into such contract (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Subcontracting Party</b><font style="font-size:12pt;">&#8221;) of all rights to any and all results of the activities undertaken and other intellectual property made, invented or generated by such Third Party Subcontractor with respect to the Licensed Compounds or Licensed Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">A Subcontracting Party will notify the other Party of the engagement or retention of any Third Party Subcontractor to conduct any Collaboration Activities outside the ordinary course of business and, upon the request of such other Party, provide such other Party with a copy of the relevant contract (which may be redacted with respect to financial terms) to ensure compliance with the provisions of this Section 3.5.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Janssen may subcontract the performance of any other Development activities conducted during the Development Term or any Janssen Independent Research Activities conducted during the Janssen Independent Research Term to any of its Affiliates or any Third Party without prior written notice to Protagonist (except as required pursuant to JSC sharing of information), </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that Janssen shall oversee the performance by such Affiliates and third parties in a manner that would be reasonably expected to result in their timely completion and shall remain responsible for the performance of such activities in accordance with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.5.3.</font></font><b style="font-size:12pt;font-weight:bold;">Records; Data Requirements</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Each Party shall prepare and maintain, and shall cause its Affiliates and Third Party Subcontractors to prepare and maintain, complete and accurate written records, accounts, notes, reports and data with respect to the Collaboration Activities (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Records</b><font style="font-size:12pt;">&#8221;), in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in conformity with Applicable Law and such Party&#8217;s standard practices, which Collaboration Records shall reflect all work done and results achieved in connection with the Collaboration Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">36</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Each Party shall retain, and cause its Affiliates and Third Party Subcontractors to retain, the Collaboration Records for at least [ * ] from the completion of the Collaboration Activities or such longer period as may be required by Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Each Party shall comply with Janssen&#8217;s data policies set forth on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:12pt;"> with regard to Collaboration Records.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">No Branding Activities</b><font style="font-size:12pt;">. &#160;During the Development Term, Protagonist shall not use or file for protection of any Trademarks or trade names for a Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Material Safety Issues</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.7.1.</font></font><font style="font-size:12pt;">If, during the Development Term, either Party determines that there is a Material Safety Issue, such Party shall promptly notify the other Party and the Parties shall promptly meet to discuss such Material Safety Issue and to seek to approve an appropriate course of action to address such Material Safety Issue (which may include delaying, modifying, suspending or terminating one or more of the Collaboration Activities). &#160;During the pendency of such discussion, each Party may suspend or delay any Collaboration Activity allocated to it under a Development Plan to the extent such activity is affected by such Material Safety Issue. &#160;If the Parties agree upon a course of action to address such Material Safety Issue, then the Parties shall thereafter take all actions necessary to implement such course of action. &#160;If the Parties do not agree upon a course of action to address such Material Safety Issue within [ * ] after becoming aware of such Material Safety Issue, then either Party may refer such matter to the Executive Officers for discussion and attempted resolution. &#160;If the Executive Officers approve a course of action to address such Material Safety Issue, then the Parties shall thereafter take all actions necessary to implement such course of action. &#160;If the Executive Officers do not approve a course of action to address such Material Safety Issue within [ * ] after the matter is referred to them, Janssen shall determine the appropriate course of action to address such Material Safety Issue and Janssen&#8217;s decision shall be final and binding on the Parties; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, Janssen may not require Protagonist to commence or continue any Collaboration Activity if </font><font style="font-size:12pt;">Protagonist</font><font style="font-size:12pt;"> determines, in good faith, that such Collaboration Activity should not be commenced or continued due to such Material Safety Issue and in such instance </font><font style="font-size:12pt;">Janssen</font><font style="font-size:12pt;"> would have the right to authorize a clinical research organization to conduct the particular activity on behalf of Protagonist</font><font style="font-size:12pt;">, at Janssen</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s sole cost</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.7.2.</font></font><font style="font-size:12pt;">If (a) a Material Safety Issue arises after the Restatement Effective Date, (b) such Material Safety Issue is not resolved by the Parties after completing the process set forth in Section 3.7.1, (c) such Material Safety Issue has existed for more than [ * ], (d) Janssen has not used Diligent Efforts to resolve such Material Safety Issue, and (e) as of such time, the Research Term has expired and there are no ongoing Janssen Independent Research Activities and (i) such Material Safety Issue applies to each Licensed Compound or Licensed Product that is specifically the subject of any ongoing Clinical Trial or Development activities or (ii) there are no other Licensed Compounds or Licensed Products (other than the Initial Product) that are specifically the subject of then-ongoing or preparation for any Clinical Trial or other Development activities, then Protagonist&#8217;s</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">37</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">obligations and restrictions under Section 6.7 shall expire on the first date that all conditions set forth in clauses (a) through (d) are satisfied and Section 6.7 shall be of no further force or effect after such date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RESEARCH ACTIVITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">4.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Generally</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.1.1.</font></font><font style="font-size:12pt;">Prior to the Restatement Effective Date, t</font><font style="font-size:12pt;">he Parties conducted Research Activities (as defined in the Existing Agreement) with respect to the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds in accordance with the Existing Agreement. &#160;The Parties selected two 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds, PN-232 and PN-235, for pre-clinical and clinical Development [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.1.2.</font></font><font style="font-size:12pt;">As soon as practicable after the Restatement Effective Date, each Party shall provide to the other Party all data and results from the Research Activities it conducted prior to the Restatement Effective Date that have not previously been provided to the other Party, [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.1.3.</font></font><font style="font-size:12pt;">Following the Restatement Effective Date, the Parties shall complete ongoing Research Activities in accordance with Section 4.2. &#160;After the Research Term, Janssen shall have the right to conduct independent research with respect to 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds in accordance with Section 4.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">4.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Completion of Ongoing Research Activities</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">4.2.1.</font></font><b style="font-size:12pt;font-weight:bold;">Definitions</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Research Activities</b><font style="font-size:12pt;">&#8221; means the discovery and research activities for 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products that were conducted by the Parties prior to the Restatement Effective Date pursuant to the Existing Agreement. &#160;Research Activities does not include any Janssen Independent Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Research Term</b><font style="font-size:12pt;">&#8221; means the period commencing on [ * ] and ending on the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2.2.</font></font><b style="font-size:12pt;font-weight:bold;">Responsibility; Diligence</b><font style="font-size:12pt;">. &#160; All Research Activities have been completed as of the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2.3.</font></font><b style="font-size:12pt;font-weight:bold;">Selection of Compounds</b><font style="font-size:12pt;">. &#160;Following the Restatement Effective Date, Janssen shall have the sole right and authority to select any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds resulting from the Research Activities for pre-clinical and clinical Development. &#160;Janssen shall notify Protagonist upon the earlier of (i) internal NME nomination of any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound or (ii) initiation of the first GLP toxicology study of any &#160;2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2.4.</font></font><font style="font-size:12pt;">[Reserved.]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">38</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2.5.</font></font><b style="font-size:12pt;font-weight:bold;">Costs</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Janssen shall fund up to [ * ] Protagonist Research FTEs at the Protagonist Research FTE Rate through the end of the Research Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Except as set forth in this Section 4.2.5, each Party shall bear its own costs incurred in its conduct of the Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Promptly following the end of the Research Term, Protagonist shall submit an invoice to Janssen for the Protagonist Research FTEs actually utilized for Research Activities during the Research Term, to the extent not previously invoiced or reimbursed by Janssen. &#160;Such invoice, if undisputed, shall be payable by Janssen in accordance with Section 7.6 (i) within [ * ] after receipt or, (ii) if disputed by Janssen, within [ * ] after resolution of such dispute and, if such dispute is resolved against Protagonist, receipt of a correct invoice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">4.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Janssen Independent Research Activities</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Right to Conduct</b><font style="font-size:12pt;">. &#160;During the period commencing on the Restatement Effective Date and ending [ * ] thereafter (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Independent Research Term</b><font style="font-size:12pt;">&#8221;), Janssen shall have the exclusive right, but no obligation, [ * ] the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Independent Research Activities</b><font style="font-size:12pt;">&#8221;). &#160;Janssen shall not have the right (a) to use or screen against Protagonist&#8217;s peptide library or (b) to generate new 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds that are not derivatives of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds that were discovered by either Party or jointly by the Parties before the end of the Research Term, in each case of (a) and (b), when conducting the Janssen Independent Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">Selection of Compounds</b><font style="font-size:12pt;">. &#160;During the Janssen Independent Research Term, Janssen shall have the sole right and authority, but no obligation, to select any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds resulting from the Janssen Independent Research Activities for pre-clinical and clinical Development. &#160;Janssen shall notify Protagonist upon the earlier of (i) internal NME nomination of any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound or (ii) initiation of the first GLP toxicology study of any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.3.3.</font></font><b style="font-size:12pt;font-weight:bold;">Conduct</b><font style="font-size:12pt;">. &#160;Janssen shall perform the Janssen Independent Research Activities in accordance with the terms and conditions of this Agreement, in good scientific manner and in compliance with Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.3.4.</font></font><b style="font-size:12pt;font-weight:bold;">Costs</b><font style="font-size:12pt;">. &#160;Janssen shall bear its own costs incurred in its conduct of the Janssen Independent Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Reports</b><b style="font-size:12pt;font-weight:bold;">. &#160;</b><font style="font-size:12pt;">During the Janssen Independent Research Term, Janssen shall provide Protagonist with [ * ] updates on its progress with respect to the conduct of the Janssen Independent Research Activities, a list of all new 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds created &#160;(including the sequences of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds being researched and progressed to late lead optimization), and a summary of the data and results from such activities for the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds that Janssen is continuing to Develop.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">39</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Protagonist Research Compounds</b><font style="font-size:12pt;">. &#160;Protagonist shall solely and exclusively own all right, title and interest in and to all Protagonist Research Compounds, subject to Section 6.7. &#160;Janssen hereby assigns, and shall cause its Affiliates to assign, to Protagonist all Collaboration Know-How and Collaboration Inventions arising from the Research Activities that solely relate to the composition of one or more Protagonist Research Compounds and do not relate to (i) other aspects of the Protagonist Research Compounds or (ii) any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Research Compound IP</b><font style="font-size:12pt;">&#8221;). &#160;The Research Compound IP shall be deemed to be Protagonist&#8217;s Confidential Information, and Protagonist shall be deemed to be the Disclosing Party and Janssen shall be deemed to be the Receiving Party with respect to such Confidential Information. &#160;Janssen shall take, and shall cause its Affiliates to take, such actions as Protagonist may reasonably request to evidence and perfect such ownership, at Protagonist&#8217;s expense. &#160; Janssen hereby grants to Protagonist, on behalf of Janssen and its Affiliates, subject to Section 6.7, a non-exclusive, perpetual, irrevocable, royalty-free, freely sublicensable through multiple tiers, transferable license under the Janssen Collaboration Know-How, Janssen Collaboration Patent Rights and Janssen&#8217;s interest in the Joint Collaboration Patent Rights related to any Protagonist Research Compound, excluding in each case the Research Compound IP, solely to the extent necessary to Develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit, Manufacture and Commercialize Protagonist Research Compounds and products containing Protagonist Research Compounds in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ACTIVITIES DURING LICENSE TERM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">General</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.1.1.</font></font><font style="font-size:12pt;">This Article 5 shall take effect on the start of the License Term except as otherwise provided in Section 5.3.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.1.2.</font></font><font style="font-size:12pt;">During the License Term, Janssen shall conduct Development, Manufacture and Commercialization of the Licensed Compounds and Licensed Products in accordance with this Article 5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Transition; Technology Transfer</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.2.1.</font></font><font style="font-size:12pt;">To facilitate an orderly transition of the Development and Manufacture of the Licensed Compounds and Licensed Products from Protagonist to Janssen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">promptly following the start of the License Term, Protagonist shall transfer to Janssen, and hereby assigns to Janssen all its right, title and interest in, to and under, all INDs, CTAs, safety databases and other Regulatory Documentation with respect to the Licensed Compounds and Licensed Products then held by Protagonist, its Affiliates and Third Party Subcontractors, if any; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">upon Janssen&#8217;s request, Protagonist shall, and shall cause its Third Party manufacturer(s) (subject to the terms of any applicable agreement(s) with such Third Party Manufacturer(s)), to transfer existing Manufacturing processes for the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">40</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Compound API and Licensed Products to Janssen (or its designee) and to provide reasonable technical assistance to Janssen (or its designee) in establishing Manufacturing processes for the Licensed Compounds and Licensed Products for a period of up to [ * ] following the start of the License Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.2.2.</font></font><font style="font-size:12pt;">Protagonist will transfer any other information in Protagonist&#8217;s control reasonably requested by Janssen (e.g., assays) in order to Develop and Manufacture the Licensed Compounds and Licensed Products. &#160;Upon Janssen&#8217;s request during the License Term, Protagonist shall promptly provide to Janssen (a) [ * ] &#160;with respect to any Licensed Compound or Licensed Product, (b) [ * ] with respect to the data described in clause (a), (c) CMC data or information generated by or on behalf of Protagonist with respect to any Licensed Compound or Licensed Product or (d) any other Protagonist Know-How that is necessary, and any other Protagonist Know-How (other than Protagonist Platform Know-How or Know-How that originates from any other Protagonist programs that are not targeting the IL23 receptor) that is specifically useful, for the Development, Manufacture or Commercialization of Licensed Compounds and Licensed Products, in each case ((a) - (d)), to the extent that such information was not previously provided by Protagonist to Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Development</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Responsibility; Diligence</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:12pt;">Janssen shall have the sole right and authority, at its sole cost and expense (other than with respect to the PTG-200 Phase 2A Activities, PN-232 Phase 1A Activities and PN-235 Phase 1A Activities), to Develop Licensed Compounds and Licensed Products in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">During the Development Term, Janssen shall use Commercially Reasonable Efforts to Develop (with the objective of obtaining Marketing Approval for) one (1) or more Licensed Product(s) (whether it is the PTG-200 Product, a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product containing PN-232, a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product containing PN-235, or any other 2nd Generation Product) for a total of [ * ] Indications in each of the Major Market Countries. &#160;For clarity, this obligation would be satisfied by Janssen using Commercially Reasonable Efforts to [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">During the License Term, Janssen shall use Commercially Reasonable Efforts to Develop and obtain Marketing Approval for one (1) Licensed Product (which may be the PTG-200 Product, a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product containing PN-232, a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product containing PN-235, or any other 2nd Generation Product) for [ * ] of the following Indications in each of the Major Market Countries: CD, UC, Psoriasis, Psoriatic Arthritis or any other Indication having commercial potential similar to any of the foregoing Indications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;"> Notwithstanding the foregoing, for purposes of determining Janssen&#8217;s satisfaction of its obligation to use Commercially Reasonable Efforts under this Section 5.3.1, payments due under this Agreement arising from a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">41</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Compound solely invented by Janssen will be assumed to be equivalent to payments that would have been due under this Agreement had such 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound been solely invented by Protagonist or jointly invented by Protagonist and Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">Janssen shall conduct all Development of Licensed Compounds and Licensed Products in accordance with the terms and conditions of this Agreement, in good scientific manner and in compliance with Applicable Law including, as applicable, those relating to GLP, GCP, pharmacovigilance and safety reporting, and requirements for the protection of human subjects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">Reports</b><font style="font-size:12pt;">. &#160;Janssen shall provide Protagonist, through the JSC, with an update (in the form of a report or presentation at a meeting of the JSC) of its progress and high-level summaries of its plans with respect to the Development of Licensed Compounds and </font><font style="font-size:12pt;">Licensed Products </font><font style="font-size:12pt;">in the Field in the Territory until the receipt of Marketing Approval for a Licensed Product one of the Indications listed in Section 5.3.1(c) in each of the Major Market Countries. &#160;Upon request, Janssen shall provide Protagonist with a copy of all materials presented at such JSC meetings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Regulatory</b><font style="font-size:12pt;">. Janssen shall have the sole right and authority, at its sole cost and expense, to seek to obtain and maintain Regulatory Approvals for the Licensed Compounds and Licensed Products in the Field in the Territory and to conduct all related regulatory matters, including communications with any Regulatory Authorities relating to the Licensed Compounds and Licensed Products. &#160;Upon Janssen&#8217;s reasonable request, Protagonist shall provide reasonable assistance as necessary for Janssen to file Drug Approval Applications and obtain and maintain Regulatory Approvals with respect to the </font><font style="font-size:12pt;">Licensed </font><font style="font-size:12pt;">Compounds and Licensed Products, up to [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Manufacturing</b><font style="font-size:12pt;">. &#160;Janssen shall have the sole right and authority, at its sole cost and expense, to Manufacture clinical and commercial supplies of Licensed Compounds and Licensed Products. &#160;Janssen will conduct such Manufacturing activities in accordance with the terms and conditions of this Agreement and in compliance with Applicable Law, including those relating to GMP.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Commercialization</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.6.1.</font></font><b style="font-size:12pt;font-weight:bold;">Responsibility; Diligence</b><font style="font-size:12pt;">. &#160;Subject to Section 5.6.2, Janssen shall have the sole right and authority, at its sole cost and expense, to Commercialize the Licensed Compounds and Licensed Products in the Field in the Territory. &#160;Janssen shall use Commercially Reasonable Efforts to Commercialize each Licensed Product, whether it is the Initial Product or a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, in each of the Major Market Countries following receipt of Marketing Approval of such Licensed Product in the applicable country. &#160;Janssen shall conduct all such Commercialization in accordance with the terms and conditions of this Agreement and in compliance with Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">5.6.2.</font></font><b style="font-size:12pt;font-weight:bold;">Protagonist Co-Detailing Option</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Definitions</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">42</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Detail</b><font style="font-size:12pt;">&#8221; means one (1) Primary Call or two (2) Secondary Calls. E-details, sample drops (if applicable) and reminder details shall not constitute a Detail. With regard to presentations made at conventions or similar gatherings, Details shall include that number of Details represented by the members of the target audience in attendance. For the avoidance of doubt, Details may occur in group situations if the definition of a Detail is met.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">IBD Indication</b><font style="font-size:12pt;">&#8221; means any chronic intestinal disease that is characterized by inflammation of the bowel, including, without limitation, UC and CD.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Primary Call</b><font style="font-size:12pt;">&#8221; means a one-on-one in-person contact in which a sales representative makes a presentation, including selling message and features and benefits of a pharmaceutical or biologic product to a healthcare professional having prescribing authority within the target audience, during which contact such product is [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Restricted Change of Control</b><font style="font-size:12pt;">&#8221; means, with respect to Protagonist, a Change of Control in which the Acquirer: (A) has, as of the time of such Change of Control a field sales force in the United States that promotes any pharmaceutical product for any IBD Indication, (B) has entered into or become the subject of a corporate integrity agreement, settlement or order with or of the Office of Inspector General, U.S. Department of Health and Human Services, or another Governmental Authority, relating to marketing or commercialization of pharmaceutical products, (C) is the subject of a bona fide investigation or proceeding with the Office of Inspector General, U.S. Department of Health and Human Services, or another Governmental Authority, with respect to the marketing or commercialization of pharmaceutical products or (D) is engaged in significant litigation or other significant legal dispute with Janssen or any of its Affiliates, as evidenced by written correspondence outlining the issues in such dispute, ongoing alternative dispute resolution proceedings or an active court case.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(5)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Secondary Call</b><font style="font-size:12pt;">&#8221; means a one-on-one in-person contact in which a sales representative makes a presentation, including selling message and features and benefits of a pharmaceutical or biologic product to a healthcare professional having prescribing authority within the target audience, in which such product is [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Co-Detailing Option</i><font style="font-size:12pt;">. &#160;Janssen hereby grants Protagonist an option to provide, at Protagonist&#8217;s election, up to thirty percent (30%) of the Details for up to two (2) Licensed Products (other than Combination Products) in the U.S. for all approved IBD Indications, as further described in this Section 5.6.2 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Co-Detailing Option</b><font style="font-size:12pt;">&#8221;). &#160;Protagonist shall have the right to exercise the Co-Detailing Option independently with respect to the Initial Product and each 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product that Janssen Commercializes, but for no more than two (2) Licensed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">43</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Products total. &#160;Notwithstanding the foregoing, (i) if Protagonist does not exercise the Co-Detailing Option with respect to the first Initial Product for which Janssen delivers top-line results in accordance with Section 5.6.2(c), then the Co-Detailing Option shall not apply to any future Initial Products and this Section 5.6.2 shall become null and void with respect to the Initial Products, and (ii) if Protagonist does not exercise the Co-Detailing Option with respect to a particular 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product for which Janssen delivers top-line results in accordance with Section 5.6.2(c), then the Co-Detailing Option shall no longer apply to such 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product and this Section 5.6.2 shall become null and void with respect to such 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product. &#160;If Protagonist exercises the Co-Detailing Option with respect to two (2) Licensed Products, Protagonist shall not have the right to provide more than thirty percent (30%) of the aggregate number of Details for all such Licensed Products for all approved IBD Indications, nor more than thirty percent (30%) of the Details for any such Licensed Product for all approved IBD Indications. &#160;Notwithstanding the foregoing, Janssen shall have the right, upon [ * ] written notice where such Co-Detailing Option has not as of such time been exercised, or upon [ * ] written notice where such option has as of such time been exercised by Protagonist, to terminate the Co-Detailing Option and Protagonist&#8217;s rights under this Section 5.6.2 in the event of the occurrence of a Restricted Change of Control of Protagonist or an assignment of this Agreement in its entirety by Protagonist (other than an assignment to an Affiliate of Protagonist), unless Janssen otherwise consents, which consent may be withheld in Janssen&#8217;s sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">Exercise of Option. </i><font style="font-size:12pt;">Protagonist may, in its sole discretion, exercise the Co-Detailing Option with respect to a Licensed Product by delivering written notice thereof to Janssen (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Co-Detailing Option Exercise Notice</b><font style="font-size:12pt;">&#8221;) within [ * ] after receipt of written notice from Janssen that the top-line results of the second Phase 3 Clinical Trial of such Licensed Product for the initial IBD Indication for which such event occurs have become available to Janssen if two Phase 3 Clinical Trials of such Licensed Product are conducted for the initial IBD Indication, and within [ * ] after receipt of written notice from Janssen that the top-line results of the first Phase 3 Clinical Trial of such Licensed Product for the initial IBD Indication have become available to Janssen if following the conduct of the first Phase 3 Clinical Trial Janssen determines in its reasonable discretion that a second Phase 3 Clinical Trial for the initial IBD Indication is not necessary to proceed with filing of a Drug Approval Application for such Licensed Product for the initial IBD Indication. &#160;Janssen shall provide such results to Protagonist promptly following the occurrence thereof, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that Janssen shall have no obligation to provide such results (and Protagonist shall have no right to exercise the Co-Detailing Option) for any Licensed Product after Protagonist has exercised the Co-Detailing Option with respect to [ * ] Licensed Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">Co-Detailing Plan. &#160; </i><font style="font-size:12pt;">If Protagonist provides a Co-Detailing Option Exercise Notice with respect to a Licensed Product, Janssen shall prepare and provide to Protagonist for its review and comment Janssen&#8217;s initial written plan for the Detailing of and allocation of calls for such Licensed Product for all approved IBD</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">44</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Indications in the U.S. (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Co-Detailing Plan</b><font style="font-size:12pt;">&#8221;) in the ordinary course of its U.S. Commercialization planning process. &#160;The Parties shall discuss, and Janssen shall consider in good faith Protagonist&#8217;s comments on, the Initial Co-Detailing Plan before Janssen finalizes such plan. &#160;For clarity, this Section 5.6.2(d) does not limit or modify Janssen&#8217;s sole authority to Commercialize such Licensed Product pursuant to Section 5.6.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><i style="font-size:12pt;font-style:italic;">Terms of Co-Detailing</i><font style="font-size:12pt;">. Promptly following Janssen&#8217;s receipt of the Co-Detailing Option Exercise Notice for the first Licensed Product, the Parties shall negotiate in good faith to enter into a separate co-detailing agreement with respect to the co-detailing of such Licensed Product (and any additional Licensed Product for which Protagonist exercises the Co-Detailing Option) in the U.S. for the approved IBD Indications on commercially reasonable terms (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Co-Detailing Agreement</b><font style="font-size:12pt;">&#8221;), which would provide for a working group or other administrative body to be established by the Parties to serve solely as an information-sharing body with respect to each Party&#8217;s detailing activities, and not as an oversight or decision-making body. In addition to such usual and customary terms that are typically found within contract sales force agreements, the Co-Detailing Agreement shall include the terms set forth below in this Section 5.6.2(e).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist would contribute a mutually agreed percentage of Janssen&#8217;s planned Details for each such Licensed Product in the U.S. for all approved IBD Indications for each Calendar Year (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such percentage shall not be less than [ * ] percent ([ * ]%) and shall not exceed thirty percent (30%) without Protagonist&#8217;s written consent), as set forth in Janssen&#8217;s call plan for such Calendar Year. &#160;Protagonist would employ a number of sales representatives sufficient to provide the agreed percentage of Details for each such Licensed Product in the U.S. for each Calendar Year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Following consultation through the working group or other administrative body established under the Co-Detailing Agreement, Janssen would have the right to allocate the planned Details for each such Licensed Product in the U.S. for all approved IBD Indications for each Calendar Year between the Parties in a manner consistent with the allocation described in clause (1) of this Section 5.6.2(e), </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that, unless the Parties agree otherwise, Protagonist would be allocated Details to healthcare professionals [ * ] for such Licensed Product in the U.S. for all approved IBD Indications. The Parties would coordinate their detailing activities for such Licensed Products in the U.S. for all approved IBD Indications in accordance with mutually agreed procedures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Janssen would reimburse Protagonist for the Details of each such Licensed Product in the U.S. performed by Protagonist at a mutually agreed cost per primary detailing equivalent, which shall be agreed between the Parties acting reasonably and in good faith and [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">45</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">All Protagonist sales representatives who would Detail any Licensed Product in the U.S. would be required to [ * ] such Licensed Product in the U.S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(5)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist would compensate its sales representatives who detail each such Licensed Product in the U.S. using a sales compensation structure [ * ] such Licensed Product in the U.S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(6)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each sales representative who details any Licensed Product in the U.S. on behalf of Protagonist would be required to [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(7)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist&#8217;s sales representatives performing Details of a Licensed Product in the U.S. would be required to comply with Applicable Law and all of Janssen&#8217;s reasonable instructions, quality standards, policies and guidelines which relate to the Commercialization of such Licensed Product for each approved IBD Indication and of which Protagonist has been given sufficient written notice.&#160; Protagonist would establish a compliance program and appoint a compliance officer to ensure that Protagonist&#8217;s detailing of such Licensed Product is in compliance with Applicable Law and such Janssen instructions, quality standards, policies and guidelines. Janssen would have the right to audit Protagonist&#8217;s records regarding performance under the Co-Detailing Agreement, solely for the purpose of determining Protagonist&#8217;s compliance with the Co-Detailing Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(8)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Janssen would have the right to terminate the Co-Detailing Agreement immediately by written notice if (i) Protagonist fails to contribute at least [ * ] &#160;percent ([ * ]%) of the Details for such Licensed Products in the U.S. for a Calendar Quarter that Protagonist is obligated to provide under the Co-Detailing Agreement and fails to remedy such shortfall within [ * ] after receiving written notice of such shortfall from Janssen or (ii) Protagonist materially breaches the Co-Detailing Agreement and fails to cure such breach within [ * ] after receiving written notice of such breach from Janssen. The Co-Detailing Agreement would be subordinate to and coterminous with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(9)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The Co-Detailing Agreement would not be assignable by Protagonist without the consent of Janssen, which consent shall not be unreasonably withheld, conditioned, or delayed with respect to assignment to an Affiliate of Protagonist. &#160;The Co-Detailing Agreement would terminate in the event of the occurrence of a Restricted Change of Control of Protagonist if Janssen terminates Protagonist&#8217;s rights as set forth in Section 5.6.2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(10)</font><font style="display:inline-block;width:16.01pt;"></font><font style="font-size:12pt;">Protagonist would have the right to terminate its obligations under the Co-Detailing Agreement on a Licensed Product-by-Licensed Product basis upon [ * ] prior written notice (or sooner, at Janssen&#8217;s election).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">46</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">LICENSE GRANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">License Grants to Janssen</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.1.</font></font><font style="font-size:12pt;">Subject to the terms and conditions of this Agreement, Protagonist hereby grants, on behalf of itself and its Affiliates, to Janssen an exclusive (even as to Protagonist, except as provided in Section 6.2), sublicensable (solely as provided in Section 6.3.1 and 6.3.2), royalty-bearing license under the Protagonist Intellectual Property to Develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit, Manufacture and Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.2.</font></font><font style="font-size:12pt;">Subject to the terms and conditions of this Agreement, Protagonist hereby grants, on behalf of itself and its Affiliates, to Janssen an exclusive (even as to Protagonist, except as provided in Section 6.2), sublicensable (solely as provided in Section 6.3.3), royalty-bearing license under the Protagonist Intellectual Property (other than Protagonist&#8217;s peptide library) to conduct the Janssen Independent Research Activities during the Janssen Independent Research Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.3.</font></font><font style="font-size:12pt;">Prior to the start of the License Term, neither Party shall conduct any Development, Manufacture or Commercialization of the Licensed Compounds or Licensed Products except (a) pursuant to the PTG-200 Clinical Development Plan, the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan or as otherwise permitted under Article 3, (b) completion of the ongoing Research Activities in accordance with Section 4.2 and (c) the Janssen Independent Research Activities conducted by Janssen in accordance with Section 4.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.4.</font></font><font style="font-size:12pt;">Each Party hereby grants, on behalf of itself and its Affiliates, to the other Party a non-exclusive, perpetual, irrevocable, world-wide, royalty-free license to use internally for its or its Affiliates&#8217; ordinary course of business during or after the Term any Confidential Information or Know-How disclosed to it by the other Party solely to the extent such Confidential Information or Know-How has been retained in intangible form in the unaided memory of such Party&#8217;s employees who have had access thereto pursuant to the terms of this Agreement; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that (a) such Party and its Affiliates shall not disclose any Confidential Information in violation of this Agreement; and (b) such employees did not intentionally memorize such Confidential Information or Know-How.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Protagonist Retained Rights</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.2.1.</font></font><font style="font-size:12pt;">Notwithstanding the rights granted to Janssen in Section 6.1, Protagonist hereby expressly retains the right to practice the Protagonist Intellectual Property in the Field in the Territory solely as necessary to exercise its rights and perform its obligations under this Agreement</font><i style="font-size:12pt;font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.2.2.</font></font><font style="font-size:12pt;">Protagonist hereby expressly retains all rights under the Protagonist Intellectual Property other than the rights under the Protagonist Intellectual Property granted to Janssen pursuant to Section 6.1 or elsewhere in this Agreement, including, without limitation, the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">47</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">right to research, develop, make and have made, and commercialize Retained Compounds under the Retained Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.2.3.</font></font><font style="font-size:12pt;">Notwithstanding Section 6.2.2, Protagonist&#8217;s right to further research, develop, make and have made, and commercialize any Retained Compound shall not include the right to research, develop, make and have made, or commercialize such Retained Compound based upon its utility as a therapeutic agent that modulates the IL23 receptor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">6.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Sublicensing</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Development Term Sublicensing</b><font style="font-size:12pt;">. &#160;Prior to the start of the License Term, except as set forth in Section 3.5.2, Janssen may not sublicense to any Third Party any of the rights granted to it by Protagonist under Section 6.1.1 without the prior written consent of Protagonist, which consent shall not be unreasonably withheld or delayed by Protagonist. Janssen may grant sublicenses to one or more Affiliates without the consent of Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">License Term Sublicensing</b><font style="font-size:12pt;">. &#160;During the License Term, Janssen may grant and authorize sublicenses of any of the rights granted to it by Protagonist under Section 6.1.1 without the consent of Protagonist to one or more of its Affiliates or to one or more Third Parties through multiple tiers. &#160;Each sublicense shall be pursuant to a written agreement that is subject to and consistent with the terms and conditions of this Agreement. &#160;Janssen shall remain directly responsible and fully liable to Protagonist for the performance of each sublicensee in accordance with this Agreement. &#160;Janssen shall provide to Protagonist a copy of each sublicense agreement that grants to any Third Party rights to Develop and/or Commercialize a Licensed Compound or Licensed Product, within [ * ] following the execution thereof, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that Janssen shall be permitted to redact commercially sensitive terms to the extent such terms are not necessary for Protagonist to confirm its rights hereunder. &#160;Notwithstanding the foregoing, Janssen shall not be obligated to provide to Protagonist any sublicense agreement that is solely for the performance of services on behalf of Janssen, its Affiliates or its sublicensees, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such service provider does not obtain under such agreement any rights to Develop or Commercialize any Licensed Compound or Licensed Product for its own account.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.3.3.</font></font><b style="font-size:12pt;font-weight:bold;">Janssen Independent Research Term Sublicensing.</b><font style="font-size:12pt;"> During the Janssen Independent Research Term, Janssen may not sublicense to any Third Party any of the rights granted to it by Protagonist under Section 6.1.2 without the prior written consent of Protagonist, which consent shall not be unreasonably withheld or delayed by Protagonist; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that Janssen may grant and authorize sublicenses of any of the rights granted to it by Protagonist under Section 6.1.2 without the consent of Protagonist to one or more Third Parties for the sole purpose of performing research on behalf of or in collaboration with Janssen or its Affiliates (which, for clarity, shall not include any Third Party that obtains any right to Develop or Commercialize any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound or product containing a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compound for its own account). &#160;Each sublicense shall be pursuant to a written agreement that is subject to and consistent with the terms and conditions of this Agreement. &#160;Janssen shall remain directly responsible and fully liable to Protagonist for the performance of each sublicensee in accordance with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">48</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">License Grant to Protagonist</b><font style="font-size:12pt;">. &#160;Subject to the terms and conditions of this Agreement, Janssen, on behalf of itself and its Affiliates, hereby grants to Protagonist a limited-term, non-exclusive license under the Janssen Collaboration Know-How and Janssen Collaboration Patent Rights solely as necessary to perform its obligations under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">No Conflicting Licenses</b><font style="font-size:12pt;">. &#160;During the Term, neither Protagonist nor any of its Affiliates shall grant any right with respect to any Licensed Compound or Licensed Product to any Third Party that would impair or conflict in any way with any of the rights granted to Janssen under this Article 6 or any other provision of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">No Implied Licenses</b><font style="font-size:12pt;">. &#160;Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by implication, estoppel, or otherwise, other than the rights and licenses that are expressly granted under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exclusivity</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.7.1.</font></font><font style="font-size:12pt;">Prior to the Restatement Effective Date, Protagonist was subject to Section 6.7 of the Existing Agreement. &#160;From the Restatement Effective Date until the end of the Exclusivity Period, neither Protagonist nor any of its Affiliates shall (a) Develop (including research), Manufacture, make, have made, use, have used, Commercialize, import, have imported, sell, have sold, offer for sale or have offered for sale any Competing Product for any Indication; or (b) collaborate with, license, enable or otherwise authorize or grant any rights to any Third Party to do any of the activities described in clause (a), or enter into any agreement, amendment to an existing agreement or option to do any of the activities described in clause (a), except in any case (clause (a) or (b)) to the extent necessary to perform Protagonist&#8217;s obligations under this Agreement. The restrictions set forth in this Section 6.7 shall not apply to an Acquirer of Protagonist, </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that such Acquirer Segregates any activities that would otherwise be prohibited by this Section 6.7.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.7.2.</font></font><font style="font-size:12pt;">For purposes of this Section 6.7:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Competing Product</b><font style="font-size:12pt;">&#8221; means any product comprising a peptide or small molecule that (i) has an IC50 value of less than or equal to [ * ] nanomolar (nM), as determined in [ * ]; or (ii) has an affinity (Kd) for IL23R less than or equal to [ * ] nM, as determined by [ * ], and, in each of case (i) and (ii), is Directed to IL23R.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Exclusivity Period</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means the period commencing on the Original Effective Date and terminating on the date of Initiation of the first Phase 3 Clinical Trial (including Initiation of the Phase 3 portion of a Phase 2/3 Clinical Trial) of the first Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Directed to IL23R</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means, with respect to a product:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist or its Affiliates Develop (including research) or Commercialize such product based on its antagonist activity against IL23R; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">49</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist or its Affiliates test such product to assess its activity against IL23R, where such testing is not required by Applicable Law or requested by a Regulatory Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Segregate</b><font style="font-size:12pt;">&#8221; means, with respect to an activity, to use reasonable, good faith efforts to segregate such activity from the Development, Manufacturing and Commercialization of Licensed Compounds and Licensed Products under this Agreement, including using such efforts to ensure that: (i) no personnel involved in performing such activity on behalf of the Acquirer have access to non-public plans or information relating to the Development, Manufacturing and Commercialization of Licensed Compounds and Licensed Products under this Agreement; and (ii) no personnel involved in performing the Development, Manufacturing and Commercialization of Licensed Compounds and Licensed Products under this Agreement have access to non-public plans or information relating to such activity of the Acquirer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FINANCIAL TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Upfront Payment</b><font style="font-size:12pt;">. &#160; The Parties acknowledge and agree that, prior to the Restatement Effective Date, Janssen paid to Protagonist Fifty Million Dollars ($50,000,000) as a one-time, non-refundable, non-creditable upfront payment in partial consideration of the license and rights granted by Protagonist to Janssen under this Agreement and Twenty Five Million Dollars ($25,000,000) as a one-time, non-refundable, non-creditable payment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cost Sharing and Reimbursement</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.1.</font></font><b style="font-size:12pt;font-weight:bold;">Phase 1 Costs</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">PN-232 Phase 1 Costs</i><font style="font-size:12pt;">. Subject to Section 7.2.1(b), Protagonist shall be responsible for one hundred percent (100%) of the Phase 1 Development Costs for the PN-232 Phase 1A Activities incurred (including costs incurred prior to the Restatement Effective Date but excluding costs of any accelerated or non-standard analyses requested by Janssen, one hundred percent (100%) of which shall be borne by Janssen), up to a cumulative maximum of Ten Million Dollars ($10,000,000), after which Janssen shall bear one hundred percent (100%) of such costs for such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">PN-232 Budget Amendments</i><font style="font-size:12pt;">. &#160;If Janssen amends the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan after the Restatement Effective Date and, as a result of such amendment, the aggregate cost of the PN-232 Phase 1A Activities exceeds [ * ] percent ([ * ]%) of the aggregate cost of the PN-232 Phase 1A Activities &#160;set forth in the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Development Budget as in effect on the Restatement Effective Date (excluding costs of any accelerated or non-standard analyses requested by Janssen), Janssen shall be responsible for one hundred percent (100%) of such excess costs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">50</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><i style="font-size:12pt;font-style:italic;">PN-235 Phase 1 Costs prior to Calendar Year 2021</i><font style="font-size:12pt;">. &#160; Janssen shall be responsible for fifty percent (50%) and Protagonist shall be responsible for fifty percent (50%) of the Phase 1 Development Costs for the PN-235 Phase 1A Activities incurred prior to the first day of Calendar Year 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><i style="font-size:12pt;font-style:italic;">PN-235 Phase 1 Costs during and after Calendar Year 2021</i><font style="font-size:12pt;">. Janssen shall be responsible for one hundred percent (100%) of the Phase 1 Development Costs for the PN-235 Phase 1A Activities incurred on or after the first day of Calendar Year 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><i style="font-size:12pt;font-style:italic;">Specified Phase 1 Percentage</i><font style="font-size:12pt;">. &#160;With respect to a Party and a type of costs, the percentage set forth in Section 7.2.1(a), Section 7.2.1(c) or Section 7.2.1(d) is referred to as its &#8220;</font><b style="font-size:12pt;font-weight:bold;">Specified Phase 1 Percentage</b><font style="font-size:12pt;">&#8221; for such costs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.2.</font></font><b style="font-size:12pt;font-weight:bold;">PTG-200 Phase 2A Costs</b><font style="font-size:12pt;">. </font><font style="font-size:12pt;">Protagonist shall be responsible for twenty percent (20%) and Janssen shall be responsible for eighty percent (80%) of the Phase 2 Development Costs for the PTG-200 Phase 2A Activities (including such costs incurred prior to the Restatement Effective Date) (with respect to a Party, such percentage is referred to as its &#8220;</font><b style="font-size:12pt;font-weight:bold;">Specified Phase 2 Percentage</b><font style="font-size:12pt;">&#8221;). &#160;Notwithstanding the foregoing, Protagonist&#8217;s cumulative responsibility under this Section 7.2.2(a) shall not exceed (i) Twenty Million Dollars ($20,000,000) or (ii) its Specified Phase 2 Percentage of [ * ] percent ([ * ]%) of the aggregate cost of the PTG-200 Phase 2A Activities set forth in the PTG-200 Development Budget as in effect on the Restatement Effective Date, whichever is less.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.3.</font></font><b style="font-size:12pt;font-weight:bold;">Other Development Costs</b><font style="font-size:12pt;">. &#160;</font><font style="font-size:12pt;">Janssen shall bear all Phase 1 Development Costs and Phase 2 Development Costs other than those described in Section 7.2.1 and Section 7.2.2 as being the responsibility of Protagonist. &#160;In addition, Janssen shall be responsible for one hundred percent (100%) of the CMC Development Costs for any Phase 3 Clinical Trial(s) incurred by either Party or any of their Affiliates and all other costs of Development of the Initial Compound, Initial Product, 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Compounds and 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products other than as set forth in Sections 4.2.5, 7.2.1 and 7.2.2. &#160;For clarity, the costs for which Janssen is responsible pursuant to this Section 7.2.3 include costs incurred prior to the Restatement Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.4.</font></font><b style="font-size:12pt;font-weight:bold;">Reporting</b><font style="font-size:12pt;">. &#160;Within [ * ] after the end of each Calendar Quarter during which either Party incurs any Phase 1 Development Costs or Phase 2 Development Costs (collectively, </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development Costs</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) for which the other Party is responsible pursuant to Section 7.2.1, 7.2.2 or 7.2.3, each Party will provide a written report to the other Party setting forth in reasonable detail such Development Costs incurred by it and its Affiliates during such Calendar Quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.5.</font></font><b style="font-size:12pt;font-weight:bold;">Pre-Restatement Effective Date Reconciliation</b><font style="font-size:12pt;">. &#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 7.2.5</u><font style="font-size:12pt;"> describes all Development Costs (including costs for Collaboration CMC Activities (as defined in the Existing Agreement)) that were invoiced prior to the Restatement Effective Date that have not yet been paid.&#160; In connection with the first reconciliation under Section 7.2.6(a) that occurs after the Restatement Effective Date, the Parties&#8217; finance teams will determine how such costs will be allocated between the Parties under the amended cost-sharing rules set</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">51</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">forth in this Section 7.2. &#160;Section 7.2.6(b) of the Existing Agreement will continue to apply to Development Costs for Collaboration CMC Activities (as defined in the Existing Agreement) incurred before the relevant dates under the amended cost-sharing rules set forth above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">7.2.6.</font></font><b style="font-size:12pt;font-weight:bold;">Post-Restatement Effective Date Reconciliation</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Quarterly Reconciliation</i><font style="font-size:12pt;">. &#160;If a Party (a) incurs more than its Specified Percentage of Development Costs for a Calendar Quarter, or, with respect to Protagonist, if its Specified Percentage exceeds the caps set forth in Section 7.2.1 or 7.2.2, or (b) incurs Development Costs for which the other Party is responsible pursuant to Section 7.2.1, 7.2.2 or 7.2.3 in such Calendar Quarter, such Party shall be able to reconcile so that it only bears the Development Costs for which it is responsible. &#160;Each Party shall, within [ * ] after delivery of the reports for such Calendar Quarter, invoice the other Party for an amount sufficient to reconcile its incurred costs to only such Development Costs for which it is responsible. &#160;Such invoices shall be sent by the Parties only after all expenses incurred by each Party in such Calendar Quarter have been agreed by the Parties and, if undisputed, shall be payable (i) within [ * ] after receipt or, (ii) if disputed by the Party receiving such invoice, within [ * ] after resolution of such dispute and, if such dispute is resolved against the invoicing Party, receipt of a correct invoice. &#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">Specified Percentage</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means the Specified Phase 1 Percentage or the Specified Phase 2 Percentage, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Excess Development Costs</i><font style="font-size:12pt;">. &#160;Notwithstanding Section 7.2.6(a), in the event a Party performing Phase 1A Activities or PTG-200 Phase 2A Activities for which it is responsible under the applicable Development Plan incurs more than [ * ] percent ([ * ]%) of aggregate Development Costs budgeted for such activities in the applicable Development Budget (the amount more than [ * ]%, </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Excess Development Costs</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">), the other Party shall not be obligated to bear its Specified Percentage of such Excess Development Costs, except: (x) if the Parties approve such Excess Development Costs (either before or after they are incurred); or (y) to the extent such Excess Development Costs are attributable to (i) a change in Applicable Law, (ii) a force majeure event, (iii) variation in actual patient enrollment from projected patient enrollment, (iv) a change to a Clinical Trial protocol required or requested by any Regulatory Authority, or (v) unanticipated increases in the cost of raw materials.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.7.</font></font><b style="font-size:12pt;font-weight:bold;">Disputes</b><font style="font-size:12pt;">. &#160;If any disputes with respect to the amounts set forth in a report or invoice delivered under this Section 7.2 are not resolved by the Parties within [ * ] after such dispute is first raised, the Parties shall mutually select and engage an independent Third Party accounting firm that has no auditing or other financial relationship with either Party or any of its Affiliates to resolve such matter. &#160;Such accounting firm shall, as soon as reasonably practicable after such firm is engaged, deliver a report to each Party with its analysis and determination of such matter. &#160;Such determination shall be final and binding on the Parties. &#160;The costs of such firm</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s services shall be shared equally by the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">52</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.8.</font></font><b style="font-size:12pt;font-weight:bold;">Audits</b><font style="font-size:12pt;">. &#160;The audit rights set forth in Section 7.7 shall apply to any payment made pursuant to this Section 7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.2.9.</font></font><b style="font-size:12pt;font-weight:bold;">No Double Charges</b><font style="font-size:12pt;">. &#160;Neither Party will double charge the other Party for any Phase 1 FTE Costs, Phase 2 FTE Costs or other costs or expenses subject to reimbursement under this Section 7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Development and Approval Milestones</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Development and Approval Milestone Events</b><font style="font-size:12pt;">. &#160;Janssen will notify Protagonist in writing within [ * ] after the first achievement by Janssen or any of its Affiliates or sublicensees of any of the milestone events set forth in the table below (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Milestone Event</b><font style="font-size:12pt;">&#8221;). &#160;In consideration of the rights and licenses granted to Janssen hereunder, Janssen shall pay to Protagonist the applicable milestone payment set forth in the table below (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Milestone Payment</b><font style="font-size:12pt;">&#8221;) within [ * ] after receipt of an invoice from Protagonist with respect to achievement of each Milestone Event that occurs prior to or on the date of database lock for the PTG-200 Phase 2A Clinical Trial and [ * ] after receipt of an invoice from Protagonist with respect to achievement of each Milestone Event that occurs after such date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:2.9pt;padding-right:0.5pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Payment<br>for Initial Product</b></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Payment<br>for 2</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">nd</sup><b style="font-size:12pt;font-weight:bold;"> Generation<br>Product</b></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:12pt;">A.&#160;&#160;[Intentionally omitted]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[Intentionally omitted]</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[Intentionally omitted]</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:12pt;">B.&#160;&#160;Completion of first Phase 1 Clinical Trial of a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product (i.e., database lock)</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$7,500,000</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.45pt;text-indent:-21.45pt;margin:0pt;"><font style="font-size:12pt;">B-1. Dosing of 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in first Phase 2B Clinical Trial of the Initial Product for CD</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$50,000,000</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:12pt;">C.&#160;&#160;Dosing of 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in first Phase 2 Clinical Trial of a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product for any Indication</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$25,000,000</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">C-1. [ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:12pt;">D.&#160;&#160;&#160;Phase 3 Clinical Trial of a Licensed Product for any Indication Meets primary clinical endpoint</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$100,000,000</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$115,000,000</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">E.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">F.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">H.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">I.&#160;&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J.&#160;&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">53</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:2.9pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:12pt;">K.&#160;&#160;&#160;Dosing of 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in first Phase 2 Clinical Trial of a Licensed Product for a Second Indication</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$10,000,000</font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$10,000,000</font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">L.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">M.&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr><tr><td style="vertical-align:top;width:42.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N.&#160;&#160;&#160;[ * ]</font></p></td><td style="vertical-align:top;width:27.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td><td style="vertical-align:top;width:30.55%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">US$[ * ] </font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">Milestone Rules</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;"> Each Milestone Payment shall be payable only once, even if the corresponding Milestone Event occurs more than once or with respect to more than one Licensed Product of the applicable type (</font><i style="font-size:12pt;font-style:italic;">i.e.</i><font style="font-size:12pt;">, if a Milestone Event occurs with respect to more than one Initial Product or a Milestone Event occurs with respect to more than one 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product). Each Milestone Payment shall be non-refundable and non-creditable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">The Milestone Payment for Milestone Event C-1 shall be payable one time only, upon the first occurrence of Milestone Event C-1 with respect to the Initial Product or any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product. &#160;For example, if Milestone Event C-1 occurs for the Initial Product before the dosing of the 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in a Phase 3 Clinical Trial of a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product for any Indication, then (x) the Milestone Payment for Milestone Event C-1 will be payable for occurrence of Milestone Event C-1 for the Initial Product, and (y) dosing of the 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in a Phase 3 Clinical Trial of a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product will not cause any obligation to pay the Milestone Payment for Milestone Event C-1 a second time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">For purposes of Milestone Event D, a Phase 3 Clinical Trial of a Licensed Product for an Indication will be deemed to meet its primary clinical endpoint on the first date when all of the following have occurred:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The statistical analysis of the data from such trial is complete;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The top-line results from such trial have become available to Janssen; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The top-line results demonstrate that the primary clinical endpoint (as described in the protocol for such trial) is formally statistically significant, where &#8220;statistically significant&#8221; is defined as achieving a pre-specified level of significance value using the procedure defined in the protocol and statistical analysis plan for such trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.3.</font></font><font style="font-size:12pt;">[ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.4.</font></font><b style="font-size:12pt;font-weight:bold;">Definition of Second Indication</b><font style="font-size:12pt;">. &#160;A &#8220;</font><b style="font-size:12pt;font-weight:bold;">Second Indication</b><font style="font-size:12pt;">&#8221; means:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">[ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">54</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">with respect to a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">as used in Milestone Event J, an Indication other than the Indication with respect to which Milestone Event F occurred for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product [ * ];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">as used in Milestone Event K, an Indication other than the Indication with respect to which Milestone Event C occurred for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">as used in Milestone Event L, either: (x) if Milestone Event C-1 occurs for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product before the dosing of the 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in a Phase 3 Clinical Trial of the Initial Product, an Indication other than the Indication with respect to which Milestone Event C-1 occurred or (y) if Milestone Event C-1 occurs for the Initial Product before the dosing of the 3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> patient in a Phase 3 Clinical Trial of a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, an Indication with respect to which Milestone Event C-1 occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.5.</font></font><font style="font-size:12pt;">[ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.3.6.</font></font><b style="font-size:12pt;font-weight:bold;">Skipped Milestones</b><font style="font-size:12pt;">. &#160;With respect to the Milestone Events set forth in the table above in Section 7.3.1 and subject to Section 7.3.2, if for any reason:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Milestone Event B does not occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product before the occurrence of Milestone Event C for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, then Milestone Event B shall be deemed to occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product concurrently with the occurrence of Milestone Event C;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Milestone Event C does not occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product before the occurrence of Milestone Event C-1 for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, then Milestone Event C shall be deemed to occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product concurrently with the occurrence of Milestone Event C-1 for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Milestone Event C does not occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product before the occurrence of Milestone Event D for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, then Milestone Event C shall be deemed to occur for a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product concurrently with the occurrence of Milestone Event D;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">[ * ];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">Milestone Event K for the Initial Product or a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, respectively, does not occur before the occurrence of Milestone Event L for the Initial Product or a 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, respectively, then Milestone Event K shall be deemed to occur for the applicable product concurrently with the occurrence of Milestone Event L for the applicable product; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">55</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:12pt;">[ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Sales Milestones</b><font style="font-size:12pt;">. &#160;Janssen will notify Protagonist in the applicable royalty report delivered pursuant to Section 7.5.4 the first time the aggregate Net Sales of Initial Products or the first time the aggregate Net Sales of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in any Calendar Year by Janssen, its Affiliates and its sublicensees in the Territory exceed the amounts set forth in the following table (each, a </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sales Milestone Event</b><font style="font-size:12pt;">&#8221;). &#160;In partial consideration of the rights and licenses granted to Janssen hereunder, Janssen shall pay to Protagonist the applicable milestone payment set forth in the table below (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Sales Milestone Payment</b><font style="font-size:12pt;">&#8221;) within [ * ] after receipt of an invoice from Protagonist with respect to achievement of each Sales Milestone Event. &#160;Each Milestone Payment shall be non-refundable and non-creditable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:99.96%;"><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Annual Aggregate Net Sales in the Territory Milestone Event</b></p></td><td colspan="2" style="vertical-align:top;width:29.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of Initial Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of Initial Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of Initial Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of Initial Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr><tr><td style="vertical-align:top;width:70.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Upon the first occasion that annual aggregate Net Sales of 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products in the Territory in a Calendar Year exceed US$[ * ] </font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">US$</font></p></td><td style="vertical-align:top;width:14.56%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Royalties</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.1.</font></font><b style="font-size:12pt;font-weight:bold;">Royalty Rates</b><font style="font-size:12pt;">. &#160;In partial consideration of the licenses and rights granted by Protagonist to Janssen under this Agreement, Janssen shall pay to Protagonist royalties on the aggregate Net Sales of each Licensed Product by Janssen, its Affiliates and sublicensees in each country in the Territory during each Calendar Year of the Royalty Term for such Licensed Product in such country at the rates set forth in the table below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:79.92%;"><tr><td style="vertical-align:top;width:71.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Annual Aggregate Net Sales of such Licensed<br>Product in the Territory</b></p></td><td style="vertical-align:top;width:28.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Royalty Rate</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">56</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:79.92%;"><tr><td style="vertical-align:top;width:71.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">For that portion of annual Net Sales of such Licensed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product in the Territory in such Calendar Year less than [ * ] (US$[ * ])</font></p></td><td style="vertical-align:middle;width:28.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]%</font></p></td></tr><tr><td style="vertical-align:top;width:71.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">For that portion of annual Net Sales of such Licensed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product in the Territory in such Calendar Year greater than or equal to [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(US$[ * ]) and less than [ * ] (US$[ * ])</font></p></td><td style="vertical-align:middle;width:28.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]%</font></p></td></tr><tr><td style="vertical-align:top;width:71.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">For that portion of annual Net Sales of such Licensed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product in the Territory in such Calendar Year greater than or equal to [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">(US$[ * ]) and less than [ * ] (US$[ * ])</font></p></td><td style="vertical-align:middle;width:28.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">[ * ]%</font></p></td></tr><tr><td style="vertical-align:top;width:71.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">For that portion of annual Net Sales of such Licensed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product in the Territory in such Calendar Year greater than or equal to [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">(US$[ * ])</font></p></td><td style="vertical-align:middle;width:28.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">10%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">By way of example, if annual Net Sales of a Licensed Product in the Territory during such Calendar Year were $[ * ], the royalties due with respect to such Licensed Product would equal the sum of (a) [ * ]% of $[ * ] (i.e., $[ * ]) and (b) [ * ]% of $[ * ] (i.e., $[ * ]), for a total of $[ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.2.</font></font><b style="font-size:12pt;font-weight:bold;">Royalty Reductions</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Janssen shall have the right to deduct, from the royalties due to Protagonist pursuant to Section 7.5.1 with respect to a Licensed Product during a Calendar Quarter, [ * ] percent ([ * ]%) of the aggregate payments made by Janssen or its Affiliate or sublicensee to such Third Party(ies) that are specifically made as consideration for a license under Third Party Blocking Intellectual Property Rights with respect to such Licensed Product during such Calendar Quarter, </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that if any agreement with such Third Party includes rights to additional intellectual property other than such intellectual property rights or covers products other than such Licensed Product, any such payment shall be equitably allocated by Janssen in good faith among all products and programs to which such agreement applies. &#160;Janssen shall provide documentation of such allocation to Protagonist, and any dispute regarding such allocation shall be subject to resolution under Article 13.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">On a country-by-country and Licensed Product-by-Licensed Product basis, the royalties due to Protagonist pursuant to Section 7.5.1 shall be reduced during the Royalty Term for such Licensed Product in such country to [ * ] percent ([ * ]%) of the amount otherwise payable from and after the date that&#160;there is no Valid Claim of any Protagonist Patent Right that Covers the composition of matter of such Licensed Product in such country. &#160;Such reduced royalty rate will be applied to the sales of the applicable Licensed Product beginning with the Calendar Quarter immediately following the Calendar Quarter during which such event first occurs and will remain in effect unless and until the event set forth in Section 7.5.2(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">57</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">If, after the date upon which&#160;there is no Valid Claim of any Protagonist Patent Right that Covers the composition of matter of a Licensed Product sold by Janssen (directly or through an Affiliate or Third Party sublicensee) in a particular country, one or more Generic Products is sold by a Third Party in such country, </font><font style="font-size:12pt;">the royalty rates provided in Section 7.5.1 for such Licensed Product shall be reduced in such country by </font><font style="font-size:12pt;">[ * ] </font><font style="font-size:12pt;">percent (</font><font style="font-size:12pt;">[ * ]</font><font style="font-size:12pt;">%) for the remainder of the Royalty Term for such Licensed Product in such country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Notwithstanding the foregoing, in no event shall the total deductions under Sections 7.5.2(a), 7.5.2(b), and 7.5.2(c) reduce the royalties payable to Protagonist under Section 7.5.1 with respect to a given Licensed Product in a given country in any Calendar Quarter by more than [ * ] percent ([ * ]%); </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that to the extent Janssen cannot deduct any amounts because of this Section 7.5.2(d), Janssen may deduct such amounts from royalties payable in future Calendar Quarters, subject to this Section 7.5.2(d).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.3.</font></font><b style="font-size:12pt;font-weight:bold;">Royalty Term Expiration</b><font style="font-size:12pt;">. &#160;Upon the expiration of the Royalty Term with respect to a </font><font style="font-size:12pt;">Licensed</font><font style="font-size:12pt;"> Product in a country in the Territory, Protagonist hereby grants to Janssen a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the Protagonist Intellectual Property to Develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit, Manufacture and Commercialize such </font><font style="font-size:12pt;">Licensed </font><font style="font-size:12pt;">Product in the Field in such country. &#160;For clarity, after the Royalty Term expires with respect to a Licensed Product in a country, the calculation of annual Net Sales of such Licensed Product in the Territory shall exclude sales of such Licensed Product in such country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.4.</font></font><b style="font-size:12pt;font-weight:bold;">Royalty Reports and Payments</b><font style="font-size:12pt;">. &#160;Commencing with the First Commercial Sale of a </font><font style="font-size:12pt;">Licensed</font><font style="font-size:12pt;"> Product by Janssen or its Affiliates or sublicensees, (a) within [ * ] after the end of each Calendar Quarter, Janssen shall make preliminary written reports to Protagonist stating in each such report, by Licensed Product, the estimated aggregate Net Sales in U.S. Dollars of Licensed Products sold in the Territory during such Calendar Quarter by Janssen and its Affiliates and sublicensees, and (b) within [ * ] after the end of each Calendar Quarter Janssen shall make final written reports to Protagonist stating in each such report, by </font><font style="font-size:12pt;">Licensed </font><font style="font-size:12pt;">Product and by region (which regions shall be the U.S., Canada, Japan, the Major European Countries and all other countries in the Territory), the aggregate Net Sales in U.S. Dollars of </font><font style="font-size:12pt;">Licensed </font><font style="font-size:12pt;">Products sold during such Calendar Quarter by Janssen and its Affiliates and sublicensees. &#160;The final report shall also show (a) the calculation of the royalty payments due to Protagonist on such Net Sales ([ * ]), (b) the amount of taxes, if any, withheld to comply with Applicable Laws, and (c) the exchange rates used in calculating the payments due Protagonist, which exchange rates shall comply with Section 7.6.2. &#160;Simultaneously with the delivery of each such final report, Janssen shall pay to Protagonist the total royalties, if any, due to Protagonist for the period of such report. &#160;If no royalties are due, Janssen shall so report. &#160;All preliminary and final reports delivered by Janssen under this Section 7.5.4 shall be Confidential Information of Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">58</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.5.5.</font></font><b style="font-size:12pt;font-weight:bold;">Royalty Conditions</b><font style="font-size:12pt;">. &#160;All royalties due to Protagonist pursuant to Section 7.5.1 are subject to the following conditions: &#160;(a) only one royalty shall be due with respect to the same unit of Licensed Product; (b) no royalties shall be due upon the sale or other transfer among Janssen or its Affiliates, but in such cases the royalty shall be due and calculated upon Janssen&#8217;s or its Affiliate&#8217;s Net Sales to the first independent Third Party, and distributors of Janssen selling Licensed Product that are not Affiliates of Janssen will not, for this purpose, be deemed to be sublicensees of Janssen and shall instead be considered as independent Third Parties; and (c) no royalties shall be due upon free samples, donations, patient assistance, test marketing programs or other similar programs or studies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Payment Terms</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.6.1.</font></font><b style="font-size:12pt;font-weight:bold;">Payments</b><font style="font-size:12pt;">. &#160;All payments due under this Agreement shall be made in U.S. Dollars by wire transfer in immediately available funds to an account designated by the receiving Party or by other mutually acceptable means.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.6.2.</font></font><b style="font-size:12pt;font-weight:bold;">Currency Conversion</b><font style="font-size:12pt;">. &#160;The rate of exchange to be used in computing the amount of currency equivalent in U.S. Dollars of Net Sales invoiced in other currencies shall be [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.6.3.</font></font><b style="font-size:12pt;font-weight:bold;">Late Payments</b><font style="font-size:12pt;">. &#160;If a Party does not receive payment of any amount due to it under this Agreement on or before the due date, such payment shall bear interest at a rate per annum equal to [ * ] or the maximum rate allowable by Applicable Law, whichever is lower.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Records; Inspection</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.1.</font></font><font style="font-size:12pt;">Each Party shall keep (and cause its Affiliates, (sub)licensees and Third Party Subcontractors to keep) complete, true and accurate books of account and records for the purpose of determining the Development Costs shared or reimbursed by the Parties under Section 7.2 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Cost Records</b><font style="font-size:12pt;">&#8221;); and Janssen shall keep (and cause its Affiliates, sublicensees and Third Party Subcontractors to keep) complete, true and accurate books of account and records for the purpose of determining royalties and Sales Milestone Payments payable by Janssen to Protagonist under Sections 7.4 and 7.5 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Records</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.2.</font></font><font style="font-size:12pt;">Each Party shall retain its Cost Records and Royalty Records for at least [ * ] following the end of the Calendar Year to which they pertain. &#160;Each Party shall, and shall cause its Affiliates and (sub)licensees to, make the Cost Records and Royalty Records available for inspection by an independent public accounting firm of national prominence selected by the other Party, and reasonably acceptable to the audited Party, during normal business hours, as may be reasonably necessary for the sole purpose of verifying the cost and royalty reports and payments delivered by the Parties pursuant to Sections 7.2, 7.4 and 7.5 during the preceding [ * ]. &#160;The records for a given Calendar Year shall be subject to audit no more than [ * ]. &#160;Such independent public accounting firm shall execute a reasonable confidentiality agreement with the audited Party prior to commencing any such inspection. &#160;Such inspections shall be made no more than [ * ] at reasonable times and on reasonable notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">59</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.3.</font></font><font style="font-size:12pt;">Following completion of an inspection pursuant to Section 7.7.2, the independent public accounting firm shall, prior to distribution to the auditing Party, share its report with the audited Party. &#160;If the audited Party provides the independent public accounting firm with justifying remarks for inclusion in the report, the independent public accounting firm shall incorporate such remarks into its report prior to sharing the conclusions of such independent public accounting firm with the auditing Party. &#160;The final audit report shall be shared with both Parties at the same time and shall specify (a) whether any royalties paid by the audited Party during the audited period were correct and, if incorrect, the amount of any underpayment or overpayment and (b) whether any Development Costs reported by the audited Party during the audited period were correct and, if incorrect, the difference between the reported amounts and the amounts actually incurred. The audit report shall only contain the information relevant to support the statement as to whether the royalties paid or costs reported to the auditing Party were calculated accurately and shall not include any confidential information (or additional information that is ordinarily not included in the royalty or cost reports delivered pursuant to this Agreement) disclosed to the independent public accounting firm during the course of the audit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.4.</font></font><font style="font-size:12pt;">The auditing Party shall bear the costs and expenses of any inspection conducted under this Section&#160;7.7 unless such inspection reveals (a) an over-reporting of Development Costs by the audited Party of more than [ * ] percent ([ * ]%) of the actual Development Costs incurred by the audited Party during the audited period or (b) an underpayment of royalties payable pursuant to Section 7.5 by the audited Party of more than [ * ] percent ([ * ]%) of the amount payable for the audited period, in which case ((a) or (b)) the audited Party shall bear the costs and expenses of such inspection.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.5.</font></font><font style="font-size:12pt;">If such inspection reveals an over-reporting of Development Costs by the audited Party pursuant to Section 7.2, then the auditing Party shall conduct the applicable calculation pursuant to Section 7.2 and invoice the audited Party for the difference between the amount paid pursuant to Section 7.2 and the amount due as a result of the corrected calculation. &#160;The audited Party shall pay such invoice within [ * ] after receipt thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.6.</font></font><font style="font-size:12pt;">If such inspection reveals an overpayment of royalties by the audited Party pursuant to Section 7.5, then the audited Party shall invoice the auditing Party for the amount of the overpayment and the auditing Party shall pay such invoice within [ * ] after receipt thereof, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the auditing Party may elect to offset such amounts against future royalties payable by the audited Party. &#160;If such inspection reveals an underpayment of royalties by the audited Party pursuant to Section 7.5, then the auditing Party shall invoice the audited Party for the amount of the underpayment and the audited Party shall pay such invoice within [ * ] after receipt thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.7.7.</font></font><font style="font-size:12pt;">If the audited Party disagrees with the findings of the audit report, the Parties will meet to attempt to mutually agree upon a resolution to the dispute. &#160;If such resolution cannot be reached, such disagreement shall be subject to the dispute resolution procedures set forth in Article 13.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">60</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.8.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Taxes</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.8.1.</font></font><font style="font-size:12pt;">Each Party sha</font><font style="font-size:12pt;">ll make all payments under this Agreement without deduction or withholding for Taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the paying Party shall use reasonable, good faith efforts to give the recipient Party advance notice of its intention to make such deduction or withholding. &#160;Any Tax required to be withheld on amounts payable under this Agreement will be timely paid by the paying Party on behalf of the recipient Party to the appropriate Governmental Authority, and the paying Party will furnish the recipient Party with proof of payment of such Tax as well as any official receipts issued by the applicable Governmental Authority or other evidence as is reasonably requested to establish that such Taxes have been paid. &#160;Any such Tax required to be withheld will be an expense of and borne by the recipient Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.8.2.</font></font><font style="font-size:12pt;">The paying Party</font><font style="font-size:12pt;"> shall pay all value added, transfer, sales, use, stamp, or similar Taxes (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Transfer Taxes</b><font style="font-size:12pt;">&#8221;) required to be paid in connection with any payment made to the other Party under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.8.3.</font></font><font style="font-size:12pt;">The Parties shall cooperate with respect to all documentation required by any taxing authority or reasonably requested to secure a reduction in the rate of applicable withholding taxes, and the Parties shall provide reasonable mutual assistance with respect to any claim of refund or exemption from Taxes under any relevant agreement or treaty. &#160;On or before the Original Effective Date, Protagonist delivered to Janssen an accurate and complete Internal Revenue Service Form W-9. &#160;The Parties acknowledge Protagonist may qualify&#160;for a reduction in the rate of applicable withholding taxes under the respective treaty between the U.S. and Germany. Accordingly, in furtherance of the first sentence of this Section, following the Restatement Effective Date and in advance of the first royalty payment due to Protagonist, if requested by Janssen, Protagonist shall use commercially reasonable efforts to secure and deliver to Janssen an accurate and complete exemption certificate under the respective treaty between the U.S. and Germany, which certificate Protagonist shall update and/or renew so that it remains in force during the remainder of the term of this Agreement; provided that the Parties will discuss the utility of such certificate in the event Protagonist determines it no longer qualifies for a reduction in the rate of applicable withholding taxes under the treaty between the U.S. and Germany; and, provided further, that the failure of Janssen to request such certificate shall not relieve Protagonist of any of its other obligations under this Section 7.8. &#160;The Parties hereby provide their consent to disclose this Agreement to the German tax authorities for purposes of obtaining such an exemption certificate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Reporting of Collaboration Inventions</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.1.1.</font></font><font style="font-size:12pt;">Each Party shall designate a patent attorney or agent as its contact to coordinate with the other Party the filing, prosecution and maintenance of Patent Rights as provided</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">61</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">in this Article (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Patent Representative</b><font style="font-size:12pt;">&#8221;). &#160;Each Party shall promptly report to the other Party&#8217;s Patent Representative any material Collaboration Invention.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.1.2.</font></font><font style="font-size:12pt;">If Protagonist reasonably [ * ] in good faith that any published Janssen patent application directed to oral, peptide or peptidomimetic IL-23 receptor antagonists claims an invention that may be Included Research Know-How, but Janssen did not disclose such invention to Protagonist, Protagonist may request a meeting of the Patent Representatives to [ * ] in good faith such patent application and, at such meeting, Janssen&#8217;s Patent Representative shall provide all relevant documentation and other Information concerning such IL-23 receptor antagonist-related invention and the Parties shall engage in a good faith discussion regarding whether such patent application should be considered a Janssen Collaboration Patent Right.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Ownership of Collaboration Inventions, Patent Rights and Know-How</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.2.1.</font></font><b style="font-size:12pt;font-weight:bold;">Collaboration Inventions and Collaboration Patent Rights</b><font style="font-size:12pt;">. &#160;Ownership in the Territory of Collaboration Inventions and Patent Rights filed after the Original Effective Date claiming one or more Collaboration Inventions (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Patent Right</b><font style="font-size:12pt;">&#8221;) shall be allocated in accordance with inventorship as determined pursuant to principles of United States patent law as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">each Collaboration Invention invented solely by one or more employees or agents of Janssen (or its Affiliates, Third Party Subcontractors or Third Parties performing Development activities or Janssen Independent Research Activities on behalf of Janssen) and each Collaboration Patent Right to the extent claiming one or more of such Collaboration Inventions shall be owned solely by Janssen (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Collaboration Patent Right</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">each Collaboration Invention invented solely by one or more employees or agents of Protagonist (or its Affiliates or Third Party Subcontractors) and each Collaboration Patent Right to the extent claiming one or more of such Collaboration Inventions shall be owned solely by Protagonist (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Collaboration Patent Right</b><font style="font-size:12pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">each Collaboration Invention invented jointly by one or more employees or agents of Janssen (or its Affiliates, Third Party Subcontractors or Third Parties performing Development activities or Janssen Independent Research Activities on behalf of Janssen) and one or more employees or agents of Protagonist (or its Affiliates or Third Party Subcontractors) and each Collaboration Patent Right to the extent claiming one or more of such Collaboration Inventions shall be owned jointly by the Parties (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Collaboration Patent Right</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">For purposes of this Agreement, except as set forth in Section 9.1, Collaboration Know-How which is the basis for a Collaboration Invention upon the filing of a Collaboration Patent Right therefor will be the Confidential Information of the owner(s) of such Collaboration Patent Right. &#160;The Janssen Collaboration Patent Rights that exist as of the Restatement Effective Date are listed on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">62</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">8.2.1(a)</u><font style="font-size:12pt;">, the Protagonist Collaboration Patent Rights that exist as of the Restatement Effective Date are listed on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 8.2.1(b)</u><font style="font-size:12pt;"> and the Joint Collaboration Patent Rights that exist as of the Restatement Effective Date are listed on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 8.2.1(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.2.2.</font></font><b style="font-size:12pt;font-weight:bold;">Other Collaboration Know-How; Excluded Research Know-How</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Subject to Section 9.1, any Collaboration Know-How generated by Janssen&#8217;s or its Affiliates&#8217; or Third Party Subcontractors&#8217; employees or agents that is not otherwise allocated pursuant to Section&#160;8.2.1 will be the Confidential Information of Janssen (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Collaboration Know-How</b><font style="font-size:12pt;">&#8221;). &#160;Subject to Section 9.1, any other Collaboration Know-How generated by Protagonist&#8217;s or its Affiliates&#8217; or Third Party Subcontractors&#8217; employees or agents that is not otherwise allocated pursuant to Section&#160;8.2.1 will be the Confidential Information of Protagonist (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Collaboration Know-How</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Janssen shall have no obligation to disclose the Excluded Research Know-How to Protagonist, and Protagonist shall have no rights under this Agreement with respect to the Excluded Research Know-How. &#160;The Excluded Research Know-How will be the Confidential Information of Janssen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.2.3.</font></font><b style="font-size:12pt;font-weight:bold;">Confirmatory Assignments; Inventor Compensation</b><font style="font-size:12pt;">. &#160;Each Party shall take all reasonable actions requested by the other Party responsible for prosecuting any Collaboration Patent Right to perfect or separately document the other Party&#8217;s ownership interest rights in such Collaboration Patent Right as provided for in this Agreement, including by causing its and its applicable Affiliates&#8217; and Third Party Subcontractors&#8217; employees and agents to execute appropriate assignment documents, and the requesting Party shall not be required to pay any remuneration to the other Party or its Affiliates or Third Party Subcontractors, or any of their employees, or agents, for the execution of any assignments or other papers pursuant to this Section 8.2.3. &#160;For clarity, each Party (directly or through its applicable Affiliate or Third Party Subcontractor) shall be solely responsible for any compensation directly due to its and its Affiliates&#8217; and Third Party Subcontractors&#8217; employees and agents (a) in connection with the assignment of their respective rights to any Collaboration Inventions and associated Collaboration Patent Rights pursuant to this Agreement, or (b) the exploitation by any Party or its Affiliates or Third Party sublicensees hereunder of any such Collaboration Inventions or associated Collaboration Patent Rights with respect to Licensed Compounds or Licensed Products, including in each case any required by operation of Applicable Law on account of any Commercialization of any such Collaboration Inventions with respect to Licensed Compounds or Licensed Products hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.2.4.</font></font><b style="font-size:12pt;font-weight:bold;">Right to Practice Jointly Owned Technology</b><font style="font-size:12pt;">. &#160;Except to the extent either Party is restricted by the express terms of this Agreement, with respect to any Collaboration Inventions and Collaboration Patent Rights that are owned jointly by the Parties pursuant to Section 8.2.1, each Party shall have the right to practice and exploit such Collaboration Inventions and Collaboration Patent Rights, with full rights to license its interest therein in the Territory, and without the duty of accounting to or any duty to seek consent from the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">63</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">other Party, and upon the reasonable request of either Party, the other Party shall execute documents that evidence or confirm the requesting Party&#8217;s right to engage in such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Prosecution of Collaboration and Joint Patent Rights</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.1.</font></font><b style="font-size:12pt;font-weight:bold;">Communications</b><font style="font-size:12pt;">. &#160;Each Party shall use reasonable efforts to handle all communications between the Parties under this Section 8.3 through their Patent Representatives and keep such communications in strict confidence to protect their attorney-client privileged status in accordance with Section 9.10.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.2.</font></font><b style="font-size:12pt;font-weight:bold;">Filing, Prosecution and Maintenance of Janssen Collaboration Patent Rights and Joint Collaboration Patent Rights Prior to the License Term</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Prior to the start of the License Term, Janssen shall be responsible for prosecuting or causing to be prosecuted in the United States and in foreign countries Janssen Collaboration Patent Rights and Joint Collaboration Patent Rights, [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Within [ * ] after the filing of an application within the Janssen Collaboration Patent Rights or Joint Collaboration Patent Rights, Janssen shall provide Protagonist with a written report indicating in which countries/regions Janssen will file a corresponding international application. &#160;Protagonist shall then notify Janssen within [ * ] of such notice in which additional countries/regions Protagonist would desire Janssen to file a corresponding international application. &#160;If Janssen does not desire to file such an international application in the additional countries/regions requested by Protagonist, Janssen shall so notify Protagonist and then Protagonist shall have the option to request that Janssen file such international application in such country(s)/region(s). &#160;Janssen shall file such international application in such country(s)/region(s), and Protagonist shall reimburse Janssen for [ * ] Patent Costs with respect to such requested international patent application(s). &#160;Protagonist, however, shall have the right to discontinue reimbursement of Patent Costs for such requested international patent application(s), upon [ * ] written notice to Janssen; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that [ * ]. &#160;If Protagonist discontinues reimbursement of the Patent Costs with respect to such requested international patent application(s), such requested international patent application(s) shall no longer be considered to be within the Janssen Collaboration Patent Rights or Joint Collaboration Patent Rights, as applicable, except for purposes of the license granted to Protagonist pursuant to 12.5.1(g).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Janssen shall provide to Protagonist: (i) copies of or access to all relevant patent applications included in Janssen Collaboration Patent Rights and Joint Collaboration Patent Rights for which Janssen is responsible for prosecuting; (ii) [ * ]; and (iii) copies of or access to all correspondence to and from the U.S. Patent and Trademark Office and foreign patent offices for such applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Protagonist shall have the right to consult with Janssen regarding the content of the patent applications included in Janssen Collaboration Patent Rights and Joint</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">64</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">Collaboration Patent Rights, [ * ] and correspondence, and to comment thereon to Janssen, or at Janssen&#8217;s request, to Janssen&#8217;s designated outside counsel. &#160;Janssen shall reasonably [ * ] in good faith all such comments offered by Protagonist; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that all final decisions respecting conduct of the prosecution of said patent applications shall rest solely in the discretion of Janssen with respect to Janssen Collaboration Patent Rights, and with Protagonist with respect to Joint Collaboration Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.3.</font></font><b style="font-size:12pt;font-weight:bold;">Filing, Prosecution and Maintenance of Protagonist Patent Rights (other than Joint Collaboration Patent Rights) Prior to the License Term</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Prior to the start of the License Term, Protagonist shall be responsible for prosecuting or causing to be prosecuted in the United States and in foreign countries the Protagonist Patent Rights other than the Joint Collaboration Patent Rights, at [ * ] as provided in Section 8.3.5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Within [ * ] after the filing of an application within such Protagonist Patent Rights, Protagonist shall provide Janssen with a written report indicating in which countries/regions Protagonist will file a corresponding international application. &#160;Janssen shall then notify Protagonist within [ * ] of such notice in which additional countries/regions Janssen would desire Protagonist to file a corresponding international application. &#160;If Protagonist does not desire to file any such additional international application in a country/region requested by Janssen, Protagonist shall so notify Janssen and then Janssen shall have the option to request that Protagonist file such international application in such country(s)/region(s). &#160;Protagonist shall file such international application in such country(s)/region(s), and Janssen shall reimburse Protagonist for [ * ] Patent Costs with respect to such requested international patent application(s). &#160;Janssen, however, shall have the right to discontinue reimbursement of the Patent Costs for such requested international patent application(s), upon [ * ] written notice to Protagonist; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that Janssen shall remain responsible for reimbursement of such Patent Costs during such [ * ] notice period. &#160;If Janssen discontinues reimbursement of the Patent Costs with respect to such requested international patent application(s), such requested international patent application(s) shall no longer be considered to be within the Protagonist Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Protagonist agrees to provide to Janssen: (i) copies of or access to all relevant patent applications included in the Protagonist Patent Rights for which Protagonist is responsible for prosecuting; (ii) [ * ]; and (iii) copies of or access to all correspondence to and from the U.S. Patent and Trademark Office and foreign patent offices for such applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Janssen shall have the right to consult with Protagonist regarding the content of the patent applications included in Protagonist Patent Rights, [ * ] and correspondence, and to comment thereon to Protagonist, or at Protagonist&#8217;s request, to Protagonist&#8217;s designated outside counsel. Protagonist shall reasonably consider in good faith all such comments offered by Janssen; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that, except as</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">65</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">provided below, all final decisions respecting conduct of the prosecution of said patent applications shall rest solely in the discretion of Protagonist. If Janssen wishes pursue patent protection on an invention relating to a Licensed Product and Protagonist decides not to pursue such patent protection, Janssen shall have the right to pursue in Protagonist</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s name, as applicable, patent rights related to such invention (collectively </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Elected Protagonist Patent Rights</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) and shall keep Protagonist informed as to the prosecution and maintenance of such Janssen Elected Protagonist Patent Rights. Without limiting the foregoing, prior to the start of the License Term, Janssen may request a patent strategy meeting with Protagonist. Protagonist agrees to reasonably [ * ] in good faith all of Janssen</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s comments at such meeting regarding the patent strategy with respect to the Protagonist IL23 Receptor Inhibitor Patent Rights. Any Patent Costs associated with subsequent actions requested by Janssen at such meeting or relating to the preparation, filing and/or maintenance of Janssen Elected Protagonist Patent Rights shall be at Janssen</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.4.</font></font><b style="font-size:12pt;font-weight:bold;">Filing, Prosecution and Maintenance of Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights), Janssen Collaboration Patent Rights and Joint Collaboration Patent Rights During the License Term.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">On and after the start of the License Term, Janssen shall have the sole right to prosecute or cause to be prosecuted in the United States and in foreign countries the Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights), Janssen Collaboration Patent Rights and Joint Collaboration Patent Rights, at Janssen&#8217;s sole expense, and in Janssen&#8217;s good faith discretion. &#160;Such right includes the right to initiate a re-issue or reexamination of any of the Protagonist Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Upon Protagonist&#8217;s reasonable request, Janssen shall provide to Protagonist: (i) notice of and copies of or access to all significant patent filings with respect to the Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights) and Joint Collaboration Patent Rights [ * ], and (ii) copies of or access to all correspondence to and from the U.S. Patent and Trademark Office and foreign patent offices for such applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.5.</font></font><b style="font-size:12pt;font-weight:bold;">Filing, Prosecution and Maintenance of Retained Patent Rights and Other Protagonist-Controlled Patent Rights</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Each Party understands and acknowledges that the Protagonist IL23 Receptor Inhibitor Patent Rights as of the Original Execution Date Cover both Licensed Compounds and Retained Compounds. &#160;After the Original Execution Date, Protagonist shall have the right to file and prosecute any divisional, continuation and continuation-in-part application(s) claiming priority to any of the Protagonist IL23 Receptor Inhibitor Patent Rights, but only so long as any such divisional, continuation and continuation-in-part application(s) do not include any claim that Covers any Licensed Compound or Licensed Product (such divisionals, continuations and continuation-in-parts, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Retained Patent Rights</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">66</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Protagonist shall have the sole right to prosecute or cause to be prosecuted in the United States and in foreign countries the Retained Patent Rights, at Protagonist&#8217;s sole expense. &#160;On and after the start of the License Term, Protagonist shall have the sole right to prosecute or cause to be prosecuted in the United States and in foreign countries any other Protagonist-Controlled Patent Rights, at Protagonist&#8217;s sole expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Protagonist agrees to provide to Janssen: (i) copies of or access to all relevant patent applications included in the Protagonist-Controlled Patent Rights; and (ii) copies of or access to all correspondence to and from the U.S. Patent and Trademark Office and foreign patent offices for such applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">Janssen shall have the right to consult with Protagonist regarding the content of patent applications included in the Protagonist-Controlled Patent Rights, and to comment thereon to Protagonist, or at Protagonist&#8217;s request, to Protagonist&#8217;s designated outside counsel. &#160;Protagonist shall reasonably [ * ] in good faith all such comments offered by Janssen; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that all final decisions respecting conduct of the prosecution of said patent applications shall rest solely in the discretion of Protagonist, so long as such decisions do not adversely impact the Protagonist IL23 Receptor Inhibitor Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.6.</font></font><b style="font-size:12pt;font-weight:bold;">Option to Prosecute and Maintain Patent Rights</b><font style="font-size:12pt;">. &#160;Either Party may cease prosecution and/or maintenance of any Patent Rights that such Party is responsible for prosecuting pursuant to this Section 8.3 on a country-by-country basis in the Territory by providing the other Party written notice reasonably in advance, i.e., approximately [ * ] before such due date. &#160;If the responsible Party elects to cease prosecution or maintenance of the relevant Patent Rights in a country, the other Party, at its sole discretion and cost, may continue prosecution or maintenance of such Patent Rights and in such country. If the other Party elects to continue prosecution or maintenance or elects to file additional applications following the responsible Party&#8217;s election to cease prosecution or maintenance pursuant to this Section 8.3.6, the responsible Party shall transfer the applicable patent files to such other Party or its designee and execute such documents and perform such acts at the responsible Party&#8217;s expense as may be reasonably necessary to allow the other Party to initiate or continue such filing, prosecution or maintenance at the other Party&#8217;s sole expense. &#160;If Janssen ceases the prosecution and/or maintenance of any Protagonist Patent Right or Joint Collaboration Patent Right that Janssen is responsible for prosecuting pursuant to this Section 8.3, then such Patent Rights shall thereafter be excluded from the Protagonist Patent Rights. &#160;Notwithstanding the foregoing, Janssen shall have no rights to prosecute or maintain, and this Section 8.3.6 shall not apply, to any Protagonist-Controlled Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.3.7.</font></font><b style="font-size:12pt;font-weight:bold;">CREATE Act</b><font style="font-size:12pt;">. The Parties acknowledge that Collaboration Inventions may be generated with different assigning entities which, during the course of U.S. patent prosecution, may benefit from use of the CREATE Act of 2004 (70 Fed. Reg. 177(54259-54267) as amended by the Leahy-Smith America Invents Act of 2011 (35 U.S.C. &#167;&#167;102(b)(2)(c) and 102(c))) (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">CREATE Act</b><font style="font-size:12pt;">&#8221;). &#160;For the purposes of the benefit of the CREATE Act, the Parties deem this Agreement and/or the written memorialization of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">67</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">transactions contemplated hereunder, such as pertaining to the Development of the Licensed Compounds and Licensed Products, to constitute a qualifying written Joint Research Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Interference, Opposition, Re-examination and Re-issue</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.1.</font></font><font style="font-size:12pt;">Each Party shall inform the other Party promptly (and, in any case, within thirty (30) days) of learning of any request for, or filing or declaration of, any Patent Proceeding relating to Protagonist Patent Rights or Collaboration Patent Rights for which such Party is responsible. &#160;The Parties shall thereafter consult and cooperate fully to determine a course of action with respect to any such Patent Proceeding. &#160;Except with respect to Janssen Collaboration Patent Rights following the </font><font style="font-size:12pt;">start of the License Term</font><font style="font-size:12pt;">, each Party has the right to review any submission, within reason, to be made in connection with the Patent Proceeding of the other Party and has the right to provide reasonable comments on any such submission related to Protagonist Patent Rights and Joint Collaboration Patent Rights, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such comments shall not be unreasonably withheld or delayed and the responsible Party will consider such comments in good faith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.2.</font></font><font style="font-size:12pt;">Prior to the </font><font style="font-size:12pt;">start of the License Term</font><font style="font-size:12pt;">, Protagonist shall have the first right, but not the obligation, to defend any Patent Proceeding relating to Protagonist Patent Rights or Joint Collaboration Patent Rights at its own expense; if Protagonist elects not to defend any such Patent Proceeding then Janssen shall have the right, but not the obligation, to defend such Patent Proceeding (other than any proceeding relating to the Protagonist-Controlled Patent Rights) at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate). &#160;Prior to the </font><font style="font-size:12pt;">start of the License Term</font><font style="font-size:12pt;">, Janssen shall have the first right, but not the obligation, to defend any Patent Proceeding relating to Janssen Collaboration Patent Rights at its own expense; if Janssen elects not to defend any such Patent Proceeding then Protagonist shall have the right, but not the obligation, to defend such Patent Proceeding at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.3.</font></font><font style="font-size:12pt;">Upon the start of the License Term and for the remainder of the Term, (a) Janssen shall have the sole right, but not the obligation, to defend any Patent Proceeding relating to Janssen Collaboration Patent Rights at its own expense, and (b) Janssen shall have the first right, but not the obligation, to defend any Patent Proceeding relating to the Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights) or Joint Collaboration Patent Rights at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate). If Janssen elects not to defend any such Patent Proceeding described in subclause (b) of this Section 8.4.3, then Protagonist shall have the right, but not the obligation, to defend such Patent Proceeding at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.4.</font></font><font style="font-size:12pt;">Each Party shall provide the other Party with written notice [ * ] (a) prior to initiating any Patent Proceeding relating to Protagonist Patent Rights or Collaboration Patent Rights for which such Party is responsible pursuant to this Agreement, and (b) if</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">68</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">such Party elects not to defend such Patent Proceeding. &#160;Any notice under subclause (b) of this Section 8.4.4 shall be made [ * ] any filing, administrative or other applicable deadline to reasonably allow the other Party to exercise its rights under Section 8.4.2 or 8.4.3, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.4.5.</font></font><font style="font-size:12pt;">In connection with any Patent Proceeding relating to Protagonist Patent Rights or Collaboration Patent Rights, the Parties shall cooperate fully and shall provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other Party informed of developments in any such action or proceeding, including, to the extent permissible by law, consultation regarding any settlement, the status of any settlement negotiations and the terms of any related offer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Enforcement and Defense</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.1.</font></font><font style="font-size:12pt;">Each Party shall promptly give the other Party notice of (a) any infringement of Protagonist Patent Rights or Collaboration Patent Rights, or (b) any misappropriation or misuse of Protagonist Know-How or Collaboration Know-How, which may come to such Party&#8217;s attention. The Parties shall thereafter cooperate to determine a course of action to terminate any such infringement of Protagonist Patent Rights or Joint Collaboration Patent Rights or any such misappropriation or misuse of Protagonist Know-How or Collaboration Know-How.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.2.</font></font><font style="font-size:12pt;">Prior to the start of the License Term:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Protagonist shall have the right, but not the obligation, to initiate and prosecute any such legal action, or to control the defense of any declaratory judgment action relating, to the Protagonist Patent Rights (other than Joint Collaboration Patent Rights) or any Protagonist Know-How at its own expense</font><i style="font-size:12pt;font-style:italic;">. </i><font style="font-size:12pt;">The costs of any legal action commenced or the defense of any declaratory judgment shall be borne by Protagonist. Protagonist shall promptly inform Janssen if it elects not to exercise such right with respect to Protagonist Patent Rights and Janssen shall thereafter have the right at its sole cost to either initiate and prosecute such action or to control the defense of such declaratory judgment action (other than with respect to any Protagonist-Controlled Patent Rights) in the name of Protagonist and, if necessary, Janssen. Each Party shall have the right to be represented by counsel of its own choice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Janssen shall have the right, but not the obligation, to initiate and prosecute any such legal action at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate), or to control the defense of any declaratory judgment action relating to Janssen Collaboration Patent Rights, Joint Collaboration Patent Rights or any Janssen Collaboration Know-How. The costs of any legal action commenced or the defense of any declaratory judgment shall be borne by Janssen. Janssen shall promptly inform Protagonist if it elects not to exercise such right with respect to Collaboration Patent Rights and Protagonist shall thereafter have the right at its sole cost to either initiate and prosecute such action or to control the defense of such declaratory</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">69</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">judgment action in the name of Protagonist and, if necessary, Janssen. Each Party shall have the right to be represented by counsel of its own choice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.3.</font></font><font style="font-size:12pt;">Upon the start of the License Term:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">Janssen shall have the right, but not the obligation, to initiate and prosecute any such legal action, or to control the defense of any declaratory judgment action relating to, the Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights, but including any Protagonist Collaboration Patent Rights and any Joint Collaboration Patent Rights) or Joint Collaboration Patent Rights, or any Protagonist Know-How or Collaboration Know-How, at its own expense and in the name of Protagonist and Janssen (or just Protagonist or just Janssen, if the laws of the jurisdiction so dictate). The costs of any legal action commenced or the defense of any declaratory judgment shall be borne by Janssen. Janssen shall promptly inform Protagonist if it elects not to exercise such right with respect to such Protagonist Patent Rights or Protagonist Know-How and Protagonist shall thereafter have the right at its sole cost to either initiate and prosecute such action or to control the defense of such declaratory judgment action in the name of Protagonist and, if necessary, Janssen; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that Protagonist shall not have the right to initiate or prosecute such action, or to control the defense of such declaratory judgment action, to the extent it relates to any Protagonist IL23 Receptor Inhibitor Patent Right without Janssen</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s prior written consent, which Janssen may grant in its sole discretion. Each Party shall have the right to be represented by counsel of its own choice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Janssen shall be solely responsible for the enforcement or defense of any Janssen Collaboration Patent Rights and shall have no obligation to Protagonist with respect to such enforcement or defense, except as set forth in Section 8.5.5 (provided that Protagonist shall have no right of consultation or approval with respect to any proposed settlement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Protagonist shall be solely responsible for the enforcement or defense of any Protagonist-Controlled Patent Rights. &#160;Janssen shall have the right to consult with Protagonist regarding such enforcement or defense of any Retained Patent Rights, and to comment thereon to Protagonist, or at Protagonist&#8217;s request, to Protagonist&#8217;s designated outside counsel. &#160;Protagonist shall reasonably consider in good faith all such comments offered by Janssen; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that all final decisions respecting conduct of such enforcement or defense shall rest solely in the discretion of Protagonist, so long as such decisions do not adversely impact the Protagonist IL23 Receptor Inhibitor Patent Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.4.</font></font><font style="font-size:12pt;">For any action to terminate any infringement of Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights) or Joint Collaboration Patent Rights, or any misappropriation or misuse of Protagonist Know-How, if Janssen is unable to initiate or prosecute such action solely in its own name (where it is permitted to do so under Sections 8.5.2 and 8.5.3), Protagonist shall join such action voluntarily, and shall execute and cause its Affiliates to execute all documents necessary for Janssen to initiate litigation to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">70</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">prosecute and maintain such action. &#160;Janssen shall reimburse Protagonist for its reasonable costs and expenses of participating in such action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.5.</font></font><font style="font-size:12pt;">In connection with any action to terminate any infringement of Protagonist Patent Rights (including the Protagonist-Controlled Patent Rights) or Joint Collaboration Patent Rights, or any Janssen Collaboration Patent Rights, the Parties shall cooperate fully and shall provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other informed of developments in any action or proceeding, including, to the extent permissible by law, the consultation and (except with respect to Janssen Collaboration Patent Rights) approval of any settlement negotiations and the terms of any offer related thereto, except as otherwise expressly noted above in Section 8.4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.6.</font></font><font style="font-size:12pt;">Any recovery obtained by either or both Janssen and Protagonist in connection with or as a result of any action contemplated by this Section 8.5, whether by settlement or otherwise, shall be shared in order as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">the Party that initiated and prosecuted the action will [ * ] in connection with the action;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">the other Party will [ * ] in connection with the action; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">the amount of any recovery remaining following such reimbursement will be [ * ]; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that that any portion of such remaining recovery that [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.7.</font></font><font style="font-size:12pt;">Janssen agrees that neither it nor any Affiliate of Janssen, acting alone or through a Third Party will assert, enforce or seek to assert or enforce any Protagonist IL23 Receptor Inhibitor Patent Rights against Protagonist or any of its Affiliates or licensees with respect to the manufacture, import, use, sale, export or offer for sale of any Retained Compound in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.5.8.</font></font><font style="font-size:12pt;">Except as expressly provided for herein, neither Protagonist, nor any Affiliate of Protagonist, acting alone or through a Third Party, shall assert, enforce or seek to assert or enforce any Protagonist IL23 Receptor Inhibitor Patent Rights against any Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Patent Term Restoration</b><font style="font-size:12pt;">. </font><font style="font-size:12pt;">The Parties shall cooperate with each other in obtaining patent term restoration or supplemental protection certificates or their equivalents (</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Patent Term Restoration</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) in any country in the Territory where applicable to Protagonist Patent Rights and Joint Collaboration Patent Rights. Janssen shall be solely responsible for any Patent Term Restoration relating to Janssen Collaboration Patent Rights and, after the start of the License Term, the Protagonist Patent Rights (other than the Protagonist-Controlled Patent Rights), and shall report to Protagonist on the status thereof through the Patent Representatives, but shall otherwise have no obligation to Protagonist with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Third Party Claims</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">71</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.7.1.</font></font><font style="font-size:12pt;">Without prejudice to Section 8.5, if any action, suit or proceeding is brought against either Party, or any Affiliate or sublicensee of either Party, alleging the infringement of the intellectual property rights of a Third Party by reason of the Development, making, having made, use, having used, sale, having sold, offering for sale, having offered for sale, import, having imported, or other exploitation or Commercialization of a Licensed Compounds or Licensed Product in the Territory, each of the Parties shall have the right, but not the obligation, to defend itself in such action, suit or proceeding at its sole expense, subject to the indemnification obligations set forth in Article 11. The Parties shall cooperate with each other in any defense of any such suit, action or proceeding. The Parties shall give each other prompt written notice of the commencement of any such suit, action or proceeding, or receipt of any claim of infringement, and shall furnish each other a copy of each communication relating to the alleged infringement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.7.2.</font></font><font style="font-size:12pt;">Neither Party shall compromise, litigate, settle or otherwise dispose of any such suit, action or proceeding without the other Party&#8217;s advice and prior consent, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the Party not having the right to defend the suit shall not unreasonably withhold or delay its consent to any settlement which does not have a material adverse effect on its rights, obligations or benefits, either under this Agreement or otherwise. Notwithstanding the foregoing, Janssen may seek to obtain a license from the applicable Third Party at its sole cost and expense (subject to the provisions of Section 8.10), </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the terms and conditions of such license do not include an admission of invalidity of any Protagonist Patent Rights or Joint Collaboration Patent Rights, or restrict the other Party&#8217;s ability to challenge or litigate the validity or applicability of any intellectual property to which the license relates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.7.3.</font></font><font style="font-size:12pt;">The Party first having actual notice of any claim, action or proceeding referenced in Section 8.7.1 shall promptly notify the other Party in writing, setting forth in reasonable detail, to its knowledge, the facts related to any such claim, action or proceeding. The Parties shall promptly discuss proposed responses to any such matters.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.8.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Product Trademarks</b><font style="font-size:12pt;">. &#160;During the Term, Janssen shall have (directly and through its Affiliates and Third Party sublicensees Commercializing Licensed Products) the right to brand, at its discretion, Licensed Products using Trademarks and trade names selected at its discretion and to file for, obtain, and maintain at its discretion and cost Trademarks for such Licensed Products in its own name.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.9.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Protagonist IL23 Receptor Inhibitor Patent Rights</b><font style="font-size:12pt;">. &#160;During the Term, if Protagonist assigns, sells, transfers or otherwise disposes of any Protagonist IL23 Receptor Inhibitor Patent Right to any Affiliate or Third Party, Protagonist shall, at or prior to consummation of such transaction and as a condition thereto, cause such Affiliate or Third Party to execute and deliver to Janssen an agreement pursuant to which such Affiliate or Third Party agrees to be bound by this Agreement to the same extent as Protagonist with respect to such Protagonist IL23 Receptor Inhibitor Patent Right.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.10.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Third Party In-Licenses.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">72</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.10.1.</font></font><font style="font-size:12pt;">During the Term, Protagonist shall be responsible for the payment of any amounts that become due to any Third Party under any agreement to which Protagonist is a party that is in effect on the Original Effective Date (including any Existing Protagonist License Agreements) as a result of either Party&#8217;s activities with respect to the Licensed Compounds or Licensed Products under this Agreement. In the event Janssen makes any such payment to a Third Party, Protagonist shall reimburse Janssen for such amount.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.10.2.</font></font><font style="font-size:12pt;">On and after the Restatement Effective Date, if Janssen or its Affiliate or sublicensee is required, or [ * ] it necessary for Janssen or one of its Affiliates or sublicensees, to obtain a license from a Third Party under any Third Party Blocking Intellectual Property Rights in a country, Janssen (or its Affiliate or sublicensee) shall have the sole right to obtain such license. Such royalties and other consideration allocable to Licensed Compounds and Licensed Products will, unless otherwise agreed by the Parties, be subject to the royalty reduction provisions set forth in Section 7.5.2(a) during the License Term. On and after the Restatement Effective Date, Protagonist shall not obtain a license from a Third Party under any Third Party Blocking Intellectual Property Rights without Janssen&#8217;s prior written consent. For the avoidance of doubt, any rights or licenses which Protagonist obtains under Third Party Blocking Intellectual Property Rights as a result of a merger with or acquisition of a Third Party who had prior to such transaction obtained such Third Party Blocking Intellectual Property Rights shall not be deemed a violation of this Section 8.10.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.10.3.</font></font><font style="font-size:12pt;">To the extent (a) Protagonist obtains a license from a Third Party after the Original Execution Date under any Know-How or Patent Rights that (i) fall within the definition of Protagonist Know-How or Protagonist Patent Rights and (ii) are not Third Party Blocking Intellectual Property Rights and (b) the sublicensing of such Know-How or Patent Rights hereunder to Janssen triggers payments to such Third Party under such license agreement, they shall not be automatically sublicensed to Janssen hereunder as Protagonist Know-How or Protagonist Patent Rights unless and until Janssen and Protagonist agree on the appropriate allocation of any royalties or other consideration payable to such Third Party between those related to the use of such Know-How or Patent Rights for Licensed Compounds or Licensed Products under this Agreement and those related to the use of such Know-How or Patent Rights for any other products covered by such license. Such royalties and other consideration allocable to Licensed Compounds and Licensed Products will, unless otherwise agreed by the Parties, be shared in accordance with the principles set forth in Section 7.2 during the Development Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CONFIDENTIALITY; PUBLICITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">9.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nondisclosure</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.1.1.</font></font><font style="font-size:12pt;">Each Party agrees that, during the Term and for a period of [ * ] thereafter, the Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Receiving Party</b><font style="font-size:12pt;">&#8221;) receiving or holding Confidential Information of the other Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Disclosing Party</b><font style="font-size:12pt;">&#8221;) shall: (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value (but no less than</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">73</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">reasonable efforts); (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted in Sections 9.3 and 9.4; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Article 9 shall not create or imply any rights or licenses not expressly granted under this Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.1.2.</font></font><font style="font-size:12pt;">Notwithstanding the foregoing, prior to the start of the License Term (or if this Agreement is terminated prior to the start of the License Term, the effective date of termination of this Agreement), all Collaboration Information shall be deemed to be Confidential Information of each Party and each Party shall: (a) maintain in confidence all Collaboration Information using not less than the efforts such Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value (but no less than reasonable efforts); (b) not disclose any Collaboration Information to any Third Party without the prior written consent of the other Party, except for disclosures expressly permitted in Sections 9.3 and 9.4; and (c) not use any Collaboration Information for any purpose except those permitted by this Agreement (it being understood that this Article 9 shall not create or imply any rights or licenses not expressly granted under this Agreement), in each case ((a), (b) and (c)), regardless of which Party is the Disclosing Party and which Party is the Receiving Party with respect to such Collaboration Information. &#160;In addition, prior to the start of the License Term (or if this Agreement is terminated prior to the start of the License Term, the effective date of termination of this Agreement), neither Party shall grant any right to any Third Party with respect to any Collaboration Know-How except (i) either Party may grant such a right to a Third Party Subcontractor solely for use in conducting Collaboration Activities in accordance with this Agreement and (ii) Janssen may grant such a right to a Third Party Subcontractor solely for use in conducting Development activities in accordance with Section 3.4.3 or Janssen Independent Research Activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.1.3.</font></font><font style="font-size:12pt;">During the License Term, the Collaboration Information as defined in subsections (a)-(f) of Section 1.17 shall be deemed to be Confidential Information of Janssen for the purposes of this Article 9 and Janssen shall be deemed the Disclosing Party and Protagonist shall be deemed the Receiving Party with respect to such information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exceptions</b><font style="font-size:12pt;">. &#160;The obligations in Section 9.1 shall not apply to the extent of any portion of the Confidential Information that the Receiving Party can show by competent written evidence:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">is known to the Receiving Party or any of its Affiliates, without any obligation to the Disclosing Party to keep it confidential or any restriction on its use, prior to disclosure to the Receiving Party or any of its Affiliates by the Disclosing Party (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that this exception shall not apply to any Collaboration Information prior to the start of the License Term);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party&#8217;s knowledge</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">74</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">after due inquiry, is not bound by a duty of confidentiality to the Disclosing Party or restriction on its use;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates in violation of this Agreement, generally known or available, either before or after it is disclosed to the Receiving Party by the Disclosing Party; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the use of or reference to the Confidential Information of the Disclosing Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Authorized Disclosure</b><font style="font-size:12pt;">. &#160;The Receiving Party may disclose Confidential Information of the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances, or to the extent permissible under the other applicable provisions of this Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">filing, prosecuting, maintaining, enforcing or defending Patent Rights as permitted by this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">as reasonably required in generating Regulatory Documentation and filing for and obtaining Regulatory Approvals as permitted by this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">subject to Section 9.4, complying with Applicable Law (including regulations promulgated by securities exchanges) or court or administrative orders;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">complying with any obligation under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:12pt;">in communications with existing or bona fide prospective investors, consultants and advisors of the Receiving Party in connection with financing transactions or bona fide prospective financing transactions, in each case on a &#8220;need-to-know&#8221; basis and under a written agreement containing confidentiality provisions that are consistent with those set forth in this Agreement; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Third Party who receives Confidential Information pursuant to this Section 9.3(f); </font><i style="font-size:12pt;font-style:italic;">provided further, however, </i><font style="font-size:12pt;">that this Section 9.3(f) does not apply to the disclosure by Protagonist of Collaboration Information (other than the terms of this Agreement) during the Term (or, if the License Term commences, after the Term) to any bona fide prospective investor that is, or is an Affiliate of, a pharmaceutical or biotechnology company, except to the extent required and when required, in the reasonable opinion of Protagonist&#8217;s counsel, to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission or the Nasdaq Stock Market or similar security regulatory authorities or stock market in other countries or other Applicable Law;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">75</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:12pt;">to its Affiliates and existing or prospective (sub)licensees, subcontractors, consultants, agents and advisors on a &#8220;need-to-know&#8221; basis in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, each of whom prior to disclosure must be bound under a written agreement containing confidentiality provisions that are consistent with those set forth in this Agreement; </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Person who receives Confidential Information pursuant to this Section 9.3(g); and </font><i style="font-size:12pt;font-style:italic;">provided, further, however</i><font style="font-size:12pt;">, that this Section 9.3(g) does not apply to the disclosure by Protagonist of any Confidential Information of Janssen (other than the terms of this Agreement) during the Term (or, if the License Term commences, after the Term) to any prospective (sub)licensee that is, or is an Affiliate of, a pharmaceutical or biotechnology company; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:12pt;">by either Party to one or more Third Parties regarding an actual or potential Change of Control of such Party, each of whom prior to disclosure must be bound under a written agreement containing confidentiality provisions that are consistent with those set forth in this Agreement; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Person who receives Confidential Information pursuant to this Section 9.3(h); </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">further</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;"> that this Section 9.3(h) does not apply to the disclosure by Protagonist of Collaboration Information (other than the terms of this Agreement) during the Term (or, if the License Term commences, after the Term) to a Third Party that is, or is an Affiliate of, a pharmaceutical or biotechnology company unless and until such Third Party has provided Protagonist with a non-binding written proposal (including financial consideration) for such a transaction and Protagonist&#8217;s board of directors has determined to engage in negotiations with such Third Party with respect to such proposal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If and whenever any Confidential Information is disclosed in accordance with this Section 9.3, such disclosure shall not cause any such information to cease to be Confidential Information for purposes of this Agreement, except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement). &#160;Notwithstanding the foregoing, (x) in the event a Party intends to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 9.3(c) or Section 9.3(d), it will, except where impracticable or not legally permitted, give [ * ] advance notice (or, if [ * ] notice is not possible under the circumstances, reasonable advance notice) to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as it would to protect its own confidential information from disclosure (but no less than reasonable efforts); and (y) in the event Protagonist intends to make a disclosure of Collaboration Information or Janssen&#8217;s Confidential Information pursuant to Section 9.3(f), 9.3(g) or 9.3(h), it will give [ * ] notice of such disclosure to Janssen (which need not include the name of the party accessing Collaboration Information or Janssen&#8217;s Confidential Information or the nature of the transaction being contemplated).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Terms of this Agreement</b><font style="font-size:12pt;">. &#160;The Parties acknowledge and agree that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of each Party. &#160;In addition to the disclosures permitted under Section 9.3, either Party may disclose the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">76</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">terms of this Agreement and other information relating to this Agreement or the transactions contemplated by this Agreement to the extent required, in the reasonable opinion of such Party&#8217;s counsel, to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission or the Nasdaq Stock Market or similar security regulatory authorities or stock market in other countries. &#160;If a Party intends to disclose this Agreement or any of its terms or other such information in accordance with this Section 9.4, such Party will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure and seek confidential treatment of portions of this Agreement or such terms or information, as may be reasonably requested by the other Party in a timely manner. &#160;The Parties hereby consent to the disclosure of a copy of this Agreement to any tax authority by the other Party (1) upon &#160;receipt of any legally enforceable information request by such tax authority, (2) in compliance with any legally enforceable filing requirement, or (3) in connection with a submitted transfer pricing analysis. &#160;In the event of such disclosure, the disclosing Party will make reasonable efforts to ensure that the information is maintained in confidence by the applicable tax authority, including marking any disclosed document as confidential.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Public Announcements</b><font style="font-size:12pt;">. &#160;Except as required to comply with Applicable Law or as permitted by Section&#160;9.3 or 9.4, each Party agrees not to issue any press release or other public statement disclosing any information relating to this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. &#160;If a Party intends to issue such a press release or other public statement as required to comply with Applicable Law, such Party will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure. &#160;Notwithstanding the foregoing, once information relating this Agreement has been publicly disclosed as permitted under this Agreement, neither Party shall be required to obtain the other Party&#8217;s consent or provide notice of its further public disclosure, provided that such information remains accurate and not misleading in all material respects at the time of such further public disclosure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Requirement to Cooperate to Enable Accurate Public Disclosure</b><b style="font-size:12pt;font-weight:bold;">.</b><font style="font-size:12pt;"> &#160;To the extent either Party discloses to the other Party any Confidential Information which is a fact, result or event relating to the Development or Commercialization of any Licensed Compound or Licensed Product or the Collaboration Activities that the receiving Party in good faith reasonably believes is insufficient to allow the receiving Party to fully understand the materiality of such Confidential Information for purposes of determining whether the receiving Party is required to disclose, to any Governmental Authority or publicly, any such Confidential Information in order to comply with Applicable Law (including securities laws or regulations and the applicable rules of any public stock exchange), the Disclosing Party agrees to discuss such Confidential Information with the Receiving Party to enable the Receiving Party to assess the materiality of such information for such public disclosure purposes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Prior Non-Disclosure Agreement</b><font style="font-size:12pt;">. &#160;As of the Original Execution Date, the terms of this Article 9 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) dealing with the subject of this Agreement, including the Nondisclosure Agreement. &#160;Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">77</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.8.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Equitable Relief</b><font style="font-size:12pt;">. &#160;Given the nature of the Confidential Information and the competitive damage that may result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 9. &#160;In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 9.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.9.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Scientific Publications</b><font style="font-size:12pt;">. &#160;Either Party may make oral or written publications (such as any abstracts, manuscripts, posters, slide presentations or other materials) of any activities or results relating to a Licensed Compound or Licensed Product, </font><i style="font-size:12pt;font-style:italic;">provided </i><font style="font-size:12pt;">that (a) Janssen shall not have such right until the start of the License Term, except with Protagonist</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s prior written consent, which consent will not be unreasonably withheld, (b) the other Party shall first have the right to review and comment on a draft of any such material proposed for publication by such Party, including for purposes of ensuring that none of its Confidential Information is disclosed without its consent, and (c) such Party may not include any Confidential Information of the other Party in such publication without the other Party</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s prior written consent, which consent will not be unreasonably withheld. The publishing Party shall deliver a complete draft to the other Party at least [ * ] ([ * ] days in the case of abstracts) prior to submitting the material to a publisher or initiating any other release. The non-publishing Party shall review any such material and give its comments to the publishing Party within [ * ] ([ * ] in the case of abstracts) after the delivery of such draft to the non-publishing Party, and the publishing Party shall consider such comments in good faith. The publishing Party shall comply with the non-publishing Party</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s request to: delete from any such proposed publication material prior to its submission or release any references to the non-publishing Party or any of its Confidential Information; or delay any submission or release for a period of up to an additional [ * ] to permit the non-publishing Party to prepare and file, or have prepared and filed, any patent applications for any Collaboration Inventions as contemplated hereunder. For the avoidance of doubt, this Section 9.9 shall not apply to public disclosures required by Applicable Laws or the rules of the United States Securities and Exchange Commission or the Nasdaq Stock Market or similar security regulatory authorities or stock markets in other countries, as applicable, which are governed by Sections 9.4 and 9.5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.10.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Attorney-Client Privilege</b><b style="font-size:12pt;font-weight:bold;">.</b><font style="font-size:12pt;"> &#160;Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing information pursuant to this Agreement (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. &#160;The Parties: (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the Disclosing Party&#39;s Confidential Information covered by such protections and privileges relates; and (d) intend that after the Original Execution Date both the Receiving Party and the Disclosing Party shall have the right to assert such protections and privileges.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">78</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Mutual Representations and Warranties</b><font style="font-size:12pt;">. &#160;Each Party represents and warrants to the other Party that, as of the Original Execution Date and the Restatement Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.1.1.</font></font><font style="font-size:12pt;">it is duly organized and validly existing under the laws of its state or country of incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions of this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.1.2.</font></font><font style="font-size:12pt;">this Agreement has been duly executed by it and constitutes a legal, valid and binding obligation of it, enforceable in accordance with its terms;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.1.3.</font></font><font style="font-size:12pt;">the execution, delivery and performance of this Agreement by it does not conflict with any material agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any material law or regulation of any Governmental Authority having jurisdiction over it, subject to obtaining any required clearance of this Agreement under the HSR Act; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.1.4.</font></font><font style="font-size:12pt;">it has not granted any right to any Third Party that would conflict with the rights granted to the other Party under this Agreement, except as set forth in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 10.1.4</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Mutual Covenants</b><b style="font-size:12pt;font-weight:bold;">.</b><font style="font-size:12pt;"> &#160;Each Party covenants that it shall not grant, during the Term, any right to any Third Party that would conflict with the rights granted to the other Party under this Agreement (including by granting a license after the Original Execution Date to a Third Party under any intellectual property that is Controlled by the granting Party on the Original Execution Date that would conflict with the rights to such intellectual property granted to the other Party under this Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional Representations and Warranties of Protagonist</b><font style="font-size:12pt;">. &#160;Protagonist represents and warrants to Janssen that, as of the Original Execution Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 10.3.1</u><font style="font-size:12pt;"> lists all Patent Rights existing as of the Original Execution Date that are owned or licensed by Protagonist or any of its Affiliates and that include any claim Covering any Licensed Compound or Licensed Product (as it exists on the Original Execution Date), or its formulation, Manufacture or use, as each is contemplated as of the Original Execution Date (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Existing Protagonist Patents</b><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.2.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 10.3.2</u><font style="font-size:12pt;"> identifies any agreement existing as of the Original Execution Date between Protagonist or any of its Affiliates and a Third Party pursuant to which any Existing Protagonist Patents or Existing Protagonist Know-How are licensed to Protagonist or any of its Affiliates (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Existing Protagonist License Agreement</b><font style="font-size:12pt;">&#8221;); each Existing Protagonist License Agreement is in effect and is valid and binding on Protagonist or its Affiliate, enforceable in accordance with its terms, and neither Protagonist nor any of its Affiliates, nor to the knowledge of Protagonist, any other party thereto, is in material breach of, or material default under, any Existing Protagonist License Agreement, and no</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">79</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">event has occurred that, with the giving of notice or lapse of time or both, would constitute a material breach or material default by Protagonist or any of its Affiliates thereunder;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.3.</font></font><font style="font-size:12pt;">Protagonist or its Affiliate is the sole and exclusive owner or exclusive licensee of the Existing Protagonist Patents (as specified in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 10.3.1</u><font style="font-size:12pt;">) and is listed (or is in the process of becoming listed) in the records of the appropriate Governmental Authorities as the sole and exclusive owner of record, if applicable, for each registration, grant and application included in such Patent Rights, except as otherwise noted therein, and Protagonist is entitled to grant the licenses under such Patent Rights specified herein;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.4.</font></font><font style="font-size:12pt;">to the knowledge of Protagonist, Protagonist has the right to use and disclose and to enable Janssen to use and disclose (in each case under appropriate conditions of confidentiality) the Protagonist Know-How existing as of the Original Execution Date (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Existing Protagonist Know-How</b><font style="font-size:12pt;">&#8221;) to the extent that Janssen is granted the right to use and disclose such Existing Protagonist Know-How pursuant to this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.5.</font></font><font style="font-size:12pt;">neither Protagonist nor any of its Affiliates is subject to any royalty or other payment obligation to any Third Party with respect to the practice, or the grant of rights to Janssen to practice, any of the Existing Protagonist Know-How and Existing Protagonist Patents with respect to the Licensed Compounds or Licensed Products under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.6.</font></font><font style="font-size:12pt;">neither Protagonist nor any of its Affiliates has received written notice of any claim or threatened claim by any Third Party, and Protagonist is not otherwise aware, that (i) any Third Party has any rights to any of the Existing Protagonist Know-How or Existing Protagonist Patents, (ii) any of the Existing Protagonist Patents (to the extent representing issued Patent Rights) are invalid or unenforceable, or (iii) any research, Development or Manufacture of any Licensed Compound or Licensed Product by or on behalf of Protagonist or its Affiliate prior to the Original Execution Date infringed or misappropriated the intellectual property rights of such Third Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.7.</font></font><font style="font-size:12pt;">(i) to Protagonist&#8217;s knowledge, there are no pending actions, claims, investigations, suits or proceedings against Protagonist or any of its Affiliates, at law or in equity, or before or by any Regulatory Authority, and (ii) neither Protagonist nor any of its Affiliates has received any written notice regarding any pending or threatened actions, claims, investigations, suits or proceedings against Protagonist or any of its Affiliates, at law or in equity, or before or by any Regulatory Authority, in either case with respect to the Existing Protagonist Know-How or Existing Protagonist Patents, and (iii) to Protagonist&#8217;s knowledge, no Existing Protagonist Patent is the subject of any interference, opposition, cancellation or other protest proceeding;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.8.</font></font><font style="font-size:12pt;">all current and former officers, employees, agents, advisors, consultants, contractors or other representatives of Protagonist or any of its Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any Protagonist Intellectual Property have executed and delivered to Protagonist or any such Affiliate a valid and enforceable assignment or other agreement regarding the protection of proprietary information and the assignment (or exclusive license) to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">80</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">Protagonist or any such Affiliate of such Person&#8217;s entire right, title and interest in and to any Protagonist Intellectual Property and, to Protagonist&#8217;s knowledge, there are no current, potential or outstanding disputes between Protagonist and any party or individual with respect to the foregoing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.9.</font></font><font style="font-size:12pt;">to Protagonist&#8217;s knowledge, no current officer, employee, agent, advisor, consultant or other representative of Protagonist or any of its Affiliates is in violation of any term of any assignment, license, consulting, employment or other agreement regarding the protection of Protagonist Intellectual Property with Protagonist or any such Affiliate;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.10.</font></font><font style="font-size:12pt;">to the knowledge of Protagonist, there is no actual infringement of any Existing Protagonist Patents by any Third Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.11.</font></font><font style="font-size:12pt;">neither Protagonist nor any of its Affiliates, nor its or their employees, officers, directors, or agents, has been debarred by the FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.12.</font></font><font style="font-size:12pt;">Protagonist and its Affiliates have conducted Development activities with respect to the Licensed Compounds and Licensed Products in material compliance with Applicable Law and regulatory standards, including as applicable those relating to GLP, GCP, pharmacovigilance and safety reporting, and requirements for the protection of human subjects; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.3.13.</font></font><font style="font-size:12pt;">the peptide with the chemical structure set forth on </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Schedule 1.59</u><font style="font-size:12pt;"> is the peptide that Protagonist refers to internally as &#8220;PTG-200&#8221; and that has been the subject of preclinical testing (including IND-enabling studies) conducted by Protagonist and its Affiliates prior to the Original Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional Representations and Warranties of Janssen</b><font style="font-size:12pt;">. &#160;Janssen represents and warrants to Protagonist that, as of the Original Execution Date, neither Janssen nor any of its Affiliates, nor its or their employees, officers, directors, or agents, has been debarred by the FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. &#160;Janssen represents and warrants to Protagonist that, as of the Restatement Effective Date, the PTG-200 Clinical Development Plan attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:12pt;"> and the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Clinical Development Plan attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:12pt;"> (a) have received appropriate internal approvals by Janssen in its ordinary course of business based on the stage of the applicable product, (b) accurately reflect the Clinical Trials and key regulatory activities that Janssen plans, as of the Restatement Effective Date, to conduct with respect to the PTG-200 Product and the 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Products, respectively, for the Indications in the applicable Development Plan as of the Restatement Effective Date, and Janssen&#8217;s anticipated timelines for such Clinical Trials and activities, and (c) Janssen is not currently contemplating and has not engaged in any discussions regarding amending either Development Plan to materially eliminate, reduce, or delay any of the Clinical Trials or regulatory activities set forth in such Development Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">81</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional Representations, Warranties and Covenants</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.1.</font></font><b style="font-size:12pt;font-weight:bold;">Assignments</b><font style="font-size:12pt;">. Each Party shall ensure that each individual employee or agent performing Collaboration Activities or Janssen Independent Research Activities shall have entered into an agreement with such Party or its Affiliate prior to the performance of any work thereunder by such employee or agent providing for the assignment to such Party or its Affiliate of all inventions and discoveries, whether or not patentable, made or arising in the course of the performance of such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.2.</font></font><b style="font-size:12pt;font-weight:bold;">Healthcare Compliance</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><i style="font-size:12pt;font-style:italic;">Anti-Kickback and Stark Compliance</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party represents and warrants to the other Party as of the Original Execution Date that the Party making such representation and warranty and its Affiliates that are or have been involved in the Development, Manufacturing and Commercialization of Licensed Compounds and Licensed Products are in compliance with all applicable state and federal laws, rules and regulations, including the federal anti-kickback statute (42 U.S.C. &#167; 1320a-7b), the related safe harbor regulations, and the Limitation on Certain Physician Referrals, also referred to as the &#8220;Stark Law&#8221; (42 U.S.C. &#167; 1395nn)(collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Anti-Kickback Laws</b><font style="font-size:12pt;">&#8221;) in connection with its activities under this Agreement. &#160;Protagonist represents and warrants to Janssen as of the Original Execution Date that it has complied with the foregoing in connection with its activities with respect to Licensed Compounds and Licensed Products prior to the Original Execution Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party covenants to the other Party that the Party making such covenant and its Affiliates involved in the Development, Manufacturing and Commercialization of Licensed Compounds and Licensed Products will comply with all Anti-Kickback Laws in connection with its activities under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">No part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services, nor are the payments intended to induce illegal referrals of business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><i style="font-size:12pt;font-style:italic;">Exclusion from Federal Health Care Programs</i><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Protagonist represents and warrants to Janssen that it and its Affiliates have conducted their respective activities with respect to the Licensed Compounds and Licensed Products prior to the Original Execution Date, in accordance with applicable state and federal laws and any applicable regulations regarding Medicare, Medicaid, and other third party-payer programs, if any.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">82</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party shall conduct its activities pursuant to this Agreement, in accordance with applicable state and federal laws and any applicable regulations regarding Medicare, Medicaid, and other third party-payer programs, if any.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party represents and warrants to the other Party, as of the Original Execution Date, that (A) it is not excluded from, and has not been convicted of any crime or engaged in any conduct that could result in exclusion from, participation in any state or federal healthcare program, as defined in 42 U.S.C. &#167;1320a-7b(f), for the provision of items or services for which payment may be made by a federal healthcare program; and (B) it has not contracted with any employee, contractor, agent, or vendor to perform work under this Agreement who is excluded from participation in any state or federal healthcare program, and in the case of Protagonist, did not contract with any employee, contractor, agent, or vendor to perform work relating to the Licensed Compounds and Licensed Products prior to the Original Execution Date who was excluded from participation in any state or federal healthcare program. Protagonist represents and warrants to Janssen, as of the Original Execution Date, that it did not contract with any employee, contractor, agent, or vendor to perform work relating to the Licensed Compounds and Licensed Products prior to the Original Execution Date who was excluded from participation in any state or federal healthcare program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party represents and warrants to the other Party, as of the Original Execution Date, that it is not subject to a final adverse action, as defined in 42 U.S.C.&#167; 1320a-7a(e) and 42 U.S.C. &#167; 1320a-7a(g), and has no adverse action pending or threatened against it.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(5)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party shall notify the other Party of any final adverse action, discovery of contract with an excluded entity or individual, or exclusion within [ * ] of such action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.3.</font></font><b style="font-size:12pt;font-weight:bold;">No Debarred Individuals</b><font style="font-size:12pt;">. &#160;Each Party agrees that it shall not engage, in any capacity in connection with this Agreement, any Person who has been debarred by FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. &#160;Each Party shall promptly inform the other Party in writing if such Party or any Person performing activities under this Agreement on such Party&#8217;s behalf is debarred or is the subject of a conviction described in 21 U.S.C. 335a, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or threatened relating to the debarment of conviction of such Party or any such Person performing activities in connection with this Agreement on such Party&#8217;s behalf. &#160;Upon written request from the other Party, a Party shall, within [ * ], provide written confirmation that it has complied with the foregoing obligation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.4.</font></font><b style="font-size:12pt;font-weight:bold;">Anti-Corruption Laws</b><font style="font-size:12pt;">. &#160;Neither a Party nor any of its Affiliates shall perform any actions in connection with this Agreement that are prohibited by local and other anti-</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">83</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">corruption laws (collectively &#8220;</font><b style="font-size:12pt;font-weight:bold;">Anti-Corruption Laws</b><font style="font-size:12pt;">&#8221;) that may be applicable to such Party, and in the case of Protagonist, Protagonist represents and warrants to Janssen that neither Protagonist nor any of its Affiliates has performed any actions in connection with the Licensed Compounds and Licensed Products prior to the Original Execution Date that are prohibited by Anti-Corruption Laws that were applicable to Protagonist or its Affiliates. &#160;Without limiting the foregoing, neither Party nor any of its Affiliates shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other Third Party related to the transactions contemplated by this Agreement in a manner that would violate Anti-Corruption Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.5.5.</font></font><b style="font-size:12pt;font-weight:bold;">Existing Protagonist License Agreements</b><font style="font-size:12pt;">. &#160;Protagonist shall not amend any Existing Protagonist License Agreement in any manner that would adversely affect any rights granted to Janssen hereunder, except with Janssen&#8217;s prior written consent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Disclaimer of Warranties</b><font style="font-size:12pt;">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ANY OF ITS AFFILIATES MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE LICENSED COMPOUNDS, LICENSED PRODUCTS OR PATENT RIGHTS THAT ARE LICENSED OR TRANSFERRED TO THE OTHER PARTY UNDER THIS AGREEMENT, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. &#160;NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT ANY OF THE DEVELOPMENT, MANUFACTURING OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY LICENSED COMPOUND OR LICENSED PRODUCT WILL BE SUCCESSFUL.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INDEMNIFICATION AND INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Indemnification</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.1.1.</font></font><b style="font-size:12pt;font-weight:bold;">Indemnification by Janssen</b><font style="font-size:12pt;">. &#160;Subject to Section 11.2, Janssen shall defend, indemnify and hold harmless Protagonist and each of its Affiliates, and each of its and their directors, officers, employees and agents (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Protagonist Indemnified Party</b><font style="font-size:12pt;">&#8221;) from and against any and all damages, losses, liabilities, judgments, fines, amounts paid in settlement, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Losses</b><font style="font-size:12pt;">&#8221;) incurred by any Protagonist Indemnified Party resulting from any claim, action or proceeding brought or initiated by a Third Party (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party Claim</b><font style="font-size:12pt;">&#8221;) against a Protagonist Indemnified Party, to the extent that such Losses arise out of or relate to, directly or indirectly:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">the breach by Janssen of any of its representations, warranties, covenants, or obligations set forth herein;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">the negligence, recklessness or wrongful intentional acts or omissions of any Janssen Indemnified Party; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">84</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">the Development, Manufacture or Commercialization of any Licensed Compound or Licensed Product by or on behalf of Janssen or any of its Affiliates on or after the Original Effective Date and during the Term (or any post-termination or post-expiration period pursuant to Section 12.5);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">except, in each case ((a) through (c)), to the extent such Losses arise directly or indirectly from (i) the breach by Protagonist of any of its representations, warranties, covenants, or obligations set forth herein, (ii) the negligence, recklessness or wrongful intentional acts or omissions of any Protagonist Indemnified Party, or (iii)&#160; </font><font style="font-size:12pt;">the Development, Manufacture or Commercialization of any Licensed Compound or Licensed Product by or on behalf of Protagonist or any of its Affiliates prior to the Original Effective Date or during any post-termination or post-expiration period pursuant to Section 12.5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.1.2.</font></font><b style="font-size:12pt;font-weight:bold;">Indemnification by Protagonist</b><font style="font-size:12pt;">. &#160;Subject to Section 11.2, Protagonist shall defend, indemnify and hold harmless Janssen and each of its Affiliates, and each of its and their directors, officers, employees and agents (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Janssen Indemnified Party</b><font style="font-size:12pt;">&#8221;), from and against any and all Losses incurred by any Janssen Indemnified Party resulting from any Third Party Claim against a Janssen Indemnified Party, to the extent that such Losses arise out of or relate to, directly or indirectly:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">the breach by Protagonist of any of its representations, warranties, or covenants or obligations set forth herein;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">the negligence, recklessness or wrongful intentional acts or omissions of any Protagonist Indemnified Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">the Development, Manufacture or Commercialization of any Licensed Compound or Licensed Product by or on behalf of Protagonist or any of its Affiliates prior to the Original Effective Date or during any post-termination or post-expiration period pursuant to Section 12.5, or the Development or Manufacture of any Licensed Compound or Licensed Product by or on behalf of Protagonist or any of its Affiliates during the Development Term; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">the research, development, manufacture or commercialization of any Retained Compound by or on behalf of Protagonist or any of its Affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">except, in each case ((a) through (d)), to the extent such Losses arise directly or indirectly from (i) the breach by Janssen of any of its representations, warranties, covenants, or obligations set forth herein, (ii) the negligence, recklessness or wrongful intentional acts or omissions of any Janssen Indemnified Party, or (iii) the Development, Manufacture or Commercialization of any Licensed Compound or Licensed Product by or on behalf of Janssen or any of its Affiliates on or after the Original Effective Date and during the Term (or any post-termination or post-expiration period pursuant to Section 12.5).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Conditions to Indemnification</b><font style="font-size:12pt;">. &#160;If either a Janssen Indemnified Party or a Protagonist Indemnified Party (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnified Party</b><font style="font-size:12pt;">&#8221;) intends to seek indemnification under Section 11.1, the Indemnified Party must: (a) give the other Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnifying Party</b><font style="font-size:12pt;">&#8221;) reasonably</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">85</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">prompt written notice upon becoming aware of any Third Party Claim with respect to which such Indemnified Party intends to seek indemnification; (b) reasonably cooperate with the Indemnifying Party at the Indemnifying Party&#8217;s request and expense, in the defense or settlement of the claim; and (c) give the Indemnifying Party the right to control the defense or settlement of the claim, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the Indemnifying Party will not enter into any settlement that adversely affects the Indemnified Party&#8217;s rights or obligations without the Indemnified Party&#8217;s prior express written consent, which will not be unreasonably withheld, conditioned or delayed. &#160;The Indemnified Party may participate in the defense or settlement of any such claim at its own expense with counsel of its choosing. &#160;Notwithstanding the foregoing, any failure of the Indemnified Party to comply with the provisions of clause&#160;(a) of this Section 11.2 will not relieve the Indemnifying Party of any defense or indemnity obligations under this Agreement except to the extent that the Indemnifying Party is prejudiced by such failure. &#160;So long as the Indemnifying Party is actively defending such Third Party Claim in good faith, the Indemnified Party shall not settle any such claim without the prior written consent of the Indemnifying Party. &#160;If the Indemnifying Party does not assume and conduct the defense of the claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this Article 11.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LIMITATIONS OF LIABILITY</b><font style="font-size:12pt;">. &#160;EXCEPT TO THE EXTENT INCLUDED IN LOSSES RESULTING FROM A THIRD PARTY CLAIM FOR WHICH ONE PARTY IS OBLIGATED TO INDEMNIFY THE OTHER PARTY (OR AN INDEMNIFIED PARTY OF SUCH OTHER PARTY) PURSUANT TO THIS Article 11 OR ANY BREACH OF Article 9 (CONFIDENTIALITY), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#8217;S AFFILIATES OR (SUB)LICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY (INCLUDING FOR LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE OR DAMAGE TO GOODWILL TO THE EXTENT THEY CONSTITUTE CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES DAMAGES), INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Insurance</b><font style="font-size:12pt;">. &#160;Each Party shall, at its own expense, procure and maintain during the Term and for a period of five (5) years thereafter, insurance policies, including product liability insurance, adequate to cover the activities to be conducted by it and its obligations under this Agreement and which are consistent with normal business practices of prudent companies similarly situated; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that in no event shall such product liability insurance be written in amounts less than USD $[ * ] per claim or per occurrence and annual aggregate. All such insurance shall include worldwide coverage. &#160;Prior to the initiation of any clinical trial of a Licensed Compound or Licensed Product, the Party responsible for such clinical trial shall secure, and maintain in full force and effect, clinical trial insurance as required by Applicable Law in those territories where such clinical trial shall be conducted. &#160;Upon request, each Party shall provide the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">86</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">other Party with a certificate of insurance evidencing the coverage required under this Section 11.4. &#160;Such insurance shall not be construed to create a limit of a Party&#8217;s liability with respect to its obligations under this Agreement. &#160;Each Party shall provide the other Party with prompt written notice of cancellation, non-renewal or material change in such insurance that could materially adversely affect the rights of such other Party hereunder, and shall provide such notice within [ * ] after any such cancellation, non-renewal or material change. &#160;Notwithstanding the foregoing, either Party&#8217;s failure to maintain adequate insurance shall not relieve that Party of its obligations set forth in this Agreement. &#160;The Parties acknowledge and agree that Janssen may meet its obligations under this Section 11.4 through self-insurance consistent with the levels set forth herein with prior written notice to Protagonist. &#160;In such event, Janssen shall provide a written certification of such self-insurance to Protagonist from upon request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 12</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Term</b><font style="font-size:12pt;">. &#160;The combined term of the Original Agreement, the Existing Agreement and this Agreement (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Term</b><font style="font-size:12pt;">&#8221;) commenced on the Original Execution Date and, unless this Agreement is terminated earlier in accordance with this Article 12, will expire upon expiration of all of the payment obligations under Article 7 with respect to Licensed Products Developed and/or Commercialized by Janssen pursuant to this Agreement. &#160;This Agreement has been executed by the Parties as of the Restatement Effective Date, with the Parties&#8217; mutual intent that on the Restatement Effective Date, the Existing Agreement shall be amended and restated in its entirety as set forth in, and thereupon superseded by, this Agreement. &#160;For clarity, except as expressly provided in Section 7.2, the terms and conditions of the Original Agreement apply to the period between the Original Execution Date and May 7, 2019, and the terms and conditions of the Existing Agreement apply to the period between May 7, 2019 and the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Termination by Janssen Without Cause</b><font style="font-size:12pt;">. &#160;Janssen may terminate this Agreement in its entirety at any time without cause by providing [ * ] prior written notice to Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Termination for Material Breach</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.3.1.</font></font><font style="font-size:12pt;">A Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Terminating Party</b><font style="font-size:12pt;">&#8221;) may terminate this Agreement in its entirety if the other Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Breaching Party</b><font style="font-size:12pt;">&#8221;) has materially breached this Agreement and such material breach has not been cured within [ * ] (or, if the basis of such material breach is failure to make payment, [ * ]) after written notice of such breach is given by the Terminating Party to the Breaching Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Cure Period</b><font style="font-size:12pt;">&#8221;). &#160;The written notice describing the alleged material breach shall provide sufficient detail to put the Breaching Party on notice of such material breach. Any termination of this Agreement pursuant to this Section 12.3.1 shall become effective at the end of the Cure Period unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period. &#160;Notwithstanding the foregoing, if such breach (other than a breach of payment obligations) is capable of being cured but is not reasonably able to be cured within the Cure Period, such termination shall not become effective until the earlier of the date such breach is cured or [ * ] after notice of termination is given pursuant to this Section 12.3.1, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that (a) the Breaching Party notifies the other Party of its plan for curing such breach during the Cure Period, (b) the Breaching Party commences such plan during the Cure Period and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">87</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(c) the Breaching Party uses diligent efforts to perform such plan and cure such breach as soon as reasonably practicable. &#160;The right of either Party to terminate this Agreement as provided in this Section 12.3.1 shall not be affected in any way by such Party&#8217;s waiver of or failure to take action with respect to any previous breach under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.3.2.</font></font><font style="font-size:12pt;">If the Parties reasonably and in good faith disagree as to whether there has been a material breach or a cure thereof, the Party that disputes whether there has been a material breach or a cure may contest the allegation in accordance with Article 13. &#160;Notwithstanding anything to the contrary contained in Section 12.3.1, the Cure Period for any material breach that is the subject of a Dispute will run from the date that written notice was first given to the Breaching Party by the Terminating Party through the resolution of such Dispute pursuant to Article 13 and for [ * ] thereafter, and no termination pursuant to Section 12.3.1 shall become effective during such period. &#160;During the pendency of such Dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the Parties&#8217; performance of their respective obligations and exercise of their respective rights hereunder that specify a date by which such obligations must be performed or such rights must be exercised shall be tolled through the resolution of such Dispute pursuant to Article 13 and for 10 days thereafter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Termination for Bankruptcy</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.4.1.</font></font><b style="font-size:12pt;font-weight:bold;">Right to Terminate</b><font style="font-size:12pt;">. &#160;A Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files a voluntary petition in bankruptcy, consents to an order for relief in connection with an involuntary petition in bankruptcy filed against such Party (or an involuntary petition in bankruptcy filed against such Party remains un-dismissed or un-stayed for a period of more than [ * ]), petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Insolvency Event</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.4.2.</font></font><b style="font-size:12pt;font-weight:bold;">Provisions for Insolvency</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">All rights and licenses now or hereafter granted by either Party to the other Party under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Janssen pursuant to Section 6.1 are, for all purposes of Section 365(n) of Title 11 of the United States Code, as amended (such Title 11, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Bankruptcy Code</b><font style="font-size:12pt;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in the Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to a Party, such Party agrees that the other Party, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">88</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Without limiting the generality of the foregoing, Protagonist and Janssen intend and agree that any sale of the Protagonist Intellectual Property licensed hereunder under Section 363 of the Bankruptcy Code shall be subject to Janssen&#8217;s rights under Section 365(n), that Janssen cannot be compelled to accept a money satisfaction of its interests in the intellectual property licensed pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser &#8220;free and clear&#8221; of Janssen&#8217;s rights under this Agreement and Section 365(n) without the express, contemporaneous consent of Janssen. &#160;Further, each Party agrees and acknowledges that all payments by Janssen to Protagonist hereunder, other than the royalty payments pursuant to Section 7.5, the Milestone Payments pursuant to Section 7.3 and the Sales Milestone Payments pursuant to Section 7.4, the allocation of recoveries under Section 8.5.6 and reimbursements for amounts paid under Third Party Blocking Intellectual Property Rights licenses pursuant to Section 8.10, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">Protagonist shall, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all Protagonist Intellectual Property licensed hereunder, in accordance with Section 3.5.3. &#160;Protagonist and Janssen acknowledge and agree that &#8220;embodiments&#8221; of intellectual property within the meaning of Section 365(n) include [ * ]. &#160;The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Protagonist under the Bankruptcy Code and any similar laws in any other country in the Territory, Janssen will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in Janssen&#8217;s or its Affiliates&#8217; possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Protagonist elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of Protagonist upon written request therefor by Janssen. &#160;Whenever Protagonist or any of its successors or assigns provides to Janssen any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 12.4.2, Janssen shall have the right to perform Protagonist&#8217;s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by Janssen shall release Protagonist from liability resulting from rejection of the license or the failure to perform such obligations. &#160;Protagonist (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall not interfere with Janssen&#8217;s rights under this Agreement, or any agreement supplemental hereto, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the Bankruptcy Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">All rights, powers and remedies of Janssen provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">89</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">hereafter existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code with respect to Protagonist. The Parties agree that they intend the following rights to extend to the maximum extent permitted by law, and to be enforceable under Bankruptcy Code Section 365(n):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">the right of access to any intellectual property (including all embodiments thereof) of Protagonist licensed to Janssen pursuant to Section 6.1, or any Third Party with whom Protagonist contracts to perform an obligation of Protagonist under this Agreement, and, in the case of the Third Party, which is necessary for the manufacture, use, sale, import or export of Licensed Compounds and Licensed Products; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">the right to contract directly with any Third Party to complete the contracted work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Effects of Termination or Expiration</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.5.1.</font></font><b style="font-size:12pt;font-weight:bold;">Effects of Termination</b><font style="font-size:12pt;">. &#160;If this Agreement is terminated for any reason, then the provisions of this Section 12.5.1 shall apply.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">The licenses and other rights granted to Janssen under this Agreement, other than those that expressly survive termination of this Agreement (including the license granted pursuant to Section 6.1.4), shall terminate on the effective date of termination, except as expressly provided in Section 7.5.3 or to the extent necessary to enable Janssen to perform any of its obligations that survive termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Janssen shall have no further obligation to commence new Development activities with respect to a Licensed Compound or Licensed Product after the date of notice of termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">If this Agreement is terminated by Janssen during the conduct of the PTG-200 Phase 2A Activities or any other Phase 2 Clinical Trial of PTG-200 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Ongoing PTG-200 Phase 2 Activities</b><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">), Protagonist shall have [ * ] after the date that Janssen notifies Protagonist of termination to notify Janssen (i) whether Protagonist elects to have Janssen complete or wind down any such Ongoing PTG-200 Phase 2 Activities (other than CMC Development activities), and (ii) whether Protagonist elects to have Janssen wind down or transfer to Protagonist any such ongoing CMC Development activities. Notwithstanding the foregoing, if Janssen terminates this Agreement pursuant to Section 12.3 or 12.4, then Protagonist shall not have the right to make the election described in this paragraph and Janssen shall wind down any ongoing activities as soon as practicable after the date of notice of termination. The following provisions of this Section 12.5.1(c) shall apply after Protagonist makes such elections.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist elects to have Janssen wind down Ongoing PTG-200 Phase 2 Activities, then Janssen shall wind-down such activities as soon as</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">90</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">practicable, subject to compliance with ethical and legal requirements, and the Parties shall continue to share the costs of such activities in accordance with Section 7.2 until such wind-down is complete.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist elects to have Janssen complete Ongoing PTG-200 Phase 2 Activities (other than CMC Development activities), then (x) Janssen shall continue to conduct such activities in accordance with Article 3, (y) Protagonist shall be responsible for all of the Development Costs for such activities incurred after the effective date of termination, except that [ * ] of the Development Costs incurred within the after the effective date of termination, and (z) Article 2, Article 3, Article 6 and Section 10.5 shall survive to the extent applicable to, or necessary to conduct, such activities, until such activities are complete.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist elects to have Janssen transfer to Protagonist on-going CMC Development activities that are Ongoing PTG-200 Phase 2 Activities, then Janssen shall use Commercially Reasonable Efforts to transfer, and Protagonist shall use Commercially Reasonable Efforts to assume, such activities as promptly as practicable (and, in any event, within [ * ] after the effective date of termination). The Parties shall continue to share the costs of such activities in accordance with Section 7.2 until the effective date of termination and, thereafter, the costs of such activities shall be borne solely by Protagonist; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that each Party shall bear its own costs associated with the transfer of such CMC Development activities from Janssen to Protagonist. Protagonist shall reimburse Janssen for any such costs for which Protagonist is solely responsible incurred by Janssen and its Affiliates after the effective date of termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">If this Agreement is terminated for any reason &#160;and Janssen is conducting any Development activity with respect to a Licensed Compound or Licensed Product on the date of notice of termination (other than any Ongoing PTG-200 Phase 2 Activities, in which case Section 12.5.1(c) shall apply), then Protagonist shall notify Janssen within [ * ] after the notice of termination: (i)&#160;with regard to any Clinical Trial, whether Protagonist elects to have Janssen (A) complete such Clinical Trial on behalf of Protagonist (unless Janssen has material safety concerns regarding continuation of such Clinical Trial of which it has notified Protagonist in writing), (B) wind down such Clinical Trial as soon as practicable, subject to compliance with ethical and legal requirements or (C) transfer such Clinical Trial to Protagonist as soon as practicable; and (ii)&#160;with regard to any other Development activity, whether Protagonist elects to have Janssen wind down or transfer such activity to Protagonist. &#160;Notwithstanding the foregoing, if Janssen terminates this Agreement pursuant to Section 12.3 or 12.4, then Protagonist shall not have the right to make the election described in this paragraph and Janssen shall wind down any ongoing Development activities as soon as practicable after the date of notice of termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(1)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist notifies Janssen of its election to have Janssen complete a Clinical Trial on behalf of Protagonist, Janssen and Protagonist</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">91</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">will negotiate in good faith a separate agreement pursuant to which Janssen would complete such Clinical Trial. &#160;If the Parties fail to reach agreement within [ * ] after Protagonist makes such election, Janssen may wind down such Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(2)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist notifies Janssen of its election to have Janssen wind down such Clinical Trial or other Development activity (or fails to provide notice within such [ * ] period), then Janssen shall wind-down such Clinical Trial or Development activity as soon as practicable, subject to compliance with ethical and legal requirements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(3)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">If Protagonist notifies Janssen of its election to have Janssen transfer such Clinical Trial or other Development activity to Protagonist, then Janssen shall use Commercially Reasonable Efforts to transfer, and Protagonist shall use Commercially Reasonable Efforts to assume, such Clinical Trial or other Development activity as promptly as practicable (and, in any event, within [ * ]) after the effective date of termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(4)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The costs of any such Development activity (other than a Clinical Trial with respect to which the Parties enter into a separate agreement pursuant to Section 12.5.1(d)(1)) shall be borne solely by Janssen until the effective date of termination (or, with respect to the wind-down of a Clinical Trial, through the completion of such Clinical Trial), and thereafter shall be borne solely by Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">(5)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Each Party shall bear its own costs associated with the transfer of any such Development activity from Janssen to Protagonist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:12pt;">Janssen shall, within [ * ] after the effective date of termination and at Janssen&#8217;s expense, return or destroy, at Protagonist&#8217;s election, all Protagonist Know-How and other Confidential Information of Protagonist (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that (i)&#160;Janssen may keep one copy of such Confidential Information subject to an ongoing obligation of confidentiality for archival purposes only, (ii)&#160;it is acknowledged that, with regard to any such Confidential Information disclosed to subcontractors, consultants, agents, advisors and other Third Parties as permitted by Section&#160;9.3, Janssen&#8217;s use of Commercially Reasonable Efforts to return or destroy such Confidential Information shall satisfy its obligation under this Section&#160;12.5.1(e), and (iii)&#160;Janssen may retain and continue to use Protagonist Know-How and other Confidential Information of Protagonist solely to practice any licenses and other rights granted to Janssen under this Agreement that expressly survive expiration or termination of this Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:12pt;">Janssen shall, and hereby does, assign to Protagonist, as of the effective date of termination, all its right, title and interest in, to and under all of Janssen&#8217;s and its Affiliates&#8217; ownership interest in any Regulatory Documentation solely related to the Licensed Compounds and Licensed Products, including any Regulatory Approvals for the Licensed Compounds and Licensed Products, and Janssen shall transfer all</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">92</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:12pt;">such Regulatory Documentation to Protagonist promptly after the effective date of termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:12pt;">Janssen shall, and hereby does, grant to Protagonist, as of the effective date of termination, on behalf of Janssen and its Affiliates, an exclusive (even as to Janssen and its Affiliates), perpetual, royalty-free, freely sublicensable through multiple tiers, transferable license under the Janssen Collaboration Know-How, Janssen Collaboration Patent Rights, and Janssen&#8217;s interest in the Joint Collaboration Patent Rights, whether related to the Initial Compound, any Initial Product, any 2</font><sup style="font-size:9pt;vertical-align:top;">nd </sup><font style="font-size:12pt;">Generation Compound or any 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Generation Product, solely to the extent necessary to Develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit, Manufacture and Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:12pt;">At Protagonist&#8217;s request, Janssen shall assign and transfer to Protagonist any inventory of Licensed Compounds or Licensed Products then in Janssen&#8217;s or any of its Affiliate&#8217;s possession or control subject to Protagonist&#8217;s reimbursement of Janssen&#8217;s reasonable, documented costs incurred in acquiring such inventory and with respect to shipping thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:12pt;">Subject to Section 6.1.4, all Collaboration Information as defined in subsections (a)-(f) of Section 1.17 that is licensed, assigned or transferred to Protagonist pursuant to this Section 12.5.1 shall be deemed to be Confidential Information of Protagonist for the purposes of Article 9 and Protagonist shall be deemed the Disclosing Party and Janssen shall be deemed the Receiving Party with respect to such information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:12pt;">Janssen shall take such other actions, and execute any instruments, assignments and documents, as reasonably requested by Protagonist as may be necessary to effect the foregoing provisions of this Section 12.5.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.5.2.</font></font><b style="font-size:12pt;font-weight:bold;">Janssen Confidential Information</b><font style="font-size:12pt;">. &#160;Protagonist shall, within [ * ] after the effective date of expiration or termination of this Agreement, and at Protagonist&#8217;s expense, return or destroy, at Janssen&#8217;s election, all Confidential Information of Janssen (</font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that (i)&#160;Protagonist may keep one copy of such Confidential Information subject to an ongoing obligation of confidentiality for archival purposes only, (ii)&#160;it is acknowledged that, with regard to any such Confidential Information disclosed to subcontractors, consultants, agents, advisors and other Third Parties as permitted by Section&#160;9.3, Protagonist&#8217;s use of Commercially Reasonable Efforts to return or destroy such Confidential Information shall satisfy its obligation under this Section&#160;12.5.2, and (iii)&#160;Protagonist may retain and continue to use Confidential Information of Janssen to practice any licenses and other rights granted to Protagonist under this Agreement that expressly survive expiration or termination of this Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.5.3.</font></font><b style="font-size:12pt;font-weight:bold;">Additional Effects of Expiration or Termination for any Reason</b><font style="font-size:12pt;">. &#160;Termination or expiration of this Agreement will not relieve the Parties of any obligations accruing prior</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">93</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">to such expiration or termination, and any such expiration or termination will be without prejudice to the rights of either Party accruing prior to such expiration or termination. &#160;The Parties acknowledge and agree that termination of this Agreement is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain available except as expressly agreed to otherwise herein. The provisions of Sections 3.5.3(a), 4.5, 6.1.4, 6.3.2 (3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> sentence only), 6.3.3 (last sentence only), 6.6, 7.2 (solely with respect to Development Costs incurred prior to the effective date of expiration or termination), 7.5 (solely with respect to Net Sales occurring prior to the effective date of such expiration or termination), 7.6, 7.7, 7.8, 8.1, 8.2, 12.1 (last sentence only), 12.4.2(a) (solely with respect to the license granted pursuant to Section 6.1.4) and 12.5, and Articles 9, 11, 13, and 14 shall survive expiration or termination of this Agreement for any reason.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 13</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">DISPUTE RESOLUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Escalation; Decision-Making Authority</b><font style="font-size:12pt;">. &#160;In the case of any dispute, claim or controversy between the Parties arising from or related to this Agreement, or the interpretation, application, breach, termination or validity of this Agreement (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Dispute</b><font style="font-size:12pt;">&#8221;), the Parties will discuss and negotiate in good faith a solution acceptable to the Parties and in the spirit of this Agreement. &#160;If, after negotiating in good faith pursuant to the foregoing sentence, the Parties fail to reach agreement within [ * ] (or such longer period as agreed in writing by the Parties), then the Dispute may be referred to the Executive Officers for resolution at the request of either Party. &#160;If, after negotiating in good faith, the Executive Officers fail to reach agreement within [ * ] of submission to the Executive Officers (or such longer period as agreed in writing by the Parties), then either Party may upon written notice to the other submit the Dispute to non-binding mediation pursuant to Section&#160;13.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Mediation</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.2.1.</font></font><font style="font-size:12pt;">If the Parties fail to resolve the Dispute pursuant to Section&#160;13.1, the Parties shall attempt in good faith to resolve any Dispute by confidential mediation in accordance with the then current </font><i style="font-size:12pt;font-style:italic;">Mediation Procedure of the International Institute for Conflict Prevention and Resolution</i><font style="font-size:12pt;"> (&#8220;</font><b style="font-size:12pt;font-weight:bold;">CPR Mediation Procedure</b><font style="font-size:12pt;">&#8221;) (www.cpradr.org) before initiating arbitration. The CPR Mediation Procedure shall control, except where it conflicts with these provisions, in which case these provisions control. The mediator shall be chosen pursuant to CPR Mediation Procedure. The mediation shall be held in [ * ].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.2.2.</font></font><font style="font-size:12pt;">Either Party may initiate mediation by written notice to the other Party of the existence of a Dispute. The Parties agree to select a mediator within [ * ] of the notice and the mediation will begin promptly after the selection. The mediation will continue until the mediator, or either Party, declares in writing, no sooner than after the conclusion of one full day of a substantive mediation conference attended on behalf of each Party by a senior business person with authority to resolve the Dispute, that the Dispute cannot be resolved by mediation. In no event, however, shall mediation continue more than [ * ] from the initial notice by a Party to initiate meditation unless the Parties agree in writing to extend that period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">94</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.2.3.</font></font><font style="font-size:12pt;">Any period of limitations that would otherwise expire between the initiation of mediation and its conclusion shall be extended until [ * ] after the conclusion of the mediation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Arbitration</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.1.</font></font><font style="font-size:12pt;">If the Parties fail to resolve the Dispute pursuant to Section&#160;13.1 or Section 13.2, and a Party desires to pursue resolution of the Dispute, subject to Section&#160;13.3.10, the Dispute shall be finally resolved by arbitration in accordance with the then current </font><i style="font-size:12pt;font-style:italic;">CPR Rules for Non-Administered Arbitration Rules </i><font style="font-size:12pt;">(&#8220;</font><b style="font-size:12pt;font-weight:bold;">CPR Rules</b><font style="font-size:12pt;">&#8221;) (www.cpradr.org), except where they conflict with these provisions, in which case these provisions control. The place of arbitration shall be [ * ]. All aspects of the arbitration shall be treated as confidential.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.2.</font></font><font style="font-size:12pt;">The arbitrators will be chosen from the CPR Panel of Distinguished Neutrals, unless a candidate not on such panel is approved by both Parties. Each arbitrator shall be a lawyer with at least [ * ] experience with a law firm or corporate law department of over [ * ] or who was a judge of a court of general jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.3.</font></font><font style="font-size:12pt;">The arbitration tribunal shall consist of three (3) arbitrators, of whom each Party shall designate one in accordance with the &#8220;screened&#8221; appointment procedure provided in CPR Rule 5.4. &#160;The chair will be chosen in accordance with CPR Rule 6.4. &#160;If, however, the aggregate award sought by the Parties is less than [ * ] U.S. Dollars ($[ * ]) and equitable relief is not sought, a single arbitrator shall be appointed in accordance with the CPR Rules. Candidates for the arbitrator position(s) may be interviewed by representatives of the Parties in advance of their selection, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that all Parties are represented.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.4.</font></font><font style="font-size:12pt;">The hearing on the merits shall be concluded within [ * ] after the initial prehearing conference and the award shall be rendered within [ * ] of the conclusion of the hearing, or of any post-hearing briefing, which briefing shall be completed by both sides within [ * ] after the conclusion of the hearing, unless the arbitrator(s) determine(s), in a reasoned decision, that the interest of justice or the complexity of the case requires that the time limit for concluding the hearing on the merits and/or rendering the award be extended. In the event the Parties cannot agree upon a schedule, then the arbitrator(s) shall set the schedule following the time limits set forth above as closely as practical.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.5.</font></font><font style="font-size:12pt;"> The hearing on the merits will be concluded in [ * ] or less, unless the arbitrator(s) determine(s), in a reasoned decision, that the interest of justice or the complexity of the case requires that the time limit for concluding the hearing on the merits and/or rendering the award be extended. Multiple hearing days will be scheduled consecutively to the greatest extent possible. A transcript of the testimony adduced at the hearing shall be made and shall be made available to each Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.6.</font></font><font style="font-size:12pt;">The Parties shall allow and participate in discovery in accordance with the United States Federal Rules of Civil Procedure. &#160;Unresolved discovery disputes shall be submitted to the arbitrator(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">95</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.7.</font></font><font style="font-size:12pt;">The arbitrator(s) shall decide the merits of any Dispute in accordance with the law governing this Agreement, without application of any principle of conflict of laws that would result in reference to a different law. The arbitrator(s) may not apply principles such as &#8220;</font><i style="font-size:12pt;font-style:italic;">amiable compositeur</i><font style="font-size:12pt;">&#8221; or &#8220;</font><i style="font-size:12pt;font-style:italic;">natural justice and equity</i><font style="font-size:12pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.8.</font></font><font style="font-size:12pt;">The arbitrator(s) are expressly empowered to decide dispositive motions in advance of any hearing and shall endeavor to decide such motions as would a United States District Court Judge sitting in the jurisdiction whose substantive law governs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.9.</font></font><font style="font-size:12pt;">The arbitrator(s) shall render a written opinion stating the reasons upon which the award is based. The Parties consent to the entry of judgment on any award rendered hereunder. Judgment on the award may be entered in any court of competent jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.10.</font></font><font style="font-size:12pt;">Notwithstanding any provision to the contrary contained in this Agreement, each Party has the right to seek from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin or other equitable relief to avoid irreparable harm, maintain the status quo, preserve its status and priority as a creditor or preserve the subject matter of the Dispute.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Waiver of Trial by Jury</b><font style="font-size:12pt;">. &#160;EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Article 14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.1.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Performance by Affiliates</b><font style="font-size:12pt;">. &#160;To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. &#160;A Party may use one or more of its Affiliates to perform its obligations and duties or exercise its rights hereunder, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that such Party will remain directly liable hereunder for the prompt payment and performance of all their respective obligations and duties hereunder. &#160;Any breach by an Affiliate of a Party of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.2.1.</font></font><font style="font-size:12pt;">Except as expressly provided in this Agreement, the amendment and restatement of the Existing Agreement shall not affect any rights or obligations of the Parties that accrued under (a) the Original Agreement between the Original Execution Date and May 7, 2019 (b) the Existing Agreement between May 7, 2019 and the Restatement Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.2.2.</font></font><font style="font-size:12pt;">Subject to Section 14.2.1, this Agreement together with the Schedules and Exhibits hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter of this Agreement and cancels and supersedes any and all prior or contemporaneous negotiations, correspondence, understandings and agreements between the Parties respecting such subject matter (including the Nondisclosure Agreement, </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that all information shared by the Parties or their Affiliates pursuant</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">96</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">to such Nondisclosure Agreement shall be deemed Confidential Information of the disclosing Party under this Agreement, and the use and disclosure thereof shall be governed by Article 9 and each Party shall retain all rights and remedies available at law or equity with respect to any breach of the Non-Disclosure Agreement occurring prior to the Original Execution Date, whether oral or written, regarding such subject matter).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.3.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Further Actions</b><font style="font-size:12pt;">. &#160;Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate to carry out the purposes and intent of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Binding Effect</b><font style="font-size:12pt;">. &#160;This Agreement and the rights granted herein will be binding upon, and will inure to the benefit of Janssen, Protagonist and their respective lawful successors and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Assignment</b><font style="font-size:12pt;">. &#160; Neither Party may assign or transfer this Agreement in its entirety or any rights or obligations hereunder without the prior written consent of the other Party, except that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">either Party may assign or transfer this Agreement in its entirety or any rights or obligations hereunder to an Affiliate of such Party without the other Party&#8217;s consent;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">either Party may assign or transfer this Agreement in its entirety to a Third Party acquirer of that portion of its business relating to the subject matter of this Agreement in a sale of assets or other similar transaction without the other Party&#8217;s consent; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">either Party may assign or transfer this Agreement in its entirety pursuant to any Change of Control of such Party</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The assigning Party shall provide the other Party with prompt written notice of any such assignment pursuant to Section 14.5(a), Section 14.5(b) or Section 14.5(c). &#160;Any permitted assignment shall be binding on the successors and permitted assignees of the assigning Party, and the successor (if the successor is an entity other than a Party) or assignee shall confirm the same in writing to the other Party. &#160;Any assignment, transfer or attempted assignment or transfer by either Party in violation of the terms of this Section 14.5 shall be null, void and of no legal effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.6.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Use of Names</b><font style="font-size:12pt;">. &#160;Neither Party shall use the name, physical likeness, employee names or Trademarks of the other Party for any purpose without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that nothing contained herein shall be construed to prevent either Party from using the name of the other Party for purposes of preparing necessary filings with the United States Securities and Exchange Commission or complying with its regulations, or other regulations applicable to the public sale of securities, including preparing proxy statements or prospectuses, or in connection with the attribution of data in accordance with good scientific practices. &#160;Nothing contained herein shall be construed as granting either Party any rights or license to use any of the other Party&#8217;s Trademarks without separate, express written permission of the owner of such Trademark.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">97</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Amendment; No Waiver</b><font style="font-size:12pt;">. &#160;No waiver, modification or amendment of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. &#160;The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.8.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Force Majeure Event</b><font style="font-size:12pt;">. &#160;Any delay in performance by a Party under this Agreement shall not be considered a breach of this Agreement if and to the extent such performance is prevented by occurrences beyond the reasonable control of the Party affected, including acts of God, embargoes, governmental restrictions (other than those imposed as a result of such Party&#8217;s failure to comply with Applicable Law), strikes or other concerted acts of workers, fire, flood, earthquakes, explosions, pandemics, riots, wars, civil disorder, rebellion or sabotage (but not including delays incident to the ordinary course of drug development); </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, the payment of invoices due and owing hereunder may not be delayed by the payor because of a force majeure affecting the payor. &#160;The Parties acknowledge and agree that the Development Plans attached to this Agreement reflect any expected delays in performance related to the COVID-19 pandemic that is ongoing on the Restatement Effective Date. &#160;The Party suffering such occurrence shall immediately notify the other Party, and any time for performance hereunder shall be extended by the actual time of delay caused by the occurrence so long as the nonperforming Party has not caused such event(s) to occur and takes reasonable efforts to remove the condition. &#160;In the event that the suspension of performance continues for [ * ] after the date such force majeure commences, the Parties shall meet to discuss in good faith how to proceed in order to accomplish the objectives of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.9.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Independent Contractors</b><font style="font-size:12pt;">. &#160;Neither Party is, nor will be deemed to be, an employee, agent or legal representative of the other Party for any purpose. &#160;Neither Party will be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor will a Party be entitled to pledge the credit of the other Party in any way or hold itself out as having authority to do so. &#160;It is expressly agreed that Protagonist, on the one hand, and Janssen, on the other hand, are independent contractors, and that this Agreement is an arm&#8217;s-length agreement between the Parties and shall not constitute or be construed as a partnership, joint venture or agency. All individuals employed by a Party shall be employees of that Party and not of the other Party and all costs and obligations incurred by reason of such employment shall be for the account and expense of such Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.10.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Notices and Deliveries</b><font style="font-size:12pt;">. &#160;Any notice, delivery or other communication required or permitted to be given to either Party hereto shall be in writing unless otherwise specified and shall be deemed to have been properly given and to be effective on the date delivered, if delivered personally, or on the next business day after being sent by reputable overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case to the other Party at the following address (or such other address as a Party may specify in writing pursuant to this Section 14.10):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If to Protagonist:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Protagonist Therapeutics, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">7707 Gateway Blvd., Suite 410</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Newark, CA 94560</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">98</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">Attention: President and CEO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Cooley LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">3175 Hanover Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Palo Alto, CA 94304</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">Attention: Marya A. Postner</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If to Janssen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Janssen Biotech, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">800/850 Ridgeview Dr.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Horsham, PA 19044</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Attention: President</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">Facsimile: [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Johnson &amp; Johnson</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">One Johnson &amp; Johnson Plaza</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">New Brunswick, NJ 08933</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Attention: General Counsel, Pharmaceuticals</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">Facsimile: [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.11.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Headings</b><font style="font-size:12pt;">. &#160;The captions to the sections and articles in this Agreement are not a part of this Agreement, and are included merely for convenience of reference only and will not affect its meaning or interpretation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.12.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Severability</b><font style="font-size:12pt;">. &#160;If any provision of this Agreement is, for any reason, held to be invalid or unenforceable in any respect, such invalidity or unenforceability will not affect any other provision hereof, and this Agreement will be construed as if such invalid or unenforceable provision had not been included herein. &#160;The Parties will in such an instance use their reasonable efforts to replace the invalid or unenforceable provision with a valid and enforceable provision that accomplishes, as nearly as possible, the original intention of the Parties with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.13.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Governing Law</b><font style="font-size:12pt;">. &#160;This Agreement will be governed by and interpreted in accordance with the laws of the State of New York without reference to its choice of laws or conflicts of laws provisions. &#160;The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. &#160;Each Party may make service on the other Party by sending or delivering a copy of the process to the Party to be served at the address and in the manner provided for the giving of notices in Section&#160;14.10. &#160; Notwithstanding anything to the contrary herein, the interpretation and construction of any Patent Rights shall be governed in accordance with the laws of the jurisdiction in which such Patent Rights were filed or granted, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">99</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.14.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Advice of Counsel</b><font style="font-size:12pt;">. &#160;Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. &#160;In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party which drafted such terms and provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.15.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Counterparts</b><font style="font-size:12pt;">. &#160;This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission), each of which need not contain the signature of more than one Party, but all such counterparts taken together will constitute one and the same agreement. &#160;Signatures provided by facsimile transmission or in Adobe&#8482; Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.16.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Construction</b><font style="font-size:12pt;">. &#160;Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to calendar days. &#160;Except where the context otherwise requires, (a) wherever used, the singular shall include the plural, the plural shall include the singular; (b) the use of any gender shall be applicable to all genders; (c) the terms &#8220;including,&#8221; &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;for example&#8221; shall not limit the generality of any description preceding such term and, as used herein, shall have the same meaning as &#8220;including, but not limited to,&#8221; and/or &#8220;including, without limitation&#8221;; (d) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (e) the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and/or&#8221; unless the context clearly dictates otherwise because the subjects of the conjunction are mutually exclusive; (f) the word &#8220;will&#8221; means &#8220;shall&#8221;; (g) if a period of time is specified and dates from a given day or business day, or the day or business day of an act or event, it is to be calculated exclusive of that day or business day; (h) references to a particular entity include such entity&#8217;s successors and assigns to the extent not prohibited by this Agreement; (i) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; and (j) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">{Signature Page Follows}</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">100</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Restatement Effective Date, each copy of which will for all purposes be deemed to be an original.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">JANSSEN BIOTECH, INC.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Thomas Cavanaugh</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Thomas Cavanaugh</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">President, Janssen Biotech, Inc.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PROTAGONIST THERAPEUTICS, INC.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">/s/ Dinesh V Patel</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Dinesh V Patel, Ph.D.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">President &amp; CEO</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[SIGNATURE PAGE TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1.56</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">JOHNSON &amp; JOHNSON UNIVERSAL CALENDAR</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1.59</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">PTG-200</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1.86</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">PN-232</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1.89</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">PN-235</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1.93</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">PROTAGONIST IL23R INHIBITOR PATENT RIGHTS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(Redacted content comprises approximately eleven and one-half pages) [ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.55%;margin-right:4.55%;margin-top:30pt;page-break-after:always;width:90.91%;border-width:0;"><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 3.4.2(e)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">PHASE 1A DATA PACKAGE ADDITIONAL INFORMATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';font-size:12pt;">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">[ * ]</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.55%;margin-right:4.55%;margin-top:30pt;page-break-after:always;width:90.91%;border-width:0;"><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 7.2.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Pre-Restatement Period Invoiced Costs</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.55%;margin-right:4.55%;margin-top:30pt;page-break-after:always;width:90.91%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 8.2.1(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">Janssen Collaboration Patent Rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 8.2.1(b)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Protagonist Collaboration Patent Rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(Redacted content comprises approximately two and one-half pages)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 8.2.1(c)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Joint Collaboration Patent Rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(Redacted content comprises approximately two pages)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.55%;margin-right:4.55%;margin-top:30pt;page-break-after:always;width:90.91%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 10.1.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXCEPTIONS TO REPRESENTATIONS AND WARRANTIES</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 10.3.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXISTING PROTAGONIST PATENTS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 10.3.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXISTING PROTAGONIST LICENSE AGREEMENTS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ASSAY DESCRIPTIONS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">PTG-200 CLINICAL DEVELOPMENT PLAN</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> GENERATION CLINICAL DEVELOPMENT PLAN (INCLUDING BUDGETS)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(Redacted content comprises approximately three pages)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">JANSSEN DATA GENERATION, PROCESSING AND STORAGE POLICIES</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-size:12pt;">[ * ]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ptgx-20210930xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-variant:small-caps;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Execution Version</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ARBITRATION RESOLUTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Made effective as of August 4</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-size:12pt;font-weight:bold;">, 2021 (&#8220;Effective Date&#8221;).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:12pt;">This binding Arbitration Resolution Agreement (the &#8220;Agreement</font><sup style="font-size:9pt;vertical-align:top;">-</sup><font style="font-size:12pt;">), is entered into on the Effective Date by and between:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">(A)</font></font><b style="font-size:12pt;font-weight:bold;">ZEALAND PHARMA A/S</b><font style="font-size:12pt;">, a corporation organized and existing under the law of Denmark and having its registered office at Sydmarken 11, 2860 Soborg, Denmark (&#8220;Zealand&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">(B)</font></font><font style="font-size:12pt;">P</font><b style="font-size:12pt;font-weight:bold;">ROTAGONIST PTY. LTD</b><font style="font-size:12pt;">., a company organized and existing under the laws of Australia and having its registered office at 306 Carmody Road, St Lucia, Brisbane Qld 4072, Australia (&#8220;Protagonist Pty. Ltd.&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">(C)</font></font><b style="font-size:12pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC</b><font style="font-size:12pt;">., a Delaware corporation having its principal place of business 7707 Gateway Blvd, #140, Newark, CA 94560 (&#8220;Protagonist Therapeutics&#8221; and together with Protagonist Pty. Ltd., collectively, &#8220;Protagonist,&#8221;) (Protagonist and Zealand, collectively, the &#8220;Parties&#8221; and each a &#8220;Party&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, the Parties entered into a Research Collaboration and License Agreement dated as of June 16, 2012 as amended by the Agreement on Addition of Additional Collaboration Program dated as of September 16, 2013 (the &#8220;Collaboration Agreement&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, the Parties entered into an Abandonment Agreement dated as of February 28, 2014 (the &#8220;Abandonment Agreement&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, in 2016, Protagonist identified as a clinical development candidate the selection of a disulfide-rich peptide compound known as Rusfertide (formerly denominated PTG-300) (&#8220;Rusfertide&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, in 2016, 2017 and 2019, Protagonist paid Zealand three initial development milestones related to Rusfertide in the aggregate amount of $1,000,000;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, in 2020, Protagonist asserted that Rusfertide is not a &#8220;Selected DRP&#8221;, &#8220;Therapeutic Peptide&#8221; or &#8220;Product&#8221; designated/selected by Zealand for further development for which Zealand is entitled to milestones and royalties pursuant to the Collaboration Agreement and Abandonment Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, in 2020, Protagonist filed a request for arbitration with the International Chamber of Commerce seeking a return of the $1,000,000 it paid to Zealand as initial development milestones and a declaration that Zealand is not entitled to any past, present or future milestone or royalty payments with respect to Rusfertide; Zealand filed an answer and counterclaims seeking a declaration that Protagonist owes Zealand milestones and royalties, if any, with respect to Rusfertide and raising counterclaims that Protagonist owes one past milestone payment and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">for misuse/infringement of Zealand intellectual property; the arbitration remains pending and is captioned </font><i style="font-size:12pt;font-style:italic;">Protagonist Therapeutics, Inc. &amp; Protagonist Pty. Ltd. v. Zealand Pharma A/S, </i><font style="font-size:12pt;">Reference Number ICC 25080/MK (&#8220;the Arbitration&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, without resolving whether Rusfertide is or is not a &#8220;Selected DRP&#8221;, &#8220;Therapeutic Peptide&#8221; or &#8220;Product&#8221; as defined in the Collaboration Agreement designated/selected by Zealand for further development, the Parties agree to resolve their dispute on the following terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NOW, THEREFORE</b><font style="font-size:12pt;">, without admission by either Party of any wrongdoing or that Rusfertide is or is not a &#8220;Selected DRP&#8221;, &#8220;Therapeutic Peptide</font><sup style="font-size:9pt;vertical-align:top;">-</sup><font style="font-size:12pt;"> or &#8220;Product</font><sup style="font-size:9pt;vertical-align:top;">-</sup><font style="font-size:12pt;"> as defined in the Collaboration Agreement designated/selected by Zealand for further development, Protagonist and Zealand agree to the following:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Unless otherwise defined herein, any capitalized terms used in this Agreement shall have the meanings ascribed to them in the Collaboration Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Protagonist will pay Zealand USD$2,500,000 within two business days of the Effective Date (the &#8220;Initial Payment&#8221;).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Protagonist will pay Zealand an additional USD$1,500,000 within one calendar year of the Effective Date (the &#8220;Anniversary Payment&#8221;).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">For purposes of this Agreement, the parties agree to treat Rusfertide as a &#8220;Selected DRP,</font><sup style="font-size:9pt;vertical-align:top;">-</sup><font style="font-size:12pt;">&#8221;Therapeutic Peptide&#8221; or &#8220;Product&#8221; as defined in the Collaboration Agreement, and that Zealand shall be entitled to milestone and royalty payments as to Rusfertide under the Collaboration Agreement and Abandonment Agreement, modified as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 0pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">a.</font></font><font style="font-size:12pt;white-space:pre-wrap;">The Parties agree that the Initial Payment and the Anniversary Payment are the only payments Protagonist shall make to Zealand in connection with the Start Phase lib and Start Phase III Initial Development Milestones.  No additional payments for those milestones will be owed, provided that Protagonist shall be obligated to pay the Initial Payment and the Anniversary Payment to Zealand regardless of whether Rusfertide reaches the Start Phase lib and/or Start Phase III Initial Development Milestones as set forth in in Section 7.2 of the Collaboration Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 0pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">b.</font></font><font style="font-size:12pt;">As to all future milestones for Rusfertide after the Start of Phase III milestones (specifically including Registration Approval and Launch Initial Development Milestones set forth in Section 7.2.1 of the Collaboration Agreement and Commercial Milestones set forth in Section 7.3.1 of the Collaboration Agreement), if and as any such Initial Development Milestones and Commercial Milestones become owing in the future, Protagonist will pay Zealand the following amounts:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">2</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:17.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Development Milestone Event</b></p></td><td colspan="9" style="vertical-align:top;width:82.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Initial Development Milestone ($ million)</b></p></td></tr><tr><td style="vertical-align:top;width:17.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Product Indication</b></p></td><td colspan="3" style="vertical-align:top;width:28.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Small</b></p></td><td colspan="3" style="vertical-align:top;width:26.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Medium</b></p></td><td colspan="3" style="vertical-align:top;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Large</b></p></td></tr><tr><td style="vertical-align:top;width:17.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Region</b></p></td><td style="vertical-align:top;width:9.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">US</b></p></td><td style="vertical-align:top;width:9.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EU</b></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ROW</b></p></td><td style="vertical-align:top;width:8.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">US</b></p></td><td style="vertical-align:top;width:8.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EU</b></p></td><td style="vertical-align:top;width:9.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ROW</b></p></td><td style="vertical-align:top;width:8.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">US</b></p></td><td style="vertical-align:top;width:8.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EU</b></p></td><td style="vertical-align:top;width:9.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ROW</b></p></td></tr><tr><td style="vertical-align:top;width:17.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Registrational Approval</b></p></td><td style="vertical-align:top;width:9.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="vertical-align:top;width:17.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Launch</b></p></td><td style="vertical-align:top;width:9.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.18%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:8.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:9.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Region</b></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Fiscal Year Sales Threshold ($ million)</b></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Commercial Milestone</b><font style="font-size:12pt;"><br></font><b style="font-size:12pt;font-weight:bold;">($ million)</b></p></td></tr><tr><td rowspan="4" style="vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">US</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Total</b></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td rowspan="4" style="vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">EU</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Total</b></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td rowspan="4" style="vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ROW</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:33.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Total</b></p></td><td style="vertical-align:top;width:33.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">[  ** ]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 0pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">c.</font></font><font style="font-size:12pt;white-space:pre-wrap;">As to royalties for Rusfertide (specifically Royalties on Net Sales set forth in Section 7.4 of the Collaboration Agreement), if and as any such Royalties become owing in the future, Protagonist will pay Zealand a [  ** ]% Royalty on Net Sales anywhere in the world whether generated by Protagonist or pursuant to a Partnering Arrangement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">3</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Protagonist shall make the payments provided under paragraph 4 above as to Rusfertide regardless of whether Protagonist enters into any Partnering Arrangement with respect to Rusfertide, and the provisions of the Collaboration Agreement that call for a cessation of payments upon a Partnering Arrangement shall no longer apply or have effect with respect to Rusfertide.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;white-space:pre-wrap;">The Parties shall cooperate in good faith to execute, acknowledge, and deliver such further instruments and to do all such other acts as may be appropriate and necessary to implement the terms of this Agreement.  The Parties agree that the terms of this Agreement are binding on the Parties regardless of whether the Parties enter into any further agreements.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">In the event of any conflict between this Agreement and either the Collaboration Agreement or Abandonment Agreement arises, this Agreement, which shall be deemed to modify and amend the Collaboration Agreement and Abandonment Agreement, shall govern.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Each Party shall be entitled to retain (i) all payments previously made to it by the other Party in connection with the Collaboration Agreement; and (ii) any payments made under this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Each Party fully releases the other Party from and against any and all claims for past and present payments under the Collaboration Agreement and/or Abandonment Agreement and each Party agrees that future payments as to Rusfertide will be subject to the terms of this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Nothing in this Agreement shall affect payments or obligations related to Selected DRPs, Therapeutic Peptides, and Products under the Collaboration Agreement and Abandonment Agreement other than Rusfertide, if any.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Zealand releases its claims against Protagonist relating to intellectual property as raised by Zealand in the Arbitration.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">On the Effective Date, the Parties will promptly cause the Arbitration to be dismissed and discontinued with prejudice, with no award to issue, and with each Party to bear its own costs and fees.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;white-space:pre-wrap;">Each Party agrees that it and its officers and employees shall not publicly or privately criticize or disparage the other Party, or any of the other Party&#8217;s products, business practices and/or personnel.  Each Party agrees not to comment publicly on the Arbitration or the Settlement, except to indicate that the matter has been amicably resolved, or as may be required by law or regulation (including laws relating to securities filings).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Each Party represents and warrants that it has not assigned or transferred any claims it may have against the other Parties.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">4</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Each person signing this Agreement represents and warrants that he or she has actual full legal authority to bind the Party for whom he or she signs and each of the Parties represents and warrants that it has the authority to enter into this Agreement and provide the performance called for hereunder.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">This Agreement is binding upon and shall inure to the benefit of (a) each Party&#8217;s officers, directors, shareholders, owners, managers, attorneys, inesurers, heirs, beneficiaries, and affiliates (which for purposes of this Agreement means every entity that controls, is controlled by or is under common control with any Party), and (b) each Party&#8217;s predecessors and past, present and future subsidiaries, divisions, parents, successors, assignees, transferees, executors, trustees, receivers, conservators or administrators (all whether voluntary or involuntary), including any entity surviving out of any merger (in any form), acquisition or reorganization, and including all persons or entities receiving any benefits, rights, obligations or liabilities of this Agreement by its terms or by operation of law.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">The Parties agree this Agreement may be signed in counterparts, and by means of electronic signatures and/or DocuSign.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">18.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">Each Party acknowledges that this Agreement is the result of the combined efforts of the Parties and, should any provision of this Agreement be found to be ambiguous in any way, such ambiguity shall not be resolved by construing such provision in favor or against either Party hereto but rather by construing the terms of this Agreement fairly and reasonably in accordance with the purpose of this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">19.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">No part of this Agreement may be waived or modified except by another written agreement signed by the Party to be charged.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">20.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;white-space:pre-wrap;">The Parties agree that this Agreement is binding and shall be enforceable in the courts located in New York, New York and the parties agree and submit to the exclusive jurisdiction of said courts for such purpose.  This Agreement shall be governed by New York law, without regard to choice of law principles.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">21.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">The Parties agree to reasonably cooperate in good faith to carry out the purposes and intent of this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">22.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;"><font style="font-size:12pt;">The prevailing party in any dispute or controversy arising out of, in relation to, or in connection with this Agreement, shall be entitled to reasonable attorneys&#8217; fees and costs incurred in connection with the dispute or controversy.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">5</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the Parties have signed this Agreement as of the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:36pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ZEALAND PHARMA A/S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">By:  </b><font style="font-size:12pt;">/s/ Emmanuel Dulac</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Name:  </b><font style="font-size:12pt;">Emmanuel Dulac</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Title:  </b><font style="font-size:12pt;">CEO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:36pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PROTAGONIST PTY. LTD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">By:  </b><font style="font-size:12pt;">/s/ Dinesh V. Patel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Name:  </b><font style="font-size:12pt;">Dinesh V. Patel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Title:  </b><font style="font-size:12pt;">President &amp; CEO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:36pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PROTAGONIST THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">By:  </b><font style="font-size:12pt;">/s/ Dinesh V. Patel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Name:  </b><font style="font-size:12pt;">Dinesh V. Patel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">Title:  </b><font style="font-size:12pt;">President &amp; CEO</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">6</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ptgx-20210930xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:28 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">SECOND</b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration:none;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">AMENDMENT</b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration:none;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">TO</b><b style="font-weight:bold;letter-spacing:-0.05pt;text-decoration:none;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0.05pt 5.8pt 0pt 29pt;">THIS<font style="letter-spacing:-0.4pt;"> </font>SECOND<font style="letter-spacing:-0.45pt;"> </font>AMENDMENT<font style="letter-spacing:-0.45pt;"> </font>TO<font style="letter-spacing:-0.4pt;"> </font>LEASE<font style="letter-spacing:-0.35pt;"> </font>(this<font style="letter-spacing:-0.4pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Amendment</u>&#8221;)<font style="letter-spacing:-0.45pt;"> </font>is<font style="letter-spacing:-0.45pt;"> </font>entered<font style="letter-spacing:-0.45pt;"> </font>into<font style="letter-spacing:-0.35pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>this<font style="letter-spacing:-2.85pt;"> </font>2<sup style="font-size:9pt;vertical-align:top;">nd</sup> day of July, 2021, by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware<font style="letter-spacing:0.05pt;"> </font>limited partnership (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Landlord</u>&#8221;), and PROTAGONIST THERAPEUTICS, INC., a Delaware<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:-0.05pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Tenant</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">A.</font>WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of<font style="letter-spacing:0.05pt;"> </font>March<font style="letter-spacing:-0.5pt;"> </font>6,<font style="letter-spacing:-0.5pt;"> </font>2017<font style="letter-spacing:-0.45pt;"> </font>(the<font style="letter-spacing:-0.55pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Original</u><u style="letter-spacing:-0.3pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Lease</u>&#8221;),<font style="letter-spacing:-0.5pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>amended<font style="letter-spacing:-0.45pt;"> </font>by<font style="letter-spacing:-0.7pt;"> </font>that<font style="letter-spacing:-0.45pt;"> </font>certain<font style="letter-spacing:-0.4pt;"> </font>First<font style="letter-spacing:-0.4pt;"> </font>Amendment<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>Lease<font style="letter-spacing:-0.4pt;"> </font>dated<font style="letter-spacing:-2.9pt;"> </font>as of January 31, 2019 (collectively, and as the same may have been further amended, amended<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>restated,<font style="letter-spacing:-0.2pt;"> </font>supplemented<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>modified<font style="letter-spacing:-0.2pt;"> </font>from<font style="letter-spacing:-0.15pt;"> </font>time<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>time,<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Existing</u><u style="letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Lease</u>&#8221;),<font style="letter-spacing:-0.25pt;"> </font>whereby<font style="letter-spacing:-0.55pt;"> </font>Tenant<font style="letter-spacing:-2.9pt;"> </font>leases certain premises (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Existing Premises</u>&#8221;) from Landlord at 7707 Gateway Boulevard in<font style="letter-spacing:0.05pt;"> </font>Newark,<font style="letter-spacing:-0.05pt;"> </font>California (the<font style="letter-spacing:0.05pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">7707 Building</u>&#8221;);</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">B.</font><font style="letter-spacing:-0.05pt;">WHEREAS,</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">Landlord</font><font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>Tenant<font style="letter-spacing:-0.7pt;"> </font>desire<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.6pt;"> </font>expand<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Existing<font style="letter-spacing:-0.8pt;"> </font>Premises<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.7pt;"> </font>include<font style="letter-spacing:-2.9pt;"> </font>that certain space<font style="letter-spacing:0.05pt;"> </font>containing approximately fifteen thousand<font style="letter-spacing:0.05pt;"> </font>twelve<font style="letter-spacing:0.05pt;"> </font>(15,012) square feet of<font style="letter-spacing:0.05pt;"> </font>Rentable Area (as more particularly described on <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u> attached hereto, the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Additional</u><font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Premises</u>&#8221;) on the first (1<sup style="font-size:9pt;vertical-align:top;">st</sup>) floor of the building located at 7999 Gateway Boulevard, Newark,<font style="letter-spacing:0.05pt;"> </font>California<font style="letter-spacing:-0.05pt;"> </font>(the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">7999</u><u style="letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Building</u>&#8221;); and</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.9pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">C.</font>WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease<font style="letter-spacing:-2.85pt;"> </font>only<font style="letter-spacing:-0.3pt;"> </font>in the<font style="letter-spacing:-0.05pt;"> </font>respects and on the conditions hereinafter stated.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises<font style="letter-spacing:0.05pt;"> </font>contained herein and for other good and valuable consideration, the receipt and sufficiency of<font style="letter-spacing:0.05pt;"> </font>which are<font style="letter-spacing:-0.1pt;"> </font>hereby<font style="letter-spacing:-0.25pt;"> </font>acknowledged, and intending<font style="letter-spacing:-0.15pt;"> </font>to be<font style="letter-spacing:-0.05pt;"> </font>legally<font style="letter-spacing:-0.25pt;"> </font>bound, agree<font style="letter-spacing:0.05pt;"> </font>as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Definitions</u>.<font style="letter-spacing:0.05pt;"> </font>For purposes of this Amendment, capitalized terms shall have the<font style="letter-spacing:0.05pt;"> </font>meanings ascribed to them in the Existing Lease unless otherwise defined herein.<font style="letter-spacing:0.05pt;"> </font>The Existing<font style="letter-spacing:0.05pt;"> </font>Lease,<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.2pt;"> </font>amended<font style="letter-spacing:-0.3pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>this<font style="letter-spacing:-0.3pt;"> </font>Amendment,<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.3pt;"> </font>referred<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.2pt;"> </font>collectively<font style="letter-spacing:-0.5pt;"> </font>herein<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Lease</u>.&#8221;<font style="letter-spacing:-0.2pt;"> </font>From<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-2.9pt;"> </font>after the date hereof, the term &#8220;Lease,&#8221; as used in the Existing Lease, shall mean the Existing<font style="letter-spacing:0.05pt;"> </font>Lease,<font style="letter-spacing:0.05pt;"> </font>as amended by<font style="letter-spacing:-0.25pt;"> </font>this Amendment.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 5.75pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.25pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Additional</u><u style="letter-spacing:-0.65pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Premises</u>.<font style="letter-spacing:1.75pt;"> </font>Effective<font style="letter-spacing:-0.65pt;"> </font>as<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>date<font style="letter-spacing:-0.65pt;"> </font>that<font style="letter-spacing:-0.55pt;"> </font>Landlord<font style="letter-spacing:-0.65pt;"> </font>first<font style="letter-spacing:-0.6pt;"> </font>delivers<font style="letter-spacing:-0.7pt;"> </font>possession<font style="letter-spacing:-2.85pt;"> </font>of the Additional Premises to Tenant (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Additional Premises Term Commencement Date</u>&#8221;),<font style="letter-spacing:0.05pt;"> </font>Landlord hereby leases<font style="letter-spacing:0.05pt;"> </font>to Tenant, and Tenant<font style="letter-spacing:0.05pt;"> </font>hereby leases from<font style="letter-spacing:0.05pt;"> </font>Landlord, the Additional<font style="letter-spacing:0.05pt;"> </font>Premises.<font style="letter-spacing:0.05pt;"> </font>Landlord shall endeavor to cause the Additional Premises Term Commencement Date<font style="letter-spacing:-2.85pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>occur<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>September<font style="letter-spacing:0.05pt;"> </font>1,<font style="letter-spacing:0.05pt;"> </font>2021<font style="letter-spacing:0.05pt;"> </font>(the<font style="letter-spacing:0.05pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Estimated</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Additional</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Premises</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Term</u><font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Commencement</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Date</u>&#8221;);<font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,<font style="letter-spacing:0.05pt;"> </font>however,<font style="letter-spacing:0.05pt;"> </font>Tenant<font style="letter-spacing:0.05pt;"> </font>agrees<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Additional<font style="letter-spacing:-2.85pt;"> </font>Premises Term Commencement Date has not occurred on or before the Estimated Additional<font style="letter-spacing:0.05pt;"> </font>Premises Term Commencement Date for any reason, then (a) this Amendment shall not be void<font style="letter-spacing:0.05pt;"> </font>or voidable (except as expressly permitted under <u style="text-decoration:underline;text-decoration-color:#000000;">Article 7</u> </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 5.75pt 0pt 28.8pt;">below), and (b) Landlord shall not be<font style="letter-spacing:0.05pt;"> </font>liable<font style="letter-spacing:2.05pt;"> </font>to<font style="letter-spacing:2.1pt;"> </font>Tenant<font style="letter-spacing:2.25pt;"> </font>for<font style="letter-spacing:2pt;"> </font>any<font style="letter-spacing:2pt;"> </font>loss<font style="letter-spacing:2.1pt;"> </font>or<font style="letter-spacing:2.1pt;"> </font>damage<font style="letter-spacing:2.05pt;"> </font>resulting<font style="letter-spacing:2pt;"> </font>therefrom. &#160;<font style="letter-spacing:1.65pt;"> </font>From<font style="letter-spacing:2.05pt;"> </font>and<font style="letter-spacing:2.2pt;"> </font>after<font style="letter-spacing:2.2pt;"> </font>the<font style="letter-spacing:2.05pt;"> </font>Additional Premises<font style="letter-spacing:-0.25pt;"> </font>Term<font style="letter-spacing:-0.25pt;"> </font>Commencement<font style="letter-spacing:-0.25pt;"> </font>Date,<font style="letter-spacing:-0.25pt;"> </font>(x)<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>term<font style="letter-spacing:-0.2pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Premises</u>&#8221;<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.25pt;"> </font>used<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Lease<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.2pt;"> </font>mean<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-2.9pt;"> </font>Existing Premises plus the Additional Premises, and (y) the term &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Building</u>&#8221; as used in the Lease<font style="letter-spacing:-2.85pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>mean the 7707<font style="letter-spacing:-0.05pt;"> </font>Building<font style="letter-spacing:-0.1pt;"> </font>and/or the<font style="letter-spacing:-0.05pt;"> </font>7999<font style="letter-spacing:0.05pt;"> </font>Building, as the<font style="letter-spacing:-0.05pt;"> </font>context may<font style="letter-spacing:-0.15pt;"> </font>require.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.1</font><u style="text-decoration:underline;text-decoration-color:#000000;">Additional</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Premises</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Term</u>.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>Term<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>respect<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Additional<font style="letter-spacing:-2.85pt;"> </font>Premises (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Additional Premises Term</u>&#8221;) shall commence on the Additional Premises Term<font style="letter-spacing:0.05pt;"> </font>Commencement<font style="letter-spacing:-0.55pt;"> </font>Date<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>shall<font style="letter-spacing:-0.5pt;"> </font>thereafter<font style="letter-spacing:-0.5pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>coterminous<font style="letter-spacing:-0.55pt;"> </font>with<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Term<font style="letter-spacing:-0.55pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Existing<font style="letter-spacing:-0.65pt;"> </font>Premises,<font style="letter-spacing:-2.9pt;"> </font>such that the Term with respect to the entire Premises (including both the Existing Premises and<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Additional Premises)<font style="letter-spacing:-0.05pt;"> </font>shall expire<font style="letter-spacing:-0.15pt;"> </font>on the<font style="letter-spacing:-0.05pt;"> </font>Term<font style="letter-spacing:0.05pt;"> </font>Expiration<font style="letter-spacing:-0.05pt;"> </font>Date (i.e., May<font style="letter-spacing:-0.2pt;"> </font>31, 2024).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.2</font><u style="text-decoration:underline;text-decoration-color:#000000;">Condition of Additional Premises</u>.<font style="letter-spacing:0.05pt;"> </font>Tenant acknowledges that (a) it is fully<font style="letter-spacing:-2.85pt;"> </font>familiar with the condition of the Additional Premises and, notwithstanding anything to the<font style="letter-spacing:0.05pt;"> </font>contrary<font style="letter-spacing:-0.55pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Lease,<font style="letter-spacing:-0.3pt;"> </font>agrees<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>take<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>same<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>its<font style="letter-spacing:-0.3pt;"> </font>condition<font style="letter-spacing:-0.3pt;"> </font>&#8220;as<font style="letter-spacing:-0.3pt;"> </font>is&#8221;<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Additional<font style="letter-spacing:-0.3pt;"> </font>Premises<font style="letter-spacing:-2.85pt;"> </font>Term<font style="letter-spacing:-0.5pt;"> </font>Commencement<font style="letter-spacing:-0.45pt;"> </font>Date,<font style="letter-spacing:-0.45pt;"> </font>(b)<font style="letter-spacing:-0.55pt;"> </font>neither<font style="letter-spacing:-0.35pt;"> </font>Landlord<font style="letter-spacing:-0.45pt;"> </font>nor<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.55pt;"> </font>agent<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>Landlord<font style="letter-spacing:-0.45pt;"> </font>has<font style="letter-spacing:-0.4pt;"> </font>made<font style="letter-spacing:-0.55pt;"> </font>(and<font style="letter-spacing:-0.45pt;"> </font>neither<font style="letter-spacing:-2.9pt;"> </font>Landlord nor any agent of Landlord hereby makes) any representation or warranty of any kind<font style="letter-spacing:0.05pt;"> </font>whatsoever,<font style="letter-spacing:-0.05pt;"> </font>express<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>implied,<font style="letter-spacing:-0.05pt;"> </font>regarding<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Additional<font style="letter-spacing:-0.1pt;"> </font>Premises,<font style="letter-spacing:-0.05pt;"> </font>including<font style="letter-spacing:-0.25pt;"> </font>(without<font style="letter-spacing:-0.05pt;"> </font>limitation)<font style="letter-spacing:-2.9pt;"> </font>any representation or warranty with respect to the condition of the Additional Premises or with<font style="letter-spacing:0.05pt;"> </font>respect to the suitability of the Additional Premises for the conduct of Tenant&#8217;s business and (c)<font style="letter-spacing:0.05pt;"> </font>Landlord<font style="letter-spacing:-0.25pt;"> </font>shall<font style="letter-spacing:-0.15pt;"> </font>have<font style="letter-spacing:-0.15pt;"> </font>no<font style="letter-spacing:-0.2pt;"> </font>obligation<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>alter,<font style="letter-spacing:-0.05pt;"> </font>repair<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>otherwise<font style="letter-spacing:-0.25pt;"> </font>prepare<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Additional<font style="letter-spacing:-0.15pt;"> </font>Premises<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-2.9pt;"> </font>Tenant&#8217;s occupancy or to pay for any improvements to the Additional Premises. Notwithstanding<font style="letter-spacing:-2.85pt;"> </font>the foregoing, Landlord shall deliver the Additional Premises to Tenant with the existing heating,<font style="letter-spacing:-2.85pt;"> </font>ventilating and air conditioning system serving the Additional Premises in good working order,<font style="letter-spacing:0.05pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>repair<font style="letter-spacing:0.05pt;"> </font>(such<font style="letter-spacing:0.05pt;"> </font>obligation,<font style="letter-spacing:0.05pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Landlord&#8217;s</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Delivery</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Obligation</u>&#8221;).<font style="letter-spacing:0.05pt;"> </font>Tenant&#8217;s<font style="letter-spacing:0.05pt;"> </font>taking<font style="letter-spacing:0.05pt;"> </font>possession of the Additional Premises shall, except as otherwise agreed to in writing by Landlord<font style="letter-spacing:-2.85pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>Tenant,<font style="letter-spacing:-0.35pt;"> </font>conclusively<font style="letter-spacing:-0.55pt;"> </font>establish<font style="letter-spacing:-0.4pt;"> </font>that<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Additional<font style="letter-spacing:-0.3pt;"> </font>Premises,<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>7999<font style="letter-spacing:-0.25pt;"> </font>Building<font style="letter-spacing:-0.55pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Project<font style="letter-spacing:-2.85pt;"> </font>were at such time in good, sanitary and satisfactory condition and repair and that Landlord&#8217;s<font style="letter-spacing:0.05pt;"> </font>Delivery Obligation was satisfied; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u> that, if Landlord fails to satisfy Landlord&#8217;s Delivery<font style="letter-spacing:0.05pt;"> </font>Obligation (a &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Delivery Shortfall</u>&#8221;), then Tenant may, as its sole and exclusive remedy, deliver<font style="letter-spacing:0.05pt;"> </font>notice of such failure to Landlord detailing the nature of such failure (a &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Shortfall Notice</u>&#8221;);<font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, further, that any Shortfall Notice must be received by Landlord no later than the date<font style="letter-spacing:0.05pt;"> </font>(the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Shortfall Notice Deadline</u>&#8221;) that is sixty (60) days after the Additional Premises Term<font style="letter-spacing:0.05pt;"> </font>Commencement Date.<font style="letter-spacing:0.05pt;"> </font>In the event that Landlord receives a Shortfall Notice on or before the<font style="letter-spacing:0.05pt;"> </font>Shortfall Notice Deadline, Landlord shall, at Landlord&#8217;s expense, promptly remedy the Delivery<font style="letter-spacing:0.05pt;"> </font>Shortfall. Landlord shall not have any obligations or liabilities in connection with a failure to<font style="letter-spacing:0.05pt;"> </font>satisfy Landlord&#8217;s Delivery Obligation except to the extent such failure is identified by Tenant in<font style="letter-spacing:-2.85pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>Shortfall Notice<font style="letter-spacing:-0.1pt;"> </font>delivered to<font style="letter-spacing:0.05pt;"> </font>Landlord on or<font style="letter-spacing:-0.05pt;"> </font>before<font style="letter-spacing:-0.15pt;"> </font>the Shortfall Notice<font style="letter-spacing:0.05pt;"> </font>Deadline.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 6.5pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.25pt;text-indent:0pt;white-space:nowrap;">2.3</font><u style="text-decoration:underline;text-decoration-color:#000000;">Base Rent for Additional Premises</u>.<font style="letter-spacing:0.05pt;"> </font>Commencing as of the Additional<font style="letter-spacing:0.05pt;"> </font>Premises Term Commencement Date, Base Rent for the Additional Premises shall equal Three<font style="letter-spacing:0.05pt;"> </font>and 30/100 Dollars ($3.30) per square foot of Rentable Area (of the Additional </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 6.5pt 0pt 28.8pt;">Premises) per<font style="letter-spacing:0.05pt;"> </font>month. Base Rent for the Additional Premises shall be subject to an annual upward adjustment of<font style="letter-spacing:-2.85pt;"> </font>three point five percent (3.5%) of the then-current Base Rent for the Additional Premises.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>first such adjustment shall become effective commencing on the first (1<sup style="font-size:9pt;vertical-align:top;">st</sup>) annual anniversary of<font style="letter-spacing:0.05pt;"> </font>the Additional Premises Term Commencement Date, and subsequent adjustments shall become<font style="letter-spacing:0.05pt;"> </font>effective<font style="letter-spacing:-0.1pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>every<font style="letter-spacing:-0.25pt;"> </font>successive<font style="letter-spacing:-0.05pt;"> </font>annual anniversary<font style="letter-spacing:-0.3pt;"> </font>for so<font style="letter-spacing:-0.05pt;"> </font>long<font style="letter-spacing:-0.2pt;"> </font>as<font style="letter-spacing:0.15pt;"> </font>the Lease<font style="letter-spacing:0.05pt;"> </font>continues<font style="letter-spacing:-0.05pt;"> </font>in effect.<font style="letter-spacing:0.15pt;"> </font>For avoidance<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>doubt,<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.25pt;"> </font>Security<font style="letter-spacing:0.2pt;"> </font>Deposit<font style="letter-spacing:0.3pt;"> </font>under<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>Lease<font style="letter-spacing:0.25pt;"> </font>shall<font style="letter-spacing:0.35pt;"> </font>remain<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:-2.85pt;"> </font>set<font style="letter-spacing:-0.05pt;"> </font>forth in the Existing<font style="letter-spacing:-0.1pt;"> </font>Lease.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.75pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.25pt;text-indent:0pt;white-space:nowrap;">2.4</font><u style="text-decoration:underline;text-decoration-color:#000000;">Base Rent Abatement</u>.<font style="letter-spacing:0.05pt;"> </font>So long as no monetary or material non-monetary<font style="letter-spacing:0.05pt;"> </font>Default (beyond any applicable notice and cure period) by Tenant has occurred, Tenant shall not<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>required<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>pay<font style="letter-spacing:-0.25pt;"> </font>Base<font style="letter-spacing:-0.05pt;"> </font>Rent<font style="letter-spacing:-0.15pt;"> </font>(with<font style="letter-spacing:-0.15pt;"> </font>respect<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>the Additional<font style="letter-spacing:-0.15pt;"> </font>Premises<font style="letter-spacing:-0.2pt;"> </font>only)<font style="letter-spacing:-0.2pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>first<font style="letter-spacing:-0.1pt;"> </font>(1<sup style="font-size:9pt;vertical-align:top;">st</sup>)<font style="letter-spacing:-0.1pt;"> </font>three (3) months of the Additional Premises Term (such period, the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Additional Premises Free Rent</u><font style="letter-spacing:0.05pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Period</u>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, however, that the total amount of Base Rent abated during the Additional<font style="letter-spacing:0.05pt;"> </font>Premises Free Rent Period shall not exceed One Hundred Forty-Eight Thousand Six Hundred<font style="letter-spacing:0.05pt;"> </font>Eighteen and 80/100 Dollars ($148,618.80).<font style="letter-spacing:0.05pt;"> </font>During the Additional Premises Free Rent Period,<font style="letter-spacing:0.05pt;"> </font>Tenant shall continue to be responsible for the payment of all of Tenant&#8217;s other Rent obligations<font style="letter-spacing:0.05pt;"> </font>under the Lease, including all Base Rent with respect to the Existing Premises, and all Additional<font style="letter-spacing:-2.85pt;"> </font>Rent with respect to the entire Premises (including both the Existing Premises and the Additional<font style="letter-spacing:-2.85pt;"> </font>Premises) such as Operating Expenses, the Property Management Fee (which shall be calculated<font style="letter-spacing:0.05pt;"> </font>as if the Additional Premises Free Rent Period was not in effect), and costs of utilities for the<font style="letter-spacing:0.05pt;"> </font>Premises.<font style="letter-spacing:0.05pt;"> </font>Upon the occurrence of any monetary or material non-monetary Default (beyond any<font style="letter-spacing:0.05pt;"> </font>applicable notice and cure period), the Additional Premises Free Rent Period shall immediately<font style="letter-spacing:0.05pt;"> </font>expire, and Tenant shall no longer be entitled to any further abatement of Base Rent pursuant to<font style="letter-spacing:0.05pt;"> </font>this Section.<font style="letter-spacing:0.05pt;"> </font>In the event of any Default that results in termination of the Lease, then, as part of<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.55pt;"> </font>recovery<font style="letter-spacing:-0.6pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>which<font style="letter-spacing:-0.4pt;"> </font>Landlord<font style="letter-spacing:-0.5pt;"> </font>is<font style="letter-spacing:-0.45pt;"> </font>entitled<font style="letter-spacing:-0.45pt;"> </font>pursuant<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Lease,<font style="letter-spacing:-0.4pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>addition<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.75pt;"> </font>other<font style="letter-spacing:-0.55pt;"> </font>rights<font style="letter-spacing:-2.85pt;"> </font>or remedies to which Landlord may be entitled pursuant to the Lease (including <u style="text-decoration:underline;text-decoration-color:#000000;">Article 31</u> of the<font style="letter-spacing:0.05pt;"> </font>Original<font style="letter-spacing:-0.25pt;"> </font>Lease),<font style="letter-spacing:-0.4pt;"> </font>at<font style="letter-spacing:-0.3pt;"> </font>law<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>equity,<font style="letter-spacing:-0.2pt;"> </font>Landlord<font style="letter-spacing:-0.4pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>entitled<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>immediate<font style="letter-spacing:-0.35pt;"> </font>recovery,<font style="letter-spacing:-0.35pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-2.85pt;"> </font>day immediately prior to such termination of the Lease, of the unamortized amount of Base Rent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:-0.05pt;"> </font>Tenant would<font style="letter-spacing:-0.05pt;"> </font>have<font style="letter-spacing:-0.1pt;"> </font>paid<font style="letter-spacing:-0.05pt;"> </font>had the<font style="letter-spacing:-0.1pt;"> </font>Additional Premises<font style="letter-spacing:-0.05pt;"> </font>Free<font style="letter-spacing:-0.05pt;"> </font>Rent<font style="letter-spacing:-0.05pt;"> </font>Period<font style="letter-spacing:0.05pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>been in<font style="letter-spacing:-0.05pt;"> </font>effect.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.75pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.25pt;text-indent:0pt;white-space:nowrap;">2.5</font><u style="text-decoration:underline;text-decoration-color:#000000;">Acknowledgement</u>.<font style="letter-spacing:0.05pt;"> </font>After<font style="letter-spacing:0.05pt;"> </font>Tenant<font style="letter-spacing:0.05pt;"> </font>takes<font style="letter-spacing:0.05pt;"> </font>occupancy<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Additional<font style="letter-spacing:0.05pt;"> </font>Premises and within ten (10) days of Landlord&#8217;s written request, Tenant shall execute and deliver<font style="letter-spacing:-2.85pt;"> </font>to Landlord written acknowledgment of the actual Additional Premises Term Commencement<font style="letter-spacing:0.05pt;"> </font>Date within ten (10) days after Tenant takes occupancy of the Additional Premises, in the form<font style="letter-spacing:0.05pt;"> </font>attached<font style="letter-spacing:-0.35pt;"> </font>as<font style="letter-spacing:-0.35pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit</u><u style="letter-spacing:-0.4pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">B</u><font style="letter-spacing:-0.5pt;"> </font>hereto.<font style="letter-spacing:2.2pt;"> </font>Failure<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>execute<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>deliver<font style="letter-spacing:-0.45pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>acknowledgment,<font style="letter-spacing:-0.45pt;"> </font>however,<font style="letter-spacing:-0.35pt;"> </font>shall<font style="letter-spacing:-2.9pt;"> </font>not affect the Additional Premises Term Commencement Date or Landlord&#8217;s or Tenant&#8217;s liability<font style="letter-spacing:-2.85pt;"> </font>hereunder.<font style="letter-spacing:0.05pt;"> </font>Failure by Tenant to obtain any governmental licensing or similar governmental<font style="letter-spacing:0.05pt;"> </font>approval of the Additional Premises required for the Permitted Use by Tenant shall not serve to<font style="letter-spacing:0.05pt;"> </font>extend<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Additional Premises<font style="letter-spacing:0.05pt;"> </font>Term Commencement<font style="letter-spacing:-0.05pt;"> </font>Date.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 5.75pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:39.2pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Rentable Area; Tenant&#8217;s Pro Rata Share</u>.<font style="letter-spacing:0.05pt;"> </font>Effective as of the Additional Premises<font style="letter-spacing:0.05pt;"> </font>Term Commencement Date, the chart in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 2.2</u> of the Original Lease is hereby deleted in its<font style="letter-spacing:-2.85pt;"> </font>entirety<font style="letter-spacing:-0.2pt;"> </font>and replaced<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:-0.05pt;"> </font>following:</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:1pt;margin-top:5.7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Definition</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">or</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Provision</b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><br></b><font style="font-size:12pt;font-weight:bold;margin-top:5.7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Means</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;">the Following<br></b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(As</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">of</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">the</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Premises</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-2.85pt;"> <br></b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Term</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.3pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Commencement Date)</b></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Existing</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Premises</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42,877</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Additional</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Premises</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">15,012</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Premises</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">57,889</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">7707</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">Building</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">148,848</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">7999</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">Building</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">178,047</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">North</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Campus</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">966,271</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Approximate</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Rentable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Area</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Project</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1,389,517</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">square</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">feet</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tenant&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Pro</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Rata</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Share of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">7707</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Building</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28.81%</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tenant&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Pro</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Rata</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Share of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">7999</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Building</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8.43%</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tenant&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Pro</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Rata</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Share of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">North Campus</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5.99%</font></p></td></tr><tr><td style="vertical-align:top;width:56.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tenant&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Pro</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Rata</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Share</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Project</font></p></td><td style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4.17%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="text-decoration:underline;text-decoration-color:#000000;">CASp</u>.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>Premises<font style="letter-spacing:0.05pt;"> </font>have<font style="letter-spacing:0.05pt;"> </font>not<font style="letter-spacing:0.05pt;"> </font>undergone<font style="letter-spacing:0.05pt;"> </font>inspection<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>Certified<font style="letter-spacing:0.05pt;"> </font>Access<font style="letter-spacing:0.05pt;"> </font>Specialist (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">CASp</u>,&#8221; as defined in California Civil Code Section 55.52).<font style="letter-spacing:0.05pt;"> </font>Even if not required by<font style="letter-spacing:0.05pt;"> </font>California law, the Premises may be inspected by a CASp to determine whether the Premises<font style="letter-spacing:0.05pt;"> </font>comply with the ADA, and Landlord may not prohibit a CASp performing such an inspection.<font style="letter-spacing:0.05pt;"> </font>If<font style="letter-spacing:-2.85pt;"> </font>Tenant requests that such an inspection take place, Landlord and Tenant shall agree on the time<font style="letter-spacing:0.05pt;"> </font>and manner of the inspection, as well as which party will pay the cost of the inspection and the<font style="letter-spacing:0.05pt;"> </font>cost to remedy any defects identified by the CASp.<font style="letter-spacing:0.05pt;"> </font>A Certified Access Specialist can inspect the<font style="letter-spacing:-2.85pt;"> </font>Premises and determine whether the Premises comply with all of the applicable construction-<font style="letter-spacing:0.05pt;"> </font>related accessibility standards under State law. Although State law does not require a Certified<font style="letter-spacing:0.05pt;"> </font>Access Specialist inspection of the Premises, Landlord may not prohibit Tenant from obtaining a<font style="letter-spacing:0.05pt;"> </font>Certified Access Specialist inspection of the Premises for the occupancy or potential occupancy<font style="letter-spacing:0.05pt;"> </font>of Tenant, if requested by Tenant. Landlord and Tenant shall agree on the arrangements for the<font style="letter-spacing:0.05pt;"> </font>time and manner of the Certified Access Specialist inspection, the payment of the fee for the<font style="letter-spacing:0.05pt;"> </font>Certified Access Specialist inspection, and the cost of making any repairs necessary to correct<font style="letter-spacing:0.05pt;"> </font>violations<font style="letter-spacing:-0.05pt;"> </font>of construction-related<font style="letter-spacing:0.1pt;"> </font>accessibility<font style="letter-spacing:-0.2pt;"> </font>standards within<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Premises.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:4.5pt 5.75pt 0pt 28.8pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.25pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Additional Premises HVAC</u>.<font style="letter-spacing:0.05pt;"> </font>Subject to the last grammatical sentence of this<font style="letter-spacing:0.05pt;"> </font>Article, for the Additional Premises, Landlord shall (a) maintain and operate the base heating,<font style="letter-spacing:0.05pt;"> </font>ventilating and air conditioning systems used for office use only (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Additional Premises </u></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:4.5pt 5.75pt 0pt 28.8pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">HVAC</u>&#8221;),<font style="letter-spacing:-2.85pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>(b)<font style="letter-spacing:-0.45pt;"> </font>subject<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.35pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">Section</u><u style="letter-spacing:-0.45pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">5(a)</u>,<font style="letter-spacing:-0.35pt;"> </font>furnish<font style="letter-spacing:-0.35pt;"> </font>Additional<font style="letter-spacing:-0.4pt;"> </font>Premises<font style="letter-spacing:-0.3pt;"> </font>HVAC<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.35pt;"> </font>reasonably<font style="letter-spacing:-0.55pt;"> </font>required<font style="letter-spacing:-0.35pt;"> </font>(except as<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Lease<font style="letter-spacing:-0.6pt;"> </font>otherwise<font style="letter-spacing:-0.65pt;"> </font>provides)<font style="letter-spacing:-0.6pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>reasonably<font style="letter-spacing:-0.7pt;"> </font>comfortable<font style="letter-spacing:-0.65pt;"> </font>occupancy<font style="letter-spacing:-0.8pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Additional<font style="letter-spacing:-0.6pt;"> </font>Premises<font style="letter-spacing:-2.9pt;"> </font>twenty-four<font style="letter-spacing:-0.25pt;"> </font>(24)<font style="letter-spacing:-0.25pt;"> </font>hours<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>day,<font style="letter-spacing:-0.2pt;"> </font>every<font style="letter-spacing:-0.45pt;"> </font>day<font style="letter-spacing:-0.45pt;"> </font>during<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Additional<font style="letter-spacing:-0.15pt;"> </font>Premises<font style="letter-spacing:-0.2pt;"> </font>Term,<font style="letter-spacing:-0.15pt;"> </font>subject<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>casualty,<font style="letter-spacing:-2.9pt;"> </font>eminent domain or as otherwise specified in this Article.<font style="letter-spacing:0.05pt;"> </font>Notwithstanding anything to the<font style="letter-spacing:0.05pt;"> </font>contrary,<font style="letter-spacing:-0.25pt;"> </font>Landlord<font style="letter-spacing:-0.35pt;"> </font>shall<font style="letter-spacing:-0.15pt;"> </font>have<font style="letter-spacing:-0.35pt;"> </font>no<font style="letter-spacing:-0.3pt;"> </font>liability,<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>Tenant<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>have<font style="letter-spacing:-0.35pt;"> </font>no<font style="letter-spacing:-0.2pt;"> </font>right<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>remedy,<font style="letter-spacing:-0.3pt;"> </font>on<font style="letter-spacing:-0.2pt;"> </font>account<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-2.9pt;"> </font>any interruption or impairment in Additional Premises HVAC services.<font style="letter-spacing:0.05pt;"> </font>Landlord and Tenant<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">acknowledge</font><font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>agree<font style="letter-spacing:-0.6pt;"> </font>that<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Additional<font style="letter-spacing:-0.6pt;"> </font>Premises<font style="letter-spacing:-0.55pt;"> </font>HVAC<font style="letter-spacing:-0.6pt;"> </font>shall<font style="letter-spacing:-0.6pt;"> </font>not<font style="letter-spacing:-0.55pt;"> </font>include<font style="letter-spacing:-0.65pt;"> </font>(x)<font style="letter-spacing:-0.6pt;"> </font>any<font style="letter-spacing:-0.85pt;"> </font>supplemental<font style="letter-spacing:-2.9pt;"> </font>HVAC serving the Premises, (y) any HVAC systems and equipment dedicated to a server room<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Additional<font style="letter-spacing:0.05pt;"> </font>Premises,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>(z)<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>systems<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>equipment<font style="letter-spacing:0.05pt;"> </font>exclusively<font style="letter-spacing:0.05pt;"> </font>serving<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-2.85pt;"> </font>Additional Premises, each of which shall be maintained, repaired and operated by Tenant at<font style="letter-spacing:0.05pt;"> </font>Tenant&#8217;s<font style="letter-spacing:-0.05pt;"> </font>sole<font style="letter-spacing:-0.05pt;"> </font>cost<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.1pt;"> </font>expense.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Generator</u>.<font style="letter-spacing:0.05pt;"> </font>Tenant acknowledges and agrees that there is no back-up generator<font style="letter-spacing:0.05pt;"> </font>serving the Additional Premises.<font style="letter-spacing:0.05pt;"> </font>Accordingly, <u style="text-decoration:underline;text-decoration-color:#000000;">Section 16.8</u> of the Existing Lease shall not apply<font style="letter-spacing:-2.85pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Additional Premises.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Late Delivery</u>.<font style="letter-spacing:0.05pt;"> </font>If the Additional Premises Term Commencement Date has not<font style="letter-spacing:0.05pt;"> </font>occurred on or before the date that is ninety (90)<font style="letter-spacing:0.05pt;"> </font>days after the Estimated Additional Premises<font style="letter-spacing:0.05pt;"> </font>Term Commencement Date (such date, the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Outside Date</u>&#8221;), then Tenant shall have the right to<font style="letter-spacing:0.05pt;"> </font>void<font style="letter-spacing:-0.6pt;"> </font>this<font style="letter-spacing:-0.55pt;"> </font>Amendment<font style="letter-spacing:-0.55pt;"> </font>by<font style="letter-spacing:-0.65pt;"> </font>delivering<font style="letter-spacing:-0.55pt;"> </font>written<font style="letter-spacing:-0.55pt;"> </font>notice<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>Landlord<font style="letter-spacing:-0.45pt;"> </font>(&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Outside</u><u style="letter-spacing:-0.6pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Date</u><u style="letter-spacing:-0.6pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Notice</u>&#8221;)<font style="letter-spacing:-0.45pt;"> </font>within<font style="letter-spacing:-0.55pt;"> </font>five (5)<font style="letter-spacing:-0.45pt;"> </font>business<font style="letter-spacing:-0.3pt;"> </font>days<font style="letter-spacing:-0.3pt;"> </font>after<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Outside<font style="letter-spacing:-0.4pt;"> </font>Date;<font style="letter-spacing:-0.2pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,<font style="letter-spacing:-0.2pt;"> </font>however,<font style="letter-spacing:-0.35pt;"> </font>that<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Outside<font style="letter-spacing:-0.35pt;"> </font>Date<font style="letter-spacing:-0.35pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>subject<font style="letter-spacing:-2.9pt;"> </font>to extension on a day-for-day basis as a result of (a) Force Majeure and (b) any delay caused by<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>action<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>inaction<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Tenant.<font style="letter-spacing:2.8pt;"> </font>In<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>event<font style="letter-spacing:-0.1pt;"> </font>that<font style="letter-spacing:-0.05pt;"> </font>Tenant<font style="letter-spacing:-0.1pt;"> </font>timely<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>properly<font style="letter-spacing:-0.4pt;"> </font>delivers<font style="letter-spacing:-0.2pt;"> </font>an<font style="letter-spacing:-0.15pt;"> </font>Outside<font style="letter-spacing:-2.9pt;"> </font>Date Notice in accordance with this Section, (x) this Amendment shall be void ab initio (as if this<font style="letter-spacing:-2.85pt;"> </font>Amendment was never executed), (y) Landlord shall not be liable to Tenant for any damages in<font style="letter-spacing:0.05pt;"> </font>connection<font style="letter-spacing:-0.3pt;"> </font>therewith,<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>(z)<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Lease<font style="letter-spacing:-0.35pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>continue<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>governed<font style="letter-spacing:-0.3pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>terms,<font style="letter-spacing:-0.3pt;"> </font>conditions<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-2.9pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Existing<font style="letter-spacing:0.05pt;"> </font>Lease.<font style="letter-spacing:0.05pt;"> </font>In<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>event<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>(aa)<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Additional<font style="letter-spacing:0.05pt;"> </font>Premises<font style="letter-spacing:0.05pt;"> </font>Term<font style="letter-spacing:0.05pt;"> </font>Commencement Date has not occurred on or before the Outside Date, and (bb) Tenant fails to<font style="letter-spacing:0.05pt;"> </font>deliver<font style="letter-spacing:-0.6pt;"> </font>an<font style="letter-spacing:-0.55pt;"> </font>Outside<font style="letter-spacing:-0.45pt;"> </font>Date<font style="letter-spacing:-0.45pt;"> </font>Notice<font style="letter-spacing:-0.6pt;"> </font>within<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>five<font style="letter-spacing:-0.6pt;"> </font>(5)<font style="letter-spacing:-0.45pt;"> </font>business<font style="letter-spacing:-0.5pt;"> </font>day<font style="letter-spacing:-0.65pt;"> </font>period<font style="letter-spacing:-0.5pt;"> </font>set<font style="letter-spacing:-0.4pt;"> </font>forth<font style="letter-spacing:-0.5pt;"> </font>above,<font style="letter-spacing:-0.55pt;"> </font>Tenant<font style="letter-spacing:-0.5pt;"> </font>shall<font style="letter-spacing:-2.9pt;"> </font>no<font style="letter-spacing:-0.05pt;"> </font>longer<font style="letter-spacing:0.05pt;"> </font>have<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>right<font style="letter-spacing:0.1pt;"> </font>to void<font style="letter-spacing:-0.05pt;"> </font>this Amendment in<font style="letter-spacing:-0.05pt;"> </font>accordance<font style="letter-spacing:-0.05pt;"> </font>with the<font style="letter-spacing:-0.1pt;"> </font>terms of this<font style="letter-spacing:-0.05pt;"> </font>Article.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="letter-spacing:-0.05pt;text-decoration:underline;text-decoration-color:#000000;">Broker</u><font style="letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.05pt;">Tenant</font><font style="letter-spacing:-0.6pt;"> </font>represents<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>warrants<font style="letter-spacing:-0.6pt;"> </font>that<font style="letter-spacing:-0.6pt;"> </font>it<font style="letter-spacing:-0.6pt;"> </font>has<font style="letter-spacing:-0.5pt;"> </font>not<font style="letter-spacing:-0.6pt;"> </font>dealt<font style="letter-spacing:-0.6pt;"> </font>with<font style="letter-spacing:-0.6pt;"> </font>any<font style="letter-spacing:-0.85pt;"> </font>broker<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>agent<font style="letter-spacing:-2.85pt;"> </font>in the negotiation for or the obtaining of this Amendment, other than Newmark (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Broker</u>&#8221;), and<font style="letter-spacing:0.05pt;"> </font>agrees to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably<font style="letter-spacing:0.05pt;"> </font>acceptable to Landlord, at Tenant&#8217;s sole cost and expense) and hold harmless the Landlord<font style="letter-spacing:0.05pt;"> </font>Indemnitees for, from and against any and all cost or liability for compensation claimed by any<font style="letter-spacing:0.05pt;"> </font>such broker or agent, other than Broker, employed or engaged by it or claiming to have been<font style="letter-spacing:0.05pt;"> </font>employed or engaged by it.<font style="letter-spacing:0.05pt;"> </font>Broker is entitled to a leasing commission in connection with the<font style="letter-spacing:0.05pt;"> </font>making of this Amendment, and Landlord shall pay such commission to Broker pursuant to a<font style="letter-spacing:0.05pt;"> </font>separate<font style="letter-spacing:-0.1pt;"> </font>agreement between<font style="letter-spacing:0.1pt;"> </font>Landlord<font style="letter-spacing:0.05pt;"> </font>and Broker.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.85pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="text-decoration:underline;text-decoration-color:#000000;">No</u><u style="letter-spacing:-0.45pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Default</u>.<font style="letter-spacing:2.2pt;"> </font>Tenant<font style="letter-spacing:-0.35pt;"> </font>represents,<font style="letter-spacing:-0.4pt;"> </font>warrants<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>covenants<font style="letter-spacing:-0.35pt;"> </font>that,<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>best<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>Tenant&#8217;s<font style="letter-spacing:-2.85pt;"> </font>knowledge,<font style="letter-spacing:-0.2pt;"> </font>Landlord<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>Tenant<font style="letter-spacing:-0.15pt;"> </font>are<font style="letter-spacing:-0.4pt;"> </font>not<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>default<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>their<font style="letter-spacing:-0.25pt;"> </font>respective<font style="letter-spacing:-0.25pt;"> </font>obligations<font style="letter-spacing:-0.3pt;"> </font>under<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-2.85pt;"> </font>Existing<font style="letter-spacing:-0.15pt;"> </font>Lease<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>no event<font style="letter-spacing:-0.1pt;"> </font>has<font style="letter-spacing:-0.2pt;"> </font>occurred<font style="letter-spacing:-0.15pt;"> </font>that, with<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>passage<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>time<font style="letter-spacing:-0.15pt;"> </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 5.85pt 0pt 29pt;">or<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>giving<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>notice<font style="letter-spacing:-0.1pt;"> </font>(or<font style="letter-spacing:-2.85pt;"> </font>both) would constitute a default by either Landlord or Tenant thereunder. Landlord represents,<font style="letter-spacing:0.05pt;"> </font>warrants and covenants that, to the best of Landlord&#8217;s knowledge, Landlord and Tenant are not in<font style="letter-spacing:-2.9pt;"> </font>default<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>their<font style="letter-spacing:0.35pt;"> </font>respective<font style="letter-spacing:0.25pt;"> </font>obligations<font style="letter-spacing:0.3pt;"> </font>under<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>Existing<font style="letter-spacing:0.3pt;"> </font>Lease<font style="letter-spacing:0.25pt;"> </font>and<font style="letter-spacing:0.4pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>event<font style="letter-spacing:0.3pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>occurred that,<font style="letter-spacing:-0.05pt;"> </font>with the<font style="letter-spacing:-0.05pt;"> </font>passage<font style="letter-spacing:-0.1pt;"> </font>of time<font style="letter-spacing:-0.05pt;"> </font>or the<font style="letter-spacing:-0.1pt;"> </font>giving<font style="letter-spacing:-0.2pt;"> </font>of notice<font style="letter-spacing:-0.05pt;"> </font>(or<font style="letter-spacing:-0.1pt;"> </font>both) would constitute a<font style="letter-spacing:-0.1pt;"> </font>default by<font style="letter-spacing:-0.3pt;"> </font>either<font style="letter-spacing:-2.85pt;"> </font>Landlord<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.1pt;"> </font>Tenant thereunder.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.85pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">10.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Notices</u>.<font style="letter-spacing:0.05pt;"> </font>Tenant<font style="letter-spacing:0.05pt;"> </font>confirms<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>notwithstanding anything in<font style="letter-spacing:0.05pt;"> </font>the Lease to<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>contrary,<font style="letter-spacing:-0.05pt;"> </font>notices<font style="letter-spacing:0.05pt;"> </font>delivered to Tenant<font style="letter-spacing:-0.05pt;"> </font>pursuant to<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Lease<font style="letter-spacing:-0.05pt;"> </font>should<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>sent to:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 137pt;">Protagonist<font style="letter-spacing:-0.25pt;"> </font>Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 137pt;">7707 Gateway<font style="letter-spacing:-0.15pt;"> </font>Boulevard, Suite<font style="letter-spacing:-0.05pt;"> </font>140</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 216.7pt 0pt 137pt;">Newark, California 94560<font style="letter-spacing:0.05pt;"> </font>Attn:<font style="letter-spacing:-0.3pt;"> </font>Chief<font style="letter-spacing:-0.35pt;"> </font>Financial<font style="letter-spacing:-0.3pt;"> </font>Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">11.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Effect of Amendment</u>. Except as modified by this Amendment, the Existing Lease<font style="letter-spacing:-2.85pt;"> </font>and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full<font style="letter-spacing:0.05pt;"> </font>force and effect and are hereby ratified and affirmed.<font style="letter-spacing:0.05pt;"> </font>In the event of any conflict between the<font style="letter-spacing:0.05pt;"> </font>terms contained in this Amendment and the Existing Lease, the terms herein contained shall<font style="letter-spacing:0.05pt;"> </font>supersede and control the<font style="letter-spacing:0.05pt;"> </font>obligations and<font style="letter-spacing:-0.05pt;"> </font>liabilities of<font style="letter-spacing:-0.05pt;"> </font>the parties.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.95pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Successors</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">and</u><u style="letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;">Assigns</u>.<font style="letter-spacing:0.05pt;"> </font>Each<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>covenants,<font style="letter-spacing:0.05pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.05pt;"> </font>contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon<font style="letter-spacing:0.05pt;"> </font>the parties hereto and their respective heirs, legatees, devisees, executors, administrators and<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:-0.3pt;"> </font>successors<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>assigns<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>sublessees.<font style="letter-spacing:2.45pt;"> </font>Nothing<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>this<font style="letter-spacing:-0.3pt;"> </font>section<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>any<font style="letter-spacing:-0.55pt;"> </font>way<font style="letter-spacing:-0.55pt;"> </font>alter<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-2.85pt;"> </font>provisions<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Lease<font style="letter-spacing:0.05pt;"> </font>restricting assignment or<font style="letter-spacing:-0.1pt;"> </font>subletting.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u>.<font style="letter-spacing:0.05pt;"> </font>This Amendment becomes effective only upon execution and<font style="letter-spacing:0.05pt;"> </font>delivery<font style="letter-spacing:-0.55pt;"> </font>hereof<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.4pt;"> </font>Landlord<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>Tenant.<font style="letter-spacing:-0.25pt;"> </font>The<font style="letter-spacing:-0.3pt;"> </font>captions<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>paragraphs<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>subparagraphs<font style="letter-spacing:-0.25pt;"> </font>in this<font style="letter-spacing:-2.85pt;"> </font>Amendment<font style="letter-spacing:-0.2pt;"> </font>are<font style="letter-spacing:-0.3pt;"> </font>inserted<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>included<font style="letter-spacing:-0.2pt;"> </font>solely<font style="letter-spacing:-0.55pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>convenience<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>shall<font style="letter-spacing:-0.15pt;"> </font>not<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>considered<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>given<font style="letter-spacing:-2.9pt;"> </font>any effect in construing the provisions hereof.<font style="letter-spacing:0.05pt;"> </font>All exhibits hereto are incorporated herein by<font style="letter-spacing:0.05pt;"> </font>reference.<font style="letter-spacing:0.05pt;"> </font>Submission of this<font style="letter-spacing:0.05pt;"> </font>instrument<font style="letter-spacing:0.05pt;"> </font>for examination<font style="letter-spacing:0.05pt;"> </font>or signature<font style="letter-spacing:0.05pt;"> </font>by Tenant<font style="letter-spacing:0.05pt;"> </font>does<font style="letter-spacing:0.05pt;"> </font>not<font style="letter-spacing:0.05pt;"> </font>constitute a reservation of or option for a lease, and shall not be effective as a lease, lease<font style="letter-spacing:0.05pt;"> </font>amendment<font style="letter-spacing:-0.05pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:-0.05pt;"> </font>execution by<font style="letter-spacing:-0.3pt;"> </font>and delivery<font style="letter-spacing:-0.3pt;"> </font>to both<font style="letter-spacing:0.1pt;"> </font>Landlord<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Tenant.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.75pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">14.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Authority</u>.<font style="letter-spacing:0.05pt;"> </font>Tenant<font style="letter-spacing:0.05pt;"> </font>guarantees,<font style="letter-spacing:0.05pt;"> </font>warrants<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>represents<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>individual<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-2.85pt;"> </font>individuals signing this Amendment have the power, authority and legal capacity to sign this<font style="letter-spacing:0.05pt;"> </font>Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability<font style="letter-spacing:0.05pt;"> </font>companies, joint venturers or other organizations and entities on whose behalf such individual or<font style="letter-spacing:0.05pt;"> </font>individuals have signed. Landlord guarantees, warrants and represents that the individual or<font style="letter-spacing:0.05pt;"> </font>individuals signing this Amendment have the power, authority and legal capacity to sign this<font style="letter-spacing:0.05pt;"> </font>Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability<font style="letter-spacing:0.05pt;"> </font>companies, joint venturers or other organizations and entities on whose behalf such individual or<font style="letter-spacing:0.05pt;"> </font>individuals<font style="letter-spacing:-0.05pt;"> </font>have<font style="letter-spacing:-0.05pt;"> </font>signed.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 29pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36.1pt;text-indent:0pt;white-space:nowrap;">15.</font><u style="text-decoration:underline;text-decoration-color:#000000;">Counterparts; Facsimile and PDF Signatures</u>.<font style="letter-spacing:0.05pt;"> </font>This Amendment may be executed<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.4pt;"> </font>one<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>more<font style="letter-spacing:-0.4pt;"> </font>counterparts,<font style="letter-spacing:-0.4pt;"> </font>each<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>which,<font style="letter-spacing:-0.25pt;"> </font>when<font style="letter-spacing:-0.4pt;"> </font>taken<font style="letter-spacing:-0.45pt;"> </font>together,<font style="letter-spacing:-0.4pt;"> </font>shall<font style="letter-spacing:-0.35pt;"> </font>constitute<font style="letter-spacing:-0.45pt;"> </font>one<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>same<font style="letter-spacing:-2.9pt;"> </font>document. A facsimile or portable document format (PDF) signature on this Amendment shall be<font style="letter-spacing:-2.85pt;"> </font>equivalent<font style="letter-spacing:-0.05pt;"> </font>to, and have<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>same force and effect<font style="letter-spacing:0.1pt;"> </font>as,<font style="letter-spacing:-0.05pt;"> </font>an original signature.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[REMAINDER<font style="letter-spacing:-0.15pt;"> </font>OF<font style="letter-spacing:-0.25pt;"> </font>THIS<font style="letter-spacing:-0.15pt;"> </font>PAGE<font style="letter-spacing:-0.1pt;"> </font>INTENTIONALLY<font style="letter-spacing:-0.1pt;"> </font>LEFT<font style="letter-spacing:-0.1pt;"> </font>BLANK]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:11.05pt 0pt 0pt 23.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:35.95pt;margin:4.5pt 5.8pt 0pt 29pt;">IN<font style="letter-spacing:-0.15pt;"> </font>WITNESS<font style="letter-spacing:-0.15pt;"> </font>WHEREOF,<font style="letter-spacing:-0.05pt;"> </font>Landlord<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>Tenant<font style="letter-spacing:-0.15pt;"> </font>have<font style="letter-spacing:0.05pt;"> </font>executed<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.2pt;"> </font>Amendment<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-2.85pt;"> </font>date<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:0.2pt;"> </font>year first<font style="letter-spacing:0.1pt;"> </font>above<font style="letter-spacing:0.05pt;"> </font>written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 0pt 29pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LANDLORD</b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 29pt;">BMR-PACIFIC<font style="letter-spacing:-0.15pt;"> </font>RESEARCH<font style="letter-spacing:-0.15pt;"> </font>CENTER LP,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 29pt;">a<font style="letter-spacing:-0.1pt;"> </font>Delaware<font style="letter-spacing:-0.15pt;"> </font>limited<font style="letter-spacing:-0.05pt;"> </font>partnership</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:28.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:47.83%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:85.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:middle;width:85.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="ptgx-20210930xex10d3001.jpg" alt="Graphic" style="display:inline-block;height:20.75pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:76.99pt;"></p></td></tr><tr><td style="vertical-align:top;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="letter-spacing:-0.05pt;">Name:&#160;</font></p></td><td style="vertical-align:middle;width:85.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Marie Lewis</p></td></tr><tr><td style="vertical-align:top;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:85.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Senior Vice President, Legal and Assistant Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:4.5pt 0pt 0pt 29pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">TENANT</b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 29pt;">PROTAGONIST<font style="letter-spacing:-0.15pt;"> </font>THERAPEUTICS,<font style="letter-spacing:-0.05pt;"> </font>INC.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 29pt;">a<font style="letter-spacing:-0.15pt;"> </font>Delaware<font style="letter-spacing:-0.05pt;"> </font>corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:28.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:46.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:84.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:middle;width:84.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="ptgx-20210930xex10d3002.jpg" alt="Graphic" style="display:inline-block;height:17.41pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:77.04pt;"></p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="letter-spacing:-0.05pt;">Name:&#160;</font></p></td><td style="vertical-align:middle;width:84.76%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Dinesh Patel</p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:84.76%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">CEO</p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:84.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">7/2/2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:28.8pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:46.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:86.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:86.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="ptgx-20210930xex10d3003.jpg" alt="Graphic" style="display:inline-block;height:21.63pt;width:77.04pt;"></p></td></tr><tr><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:86.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Don Kalkofen</p></td></tr><tr><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="letter-spacing:-0.05pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:86.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">CFO</p></td></tr><tr><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:86.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">7/2/2021</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-family:'Lucida Console';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:2.23;text-align:center;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">EXHIBIT</b><b style="font-weight:bold;letter-spacing:3pt;text-decoration:none;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">A</b><b style="font-weight:bold;letter-spacing:0.05pt;text-decoration:none;text-decoration-color:#000000;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:2.23;text-align:center;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ADDITIONAL</b><b style="font-weight:bold;letter-spacing:-0.65pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"><img src="ptgx-20210930xex10d3004.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:254.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:337.5pt;"></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"><img src="ptgx-20210930xex10d3005.jpg" alt="Graphic" style="display:inline-block;height:22.5pt;width:58.5pt;"></b><font style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;=</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Additional</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Premises</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:4.5pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">EXHIBIT</b><b style="font-weight:bold;letter-spacing:-0.05pt;text-decoration:none;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ACKNOWLEDGEMENT</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OF</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">TERM</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">COMMENCEMENT</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 65pt;">THIS<font style="letter-spacing:1.05pt;"> </font>ACKNOWLEDGEMENT<font style="letter-spacing:0.95pt;"> </font>OF<font style="letter-spacing:0.8pt;"> </font>TERM<font style="letter-spacing:0.9pt;"> </font>COMMENCEMENT<font style="letter-spacing:0.85pt;"> </font>DATE<font style="letter-spacing:1.05pt;"> </font>is<font style="letter-spacing:0.9pt;"> </font>entered<font style="letter-spacing:0.9pt;"> </font>into</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 5.85pt 0pt 29pt;">as<font style="letter-spacing:5.45pt;"> </font>of<font style="letter-spacing:5.45pt;"> </font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:42.11pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>],<font style="letter-spacing:2.5pt;"> </font>20[<u style="letter-spacing:2.8pt;text-decoration:underline;text-decoration-color:#000000;"> </u>],<font style="letter-spacing:2.45pt;"> </font>with<font style="letter-spacing:2.45pt;"> </font>reference<font style="letter-spacing:5.4pt;"> </font>to<font style="letter-spacing:5.45pt;"> </font>that<font style="letter-spacing:5.45pt;"> </font>certain<font style="letter-spacing:5.65pt;"> </font>Second<font style="letter-spacing:5.45pt;"> </font>Amendment<font style="letter-spacing:5.45pt;"> </font>to<font style="letter-spacing:5.55pt;"> </font>Lease<font style="letter-spacing:-2.9pt;"> </font>(the<font style="letter-spacing:-0.15pt;"> </font>&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Amendment</u>&#8221;)<font style="letter-spacing:-0.3pt;"> </font>dated<font style="letter-spacing:-0.25pt;"> </font>as<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:14.12pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>],<font style="letter-spacing:-0.3pt;"> </font>20[<u style="letter-spacing:5.85pt;text-decoration:underline;text-decoration-color:#000000;"> </u>],<font style="letter-spacing:-0.35pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>PROTAGONIST<font style="letter-spacing:-0.3pt;"> </font>THERAPEUTICS,<font style="letter-spacing:-0.2pt;"> </font>INC.,<font style="letter-spacing:-2.9pt;"> </font>a Delaware corporation (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Tenant</u>&#8221;), in favor of BMR-PACIFIC RESEARCH CENTER LP, a<font style="letter-spacing:0.05pt;"> </font>Delaware limited partnership (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Landlord</u>&#8221;).<font style="letter-spacing:0.05pt;"> </font>All capitalized terms used herein without definition<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>have<font style="letter-spacing:-0.05pt;"> </font>the meanings<font style="letter-spacing:0.1pt;"> </font>ascribed to them in<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 65pt;">Tenant<font style="letter-spacing:-0.05pt;"> </font>hereby<font style="letter-spacing:-0.3pt;"> </font>confirms<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:31.6pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Tenant accepted possession of the Additional Premises for use in accordance with the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Permitted</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Use</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">[</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:42.08pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">],</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">20[</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.8pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">].</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.7pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Tenant</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">first</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">occupied</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Additional</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Premises</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-2.9pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Permitted</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Use</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">on [</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:26.92pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">], 20[</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.9pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">].</font></td><td style="width:5.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:31.6pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Additional</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Premises</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">good</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">order,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">condition</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">repair.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:28.95pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:31.6pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">In</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">accordance with</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the provisions</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the Amendment,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Additional Premises</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Term</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Commencement</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">Date</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">[</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:42.1pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">], 20[</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:2.9pt;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"> </u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">].</font></td><td style="width:5.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:35.95pt;margin:0pt 6.15pt 0pt 29pt;">IN<font style="letter-spacing:2.4pt;"> </font>WITNESS<font style="letter-spacing:2.35pt;"> </font>WHEREOF,<font style="letter-spacing:2.3pt;"> </font>Tenant<font style="letter-spacing:2.35pt;"> </font>has<font style="letter-spacing:2.45pt;"> </font>executed<font style="letter-spacing:2.3pt;"> </font>this<font style="letter-spacing:2.35pt;"> </font>Acknowledgment<font style="letter-spacing:2.3pt;"> </font>of<font style="letter-spacing:2.3pt;"> </font>Term<font style="letter-spacing:-2.85pt;"> </font>Commencement<font style="letter-spacing:-0.05pt;"> </font>Date<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:-0.1pt;"> </font>date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 29pt;">TENANT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 29pt;"><font style="font-size:12pt;">[</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:42.05pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:12pt;">],</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 29pt;">a<font style="letter-spacing:-0.05pt;"> </font>[<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:42.08pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:18pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 291.1pt 0pt 29pt;">By:<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:165.41pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> Name:<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:5.26pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> Title: &#160;<font style="letter-spacing:0.95pt;"> </font><u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:30.06pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.23;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="ptgx-20210930xex10d3006.jpg" alt="Graphical user interface, text, application, email&#10;&#10;Description automatically generated" style="display:inline-block;height:631.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;"></font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ptgx-20210930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">I, Dinesh V. Patel, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Protagonist Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15(f)) for the registrant and we have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date:&#160;&#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dinesh V. Patel, Ph.D.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">President, Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ptgx-20210930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Don Kalkofen, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Protagonist Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Don Kalkofen</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Don Kalkofen</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ptgx-20210930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/3/2021 09:05:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Dinesh&#160;V.&#160;Patel, Chief Executive Officer of Protagonist Therapeutics, Inc. (the &#8220;Company&#8221;), and Don Kalkofen, Chief Financial Officer of the Company, each hereby certify that, to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date:&#160;&#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dinesh V. Patel, Ph.D.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">President, Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date:&#160;&#160;November 3, 2021</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Don Kalkofen</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Don Kalkofen</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">&#8220;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Protagonist Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#8221;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ptgx-20210930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< H$# 2(  A$! Q$!_\0
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M8^]5/^$7UO\ Z!TG_?2_XUU)JQR-2N/TFUU?67E2VU"93$%+;YI/XC@=,_\
MUJNMH6OK'$_]HL?,*\?:9!@$$YR>"  2<$XJK%H7B&"WG@BL952<*) "N3@Y
M'.>.:N);>+8Q&%MI,1;/+!"';L&T8Y]"0?4=:3?9C2[HK1Z;JTBI(NL+]GDV
MB.?[5)LD)) 4<9S\ISD#&*=)I.N164-S]OE82E J+/)D[CM&#T//8$^M6HXO
M%T,H>.SV !0D8CC")C)!5>@/)Y'J:18O%ZL&-M(Q7:5+JAVE<X8<\-\QYHN.
MWJ0IH?B"2:>*._=S#+'&2MR^&W]&![KSS5>\L=8L;.6YEU)RD<S0$)<.22#@
M^WY\XYQ6B@\9QK@0REBNTNP0L1@CDYYX)JO/8^*;BVG@DLFV3OYDNU$!8YW<
MD<XSSBB_H%O)F%_:%]_S^W7_ '^;_&C^T+[_ )_;K_O\W^-7O^$7UO\ Z!TG
M_?2_XT?\(OK?_0.D_P"^E_QJKQ(M(H_VA??\_P!=?]_F_P :TOLFK8MU_M-O
M/F,>+?[4_F /]TD>F.>.G>H_^$7UO_H'2_\ ?2_XUIQ6_BV".)([,@Q@!7\N
M/?@ @?-UX!./2DVN@TGU(8]%U^66>..^D;R9EB=A<N1\PR&'JN".?>C^R-:+
M%$U7>R*&D5;F3,>4WC.?4 ],U91/&,;HX@EWJ1\Y"$MA2OS'//!QS[4AB\7'
M&+/:=NUBL<8+C;M&[UP.!GI2OZ%679E8Z3K/VY+6/5?,)=XWD6Z<+&R %@V>
MG4?G4=CI^JWV575S%*)_LYBEGD#!^<#@$?PG\JO.GC!G=UMFA=\[FA2-"22"
M3QW.!D^U0I8^*H[MKI;)A,\XN&.U,&0 @'&?]H_G1<+>1E7[:CI]T;>74+EG
M"@Y$DB]?9L']*K?VA??\_MU_W^;_ !K5NM"U^\F\V73-K8Q^[5$'Y U!_P (
MOK?_ $#I/^^E_P :::):94BO+^::.);ZYW.P09G;J3CUK6DTG6D#LFJ^8B/Y
M9=;IP ^\(5YQT+#VQ5:/PWKL4J2)I\H=&#*<KP0<CO6C+!XMEW@V6U7.61(X
MPI.X-G'3)(&?6AM=!I=RM/IFKVK2B?5Q$L;; TES(H=MN[:,CKCUP.10-+UE
MLHNIEID ,D(N7W1DJ653[D ],\\5::'Q:Y;=99& %4Q1D)@$ J/X3@GD4UK7
MQ8PA_P!$<-$Z.'54#,R<*6/5L>]*X[>1"VD:TEK]H?4Y%7@%?.E)4D*<$@8!
M^8=33YM"UZ*Y6V&I%IFW%4^TR*3M(#8W8X&<YZ8!QG%/^R^*BDBO8"3?*TQ,
MD<;$.V,D$GCH/RIDECXJFFCFDM':2/S-K$)D!\[AUZ<G [9XHOYH+>1B27M[
M'*Z#4;APK$!TG?#8[CGI3?[0OO\ G]NO^_S?XU>'A?6P,?V=+^:_XT?\(OK?
M_0.D_P"^E_QJKQ)M(H_VA??\_MU_W^;_ !K3TNRUC5X9Y;?4)5$+*I#SR<D@
MD=,X'!Y.!47_  B^M_\ 0.D_[Z7_ !J9-"\11V<MHEC*L,KJ[@%<D@$#G/N:
M3:Z D^J+?]@Z]NA']I-F09'[Z7CY-_I\W _ASS5%;753<W$1U*:.*W&Z6XDE
ME6->@QR,YR0,8K12'Q<C;C:,V.@=$8#Y-AP">,KP?6HTL?%,<SNEB0CC#0;4
M,1Z?P9V]@>E*_F5;R*8M-6-U:VZZD[-<EQ&R73%3L)!.?3CBK;Z%XAC5B;V3
M 4,O^D/\XVEN/RQ]:E$'BL%6-@K2(S,DC0QEE+$DX/8<]*4Q^,#&\?V>3:Y)
M(PG!*[>.>./\:+^@6]2FFFZM)J"646KK)*=^_;=OB(KP0WIR0 >A-4+E]3M(
MX&EO;D><K,%\]\C#%2#SUR#6V8O&&69+9HG8'<\21HQR0221W) R>^*AO-/\
M37T)CN--5N2=XBC##+;CANHR2?SH3$T87]H7W_/[=?\ ?YO\:/[0OO\ G]NO
M^_S?XU>_X1?6_P#H'2?]]+_C1_PB^M_] Z3_ +Z7_&JO$FTBC_:%]_S^W7_?
MYO\ &C^T+[_G]NO^_P W^-7O^$7UO_H'2?\ ?2_XT?\ "+ZW_P! Z3_OI?\
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MHO$+2*!U&] S]MNO^_S?XUO3Z%X@AC+B]FE(C+[(YI"QP < 8^;AATR*H?\
M"+ZWC']G2_FO^-79--\423W$S6DOF7$7E2$%1\O' YX^Z.E)M=&4D^J*]U8:
MW9VUW/)>S;;601N!</DG R0/0;E!]S5L:#KOF.AU-\HBNVV:5N"<#  )/3J.
M/>I)H?%\\4D4EO(8I%97C 0*V>I(SUX'/M3]GB[R_+-BK1[=OEF&/;USG'KF
ME?T';R9CPQZG-I]S>)J;[;<G<AN6#D @9 ],D=<9JE_:%]_S^W7_ '^;_&ME
M=)\1I8360TP>3,_F./+3.[V.<C':JG_"+ZW_ - Z3_OI?\:::):91_M"^_Y_
M;K_O\W^-3KJ%[L7_ $VYZ?\ /9O\:G_X1?6_^@=)_P!]+_C4R^&=9"@?8).G
MJO\ C7;@Y4U)\S1XV<TZTJ4?9IMWZ7[%/^T+[_G]N?\ OZW^-']H7W_/[<_]
M_6_QJY_PC6L_\^$GYK_C1_PC6L_\^$GYK_C7H>TH]U^!\[]7QG\DON93_M"^
M_P"?VY_[^M_C1_:%]_S^W/\ W];_ !JY_P (UK/_ #X2?FO^-'_"-:S_ ,^$
MGYK_ (T>TH]U^ ?5\9_)+[F4_P"T+[_G]N?^_K?XT?VA??\ /[<_]_6_QJY_
MPC6L_P#/A)^:_P"-'_"-:S_SX2?FO^-'M*/=?@'U?&?R2^YE6.]OY)4C6]N,
MLP49F;O^-;1T774NGMI-0=)40R,OFR,=N[:#@ GD]/;TJBGAS6HY%=;&3<I#
M#E>H_&M-8O%0+EK3S-Y;=YD:-]Y@Q'/;(SBLJE2/V)1_ Z*%"HD_:PG\DS.N
M8-4M;(W;:DS0[MBE9WRS9(*X/.1C)SV(]:LC2M9:,2)J8="F5*W+$,W/RCW^
M4^W'6HIM&U^>$0O8L(Q(TH50H 9L9Z'IP.*N&+Q3\VVR5=T8C.V*,< 8'X@$
M@'W-)S5M)1_ N-"7,^:G.VG1_,J26&KQQF0:F'40&?Y+ICD X('J?IQ[TRWM
M-6GM?/.I&)0X5EEN65D![GT'ZGTJS-8^))Y/,:Q"MY)@RB(OR8QCCVI\=MXG
MCCC0V?F>7)YH:5$=MP[DGDTO:*WQ1_ ?L'S?!.WHRO'INMRW%Y!'>R.]H4#A
M9V^;<>,?USBB_P!.UG3;>6:;4'*Q-M.R=R?O%>/Q%3P6OB>VN)YX+0QR3G+E
M50#.".G;J:D:/Q3(C)+9+*C#!62*-@><]#[FCVFOQ1L5[#W7[E2^O1^=OT(&
MTG6EFMHCJ+[YQN7][* !MW=<8)QV&34<-AJDWF!-7&])O)*&>0'=R?3&,*3^
M%6'MO$LDL4CZ?&SQ# )ACY&-N#Z\4S[%XG%P\XMY/->83EOE^^ 1^6"1BCGT
M^*/X"=%WTISMZ/;_ #N)#I&N7,8EMM0,T1V%9$N'PP9BN1GG@@YXI)-)UJ,V
MRG46W7#!4_?2 #.>K8QVZ9S[586/Q7'(CQ6S1;"I18T157;G  '&/F.?7--D
MM_$TOE;[!&,6-K&*,G ['U'-+G=_BC8KV*M_#J7]&8UW/J%E=26[WT[/&<$K
M*^/UP:A_M"^_Y_;G_OZW^-:=WHNOWURUQ<63M(P )&T  # & ?2H/^$:UG_G
MPD_-?\:WC4I65VK^J.*>'Q7,^6$K=-&4_P"T+[_G]N?^_K?XT?VA??\ /[<_
M]_6_QJY_PC6L_P#/A)^:_P"-'_"-:S_SX2?FO^-/VE'NOP)^KXS^27W,I_VA
M??\ /[<_]_6_QH_M"^_Y_;G_ +^M_C5S_A&M9_Y\)/S7_&C_ (1K6?\ GPD_
M-?\ &CVE'NOP#ZOC/Y)?<RG_ &A??\_MS_W];_&E74+W</\ 3;GK_P ]6_QJ
MW_PC6L_\^$GYK_C2KX:UD,/] DZ^J_XT>TH]U^ ?5\9_)+[F>Q?C12X-%?,G
MZ(9#??;ZFDJ\+$,-WF$9YZ4?V>/^>I_*BX[%&BKW]GC_ )ZG\J/[/'_/4_E1
M<+%&BKW]GC_GJ?RH_L\?\]3^5%PL4:*O?V>/^>I_*C^SQ_SU/Y47"Q1HJ]_9
MX_YZG\J/[/'_ #U/Y47"Q1HJZM@",^8>N.E+_9X_YZG\J+A8HT5>_L\?\]3^
M5']GC_GJ?RHN%BC15[^SQ_SU/Y4?V>/^>I_*BX6*-%7O[/'_ #U/Y4@L <_O
M#P<=*+A8I45>_L\?\]3^5']GC_GJ?RHN%BC15[^SQ_SU/Y4?V>/^>I_*BX6*
M-%7O[/'_ #U/Y4?V>/\ GJ?RHN%BC15[^SQ_SU/Y4C6 7'[P\G'2BX6*5%7O
M[/'_ #U/Y4?V>/\ GJ?RHN%BC15[^SQ_SU/Y4?V>/^>I_*BX6*0ZBN)N_$FL
MPVLKB..-5^V;)<*=_EN ORXXP/7K7H?]GC_GJ?RH_LY?^>A_(4[BL>;W7B;5
M+-+-XKB*[5Q*)1&(Y,-\JQ\H .&8$CTJSIOB7499-,-RA>WV+'?2K#A1*Y(7
MG^'&%X_VO:N_&G*.C_\ CHH_L]?^>A_[YHN@L<+-J.IVMU<I/JHCMH[Y;5KA
M[9,0H8P^X]LDG;SQS4FD^(Y9+OR;^>$;K?=;Y7R_M+>8ZAE!_O!5X]Z[;^SU
M_P">A_(4GV!2V-YX _AHN@L>?)XCU'[.'2ZBG9X5DN"+?']GL9 I# <G +'!
MY^7/2IH]:U66S26VN(Y@;TV0DEB4!MV-D@*D@[3G..#^%=Y_9X_YZG\J/[/7
M@>8?RHN@L<7XDUZ?1=0TZ))<0GYKDF(,77<!\H[GKD+TR#TJ'Q+KM_INII':
M3Q)%]E$P1PF9&WXP,\MQV7!KNO[/7_GH?RH_L]>OF'\J+H+,XG_A(W;2;HK=
M0K>QW;1L"N6@A\S;YA3OA>:@.O7?^K?588;023"/4S;@K/M"E5 Z=2PR.NWB
MN]_LY1SYA_[Y%']GKC'F''IBBZ"QP5EX@U&?484EFC29I8$;3O*&[8\89WS]
MX;22>>.U/N]=O8=8O((KR-FBN?*2S\H;O+\K<9,]>#^':NZ_L]<Y\PY]<"C^
MSU_YZ'_OFBZ"QP \1ZDEU"N])VDT\3);QQ DR^5O.X?> )Z$9';@TQ]?U,B.
M.SO?MZO)"#<6]L@8%E<M& ?E)&T'GD9P>:]!-B R_O#SQTI?[/7_ )Z'\J+H
M+'G<7B/46\@M?0>=]G@=+98ES<L\A5E]00 ,XZ'-,A\0ZM+;3,MY&T_VA8DA
MC$1=09MGW< @X_O''->C_P!GKG/F'_OD4?V<O]__ ,=%%T%CSZ7Q#J4&F6-Q
M)<HK-<2I,AB7SBJL %V=-P[JISR",UVE7?[/7_GH?R%']GC_ )ZG\J+A8HT5
M>_L\?\]3^5']GC_GJ?RI7'8HT5>_L\?\]3^5(M@",^8?RHN%BE15[^SU_P">
MI_*C^SU_YZG\J+A8HT5>_L\?\]3^5']GC_GJ?RHN%BC15[^SQ_SU/Y4?V>/^
M>I_*BX6*-%7O[/'_ #U/Y4?V>/\ GJ?RHN%BC15[^SQ_SU/Y4?V>/^>I_*BX
M6*-%7O[/'_/4_E1_9X_YZG\J+A8HT5>_L\?\]3^5']GC_GJ?RHN%BC15[^SQ
M_P ]3^5']GC_ )ZG\J+A8HT5>_L\?\]3^5']GC_GJ?RHN%BC15[^SQ_SU/Y4
M?V>/^>I_*BX6*-%7O[/'_/4_E1_9X_YZG\J+A8HT5>_L\?\ /4_E1_9X_P">
MI_*BX6*-%7O[/'_/4_E0=/4#/F'\J+A8N45#YK>U%(9+'_JU^E.IL?\ JU^E
M.H **** "BBB@ HHHH **** &I]W\3_.J<VL:=;W?V2:]@2X^7]TS@-\QP./
M>KB?=_$_SK'OM M[J6^E:ZDBDNC VX;?D,1RI&>O/K35NHU;J6GUO2XY1$]_
M;B0EE"F09RI((_ @C\*K:?XHTG4;>*9+E8O-W%$F8*S*N<G&>G!_*J*>$K:.
MZM[AM2F,L4K3,V$5G)<OU R!D].E1CP/8%X?]*D8PP"$Y52> VTYQP?F/3K@
M5=H=RK0+Z^+-'EO%M8+I9Y&V8,9!4[VVC!)Y_P#KU*OB;2&N9X1>Q$0(&DE#
M#8,L5VY]<CI567PK;236S?;)52"*"-HP%PXB)*D\9'4]*IOX'M'C5'U"=@B(
MEON5#Y:H6('3YOO$<T6@%H'51R)-&LD3J\;@%64Y!'J*5/XO]ZH+"SBT^P@M
M(?\ 50H$7@#@?3BIT_B^M9D#J*** "BBB@ HHHH *:_\/^\*=37_ (?K0 ZB
MBB@ HHHH **** "BBB@ IH_UA^@IU-'^L/T% #J*** "BBB@ HHHH **** &
MM]]/J:=36^^OUIU !1110 4444 %%%% !6;K,$MSX?U""W4M-)!(J*#@EB#@
M5I5!)*8+6641O(4#-LC&6;&> /6FMP6YQ\GAB^TJP34=/Q/J4+QR+;HHB0@*
M59<9QDALDYYVBN@T*P?3;:.T<SLT<";V8@QLY)+$=\DDYS[5HVDYNK2*<PRP
MF1 WERKATSV([&N>N]<U&..\N;>(-#!,Z*&B^4JHP3NSUWY  _\ KU=Y2T+N
MY:'3T5STFLWKQHD*1"Z$C1&'!<RNNW.#QA!DY8]"._>?5]?_ +,EDC6W#E8B
MX9GV@M@G;]> <=<'@&IY6+E9M45@GQ$8?)ADMM]R\I@PC_*7&T$@GHN]MOX4
MRP\1/<W/V:2W'G2RGR%1N#&&968GT&TG/?(%'*PY6=#17/2>(I(;F_5K9&BM
M][*0^"40*&//4[C@#VZU:U#6_L-QY2VK2X6,DAL89V*JN,$]B3Z 4<K%RLUZ
M*Y]O%,:;6DM'2/8S,Q; RN[(&>IPN<'!((P.M%QXG,,LD2V+.\0!D E P?DX
M'J=SA?J#1R,?*SH**P(/$PGNS;BRDW)*(9&!W $L5!! Y'RDGIQZUJ:>;YK8
M_P!H+"LVX\0D[=N>.O?%)Q:W$TUN6Z***0@HHHH **** "BBB@ HHHH ****
M "D/W3]*6D/W3]* *U%%%,"Q'_JU^E.IL?\ JU^E.I %%%% !1110 4444 %
M%%% #4^[^)_G7%ZCH]SJFOW,?EC*WL4A>2,.@A\A@/E;AOGW<>IS7:)]W\3_
M #IU5&7+L.,K'*2^$X(IM$BCMTN([8R"::5%)P4;;D=P&(P.W%5M(TG5;&\M
MC'I=K%/%;ND]W*V3+(?XMRME@QYPRY':NNN[C[+9SW&S?Y4;/M! S@9QD\"L
M*W\6Q2Z!<ZD]MLD@?RVMQ*"<_+C)(&/O#/'%4I2:+3DT9&IZ'JEWJ-S/'IJ(
MSQ;;@I,-ET-Z-A>A!(5E(;@#IU-1VWA[4HM0MII;/9")%DC)D7_0XA([-'P>
MZ,HXR.W05V6G7OVVV#NL22@D-'',) ,''4?_ %JN4>T:T#G:T,?PNLR>&K%9
M@RML.T/U"9.P'_@.*\P\2ZAK,GCJ\T^QU&[C,EPD<4:W#*H)5<=^.37L]>&>
M)[S^S_B-=W@17:WNDD"$X#853BKHZR;+I:R87 \66[1!-3O+KS6=%-I=/+\R
M?>!QSD9J"6Y\4Q6MO<-?ZD8Y\A-L[D@ABF&'8E@0!WJ.+Q5=FZNI+UI+R&Y0
MQM$\[*47>' 5AR.0/K6G!XY+W4MW=1(LBPR"..-=RO(TF]&.3\NTX]<UT6DN
MAM9]C-:]\5)"96N=8$0W9<O)@;?O<^V#GZ5=MX/&=S9_:H[K4Q$0Q!>=P6"J
M&X'N#QZ]JCT_Q3"+O3WOHF7[.BQS2H[/YL:AAM,>0N6#$%N::?&4S0WB-;*7
MG>=HY!*5\H2($P!WP ,?2AI]@L^Q7-_XI42EKK6%$+!9,O)\A/0'T/(_.IO-
M\7JZK)/K,0+*NZ1Y54%C@9/;FK+^/+I[5X!;1KD *PE/ VHISQSG9^&>])_P
MG=Q]H\TVJ$9E.PS-CYY5D_3;CZ46EV#7L4+C4?$UK$TLM_JBPJYC\WS9-A8$
MC /0]#5MQXL4S@:C>OY*1.=ETS;Q)]S9C[Q//3T-1:CXM.H:-+IQL8HED<2,
MZR$\ARV<8_VL=:?9>-;JRM=/@6")A:!E9BWS2KM95!/;:&.*+2ML%GV(ENO%
MK@E)]:8*_EG#2<-_=^OM207OB::[EM1J.H1S0QM)(LMPZ;%49).3Q_\ 7%3R
M^,YI[JVFFM4D6"620(TI^;<@09..H X./PJ-_$R7>LZA?7,/E+>61MBJ'=M.
MT!3SCNHS]:+/L%GV+[V/C!#,%U>61H"RRK'?LQ1@I;:1ZX!('M5"XN/$]KIR
M7TNJWGDLD;X%VQ95?.PD9XSM/Z5%<>+=0N-=CU)YGVQ3B:.U,I,:<8*CV(R/
MQHO?$"7UGJH>/9-?20!8U^Y%%&#@ _D/SH2?5 D^J-2.Q\7RE5BUB5Y"(V,:
MW[;D#C*%AVS5:T7Q=>.\:ZA?0RK@".XNFC=R02 H)R20#4 \87PU2SNRS&"U
M6,+:><?+)5-N?KWI;?Q5'%"@ET]99TM!9K<BX*R*F6)(.#@G=@^U%I=@M+L3
M:=_PE&J6R3VVLSX>5H8TDOF5Y'"[BJ@GDX-06]QXKN9+=([O5%%QGRG>9U1@
M!DG<3C  ))JC#KUU:Z)_9EK,]NAF:5Y(I"I<,H7:<=N/UK47QK.D:*MG#E@B
MW&9&*RJL9C  _@^4G..]#3[!9]BK>ZEK]A)&DFN7$JR()$>"],BLOU!]JJ_\
M)!K7_07O_P#P(;_&JUY<VD\D?V2S2TC1 NT2%RQ_O,3U/X"JVY?45:BNQ22-
M+_A(-:_Z"]__ .!#?XT?\)!K7_07O_\ P(;_ !K-W#U%&X>HHY5V'9&E_P )
M!K7_ $%[_P#\"&_QH_X2#6O^@O?_ /@0W^-9NX>HHW#U%'*NP61I?\)!K7_0
M7O\ _P "&_QH_P"$@UK_ *"]_P#^!#?XUF[AZBC</44<J[!9&E_PD&M?]!>_
M_P# AO\ &C_A(-:_Z"]__P"!#?XUF[AZBC</44<J[!9&E_PD&M?]!>__ / A
MO\:/^$@UK_H+W_\ X$-_C6;N7U%&X>HHY5V"R-+_ (2#6O\ H+W_ /X$-_C1
M_P )!K7_ $%[_P#\"&_QK-W#U%&X>HHY5V"R-+_A(-:_Z"]__P"!#?XT?\)!
MK7_07O\ _P "&_QK-W#U%&X>HHY5V"R-+_A(-:_Z"]__ .!#_P"->F>!_'"Z
MJJ:9JD@6_48CE/ G'_Q7\Z\AW#U%>D^ _ QD:'6=6C*H"'MK=N"3V=OZ#\:R
MJQARZF=51Y=3U&FI]W\3_.G5#)$9[66(2/$7#+OC.&7.>0?6N(XR:J+3Z9'F
MS>2U4*<F$E0 ?O=/7O\ K5BU@-K:0P&:68QH%\V4Y=\=R>YK"N/#T]UIUVDD
MQ,]Q.\NS?^[4DX!X&20F/Q%4DNHU8U)8M*CDBFE2T21S^[=@H)).>#[GFI;B
MTL6+37,%N2P",\BCG/ !)^N/QK&.C761;&*,V32.7VR?.(R1B,$CA2%!;!Y/
MYTNK:3J%[?M)"T93>CQL\K#9M!.W:!W?:<_X4[+N.WF:SV&GASOM;;?-\IRB
MY?OCWZ9_#-$&F6EM=&XBB5'$?E(% "HN<D*!TR>37.KX>U+>78H=N_R09CE,
MJBYX'WB _/J15^+2]0CT=;=W5W^U&5XA(0&CW$A <<<8]NH[T->8VO,UFL+-
MV#-:PE@_F E!][U^O _*E:&TG>:-XX9&(7S5(!/^SG^E<^-"U%869Y4EE+J
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M/W3]*6D/W3]* *U%%%,"Q'_JU^E.IL?^K7Z4ZD 4444 %%%% !1110 4444
M-3[OXG^=.IJ?=_$_SIU ",H92K %2,$'H159--L8T")96ZH RA5B4##=1T[]
MZM44 00V=K;8\BVABPNP>6@7"YSCCMFIZ** "H1!"[,6BC)SU*BIJ:G\7UH
M9]F@_P">$?\ WP*/LT'_ #PC_P"^!4M% $7V:#_GA'_WP*/LT'_/"/\ [X%2
MT4 1?9H/^>$?_? H^S0?\\(_^^!4M% $7V:#_GA'_P!\"FM;P#;^XBZ_W!4]
M-?\ A^HH 9]F@_YX1_\ ? H^S0?\\(_^^!4M% $7V:#_ )X1_P#? H^S0?\
M/"/_ +X%2T4 1?9H/^>$?_? H^S0?\\(_P#O@5+10!%]F@_YX1_]\"C[-!_S
MPC_[X%2T4 1?9H/^>$?_ 'P*:+:#>?W$?0?P"IZ:/]8?H* &?9H/^>$?_? H
M^S0?\\(_^^!4M% $7V:#_GA'_P!\"C[-!_SPC_[X%2T4 1?9H/\ GA'_ -\"
MC[-!_P \(_\ O@5+10!%]F@_YX1_]\"C[-!_SPC_ .^!4M% $#6T 9?W$?\
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MS_:\FB13&-C=SR+*\.1^Z0#.SGZ 'W8U.WB2Q66- )2&W;SL(V8"D9'7)WJ
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M\JRRD"(-N8(2N5&XJ".I YQ1=KH*[70RFCU]6D5WD9(W4!T*@R!@NXX]%PP
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M_:'B93T.1R*Q;;PS%!%<*]P\IFC\L%ER$& . <]@H_"FK=1JW4M.^BJ&1TM
M($$IS&,(,<'IQQCWIBW&A?(RBT'SDJ?+ PQQSTXSE>?<>U,;P]&;][D7! 9R
M_E[!@L<8W'^( J"!VQ35\/$?,;LM*P'FR&,$R,K;E8Y/KC(Z$ #@"JT[E:=R
MS!)H\L"P0K:^7.Y B" ;V S]W'/&#],5:#6,!8@V\9CX;&T;<]CZ9P/RJK::
M0ELUN[R>9+"79I"F&D9A@DG)Y_3\JJ/X926\GN)+IG,BN "@X)W8/N1NXZ=!
M2T[BT[FP+JW:Y-LLR-,%+&,') XZCMU%5GT?3+B:2:?3K261F^9W@5B?J2*A
MTS1(],G>1)-XV>6@*@%5W%CD_P 1R>I]*TU_B^M+;86VQ1_L'1_^@38_^ R?
MX4?V#H__ $";'_P&3_"M"BB["[,_^P='_P"@38_^ R?X4?V#H_\ T";'_P !
MD_PK0HHNPNS/_L'1_P#H$V/_ (#)_A1_8.C_ /0)L?\ P&3_  K0HHNPNS/_
M +!T?_H$V/\ X#)_A37T'1QM_P")38]?^?=/\*TJ:X^[]:+L+LH_V#H__0)L
M?_ 9/\*/[!T?_H$V/_@,G^%:%%%V%V9_]@Z/_P! FQ_\!D_PH_L'1_\ H$V/
M_@,G^%:%%%V%V9_]@Z/_ - FQ_\  9/\*/[!T?\ Z!-C_P" R?X5H447879G
M_P!@Z/\ ] FQ_P# 9/\ "C^P='_Z!-C_ . R?X5H447879G_ -@Z/_T";'_P
M&3_"FC0='WG_ (E-CT'_ "[I_A6E31]\_0478791_L'1_P#H$V/_ (#)_A1_
M8.C_ /0)L?\ P&3_  K0HHNPNS/_ +!T?_H$V/\ X#)_A1_8.C_] FQ_\!D_
MPK0HHNPNS/\ [!T?_H$V/_@,G^%']@Z/_P! FQ_\!D_PK0HHNPNS/_L'1_\
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M]_\  A_\:H[U_O#\Z-Z_WA^=%D%D7O[6U+_H)7O_ ($/_C1_:VI?]!*]_P#
MA_\ &J.]?[P_.C>O]X?G19!9%[^UM2_Z"5[_ .!#_P"-']K:E_T$KW_P(?\
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MJW>G:/<+1[F\FH6CR/&)T#+(8\,<98 $@9Z]1TI+?4K*[C1X+J)Q("4^898
MD$@>G!K&C\)I&^1>.0<;LJ<_*Q9<<XZD=<_='2FGPBC1-&;L[2BCA#PRQ[ 0
M-V,=3CW/-%H]QVCW-VWOK:Z>5()5D\K =EY'(R.>AXKSI?BI>W>I26VFZ$ER
MN]A$WV@@L@/WC\N ,<]>*ZO4],U&W\-:O'IVR?4KS<5V@1!2P"<9/\*C/)[5
MYS)X1\:MI<>GQ:7;PQ(@C)CEB5I0#\H<@Y8"NO!TZ$KNJUY7=OF>?C*E:-E1
M3^ZYZ7X1UZX\2:*=1N+)+7,SQHJ2;PRJ<;LX'?(_"MZJ&BZ;'H^B66G18VV\
M*QY'<@<G\3D_C5^N.33DW'8ZXIJ*4MPHHHJ2@HHHH **** "BBB@ I#]T_2E
MI#]T_2@"M1113 L1_P"K7Z4ZFQ_ZM?I3J0!1110 4444 %%%% !1110 U/N_
MB?YTI (P1D'M2)]W\3_.G4 5S96AE24VT/F( %;8,C'3'TIATRP(E!L[?$O$
MG[L?-SGG\>:MT4787*C:;8N"'M(6!4*<H#D Y _05.D,<6-B*N%"C [#M4E%
M%PN%5WLK21R\EK ['JS1@DU8KD]3^(6C:3J5Q87*79F@;:VR($= >#GWJHIO
M8:3>QT?]G6/_ #YV_P#WZ7_"C^SK'_GSM_\ OTO^%<E_PM+P_P#W+[_OR/\
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ML_J36F?NGZ4  #@4'[I^E(96HHHI@6(_]6OTIU-C_P!6OTIU( HHHH ****
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MX5-J7_04M?\ OVU(?A/J(_YBEI_W[:J]M#N/VL.YY_17H/\ PJ;4O^@I:_\
M?MJ/^%3:E_T%+7_OVU'MH=P]K#N<):75Q8W<5U:RM%/&V4=>H/\ 7Z5]!:'=
M7U[HUM<:C:_9KITR\>>GO[9ZX[5RWA;X=1:-??;=1GCNYHS^X55(5#_>YZGT
M]*[JN>M.,M$859J6P4445@8A1110 4T?ZP_04ZFC_6'Z"@!U%%% !1110 44
M44 %%%% #6^^GU-.IK??2G4 %%%% !1110 4444 %-3[OXG^=.IJ?=_$_P Z
M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4A^Z?I2TA^Z?I0!6HHQ13 H-G>W/<TF3ZU.;29B2%&#R.:/L4_]T?G
M0209/K1D^M3_ &*?^Z/SH^Q3_P!T?G3 @R?6C)]:G^Q3_P!T?G1]BG_NC\Z
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MH_.@"#)]:,GUJ?[%/_='YT?8I_[H_.@"#)]:,GUJ?[%/_='YT?8I_P"Z/SH
M@R?6C)]:G^Q3_P!T?G1]BG_NC\Z (,GUHR?6I_L4_P#='YT?8I_[H_.@"#)]
M:,GUJ?[%/_='YT?8I_[H_.@"#)]:,GUJ?[%/_='YT?8I_P"Z/SH @R?6C)]:
MG^Q3_P!T?G1]BG_NC\Z (,GUHR?6I_L4_P#='YT?8I_[H_.@"#)]:3)]:L?8
MI_[H_.D^QS ?='YT :=%,\U?>BI*(;IIX],G>U0/<K"QB4]"^#@?GBN9.HWT
M$ML-/N);E98XUN6N$+"*1I$7..,'!?*]!@=*ZZ/_ %:_2G4 <:NOZE=:Q;VN
MQEA^T#+)&5. Y4JPYP",'G!_"K5[>W,5[>&62Y$T=Q&+:"%MH>+"\J,$.22P
M.>F.U/7Q.]RDL=O:XF\D2)M;S"N6*C<H&<C!)';CUJKIVMWMY=VL;W6U98XD
M8!%SEH=Y;;C(YSSTXZ4Q$C7&HR:%8$/.TTFHM&^&*%H_,< $XR!@#GZ56MM<
MU:W"P&(LWFM\DX+,I\S'E;OXB%.=P!R".PS6C)J5W!H8F629GDE1HYG1<"-I
M0H!X R5/IWJF?%%])]F80PQJ[AR%)8LFZ12O/\1*#'UQ0!'-KVJ;1(I7? )6
M94B+12-Y3,JALY/(Z<'VJPNLZG'?SVLC1H$D(29H'82G"?*H!.#\Q/&?YU$?
M&%Q]ED?[-;HR0M.'DDPA 0-LR/XN?R&<=J>?%%Z9;7;;P8N9GAC&\\8E2/+<
M?[6>*8%:S\0ZS':PH;?[3(L"G#(0\IV%BPP>S#;C'8\@XK?T&ZFNC?M+<BX1
M;@+'(J%%V^6AP ?<G\<U;TN\:_T^.X=%1RSHP4Y&58J<>W%7*0#4^[^)_G3J
M:GW?Q/\ .G4AA142W$+@E9HV (!PP.#3]Z$,0RX7@\]*!70ZBF"1"JL'4JWW
M3G@TJNCYVLK8.#@YP?2@=QU-3^+_ 'J=7'ZGX^LM)U2YL9+*Y=X6P64K@\ ^
MOO51A*3M$F4XPUD=A17"_P#"S]/_ .@==_FO^-'_  L_3_\ H'7?YK_C5^PJ
M=C/V]/N=U17"_P#"S]/_ .@==_FO^-'_  L_3_\ H'7?YK_C1["IV#V]/N=U
M17"_\+/T_P#Z!UW^:_XT?\+/T_\ Z!UW^:_XT>PJ=@]O3[G=4U_X?]X5P_\
MPL_3_P#H'7?YK_C2'XG:><?\2Z[X.>J_XT>PJ=@]O3[G=T5PO_"S]/\ ^@==
M_FO^-'_"S]/_ .@==_FO^-'L*G8/;T^YW5%<+_PL_3_^@==_FO\ C1_PL_3_
M /H'7?YK_C1["IV#V]/N=U17"_\ "S]/_P"@==_FO^-'_"S]/_Z!UW^:_P"-
M'L*G8/;T^YW5%<+_ ,+/T_\ Z!UW^:_XT?\ "S]/_P"@==_FO^-'L*G8/;T^
MYW5-'^L/T%</_P +/T__ *!UW^:_XTG_  L[3]V?[.N^F.J_XT>PJ=@]O3[G
M=T5PO_"S]/\ ^@==_FO^-'_"S]/_ .@==_FO^-'L*G8/;T^YW5%<+_PL_3_^
M@==_FO\ C1_PL_3_ /H'7?YK_C1["IV#V]/N=U17"_\ "S]/_P"@==_FO^-'
M_"S]/_Z!UW^:_P"-'L*G8/;T^YW5%<+_ ,+/T_\ Z!UW^:_XT?\ "S]/_P"@
M==_FO^-'L*G8/;T^YW#??3ZFG5PA^)VGD@_V==\>Z_XTO_"S]/\ ^@==_FO^
M-'L*G8/;T^YW5%<+_P +/T__ *!UW^:_XT?\+/T__H'7?YK_ (T>PJ=@]O3[
MG=45PG_"T-/_ .@==_FO^-=9I&L6FMV"W=F^5/#*?O(WH1ZU,J<XJ[14:L).
MR9?HHHJ#0*:GW?Q/\Z=3!GRSM W<X!/% #Z*Y7^V]02S@N9WBV1M/]I\C;N^
M6;8NU6.2,9_3Z5/I.M7=VSF9HVWVK7"J%QY)#E=I]>GY@T["N='17)6FL:RR
MZ9*R(]O=^2'>9 A#,"2$QG(QZ^U6[C4=4;6KNVLQO6"2$!#&-FU@"Y9LY!QD
MC'M18=SHJ*Y*/Q%>SZ7&2T4-YY$4BJB^8;AI%)55'&#E3GK@=^]7M2U#4(KZ
MRM8MRR2VLDKK#&)#O78 .2./F/Z46%<WZ*Y2?Q5=6]D?,LXUN!NB9@^Y4D3;
MO)7L@W$YST';-:RWD]K#?;IH[^6W176.(!'Y&<'G'../:E89JT5S4?B65]01
M/)B: ^7&X5F#1R-*R'.5'3 XP*@;Q9<7$<$MC9H5\X1O&TOSO^[9\*,>PY_2
MG85SK**HZ7J*:K:&ZA0B!G(B?/\ K%'&[VYS^57J0PHHHH **** "BBB@ HH
MHH **** "BBB@ I#]T_2EI#]T_2@"M1113 L1_ZM?I3J;'_JU^E.I <[K>LM
MI>H0);PHRH//O"(BQ6(L%X(Z'JV3V0U3;6T@O3);6$22W-P$,KR9#1I*(6/3
MY> "!T]:ZDV\+&0F*,F5=LA*CYQZ'U')_.H_[/LMBI]D@V*,*/+&!SGC\>?K
M3$8$?B^.=_L\5@3*4$L8>3:C)L9\[B/]GZ>^.:0^+(3;).NG923*Q#>,EQMR
M#QP,MP?;W%:UUX?TVZ@,/V:.)&.6\E N[@C!X]S5A-,L(P-EG /D5,^6"2HQ
M@9]L#\A1H&IS5WJUK=&:&;2V=+<MYP60B-#ND5B=HR0=G4C'/.*M6GB!C(!-
M:0B W3Q1SHWR* X5><'YCD'G /8UN2:;8RY\RSMVR<G,0.3R?3W/YFC^SK'S
M1+]CM_,#;@WEC.?7/X"BX%D  8  'M2T44AC4^[^)_G22*6B=1U*D"E3[OXG
M^=.H \_3P)-_85K&Y87;B".98]D8B17!8@J!N8>IR:M6N@ZZ-!U.RNC SW,\
MLCE#AYLA=K*<X&=O((]1Q7;45LZ\WN<BP5);7VL>?1>&O$21Z:=MKY5O?&Y%
MOYFP1Y<GD#*X Z 'C)ZUO>&=+N=/O-1EEL8[.&<H5B1PWS $,1C'RGC&1GKF
MNCHI2K2DK,=/"0IR4DWI_E8*\=UQ8'^(LR704V[7<8EW' VD+G->Q5P&M^ +
MK5M:N[Z._@C29P0C1DD< >OM58>48R?,[%8B,I17*KF/'H-I%8W*7END-SFY
M:,NW*QKL"-C/09./6DB\(64E]/ \]Y$D0^7<$+2C=CS%QGY._([]:M?\*OO?
M^@G;_P#?IO\ &C_A5U[_ -!.W_[]-_C71[2/\YS^SE_(4[+PKIUU=16_VJX_
MX]XYI)04V@N<# QG QS]1TJ2;0=)&F6KD20K(((WGR"=[,X8CTP0,CTQTJQ_
MPJ^]_P"@G;_]^F_QH_X5???]!.W_ ._3?XT>TC_.'LY?R% ^%K!;6_9M0D,U
MF-CA%!59 FXYX^[D[1TZ'KTJK86$4FAPSP:;#?2/YWVIY)2AM]H^4 Y 7CG)
MSGI6S_PJ^]_Z"=O_ -^F_P :/^%7WO\ T$[?_OTW^-/VL/YA>RGTB58/#5A#
MMDDE>5?)8J9"H2<F$ONCP<X4@ Y_^M5BX\/Z6MK<-%%^\B\[=)GY5Q$K*,9X
MY/'OFG?\*OO?^@G;_P#?IO\ &@_#"]&/^)G;_P#?IO\ &E[2/\Y7LY)? 9-]
MX=M+/6-*MDGE:"[E".9<!OO $X'0'/'Z$U:.D64DL5V+-([%+>Z^T,&.V.16
M<(#SU'RX'>KJ_#"^1@RZI;@@@@B-N/UITOPTU&>9YI=5@>1V+,QB.23WZT>T
MC_,+V4_Y2B^E6RZI:VXTB%M/>ZBBBNQ,=TZ,.3C/S=<Y &,8JGI,&DVVG7EQ
MJ,<<R0WRPAC&SEDPV0H##!..O.*VX/AMJ5M,LT&KPQRI]UUC;([<<U'_ ,*O
MO?\ H)V__?IO\:/:0M;F#V<[WY?R*C:)IMQ]GELK61Y1#;R&U:4!)?,9A@MU
M!& 2?:H_[/T^/Q3/!+9K'!#9/(RNC;#(J9+JI.2N1P,\U?\ ^%7WW_03M_\
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MC\Z- %'B.Q+;=LP*MLE^3_4G?L^;GNW'&:<=?A E!M+P/$H=XS&,JA!(8\X
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MT?E1M7^Z/RH ,CU%&1ZBC:O]T?E1M7^Z/RH ,CU%&1ZBC:O]T?E1M7^Z/RH
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MG>2<8<-QSZBFW%_+<1RHZH!+.9VP/XB,8^E>NHSOK8^5E.DU>-[EF*QU20N
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M)ONNS@*?H:QQ,X3JN5-:?\ Z,-"<*:C4W)J*HW.KZ=:)(TUY"/+(#@."5)(
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M:QB."% D:#HJC@"L.X\+?:)9Y#=JCR!@72$*SY((\S!P^,<< ^]=%10!SO\
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,A^Z?I0!6HHHI@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ptgx-20210930xex10d3003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )(# 2(  A$! Q$!_\0
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MH.!Q\Q'/0=ZYRWUWQ)IO@>UDL- M[2"VLX8;7[=<B26XD*JD:K'%D89BHR9
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2UL44 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ptgx-20210930xex10d3002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A )(# 2(  A$! Q$!_\0
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M71K:"\V*[33S20,KDNV J?*IR!NR?XNQ];IDT,=Q!)#,BO%(I1T89# C!!H
M\IT>&2PU.X^(.DV]Q?VFI7US!?06P,CO;B39%-&H^\5,9. "2LA]*]#\.WFI
MZCI9OM3M?L;7$C206K(5DAA_@$G)^<@;B.,;L=LFYIVGVFDZ;;:?8PB&TMHU
MBBC!)VJ!@#)Y/U/-6J "N4^&TLDOP]TD2(Z>2CVZ!U*GRXY&1#@^JJI_&NKH
MH X+QB]TWC30OM&D7VH:9:127<$5I"9!)?!E6,2'&U JLS!F(&<GM6?X.F\1
M:?I-]IB:!+%XAN=0N+F^N[A"MDCR.2)%;.91MV@*G/&"5ZUZ;10!Y/)H5R/A
MIXC\"Q.CZC8RNUFA 4W,;/\ :8RJGL3O3TRC>E65M9-4\+7'A7PY87\3ZFDK
MZGJNJ6$ENJO+GS6*L%,DC$X 7Y5XYP #Z0]E:27D5X]M"UU$I2.=HP713U ;
MJ <#(J>@#S?PK<:M9:);Z18Z=>CQ!<3F;5KS4;1U@B?($CAL*LN0 L:H3P%S
M@ UZ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptgx-20210930xex10d3006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /F O\# 2(  A$! Q$!_\0
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M (63X>_YZ7'_ 'Y-'_"R?#W_ #TN/^_)JS_P@'AC_H&?^1Y?_BJ/^$ \,?\
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M7X!RYCWA^)6_X63X>_YZ7'_?DT?\+)\/?\]+C_OR:L_\(!X8_P"@9_Y'E_\
MBJ/^$ \,?] S_P CR_\ Q5%\)VE^ <N8]X?B5O\ A9/A[_GI<?\ ?DT?\+)\
M/?\ /2X_[\FK/_" >&/^@9_Y'E_^*H_X0#PQ_P! S_R/+_\ %47PG:7X!RYC
MWA^)6_X63X>_YZ7'_?DT?\+)\/?\]+C_ +\FK/\ P@'AC_H&?^1Y?_BJ/^$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.\<#<N<9'(.?2LKX=:GNT0V;VEX=IDE:Y:/]TW(XW9Y;VKM+A52RE50 JQD
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M\E(TS_MA_P"AFO4Z\L\:?\E(TS_MA_Z&:]3KLQ/\.GZ'F8'^-6_Q!7EFB?\
M)7KK_KM/_(UZG7EFB?\ )7KK_KM/_(T87X:GH&8?Q*/^)'J=%%%<9Z84444
M<[XOT&ZU_3[:"TDA1XIQ*3*2!@ CC //-=%VHHJG-N*CT1FJ45-U%N[?A?\
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M1C3;LHK3_%W]%V.,\>JM_HNF:G!)(UI%.LCR0'#*A_B'H1^E3MH=BFFG4/\
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M5>3V4;<M[WUO\5[;?C^!K4445RGH!1110 4444 %%%% !1110 4444 %%%%
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M -#->IUV8G^'3]#S,#_&K?X@KRS1/^2O77_7:?\ D:]3KRS1/^2O77_7:?\
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M,/XE'_$CU.BBBN,],**** .:U3_D?]%_[!=__P"C;2M:LG5/^1_T7_L%W_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQW_Y*'I'_8*OO_1MI73US#_\E#TC_L%7W_HVTKIZ "BBB@#RSQI_R4C3/^V'
M_H9KU.O+/&G_ "4C3/\ MA_Z&:]3KLQ/\.GZ'F8'^-6_Q!7EFB?\E>NO^NT_
M\C7J=>6:)_R5ZZ_Z[3_R-&%^&IZ!F'\2C_B1ZG1117&>F%%%% '-:I_R/^B_
M]@N__P#1MI6M63JG_(_Z+_V"[_\ ]&VE:U &!/9:U9:O>76E1V$T5]L:3[7,
M\9A95"Y 56WC 'RY7D'GGC%UOP/<ZFNHSH]I]LN+M)MQ50)8A$B&)B\<@"EE
MW8VL.!WZ=S10.YYY-X(U:5=*3_0";$1NMS(Z-/&PD+,@?[.,H1@#9Y>,8P15
M>_\ AWJ$]P3;_8X8/M<\H2"5(R/,?<)06MY-L@'R_+@X PXZ5Z713OK<72QQ
M=IX2O+?Q%]ODM].G423N]T\A\^X#J0L<@V8VKG Y/'8<@]A;IY=M$GE1Q;4
M\N,_*F!T' X'T'TJ2BD%M;A1110 4444 %%%% !7/ZQ9ZW>:M;I%;6,^D)M9
MXY;MXG9PV<L!$P8# (&1D]:Z"B@#CH]"\069WVATTR644T5BSRN/,\V16)D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8[_ /)0](_[!5]_Z-M*Z>N8?_DH>D?]@J^_]&VE=/0 4444 >6>-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )*]=?\ 7:?^1HPOPU/0,P_B4?\ $CU.BBBN,],**** .:U3_D?]%_[!=_\
M^C;2M:LG5/\ D?\ 1?\ L%W_ /Z-M*UJ .#\3V2?\)";R/3)KR]"H(4ET^25
M3C_GE<(?]'.3R6.#CIWJM>W&MZ?%J$%E+KANY=0F>-UM5\L A2JEOL\GRG/#
M 8RN"PKT6BE;^ON_R#J>?:?J&L6&L3W5TFK/'=2Q/-$M@S*FZV&-N$S_ *P$
M'D[<#.,DFQ::CXA_M311=2:BR36<1NH(K/8L<A7YF=C"5//\(D0C  5LUW-%
M4V)+2Q!9MNLH&\R:3,:G?/'L=N.K+A=I]1@8]!4]%%)C"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH QW_ .2AZ1_V"K[_ -&VE=/7
M,/\ \E#TC_L%7W_HVTKIZ "BBB@#RSQI_P E(TS_ +8?^AFO4Z\L\:?\E(TS
M_MA_Z&:]3KLQ/\.GZ'F8'^-6_P 05Y9HG_)7KK_KM/\ R->IUY9HG_)7KK_K
MM/\ R-&%^&IZ!F'\2C_B1ZG1117&>F%%%% '-:I_R/\ HO\ V"[_ /\ 1MI6
MM63JG_(_Z+_V"[__ -&VE:U !17-:E;:D?%%E%#X@U"WMKE9':WCCMRJ[-F
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MS1)I]U,0,.HDC>-06(Y^7+Y&1T/I3M_7H!U=%<CJ=WJ&AZ<\L>NR:G.[0/'
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M:+J"VDLS3#S';RC(0(ROW<8^8-GCICFNIHZ7#K8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH QW_Y*'I'_ &"K[_T;:5T]<P__ "4/2/\ L%7W_HVTKIZ
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M2N3T-3VFD:;I\,45EIUI;1Q,S1I# J!">"0 .">]7** ,^WT'1K-;@6VDV$
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M2/\ GXUO_P 'E[_\=KHJ* .=_P"$*TC_ )^-;_\ !Y>__':/^$*TC_GXUO\
M\'E[_P#':Z*B@#G?^$*TC_GXUO\ \'E[_P#':/\ A"M(_P"?C6__  >7O_QV
MNBHH YW_ (0K2/\ GXUO_P 'E[_\=H_X0K2/^?C6_P#P>7O_ ,=KHJ* .=_X
M0K2/^?C6_P#P>7O_ ,=H_P"$*TC_ )^-;_\ !Y>__':Z*B@#G?\ A"M(_P"?
MC6__  >7O_QVC_A"M(_Y^-;_ /!Y>_\ QVNBHH YW_A"M(_Y^-;_ /!Y>_\
MQVC_ (0K2/\ GXUO_P 'E[_\=KHJ* .=_P"$*TC_ )^-;_\ !Y>__':/^$*T
MC_GXUO\ \'E[_P#':Z*B@#G?^$*TC_GXUO\ \'E[_P#':/\ A"M(_P"?C6__
M  >7O_QVNBHH YW_ (0K2/\ GXUO_P 'E[_\=H_X0K2/^?C6_P#P>7O_ ,=K
MHJ* .=_X0K2/^?C6_P#P>7O_ ,=H_P"$*TC_ )^-;_\ !Y>__':Z*B@#G?\
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M^?C6_P#P>7O_ ,=KHJ* .=_X0K2/^?C6_P#P>7O_ ,=H_P"$*TC_ )^-;_\
M!Y>__':Z*B@#G?\ A"M(_P"?C6__  >7O_QVC_A"M(_Y^-;_ /!Y>_\ QVNB
MHH YW_A"M(_Y^-;_ /!Y>_\ QVC_ (0K2/\ GXUO_P 'E[_\=KHJ* .=_P"$
M*TC_ )^-;_\ !Y>__':/^$*TC_GXUO\ \'E[_P#':Z*B@#G?^$*TC_GXUO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQI_P E(TS_ +8?^AFO4Z\L
M\:?\E(TS_MA_Z&:]3KLQ/\.GZ'F8'^-6_P 05Y9HG_)7KK_KM/\ R->IUY9H
MG_)7KK_KM/\ R-&%^&IZ!F'\2C_B1ZG1117&>F%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 >6>-/^2D:9_P!L/_0S7J=>
M6>-/^2D:9_VP_P#0S7J==F)_AT_0\S _QJW^(*\LT3_DKUU_UVG_ )&O4Z\L
MT3_DKUU_UVG_ )&C"_#4] S#^)1_Q(]3HHHKC/3"BBB@#D_$'C1]"\26^D+I
MC7'G6%Q>>:)=N/*&=N-ISGUSQGH:Q;OXFWRZ%X7O=.\,_;;S7]WE6?VY8MA
MS]]DP>/7%=O=:-I]YJ$5]<6RO<Q0R0(Y8\(^-PQG'.!7FWQ!@D\/:QX M] T
MK[6UG<21VMC]H$>\", +O?...YJ5T3ZM?F_TM]P.^K79_DOUO]YIW'Q#\2:+
M$+WQ-X"N--TI6"RW<&I171BR0,E% .WU-:/BSQQ>Z'J6B:?HNA#6[C5ED>%1
M>K;C"@'JRD'(.>HZ5AZV?'_C;2)] N/"-MH-I=X2XO)]3CN2(\C<%1!G=QWX
MJIX[M-3L/&_@&S\.?8OML$-Q%;_;]_E86-1\VSYN@/3O5+5I/O\ H_U%WMV?
M_ -2[^(7BK1;<WVO_#VXLM+CQY]S;ZG#<M$O][8H!('UKK=9\4Z3H7A\:W>3
MG[(ZJ8O+7<\Q;[JH.Y/I7F?B6\\>WEU;>%?%-YX?TK3=9S!]OL(9GWGO$"YP
MK,,XR![&MCQ79)8^,OASI 4G2X)I%4/R#(D8$>3Z]:%K9=W;_/\ X -V;?9-
M_P"7ZW+C^/\ Q-;1&_O/AWJ,.D*N]IUO(GG5.Y, ^88YXS7;Z9J5IK&F6^HV
M$RS6MP@DCD7N#5H@$$'&.^:YC4O&'A'P?H]G-<7]K::;,3';&UA:2,D<D 1*
M0*+I;A9CO''BN7P?HD-]!IO]HS374=M'!YXARSY ^8@^E8,_CKQIIL$EYJGP
MVG@L(5+SRV^KPSNBCJ0@ +5C_$?Q1IWB7P%INJ^'I?[0B36K=8QM:'?(I^[\
MX&.W.,<UJ7VL_$?6K"XTV/P';:8US&T7VNYUB*9(P1@G:@R:GWK-K>_Z)_J.
MZNNUOU:_0[S2M3M-:TJUU*QD\RUN8Q)&WJ#Z^]7*\H\0:3J/A?2/ GAK1M7G
MM&:\%K+<1L1O!1BQ*]#SD@'(SBK>JVFJ:;?Z)X'TKQ%JN_4/.N;K4[R837*Q
M(!\J,1@$D\''%6[7?+WLOS_(B+:2YM[)O\OS/3*S=/URQU34=1L;21GFTZ18
MKC*$!7(S@9Z\8]N:X<VVI^ ?$FAVX\0ZIJ^DZO<&SDCU.432Q2%25='P#CC!
M%9OP_P##S:=XU\972:UJD[V-SY:I>7F8IBT0.Z;Y>2.@/85*:N^R3^]6_P _
MQ0VWHNMU]SO_ )'KE%?/M]KJ365Q?#QUXJU#78DD;;H:.=/21<ML * ,H'4Y
MZ=:[.X\2:QK^A^"]+M=0.GW^OP>=<WD2#<B(@9]G8,Q(^G--7:T\OQO_ ),;
M=GKY_@>GT5Y=<:3K7A3Q?X4LHO$^K:AI5W>2+(E_/OEW")C@N,;D/7# X(&*
M?;6>J_$36=:GD\2ZMI.E:=>M96MOI4P@=V0#<[O@DY)X%&^W]6M_F%[;_P!7
MO_DSTZBO'-7\0Z[IO@WQMHEUJLTVHZ)Y1M]10^5*\4A!7<5Q\PY!(ZU-XBTS
MQ!X9\-1^,O\ A,-7GU"$PR7%I(X^QLK,H9%B XQGKDGBA:^FGX[?\$-=K:Z_
MA_P^AZ:]WJ"Z[%:+IF[3F@+O?>>HV2 X$?E]3D<YZ5H5P\^HWA^,&G6B74PL
MY-%DF-N)"(R_F##%>F<<9KSNYUB[AO[H^)_&'B3P[XC\V06J."NF'!^0 *I#
MK@C))_IE)[?/\&U_7D/NUY?BKGM6IZY8Z1<Z?;W<C";4+@6]NJH3N?&>O0
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M?3FL[JVCM;Z&[WB0(K$YB*C&>?XN*[.BDE:WE^M_\P:O?S_X'^1YNGPZU!_
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M -#->IUY9XT_Y*1IG_;#_P!#->IUV8G^'3]#S,#_ !JW^(*\LT3_ )*]=?\
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M2G?&69AY8! 0C<0"=W'7)YKL**3BFK/^M+%+3;^NIPLOP]EG?3DEU.U>*R6
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M:;]FG<L.1.Y<F0CK]U>>:?K&K^)H_%ZPZ5!J+VRR>7)%- /L[ QDJZL(>F_
M),N1C[N#D=[152]YC[ON>46MSXB74;F^\W7-DT5G%=W;:5B:$#SRZQ1^5APK
M%!D*W#9YZU:TH^+;;1;K[']M5K:Q\VWMIK58Q-,\TV[<2A;(78VT>W!!P?3:
M*):W%;6_]=/\K'EO]L>,1HD%P]S?,RW+ 106$OVB9-HPK,]D%7G=SY:@Y WC
M!)U[/4M;.O:G!>W&L?8_)=XY8+#"VO3"JIM_WC\]5>0$@_*.*[NBG?6X6T.<
M\9Z=-J7AMT@>[WQO'((H.#+AAPP R1WP,=.>*Q[B&PN?B'&PTJ^MKFWF5FU
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:TSOEVML+,#AV.[^&NGU+2[O4OASIFG_ -F1Q2F>U5K6XA>YC1!*OWT9MQ7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y9XT_Y*1IG_;#_P!#->IUY9XT_P"2D:9_VP_]#->IUV8G^'3]
M#S,#_&K?X@KRS1/^2O77_7:?^1KU.O+-$_Y*]=?]=I_Y&C"_#4] S#^)1_Q(
M]3HHHKC/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO6N+MC)J%]'91K#'.T:*#M.Y\# &.Q)(IO3<5]+GIE%>?7'Q4LX=)FOTT]G
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M%3<^;NV$B#:"8]W&[(..=N*[ZA:J_0=];!1110,**** "BBB@ HHHH ****
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M,X8#H<$'!]:/Z_7\_P 0T_K[O^ 4]'T6WT:&=8Y9IYKF4S7%Q.09)G( W':
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M )L?6YQUWX#62.:Z75;NZU?]T8;N]$9V^6250K&B@J<L"<;L,>:Y:+P?K_\
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M6%I"<DY"[\$\E=VT^E;]%%"T5A];A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y9XT_Y*1IG_;#_ -#->IUY
M9XT_Y*1IG_;#_P!#->IUV8G^'3]#S,#_ !JW^(*\LT3_ )*]=?\ 7:?^1KU.
MO+-$_P"2O77_ %VG_D:,+\-3T#,/XE'_ !(]3HHHKC/3"BBB@ HHHH *X[5;
M2^OO$PM_[!N$TX21S&]MS;CSI0,*TA,@<*G' 4DXZXX/8T4G%/<.ECS6STK7
M].L(I8?"Z275C906,<320,)9%?/GJ"X!"C) 9E8EB/EZUJQ>&O,L="G73;J*
M[M-0-Q(+N6/>N]F:1\1NR<DY^4D@''J*[6BGY^=_QO\ U_PQ+BFFN_\ E;\O
MZW.2UFQUP:A::@T%OJ\-M-(8[2VB$$BHZ,H):24JY&0"?EX)P.U,T7P_J-N=
M#M;T(T&E:<NQB0R&Z/RYQD'Y%! /'W_7IV%%)*W]>37Z_>.W]?U]QP?B'1/$
M%R)?-MK;59[O3IK#S;:-;=+=G((<K)(QV^I4D_*.*AT7P[K=GXR2ZN(9C;QW
M,\AD>2(P%'0*&C /F^8=J[@_RCYL=J]"HIK3\?Q=P<4_S_0IQ1:B+RX:>[M7
MM&&((X[9DDC]=SER&_!5KB/#&@ZWI)6VO[2ZN+>W@$/FJ\$<CMYJD&%XV5_+
M/+.)#DGH#T/H=%"T=P:NK'F-]X3UN^M[C3X[!;<PM>R+>F2,K=^=)O5 ,EN1
MPVX 948S6UHUCJ<-A>MJ6C7-RTKR-%%*UM'),OE!=MP(F$3Y(*KPV!C.*[2B
ME;1KRL%E>_G<\^;0+S7?"NOQZCHEU;ZE>6^U())(4B+*C"-$\N5AM4GJ^,DY
MP!@#H/$.E7NH^'[.SM'DBG2XMG:2(INC"2*68;P5) !/(/T-=#13_P T_N#E
MTMZ_B>=>(? MY)=6EWI\]Q>W\3RWAO+IXU;[0J((@0@10#L"G:HX)S6SX/T"
M]T;^UOM8Q->R).\RL#OE,8\PCDD -D 'L!VKK**5MU_7];?<@MK?^OZ_S9Y]
M::+KL<6C:8+.>)=,9?-N&^RO;7./O2#(,RR,">@7DG)/6L/2O .O6=CIEI)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M N,<8H=];?U_77^D6<A=_$#6KV":_P!'$2PR6NG2Q03L (S-.Z/\P0[LX ]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!Y9XT_Y*1IG_;#_ -#->IUY9XT_Y*1IG_;#
M_P!#->IUV8G^'3]#S,#_ !JW^(*\LT3_ )*]=?\ 7:?^1KU.O+-$_P"2O77_
M %VG_D:,+\-3T#,/XE'_ !(]3HHHKC/3"BBB@!"0H))  ZFH+.\@OH!-;MN0
MDX.,9&<9'L:QM3D%W?RV\HDDMX#'OA601KSRSNWH 5XSSSUK,L=1LK"Z,OGW
M#6J,S6\$/*QQ<J&<GD@G) [#''2G8Y9XGEG9[':45%!/%=0)/!(LD3C*LIX(
MKCWT]=:\?ZS;7=[J:06]G:M%';:C/;JI8R;CB-U!)P.N>E(Z;JUSM:*\\T7Q
M%KU[*NAV=Q:M<PO=_P"GWT32AXH9?+7Y49=S'/+9'3H<U/I'BO7_ !.98])B
MTRUFLX5:X6Z62199"[J51E(VK^[)W$-U^[Q0G=)]PO9M/=:?,[RBN*N?%VHV
M^FW\YAM1+;ZU#IZKABNQWC4GJ,M\YP>!P.*HV/BGQ3?MI>W^QXUU.>Y@BS;R
ML8?*+?.?W@WY"_=^7_>[4D[I/^MD_P!4+F7]>K7Z'H=%>9)\1-5NV@MK>V2.
MZCMC/.R:9<WBR,)'C"*(<F,'RR=S$XST-6+SQIXB-KJE];6=G:0:;I\%]+;7
ML$AF8NI9HCAEV$;>I!^E-.ZO_7]:?UH.^MOZZ?Y_UJ>BT5R/A2]U2\\2>)OM
MEZDMI%<1+!"(V!B#1(V 2Q&/FYXY.3[#,TSQWJFHZI&R:?*]A)>O:F&/2[HM
M&BLR^:;C'E'E>5 X!ZDC%'9/KJ%U:YZ#17'ZUXIO_L<$^B6=V(/-*7,]UH]T
M[1#'!$'[MW!SRRYQCH:QH_&M^]^_V9;*:XN;:Q2)TEF, EEED1CM8C@;>@56
M/0GI@6NGR^_8&TE=GI-%>>3>*?%,&NKHC'1VN6U!+1;@6\@38UNTNXIYF<@K
MTW=.,]ZA;Q_JO^C:<8H4U%KF[AEN8=.N+J,+ X7<(8B7^;<.K8'J:5T]OZ_J
MX_Z_/_)GI-%>=KXL\0:W:W=K9VL6FW5KI[7%Q]MMY4:0EI$7RP2K1@^7N#,#
MC(XJ?6]0U"+X16=[;W4JWS063"8RLK,S/'G<PYYR0?8FCO\ +\6U^@KZI?UT
M_P SO:*X&_\ &6L:#?SV^J)830V+V\M[<6\+H%MIBZ[@I=L%&4$DD@KD\5J6
M^M7FK> ]1U=BD(EAN)+-H<J1$-WEMG/WB &R,=12E+EBY=OZ_KYC6LE'O_7]
M>J.JHKQ>X\2ZTGPQET8:C<?VY"C%KWS&$OD+#YXDW9SDJ53/J:Z36/&FH:1;
MF2"[TR5;6* R6OD37$\FX+N+NI"PGG/(8<@DC-6U9M?UJ2I7BI=[_@>B45Y^
MWB35[M?M,IM%M4UX:<D42RI(0LNW<SK( >/X<$'J>.*-!\<ZIK&H6;_V?*]C
M>7#Q"./2[I3;H-VV1KAAY3@[1D#&-W4XJ8OFV_K1/]1MV;7;_-K]#T"BN=%S
M/_PL4VOG2?9_[*\SRMYV;O-QNQTSCC-8.K^.=3M]=U2UTZQEGCTQD1H(]+N;
MA[IBH<A98QLBX88W Y/H.:(N]O._X.P=6NW^5ST"BO.I_B'>V6K6]A=6]NK1
M:A)%?OL91%;DIY3C)X)\Z+.<CAJC@\5>(9Y[^>VTY)+DV5K<1Q*LK^7%++*
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MW50I'!Q@BKT/B/7M)N?$&HW%U!=Z987ELLT+0OOB@:)"S*V\C(W;CQSACQD
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'EGC3_ )*1IG_;#_T,UZG7EGC3_DI&F?\
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M*,# '7+K;P_KH\ V6BP7-I9,NFFVGBD@,CARFT;9%D 7![X:NSHHMI;^NO\
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M(&T&-E''?DCI6M13&U<\ZN= \4W/VF0W.I)(C.UL(M1* DW3D9 ?!'DD8#<
M8&,@8@UG0?&*K!!IUU?FRBN)PH%PTLX4E3$Y8W$191\_#.W;*MV],HI*-G?^
MOZ[#>K;[G,^(+"[N-,TUQ:7MW>6K!_.LIHH9XGV%2ZK(?+;J<JQQSWKF[C2/
M%9TZ%?LMVK&*;R(]/NX[4PSM(2DLX1E1^"-P7>"<_*<UZ513ZW%;1(\\OK+Q
ME+:W=E%%>^:INW2\2\15DWQ-Y03Y]PVL1U  .,>HN1:/JUGK5PNS5[A"@^P7
M7]I,T%O\G(FC:4%SOW'.U^" , 8';T4K:6!*W]>G^1P?@_3?$=F)?[>.I39D
MBPAEP X)W2!C=2$H<C*84<#"=15W7;'6W\7Z==Z?'?36RA5E4W/E6R#)RQ"S
M*2V#T:.0' 'R\FNOHIO5I]O^&%RZ-=SR[3]"\<%+B*_O+\N\L(E>*;8L@\]"
M[QO]I8J/+##:L<8(/3-:5QH?BR*34[/3[R>.TMX'.FSS7C2O*\F,K)N;<=F&
M"DG^,<\5W]%*VEOZ_KMV*>KO\SSW0="\2-)8KJ=SJ:6T<DLACDN&C*':FQ6*
MW,K2+N#'!<]2.!Q70ZOIVK7GAA[2>6VO+XS1-NMX3 A42*Q^5G;H ?XN:Z&B
MF]1)6.0T7PK<K/+/J5]>B-=3GNX;',/DC,K,CY5-_0YP7[].U5O$EGXDN/%%
MI-I=K=I;PRP,T\=Z1')'O'F*T9F50=N>L;Y'<'&.XHH6C3[#>K;[_P##GETW
MA_Q4^I27*0Z@+E+>:.6Y;4%*S;IXFVP#>3%F-64<)@X_WJGLO#?B(M.;<:CI
MR,MW+;K<:B7(E(A$!E*NWF8VOU+#CG.>?2J*25DEV37W_P!:=@ZW\[GF%OHO
MBW_A&[N&ZFUDW'G1M'##(JLQ .X[S>ERA)!($D9^48&"16C8:?XEC\16%S/:
MWYA:W5;F-]08P083!$>)\NV>N^-CD_?&!7?44_Z_"PN73^O4Q-2TF+5O"$NG
M2VEQB2UVBWN)RTF[;PKON.XYQDEB#W)K!O;'47FTW3W\.3RV0MK<7=W;-;^9
M(R'(C8O(K!%/.0&SD@8ZGN:*.K?I^%_\P:NK?UK;_(X/QOX=UWQ+!;W%B\<0
MMIHREC=0!SO693YP99@OW1D Y."1P3PS2M&U_2O$<TTEO)>6PN;FZ+E+;8P<
M$J(B2)5ER0IW'9M'6N_HH2MMY_C;_(;5]SE]0T W7BNUU5+,LKZ?<6]RSS8Q
MN\O8G4XZ-RHQWKF+7PKK ANKN6RU3=%':Q6T#7=KYZ&)F.Z,A?*8*&PHDP6Y
MW8KT^BE;M_6K?ZB:NK/^OZL<IX<T2X@\-R:3JUO<.+IYYY"TJ?*))"PC8H1\
MV#SM&WKS6!>>%]6C\*:%:V^G77VZ#3GLI3;7,"B/<J@I() 08R1RR'<,<9S7
MI5%#2>_];_YC6G]?UUU//M/\'Z]I_C?2M4FO[:\MXK:6&64VQ5XTVH%CSYO/
M*DY"CG=D'(QZ#1157TL)12T04444AA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!Y9XT_Y*1IG_;#_P!#->IU
MY9XT_P"2D:9_VP_]#->IUV8G^'3]#S,#_&K?X@KRS1/^2O77_7:?^1KU.O+-
M$_Y*]=?]=I_Y&C"_#4] S#^)1_Q(]3HHHKC/3"BBB@ HK,UC7;'0X%DNW.6X
M2-!EF_"LS3/'&EZC=);%9;>1SA3*!M)],@\4[/<QEB*49\DI*YTU%%%(V"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9L=N"2,@&NE\1^#+363#)##&LQGMOM#/*XW0PL6"C'0C<<$8/O6A!X3T2!8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+/&G_ "4C3/\
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MCYJATCP;J&G>+!J+RP&W2:63S1<2,TB.NT)Y)&R,C"YD4[FV\]31'S\_^!^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'EGC3_ )*1IG_;#_T,UZG7EGC3_DI&F?\ ;#_T,UZG79B?X=/T
M/,P/\:M_B"O+-$_Y*]=?]=I_Y&O4Z\LT3_DKUU_UVG_D:,+\-3T#,/XE'_$C
MU.BBBN,],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA_$H_P")'J=%%%<9Z84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y9XT_Y*1IG_;#_ -#->IUY9XT_Y*1IG_;#_P!#->IU
MV8G^'3]#S,#_ !JW^(*\LT3_ )*]=?\ 7:?^1KU.O+-$_P"2O77_ %VG_D:,
M+\-3T#,/XE'_ !(]3HHHKC/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /+/&G_)2-,_[8?\ H9KU.O+/&G_)2-,_[8?^
MAFO4Z[,3_#I^AYF!_C5O\05Y9HG_ "5ZZ_Z[3_R->IUY9HG_ "5ZZ_Z[3_R-
M&%^&IZ!F'\2C_B1ZG1117&>F%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >6>-/^2D:9_VP_\ 0S7J=>6>-/\ DI&F?]L/
M_0S7J==F)_AT_0\S _QJW^(*\LT3_DKUU_UVG_D:]3KRS1/^2O77_7:?^1HP
MOPU/0,P_B4?\2/4Z***XSTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#RSQI_R4C3/^V'_H9KU.O+/&G_ "4C3/\ MA_Z
M&:]3KLQ/\.GZ'F8'^-6_Q!7EFB?\E>NO^NT_\C7J=>6:)_R5ZZ_Z[3_R-&%^
M&IZ!F'\2C_B1ZG1117&>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >6>-/\ DI&F?]L/_0S7J=>6>-/^2D:9_P!L/_0S
M7J==F)_AT_0\S _QJW^(*\LT3_DKUU_UVG_D:]3KRS1/^2O77_7:?^1HPOPU
M/0,P_B4?\2/4Z***XSTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#RSQI_P E(TS_ +8?^AFO4Z\L\:?\E(TS_MA_Z&:]
M3KLQ/\.GZ'F8'^-6_P 05Y9HG_)7KK_KM/\ R->IUY9HG_)7KK_KM/\ R-&%
M^&IZ!F'\2C_B1ZG1117&>F%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >6>-/^2D:9_P!L/_0S7J=>6>-/^2D:9_VP_P#0
MS7J==F)_AT_0\S _QJW^(*\LT3_DKUU_UVG_ )&O4Z\LT3_DKUU_UVG_ )&C
M"_#4] S#^)1_Q(]3HHHKC/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /+/&G_)2-,_[8?^AFO4Z\L\:?\E(TS_MA_P"A
MFO4Z[,3_  Z?H>9@?XU;_$%>6:)_R5ZZ_P"NT_\ (UZG7EFB?\E>NO\ KM/_
M "-&%^&IZ!F'\2C_ (D>IT445QGIA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'EGC3_DI&F?]L/\ T,UZG7EGC3_DI&F?
M]L/_ $,UZG79B?X=/T/,P/\ &K?X@KRS1/\ DKUU_P!=I_Y&O4Z\LT3_ )*]
M=?\ 7:?^1HPOPU/0,P_B4?\ $CU.BBBN,],**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \L\:?\E(TS_MA_P"AFO4Z\L\:
M?\E(TS_MA_Z&:]3KLQ/\.GZ'F8'^-6_Q!7EFB?\ )7KK_KM/_(UZG7EFB?\
M)7KK_KM/_(T87X:GH&8?Q*/^)'J=%%%<9Z84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Y9XT_Y*1IG_;#_P!#->IUY9XT
M_P"2D:9_VP_]#->IUV8G^'3]#S,#_&K?X@KRS1/^2O77_7:?^1KU.O+-$_Y*
M]=?]=I_Y&C"_#4] S#^)1_Q(]3HHHKC/3"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /+/&G_)2-,_[8?^AFO4Z\L\:?\
M)2-,_P"V'_H9KU.NS$_PZ?H>9@?XU;_$%>6:)_R5ZZ_Z[3_R->IUY9HG_)7K
MK_KM/_(T87X:GH&8?Q*/^)'J=%%%<9Z84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y9XT_P"2D:9_VP_]#->IUY9XT_Y*
M1IG_ &P_]#->IUV8G^'3]#S,#_&K?X@KRS1/^2O77_7:?^1KU.O+-$_Y*]=?
M]=I_Y&C"_#4] S#^)1_Q(]3HHHKC/3"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQI_R4C3/^V'_H9K
MU.O+/&G_ "4C3/\ MA_Z&:]3KLQ/\.GZ'F8'^-6_Q!7EFB?\E>NO^NT_\C7J
M=>6:)_R5ZZ_Z[3_R-&%^&IZ!F'\2C_B1ZG1117&>F87C&_GTWPI?W-LYCF5
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MFK)J%CKSVMO&+H^4B @\+USEO7''2OJ6)B\*,>I4$T /HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \L\:?\ )2-,_P"V'_H9KU.O+/&G_)2-,_[8?^AFO4Z[,3_#I^AYF!_C5O\
M$%>6:)_R5ZZ_Z[3_ ,C7J=>6:)_R5ZZ_Z[3_ ,C1A?AJ>@9A_$H_XD>IT445
MQGIG.>.H9+CP=?QQ(7?:#@>Q!KQOP]KRZ#)-*+,33-MV/OV[<9X/!."<9 ()
MQC.":^A9(TEC:.10RL,$'O7-7'@/0[B8R&U12>2 HKOPN,C2IRISC=,31X=?
MWUQJ=_->W3[YYFW.<?R]NU1232S;1)([[1A=S$X'M7N/_"O=#_YX+_WPO^%3
MVG@;1+2=95M49EZ94<5W_P!KTTK* N4O^'82GA73()5(86D:,.F/E -2V6A:
M5INC'1[.QAATXJR&W5?E(;.X'USD_G6@JJBA5 "@8 ':EKPI/F;91RU[\./!
M^H:7;:;<Z#:M:VQ)A5=R&/)+$!E(8 DDXSCFK%QX&\+W7A]-"ET2T.FH=R0*
MFW:W]X,.0WOG)KH:*0'-R^ ?"LWAZ/07T2V_LR-Q(L !&'P1NW [BV"1G.>:
MM:+X2T#P[I\EAI6DVUM;2KME4+N,HQC#ELEN">I/6MJB@#G-$\!>%_#FJS:G
MI&CP6EY*I5I$9B #U"J3A1QV HU_P%X7\47L5[K.D0W5S$H59"S*=H)(!VD9
M')X.:Z.B@#G-7\&Z5?Z>L=I:P6=[:VDEMI]S$F#:;T*Y0#IC->1:=\%]?=]+
ML[RPT&R2RN%DEU6TFF-S*H;/ /&3ZD#'MTKZ HH PG\&>')-)GTI](MFL9YS
M<RP$':TIQECSUX%;@ 50H& !@4M% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKY?>']K8?S^X]3HKRS_A87BG_H$6_P#X#2__ !5'_"PO%/\ T"+?_P !I?\
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M (6%XI_Z!%O_ . TO_Q5'U&KY?>']K8?S^X]3HKRS_A87BG_ *!%O_X#2_\
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M3_T"+?\ \!I?_BJ/^%A>*?\ H$6__@-+_P#%4?4:OE]X?VMA_/[CU.BO+/\
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M TO_ ,51]1J^7WA_:V'\_N/4Z*\L_P"%A>*?^@1;_P#@-+_\51_PL+Q3_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptgx-20210930xex10d3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F (T# 2(  A$! Q$!_\0
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EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ptgx-20210930xex10d3004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 <(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ KS
M#XX7=U9>$;%[2YFMW;4%4M#(R$CRY.,@UZ?7E7Q[./!NG'_J(K_Z*DH R_@=
MK4LL>MC4M1FE.Z'RS<2LX7A\\GIVKV=6#*"""#R"*\+^ ]U%;W6MJPD)9(2!
M'$S\9;^Z#7J%QK]GI-S)9PQS[G598X3;R *"Q5S]WH.#CWH Z:BO,K+X@^*]
M86:YT3P<M_8+,\4=RMXJ"3:V,[6P15O_ (2SQ]M_Y$%LXZ?;X_\ &@#T*D)
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M469&8_D#0!U%%< ?C+X*'_+_ ''U^R2?_$U(OQ=\(L@=;F\*-C#"QEP?_':
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M (5I4=:WA2A!62/+Q&.KXBHZDY.[,2]\-V#6-PMEIFG)=F-A TMNI0/CY2P
MSC-<T_A6^&DJ-4L=*FF\Y-QTZ#9\N\=MC-CUYZ9KT&BJY5V,57JK[3^\\XO]
M!TRV\,3/'ID46I"7]W)+:/L!,WRY^4<8QQ^%7_"VB6=V;Z2_L-.G?S!M>*TV
M)C)QM5AD<8ZUUNH?\>R?]=X?_1BU;HY(]AO$57]I_>97_"-:'_T"++_P'3_"
MC_A&M#_Z!%E_X#I_A6KBC%'+'L3[>K_,_O,K_A&M#_Z!%E_X#I_A3?\ A%]!
M_P"@/8?^ R?X5K44<L>P_;U?YG]YD?\ ",:#_P! >P_\!T_PKSGQQJ.C)*=
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MEU.49DD8Y"9[#^I[UV7FI_?7\ZY[QML?PW,#M8<D=^0C$'\ZM_\ ")Z%_P!
MV+\V_P :WA!07+$\O$XFIB:CJU7=LU_-C_OK^=8'C>1#X+U;#J?]'?O[58_X
M1/0O^@;%^;?XUA^,/#FCVGA'4YX+&-)4@8JP)X./K2J? RL'_O%/U7YA\*AC
MP/;>\DG_ *$:[4UQGPL_Y$2T_P"NDO\ Z&:[.IH?PX^AMFG^^U?\3_,6BBBM
M3@"BBB@ K$\4:[/X>T@WL&EW.HOO5!# "2,_Q' )Q] ?I6W10!Y@OQ%U"]N[
M47'A&]@2.97,RK<,47.&P# ,_*3QFNOT;Q?I^MZDUA!!?P3B(RA;NU>#>H(!
MV[@,XW+G'J*Z"N<U!)8_'6E7?D3-;IIUW&TD<3.%9I("H.!U.UOR- '0;E#A
M,C<02!WP/_UBL77?%-CX?NK:WN8+V>6X5W5+2V:8A5P"6"\@?,.:F-O=-.-3
MVL)U7:MMN!_=GDKZ;B0#GV Z<U3 DN/'5G=+;W @33)XV=X64*YEB(7)&,X!
M_(T 5D^(.FN#C3=<&/72YA_[+4NG^.=*U'5;;35M]3@N+G<(OM5C)"&*J6/+
M =A73UR7B/\ Y'GP?_UVNO\ T30!UM%%% 'C_@8[_BUK9]/M'Z2J*]@KQ#PS
M?2:=\1_$-W'%'+Y0NF99)1&,"4$X)'7BO1=$\63ZW):I#80)]IM/M:9N]V$W
M 8.U3@_,.*Y\-\#]6>OG7\>/^&/Y'5454\S4?^?6U_\  EO_ (B@2:AGYK:V
M ]KAC_[)70>06Z*@@:Y8GSXHHQV\N4OG\U%3T %%4[V>\@"?9+(7).=P,H3'
MIUK/.H^( V!H$)7U^WC/_H% &Y16'_:>O;@/^$>7'J+U/\*<VHZV%RN@ GT^
MV(* -FLOQ&Q3POJS*,L+*8@>OR&J_P#:7B KQX?CS_M7RC_V4US'C+QM<:1I
M<MA?:7''=7D+QJB70DV@C&X_+TY_&IG-07-(VP^'J8BHJ=)7;'ZOXWM?#'A+
M38(BLNIR647EP]ER@^9O;^=4_ ?@NY-X?$FO;GOI29(HW[9_B;W]!V_E6\!>
M!Y;J6+Q!KP+R$*;>!^P P&8?0# _R/51QTKGA&527M)[=$>KB:]/!4GA<,[R
M?QR_1>7YBT445U'B&%J]G?W>IVR0:W>Z="Z%1]F2%@SCG!\Q&/3/3^[3M-T&
M>RU+[==ZU?ZC*L1BC%PL2A Q!/$:+D_*.M7-182H+)41YIP2H?.% _C..>"1
MTYR1TZB2QM9K6$)+>2W+8ZR!>/I@9_,D^] %NBBB@ HHI"0!D]* *LFGVDE]
M%?O$#<Q*520DY4'.1^IKSGQEXSN-7NAX<\+F2:YD8K--%T [J#_,TSQ?XWNM
M6O3X;\,J\DTC&*6=!^!"GL/5O_UUT_@OP5:^%K/>Y6;495Q+-C@#^ZOH/YUR
MRFZLN2&W5_Y'N4,/3P%-8G$J\W\,?U?EY#/ _@J'PM9&68K+J,RCS9,<*/[J
M^W\ZZ^BBNB$%!<L3R<1B*F(J.K4=VQ:JW%C;74T$T\0>2!MT3'/RGCG]!5JB
MJ,0HHHH **** (;BWANH6@N(8YHF^\DBAE/U!JG_ ,(]HG_0'T__ ,!D_P *
M?K.I#2-(N;\Q^:(5W;"X3/..IZ5G^%/$J>*=&&HI;&V1B,(S[S@J&ZX]Z +G
M_"/:)C_D#Z?_ . R?X5YIXUUC36N_P#A'?#>D64NH2-Y<DL5LF4/]U#CKUR>
MWUZ:'C7QO<3WA\-^' TMY*?+EFBYVYZJOOZGM_+;\#>"(?#-I]HN@LNIRC]Y
M(.0@_NK_ %/>N:<W4?)#YL]O#X>G@J:Q6*5V_ACW\WY?F5_!WP]L='L!)J=M
M!=7TH!?S4#K'_LKG^==1_P (]HG_ $!]/_\  9/\*TJ*WA!07+$\O$XFIB:C
MJ57=LY#Q;H^F6>@RS6VG6D$H#8>.!5(^1NX%=A7":_J][<BXM;C3\VN\*(GL
M9W8\<?.K ')XX_O8K3\/7^H20M)<F0VXE$>V6WDC9=V,8WDD\G'4]>V.:,#J
M*YSQW_R)&K?]<#715SGCSCP1JI_Z8$5%3X'Z'3@O]YI_XE^92^%__(@V'^]+
M_P"C&KL:X_X8#'@#3N.IE_\ 1C5V%31_AQ]$:9E_OE7_ !/\PHHHK4X@HHHH
M **** "BBB@ HHHH *Y+Q'_R//@__KM=?^B:ZK>GF>7N&_&[;GG'K7*^(_\
MD>?!_P#UVNO_ $30!UM%%% 'B_@VT@O?BGKD5Q'O3-P<9(Y\X>E>LVND6%E<
M&>WME24J4WY).TD$CGZ#\J\M\!'_ (NQKG_;S_Z.6O8:Y\-\#]6>OG?^\1_P
MQ_(****Z#R HHHH **** $HHKG_%GBBT\+Z4US,0UPX*P0]W;'\O4TI245=F
ME&C.M-4Z:NV0^,O%MOX7TII-RO>R BWA)^\?4^PKD?!OA.Z\07A\3^)M\TDA
M#6\4@P".S$>GH/QJ#P?X7OO%6I_\)-XD)EA8[H(9!D2=>W9!V'?^?K*J% "@
M #H!7-&+K/GEMT7ZGLXBK#+Z;PU!WJ/XI+I_=7ZCP !@4445U'A!1110!0O-
M,^UW"SK>75NX39^Y91D9SW!JC EQ9>(H+8W]U<0RVTCE)BIPRL@!&%']XUNU
MDS_\C99_]><W_H<= &M112%@H))P!0 A( R>E>4^+_&-[KVHKX;\+,TA<E)I
MHB/G]0I[ <Y/^2WQ;XNOO$^I#PUX8WL&;;-/&2-_8C/91W/?^?9^$/!]GX5L
M=J8EO)!^^G(Y;V'H*Y92=5\D-NK_ ,CW:-"GE\%B,2KU'\,?UE^B$\(>#;+P
MO9+M19+YU FG/4^P]!73T45T1BHJR/'KUZE>HZE1W;%HHHJC(**** "BBB@
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MFK\]V@\8V]GSYIA67MC;B4>N>]4?$?\ R/'@_P#Z[77_ *)- '64444 >.^
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M/WAZT =11110 E+25'--';Q/+*ZI&@)9F. !ZDT DV[()94AB:21PB*,EF.
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MJ,0HHHH **** ,K7P&TS[V/*FAG(P22L<JN0 .3D+C\:YFW^) NKF*"/P[K
MDE=47?:R(N2<#+,H Y/4UI:UX;2XU*;4C?Q0^<(XV$\'F ,-R*%^88SYG3UQ
M5/P[X9O+6\AN+B1!#&,E3!L9VPN,?,3M&T=<$XH W/[4U?\ Z%Z;_P "HO\
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M]<S_ .A&NGKII?!'T/#Q_P#O57_$_P PHHHK0Y HHHH **** "BBB@ HHHH
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M"U+\H_\ XNC^VKG_ * 6I?E'_P#%UKT4 9']M7/_ $ M2_*/_P"+H_MJY_Z
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M1-E(OV6XG>9A\R!3:SKG=Z991SCK70:-;P6>F+:VT2100R2I'&@PJJ)&  %
M$']LW/\ T ]2_*+_ .+I?[:N?^@'J7Y1?_%UK50U;5K/1-/DOKZ41PQC)SU)
M] .YI-I:LJ$)3DHQ5VS,U'Q6FDV,EY>Z5?PP(.6;R_R^_7FE[=ZS\2]6!BM;
ME-%MG^Y$ 3]<D@%C]?ES^<]K%JWQ1U\S71D@T&WD.%4X ]%]V(/)[9KUK3M.
MM-*L8[.R@6&",855'Z_6N;6N_P"[^?\ P#W;T\JC;>N_NC_]L<RRQ:?H5IIM
MKH]W9VT5U:[6E"8)%Q&><,26)_4UM_VS<_\ 0#U+\HO_ (NG>(?^09%_U_6?
M_I1'6J*Z4K*R/!G*4Y.4G=LR?[9N?^@%J7Y1_P#Q=<M\1-3FN/ ]_$^EWL 8
MQ?O)0FT?O%/.&)[5Z!7'?%#_ )$&_P#]Z+_T8M9UOX<O1G9EO^^4O\2_,N>
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M>L]E_+YOS[(/#_AZQ\.::EG91X'5Y#]YSZDTZ#_D:KW_ *\X?_0I*U:R8/\
MD:KW_KTA_P#0I*Z4DE9'B5*DJDG.;NV:]%%%,@P1_P C\_\ V"U_]&FMZL$?
M\C\__8+7_P!&FMZ@ HHHH *P=2_Y'#0O^N5U_)*WJP=2_P"1PT+_ *Y77\DH
M W:.U%>=>./'<EI/_86@@SZE*=CO'R8SZ =V_E6=2HJ:NSIPF$JXJI[.FO\
M)+NRIX_\8BWUBSLM%8RZG;ET)5=P1G 7 ]6Z_3]*T_ O@+^PF.IZHPFU20'O
MN$0/7GNWJ?\ )S?#'@P^'M<T:[OI#-J%T9GDSR(SY9.,]SR<FO3ZRITY3E[2
MI\EV/0Q>+I4*?U7"/3[4NLO^ +11172>,%8VM?\ 'WIW_7=?_0TK9K&UK_C[
MT[_KNO\ Z&E &S1110 4444 97B+_D#-_P!=X/\ T:E:M97B+_D#-_UW@_\
M1J5JT %%%-9U12S$!0,DF@!'"E"&X!'/TKRCQ!XKDG?_ (1CPD9[B>60I+<C
M!XQ@A3_-NV/QIOB7Q?>^+]1;PSX;3,4A*RW.>'7O]$]3W_GV7@_P79>%;4LI
M$][(,27!7!(_N@=A7+*<JKY8;=7_ )'N4L/2P$%6Q2O-_#']9?Y&5X<^&FGV
M&CR1:HHN+RY0I.ZG@*<@JN>Q!P3WKKH]'L(G5DA;*$$ RL1QTXS6A1[UT0A&
M"Y8GE8G$U<14=2J[MB>6G]Q?RH\M/[B_E3J*HP&^6G]Q?RK.UUDM] U"; 79
M;NV0!D?*:TZSM>C\W0+^/^] Z_I0!)I:E++:6+D2R#<>I^=N:NUD^&Y_M/A^
MUGS_ *P,_(]6-:U "55O[^VTRREO+R98H(EW.[=A_6H]5U6TT;3IKZ]E$<,8
MR2>I] /4FO)V;5_BOJ^Q<V6C6K<GKS_5L?@ ?SQJU>3W5JV>A@< Z]ZM1\M.
M.[_1=V.U/4M8^)NJ?V=I"O;Z1$09))!@$^K8Z^R_C]/3?#_AZQ\.:<MG91[1
MU=SRSGU)J;1=%LM!TZ.RL(A'$O)/=F[L3W)K1S12I6?-+616-QZJQ5"@N6FM
MEW\WYBT445L>:%%%% '#Z]>>(M'N(4BU>UE6<R, ]HP* 8(&$W$\$\X XKA?
M#,LE[\64O;NXC:16+L\<3[7)38 ,@$?>') KV#5-%M-5\MYQ(DT6?*FB<JZ9
M&#@_TKR?0XDL/C))8-NE5W9 V\C!51("<Y)^X.,USU_BAZGL95_#Q'^!_FCV
MJBBBN@\<\&CLX/"GC/5(M<G6+S;*5[>6)6<"1W!3C'7@]1BNG\'^.]"TW2MF
MJ:F1=/@R$6S\MSG[JX]*[#6/!6@:]??;=1LVEGVA=PF=>!TX!Q5#_A6'A+_H
M&O\ ^!$G_P 57*H5H:0M8]Z>*R[$VJ8KGY[*]N6VG:X[_A9WA'_H*-_X#2__
M !-'_"SO"/\ T%&_\!I?_B:;_P *O\)?] Y__ B3_P"*H_X5?X2_Z!S_ /@1
M)_\ %4_]H\OQ,_\ A&_Z>?\ DH[_ (6=X1_Z"C?^ TO_ ,31_P +.\(_]!1O
M_ :7_P")IO\ PJ_PE_T#G_\  B3_ .*I1\,/"0_YAC'_ +>)/_BJ/]H\OQ#_
M (1O^GG_ )*95I\0?#,7B/4KM]1/DS10K&WD2<E=V>-OO7'>+?&W_"5:HFGQ
MWAL=%#X>4JQ+C^\5 S]!^?MZ-_PK'PC_ - QO_ F7_XJD7X8>$U7!TUV]S<2
M?_%5%2&(FK-K\3JPF*RC#3]I&,V^E^73S7F9F@^+_ GAW34LK'4"J@9=S;2[
MG;NQ.WK6I_PL[PCC_D*M_P" TO\ \31_PK'PC_T"V_\  F7_ .*I?^%8^$?^
M@8W_ ($R_P#Q54E72LN7\3GJ3RFI)SFZC;_PA_PL[PC_ -!1O_ :7_XFN#\7
M^*-&U?7FN;.2SN8/L)BWW,4BLK[\C9\AYP6ZX'/6N\_X5CX1_P"@8W_@1+_\
M51_PK'PC_P! QO\ P(E_^*I_[1Y?B3_PC?\ 3S_R4Y<^-]"@TJPA@U:[$B6?
MESA3/D2;4 VY(&?O>U6#\3[?[5:B/4[7[-N7S_.M9=^W<N<;1UV[OQQ70?\
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ptgx-20210930xex10d3005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20210930xex10d3005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > $X# 2(  A$! Q$!_\0
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M2V>2\B>.<OJ,O6ZEW1AL#'W5PJC''4#IDVBS&);64,\-RQDU27S");UL#"Y
M_=I[#MP.I)8\5[K&K"YE,,*11R1101D[(H\IM &.O!R>_'  J:DDXV1KAJ,X
-5%*6VO\ 7]>KU>G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>ptgx-20210930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2021 9:05:01 PM-->
<!--Modified on: 11/3/2021 9:05:01 PM-->
<schema targetNamespace="http://www.protagonist-inc.com/20210930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptgx="http://www.protagonist-inc.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss" id="StatementStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00500 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails" id="DisclosureAccruedExpensesAndOtherPayablesDetails">
        <link:definition>40601 - Disclosure - Accrued Expenses and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" id="DisclosureLeasesLeaseCostInformationDetails">
        <link:definition>41004 - Disclosure - Leases - Lease cost information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" id="DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails">
        <link:definition>41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2" id="DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2">
        <link:definition>41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details) Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" id="DisclosureLicenseAndCollaborationAgreement">
        <link:definition>10301 - Disclosure - License and Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" id="DisclosureResearchCollaborationAndLicenseAgreement">
        <link:definition>10701 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31003 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" id="DisclosureEquityPlansTables">
        <link:definition>31303 - Disclosure - Equity Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" id="DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - Organization and Description of Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails">
        <link:definition>40204 - Disclosure - Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails" id="DisclosureLicenseAndCollaborationAgreementNarrativeDetails">
        <link:definition>40301 - Disclosure - License and Collaboration Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" id="DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails">
        <link:definition>40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" id="DisclosureResearchCollaborationAndLicenseAgreementDetails">
        <link:definition>40701 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" id="DisclosureGovernmentProgramsDetails">
        <link:definition>40801 - Disclosure - Government Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails" id="DisclosureTermLoanFacilityDetails">
        <link:definition>40901 - Disclosure - Term Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" id="DisclosureLeasesAgreementDetails">
        <link:definition>41001 - Disclosure - Leases - Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41101 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>41201 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" id="DisclosureEquityPlansNarrativeDetails">
        <link:definition>41301 - Disclosure - Equity Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails" id="DisclosureEquityPlansStockOptionActivityDetails">
        <link:definition>41302 - Disclosure - Equity Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" id="DisclosureEquityPlansStockOptionsValuationAssumptionsDetails">
        <link:definition>41303 - Disclosure - Equity Plans - Stock Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" id="DisclosureEquityPlansRestrictedStockUnitsDetails">
        <link:definition>41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails" id="DisclosureEquityPlansPerformanceStockUnitsDetails">
        <link:definition>41305 - Disclosure - Equity Plans - Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" id="DisclosureEquityPlansEmployeeStockPurchasePlanDetails">
        <link:definition>41306 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" id="DisclosureEquityPlansStockBasedCompensationExpenseDetails">
        <link:definition>41307 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlanDetails" id="Disclosure401KPlanDetails">
        <link:definition>41401 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41501 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" id="DisclosureRestructuringDetails">
        <link:definition>41701 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" id="DisclosureCashEquivalentsAndMarketableSecurities">
        <link:definition>10501 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables" id="DisclosureAccruedExpensesAndOtherPayables">
        <link:definition>10601 - Disclosure - Accrued Expenses and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" id="DisclosureGovernmentPrograms">
        <link:definition>10801 - Disclosure - Government Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureTermLoanFacility" id="DisclosureTermLoanFacility">
        <link:definition>10901 - Disclosure - Term Loan Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11001 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11201 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlans" id="DisclosureEquityPlans">
        <link:definition>11301 - Disclosure - Equity Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlan" id="Disclosure401KPlan">
        <link:definition>11401 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11501 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11601 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>11701 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" id="DisclosureLicenseAndCollaborationAgreementTables">
        <link:definition>30303 - Disclosure - License and Collaboration Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables" id="DisclosureAccruedExpensesAndOtherPayablesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31603 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" id="DisclosureLeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>41002 - Disclosure - Leases - Supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" id="DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails">
        <link:definition>41003 - Disclosure - Leases - Weighted average lease term and discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" id="DisclosureLeasesCashFlowInformationDetails">
        <link:definition>41005 - Disclosure - Leases - Cash flow information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" id="DisclosureNetLossPerShareComputationDetails">
        <link:definition>41601 - Disclosure - Net Loss per Share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20210930_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20210930_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20210930_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20210930_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <element name="AccruedClinicalAndResearchRelatedExpensesCurrent" id="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element id="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" name="CashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="CollaborativeAgreementUpfrontPayment" id="ptgx_CollaborativeAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element name="GovernmentProgramsDisclosureTextBlock" id="ptgx_GovernmentProgramsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="ptgx_GovernmentProgramsLineItems" name="GovernmentProgramsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="GovernmentProgramsTable" id="ptgx_GovernmentProgramsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="OverseasFindingsMember" id="ptgx_OverseasFindingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="ResearchAndDevelopmentExpensesReduction" id="ptgx_ResearchAndDevelopmentExpensesReduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element name="ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" id="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" id="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="SmallBusinessInnovationResearchGrantMember" id="ptgx_SmallBusinessInnovationResearchGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="SummaryOfSignificantAccountingPolicyLineItems" id="ptgx_SummaryOfSignificantAccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="SummaryOfSignificantAccountingPolicyTable" id="ptgx_SummaryOfSignificantAccountingPolicyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="CashNumberOfFinancialInstitutions" id="ptgx_CashNumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element name="ResearchAndDevelopmentTaxIncentiveRevenueCriteria" id="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element name="ResearchCollaborationAndLicenseAgreementDisclosureAbstract" id="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" id="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="CollaborativeArrangementDisclosureAbstract" id="ptgx_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="JanssenLicenseAndCollaborationAgreement26May2017Member" id="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="SaleOfStockValueOfSharesAuthorized" id="ptgx_SaleOfStockValueOfSharesAuthorized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element id="ptgx_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_JanssenBiotechIncMember" name="JanssenBiotechIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" name="CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerAssetNetRollForward" name="ContractWithCustomerAssetNetRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="ContractWithCustomerAssetAdditions" id="ptgx_ContractWithCustomerAssetAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element name="ContractWithCustomerAssetDeduction" id="ptgx_ContractWithCustomerAssetDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerLiabilityNetRollForward" name="ContractWithCustomerLiabilityNetRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="ContractWithCustomerLiabilityAdditions" id="ptgx_ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerLiabilityDeduction" name="ContractWithCustomerLiabilityDeduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_EquityIncentivePlan2016Member" name="EquityIncentivePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EmployeeStockPurchasePlan2016Member" name="EmployeeStockPurchasePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_GovernmentProgramsAbstract" name="GovernmentProgramsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_RevenueSourceAxis" name="RevenueSourceAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_RevenueSourceDomain" name="RevenueSourceDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" name="PayableToCollaborationPartnerRelatedPartyAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_InducementStockPlanMember" name="InducementStockPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" name="SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" name="WarrantsPurchaseAmountPerSharePriceOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" name="WarrantsPurchaseAmountPerSharePriceTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_UpfrontCashPaymentMember" name="UpfrontCashPaymentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_BiotechnologyValueFundL.pMember" name="BiotechnologyValueFundL.pMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" name="AccruedMilestonePaymentToFormerCollaborationPartner" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_AtMarketingOfferingMember" name="AtMarketingOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_StockExchangedForPreFundedWarrants" name="StockExchangedForPreFundedWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ClassOfWarrantOrRightTermOfWarrants" name="ClassOfWarrantOrRightTermOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" name="ContractWithCustomerAssetRelatedPartyAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" name="ContractWithCustomerAssetRelatedPartyDeduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_NumberOfOperatingLeaseAgreement" name="NumberOfOperatingLeaseAgreement" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" name="LeaseBalanceSheetDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" name="LeaseCashFlowInformationDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentLoanOriginationFeePercentage" name="DebtInstrumentLoanOriginationFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_TermLoanCreditAgreementMember" name="TermLoanCreditAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentTrancheInstallmentAmount" name="DebtInstrumentTrancheInstallmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" name="DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentFloorRate" name="DebtInstrumentFloorRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" name="DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" name="DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" name="DebtInstrumentRepaymentAfterSecondAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentPrepaymentPremiumPercentage" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" name="DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DueToRelatedPartyAdditions" name="DueToRelatedPartyAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_DueToRelatedPartyDeductions" name="DueToRelatedPartyDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" name="AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" name="ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_UsTreasuryAndAgencySecuritiesMember" name="UsTreasuryAndAgencySecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" name="CashEquivalentsAndMarketableSecuritiesAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" name="CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" name="CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" name="CashEquivalentsAndMarketableSecuritiesFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" name="CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" name="AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" name="ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" name="ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" name="PercentageOfEmployeeBaseImpactedByRestructuringPlan" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_AccruedLiabilitiesAndOtherPayablesMember" name="AccruedLiabilitiesAndOtherPayablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PercentagesRoyaltiesOnNetProductSales" name="PercentagesRoyaltiesOnNetProductSales" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementEligibleAmountReceived" name="CollaborativeArrangementEligibleAmountReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_ZealandPharmaMember" name="ZealandPharmaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AggregateAmountOfDevelopmentMilestonePayment" name="AggregateAmountOfDevelopmentMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_NumberOfDevelopmentMilestonePayments" name="NumberOfDevelopmentMilestonePayments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" name="NoncurrentContractualMaturitiesMaximumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" name="NoncurrentContractualMaturitiesMinimumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CurrentContractualMaturitiesMaximumPeriod" name="CurrentContractualMaturitiesMaximumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" name="SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" name="SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" name="PotentialQualifiedDiscountFederalIncomeTaxCredit" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" name="SupranationalAndSovereignGovernmentSecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue" name="CashCashEquivalentsAndMarketableSecuritiesCarryingValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_FinancingFacilitySalesAgreementMember" name="FinancingFacilitySalesAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseThreeClinicalTrialMember" name="PhaseThreeClinicalTrialMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" name="ResearchAndCollaborationAgreementDevelopmentMilestonePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" name="SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ReimbursementForServicesPerformed" name="ReimbursementForServicesPerformed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" name="ResearchAndCollaborationAgreementDevelopmentCostPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" name="SecondGenerationPhase2aAnd2bMilestonePaymentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" name="SecondGenerationPhase2StudiesMilestonePaymentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" name="SecondGenerationPhase2aEvaluatingPtg200Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" name="LicenseAndCollaborativeAgreementAmendedAndRestatedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" name="CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" name="Ptg200PhaseAndSecondGenerationCompoundMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_FacilityLeaseAmendmentAgreementMember" name="FacilityLeaseAmendmentAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AdditionalSecurityDeposit" name="AdditionalSecurityDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ArbitrationResolutionAgreementWithZealandMember" name="ArbitrationResolutionAgreementWithZealandMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" name="ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" name="RoyaltiesOnNetProductSalesPercentagesReduction" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" name="LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" name="CollaborativeArrangementFutureDevelopmentMilestonePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" name="CollaborativeArrangementRegistrationProposalExpensesPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" name="CollaborativeArrangementCommercialLaunchExpensesPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" name="LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NumberOfBusinessDays" name="NumberOfBusinessDays" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NumberOfGeographicTerritories" name="NumberOfGeographicTerritories" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_OriginalAgreementMember" name="OriginalAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" name="PhaseOneStudiesOfSecondGenerationCompoundsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DevelopmentCostsEliminated" name="DevelopmentCostsEliminated" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_UpcomingPotentialDevelopmentMilestonesPayment" name="UpcomingPotentialDevelopmentMilestonesPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" name="SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DurationOfResearchCollaborationAgreement" name="DurationOfResearchCollaborationAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" name="ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" name="ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseTwoClinicalTrialSecondIndicationMember" name="PhaseTwoClinicalTrialSecondIndicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" name="PhaseThreeClinicalTrialForAnyIndicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" name="DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" name="DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" name="ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>ptgx-20210930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2021 9:05:01 PM-->
<!--Modified on: 11/3/2021 9:05:01 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementBalanceSheets" roleURI="http://www.protagonist-inc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfOperations" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfComprehensiveLoss" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureAccruedExpensesAndOtherPayablesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesLeaseCostInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2" />
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_637715702980986115" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702980986115" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_RestrictedCashCurrent_637715702980986115" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_MarketableSecuritiesCurrent_637715702980986115" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637715702980986115" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_IncomeTaxesReceivable_637715702980986115" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637715702980986115" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637715702980986115" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637715702980986115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637715702980986115" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637715702980996058" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637715702980996058" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_637715702980996058" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637715702980996058" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637715702980996058" xlink:to="us-gaap_LiabilitiesCurrent_637715702980996058" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637715702980996058" xlink:to="us-gaap_AccountsPayableCurrent_637715702980996058" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637715702980996058" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637715702980996058" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637715702980996058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637715702980996058" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637715702980996058" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637715702980996058" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637715702981006119" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637715702980996058" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637715702981006119" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637715702980996058" xlink:to="us-gaap_LongTermDebt_637715702981006119" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637715702980996058" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702981006119" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637715702980996058" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637715702981006119" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637715702981006119" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637715702981006119" xlink:to="us-gaap_PreferredStockValue_637715702981006119" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637715702981006119" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637715702981006119" xlink:to="us-gaap_CommonStockValue_637715702981006119" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637715702981006119" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637715702981016095" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637715702981006119" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637715702981016095" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637715702981006119" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637715702981016095" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637715702981016095" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637715702981016095" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637715702981016095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" xlink:to="us-gaap_InvestmentIncomeInterest_637715702981016095" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" xlink:to="us-gaap_InterestExpense_637715702981026047" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702981026047" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702981016095" xlink:to="us-gaap_OperatingIncomeLoss_637715702981026047" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637715702981026047" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637715702981026047" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637715702981026047" xlink:to="us-gaap_OperatingExpenses_637715702981026047" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637715702981026047" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637715702981026047" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637715702981026047" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637715702981026047" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637715702981026047" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637715702981026047" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637715702981036076" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637715702981036076" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_ProfitLoss_637715702981036076" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637715702981036076" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_Depreciation_637715702981036076" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637715702981036076" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702981036076" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_637715702981036076" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637715702981036076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637715702981036076" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637715702981046102" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_ShareBasedCompensation_637715702981046102" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_637715702981046102" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637715702981046102" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637715702981046102" order="12" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637715702981046102" order="13" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637715702981046102" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637715702981046102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637715702981046102" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_OperatingLeasePayments_637715702981056079" order="16" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702981036076" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637715702981056079" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702981056079" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702981056079" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637715702981056079" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702981056079" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637715702981056079" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702981056079" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637715702981056079" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702981066349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702981066349" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637715702981066349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637715702981066349" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702981066349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702981066349" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637715702981066349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637715702981066349" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637715702981066349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637715702981066349" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637715702981077313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702981056079" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637715702981077313" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702981077313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702981077313" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702981077313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702981077313" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent_637715702981085996" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_637715702981085996" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637715702981085996" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637715702981085996" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702981085996" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_637715702981085996" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_MarketableSecuritiesCurrent_637715702981085996" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637715702981085996" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637715702981085996" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses and Other Payables (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637715702981096087" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637715702981096087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_637715702981096087" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637715702981096087" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637715702981096087" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Lease cost information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637715702981096087" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome_637715702981096087" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637715702981096087" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637715702981096087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637715702981096087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637715702981106000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637715702981106000" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637715702981106000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637715702981106000" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details) Calc2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637715702981106000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637715702981106000" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637715702981106000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637715702981106000" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>ptgx-20210930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2021 9:05:01 PM-->
<!--Modified on: 11/3/2021 9:05:01 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureResearchCollaborationAndLicenseAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansTables" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreementNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureGovernmentProgramsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureTermLoanFacilityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansRestrictedStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansPerformanceStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansEmployeeStockPurchasePlanDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansStockBasedCompensationExpenseDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637715702981106000" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637715702981106000" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637715702981116268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637715702981116268" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_AtMarketingOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_AtMarketingOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637715702981146096" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637715702981146096" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" xlink:type="extended" xlink:title="10301 - Disclosure - License and Collaboration Agreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702981226012" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702981226012" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" xlink:type="extended" xlink:title="10701 - Disclosure - Research Collaboration and License Agreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" xlink:type="extended" xlink:title="31303 - Disclosure - Equity Plans (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702981236073" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702981236073" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637715702981255971" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_637715702981255971" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637715702981266196" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637715702981266196" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637715702981266196" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637715702981266196" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ptgx_SummaryOfSignificantAccountingPolicyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License and Collaboration Agreement - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637715702981276044" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637715702981276044" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_JanssenBiotechIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OriginalAgreementMember" xlink:label="ptgx_OriginalAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_OriginalAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637715702981286077" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637715702981286077" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_UpfrontCashPaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702981306004" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702981306004" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:to="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:to="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialSecondIndicationMember" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:to="ptgx_PhaseTwoClinicalTrialSecondIndicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_FinancialServiceOtherMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeAgreementUpfrontPayment" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeAgreementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DurationOfResearchCollaborationAgreement" xlink:label="ptgx_DurationOfResearchCollaborationAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_DurationOfResearchCollaborationAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DevelopmentCostsEliminated" xlink:label="ptgx_DevelopmentCostsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_DevelopmentCostsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpcomingPotentialDevelopmentMilestonesPayment" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_UpcomingPotentialDevelopmentMilestonesPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ReimbursementForServicesPerformed" xlink:label="ptgx_ReimbursementForServicesPerformed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_ReimbursementForServicesPerformed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_JanssenBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_DueToRelatedPartyAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_DueToRelatedPartyDeductions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637715702981526083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637715702981526083" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702981526083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702981526083" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637715702981526083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637715702981526083" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702981546112" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702981546112" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Government Programs (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637715702981566094" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637715702981566094" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="ptgx_OverseasFindingsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="ptgx_RevenueSourceAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain_637715702981576794" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceDomain_637715702981576794" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_RevenueSourceDomain" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_GovernmentProgramsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="us-gaap_IncomeTaxesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan Facility (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637715702981585963" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637715702981585963" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637715702981596093" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_637715702981596093" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637715702981596093" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637715702981596093" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ptgx_TermLoanCreditAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentFloorRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637715702981626155" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637715702981626155" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FacilityLeaseAmendmentAgreementMember" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_FacilityLeaseAmendmentAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ptgx_NumberOfOperatingLeaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AdditionalSecurityDeposit" xlink:label="ptgx_AdditionalSecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ptgx_AdditionalSecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_ZealandPharmaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_637715702981646080" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_637715702981646080" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ArbitrationResolutionAgreementWithZealandMember" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ptgx_ArbitrationResolutionAgreementWithZealandMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_PhaseTwoClinicalTrialMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialMember" xlink:label="ptgx_PhaseThreeClinicalTrialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_PhaseThreeClinicalTrialMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfBusinessDays" xlink:label="ptgx_NumberOfBusinessDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_NumberOfBusinessDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfGeographicTerritories" xlink:label="ptgx_NumberOfGeographicTerritories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_NumberOfGeographicTerritories" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637715702981676041" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637715702981676041" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_ExchangeAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_BiotechnologyValueFundL.pMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FinancingFacilitySalesAgreementMember" xlink:label="ptgx_FinancingFacilitySalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_FinancingFacilitySalesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UnderwrittenPublicOfferingMember" xlink:label="ptgx_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_UnderwrittenPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_UnderwrittenPublicOfferingMember" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_NumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_StockExchangedForPreFundedWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Equity Plans - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637715702981746128" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637715702981746128" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_EquityIncentivePlan2016Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_InducementStockPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Equity Plans - Stock Options Valuation Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Equity Plans - Performance Stock Units (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41307 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637715702981836168" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637715702981836168" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637715702981846086" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637715702981846086" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockWarrantsMember" xlink:label="ptgx_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ptgx_CommonStockWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>ptgx-20210930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2021 9:05:01 PM-->
<!--Modified on: 11/3/2021 9:05:01 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Available-for-sale Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from Affiliate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Receivable from collaboration partner and contract asset - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Income Taxes Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable securities - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to Affiliate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value, 90,000,000 shares authorized; 47,671,654 and 43,745,465 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, Beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">License and collaboration revenue - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on early repayment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on early repayment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per shares, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares used to compute net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">(Loss) gain on translation of foreign operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock under equity incentive and employee stock purchase plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock under equity incentive and employee stock purchase plans (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other comprehensive (loss) gain</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:to="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Shares withheld for net settlement of tax withholding upon vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Represents the number of shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Shares withheld for net settlement of tax withholding upon vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amount of amortization expense attributable to right-of-use asset from operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Operating Lease Right of Use Asset Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Operating lease right-of-use asset amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Net amortization of premium (accretion of discount) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amortization Of Debt Issuance Costs And Debt Instrument, Accretion Of Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amortization of debt issuance costs and accretion of debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Income Tax Credits and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Change in deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Receivable from collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow used by operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Tax withholding payments related to net settlement of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs related to long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from at-the-market offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Early repayment of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash reported on condensed consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Financing and Investing Information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Issuance costs related to common stock offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US">License and Collaboration Agreement.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">The license and collaboration agreement with Janssen Biotech, Inc. (Janssen) dated May 26, 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">Janssen License And Collaboration Agreement26 May2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Payables</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_lbl" xml:lang="en-US">The entire disclosure of accrued liabilities and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities And Other Payables Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Payables</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">This member stands for research collaboration and license agreement abandoned October2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">Research Collaboration And License Agreement Abandoned October2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsAbstract_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsDisclosureTextBlock" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsDisclosureTextBlock" xlink:to="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to the government programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">Government Programs Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Term Loan Facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Term Loan Facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US">Restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash as Reported in Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:to="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for research and development incentive grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Research And Development Incentive Grant [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Research and Development Tax Incentive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash as reported in the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in contract assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value of financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:to="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Lease Balance Sheet Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of balance sheet information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease cost information</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:to="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">Lease Cash Flow Information Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum lease payments and lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of activity under equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Black-Scholes option-pricing model assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of performance stock unit activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of the basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities excluded from diluted net loss per share calculations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:to="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" xml:lang="en-US">Retained Earnings Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" xml:lang="en-US">Net losses from operations since inception</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue" xlink:label="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue" xlink:to="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_lbl" xml:lang="en-US">The carrying amount of cash, cash equivalents and marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_lbl" xml:lang="en-US">Cash, Cash Equivalents And Marketable Securities, Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_lbl" xml:lang="en-US">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashNumberOfFinancialInstitutions" xlink:label="ptgx_CashNumberOfFinancialInstitutions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashNumberOfFinancialInstitutions" xlink:to="ptgx_CashNumberOfFinancialInstitutions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">The number of financial institutions that hold the entity's cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">Cash, Number of Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">Number of financial institutions at which cash is held</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Aggregate amounts of cash and cash equivalents and the restricted cash</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" xlink:label="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" xlink:to="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_lbl" xml:lang="en-US">The threshold number of performance obligation to allocate transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_lbl" xml:lang="en-US">Threshold Number Of Performance Obligation To Allocate Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_lbl" xml:lang="en-US">Number of performance obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePracticalExpedientAbstract" xlink:label="us-gaap_RevenuePracticalExpedientAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientAbstract" xlink:to="us-gaap_RevenuePracticalExpedientAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePracticalExpedientAbstract_lbl" xml:lang="en-US">Revenue, Practical Expedient [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:to="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" xml:lang="en-US">Revenue, Practical Expedient, Financing Component [true/false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" xml:lang="en-US">Financing component</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:to="ptgx_SummaryOfSignificantAccountingPolicyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable_lbl" xml:lang="en-US">Summary of significant accounting policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable_lbl" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable_lbl" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian Taxation Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ptgx_SummaryOfSignificantAccountingPolicyLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems_lbl" xml:lang="en-US">Summary of significant accounting policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policy [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policy</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" xlink:to="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_lbl" xml:lang="en-US">Represent the potential Federal income tax credit discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_lbl" xml:lang="en-US">Potential Qualified Discount, Federal Income Tax Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_lbl" xml:lang="en-US">Potential Federal income tax credit discount</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" xlink:to="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_lbl" xml:lang="en-US">The revenue criteria for availability of a research and development tax incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_lbl" xml:lang="en-US">Research And Development Tax Incentive, Revenue Criteria</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_lbl" xml:lang="en-US">Revenue for availability of research and development tax incentive</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeAgreementUpfrontPayment" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeAgreementUpfrontPayment" xlink:to="ptgx_CollaborativeAgreementUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment_lbl" xml:lang="en-US">The amount of upfront payment based on the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment_lbl" xml:lang="en-US">Collaborative Agreement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Represents the amount received from a collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Collaborative Arrangement, Eligible Amount Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Eligible amount received</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DurationOfResearchCollaborationAgreement" xlink:label="ptgx_DurationOfResearchCollaborationAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DurationOfResearchCollaborationAgreement" xlink:to="ptgx_DurationOfResearchCollaborationAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DurationOfResearchCollaborationAgreement_lbl" xml:lang="en-US">Represents the duration of the parties' research collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DurationOfResearchCollaborationAgreement_lbl" xml:lang="en-US">Duration Of Research Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DurationOfResearchCollaborationAgreement_lbl" xml:lang="en-US">Duration of the parties' research collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_lbl" xml:lang="en-US">Amount of development cost payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_lbl" xml:lang="en-US">Research And Collaboration Agreement Development Cost Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_lbl" xml:lang="en-US">Development cost payable</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Represents the percentage of development cost incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Collaborative Arrangement Percentage of Development Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Development cost incurred, percentage</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DevelopmentCostsEliminated" xlink:label="ptgx_DevelopmentCostsEliminated" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DevelopmentCostsEliminated" xlink:to="ptgx_DevelopmentCostsEliminated_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DevelopmentCostsEliminated_lbl" xml:lang="en-US">Represents the development costs that have been eliminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DevelopmentCostsEliminated_lbl" xml:lang="en-US">Development Costs Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DevelopmentCostsEliminated_lbl" xml:lang="en-US">Expense obligations eliminated</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_lbl" xml:lang="en-US">Represents the percentage of development cost eliminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_lbl" xml:lang="en-US">Collaborative Arrangement Percentage Of Development Costs Incurred Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_lbl" xml:lang="en-US">Percentage of development cost eliminated</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpcomingPotentialDevelopmentMilestonesPayment" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UpcomingPotentialDevelopmentMilestonesPayment" xlink:to="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_lbl" xml:lang="en-US">Represents upcoming potential development milestones payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_lbl" xml:lang="en-US">Upcoming Potential Development Milestones Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_lbl" xml:lang="en-US">Upcoming potential development milestones</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_lbl" xml:lang="en-US">The amount of development milestone payable under the research and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_lbl" xml:lang="en-US">Research and Collaboration Agreement, Development Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_lbl" xml:lang="en-US">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ReimbursementForServicesPerformed" xlink:label="ptgx_ReimbursementForServicesPerformed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ReimbursementForServicesPerformed" xlink:to="ptgx_ReimbursementForServicesPerformed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ReimbursementForServicesPerformed_lbl" xml:lang="en-US">Represents the amount of reimbursement for services performed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ReimbursementForServicesPerformed_lbl" xml:lang="en-US">Reimbursement For Services Performed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ReimbursementForServicesPerformed_lbl" xml:lang="en-US">Reimbursement for services performed</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">The percentages on net product sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">Percentages Royalties on Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">Maximum percentages royalties on net product sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xml:lang="en-US">Increase (decrease) in transaction price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Transaction price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Collaboration revenue recorded following the contract modification</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Recognized revenue from deferred revenue contract liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_JanssenBiotechIncMember" xlink:to="ptgx_JanssenBiotechIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Represents the information pertaining to the related party Janssen Biotech Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Janssen Biotech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Janssen</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">Contract with Customer, Asset, Net [Roll forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">Receivable from collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Contract with Customer, Asset, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetAdditions" xlink:to="ptgx_ContractWithCustomerAssetAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Contract with Customer, Asset, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetDeduction" xlink:to="ptgx_ContractWithCustomerAssetDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Contract with Customer, Asset, Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xml:lang="en-US">Contract asset - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract asset - related party, Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract asset - related party, Balance at Beginning of Period</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Contract With Customer Asset Related Party Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Contract asset - related party, Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Contract With Customer Asset Related Party Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Contract asset - related party, Deductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">Contract with Customer, Liability, Net [Roll forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">Deferred revenue - related party</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityAdditions" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Contract with Customer, Liability, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityDeduction" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Contract with Customer, Liability, Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">Payable to Collaboration Partner - Related Party [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DueToRelatedPartyAdditions" xlink:to="ptgx_DueToRelatedPartyAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Additional amount of payable due to a related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Due To Related Party Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DueToRelatedPartyDeductions" xlink:to="ptgx_DueToRelatedPartyDeductions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Deduction from obligation to transfer good or service to related party for payable amounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Due To Related Party Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule cash equivalents and available for sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule Cash Equivalents and Available for Sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule Cash Equivalents and Available-for-Sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Cash Equivalents and Available for Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Gross Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Gross Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Total cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCashAbstract" xlink:label="us-gaap_InvestmentsAndCashAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCashAbstract" xlink:to="us-gaap_InvestmentsAndCashAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCashAbstract_lbl" xml:lang="en-US">Investments and Cash [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCashAbstract_lbl" xml:lang="en-US">Classified as:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Fair Value, Rolling Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" xml:lang="en-US">Contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:to="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Represents the maximum period of current contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Current Contractual Maturities, Maximum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Maximum period of current contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:to="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Represents the minimum period of noncurrent contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Noncurrent Contractual Maturities, Minimum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Minimum period of noncurrent contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:to="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Represents the maximum period of contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Noncurrent Contractual Maturities, Maximum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Maximum period of Noncurrent contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Current portion of accrued clinical and research related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Accrued Clinical and Research Related Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Accrued clinical and research related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional service fees</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" xlink:to="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_lbl" xml:lang="en-US">Current portion of accrued milestone payment to former collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_lbl" xml:lang="en-US">Accrued Milestone Payment to Former Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_lbl" xml:lang="en-US">Accrued milestone payment to former collaboration partner</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfDevelopmentMilestonePayments" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfDevelopmentMilestonePayments" xlink:to="ptgx_NumberOfDevelopmentMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">The number of development milestone payments in collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">Number of Development Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">Number of development milestone payments</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:to="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">The aggregate amount of development milestone payment made by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">Aggregate Amount Of Development Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">Aggregate development milestone payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="ptgx_GovernmentProgramsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Disclosure of government programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Government Programs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Government Programs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OverseasFindingsMember" xlink:to="ptgx_OverseasFindingsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">This member stands for overseas findings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">Overseas Findings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">Overseas Findings</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_GovernmentProgramsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Government Programs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentExpensesReduction" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">The amount of reduction of research and development expense in connection with the research and development tax incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">Research And Development Expenses Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">Reduction to research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Loan facility for general corporate</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Represents the tranche installment amount under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Debt Instrument, Tranche Installment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Tranche Installment Amount</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Debt Instrument, Threshold Percentage On Outstanding Debt To Be Maintained As Cash And Cash Equivalents Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Cash and cash equivalents ( In percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Represents the percentage of loan origination fee under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Debt Instrument, Loan Origination Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Loan Origination Fee (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">prime rate (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentFloorRate" xlink:to="ptgx_DebtInstrumentFloorRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Represents the floor rate of the debt instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Debt Instrument, Floor Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Floor rate (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">The percentage of prepayment premium under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">Prepayment premium (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">Debt Instrument, Additional Prepayment Or Repayment Premium Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">Additional Prepayment (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Outstanding balance paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Prepayment and exit fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Accelerated capitalized and unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfOperatingLeaseAgreement" xlink:to="ptgx_NumberOfOperatingLeaseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Represents the number of operating lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Number of Operating Lease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Number of operating lease agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Additional base rent over the lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AdditionalSecurityDeposit" xlink:label="ptgx_AdditionalSecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AdditionalSecurityDeposit" xlink:to="ptgx_AdditionalSecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AdditionalSecurityDeposit_lbl" xml:lang="en-US">Amount of additional security deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AdditionalSecurityDeposit_lbl" xml:lang="en-US">Additional Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AdditionalSecurityDeposit_lbl" xml:lang="en-US">Additional security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Less: sublease income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">Operating Leases:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">New operating lease asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Minimum lease payments:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_lbl" xml:lang="en-US">Research And Collaboration Agreement Development Additional Milestone Payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_lbl" xml:lang="en-US">Research And Collaboration Agreement Development Additional Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_lbl" xml:lang="en-US">Additional milestone payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage_lbl" xml:lang="en-US">Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage_lbl" xml:lang="en-US">Litigation Settlement, Collaborative Arrangement Milestone Payment Reduction Percentage</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfBusinessDays" xlink:label="ptgx_NumberOfBusinessDays" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfBusinessDays" xlink:to="ptgx_NumberOfBusinessDays_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfBusinessDays_lbl" xml:lang="en-US">Number Of Business Days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfBusinessDays_lbl" xml:lang="en-US">Number Of Business Days</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" xlink:to="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_lbl" xml:lang="en-US">Percentage of reduction in royalty payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_lbl" xml:lang="en-US">Royalties On Net Product Sales, Percentages Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_lbl" xml:lang="en-US">Percentage of reduction in royalty payable</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_lbl" xml:lang="en-US">Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_lbl" xml:lang="en-US">Litigation Settlement, Collaborative Arrangement Sales Milestone Payment Reduction Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_lbl" xml:lang="en-US">Percentage of sales milestone reductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" xlink:to="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_lbl" xml:lang="en-US">The amount of future development milestone payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_lbl" xml:lang="en-US">Collaborative Arrangement Future Development Milestone Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_lbl" xml:lang="en-US">Future development milestone payable</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" xlink:to="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_lbl" xml:lang="en-US">The amount of future development milestone including registration proposal payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_lbl" xml:lang="en-US">Collaborative Arrangement, Registration Proposal Expenses Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_lbl" xml:lang="en-US">Registration proposal payable</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" xlink:to="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_lbl" xml:lang="en-US">The amount of future development milestone including commercial launch expenses for launch in the three geographic territories payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_lbl" xml:lang="en-US">Collaborative Arrangement, Commercial Launch Expenses Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_lbl" xml:lang="en-US">Commercial launch expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Loss contingency accrual</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfGeographicTerritories" xlink:label="ptgx_NumberOfGeographicTerritories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfGeographicTerritories" xlink:to="ptgx_NumberOfGeographicTerritories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfGeographicTerritories_lbl" xml:lang="en-US">Number of geographic territories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfGeographicTerritories_lbl" xml:lang="en-US">Number Of Geographic Territories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfGeographicTerritories_lbl" xml:lang="en-US">Number of geographic territories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US">Class of Stock Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US">Stock transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Aggregate shares of common stock sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Common stock sold, price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale Of Stock, Value Of Shares Authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from sale of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued to purchase common stock, number of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrants exercisable date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock issued, price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Common stock available for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Remaining number of Exchange Warrants unexercised</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SaleOfStockValueOfSharesAuthorized" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">The maximum amount of shares permits the offering, issuance, and sale by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">Sale Of Stock, Value Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">Maximum aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfWarrantsExercised" xlink:to="ptgx_NumberOfWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">The number of warrants exercised for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockExchangedForPreFundedWarrants" xlink:to="ptgx_StockExchangedForPreFundedWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">The number of shares exchanged for pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">Stock Exchanged for Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">Common stock exchanged for pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">The duration of warrants from date of issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">Class of Warrant or Right, Term of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">Duration of warrants from date of issuance (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Exercise price as a percentage of the fair market value of common stock on grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase price of stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Expected Volatility Calculation, Percentage Of Average Volatility Expected Term Of Stock Option Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Average volatility</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Expected Volatility Calculation, Percentage Of Volatility Of Stock Price Since IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Percentage of volatility of stock options since IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Outstanding, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Outstanding, Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Options Outstanding, Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Outstanding, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years), Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Options, weighted-average grant-date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in year)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Unvested, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Grant date fair value, price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage of requisite service period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Maximum payroll deduction for share purchases (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Shares issued in period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized stock-based compensation costs related to stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period of unrecognized stock-based compensation costs to be recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Match percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Company match contribution, maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Contributions expense recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions made</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective tax rate of provision for income taxes difference from federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">ESPP rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Potentially dilutive securities have been excluded from diluted net loss per share calculations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:to="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Represents the percentage of employee base impacted by the restructuring plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Percentage of Employee Base Impacted by Restructuring Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Percentage of employee base impacted by the restructuring plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Total cash expenditures for the reduction in force plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AtMarketingOfferingMember" xlink:to="ptgx_AtMarketingOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">The sale of stock by a private company to public at market offer price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">At Marketing Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">At-the-market offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">It represents the information pertaining to the accrued liabilities and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">Accrued Liabilities And Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Stock Units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter Of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of credit</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OriginalAgreementMember" xlink:label="ptgx_OriginalAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OriginalAgreementMember" xlink:to="ptgx_OriginalAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OriginalAgreementMember_lbl" xml:lang="en-US">Represents the Original Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OriginalAgreementMember_lbl" xml:lang="en-US">Original Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OriginalAgreementMember_lbl" xml:lang="en-US">Original Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_lbl" xml:lang="en-US">Represents information relating to amended and restated agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_lbl" xml:lang="en-US">License And Collaborative Agreement Amended And Restated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_lbl" xml:lang="en-US">Restated Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UpfrontCashPaymentMember" xlink:to="ptgx_UpfrontCashPaymentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Represents the upfront cash payment received as part of the license and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Upfront Cash Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Upfront cash payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" xlink:to="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_lbl" xml:lang="en-US">Represents second-generation oral Interleukin ("IL")-23 receptor antagonist development compound (second-generation compounds").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_lbl" xml:lang="en-US">Second Generation Oral Interleukin Il23 Receptor Antagonist Development Compound [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_lbl" xml:lang="en-US">Second-generation Oral Interleukin ("IL")-23 Receptor Antagonist Development Compound</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:to="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Represents Phase 1 studies of second-generation compounds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Phase One Studies Of Second Generation Compounds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Phase 1 studies of second-generation compounds</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:to="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Represents three phase 1 studies of second-generation compounds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Three Phase One Studies Of Second Generation Compounds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_lbl" xml:lang="en-US">Three phase 1 studies of second-generation compounds</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" xlink:to="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_lbl" xml:lang="en-US">Represents information relating to second generation phase 2a and 2b milestone payment for a PTG 200 second generation product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_lbl" xml:lang="en-US">Second Generation Phase2a And2b Milestone Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_lbl" xml:lang="en-US">Phase 2a and 2b costs for PTG-200</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:to="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_lbl" xml:lang="en-US">Represents information relating to second generation phase 2 studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_lbl" xml:lang="en-US">Second Generation Phase2 Studies Milestone Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_lbl" xml:lang="en-US">Phase 2 studies for second-generation products</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" xlink:to="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">Represents 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">Third Patient In First Phase2 Clinical Trial For Any Second Generation Compound For Any Indication [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialSecondIndicationMember" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseTwoClinicalTrialSecondIndicationMember" xlink:to="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_lbl" xml:lang="en-US">Represents phase two Clinical trial second indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_lbl" xml:lang="en-US">Phase Two Clinical Trial Second Indication [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_lbl" xml:lang="en-US">3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" xlink:to="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_lbl" xml:lang="en-US">Represents information relating to second generation phase 2a evaluating PTG 200.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_lbl" xml:lang="en-US">Second Generation Phase2a Evaluating Ptg200 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_lbl" xml:lang="en-US">Phase 2a study evaluating PTG-200 for the treatment of CD</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">Represents dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">Dosing Of Third Patient In Phase3 Clinical Trial For Second Generation Compound For Any Indication [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_lbl" xml:lang="en-US">Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_lbl" xml:lang="en-US">Represents dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for a second indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_lbl" xml:lang="en-US">Dosing Of Third Patient In Phase3 Clinical Trial For Second Generation Compound For Second Indication [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_lbl" xml:lang="en-US">Dosing Of Third Patient In Phase 3 Clinical Trial For Second Generation Compound For A Second Indication [Member]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" xlink:to="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_lbl" xml:lang="en-US">Represents phase three clinical trial for any indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_lbl" xml:lang="en-US">Phase Three Clinical Trial For Any Indication [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_lbl" xml:lang="en-US">Phase 3 clinical trial for a second-generation compound for any indication</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" xlink:to="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_lbl" xml:lang="en-US">Represents information relating to PTG 200 phase and second generation compound development related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_lbl" xml:lang="en-US">Ptg200 Phase And Second Generation Compound [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_lbl" xml:lang="en-US">Services performed for IL-23 receptor antagonist compound research costs and other services</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" xlink:to="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_lbl" xml:lang="en-US">Represents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_lbl" xml:lang="en-US">Clinical Data Collection For Phase1 Activities Pn232 And Pn235 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_lbl" xml:lang="en-US">Completion of clinical data collection for Phase 1 activities for the first of either PN-232 or PN-235</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialServiceOtherMember" xlink:to="us-gaap_FinancialServiceOtherMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialServiceOtherMember_lbl" xml:lang="en-US">Financial Service Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialServiceOtherMember_lbl" xml:lang="en-US">Additional services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">This category includes information about debt securities issued by the United States Department of the Treasury and Agency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">Us Treasury And Agency Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">U.S. Treasury and agency securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:to="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_lbl" xml:lang="en-US">Represents supranational and sovereign government securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_lbl" xml:lang="en-US">Supranational And Sovereign Government Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_lbl" xml:lang="en-US">Supranational and sovereign government securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RevenueSourceAxis_lbl" xml:lang="en-US">Information by source of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RevenueSourceAxis_lbl" xml:lang="en-US">Revenue Source [Axis]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RevenueSourceDomain" xlink:to="ptgx_RevenueSourceDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Major payer source of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Revenue Source [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Revenue Source [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SmallBusinessInnovationResearchGrantMember" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">This member stands for small business innovation research grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">Small Business Innovation Research Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">SBIR Grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring through and including the first anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment On Or Before First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment On Or Before First Anniversary</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring after first anniversary and through and including the second anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment Between First And Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment Between First And Second Anniversary</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring after second anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment After Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment After Second Anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_TermLoanCreditAgreementMember" xlink:to="ptgx_TermLoanCreditAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to term loan credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Term Loan Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Term Loan Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US">C [A]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US">Newark, California</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FacilityLeaseAmendmentAgreementMember" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_FacilityLeaseAmendmentAgreementMember" xlink:to="ptgx_FacilityLeaseAmendmentAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember_lbl" xml:lang="en-US">Represents information relating to facility lease second amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember_lbl" xml:lang="en-US">Facility Lease Amendment Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember_lbl" xml:lang="en-US">Second Amendment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ZealandPharmaMember" xlink:to="ptgx_ZealandPharmaMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Represents information pertaining to Zealand Pharma.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Zealand Pharma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Zealand Pharma</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ArbitrationResolutionAgreementWithZealandMember" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ArbitrationResolutionAgreementWithZealandMember" xlink:to="ptgx_ArbitrationResolutionAgreementWithZealandMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember_lbl" xml:lang="en-US">Represents information relating to arbitration resolution agreement with Zealand.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember_lbl" xml:lang="en-US">Arbitration Resolution Agreement With Zealand [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember_lbl" xml:lang="en-US">Arbitration Resolution Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseTwoClinicalTrialMember" xlink:to="ptgx_PhaseTwoClinicalTrialMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">This member stands for phase 2 clinical trial, related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners. A collaborative arrangement is a contractual arrangement with a specific party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase Two Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase 2 clinical trial</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialMember" xlink:label="ptgx_PhaseThreeClinicalTrialMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseThreeClinicalTrialMember" xlink:to="ptgx_PhaseThreeClinicalTrialMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Represents the information pertaining to Phase 3 clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase Three Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase 3 clinical trial</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">Represents the first group of warrants which may be purchased at a different price than another group of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">Warrants Purchase Amount Per Share Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">$10.00 per share</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">Represents the second group of warrants which may be purchased at a different price than another group of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">Warrants Purchase Amount Per Share Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">$15.00 per share</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExchangeAgreementMember" xlink:to="ptgx_ExchangeAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">This member stands for exchange agreement for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_BiotechnologyValueFundL.pMember" xlink:to="ptgx_BiotechnologyValueFundL.pMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Represents Exchange Agreement with Biotechnology Value Fund, L.P</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Biotechnology Value Fund L.p [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Exchanging Stockholders</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">This member represents transactions associated with the Securities Purchase Agreement with certain accredited investors (each, an "Investor" and, collectively, the "Investors").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">Securities Purchase Agreement With Accredited Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">Investors</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">Represents common stock, preferred stock, debt securities and warrants (the "2019 Form S-3").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">Common Stock Preferred Stock Debt Securities And Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">2019 Form S-3</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FinancingFacilitySalesAgreementMember" xlink:label="ptgx_FinancingFacilitySalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_FinancingFacilitySalesAgreementMember" xlink:to="ptgx_FinancingFacilitySalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_FinancingFacilitySalesAgreementMember_lbl" xml:lang="en-US">Represents the 2019 Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_FinancingFacilitySalesAgreementMember_lbl" xml:lang="en-US">Financing Facility Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_FinancingFacilitySalesAgreementMember_lbl" xml:lang="en-US">2019 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UnderwrittenPublicOfferingMember" xlink:label="ptgx_UnderwrittenPublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UnderwrittenPublicOfferingMember" xlink:to="ptgx_UnderwrittenPublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Represents the underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">underwritten public offering, Additional offering</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">Employee Consultants And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">Stock options - employees, consultants, directors</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EquityIncentivePlan2016Member" xlink:to="ptgx_EquityIncentivePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Represents the 2016 Equity Incentive Plan approved by the entity's board of directors and stockholders in July 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">2016 Plan</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_InducementStockPlanMember" xlink:to="ptgx_InducementStockPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">Represents the 2018 Inducement plan, a non-stockholder approved stock plan in order to award options and restricted stock unit awards to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">Inducement Stock Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">2018 Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EmployeeStockPurchasePlan2016Member" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">Represents the 2016 Employee Stock Purchase Plan approved by the board of directors and stockholders in July 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">Employee Stock Purchase Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">2016 ESPP</label>
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockWarrantsMember" xlink:label="ptgx_CommonStockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CommonStockWarrantsMember" xlink:to="ptgx_CommonStockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CommonStockWarrantsMember_lbl" xml:lang="en-US">Represents common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common stock warrants</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>ptgx-20210930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/3/2021 9:05:01 PM-->
<!--Modified on: 11/3/2021 9:05:01 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementBalanceSheets" roleURI="http://www.protagonist-inc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfOperations" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfComprehensiveLoss" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#StatementStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecurities" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureAccruedExpensesAndOtherPayables" roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureResearchCollaborationAndLicenseAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureGovernmentPrograms" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureTermLoanFacility" roleURI="http://www.protagonist-inc.com/role/DisclosureTermLoanFacility" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeases" roleURI="http://www.protagonist-inc.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlans" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlans" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#Disclosure401KPlan" roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlan" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureIncomeTaxes" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureNetLossPerShare" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureRestructuring" roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuring" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreementTables" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureAccruedExpensesAndOtherPayablesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansTables" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreementNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureAccruedExpensesAndOtherPayablesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureResearchCollaborationAndLicenseAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureGovernmentProgramsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureTermLoanFacilityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesLeaseCostInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesCashFlowInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansStockOptionActivityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansRestrictedStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansPerformanceStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansEmployeeStockPurchasePlanDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureEquityPlansStockBasedCompensationExpenseDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#Disclosure401KPlanDetails" roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureNetLossPerShareComputationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20210930.xsd#DisclosureRestructuringDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" />
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637715702981885796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637715702981885796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637715702981885796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637715702981885796" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637715702981885796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637715702981885796" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637715702981896073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637715702981896073" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637715702981896073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637715702981896073" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637715702981896073" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637715702981896073" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637715702981896073" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637715702981896073" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637715702981896073" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637715702981896073" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637715702981896073" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637715702981896073" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637715702981896073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637715702981896073" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637715702981906093" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637715702981906093" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637715702981906093" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637715702981906093" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637715702981906093" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637715702981906093" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637715702981906093" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637715702981906093" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637715702981906093" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637715702981906093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637715702981906093" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637715702981916098" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637715702981916098" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637715702981916098" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637715702981916098" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637715702981916098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_AssetsCurrentAbstract_637715702981916098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702981916098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637715702981916098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_MarketableSecuritiesCurrent_637715702981916098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_RestrictedCashCurrent_637715702981926147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637715702981926147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_IncomeTaxesReceivable_637715702981926147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637715702981926147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637715702981916098" xlink:to="us-gaap_AssetsCurrent_637715702981926147" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637715702981926147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637715702981926147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_RestrictedCashNoncurrent_637715702981926147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637715702981926147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637715702981916098" xlink:to="us-gaap_Assets_637715702981926147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_AccountsPayableCurrent_637715702981936155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637715702981936155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637715702981936155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637715702981936155" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637715702981936155" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637715702981936155" xlink:to="us-gaap_LiabilitiesCurrent_637715702981936155" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_LongTermDebt_637715702981936155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702981936155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702981936155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637715702981946200" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_Liabilities_637715702981946200" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_CommitmentsAndContingencies_637715702981946200" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_StockholdersEquityAbstract_637715702981946200" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_PreferredStockValue_637715702981946200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_CommonStockValue_637715702981946200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637715702981946200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637715702981946200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637715702981946200" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637715702981956071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637715702981956071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637715702981956071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637715702981946200" xlink:to="us-gaap_StockholdersEquity_637715702981956071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637715702981956071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637715702981926147" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637715702981956071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637715702981956071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637715702981956071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637715702982026048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637715702982026048" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637715702982026048" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637715702982026048" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637715702982026048" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637715702982026048" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637715702982026048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637715702982026048" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637715702982036064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637715702982036064" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_637715702982036064" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637715702982036064" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637715702982036064" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637715702982036064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637715702982036064" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637715702982036064" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637715702982036064" xlink:to="us-gaap_OperatingExpenses_637715702982036064" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637715702982036064" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_637715702982036064" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_637715702982036064" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982036064" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637715702982036064" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702982036064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637715702982036064" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637715702982045987" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637715702982045987" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637715702982045987" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637715702982045987" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637715702982045987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637715702982045987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637715702982045987" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637715702982045987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637715702982045987" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637715702982045987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637715702982045987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637715702982045987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982045987" xlink:to="us-gaap_StatementEquityComponentsAxis_637715702982045987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637715702982045987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982045987" xlink:to="us-gaap_CommonStockMember_637715702982045987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982045987" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637715702982056000" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982045987" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637715702982056000" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982045987" xlink:to="us-gaap_RetainedEarningsMember_637715702982056000" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982045987" xlink:to="us-gaap_EquityComponentDomain_637715702982056000" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982045987" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637715702982056000" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637715702982056000" xlink:to="ptgx_AtMarketingOfferingMember_637715702982056000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637715702982056000" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982056000" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982045987" xlink:to="us-gaap_StatementLineItems_637715702982056000" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982056000" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_StockholdersEquity_637715702982056000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_CommonStockSharesOutstanding_637715702982056000" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637715702982056000" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637715702982056000" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637715702982056000" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637715702982056000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637715702982056000" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637715702982056000" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637715702982066112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637715702982066112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637715702982066112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702982066112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702982066112" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares_637715702982066112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_NetIncomeLoss_637715702982066112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_StockholdersEquity_637715702982066112" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637715702982066112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637715702982056000" xlink:to="us-gaap_CommonStockSharesOutstanding_637715702982066112" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_637715702982076042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982076042" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637715702982076042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637715702982076042" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982076042" xlink:to="us-gaap_IPOMember_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982076042" xlink:to="ptgx_AtMarketingOfferingMember_637715702982076042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982076042" xlink:to="us-gaap_BalanceSheetLocationAxis_637715702982076042" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637715702982076042" xlink:to="us-gaap_BalanceSheetLocationDomain_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637715702982076042" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637715702982076042" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637715702982076042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982076042" xlink:to="us-gaap_StatementLineItems_637715702982076042" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_ProfitLoss_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637715702982076042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_ShareBasedCompensation_637715702982076042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_637715702982087556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_Depreciation_637715702982087556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637715702982087556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982087556" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637715702982087556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_637715702982087556" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637715702982087556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637715702982087556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637715702982087556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637715702982087556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637715702982087556" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637715702982087556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637715702982087556" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637715702982087556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_OperatingLeasePayments_637715702982087556" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637715702982087556" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637715702982105865" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637715702982076042" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637715702982105865" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637715702982105865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637715702982105865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637715702982105865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637715702982105865" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702982116076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637715702982116076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits" xlink:label="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits_637715702982116076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637715702982116076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637715702982116076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637715702982116076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637715702982116076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702982126076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637715702982105865" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637715702982126076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982126076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982126076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637715702982126076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637715702982126076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982126076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982126076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377157029821260761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377157029821260761" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637715702982126076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982076042" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637715702982126076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637715702982136095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637715702982126076" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637715702982136095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_637715702982136095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637715702982126076" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_637715702982136095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637715702982136095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637715702982136095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637715702982146153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" xlink:type="extended" xlink:title="10301 - Disclosure - License and Collaboration Agreement">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982146153" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982146153" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982146153" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982146153" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982146153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982146153" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_637715702982146153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982146153" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982146153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982146153" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637715702982146153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637715702982146153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637715702982146153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" xlink:type="extended" xlink:title="10501 - Disclosure - Cash Equivalents and Marketable Securities">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637715702982156046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses and Other Payables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock_637715702982156046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" xlink:type="extended" xlink:title="10701 - Disclosure - Research Collaboration and License Agreement">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982156046" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982156046" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982156046" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982156046" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982156046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982156046" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637715702982156046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982156046" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982156046" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637715702982156046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982156046" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637715702982156046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" xlink:type="extended" xlink:title="10801 - Disclosure - Government Programs">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsDisclosureTextBlock" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_637715702982166258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsDisclosureTextBlock_637715702982166258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureTermLoanFacility" xlink:type="extended" xlink:title="10901 - Disclosure - Term Loan Facility">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637715702982166258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637715702982166258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11001 - Disclosure - Leases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637715702982166258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637715702982166258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11101 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637715702982166258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637715702982166258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11201 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637715702982176129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637715702982176129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlans" xlink:type="extended" xlink:title="11301 - Disclosure - Equity Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637715702982176129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637715702982176129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/Disclosure401KPlan" xlink:type="extended" xlink:title="11401 - Disclosure - 401(k) Plan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637715702982176129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637715702982176129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11501 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637715702982186054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637715702982186054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11601 - Disclosure - Net Loss per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637715702982186054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637715702982186054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureRestructuring" xlink:type="extended" xlink:title="11701 - Disclosure - Restructuring">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_637715702982186054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_637715702982186054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637715702982196116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637715702982196116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637715702982196116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637715702982196116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_637715702982196116" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637715702982196116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637715702982196116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637715702982196116" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637715702982196116" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637715702982196116" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_637715702982196116" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637715702982196116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637715702982196116" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637715702982206074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637715702982206074" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637715702982206074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637715702982206074" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637715702982206074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637715702982206074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" xlink:type="extended" xlink:title="30303 - Disclosure - License and Collaboration Agreement (Tables)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637715702982206074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637715702982206074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637715702982216318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637715702982216318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637715702982216318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637715702982216318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses and Other Payables (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637715702982216318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637715702982216318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Leases (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_637715702982225831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637715702982225831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_637715702982225831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637715702982225831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" xlink:type="extended" xlink:title="31303 - Disclosure - Equity Plans (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637715702982225831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982225831" xlink:to="us-gaap_AwardTypeAxis_637715702982225831" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637715702982225831" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982225831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982225831" xlink:to="us-gaap_EmployeeStockOptionMember_637715702982225831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982225831" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637715702982225831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637715702982225831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982225831" xlink:to="us-gaap_PerformanceSharesMember_637715702982225831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637715702982225831" xlink:to="us-gaap_StatementLineItems_637715702982236066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982236066" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637715702982236066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982236066" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637715702982236066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982236066" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_637715702982236066" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637715702982236066" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637715702982236066" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31603 - Disclosure - Net Loss per Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637715702982236066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637715702982236066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Description of Business - Liquidity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637715702982236066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_637715702982236066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsNoteDisclosureAbstract_637715702982236066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue" xlink:label="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsNoteDisclosureAbstract_637715702982236066" xlink:to="ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue_637715702982246065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsNoteDisclosureAbstract_637715702982236066" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637715702982246065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashNumberOfFinancialInstitutions" xlink:label="ptgx_CashNumberOfFinancialInstitutions_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ptgx_CashNumberOfFinancialInstitutions_637715702982246065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable_637715702982246065" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_637715702982246065" xlink:to="us-gaap_CreditFacilityAxis_637715702982246065" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_637715702982246065" xlink:to="us-gaap_CreditFacilityDomain_637715702982246065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_637715702982246065" xlink:to="us-gaap_LetterOfCreditMember_637715702982246065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_637715702982246065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_637715702982246065" xlink:to="us-gaap_LineOfCreditFacilityLineItems_637715702982246065" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_637715702982246065" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637715702982256012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" xlink:to="us-gaap_RestrictedCashCurrent_637715702982256012" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" xlink:to="us-gaap_RestrictedCashNoncurrent_637715702982256012" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637715702982256012" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637715702982256012" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice" xlink:label="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice_637715702982256012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePracticalExpedientAbstract" xlink:label="us-gaap_RevenuePracticalExpedientAbstract_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenuePracticalExpedientAbstract_637715702982256012" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent_637715702982256012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuePracticalExpedientAbstract_637715702982256012" xlink:to="us-gaap_RevenuePracticalExpedientFinancingComponent_637715702982256012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyTable" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyTable_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ptgx_SummaryOfSignificantAccountingPolicyTable_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable_637715702982265699" xlink:to="srt_RangeAxis_637715702982265699" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637715702982265699" xlink:to="srt_RangeMember_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637715702982265699" xlink:to="srt_MaximumMember_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable_637715702982265699" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637715702982265699" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637715702982265699" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637715702982265699" xlink:to="us-gaap_AustralianTaxationOfficeMember_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="ptgx_SummaryOfSignificantAccountingPolicyLineItems_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyTable_637715702982265699" xlink:to="ptgx_SummaryOfSignificantAccountingPolicyLineItems_637715702982265699" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit" xlink:label="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems_637715702982265699" xlink:to="ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria" xlink:label="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SummaryOfSignificantAccountingPolicyLineItems_637715702982265699" xlink:to="ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria_637715702982265699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License and Collaboration Agreement - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="srt_CounterpartyNameAxis_637715702982265699" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637715702982265699" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982265699" xlink:to="ptgx_JanssenBiotechIncMember_637715702982265699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982265699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982265699" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982265699" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982280654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OriginalAgreementMember" xlink:label="ptgx_OriginalAgreementMember_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982280654" xlink:to="ptgx_OriginalAgreementMember_637715702982280654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982280654" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_637715702982280654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="srt_ProductOrServiceAxis_637715702982280654" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637715702982280654" xlink:to="srt_ProductsAndServicesDomain_637715702982280654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637715702982280654" xlink:to="us-gaap_LicenseAndServiceMember_637715702982280654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember_637715702982280654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637715702982280654" xlink:to="ptgx_UpfrontCashPaymentMember_637715702982280654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="srt_RangeAxis_637715702982286361" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637715702982286361" xlink:to="srt_RangeMember_637715702982286361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637715702982286361" xlink:to="srt_MaximumMember_637715702982286361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637715702982286361" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637715702982286361" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_637715702982286361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_637715702982286361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_637715702982286361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember" xlink:label="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_637715702982286361" xlink:to="ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_637715702982296117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_637715702982296117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_637715702982296117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_637715702982296117" xlink:to="ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_637715702982296117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialSecondIndicationMember" xlink:label="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_637715702982296117" xlink:to="ptgx_PhaseTwoClinicalTrialSecondIndicationMember_637715702982296117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecondGenerationPhase2aEvaluatingPtg200Member" xlink:label="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_637715702982296117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_637715702982296117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember" xlink:label="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_637715702982296117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_637715702982296117" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialForAnyIndicationMember" xlink:label="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_637715702982306103" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_Ptg200PhaseAndSecondGenerationCompoundMember" xlink:label="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_637715702982306103" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member" xlink:label="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_637715702982306103" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637715702982286361" xlink:to="us-gaap_FinancialServiceOtherMember_637715702982306103" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637715702982265699" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeAgreementUpfrontPayment" xlink:label="ptgx_CollaborativeAgreementUpfrontPayment_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_CollaborativeAgreementUpfrontPayment_637715702982306103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived_637715702982306103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DurationOfResearchCollaborationAgreement" xlink:label="ptgx_DurationOfResearchCollaborationAgreement_637715702982306103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_DurationOfResearchCollaborationAgreement_637715702982306103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable_637715702982316111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_637715702982316111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DevelopmentCostsEliminated" xlink:label="ptgx_DevelopmentCostsEliminated_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_DevelopmentCostsEliminated_637715702982316111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated_637715702982316111" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UpcomingPotentialDevelopmentMilestonesPayment" xlink:label="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_UpcomingPotentialDevelopmentMilestonesPayment_637715702982316111" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_637715702982316111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_637715702982316111" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ReimbursementForServicesPerformed" xlink:label="ptgx_ReimbursementForServicesPerformed_637715702982326007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_ReimbursementForServicesPerformed_637715702982326007" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_637715702982326007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales_637715702982326007" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_637715702982326007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_637715702982326007" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637715702982326007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637715702982326007" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637715702982326007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637715702982326007" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637715702982336094" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637715702982306103" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_637715702982336094" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_637715702982336094" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637715702982336094" xlink:to="srt_CounterpartyNameAxis_637715702982336094" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637715702982336094" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982336094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982336094" xlink:to="ptgx_JanssenBiotechIncMember_637715702982336094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637715702982336094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637715702982336094" xlink:to="srt_ProductOrServiceAxis_637715702982336094" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637715702982336094" xlink:to="srt_ProductsAndServicesDomain_637715702982346020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637715702982346020" xlink:to="us-gaap_LicenseAndServiceMember_637715702982346020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637715702982336094" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_637715702982346020" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637715702982346020" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637715702982346020" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637715702982346020" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" xlink:to="us-gaap_ContractWithCustomerAssetNet_637715702982346020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" xlink:to="ptgx_ContractWithCustomerAssetAdditions_637715702982346020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" xlink:to="ptgx_ContractWithCustomerAssetDeduction_637715702982346020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_6377157029823460201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" xlink:to="us-gaap_ContractWithCustomerAssetNet_6377157029823460201" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637715702982346020" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_637715702982346020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_637715702982346020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_637715702982346020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_637715702982356042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637715702982346020" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_637715702982356042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637715702982346020" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637715702982356042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions_637715702982356042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction_637715702982356042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_6377157029823560421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_6377157029823560421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637715702982356042" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637715702982356042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions_637715702982356042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" xlink:to="ptgx_DueToRelatedPartyAdditions_637715702982356042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" xlink:to="ptgx_DueToRelatedPartyDeductions_637715702982366140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637715702982356042" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637715702982366140" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637715702982366140" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637715702982366140" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637715702982366140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637715702982366140" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637715702982366140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637715702982366140" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637715702982366140" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702982366140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637715702982366140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702982366140" xlink:to="us-gaap_FairValueInputsLevel1Member_637715702982366140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637715702982366140" xlink:to="us-gaap_FairValueInputsLevel2Member_637715702982376208" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" xlink:to="us-gaap_InvestmentTypeAxis_637715702982376208" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637715702982376208" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" xlink:to="us-gaap_MoneyMarketFundsMember_637715702982376208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" xlink:to="us-gaap_CommercialPaperMember_637715702982376208" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_637715702982376208" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637715702982376208" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982376208" xlink:to="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_637715702982376208" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637715702982366140" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637715702982376208" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637715702982376208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637715702982376208" xlink:to="us-gaap_AssetsFairValueDisclosure_637715702982376208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637715702982386815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637715702982386815" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637715702982386815" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637715702982386815" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702982386815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702982386815" xlink:to="us-gaap_MoneyMarketFundsMember_637715702982386815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637715702982386815" xlink:to="us-gaap_CommercialPaperMember_637715702982386815" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637715702982386815" xlink:to="us-gaap_InvestmentTypeAxis_637715702982386815" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637715702982386815" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637715702982386815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982386815" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_637715702982386815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982386815" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637715702982386815" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SupranationalAndSovereignGovernmentSecuritiesMember" xlink:label="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_637715702982386815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637715702982386815" xlink:to="ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_637715702982386815" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637715702982386815" xlink:to="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_637715702982396170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637715702982396170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637715702982396170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637715702982396170" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702982396170" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCashAbstract" xlink:label="us-gaap_InvestmentsAndCashAbstract_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsAndCashAbstract_637715702982396170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637715702982396170" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_637715702982396170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637715702982396170" xlink:to="us-gaap_MarketableSecuritiesCurrent_637715702982396170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637715702982396170" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637715702982396170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702982396170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637715702982396170" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637715702982396170" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637715702982406078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637715702982406078" xlink:to="ptgx_CurrentContractualMaturitiesMaximumPeriod_637715702982406078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637715702982406078" xlink:to="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_637715702982406078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637715702982406078" xlink:to="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_637715702982406078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses and Other Payables (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637715702982406078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637715702982406078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637715702982406078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AccruedMilestonePaymentToFormerCollaborationPartner" xlink:label="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ptgx_AccruedMilestonePaymentToFormerCollaborationPartner_637715702982406078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637715702982406078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637715702982406078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Research Collaboration and License Agreement (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfDevelopmentMilestonePayments" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_637715702982406078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="ptgx_NumberOfDevelopmentMilestonePayments_637715702982406078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="ptgx_AggregateAmountOfDevelopmentMilestonePayment_637715702982416017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Government Programs (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsTable_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637715702982416017" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637715702982416017" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637715702982416017" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637715702982416017" xlink:to="ptgx_OverseasFindingsMember_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637715702982416017" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637715702982416017" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637715702982416017" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637715702982416017" xlink:to="us-gaap_AustralianTaxationOfficeMember_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637715702982416017" xlink:to="ptgx_RevenueSourceAxis_637715702982416017" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_RevenueSourceAxis_637715702982416017" xlink:to="ptgx_RevenueSourceDomain_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_RevenueSourceDomain_637715702982416017" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember_637715702982416017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems_637715702982416017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637715702982416017" xlink:to="ptgx_GovernmentProgramsLineItems_637715702982416017" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637715702982416017" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction_637715702982426074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637715702982416017" xlink:to="us-gaap_IncomeTaxesReceivable_637715702982426074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637715702982416017" xlink:to="us-gaap_GrantsReceivable_637715702982426074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan Facility (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637715702982426074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637715702982426074" xlink:to="srt_StatementScenarioAxis_637715702982426074" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637715702982426074" xlink:to="srt_ScenarioUnspecifiedDomain_637715702982426074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637715702982426074" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_637715702982426074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637715702982426074" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_637715702982426074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637715702982426074" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_637715702982426074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637715702982426074" xlink:to="us-gaap_VariableRateAxis_637715702982426074" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637715702982426074" xlink:to="us-gaap_VariableRateDomain_637715702982426074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_637715702982426074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637715702982426074" xlink:to="us-gaap_PrimeRateMember_637715702982426074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637715702982426074" xlink:to="us-gaap_DebtInstrumentAxis_637715702982435977" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637715702982435977" xlink:to="us-gaap_DebtInstrumentNameDomain_637715702982435977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637715702982435977" xlink:to="ptgx_TermLoanCreditAgreementMember_637715702982435977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637715702982426074" xlink:to="us-gaap_DebtInstrumentLineItems_637715702982435977" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637715702982435977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_LongTermDebt_637715702982435977" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount_637715702982435977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_637715702982435977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage_637715702982435977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637715702982435977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate_637715702982435977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentFloorRate_637715702982435977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage_637715702982446051" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_637715702982446051" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_RepaymentsOfDebt_637715702982446051" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637715702982446051" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_DebtInstrumentFeeAmount_637715702982446051" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637715702982435977" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_637715702982446051" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637715702982446051" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637715702982446051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637715702982446051" xlink:to="srt_StatementGeographicalAxis_637715702982446051" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637715702982446051" xlink:to="srt_SegmentGeographicalDomain_637715702982456076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637715702982456076" xlink:to="stpr_CA_637715702982456076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637715702982446051" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982456076" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982456076" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982456076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FacilityLeaseAmendmentAgreementMember" xlink:label="ptgx_FacilityLeaseAmendmentAgreementMember_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982456076" xlink:to="ptgx_FacilityLeaseAmendmentAgreementMember_637715702982456076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637715702982446051" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="ptgx_NumberOfOperatingLeaseAgreement_637715702982456076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_AreaOfLand_637715702982456076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_SecurityDeposit_637715702982456076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_OperatingLeaseExpense_637715702982456076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637715702982456076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_OperatingLeaseLiability_637715702982456076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_AdditionalSecurityDeposit" xlink:label="ptgx_AdditionalSecurityDeposit_637715702982456076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="ptgx_AdditionalSecurityDeposit_637715702982456076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637715702982456076" xlink:to="us-gaap_SubleaseIncome_637715702982466040" order="8" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Supplemental balance sheet information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_637715702982466040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637715702982466040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_637715702982466040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637715702982466040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637715702982466040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637715702982466040" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637715702982466040" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637715702982466040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiability_637715702982466040" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637715702982466040" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637715702982476045" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Leases - Weighted average lease term and discount rate (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637715702982476045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637715702982476045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Lease cost information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost_637715702982476045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome_637715702982476045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637715702982476045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost_637715702982476045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Leases - Cash flow information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637715702982546058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments_637715702982546058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637715702982546058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637715702982546058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637715702982556092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637715702982556092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637715702982556092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637715702982556092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637715702982556092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637715702982556092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637715702982556092" xlink:to="us-gaap_OperatingLeaseLiability_637715702982556092" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_637715702982556092" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637715702982556092" xlink:to="srt_CounterpartyNameAxis_637715702982556092" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637715702982556092" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982556092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember_637715702982556092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982556092" xlink:to="ptgx_ZealandPharmaMember_637715702982556092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637715702982556092" xlink:to="srt_LitigationCaseAxis_637715702982565976" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_637715702982565976" xlink:to="srt_LitigationCaseTypeDomain_637715702982565976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ArbitrationResolutionAgreementWithZealandMember" xlink:label="ptgx_ArbitrationResolutionAgreementWithZealandMember_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_637715702982565976" xlink:to="ptgx_ArbitrationResolutionAgreementWithZealandMember_637715702982565976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637715702982556092" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982565976" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982565976" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982565976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982565976" xlink:to="ptgx_PhaseTwoClinicalTrialMember_637715702982565976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PhaseThreeClinicalTrialMember" xlink:label="ptgx_PhaseThreeClinicalTrialMember_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982565976" xlink:to="ptgx_PhaseThreeClinicalTrialMember_637715702982565976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637715702982556092" xlink:to="us-gaap_LossContingenciesLineItems_637715702982565976" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable_637715702982565976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable" xlink:label="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable_637715702982565976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage_637715702982565976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfBusinessDays" xlink:label="ptgx_NumberOfBusinessDays_637715702982565976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_NumberOfBusinessDays_637715702982565976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_RoyaltiesOnNetProductSalesPercentagesReduction" xlink:label="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_RoyaltiesOnNetProductSalesPercentagesReduction_637715702982576295" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage" xlink:label="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage_637715702982576295" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable" xlink:label="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable_637715702982576295" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable" xlink:label="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable_637715702982576295" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable" xlink:label="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable_637715702982576295" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_637715702982576295" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfGeographicTerritories" xlink:label="ptgx_NumberOfGeographicTerritories_637715702982576295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637715702982565976" xlink:to="ptgx_NumberOfGeographicTerritories_637715702982576295" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637715702982585987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637715702982585987" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637715702982585987" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637715702982585987" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_637715702982585987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="us-gaap_TypeOfArrangementAxis_637715702982585987" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637715702982585987" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637715702982585987" xlink:to="ptgx_ExchangeAgreementMember_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="srt_CounterpartyNameAxis_637715702982585987" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637715702982585987" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982585987" xlink:to="ptgx_BiotechnologyValueFundL.pMember_637715702982585987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_637715702982585987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637715702982585987" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_637715702982585987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="us-gaap_StatementEquityComponentsAxis_637715702982595756" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637715702982595756" xlink:to="us-gaap_EquityComponentDomain_637715702982595756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637715702982595756" xlink:to="us-gaap_CommonStockMember_637715702982595756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637715702982595756" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637715702982595756" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" xlink:to="us-gaap_PrivatePlacementMember_637715702982595756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_637715702982595756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_FinancingFacilitySalesAgreementMember" xlink:label="ptgx_FinancingFacilitySalesAgreementMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" xlink:to="ptgx_FinancingFacilitySalesAgreementMember_637715702982595756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_UnderwrittenPublicOfferingMember" xlink:label="ptgx_UnderwrittenPublicOfferingMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637715702982595756" xlink:to="ptgx_UnderwrittenPublicOfferingMember_637715702982595756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_UnderwrittenPublicOfferingMember_637715702982595756" xlink:to="us-gaap_OverAllotmentOptionMember_637715702982595756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637715702982595756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637715702982585987" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637715702982595756" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637715702982595756" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637715702982606078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_SaleOfStockPricePerShare_637715702982606078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637715702982606078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637715702982606078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_637715702982606078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637715702982606078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637715702982606078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637715702982606078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637715702982616105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_SharesIssuedPricePerShare_637715702982616105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_WarrantsAndRightsOutstanding_637715702982616105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637715702982616105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized_637715702982616105" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="ptgx_NumberOfWarrantsExercised_637715702982616105" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702982616105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637715702982616105" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants_637715702982626013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="ptgx_StockExchangedForPreFundedWarrants_637715702982626013" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637715702982626013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637715702982626013" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_637715702982626013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants_637715702982626013" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637715702982626013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637715702982606078" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637715702982626013" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Equity Plans - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982635712" xlink:to="us-gaap_AwardTypeAxis_637715702982635712" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637715702982635712" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982635712" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637715702982635712" xlink:to="us-gaap_EmployeeStockOptionMember_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982635712" xlink:to="us-gaap_PlanNameAxis_637715702982635712" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637715702982635712" xlink:to="us-gaap_PlanNameDomain_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637715702982635712" xlink:to="ptgx_EquityIncentivePlan2016Member_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637715702982635712" xlink:to="ptgx_InducementStockPlanMember_637715702982635712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982635712" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982635712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637715702982635712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637715702982635712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637715702982646093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_637715702982646093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_637715702982646093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982635712" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637715702982646093" order="6" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Equity Plans - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637715702982646093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637715702982646093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637715702982646093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637715702982646093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637715702982646093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377157029826460931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377157029826460931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637715702982656308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637715702982646093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637715702982656308" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637715702982656308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637715702982656308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637715702982656308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637715702982656308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377157029826563081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377157029826563081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637715702982656308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637715702982656308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637715702982656308" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637715702982656308" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637715702982666069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637715702982666069" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637715702982666069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637715702982666069" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637715702982666069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637715702982666069" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637715702982666069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637715702982666069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637715702982666069" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637715702982666069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637715702982666069" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637715702982666069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637715702982666069" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637715702982666069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637715702982666069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637715702982666069" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Equity Plans - Stock Options Valuation Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982676065" xlink:to="us-gaap_AwardTypeAxis_637715702982676065" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982676065" xlink:to="us-gaap_EmployeeStockOptionMember_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982676065" xlink:to="srt_RangeAxis_637715702982676065" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637715702982676065" xlink:to="srt_RangeMember_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637715702982676065" xlink:to="srt_MinimumMember_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637715702982676065" xlink:to="srt_MaximumMember_637715702982676065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637715702982676065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637715702982676065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637715702982676065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637715702982676065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637715702982686071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637715702982686071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982676065" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637715702982686071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636590679422769450" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636590679422769450" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982686071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982686071" xlink:to="us-gaap_AwardTypeAxis_637715702982686071" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637715702982686071" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982686071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637715702982686071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982686071" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637715702982686071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982686071" xlink:to="us-gaap_PerformanceSharesMember_637715702982695731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982686071" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982695731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637715702982695731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982695731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637715702982695731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637715702982695731" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6377157029826957311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6377157029826957311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637715702982695731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637715702982695731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637715702982706067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637715702982706067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637715702982706067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637715702982695731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637715702982706067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Equity Plans - Performance Stock Units (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637631820490353628" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637631820490353628" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982706067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982706067" xlink:to="us-gaap_AwardTypeAxis_637715702982706067" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637715702982706067" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982706067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637715702982706067" xlink:to="us-gaap_PerformanceSharesMember_637715702982706067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982706067" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982706067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982706067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637715702982716066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637715702982716066" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982716066" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637715702982716066" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982706067" xlink:to="us-gaap_ShareBasedCompensation_637715702982716066" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637219361260651801" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637219361260651801" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982716066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982716066" xlink:to="us-gaap_PlanNameAxis_637715702982716066" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637715702982716066" xlink:to="us-gaap_PlanNameDomain_637715702982716066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637715702982716066" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member_637715702982716066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637715702982726049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637715702982726049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637715702982726049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_637715702982726049" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637715702982726049" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637715702982726049" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637715702982726049" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637715702982726049" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637715702982726049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637715702982716066" xlink:to="us-gaap_ShareBasedCompensation_637715702982726049" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41307 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637715702982736042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637715702982736042" xlink:to="us-gaap_IncomeStatementLocationAxis_637715702982736042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637715702982736042" xlink:to="us-gaap_IncomeStatementLocationDomain_637715702982736042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637715702982736042" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637715702982736042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637715702982736042" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637715702982736042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637715702982736042" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637715702982736042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637715702982736042" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637715702982736042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637715702982736042" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637715702982736042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637715702982736042" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637715702982736042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/Disclosure401KPlanDetails" xlink:type="extended" xlink:title="41401 - Disclosure - 401(k) Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637715702982736042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637715702982736042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637715702982746047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_637715702982746047" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637715702982746047" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636607825133049664" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636607825133049664" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637715702982746047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637715702982746047" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637715702982746047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637715702982746047" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637715702982746047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637715702982746047" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637715702982746047" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net Loss per Share - Computation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_636878483028362637" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637715702982746047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_636878483028362637" xlink:to="us-gaap_NetIncomeLossAbstract_637715702982746047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637715702982746047" xlink:to="us-gaap_NetIncomeLoss_637715702982756057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_636878483028362637" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637715702982756057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637715702982756057" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637715702982756057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637715702982756057" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637715702982756057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637715702982756057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637715702982756057" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637715702982756057" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637715702982756057" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" xlink:to="us-gaap_EmployeeStockOptionMember_637715702982756057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_CommonStockWarrantsMember" xlink:label="ptgx_CommonStockWarrantsMember_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" xlink:to="ptgx_CommonStockWarrantsMember_637715702982756057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637715702982756057" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" xlink:to="us-gaap_PerformanceSharesMember_637715702982756057" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637715702982756057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637715702982756057" xlink:to="us-gaap_EmployeeStockMember_637715702982756057" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637715702982765704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637715702982756057" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637715702982765704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637715702982765704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637715702982765704" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637715702982765704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Restructuring (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20210930.xsd#ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_637715702982765704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_637715702982765704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_637715702982765704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringCharges_637715702982765704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ptgx-20210930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgx="http://www.protagonist-inc.com/20210930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgx-20210930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_9Z964QKwJE2qr29wKQspDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_zKmsy6v6FUaz1H9GRlgxZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_UN3M56DNcEqfJFsFQtlo7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_34DT_TXcJ0G9oeklOaHaWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_eu303YctzUm4oyVCdG6opQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ffkr2mgme0Kc83elbZL7aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8X-9N-uxzEWLV5_AkyjFPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAo-gksv90emgd8j5zQ9WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T3JUh_bQFUWzNCgqWLw-SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ScZrHzQctkadsqBzu4TDGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_URkiGm8zuEaVvS65J30DTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4dru7UabbEO8vq8Kk60BLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_07-nJWm-n0OlxE7BAmCSvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o9SfVFUv-UWAdi0N3P_IpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cofzvfw-4UGemNVWygkS8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dmfd75drp0Sl92sRinfLjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_hze2TlFsxEWN43owngJkXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iXBhd1us706tUU2Z6TGdoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A4ngj4JfEEud5h_rZa61rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wDJZBP8oWkmr1-cnJEWO_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_15NQ36sPLUyBE0gs8_H_zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qLCgYz5FGUGJWujpfLA26w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EyCHRvQf9UG7GDeEg-B-bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_NpkY5Or850q-_7gddnu5kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6k8OGpvpa0CnTaIinonZ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ShsA1tWpGUmhQJqfvR21Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pjYolJb8NUSZoqWWvsTjEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2VW_uzB5fkeRI3qxZyicNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_sPnFRiazY0WPCIV18TjFyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ZWhhGQPBKUuEzunwWJ1GhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8zEeV8gTA0OQG69UlVTpzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_ChADps65pUSE5xPbZYa91Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_MLttZWHz2UiEm3p_zIvcnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_RdllORFsOUWkT56_8WgrPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NQqJPEuYYU24niCb9tj5og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEkXG0l4dU-MPpEChb8m2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MdN54EnQNUy4goQYips2hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rFCznfZHPUidpHv3XziwjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OQZenvrZlk6VJmwZFGIrag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_HO9dXCVgUUKyFTdCLwfdHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3v_HJaV_TEawCCjJ-8U_bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8bkYSfa3AECmsmdja2QoLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2018_To_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_tOd2A-ZoskaNnweabNr7Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_VXWpZKcTTkKp8eVZQhziGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_F2fAANpPG0qxaN1I2cAc1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_StatementGeographicalAxis_stpr_CA_Ujq4sL4CxEW0D5YwkaKV3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9KOXTrTqMUiTDI99y3z_ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__vWz_fmTEUCSA1s4LTbr_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_ZNKaf1RmykO0-f7B2C1WOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_9rUNAqUsGU-Kz_BLZ_8PsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k2WesrzFCUWJheqmlJkQMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-pvHJ7QJ90yW1k3Cfl4qtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ESv4u0HBt0CnfQx4AKYNAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_picUoPu6YU6hAp4STfCryA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I6LDpOFLME2hRdBnUQSKZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T6A4i7LXhkGkWOztGamCHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_D-unIeqFvkKbPDLT1e3qMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vnFLoq50b0y_n6K8gPk8yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_IcQjRh5fKEOqMWWM3N6bgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_O2mng1-tskSGO5KBeSuZsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_NLWK1h6eUUCL1SCn1CQ7wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_82q0nTVsSUC8bXZMRz6aLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_lvaVnROBNEGcQD3RONq0EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_K7Od3CM6-kOKjqWB7rXSfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MZM0ma8qsUmURiga3ySKXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_mjNjDSCfZ0OjAafvNYLJ9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_HREnfaqhhk6qERJYnhneIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_562smoZuLkS9KsBvdrpLtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_potMVrgeoEGalpEJm2UCjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_9QJowPauUk-gaWt5sFT-HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M3p7YmD9vkCTXzn0pO5cbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_NvuFc-sXQUC2i1aTvziUiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yX6TYuMbYEicxZwbaMBgVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_EXzMSWZYJkq4Gd12kF9Hhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_lZeL8hdzf028kJ3_rDwFag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yFhWkhHuuEaQKk7rwr082w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jxODNBy8nUGGb5t1661FYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VRhvgs9oa0mTUaqYjRO3ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EnjUd2zZYk6vz2-cHlqtXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:JanssenLicenseAndCollaborationAgreement26May2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_YTpXeQgJJUeKa5oZr8AiAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_M6ZuWy-_Aky-LJndvpy4bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_DkFNZeRNm0ydJRjGjJnj3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_gec9OfdVA0-QavCdRuU7ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_b77QUVVp-EabKEv4WpeA6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_quwzsXAt80GJsdttydqn8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_xC4RqMR0Q0KyABMRO1X4UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_RyDegFl_A06Zzlx5SUabIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_gJztAK_pJkSEMdZvVKmVEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_Jby6BCZwZEmx5lkgaQcFoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_Yd94PRDSaEyHbItBmTnC2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember__UavJt8cZ0e-l_KQU4eymg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6QBcAGRDREGf4rn_KPZpcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-jIggHYH1UmbKLFheHzbgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZdtE_xThKkSdI-Vaaceeog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_8Myl1B2k-kSOnAjEMsdY-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_R2T0FeSCkU-4AuqwK_udIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_GTf2MVxlEEGBedzfKpF1Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_qZvf9xKSG0OZSn-Pah-mXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_7TCHAu-iM0K20R1_6ZSBeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_W-JTrmc1iUqyssBi9jfgmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_0Hh9M4XK4UiFA8GLjbeoAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OKk9lwDz4EGN0BwH0atvlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fUK5OnhlFU66Xq1kj7KKrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_mBhTXxceV02MtGdxdWbrGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:FacilityLeaseAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_r1RtIdBqNkaMdBGIaOjSHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_1dBmY6pAUU6RcuwSZPcgtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbxkG_gzsk-x_bM6qbI8_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_YzrwOrK_Z0OF0-Mj3NtBLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_nTdQkTXU-0S6ergKcYz3vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptgx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_n0Ta9bA0r0Kq2dDdfjjplg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SpzSmd-Mk2osYBgelFKpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GzDm5mfuBEe6F8PeGg2E1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_tLWEwGzi6E-KqzZmPdOOrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptgx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T0H8ABLR8UW5UTiO70X3Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AcXFvIPtgkyUmawuHCqSow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2I_k75JCq0eeHRkxbMxQXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_t-wbdQnITUaC7MfBqxrb9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_a0FuumrKYUO7tJOSkOvu3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9O0ysWYJAk2T3ppTE9BJ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l6HbK0TvKE283tUIhVWh1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RLO4WIMRGkC7XbCfwot3cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_M8yFhIOS4UWfLn0-racdCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseTwoClinicalTrialSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_k7-5iEviVkaUoyPynKb8ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseTwoClinicalTrialSecondIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_zpwdW8FrMU2yPOUewuio1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_E3q_5X1xx0W9IH0IDoVYIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_27_2019_To_11_27_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_xRIStPOlqkO3ZRkjqtTj2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-27</startDate>
            <endDate>2019-11-27</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_3MZvEqMKLkqJJimay3c3Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:FinancingFacilitySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_uyHNYHVIIUOFt7eISFZ0iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_RUQmYM3F3ku4NzFw_8JxVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_OrLsItNoVUWmXfX_oVcZTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_fHticHz3nEOKl7dkY7LJ5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_W5_EmxclnkqveI5CjIX6wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_aGR3Nn_0oUCmeAgOesXdXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_5wmoKVR2DU2fW1JWG3YE4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_DR8YsZ1k4EKWFSFZzgo99w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseThreeClinicalTrialForAnyIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_QqjayIBfTU2Zb8ZXHEhcpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_AHS1J3rNPkunnKl_uozAJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseThreeClinicalTrialMember_PxpJvRYYhEWj49AtdxBe5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_T5go7T86jkGHW8Ogcd55BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_ebVRPtOngkuKafR-yF0DZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_sxi-lVVXP0eAqntyNRA1rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_e1g49FhL7kmfXyQdu4N9Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_HNZLcuNLlkC4l1XQ9mRg5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__XGvkKYt2kq50PQcaNBpsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_6kgROCjubEaK_kfQMy3jkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_EKO4dc3A9kW58GT-34PVkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_htTtbMn45UOqoFQw4o06MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:Ptg200PhaseAndSecondGenerationCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-05-07</startDate>
            <endDate>2020-05-07</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JyX857Du9kCccikwVOJK1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_nJ2YdyBimE6P9t5VGQxkZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_GjbbJITBaUG01OT1oWNJlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_5LG8Bd8oPkGEzWl62U-nbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_f6vGdpv7dkiDKg1sBRHOoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_y3q_xyeqpEq7Mcn87B_l1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_df9Ci-g-EECi012fGqcB-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_8VDg-9H-LkmeiUYsHBLxHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_CXrEby6GiEaljTlG3GLsBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_PIZR72h8sUiUXP2iC_lkKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2StudiesMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_ml2M2iwfc0KpJiIzGxvCug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:PhaseOneStudiesOfSecondGenerationCompoundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_r2A-BxT7r0GiRUZodoE_Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_xBi47oQ55EWzPVnVxo6vOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aAnd2bMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_vlCXpQQLhUe0YkX2S-ZJvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationPhase2aEvaluatingPtg200Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_eY73vDQa7U23JqhEa2BFLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ptgx:SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_rRvBtxUPXUy-HfoqhGT3wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ptgx:ArbitrationResolutionAgreementWithZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendedAndRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_s96udydX3kChOKXdoymkjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:OriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:SupranationalAndSovereignGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:FacilityLeaseAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_29_2021_AWZjUpWCCEa46ziiy36xdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_ulf2uGevlEWfB2AwE0yW3g">
        <measure>ptgx:segment</measure>
    </unit>
    <unit id="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA">
        <measure>ptgx:Institution</measure>
    </unit>
    <unit id="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w">
        <measure>ptgx:payment</measure>
    </unit>
    <unit id="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg">
        <measure>ptgx:item</measure>
    </unit>
    <unit id="Unit_Standard_lease_l-KtIo8rkUevq1Vg6RPLug">
        <measure>ptgx:lease</measure>
    </unit>
    <unit id="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      id="Hidden_WI9K15k_20GZnOd8VNG8IQ">usgaap:LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      id="Hidden_ZbKry8j0sUCaJBlX4me6bA">usgaap:LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Hidden_x34gDY71902u0Osenos8WA">usgaap:LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      id="Hidden_W6anfsYeE0emhqkDRNQTkw">usgaap:LicenseAndServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_Iw4yYFTj806qmla4EB7gTQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_Ug3l-MxwREOmKYIwED51ZQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_mgvgdq6FiEyJOe8QmZFQqQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_1KAK1AR2YkOh-f0KOSdQPw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_DprURJf_sUCs9NbETOeebA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_P9F1pxSCpEGbW6iv8r1a5g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Hidden_ISrdM4PW902gdSwI2P7geg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Hidden_cKlt8s2Pyk2lMzvXw3U3UQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Hidden_iwPIj70IREOqVhapJq4v9A"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47671654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Hidden_qms1Q3i8VEe1Czi4YEu9FA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">43745465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Hidden_u4SjkEALd06OJORFVCaVuQ"
      unitRef="Unit_Standard_segment_ulf2uGevlEWfB2AwE0yW3g">1</us-gaap:NumberOfOperatingSegments>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_ucGo2JKJ50qPq7diRg0E2A_2_1">0001377121</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_f1xXwSkjS0i9OBSmE8EKDA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_cNhuSROELUiGIYomMqRvRA_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_Y82Fma2h0EycDWln1zw5Hw_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_UDa3bh5WiUe7gBzE4HYJnQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_If59OPpEK02lxvyiRk3sOQ">us-gaap:OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_GABQ-ji7AkWiSoCyPdZ-iA">us-gaap:OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_VdeOmiqn-EmGbvHLuN1aAA">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_LH77hsw29EuHMm-jjFeFDQ">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_K67XINXtckW2yeWVvsxsDQ">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_CT0nErfOFkCb97eo7Czw9g">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Hidden_b6WSSFcN8kyrZANs0pC1gg">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Hidden_Td8JIgKxPEyJEBQXFFlrvQ">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA"
      decimals="-5"
      id="Hidden_W9bIUIMLtUuXqk-5ssyS9Q"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1400000</us-gaap:OperatingLeaseLiability>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_or1jKlXV7U2GvOwWu5hvCA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_gtete85zQU2rdwA4y-bokA_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_I0ExGzF9sUa5HgVO-Bjc0g">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_jqEfzZZUR0ut4PKsdWmtlg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_Tmiigh4AyUaX7CeNHxa1Pw">001-37852</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_YlNy9RWTOE-D8tY_g3H1mg">PROTAGONIST THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc__0WwrSiew0OvaUPcszI2Kw_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_KDVRiXON2kGphjDi37T8Zg_0_2">98-0505495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_gtETPZkzNkyGsJkP-34JJA">7707 Gateway Boulevard, Suite&#160;140</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_h6qf2hOnekqdf4FgZqUFqg">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_b0Na5aFEQECGdVok-e07Kg">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_gokBQWmiqUSk-h2sHkXUjQ">94560-1160</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_vcDwbyNliESQnhQWCawBAA">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_QBD4MTvFP0OM40NBsritdg">474-0170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_f3Zfyv_DfUmjiT7-4SGHog">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_s1UYzmzGbU-pHYT8loDOGg_2_1">PTGX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_cPuy3vXGYEiSUzg79MuTgg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_1VjeC-WWzEOp0Ed5QRMFhg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_s_SCVLk9ekKt_JVkpXADPw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_-Q9tfckU60ar6x9F8pEMMQ_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_-D9AwjZ6qki_MiGZNBkmJw_4_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_fLshVKg0-kaAJIT7nvyABA_4_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_fZmtoIYjZU2aGXTC5r1qhA">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_mD7-ONolDk6X7CDzjVkegQ">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_10_29_2021_AWZjUpWCCEa46ziiy36xdQ"
      decimals="INF"
      id="Narr_mcpYVBdeuEuWAcvI6JEE4w"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47728227</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_LRYGB8jYOUShM-zpBCONlw_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120542000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_s_YSSqhdOEq7cn6ay5yhhw_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">117358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_hEIS-8L6Jk-KbCGhDoTHKQ_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">193759000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_GSzBCHT6uk29UlVlARzr5g_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">188451000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_GE4EntS7b06jfACZk9g30A_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_ZK_q_VX6aES84aNy4rIoDg_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2638000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_VXAKzbKaMEy3oYIIzNG84Q_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2426000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_mj_R4yOWGk-RCvASlHOjHQ_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1871000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_yn68QtIt0E6YIcWrRrLUGA_9_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1084000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_Odnsr24F9E-Cxu4RNz3hcA_10_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8877000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_3jTi0PCkrkOoZcszQmTaTQ_10_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6277000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_GvAJhHreZ0SGcpd-4zMpIQ_11_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">327687000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_jJ_HyPcbH0C7_ul1VQsppg_11_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">315606000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_wcytnh2xb0egdx3Hi9AJUg_12_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">38169000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_qzKfujUPSkWpoDWEuEpujw_12_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_BG7Bn_Zh6ECNNnpbHyImpQ_13_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_ft-DVJibY0-s2juN15cPww_13_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1462000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_t-ZWQ5TpREy66Y5yFtmFWg_14_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">225000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_CUbF0dSxBEuJuZmh2I0f6A_14_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_uqXsYmOtCEiNGCQCVqGg7w_15_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5371000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_DYkWlaxvGEmfr_rip9l4BA_15_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4950000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_FDkMnK5iVUuV1Eyi6lEZjQ_16_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">373175000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_Qn7Cg8cO1kuZzbGknYeddw_16_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">324468000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_YFJnnDEiWkK6Tn5sbBRXiQ_19_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">706000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_4ZdqQ50SFEGsdfQgfoSkjQ_19_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3075000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_FcbrgcO2yk68RJTzxIlcww_20_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1121000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_kGp7lra9kUy9-oEgBaUfnw_20_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2732000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_EinRtL9Jr0W8FgOp2yGL6w_21_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">33061000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_gY6j1a_lJ02em99t1WvjFQ_21_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">18498000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_vwv2ZQBc3UOphwHsnxGQCg_22_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2241000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_xT9mxtk870OnoBwHfrb_Uw_22_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">14477000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_XZmcaCAu3UaIMMYpUY5IqA_23_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2027000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_7MKV_vSBqEeb8uNuyvkqHA_23_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_rhiMlymBCkuWfVFow1P3cw_24_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">39156000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_5Tu4bkPsBEeHO7kv1exx6g_24_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">40241000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_D3Rp8u3s8kq1_2Y0I9cb2A_25_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4238000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_AaTDubJV0E6KuTEv78FbdA_25_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_BhZCMe5En0WkENkfHjYjrA_26_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_MnQ4ygkC50WRk_D0mse0Mg_26_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_SFkaKQJIRkGbq1sUV7iu7A_27_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">43515000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_1DGJ1hfIYEmlTAU8dJ7-DA_27_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">44862000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_gOG9tBxhUUm2c7C0djkMxA"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_jcjgb1aai0K4l3MpxR_Qvw"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_SQwKrAAXSkOVCHHactB3KQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_IUntXhUyrkiNse5o1XoYDA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_PgzmZV9FWkGwDX4JkcIbXw"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_cuskBHInYEWkVqI7fTz33w"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_AxAE0n3h_0WugbY_Kj_TQw"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_qdH-Elrh5EO70f5uJp9Bdg"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_Pl03hwHoSkOEguTd-5XhgQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_3F8X2wdjzUiuezg0iydCHA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_hqFn4zJQ8U2y2kk3SwUy2g"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47671654</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Narr_bCJGXo6KM0eO0DBd5KXdPw"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">43745465</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_BEhenKxB5EeQZRJs9Gbedg_32_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">702319000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_54nTOhdDtE2lDH57PiDy2A_32_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">563389000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_9zI4QsUFSk-zdGn-QyTDgQ_33_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-204000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_gZ7qEbK_tkKfk0IpjHGTGg_33_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">28000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_7HtNCEHXA0GAzd4ISjhjEQ_34_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-372455000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_X32aIRrshkKq_EEgheoo2g_34_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-283811000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_wZOb5By_bUeUDFQU0S63Jw_35_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">329660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_1kBfzvzwIEGG3cmk1jcfsA_35_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">279606000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_hMiAltOlCU6q6pELxINYqw_36_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">373175000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_b9Lx7b1J3EW3ELp5KsFOUg_36_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">324468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_yjITiuozsEya1gywAWfGvA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10286000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_Wacz94UvwEqNF4iuylv_ww_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">13114000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_kTC1jl3d6Emt8W_tnPpwOA_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">18740000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_KMgclmLVFkyX-kibL3U1GQ_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">22978000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_CYQL2SE8g0-gATzn5Dfs1g_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">36956000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_-pWp5p9fEU2kTIZ-NrTIVQ_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">15995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_JpWtmLu5xEaplhHmZetF8w_7_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">87633000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_CJZomGf7K0WgqmYKuralGw_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">55020000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_T9qF-bnv0UG96F_4SzbM9Q_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">7256000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_M5z4jBoSZEyDLgJryWO6Xg_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4891000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_ohMnsx9O2kK9YwlxZFGg0A_8_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">19936000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_d_EiezEzk0mNGczRYxaw0Q_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">13644000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_fHcuEwrs0kWSd4N3gaeIUQ_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">44212000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_HNNwnzDvKEyGbPgTahE3CQ_9_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20886000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_88rMvS1PV0G6o-foc70T7Q_9_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">107569000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_jOijU6t-CkGkRP1LnEhrpQ_9_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">68664000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_EFhG6oMprkOjwYhlXs2n-w_10_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33926000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_tdofUpxOT0yn99yr84eA6Q_10_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7772000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_HkrZuhUnLki2sTKusNUTcg_10_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88829000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_tLp-Z0Rp2U28PuPw45sOKQ_10_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-45686000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_oIiJQAoh7EOrArvfnQ8SXg_11_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">122000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_tlhIzMzqzkCAosDk5LbiCA_11_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">87000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_6owtcce2o0eEFfG27XX-og_11_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">321000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_cfJ-Glr2nEqmFR_mjRvMjA_11_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">820000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_scbokXVWTkeWoyJimhRdNQ_12_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">19000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_23AtYMNci0qCS2Rq1MDlJw_12_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">471000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_fSn2ds7XoEa7URs0da6vkA_13_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-585000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_edYgQ0G0lE-u2aLSk3J3bA_14_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-59000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_Ztpu2ZzXjUKNqyyH8GKZhg_14_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-136000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_NWGU-5OVWE6GIa7zGb9euw_14_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-37000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_x9Him8dRFkqqA6s2R1usPw_15_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_v53Od1zm2EKHsV_patgTbQ_15_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_irbTE339oUep-0nGsPKJLA_15_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_xTUez_dPtE-n95SbipR2Og_15_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-45959000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_ggayimcUNUScmw7prKb9cw_16_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_QWrSfZPsW0W-O1RJu81iMA_17_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_mY11Ph9KT0aJ1dz8LnsG5w_17_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_zVF-Tz-k2UGegsQQP7MK7Q_17_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_8tofxM5fvEqZv9P8uca37g_17_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="2"
      id="Tc_jND37E3PUEKFmORDc4MRcQ_18_3"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="2"
      id="Tc_B1aLYjE6oU6nTUJ48alIzw_18_6"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Tc_SVVlstFZnk2Nc2R75W3ubw_18_9"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-1.94</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="2"
      id="Tc_autMS-LEuU2B-4M7srR38g_18_12"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-1.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="0"
      id="Tc_X7lx4W_tbkivnSisVjb3IA_19_3"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47987184</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="0"
      id="Tc_57OgTEwEtk-CWZDwfdLNZg_19_6"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">37386881</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="0"
      id="Tc_vSIGRKSlqUW7R1FZRtGTJw_19_9"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">45705782</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="0"
      id="Tc_-wyfAM4LoEqbW14oS1LAew_19_12"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">32647524</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_pwB5nhjT90a41KgiRP1-Qg_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc__lCNrGUNdUCPqBfJbSflzw_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_NoV67kZEKUWUOrQYcH-dcg_4_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_RL89nlvEBEyipS7UTH1l4Q_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_m-BwgUEYxEac0agWrMDB9Q_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-140000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_d7cAuBoTBUSR4gWEc0Udow_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">129000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_w-bYJLWqZE2CXcsPwNpBng_6_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-207000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_NH2OmmhgKECdPT7HEoaLzg_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">143000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_Sgw5fdtMFkqYBdjd1EUk_g_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_ywPkWeZ300-ssO3NGx88Lg_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_ouoFY9Irb0qeu4o18VfGcg_7_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_s_dhVWZjd0-ndsy6SJz9gw_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_k0tvlkdIUE2UmWUeXeB1UQ_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33949000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_eOPNr5tYRkiDMmxSmFBC8w_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7643000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_GW_Ne8kq8kua4TGPffnQzw_8_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88876000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_pyu9fDV3R0e4QsiZD4nEWg_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47131000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jxODNBy8nUGGb5t1661FYg"
      decimals="INF"
      id="Tc_lYs4JvpVZkWveY3bKpkcPA_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47525560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Cofzvfw-4UGemNVWygkS8g"
      decimals="-3"
      id="Tc_8UQB76iYxU-crzfzT6EwCQ_6_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">696157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dmfd75drp0Sl92sRinfLjg"
      decimals="-3"
      id="Tc_YIRTor-m8Ee86kZFLG8xCQ_6_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_o9SfVFUv-UWAdi0N3P_IpQ"
      decimals="-3"
      id="Tc_A--bMrZuO02YsvSwzzPkmA_6_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-338651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_hze2TlFsxEWN43owngJkXQ"
      decimals="-3"
      id="Tc_hRS_QjgmEUacJWT8GTuG4Q_6_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">357447000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg"
      decimals="-3"
      id="Tc_M2krQ_WjQkiNrLewQwJ06w_7_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_x803EC56uU-Onfn95lJr5A_7_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8X-9N-uxzEWLV5_AkyjFPg"
      decimals="INF"
      id="Tc_teUwdMyXyU-8tT82bIqG7w_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">146094</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg"
      decimals="-3"
      id="Tc_9RjF8wH6kES0uEoCfc7RpQ_8_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1381000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_ph3viNlDzE6H1SwZPF65YQ_8_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1381000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wjHP37sgIUuBrpu6lGIQNg"
      decimals="-3"
      id="Tc_9jyOKDei-UOLQf61NSDV6Q_9_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_0gXvrgmZrEiYRQP9y1n2cA_9_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k2WesrzFCUWJheqmlJkQMA"
      decimals="-3"
      id="Tc_cFc8mEtBKUqx1_crlUJbyw_10_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-145000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_h1rQdHBnF0CPfmWAY-iK0g_10_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-145000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I6LDpOFLME2hRdBnUQSKZQ"
      decimals="-3"
      id="Tc_xbJJ3JcT5kWUY8bF-2BndQ_11_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_ShgOTFjDrk6G2h3kd-AyxA_11_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA"
      decimals="INF"
      id="Tc_nJWFytjhqk-6jDmpJH89xA_12_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47671654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw"
      decimals="-3"
      id="Tc_vx8zqhba0kSzEeLGrhw-iQ_12_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">702319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw"
      decimals="-3"
      id="Tc_GqRu2g0eMU61hvw1Th5Jhw_12_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w"
      decimals="-3"
      id="Tc_LUwide3JiUGcHhf7bE7dLQ_12_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-372455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_XCw4_Nh-sUqi1I-Gi7qosA_12_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">329660000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VRhvgs9oa0mTUaqYjRO3ng"
      decimals="INF"
      id="Tc_TQvbE7et90OHz-hgm2NkpQ_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">36802139</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qLCgYz5FGUGJWujpfLA26w"
      decimals="-3"
      id="Tc_Zchm2ifmrEaOkA4HqMui1A_6_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">424855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EyCHRvQf9UG7GDeEg-B-bw"
      decimals="-3"
      id="Tc_45rg6CzG2U2wG2al3m9_yA_6_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_15NQ36sPLUyBE0gs8_H_zg"
      decimals="-3"
      id="Tc_mQuUPz9SukmE01c2P8KQVQ_6_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-257162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_NpkY5Or850q-_7gddnu5kg"
      decimals="-3"
      id="Tc_2AYTgAKcY0GMDG8CwSfdhQ_6_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">167485000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA"
      decimals="-3"
      id="Tc_91K_2ELtnEOtwaUZo3KVeg_7_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_wcSVooANzEqR-RKPFm-cpA_7_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ScZrHzQctkadsqBzu4TDGg"
      decimals="INF"
      id="Tc_n0y6P9hAVE61QZv93tlx1A_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">333047</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_UN3M56DNcEqfJFsFQtlo7Q"
      decimals="-3"
      id="Tc_IMg9BpNyo02Lqgf03vxbNg_8_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6368000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_34DT_TXcJ0G9oeklOaHaWQ"
      decimals="-3"
      id="Tc_ftggLD1VdUqKqYxV_-MDQw_8_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6368000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VAo-gksv90emgd8j5zQ9WA"
      decimals="INF"
      id="Tc_TPfDnE8W6E6_dGlYK2zvrQ_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">179687</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA"
      decimals="-3"
      id="Tc_ZGPlhxXHFkSSSX9bQqnwuA_9_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1495000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_EnSYfV_OP0yMiriXObhUXw_9_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1495000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uesTY59Gj0GQFlbzL0N5AA"
      decimals="-3"
      id="Tc_P1_G7xgadki7WeEfJ0JuwA_10_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1888000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_IoV75eM1XkK2rdAFxMs8ZQ_10_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1888000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ESv4u0HBt0CnfQx4AKYNAg"
      decimals="-3"
      id="Tc_rSRNYnQZwEqCL0QksgvEXg_11_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_E6alF6NfU0WZOWYt8Aaftg_11_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_D-unIeqFvkKbPDLT1e3qMA"
      decimals="-3"
      id="Tc_M0aNzuw26kyjnYUDe_HuWA_12_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_PfXl0rrwG06GyaqbGyRIOw_12_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg"
      decimals="INF"
      id="Tc_k1hvRxrVskGOQj7Q6RSOsQ_13_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">37314873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA"
      decimals="-3"
      id="Tc_8zX-Qwkf3EWpe4qY-ZjSZw_13_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">434603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A"
      decimals="-3"
      id="Tc_XMwRDBRu8Ei39Lw9JBpIBg_13_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg"
      decimals="-3"
      id="Tc_uEv_1AwrqE6tpR5p3n3M0A_13_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-264925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_vzZ7qPCULEu6Au43DY3jtg_13_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">169590000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew"
      decimals="INF"
      id="Tc_JpojdPPBcEKVKqdHAkFqVw_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">43745465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A4ngj4JfEEud5h_rZa61rg"
      decimals="-3"
      id="Tc_NL9ti-eLV0GdyMncvs9rvg_6_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">563389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wDJZBP8oWkmr1-cnJEWO_w"
      decimals="-3"
      id="Tc_uwep9awLqUKgovLQwfvm0Q_6_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iXBhd1us706tUU2Z6TGdoQ"
      decimals="-3"
      id="Tc_AnGE8YQwVkShayT4EEWE0A_6_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-283811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_-rXRAda1b0qfiCXWBS54yw_6_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">279606000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw"
      decimals="INF"
      id="Tc_Ce49V8LrpUKA30rspUIk8w_7_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">3503311</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA"
      decimals="-3"
      id="Tc_Ut0HLu1GOE2N7v4nWFE4dQ_7_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">123804000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_GOf54niwbEqRkApkaEKvOQ_7_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">123804000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw"
      decimals="INF"
      id="Tc_Vi3q53g7JEK7-k__ioZ8OQ_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">429938</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA"
      decimals="-3"
      id="Tc_UJr9WlJ4LUWlpNgJDPeAWg_8_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3944000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_ZO04PjJ0wUCtOnQbgPfycA_8_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3944000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QflbceNp8kqHObc92fbwnw"
      decimals="INF"
      id="Tc_SUJzi8Dr10-7rEQqTG2pKQ_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">-7060</ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares>
    <ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA"
      decimals="-3"
      id="Tc_u8polFbSXku1Est06zoWQA_9_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">189000</ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits>
    <ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_4xtAMszJ10aFdWcaPB2R3Q_9_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">189000</ptgx:SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7URUJWkNpUeNxkhfaOB1yA"
      decimals="-3"
      id="Tc_ZByrsBpQP0WBNJFBXjKHuQ_10_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_UrV-A9OoHUmD9JNLjFsnvA_10_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-pvHJ7QJ90yW1k3Cfl4qtA"
      decimals="-3"
      id="Tc_KWxPFD8slEyQFCNiAbNTFg_11_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_SbNoyJfdVUGugf8hTy_0Mw_11_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T6A4i7LXhkGkWOztGamCHA"
      decimals="-3"
      id="Tc_1oeAZB-URkOMdM0P48dOKw_12_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_ZMwdHRIxGE-tDtR_F_KyLA_12_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MQAGuH6TF0-YDdIEreiSGA"
      decimals="INF"
      id="Tc_8cmpS1AZF0Si9dL0vWa6NQ_13_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47671654</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fDiwP1ksEE2PN9UYYG_JBw"
      decimals="-3"
      id="Tc_0sLiuoTESkOnwgM5TQnmIA_13_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">702319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_urf5BhflZk-ram-4RXJyYw"
      decimals="-3"
      id="Tc_d7STEdoTIEyhcltpv3IG0g_13_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_36us4P-1R0yx6Oi4xnM3-w"
      decimals="-3"
      id="Tc_BSosxA54OUiwFSKJFnGCrg_13_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-372455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_kk9LWOUG20-AeHdnsB8FLQ_13_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">329660000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EnjUd2zZYk6vz2-cHlqtXg"
      decimals="INF"
      id="Tc_ff79DFH5hES6ae0_KVl1Fg_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">27217649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ShsA1tWpGUmhQJqfvR21Pg"
      decimals="-3"
      id="Tc_OBqGqprkGUu250Wt8RBYbA_6_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">297846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pjYolJb8NUSZoqWWvsTjEg"
      decimals="-3"
      id="Tc_KzX4RV0T10KlLyaeV88rtg_6_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6k8OGpvpa0CnTaIinonZ3g"
      decimals="-3"
      id="Tc_pRfCZ1L0DEqK_GKt-oVhyw_6_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-217661000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ"
      decimals="-3"
      id="Tc_ZBf-i5XHGkG7DkHdMsxy8A_6_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">79964000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA"
      decimals="INF"
      id="Tc_gnvpeX4krkinNj_Wu2dYZg_7_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog"
      decimals="-3"
      id="Tc_wqbf_psxD0yk5n_MrH7ZKw_7_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">105328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_d89gJv5sV0GRMxUDV3R8QQ_7_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">105328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_07-nJWm-n0OlxE7BAmCSvQ"
      decimals="INF"
      id="Tc_d7SsSk6RakCDyLHYC79gXw_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1565840</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_eu303YctzUm4oyVCdG6opQ"
      decimals="-3"
      id="Tc_fXML86g8e0uG2XyjIl19lA_8_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">23011000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_ffkr2mgme0Kc83elbZL7aQ"
      decimals="-3"
      id="Tc_JscEZ-CfYEmizMfM2iEVAQ_8_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">23011000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_POK-3JBndEGoxbMIyhfvGA"
      decimals="INF"
      id="Tc_3uqao9Gh5k-1nYPI6Z3qzQ_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">481384</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog"
      decimals="-3"
      id="Tc_2PzhyjQ24kiGHt5y03KtNQ_9_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2486000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_1TmSrkQY-E-sBmwJCbGiyg_9_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2486000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T4y2eNau7kaDp_B2GhiHog"
      decimals="-3"
      id="Tc_zxBODRL-IkWqTUgXVhJS0A_10_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5932000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_COn8ApiYUU-e69lCFrE0lA_10_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5932000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_picUoPu6YU6hAp4STfCryA"
      decimals="-3"
      id="Tc_Jepq_osRMEOUm6GJ1m7_pQ_11_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">133000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_xPZJWjtE-E6UbGFJ8K9vVQ_11_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">133000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vnFLoq50b0y_n6K8gPk8yA"
      decimals="-3"
      id="Tc_DSDFxp0Q4k6AGQwn9Fqo1Q_12_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_6b5s73e7aU-lcwexL2w_Zg_12_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Z0z4pEu0B0yDzgHmOFDFzg"
      decimals="INF"
      id="Tc_o6u_W_PMkUKyXjCNdur-3w_13_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">37314873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bCGcToGx30iKNPEC7YcbWA"
      decimals="-3"
      id="Tc_LsUIxTLRQUSNqg4ttrB56A_13_8"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">434603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Qg1TtYj7GE6TnjtYKRrf5A"
      decimals="-3"
      id="Tc_Ljv3iBLB50qnZn5DJH_zMg_13_11"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAVj9liXdUeU3Jm5-ZRAPg"
      decimals="-3"
      id="Tc_8KKmFDE9vkGfEWCazGl11Q_13_14"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-264925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_2dY-SRCZyEm1HBK1U0olzw_13_17"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">169590000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_M_CsAYooq0WBjQVACV_pVQ_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_B7OkbC-hyk-1oRZsBuP5gA_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_IuZhMflpC0Spa4zPcJDLHQ_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11371000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_s3mYNa180k-A1kMHuRSzhw_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5932000</us-gaap:ShareBasedCompensation>
    <ptgx:OperatingLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_XDUcHxVfJ0avpEF8SpYeWg_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1378000</ptgx:OperatingLeaseRightOfUseAssetAmortization>
    <ptgx:OperatingLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_MxF0P45jp0qPWPKq7mvzDA_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1331000</ptgx:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_o88B4u40UEGcF8dg6YGvWg_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">578000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_q1JsYzW2hk6tDXKLUurCdg_9_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">601000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_h57uriS8RUq9nhpTCdkjLg_10_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-1321000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_vOZqyZEDeEybS_CiCaJ5dg_10_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">155000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_bIUoPTM_FEaRIKXwtzxXTQ_11_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-585000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_VWQldjsE_kyDTAQiO8KghQ_12_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">22000</ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_ZuS7qp0vrUWD6jaRrJ8szg_13_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1404000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_DoCRj5GOC0i7FCgKLPlyuw_15_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">854000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_UuVsE1FptE61nh_lJh_-1Q_15_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">517000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_Whi7tEq-60ynpwYnn5IxUg_16_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">212000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_b3-gQ5pK-0q8nOL0CI--0Q_16_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-3966000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_oL9U57BbM0Oq2FvZhEr-tA_17_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2632000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_kG1RSvqCyEq8ZY8TGf52nA_17_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1566000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_A072urdPCkitmYn47Tl_tA_18_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-2285000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_GeMkHZrX6EGmGCayZFbz2w_18_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">32000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_xT1BPXdeekWTdhc8O9_-5Q_19_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-1611000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_7ozcJUysJk6A2sskqGXG8g_19_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">815000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_O0OKEFFNE0uZTl0-outqQA_20_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">14393000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_ezgr6zgIg0C3gpr-yjmyrg_20_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3130000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_qhDDWPu7KEOHn2RVCNv70A_21_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-12236000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_2DjXk-V6eEiA9Q_OF8hFDQ_21_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-20653000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_L9Mo84oygEG2MSd4hrAxKA_22_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1493000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_xqT_WSbdvUeZRS6nL7jXrw_22_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1450000</us-gaap:OperatingLeasePayments>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_SiZM2zvClkKiXwu9crsQMQ_23_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">170000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_tjM8jZHqHk61_c7oAfHiUQ_24_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-80926000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc__FLSCiE_bke3BLKWWFJdkA_24_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-53617000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_rpEuCbrjKUONoQaYxqPurg_26_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">255902000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_oFZQF9jdZUKPlt-R5WCalQ_26_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">147600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_a_T54AUgqU6jesdu7DTHtg_27_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">213080000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_BfS1vTYRI0a5hDfhf-z3Nw_27_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">131383000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_ar-f8iNWiU2iB8hREIVD4Q_28_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">905000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_4OIfLiqx-0GCRa2CUbvbtQ_28_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">346000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_RTWO22ChWUO5EfzmsIYl_A_29_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-43727000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_ee2r16slWE6699MoD-W4vg_29_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-16563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_FmbCFjR71EiWNIgASNX_zA_31_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">123995000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_rkSbpl9NsEC64qN7JsD6zw_31_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">105478000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_Ku0vogj5_0mcBOrcMZRlZA_32_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3944000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_r8HGcXLclEOaVE7r4wDB8w_32_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2486000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_4_ke0WxkHUO4ytO5WHtO9g_33_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">189000</ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_kSmyLHeyAkC4R2D5Xwe6Rg_34_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">23219000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_tZdwQDbtsU60yjI6lYcNdg_35_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">14000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_JJbOnIcO_kKh43dTnrBnjA_36_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10524000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_EJU8HMJGF0e5Jy0_6EeBRg_37_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">127750000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_XFE1mkcQ8EOrHlPfuOnVkA_37_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120645000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_N370q8sFDUKHB2HnYm1U8Q_38_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-148000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_LXROJqlEXkSADV-Y4T7rzQ_38_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">154000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_10nbfLIvNE6X4_9Q2NvB8A_39_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_QR4CyHD7p0SIQ8Ywg2Gm-A_39_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">50619000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_OC62nECye0SBBYefXBnauw_40_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">117818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_Hh4zG___w0WtfVlLqNXYhQ"
      decimals="-3"
      id="Tc_ykTHWEOrXEmYtTETaJHieg_40_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">33466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_pEQ-xNGK6ki6UAyyyb_1dQ_41_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120767000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_PEycGniOqEeL50-h7lRhFQ_41_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">84085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_DtOFqRINUkiMK9uNQtRPcw_43_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">24000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_DiQDT3UWA0az39cPxnbJAg_43_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_lvaVnROBNEGcQD3RONq0EA"
      decimals="-3"
      id="Tc_9AYEXrWbeEq1lLZf60susw_44_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">191000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MZM0ma8qsUmURiga3ySKXA"
      decimals="-3"
      id="Tc_IOAfLq5nbkGMltJFRCpjxg_44_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_HREnfaqhhk6qERJYnhneIg"
      decimals="-3"
      id="Tc_21ua8SU2gEuo0QhlhuFsUg_45_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">125000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_K7Od3CM6-kOKjqWB7rXSfA"
      decimals="-3"
      id="Tc_SJSVFXIoOUuHgS8M1VkKNQ_46_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">191000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_mjNjDSCfZ0OjAafvNYLJ9g"
      decimals="-3"
      id="Tc_0zENxB4j8Eap9iArfGUupQ_47_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">17000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_FrKCjKV9mESwkuNnEunxYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;Note&#160;1.&lt;/b&gt;&lt;/span&gt;Organization and Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Protagonist Therapeutics,&#160;Inc. (the &#x201c;Company&#x201d;) is headquartered in Newark, California. The Company &lt;span style="background-color:#ffffff;"&gt;is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform. &lt;/span&gt;Protagonist Pty Limited (&#x201c;Protagonist Australia&#x201d;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. The Company manages its operations as a &lt;span style="-sec-ix-hidden:Hidden_u4SjkEALd06OJORFVCaVuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;single&lt;/span&gt;&lt;/span&gt; operating segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2021, the Company had cash, cash equivalents and marketable securities of $352.5 million. The Company has incurred net losses from operations since inception and has an accumulated deficit of $372.5 million as of September&#160;30,&#160;2021. The Company&#x2019;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#x2019;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under license and collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Risks and Uncertainties &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks and uncertainties as a result of the&#160;ongoing COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities remains uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#x2019;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#x2019;s clinical trial sites are located; the development and spread of COVID-19 variants, the timing, extent, effectiveness and durability of COVID-19 vaccine programs or other treatments; and new or continuing travel and other restrictions and public health measures,&#160;such as social distancing, business closures or disruptions. Accordingly, the extent and severity of the impact on the Company's existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company's future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these condensed consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company's future financial condition, liquidity or results of operations remains uncertain.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Narr_A4KfBT-PvE6hcE1privaXg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">352500000</ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Narr_TFp1JJlLlkCTLgjRaP_Lig"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-372500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_cXlgIFK6yk-WdQwGV39GaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;Note&#160;2. &lt;/b&gt;&lt;/span&gt;Summary of Significant Accounting Policies &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) and applicable rules&#160;and regulations of the SEC regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the condensed consolidated balance sheet as of&#160;December 31, 2020&#160;has been derived from the Company&#x2019;s audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair presentation of the Company&#x2019;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2021&#160;are not necessarily indicative of the results to be expected for the&#160;year ending&#160;December 31, 2021&#160;or for any other interim period or for any other future&#160;year. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the&#160;year ended&#160;December&#160;31, 2020&#160;included in the Company&#x2019;s Annual Report on Form&#160;10-K, filed with the SEC on March&#160;10, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#x2019;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held by two financial institutions &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;that management believes are of high credit quality. Such financial instruments regularly exceed federally insured limits. The primary focus of the Company&#x2019;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#x2019;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#x2019;s investment policy. The Company&#x2019;s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash balances held as security in connection with a letter of credit related to the Company&#x2019;s facility lease entered into in March&#160;2017. The letter of credit balance decreased from $0.5 million at December 31, 2020 to $0.2 million at September 30, 2021 pursuant to the terms of the Company&#x2019;s May 2017 facility lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash as Reported in Condensed Consolidated Statements of Cash Flows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,542&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash reported on condensed consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three&#160;months but no longer than 365&#160;days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive gain or loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, and that expectation is consistent with the Company&#x2019;s historical experience. Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;financing component&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the condensed consolidated balance sheets and within research and development expense in the condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number of locations of sites activated may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. federal income tax credit on qualifying clinical study expenditures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Tax Incentive&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#x201c;ATO&#x201d;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available.&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company granted performance share units (&#x201c;PSUs&#x201d;) to certain executives of the Company. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing price of the Company&#x2019;s common stock on the grant date. The Company recognizes compensation expense over the vesting periods of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the Company&#x2019;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260,&lt;i style="font-style:italic;"&gt; Earnings Per Share&lt;/i&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible, and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholder&#x2019;s Equity for additional information regarding the Exchange Warrants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, &lt;/i&gt;which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company adopted this guidance effective January 1, 2021 and there was no impact on its condensed consolidated financial statements and disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments&#160;- Credit Losses (Topic 326)&lt;/i&gt;, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#x2019;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its condensed consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_fmRiHL3PyEW9Y4DcaC4Drw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) and applicable rules&#160;and regulations of the SEC regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the condensed consolidated balance sheet as of&#160;December 31, 2020&#160;has been derived from the Company&#x2019;s audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair presentation of the Company&#x2019;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2021&#160;are not necessarily indicative of the results to be expected for the&#160;year ending&#160;December 31, 2021&#160;or for any other interim period or for any other future&#160;year. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the&#160;year ended&#160;December&#160;31, 2020&#160;included in the Company&#x2019;s Annual Report on Form&#160;10-K, filed with the SEC on March&#160;10, 2021.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_gXWe2bF7rk2k4J-Im37qBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_ejlO4bavsEiQ4zpFFwewyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#x2019;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_o7oq46GWxkS4nmDiDVFqBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held by two financial institutions &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;that management believes are of high credit quality. Such financial instruments regularly exceed federally insured limits. The primary focus of the Company&#x2019;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#x2019;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#x2019;s investment policy. The Company&#x2019;s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <ptgx:CashNumberOfFinancialInstitutions
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Narr_WVz0xNt2X0mjIkK10xGQOA"
      unitRef="Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA">2</ptgx:CashNumberOfFinancialInstitutions>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_NCjBZ4-IzUy67mkRgnkaCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_u0Cl5k74aESbgVGabcNSTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash balances held as security in connection with a letter of credit related to the Company&#x2019;s facility lease entered into in March&#160;2017. The letter of credit balance decreased from $0.5 million at December 31, 2020 to $0.2 million at September 30, 2021 pursuant to the terms of the Company&#x2019;s May 2017 facility lease. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_9rUNAqUsGU-Kz_BLZ_8PsQ"
      decimals="-5"
      id="Narr_gfpFsaJ33EaLN3EsEa1V0Q"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2021_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_ZNKaf1RmykO0-f7B2C1WOQ"
      decimals="-5"
      id="Narr_myyjsA30jU2v-2hpNmQRRg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_20eRDPXjpUur3tCW8MjALQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash as Reported in Condensed Consolidated Statements of Cash Flows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,542&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash reported on condensed consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_vVkI8FbNTEiSzzGOtVI9Cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,542&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash reported on condensed consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_f_fgHk_BaEusybSEryd_Ng_3_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120542000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_gDdfmaIzY0KxznxJVdJUJQ_3_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">83625000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_KwGD88gqBUylTpyWHiLHGQ_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_6mHl8IW9VkKQffMIVOJnlg_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">225000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc_IaFr67ZprU-Aym5G3zuDGw_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_6PhkmQCx-EKcBfFx2u9kOQ_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">120767000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A"
      decimals="-3"
      id="Tc__SuzZlWTe0qp5mZVjnuylA_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">84085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_-8TU5KQl30WaOmiU86FvLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three&#160;months but no longer than 365&#160;days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive gain or loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_LM--ATrW0E2cHQ69vNPqaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, and that expectation is consistent with the Company&#x2019;s historical experience. Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;financing component&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;. &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ptgx:ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Narr_YdsewHt_jU25FqPFsSYpPQ"
      unitRef="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg">1</ptgx:ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice>
    <us-gaap:RevenuePracticalExpedientFinancingComponent
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_cTFywX8oEUSAe5TFh72i-w">true</us-gaap:RevenuePracticalExpedientFinancingComponent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_Hq4gh3AB0kOMN7rt6Bln9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the condensed consolidated balance sheets and within research and development expense in the condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number of locations of sites activated may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. federal income tax credit on qualifying clinical study expenditures.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="0"
      id="Narr_NAcZj3J5GUepTD3MdVehgg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">25</ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit>
    <ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_M9jaB3H0j0KosDfzsECjsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development Tax Incentive&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#x201c;ATO&#x201d;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available.&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;&lt;/p&gt;</ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock>
    <ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_RUQmYM3F3ku4NzFw_8JxVA"
      decimals="-5"
      id="Narr_-jNxEr__6UWKzwxEiKHIZA"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">20000000.0</ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_qGLOtMd9uEuA1-xDUmxb6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company granted performance share units (&#x201c;PSUs&#x201d;) to certain executives of the Company. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing price of the Company&#x2019;s common stock on the grant date. The Company recognizes compensation expense over the vesting periods of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_U2HSJ8pYWkC0EhasQrk47w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the Company&#x2019;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260,&lt;i style="font-style:italic;"&gt; Earnings Per Share&lt;/i&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible, and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholder&#x2019;s Equity for additional information regarding the Exchange Warrants. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_gQ1GL-B0FkuOHb_ky3SLew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, &lt;/i&gt;which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company adopted this guidance effective January 1, 2021 and there was no impact on its condensed consolidated financial statements and disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments&#160;- Credit Losses (Topic 326)&lt;/i&gt;, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#x2019;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its condensed consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg"
      id="Tb_RlpdSpR8TUWltelwVMnn6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Note&#160;3. License and Collaboration Agreement&lt;/b&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Agreement Terms&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 27, 2021, the Company entered into an amended and restated License and Collaboration Agreement (&#x201c;Restated Agreement&#x201d;) with Janssen Biotech, Inc., a Pennsylvania corporation (&#x201c;Janssen&#x201d;). The Restated Agreement amends and restates the License and Collaboration Agreement, dated May 26, 2017, by and between the Company and Janssen (as amended by the First Amendment thereto, effective May 7, 2019, the &#x201c;Original Agreement&#x201d;). Janssen is a related party to the Company as Johnson &amp;amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp;amp; Johnson. The Original Agreement became effective on July 13, 2017. Upon the effectiveness of the Original Agreement, the Company received a non-refundable, upfront cash payment of $50.0 million from Janssen. Upon the effectiveness of the First Amendment, the Company received a $25.0 million payment from Janssen in 2019. The Company also received a $5.0 million payment triggered by the successful nomination of a second-generation oral Interleukin (&#x201c;IL&#x201d;)-23 receptor antagonist development compound (&#x201c;second-generation compounds&#x201d;) during the first quarter of 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Restated Agreement relates to the development, manufacture and commercialization of oral IL-23 receptor antagonist drug candidates. The candidates currently in development as of the balance sheet date pursuant to the Restated Agreement include PTG-200, PN-232 and PN-235. PTG-200 is an oral IL-23 receptor antagonist in that was in Phase 2a development for the treatment of Crohn&#x2019;s disease (&#x201c;CD&#x201d;). PN-232 and PN-235 are second-generation products currently in Phase 1 studies. Janssen is primarily responsible for the conduct of the PTG-200 Phase 2a trial and the Company is primarily responsible for the conduct of the PN-232 and PN-235 Phase 1 studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Restated Agreement, the parties have:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;amended development milestones to reflect Janssen&#x2019;s expected development of collaboration compounds for multiple indications in the IL-23 pathway;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;limited the Company&#x2019;s further development and related expense obligations under the Restated Agreement to the PTG-200 Phase 2a study, and the ongoing Phase 1 studies in PN-232 and PN-235; Janssen is responsible for all other future development and related expenses under the Restated Agreement; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;concluded the parties&#x2019; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;two-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; research collaboration, while enabling Janssen to continue conducting additional research through July 2024 on compounds developed pursuant to the Original Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Restated Agreement enables Janssen to develop collaboration compounds for multiple indications. Under the Restated Agreement, Janssen is required to use commercially reasonable efforts to develop at least one collaboration compound for at least two indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s development cost obligations in the Original Agreement for the period following the effective date of the Original Agreement were as follows: (a) up to $20.0 million of costs related to up to three Phase 1 studies of second-generation compounds; (b) up to $20.0 million of costs related to Phase 2a and 2b costs for PTG-200 (i.e., 20% of the first $100.0 million in costs); (c) up to $25.0 million in costs related to up to two Phase 2 studies evaluating second-generation compounds. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s continuing development expense obligations under the Restated Agreement are as follows: (a) the Company will continue to fund 20% of the costs related to the Phase 2a study evaluating PTG-200 for the treatment of CD (subject to a $20.0 million cap); (b) the Company is responsible for 50% of agreed-upon costs related to the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ongoing Phase 1 study evaluating PN-235 incurred through January 4, 2021; (c) the Company is responsible for 100% of agreed-upon costs related to the ongoing Phase 1 study evaluating PN-232. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of the Company&#x2019;s previous development expense obligations under the Original Agreement have been limited or eliminated as follows: (a) the Company&#x2019;s previous $25.0 million obligation for 20% of costs related to Phase 2 studies for second-generation products has been eliminated; (b) the Company&#x2019;s previous $5.0 million obligation for 50% of the costs of a potential third Phase 1 study evaluating a second-generation compound has been eliminated; and (c) the Company has no obligation to fund any portion of any Phase 2b or other study evaluating PTG-200 beyond the Phase 2a study in CD. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;One milestone for second-generation Phase 2 development was reduced from $50.0 million to $25.0 million in the Restated Agreement; otherwise, t&lt;span style="white-space:pre-wrap;"&gt;he various milestone payment amounts in the Restated Agreement remain substantially the same as in the Original Agreement. To reflect parallel development of multiple indications in the IL-23 pathway, milestone payments under the Restated Agreement generally now correspond to the achievement of specified milestones in: (a) any initial indication (rather than CD, as in the Original Agreement); (b) any second indication (rather than ulcerative colitis (&#x201c;UC&#x201d;), as in the Original Agreement); and (c) any third indication. With respect to second-generation compounds, milestone payments for second and third indications may be triggered by any second-generation compound (i.e., not necessarily the second-generation compound that triggered the initial payment for any indication, or the payment for a second indication).  In addition, the opt-in payments contemplated by the Original Agreement related to the scope of Janssen&#x2019;s license rights have been converted into development milestones in the Restated Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upcoming potential development milestones for second-generation compounds include: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$7.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for completion of the first Phase 1 clinical trial of a second-generation compound; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication (i.e., an indication different than the indication which triggered the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million milestone described above); &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$50.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$15.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for a second indication; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:56.25pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$115.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; million for a Phase 3 clinical trial for a second-generation compound for any indication meeting its primary clinical endpoint.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Development milestones for PTG-200 were unchanged under the Restated Amendment, except that milestone achievement is generally no longer indication-specific. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Restated Agreement, the Company remains eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to ten percent. The sales milestone payments in the Original Agreement also remain the same in the Restated Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to both the Original and Restated Agreements, payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Janssen retains exclusive, worldwide rights to develop and commercialize IL-23 receptor antagonist compounds derived from the research collaboration conducted under the Original Agreement, or Janssen&#x2019;s further research under the Restated Agreement. Any further research and development will be conducted by Janssen. The Company will have the right to co-detail (for CD and UC indications) up to two of the IL-23 receptor antagonist compounds under the collaboration in the U.S. market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Restated Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Restated Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Restated Agreement contains a single performance obligation for the development license; Phase 1 development services for PTG-200, PN-232 and PN-235; the Company&#x2019;s services associated with Phase 2a development for PTG-200 in CD; the initial year of second-generation compound research services; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200 through Phase 2a and PN-232 and PN-235 through Phase 1. Under the Restated Agreement, development services performed by the Company for PTG-200 beyond Phase 2a and PN-232 and PN-235 beyond Phase 1 are no longer required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the license was not distinct from the revised development services within the context of the agreement because the revised development services did not change the utility of the intellectual property. The Company also concluded that the remaining development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the Restated Agreement of the development license and PTG-200, PN-232 and PN-235 services, including compound supply and other services. Therefore, the Restated Agreement is treated as if it were part of the Original Agreement. The Restated Agreement will be accounted for as if it were a modification of services under the Original Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the Restated Agreement, the Company calculated the adjusted cumulative revenue under the Restated Agreement with primary updates to the transaction price, including the release of and update of prior constraints and fewer remaining services to be provided, resulting in a cumulative adjustment that increased revenue by $8.0 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the duration of the Restated Agreement began on the Original Agreement effective date of July 13, 2017 and ends upon the later of the end of Phase 2a for PTG-200 in CD or the completion of a Phase 1 clinical trial for either PN-232 or PN-235.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the effective date of the Restated Agreement consists of future milestone payments and cost sharing payments for agreed upon services offset by development costs reimbursable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract are included in the transaction price at the Company&#x2019;s share of the estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen related to agreed-upon services for activities that Janssen performs within the duration of the contract are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The transaction price of the initial performance obligation under the Restated Agreement was $105.7 million as of September 30, 2021, an increase of $9.9 million from the transaction price of $95.8 million as of June 30, 2021, under the Original Agreement. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. The transaction price as of September 30, 2021 includes the $80.0 million of nonrefundable payments received to date, $17.9 million of reimbursement from Janssen for services performed for IL-23 receptor antagonist compound research costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;completion of the clinical data collection for Phase 1 activities for PN-235 and $8.4 million of development cost reimbursement receivable from Janssen, partially offset by $8.1 million of net cost reimbursement due to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of September 30, 2021 is not probable. The Company concluded that the variable consideration constraint is appropriately reflected in the estimated transaction price as of September 30, 2021. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation, revenue is recognized as these services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input methods of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $8.0 million, and also recorded $2.3 million of license and collaboration revenue following the contract modification for the Restated Agreement. For the three months ended September 30, 2020, the Company recognized license and collaboration revenue of $12.6 million. In addition, the Company recorded zero and $0.5 million in revenue for the three months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the nine months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $8.0 million, and also recorded $9.9 million of license and collaboration revenue following the contract modification for the Restated Agreement. For the nine months ended September 30, 2020, the Company recognized license and collaboration revenue of $22.0 million. In addition, the Company recorded $0.8 million and $1.0 million in revenue for the nine months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following tables present changes in the Company&#x2019;s contract assets and liabilities during the periods presented (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,732&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,520)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,477&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,951)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,396)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,284&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,114&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,299)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three and nine months ended September 30, 2021, the Company recognized revenue of $0.2 million and $1.7 million, respectively, from amounts included in the deferred revenue contract liability balance at the beginning of each period. During the three and nine months ended September 30, 2020, the Company recognized revenue of $8.5 million and $11.8 million, respectively, for each period from amounts included in the deferred revenue contract liability balance at the beginning of each period. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ptgx:CollaborativeAgreementUpfrontPayment
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_s96udydX3kChOKXdoymkjg"
      decimals="-5"
      id="Narr__o2j4-DZG0O_nGHjeLywVg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">50000000.0</ptgx:CollaborativeAgreementUpfrontPayment>
    <ptgx:CollaborativeArrangementEligibleAmountReceived
      contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_rRvBtxUPXUy-HfoqhGT3wg"
      decimals="-5"
      id="Narr_1YHyQcBi_EuJwuvp4WnLSA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:CollaborativeArrangementEligibleAmountReceived>
    <ptgx:CollaborativeArrangementEligibleAmountReceived
      contextRef="As_Of_3_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_eY73vDQa7U23JqhEa2BFLA"
      decimals="-5"
      id="Narr_GrK73bypKES6U6ezbM1I1w"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5000000.0</ptgx:CollaborativeArrangementEligibleAmountReceived>
    <ptgx:DurationOfResearchCollaborationAgreement
      contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_GjbbJITBaUG01OT1oWNJlw"
      id="Narr_2PJ0oInR1EaS51osyZHA7A">P2Y</ptgx:DurationOfResearchCollaborationAgreement>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_6kgROCjubEaK_kfQMy3jkg"
      decimals="-5"
      id="Narr_-LQKtp3V4EOPV5DcUX68QA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_EKO4dc3A9kW58GT-34PVkA"
      decimals="-5"
      id="Narr_i9RJ04OetkWLbiytoWpq1A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_xBi47oQ55EWzPVnVxo6vOg"
      decimals="2"
      id="Narr_an8aTN2eLEmh9V-URlfwdA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__XGvkKYt2kq50PQcaNBpsA"
      decimals="-5"
      id="Narr_MfD5FmLFN0aLrOqEvVvOgQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">100000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_sxi-lVVXP0eAqntyNRA1rg"
      decimals="-5"
      id="Narr_EJqVYKC29EerO7__8haK3A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_r2A-BxT7r0GiRUZodoE_Qg"
      decimals="2"
      id="Narr_6pHbbvdwTEOZ0ManXT25Bw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_e1g49FhL7kmfXyQdu4N9Bw"
      decimals="-5"
      id="Narr_bbSK_Nc8KkmzyKZBypBSmw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2aEvaluatingPtg200Member_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_vlCXpQQLhUe0YkX2S-ZJvg"
      decimals="2"
      id="Narr_5vLSmm2EfkuPdYZIiHFWIg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_ml2M2iwfc0KpJiIzGxvCug"
      decimals="2"
      id="Narr_qLcOMSVP0UavRERn93T9Gg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">1</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated>
    <ptgx:DevelopmentCostsEliminated
      contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_5LG8Bd8oPkGEzWl62U-nbw"
      decimals="-5"
      id="Narr_-0_eytr2uk-bNCz-l2rWkQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:DevelopmentCostsEliminated>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated
      contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_PIZR72h8sUiUXP2iC_lkKw"
      decimals="2"
      id="Narr_NtRgC3JKckO-WyYOW_8CxA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated>
    <ptgx:DevelopmentCostsEliminated
      contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_f6vGdpv7dkiDKg1sBRHOoA"
      decimals="-5"
      id="Narr_q9zfnIbREka4X20aKiP1qg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5000000.0</ptgx:DevelopmentCostsEliminated>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated
      contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_CXrEby6GiEaljTlG3GLsBA"
      decimals="2"
      id="Narr_TPSb87H2M0aZMUwSjoQ3sw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember_ebVRPtOngkuKafR-yF0DZg"
      decimals="-5"
      id="Narr_3tAscp4dp0yBtuH-mGqR_A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">50000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_T5go7T86jkGHW8Ogcd55BQ"
      decimals="-5"
      id="Narr_jMhtwWQ0oUu3M76w6-5siQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:UpcomingPotentialDevelopmentMilestonesPayment
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_zpwdW8FrMU2yPOUewuio1A"
      decimals="-5"
      id="Narr_OHN1IjEhskesBMCRjLXEnw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">7500000</ptgx:UpcomingPotentialDevelopmentMilestonesPayment>
    <ptgx:UpcomingPotentialDevelopmentMilestonesPayment
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_M8yFhIOS4UWfLn0-racdCw"
      decimals="-5"
      id="Narr_dSAm2-0j_0SrotguI-hNdQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:UpcomingPotentialDevelopmentMilestonesPayment>
    <ptgx:UpcomingPotentialDevelopmentMilestonesPayment
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseTwoClinicalTrialSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_k7-5iEviVkaUoyPynKb8ag"
      decimals="-5"
      id="Narr_gUeaTRUuw0OINytgVaROzQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000000.0</ptgx:UpcomingPotentialDevelopmentMilestonesPayment>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_HNZLcuNLlkC4l1XQ9mRg5Q"
      decimals="-5"
      id="Narr_ro_dzCZpoU6w_QHDUhV-2g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">25000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <ptgx:UpcomingPotentialDevelopmentMilestonesPayment
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_E3q_5X1xx0W9IH0IDoVYIA"
      decimals="-5"
      id="Narr_WDXxKezFLk-Gsrhb221aKA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">50000000.0</ptgx:UpcomingPotentialDevelopmentMilestonesPayment>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_5wmoKVR2DU2fW1JWG3YE4w"
      decimals="-5"
      id="Narr_1QgjIRnMMUGAZX4k2hC2Vg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">15000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_PhaseThreeClinicalTrialForAnyIndicationMember_DR8YsZ1k4EKWFSFZzgo99w"
      decimals="-5"
      id="Narr_76cYwbNhzkWi9H_hGfHrFg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">115000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:PercentagesRoyaltiesOnNetProductSales
      contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA"
      decimals="2"
      id="Narr_suNkRJTouUamJPvGD-iEhg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.10</ptgx:PercentagesRoyaltiesOnNetProductSales>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_7_27_2021_To_7_27_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember__XF8yUM9GEiWBv_kI8sAaA"
      decimals="-5"
      id="Narr_Vgq30GA-ukarshgbZ9MDfQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ"
      decimals="-5"
      id="Narr_H_G4HDOLo0qcDZdPrMyNAA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">105700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yFhWkhHuuEaQKk7rwr082w"
      decimals="-5"
      id="Narr_eN5lqHXgTEy4h4P1Z0y_iw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">9900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_OriginalAgreementMember__vWz_fmTEUCSA1s4LTbr_Q"
      decimals="-5"
      id="Narr_PyVwCiExo0eDfjRL17IZ9A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">95800000</us-gaap:RevenueRemainingPerformanceObligation>
    <ptgx:CollaborativeAgreementUpfrontPayment
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ"
      decimals="-5"
      id="Narr_hJnFcTg430yd8gs88cXCXg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">80000000.0</ptgx:CollaborativeAgreementUpfrontPayment>
    <ptgx:ReimbursementForServicesPerformed
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_Ptg200PhaseAndSecondGenerationCompoundMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_htTtbMn45UOqoFQw4o06MQ"
      decimals="-5"
      id="Narr_G5Mk5pcX6kyUM5TX8vcv4A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">17900000</ptgx:ReimbursementForServicesPerformed>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member_QqjayIBfTU2Zb8ZXHEhcpA"
      decimals="-5"
      id="Narr_zAEI7g1hQEaqP-arv28xNQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">7500000</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:ReimbursementForServicesPerformed
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ"
      decimals="-5"
      id="Narr_fkfm_bk54EOwUk8gVq5nuw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8400000</ptgx:ReimbursementForServicesPerformed>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_cVsaEkm30UuIJ0gcC93WaQ"
      decimals="-5"
      id="Narr_Y7wyWB0BDEOqaFLr-Zl9fg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8100000</ptgx:ResearchAndCollaborationAgreementDevelopmentCostPayable>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_lZeL8hdzf028kJ3_rDwFag"
      decimals="-5"
      id="Narr_-x82PhruRE2cZGG8ke93Xw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_yX6TYuMbYEicxZwbaMBgVg"
      decimals="-5"
      id="Narr_Ko0mKjbkyEO9IHaIKAzeBA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2300000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_M3p7YmD9vkCTXzn0pO5cbQ"
      decimals="-5"
      id="Narr_tB1XWuSou0yXv0xkpHvrTQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">12600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_562smoZuLkS9KsBvdrpLtw"
      decimals="-5"
      id="Narr_j6e5xK5sEEiNtrlz2T4Khw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_9QJowPauUk-gaWt5sFT-HA"
      decimals="-5"
      id="Narr_2In6wRUYqEGkk0zF0ZYl2Q"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-5"
      id="Narr_HzC5ZcUZE0OGtglpgsVLaw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_EXzMSWZYJkq4Gd12kF9Hhw"
      decimals="-5"
      id="Narr_eXIzeH5mnUO8_nh3dWeLnQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">9900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-5"
      id="Narr_pUE74Zua4EKsvZdbcBx8ZQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">22000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_potMVrgeoEGalpEJm2UCjQ"
      decimals="-5"
      id="Narr__z1t8dHuF0WYYSSZn24uyA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember_NvuFc-sXQUC2i1aTvziUiQ"
      decimals="-5"
      id="Narr_vbOxLbP0DU2S5OCVtYZ1TQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_F3RFb5HA60OJd6f2l94Plw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following tables present changes in the Company&#x2019;s contract assets and liabilities during the periods presented (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,732&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,520)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,477&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,715&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,951)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,396)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,284&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,114&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,299)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w"
      decimals="-3"
      id="Tc_NvYWA_ruNkqosH-Y8odMWA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2426000</us-gaap:ContractWithCustomerAssetNet>
    <ptgx:ContractWithCustomerAssetAdditions
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_yrvtl3fX7kGoLX3E-UZ40A_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5732000</ptgx:ContractWithCustomerAssetAdditions>
    <ptgx:ContractWithCustomerAssetDeduction
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_vgfyi8kA1UinkQeStlHUeg_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5520000</ptgx:ContractWithCustomerAssetDeduction>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg"
      decimals="-3"
      id="Tc_QyKbm0omFU-SGqlLsjygbA_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2638000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w"
      decimals="-3"
      id="Tc_Im1rUCZcTkqSssDVJ5eaRg_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">14477000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ptgx:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_s4dl53S8iEqg3UQvg1ekhA_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">16715000</ptgx:ContractWithCustomerLiabilityAdditions>
    <ptgx:ContractWithCustomerLiabilityDeduction
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_vpOQsTB3ckuUYnpsLj0uKw_7_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">28951000</ptgx:ContractWithCustomerLiabilityDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg"
      decimals="-3"
      id="Tc_LAiwT-Me4UqURkpmX5NlZw_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2241000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w"
      decimals="-3"
      id="Tc_3a8xYtYCtkW1s79SgjVdMw_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2732000</us-gaap:DueToRelatedPartiesCurrent>
    <ptgx:DueToRelatedPartyAdditions
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_r1gYehCDCU-nR5mS9tu1hA_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">9785000</ptgx:DueToRelatedPartyAdditions>
    <ptgx:DueToRelatedPartyDeductions
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_UZ0cKC3o5UWxA_o2QxnDUw"
      decimals="-3"
      id="Tc_P8RrVn6mDk6eTQFLDENB2A_8_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11396000</ptgx:DueToRelatedPartyDeductions>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kASlUrLoh0ChxePvyj6ktg"
      decimals="-3"
      id="Tc_3SOJ6Wxov0yr4YwCgVZ4hQ_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1121000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw"
      decimals="-3"
      id="Tc_WZF4AMPE_k2R5fN89glORQ_15_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5955000</us-gaap:ContractWithCustomerAssetNet>
    <ptgx:ContractWithCustomerAssetAdditions
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_5he34gmLckW4jVSOwYaVbg_15_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5284000</ptgx:ContractWithCustomerAssetAdditions>
    <ptgx:ContractWithCustomerAssetDeduction
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_VZBNmpiyHUq_L3Odupwbww_15_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8450000</ptgx:ContractWithCustomerAssetDeduction>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q"
      decimals="-3"
      id="Tc_Ex5s1OXZ40yae-Xopc0qDg_15_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2789000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw"
      decimals="-3"
      id="Tc_sgE9lqDduU6bh81NC5BPww_16_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ptgx:ContractWithCustomerAssetRelatedPartyAdditions
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_3cxIr_SStUeu3Y7a3o5flg_16_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">342000</ptgx:ContractWithCustomerAssetRelatedPartyAdditions>
    <ptgx:ContractWithCustomerAssetRelatedPartyDeduction
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_dhg-Yds0lEmvBxzJ8tAxBg_16_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-1142000</ptgx:ContractWithCustomerAssetRelatedPartyDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw"
      decimals="-3"
      id="Tc_H52jvVJRSEiQY_am8-RySg_18_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">41530000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ptgx:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_nrRUJmRlRU-CCET2ClnTjQ_18_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3500000</ptgx:ContractWithCustomerLiabilityAdditions>
    <ptgx:ContractWithCustomerLiabilityDeduction
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_nfR_2i41p0miA_TX9VXb_g_18_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">24153000</ptgx:ContractWithCustomerLiabilityDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q"
      decimals="-3"
      id="Tc__sFh1wyuJE2Hzhw-3nN5OA_18_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20877000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_qoq_jXW-o0OZ6W4SdXjDsw"
      decimals="-3"
      id="Tc_mM8S24zP3USv2y5HRTG05g_19_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1262000</us-gaap:DueToRelatedPartiesCurrent>
    <ptgx:DueToRelatedPartyAdditions
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_OiBD93jnoE6In-fQZ6xLIg_19_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2114000</ptgx:DueToRelatedPartyAdditions>
    <ptgx:DueToRelatedPartyDeductions
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_U5tRvp0-kkOBlxnQavUwgg"
      decimals="-3"
      id="Tc_9stYQxVuLkakQ7S1gofk-g_19_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1299000</ptgx:DueToRelatedPartyDeductions>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_tqj6IITgwk2zQ-H8hRGk0Q"
      decimals="-3"
      id="Tc_Dcto2LKN1UWBvCRGiZ8FQw_19_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2077000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-5"
      id="Narr_lwRTe7RU6EO9rN8iKlinog"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">200000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-5"
      id="Narr_qkNmOc33_0azBdQ6KrflWg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1700000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-5"
      id="Narr__lLKjKsCX0Kawnq5iZ_3ZQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">8500000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-5"
      id="Narr_pTYf0RWxTkaVOQ_4IhXnCw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11800000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_Rdb5ePYt60GFAvmRiG9zZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;4. Fair Value Measurements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 1&lt;/i&gt;&#x2014;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 2&#x2014;&lt;/i&gt;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3&lt;/i&gt;&#x2014;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Supranational and sovereign government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 290,919&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 276,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s commercial paper, U.S. Treasury and agency securities, corporate debt securities, U.S. Treasury and agency securities, including U.S. Treasury bills, and supranational and sovereign government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_g8pKDMSodkOa7mntJuGjsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Supranational and sovereign government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 290,919&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 276,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_xC4RqMR0Q0KyABMRO1X4UA"
      decimals="-3"
      id="Tc_YhlC6OtEY0iAjRZlSKi_jg_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">57077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_RyDegFl_A06Zzlx5SUabIw"
      decimals="-3"
      id="Tc_ibMOpVE3cEqcfvwopPnxrw_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">57077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_gec9OfdVA0-QavCdRuU7ig"
      decimals="-3"
      id="Tc_4rv_Kg5pYku0WkSF7031CQ_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">161312000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_Jby6BCZwZEmx5lkgaQcFoA"
      decimals="-3"
      id="Tc_KfQhJGdOL0iVu-yUJJevEg_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">161312000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_DkFNZeRNm0ydJRjGjJnj3g"
      decimals="-3"
      id="Tc_l7Cd_m_jXEi0qj4X4ny4Zg_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">81392000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_gJztAK_pJkSEMdZvVKmVEA"
      decimals="-3"
      id="Tc__-xKdlvTl0yzMsIRQTO2eA_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">81392000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_b77QUVVp-EabKEv4WpeA6A"
      decimals="-3"
      id="Tc_luD1ot8Er0Caid8fcRuvuw_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">42187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_Yd94PRDSaEyHbItBmTnC2w"
      decimals="-3"
      id="Tc_ZOeexGnq1EK9o5tIkPP6dA_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">42187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_quwzsXAt80GJsdttydqn8A"
      decimals="-3"
      id="Tc_HpHqikTxE0qR9cLwSy_iGQ_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6028000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember__UavJt8cZ0e-l_KQU4eymg"
      decimals="-3"
      id="Tc_bAsP3U3Yjkqdwge7qhYjYA_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6028000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-jIggHYH1UmbKLFheHzbgg"
      decimals="-3"
      id="Tc_9W3j1GRgUU-hds78VO4HYA_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">57077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6QBcAGRDREGf4rn_KPZpcw"
      decimals="-3"
      id="Tc_-hSYeRXDtUmu0l8VPlfT4A_9_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">290919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA"
      decimals="-3"
      id="Tc_2qloWJvvrki-oGWKTu7mdQ_9_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">347996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_GTf2MVxlEEGBedzfKpF1Eg"
      decimals="-3"
      id="Tc_trr4E79dD02wTj0fyTFizw_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_qZvf9xKSG0OZSn-Pah-mXg"
      decimals="-3"
      id="Tc_SDfFN6fscES_wNaPIWpKwg_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_8Myl1B2k-kSOnAjEMsdY-A"
      decimals="-3"
      id="Tc_AIAEVAFA1EaUXeBSXo26fg_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">65863000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_W-JTrmc1iUqyssBi9jfgmQ"
      decimals="-3"
      id="Tc_ZCGFffV6P0683QquPNHG-g_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">65863000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_ZdtE_xThKkSdI-Vaaceeog"
      decimals="-3"
      id="Tc_C1Z4PM8Aa0SS-xVrTQxnBg_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27590000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_7TCHAu-iM0K20R1_6ZSBeg"
      decimals="-3"
      id="Tc_cckGQoGLpkqbExr2XmxUnw_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27590000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_R2T0FeSCkU-4AuqwK_udIw"
      decimals="-3"
      id="Tc_CKhGzjG9wUGMUdHbv0Ht8Q_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">183210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_0Hh9M4XK4UiFA8GLjbeoAg"
      decimals="-3"
      id="Tc_4MBMpAg7J0qdToz4lCIw-g_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">183210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fUK5OnhlFU66Xq1kj7KKrg"
      decimals="-3"
      id="Tc_C7z2OXOwTUyI20sHyzHjhQ_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OKk9lwDz4EGN0BwH0atvlA"
      decimals="-3"
      id="Tc_Cs4ei-zr4U2ebbMwTi_t8Q_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">276663000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_mBhTXxceV02MtGdxdWbrGg"
      decimals="-3"
      id="Tc_tAP-qgdCZEyjzKiNagYLkA_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">304144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_jdE8I8YgC0634dC19iboZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5. Cash Equivalents and Marketable Securities &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents and marketable securities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,413&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Supranational and sovereign government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 348,019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 116,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 193,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,592&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,142&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 188,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Marketable securities &#x2013; current of $193.8 million and $188.5 million held at September 30, 2021 and December&#160;31, 2020, respectively, had contractual maturities of less than &lt;span style="white-space:pre-wrap;"&gt;one&#160;year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;. Marketable securities &#x2013; noncurrent of $38.2 million and $2.0 million held at September 30, 2021 and December 31, 2020 had contractual maturities of at least &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;one year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; but less than &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;two years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;. The Company does not intend to sell its securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell its securities before recovery of their amortized cost basis, which may be at maturity. There were no realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_RPcUBFwLYkCLp4tbKpLBow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents and marketable securities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 161,312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,413&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 42,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Supranational and sovereign government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 348,019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 116,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 193,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 347,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,592&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,142&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 188,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg"
      decimals="-3"
      id="Tc_VD9UQ_OiCE6_WRK8A7mLLg_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">57077000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_gTB3SYv4SE6Q39lAULQLMg"
      decimals="-3"
      id="Tc_0ezqK4upIkGBLJEfwaopCQ_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">57077000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA"
      decimals="-3"
      id="Tc_4n-VPyhvF0CF48BSB5Oy2Q_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">161315000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA"
      decimals="-3"
      id="Tc_3F5lg37slEWGbwjavskCUg_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA"
      decimals="-3"
      id="Tc_ts856BjxfU6re4yWtUBSVg_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_DDDc1teCTEab5e9YJTgQkA"
      decimals="-3"
      id="Tc_AKzpqLJ2P02arAoG2xim2A_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">161312000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA"
      decimals="-3"
      id="Tc_qjbcNCBk3Uu7VoRuBBLrSQ_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">81413000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA"
      decimals="-3"
      id="Tc_YFRoXpiOG0O54l_lYFjQWA_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA"
      decimals="-3"
      id="Tc_1RQ-VxoiTUGFVW64sud23w_6_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">22000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_BPwpqau7B0CLFocaZyAzQA"
      decimals="-3"
      id="Tc_mzUF8u8jREuNOAlEEa9M0w_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">81392000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ"
      decimals="-3"
      id="Tc_AGHzcjYih0uj1014pOZ7sg_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">42186000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ"
      decimals="-3"
      id="Tc_pwyjyYPwQEObvMBHPN0qcA_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ"
      decimals="-3"
      id="Tc_wQ7HKLkjnUq5otVTkyJaoA_7_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uECTNRwoxECKGQUnMgRBCQ"
      decimals="-3"
      id="Tc_Pw6OeXA0Ek-ooULTgJ_YXQ_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">42187000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg"
      decimals="-3"
      id="Tc_pM4Wx3ORi0mu0i6RKYEpKg_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6028000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_us-gaap_InvestmentTypeAxis_ptgx_SupranationalAndSovereignGovernmentSecuritiesMember_tutd1r1slEGmITDuAr5-wg"
      decimals="-3"
      id="Tc_BG8c373S9kSpjt-2CSHFXA_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6028000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_Pijo4i4zPkyGwmdFy4tWCw_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">348019000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_GHabeJpEv0ajjwhlgKy-sQ_9_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_KfasBluXDkyE0i1fhR2Bdw_9_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">29000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_FcEcI2T1wkqm_OhQN6zVMg_9_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">347996000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_Ofu0oIliiEW34aeJIRaDlA_11_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">116068000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_ehT_oElk7kmVkfqDPXjyGg_12_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">193759000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_RDL0vwiKwEuG6o48lLN7Hg_13_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">38169000</us-gaap:MarketableSecuritiesNoncurrent>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_ugm6GrC3F0C24zbvEHBASw_14_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">347996000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg"
      decimals="-3"
      id="Tc_js-E9DgxEk6mIidCRo9wrw_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27481000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_7lTsFxQftkKEV9-jAYKsMg"
      decimals="-3"
      id="Tc_Y76P8gf74kerg6hRweq7pw_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27481000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg"
      decimals="-3"
      id="Tc_ZMUG0RmyiU2BJK22lRaWzA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">65866000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg"
      decimals="-3"
      id="Tc_yqoh8_1vQEeiMCRLaxdiQg_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_yGmYzXabEEKIqy-Mk6zZgg"
      decimals="-3"
      id="Tc_DWrtu37snECueM5tESufOA_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">65863000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg"
      decimals="-3"
      id="Tc_zCBDtEJAsUibZdraX51acA_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27592000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg"
      decimals="-3"
      id="Tc_Y3UR7mpyqUm0H86QfBEv8Q_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg"
      decimals="-3"
      id="Tc_7_XwefbnfUy13b2yQpWQoA_6_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_r8Q2j9VzYUGylgYg93cbPg"
      decimals="-3"
      id="Tc_tNgGRNWcUEuHJ7IHWH7Cig_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27590000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ"
      decimals="-3"
      id="Tc_O3RH-oUn8E-tNZ8fUBvGUQ_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">183203000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ"
      decimals="-3"
      id="Tc_ScMIvEHpCkare4r6K3hduA_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ"
      decimals="-3"
      id="Tc_d2mBs6ebbEuG3_9Z4U9Pvg_7_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eZqdRIY2tU2ZbQiuXwVmbQ"
      decimals="-3"
      id="Tc_OM0XrzneEUiYiy_sGzQ1Xg_7_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">183210000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_WZ4bwMmqTkCzkpGU_T1dcw_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">304142000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_OxCKUsAAhE-s_DH-GnXl2Q_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">12000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_oWevcwERvEeVfCRKy3hZrA_8_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_SKuyCVh2T0KJds6f8olkrg_8_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">304144000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_YwWHMFcCuU6hO2_F0_n_fQ_10_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">113693000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_yqEE_EiBtESsdbOx4k0jDw_11_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">188451000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_XwPIp6gvZkqwFkmtNYKoKA_12_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000000</us-gaap:MarketableSecuritiesNoncurrent>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_0vugfEuFoEatWoZZDf_zFA_13_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">304144000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Narr_9lVein4g1EeJva4jyi7XTg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">193800000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-5"
      id="Narr_iREWWlwer0qBVTF08994IA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">188500000</us-gaap:MarketableSecuritiesCurrent>
    <ptgx:CurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_ilfoLTzRtkexvS9m67khZg">P1Y</ptgx:CurrentContractualMaturitiesMaximumPeriod>
    <ptgx:CurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      id="Narr_ngduljyBR0Gdmcq_vYjUeQ">P1Y</ptgx:CurrentContractualMaturitiesMaximumPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Narr_1GijMXh6NkyHXntolPawHA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">38200000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-5"
      id="Narr_wwtCBwW13k6Rnl4NsIgaTg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <ptgx:NoncurrentContractualMaturitiesMinimumPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_MymoDp1qAkag2Jl6OPoZ_g">P1Y</ptgx:NoncurrentContractualMaturitiesMinimumPeriod>
    <ptgx:NoncurrentContractualMaturitiesMinimumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      id="Narr__jpVzh6WDUGeeOpye67duA">P1Y</ptgx:NoncurrentContractualMaturitiesMinimumPeriod>
    <ptgx:NoncurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_B_KVQMctHE-B3-iks0761A">P2Y</ptgx:NoncurrentContractualMaturitiesMaximumPeriod>
    <ptgx:NoncurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      id="Narr_ndo2WzZmY0ChqQIU8UXuRg">P2Y</ptgx:NoncurrentContractualMaturitiesMaximumPeriod>
    <ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_5X1MlmgcGkKPHdPXw6mjgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"&gt;Note&#160;6. &lt;/b&gt;&lt;/span&gt;Accrued Expenses and Other Payables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other payables consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,482&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,566&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued collaboration payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued expenses and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_SJwOZ5S3bkya93MhN3skhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other payables consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,482&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,566&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued collaboration payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued expenses and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_PFfMM4xWG0yz64Jkc_zIYQ_3_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">24482000</ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent>
    <ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_8u6Nj-zU5ESAdWieTtzc0w_3_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11335000</ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_pHZ80JZMdEqdsIeAP-2a7A_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4722000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_g6089Ohd3E-0tnoH0qVm9Q_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6413000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_hV6WYAUZtke_a6ksX1PSkQ_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1566000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_MjbSc7mfG0GcysrsLFX6kQ_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">668000</us-gaap:AccruedProfessionalFeesCurrent>
    <ptgx:AccruedMilestonePaymentToFormerCollaborationPartner
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_3uFdkK3740O1ftfJx1Wm5Q_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1500000</ptgx:AccruedMilestonePaymentToFormerCollaborationPartner>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_E5SJac7Uc0GdqsH-0Zx7Ew_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">791000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_4Ye1YLRhpUeF7p2FhN3z_g_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">82000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_3q8ord31zUCKvvJAsQEqfg_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">33061000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_pxxkHp5DJUCcgGoqnIVsTA_8_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">18498000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q"
      id="Tb_hXcVH0xyAkOh2e0PxEA0bA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company and Zealand Pharma A/S (&#x201c;Zealand&#x201d;) entered into a collaboration agreement in June 2012. In October 2013, Zealand abandoned the collaboration, and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#x2019;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company previously determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made three development milestone payments for an aggregate amount of $1.0 million under the agreement. However, upon reevaluation, the Company concluded in 2019 that rusfertide is not a compound requiring post-termination payments under the agreement and initiated an &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;arbitration proceeding in January 2020. On August 4, 2021, the Company and Zealand agreed to resolve the dispute and entered into an Arbitration Resolution Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11. Commitments and Contingencies &#x2013; Legal Proceedings for additional information on the results of arbitration proceedings related to this research and collaboration agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. $4.0 million in research and development expense was recorded under the agreement for the three and nine months ended September 30, 2021. No research and development expense was recorded under the Zealand collaboration agreement for the three and nine months ended September 2020. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ptgx:NumberOfDevelopmentMilestonePayments
      contextRef="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw"
      decimals="0"
      id="Narr_v3G_CQQNwUaSYMzcvepNoA"
      unitRef="Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w">3</ptgx:NumberOfDevelopmentMilestonePayments>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw"
      decimals="-5"
      id="Narr_gjhOPfdlSUGaQ8exq6jG2A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1000000.0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-5"
      id="Narr__mK4c4pVG0-XaXKZM_4sSA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4000000.0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-5"
      id="Narr_poQAIBlfWEqoSqKH5tonig"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4000000.0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-5"
      id="Narr_lU4m-STxWk-396EV7zAhRg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-5"
      id="Narr_uyrKPBy1Uk6Jguqn8Gtfdw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <ptgx:GovernmentProgramsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_b2f98-sC902tbhLH7M8AjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;8. Government Programs &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Tax Incentive&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three and nine months ended September 30, 2021, the Company recognized AUD 0.6 million ($0.5 million) and AUD 2.9 million ($2.2 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the three and nine months ended September 30, 2020, the Company recognized AUD 0.4 million ($0.3 million) and AUD 0.8 million ($0.5 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. As of September 30, 2021 and December 31, 2020, the research and development cash tax incentive receivable was AUD 2.6 million ($1.9 million) and AUD 1.4 million ($1.1 million), respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Small Business Innovation Research (&#x201c;SBIR&#x201d;) Grants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received SBIR grants from the National Institutes of Health (&#x201c;NIH&#x201d;) in support of research aimed at its product candidates. The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $0.1 million as a reduction of research and development expenses for the nine months ended September 30, 2021. The Company recorded $0.3 million as a reduction of research and development expenses for the nine months ended September 30, 2020. No such amounts were recorded during the three months ended September 30, 2021 and 2020. The Company records a receivable to reflect the eligible costs incurred under the grants that are contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the condensed consolidated balance sheets. There was no such receivable as of September 30, 2021 or December 31, 2020.&lt;/p&gt;</ptgx:GovernmentProgramsDisclosureTextBlock>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA"
      decimals="-5"
      id="Narr_idl2biIFfkKt8Igq3UiAMQ"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">600000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_u2V98pFNTkeDEjtkepHGVA"
      decimals="-5"
      id="Narr_FKCSrWytdEa262v1X46TSQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">500000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg"
      decimals="-5"
      id="Narr_BpRQs8x6YkCCSSg0oz--EA"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">2900000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_s25eaJWuWEqWHpudMoWMBg"
      decimals="-5"
      id="Narr_s3nBFRKafUOvuOns33cxlQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2200000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ"
      decimals="-5"
      id="Narr_COB_IPiB-US8U8_cvNzsNw"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">400000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_QssweoPc2UycDi7EdHiRsQ"
      decimals="-5"
      id="Narr_2tMAZ07W60W61AMsXkv96A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">300000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ"
      decimals="-5"
      id="Narr_GZAA8KjmaE29xIPWFXlUiw"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">800000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_1_Mk5l9XjEWDJqHkpleEMQ"
      decimals="-5"
      id="Narr_0Wq-2G1ePUyrLjB3Hal2lw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">500000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg"
      decimals="-5"
      id="Narr_X0RhiD3AwEOo9O-0DmPtbQ"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">2600000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_jj4KZJksE0yM5wbi17N9Eg"
      decimals="-5"
      id="Narr_dyYdTCq_gkS3U2y7e0IFqw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1900000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag"
      decimals="-5"
      id="Narr_40U4NDySeEGB5uKOgNBnUA"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">1400000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_PjexJA7yZESN-nYy9ZKIag"
      decimals="-5"
      id="Narr_gJ-Q8C6FAEWrJYn4YYcnCw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1100000</us-gaap:IncomeTaxesReceivable>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_fHticHz3nEOKl7dkY7LJ5A"
      decimals="-5"
      id="Narr_qZaZgsN23kSmouoJqLzt3g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">100000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_aGR3Nn_0oUCmeAgOesXdXA"
      decimals="-5"
      id="Narr_Hvrkl6qUj0q1IGpy4EzDmw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">300000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2020_To_9_30_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_W5_EmxclnkqveI5CjIX6wQ"
      decimals="-5"
      id="Narr_uLZtdj_Tj0yYoYX5fZwknw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_7_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_OrLsItNoVUWmXfX_oVcZTA"
      decimals="-5"
      id="Narr_ZtpJFpB5oUqSmo-763PAMQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</ptgx:ResearchAndDevelopmentExpensesReduction>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_NLWK1h6eUUCL1SCn1CQ7wg"
      decimals="-5"
      id="Narr_CKAte0wUlEiE8co6dZP7Ew"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_82q0nTVsSUC8bXZMRz6aLA"
      decimals="-5"
      id="Narr___mAcEHxk0qBeUa7IuEw4g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:GrantsReceivable>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_jN3h5rGTo0-7CCQ1qKC71Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Note 9.   Term Loan Facility &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#x201c;Closing Date&#x201d;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#x201c;Agent&#x201d;) (such agreement, the &#x201c;Term Loan Credit Agreement&#x201d;), which provided for a $50.0 million term loan facility. The Term Loan Credit Agreement provided for (i) on the Closing Date, $10.0 million aggregate principal amount of term loans, (ii) at the Company&#x2019;s option, until December 31, 2020, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#x2019;s option, until September 30, 2021, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#x201c;Term Loans&#x201d;). The Company used proceeds from drawdowns on the Term Loans for general corporate purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Term Loans were subject to an origination fee of 0.25% for each funded tranche under the Term Loan Credit Agreement and bore interest at an annual rate based on prime rate plus 2.91%, subject to a prime rate floor of 4.94%. At the Company&#x2019;s option, the Company could prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of 3.0% of any amount prepaid if the prepayment occurred through and including the first anniversary of the Closing Date, 2.0% of the amount prepaid if the prepayment occurred after the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;first anniversary of the closing date through and including the second anniversary of the closing date, and 1.0% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of 2.85% of the amount of Term Loans advanced by the Lenders was due upon prepayment or repayment of the Term Loans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Term Loan Credit Agreement required the Company to maintain cash and cash equivalents of at least 35% of the outstanding Term Loans at all times and was secured by a perfected security interest in all of the Company's assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contained other covenants that limit the Company&#x2019;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balance above a certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants would result in default for the Company. The Term Loan Credit Agreement included a clause which allowed lenders to accelerate repayment upon the occurrence of certain events of default. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company prepaid the outstanding $10.0 million balance on the term loan as well as $0.6 million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $0.1 million related to capitalized and unamortized debt issuance costs, which is included as part of the $0.6 million loss on early repayment of debt. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Company executed a payoff letter to release all obligations under the Term Loan Credit Agreement. As a result, the Company had no outstanding balance and no obligations related to the Term Loan Credit Agreement as of September 30, 2021.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q"
      decimals="-5"
      id="Narr_b65_5Ylza0ihVIeuPpG-fQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q"
      decimals="-5"
      id="Narr_fibjtOdW0U-xqYczxkBtgw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000000.0</us-gaap:LongTermDebt>
    <ptgx:DebtInstrumentTrancheInstallmentAmount
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q"
      decimals="-5"
      id="Narr_68HeQQ-jaEqpoPfuFZn2gA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20000000.0</ptgx:DebtInstrumentTrancheInstallmentAmount>
    <ptgx:DebtInstrumentTrancheInstallmentAmount
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q"
      decimals="-5"
      id="Narr_CO1KBosHwE-uH2kRDaBYQw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">20000000.0</ptgx:DebtInstrumentTrancheInstallmentAmount>
    <ptgx:DebtInstrumentLoanOriginationFeePercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw"
      decimals="4"
      id="Narr_mwVXfzm0P0OvvplhTNz5Ww"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0025</ptgx:DebtInstrumentLoanOriginationFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg"
      decimals="4"
      id="Narr_zhExiO0jPk60lu-YQkVFRg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0291</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ptgx:DebtInstrumentFloorRate
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_80WQTFoJF0azjHmXwm3MNg"
      decimals="4"
      id="Narr_k1zrrl0QcUqUuwyMXcna2g"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0494</ptgx:DebtInstrumentFloorRate>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_y3q_xyeqpEq7Mcn87B_l1w"
      decimals="3"
      id="Narr_Lqm8EYzlC0qPzhtwo3wk9Q"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.030</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_df9Ci-g-EECi012fGqcB-A"
      decimals="3"
      id="Narr_9HA-xZGZnUadqleb0Io9Wg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.020</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_8VDg-9H-LkmeiUYsHBLxHQ"
      decimals="3"
      id="Narr_gcX-C30mF0uUBMuHkjcQwA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.010</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw"
      decimals="4"
      id="Narr_Ka_Eu01j-UuuUQvZWjgPDQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0285</ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage>
    <ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_4R7Jmm0BaUWV_26Q7RtkJw"
      decimals="2"
      id="Narr_ZB1aH9fyHE-lB5qPYTHLkQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.35</ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw"
      decimals="-5"
      id="Narr_ClpTux2il0Ccz2NiV5wrtA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">10000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw"
      decimals="-5"
      id="Narr_zqpIb6znwUyXAs9CVKNcDA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">600000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_X-Iefnbj_ESZC2EhPRGpUw"
      decimals="-5"
      id="Narr_4UoObvMOQ0qCPLwc0UjSXA"
      unitRef="Unit_Standard_AUD_5CNdexGf5kmBq9dQy3v34A">100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_JDwZZFanWkeqUf8FUxRYmw"
      decimals="-5"
      id="Narr_oOcvu1HZSEWu0eprAr7nEQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_O2mng1-tskSGO5KBeSuZsw"
      decimals="-5"
      id="Narr_OsvwrJPuWUW0E5Rq3MGpDg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:LongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_-UnjUVwmXEac2BPjFIC_wA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 10.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC 842, to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company has elected to account for each separate lease component and non-lease components as one single component for all lease assets. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has one operating lease agreement entered into in March 2017 for approximately 42,900 square feet of laboratory and office space located in Newark, California. The Company provided the landlord with a $450,000 letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. The security deposit for the lease was later reduced to $225,000 in March 2021. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 2, 2021, the Company entered into an amendment (the &#x201c;Second Amendment&#x201d;) to its facility lease agreement dated as of March 2017, as amended, to lease approximately 15,000 square feet of additional office space in Newark, California. The Company commenced operations in the additional space in September 2021. Under the Second Amendment, the Company will pay additional base rent of approximately $1.5 million over the lease term, which expires in May 2024. As a result of this amendment, the Company recorded an additional right-of-use asset and the related &lt;span style="-sec-ix-hidden:Hidden_W9bIUIMLtUuXqk-5ssyS9Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"&gt;liability&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; of $1.4 million as of September 30, 2021. The Company will be responsible for its proportional share of operating expenses and tax obligations. No additional security deposit was required pursuant to the Second Amendment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides balance sheet information related to operating leases is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_If59OPpEK02lxvyiRk3sOQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VdeOmiqn-EmGbvHLuN1aAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,027&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K67XINXtckW2yeWVvsxsDQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - noncurrent&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b6WSSFcN8kyrZANs0pC1gg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,265&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.6%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Other information related to the Company&#x2019;s operating leases is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flow used by operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,493&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New operating lease asset obtained in exchange for operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Future lease payments required under lease obligations as of September&#160;30, 2021 are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (855)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ptgx:NumberOfOperatingLeaseAgreement
      contextRef="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_nJ2YdyBimE6P9t5VGQxkZA"
      decimals="INF"
      id="Narr_moBfgBhRK0WoYR3opo4dqA"
      unitRef="Unit_Standard_lease_l-KtIo8rkUevq1Vg6RPLug">1</ptgx:NumberOfOperatingLeaseAgreement>
    <us-gaap:AreaOfLand
      contextRef="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA"
      decimals="0"
      id="Narr_nCt9QlWrikuA6Q7uB9hZSg"
      unitRef="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A">42900</us-gaap:AreaOfLand>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_4caB6I0uWkeio0ZlvYXWnA"
      decimals="0"
      id="Narr_Ju9kWTVDMUqHTTnNsSW0UA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">450000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_3_31_2021_srt_StatementGeographicalAxis_stpr_CA_Ujq4sL4CxEW0D5YwkaKV3Q"
      decimals="0"
      id="Narr_jkccl0IKOECLwxF5O7Z8fA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">225000</us-gaap:SecurityDeposit>
    <us-gaap:AreaOfLand
      contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA"
      decimals="0"
      id="Narr_VUa-HqF78UuLY1H22wJtbw"
      unitRef="Unit_Standard_sqft_BIpZEbXSQkiACJvYOFku8A">15000</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA"
      decimals="-5"
      id="Narr_HCY5n-DdJUmr8db9V7rBYA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_giTOInCQAESH-WTG_a2EaA"
      decimals="-5"
      id="Narr_C8raKfwT7ECsix3Muf5CyQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ptgx:AdditionalSecurityDeposit
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_StatementGeographicalAxis_stpr_CA_us-gaap_TypeOfArrangementAxis_ptgx_FacilityLeaseAmendmentAgreementMember_lP0N1Fncak2aTabKTfpxOA"
      decimals="-5"
      id="Narr_cTwXinh98Umu_JUA75hVXw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</ptgx:AdditionalSecurityDeposit>
    <ptgx:LeaseBalanceSheetDisclosureTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_yYjQgigMfUuG-Fa3wsWT8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_If59OPpEK02lxvyiRk3sOQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VdeOmiqn-EmGbvHLuN1aAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,027&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K67XINXtckW2yeWVvsxsDQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - noncurrent&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b6WSSFcN8kyrZANs0pC1gg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,265&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.6%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ptgx:LeaseBalanceSheetDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_oHNXLhD2mEOWChFQaei_zQ_3_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5371000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_nDiACAvtr0a5_iF46_D5WA_3_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4950000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_jzPvgv-ZckC8BiYpZi-vrA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2027000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_SqXTTKX23E28Iq_dJqdUCg_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_ddrERsoL9kOd-P_sGX_-hw_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4238000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_Qz1NU_ora0eqKpc4wjMmwA_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_sm3VenmD0UeFG4osxtEcCQ_7_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6265000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-3"
      id="Tc_MWzvVibD-06CcyTif7OFnA_7_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5959000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      id="Tc_jGJkY5y9tky5Cy_54bEv2w_9_3">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      id="Tc_1nP5USJs7kK51sUuBnbMjA_9_6">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="4"
      id="Tc_SJqbWpMDMUC1LPMRbiQV2Q_10_3"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="4"
      id="Tc_GifiPv0HpEyEp_lheXw_ig_10_6"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.110</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_LhztC8oTxECON7MAqQMIRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:65.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_5qKGxVmzrUu4mBviXcHskA_3_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1378000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_YB-vixteRE2MlpWNsbjYGg_3_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1331000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_VDM1d-V2Pk-xynfve2j0Rg_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">68000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_VKoxcPaoc06733MKUGFTVw_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">22000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_FjTHOFIahEeugqdSQyM6sA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1310000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_zvAPeMhSr0GqBGnl9Tp3_A_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1309000</us-gaap:LeaseCost>
    <ptgx:LeaseCashFlowInformationDisclosureTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_LAnnaICZ_k6alVHP9U-U6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flow used by operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,493&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New operating lease asset obtained in exchange for operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ptgx:LeaseCashFlowInformationDisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_3jVXvoREF0y0eXpHfXq4Qw_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1493000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_PhpnMqBUYUi4vuo4ekVExQ_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1450000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_G6oSq_H3B0a5WOhyR2oeXQ_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1373000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_Q8CoNzYnDUm7GV3VgH-K-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (855)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_iGX_K45N_EeaeOGnY3vWSg_2_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_RBc8qmtmgkC7ixLk1NQ5Uw_3_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2660000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_su2FVZQRfkG8cX6N4RCfpg_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2744000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_dMk1belQlUuVdWTKEIuBWw_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1160000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_7tNbNx-qn0i-V4ZEvBReGg_8_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">7120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_DCWfuA_Bw0qfE22gLU67OA_9_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">855000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-3"
      id="Tc_0bl7xS5a4UahMBpr7klktw_10_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6265000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_EpfqmBUfJUWTVwbR09E4WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 11. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Legal Proceedings &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accruals for legal actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand related to a collaboration agreement the Company and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 4, 2021, the Company and Zealand agreed to resolve the dispute and reached an Arbitration Resolution Agreement. Under the Arbitration Resolution Agreement, (1) the Company is required to make an additional payment of $1.5 million to Zealand in August 2022 with respect to rusfertide, (2) all development milestones with respect of rusfertide have been reduced by 50%, except that the Company agreed to pay in full within two (2) business days after the effective date of the Agreement (and timely paid): (i) a $1.0 million milestone for initiation of a Phase 2b clinical trial; and (ii) a $1.5 million milestone for initiation of a Phase 3 clinical trial; (3) the royalty rate payable by the Company on net sales of rusfertide has been reduced by 50%; (4) all sales milestone payments on net sales of rusfertide have been reduced by 50%; (5) the parties agreed that each party will retain all payments previously made by the other party in connection with the original collaboration agreement; and (6) the parties have released claims related to the original collaboration agreement, the abandonment agreement and the arbitration. In addition to the payments specified in items (1) and (2) above, the Company may also be required to pay Zealand up to $2.75 million in future development milestone payments relating to rusfertide. Those payments include up to $1.0 million in the aggregate for registrational proposals and up to $1.75 million in the aggregate for commercial launch in the three geographic territories specified in the original collaboration agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company considered the outcome of these arbitration proceedings as being related to its research and development project; therefore, payments or milestone payments were recorded as research and development expenses. As a result, no related legal accruals were recognized as of September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable
      contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw"
      decimals="-5"
      id="Narr_1BelnrDrB0WOPIIBMp8lxA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1500000</ptgx:ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable>
    <ptgx:LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage
      contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw"
      decimals="2"
      id="Narr_72JKOdXUekOpRWJBkxCTaA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage>
    <ptgx:NumberOfBusinessDays
      contextRef="Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg"
      decimals="INF"
      id="Narr_PAK1Ee93XUytMNIxdvzQRA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2</ptgx:NumberOfBusinessDays>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_AHS1J3rNPkunnKl_uozAJw"
      decimals="-5"
      id="Narr_dgbO-btnd0ybeBpE4HlD-g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1000000.0</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseThreeClinicalTrialMember_PxpJvRYYhEWj49AtdxBe5A"
      decimals="-5"
      id="Narr_Mt2yN-ruK0COTZKL9PE15Q"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1500000</ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable>
    <ptgx:RoyaltiesOnNetProductSalesPercentagesReduction
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"
      decimals="2"
      id="Narr_ud3cIrnqjEWL5pmgGo_q3Q"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:RoyaltiesOnNetProductSalesPercentagesReduction>
    <ptgx:LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"
      decimals="2"
      id="Narr_9RwpMa6lUEewf9LytC6Vdw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage>
    <ptgx:CollaborativeArrangementFutureDevelopmentMilestonePayable
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"
      decimals="-4"
      id="Narr_pnHWwR-U8E-FbDqQP01oDg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2750000</ptgx:CollaborativeArrangementFutureDevelopmentMilestonePayable>
    <ptgx:CollaborativeArrangementRegistrationProposalExpensesPayable
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"
      decimals="-5"
      id="Narr_Wa8dQWm3Xkubah5Te221gw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1000000.0</ptgx:CollaborativeArrangementRegistrationProposalExpensesPayable>
    <ptgx:CollaborativeArrangementCommercialLaunchExpensesPayable
      contextRef="As_Of_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_RSbkmYZyeUWdxHNC86eUtg"
      decimals="-4"
      id="Narr_ilhTxGcpS0-EWgRyO6Dqmw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1750000</ptgx:CollaborativeArrangementCommercialLaunchExpensesPayable>
    <ptgx:NumberOfGeographicTerritories
      contextRef="Duration_8_4_2021_To_8_4_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_LitigationCaseAxis_ptgx_ArbitrationResolutionAgreementWithZealandMember_nSu70Mu-rUiyfOM18Z7Vdw"
      decimals="INF"
      id="Narr__4ecKI8wdUudRTrM5OPlxg"
      unitRef="Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg">3</ptgx:NumberOfGeographicTerritories>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_IcQjRh5fKEOqMWWM3N6bgQ"
      decimals="0"
      id="Narr_76HSXIOHBU6NqaPxZXAYFg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_rRA2mK-u5Uq5DnNZo5BC7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 12. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#x201c;Investor&#x201d; and, collectively, the &#x201c;Investors&#x201d;), pursuant to which the Company sold an aggregate of 2,750,000 shares of its common stock at a price of $8.00 per share, for aggregate net proceeds of $21.7 million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of 2,750,000 shares of its common stock (each, a &#x201c;Warrant&#x201d; and, collectively, the &#x201c;Warrants&#x201d;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase 1,375,000 shares of the Company&#x2019;s common stock have an exercise price of $10.00 per share and Warrants to purchase 1,375,000 shares of the Company&#x2019;s common stock have an exercise price of $15.00 per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480&lt;i style="font-style:italic;"&gt;, &lt;/i&gt;Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;), and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of September 30, 2021, none of the Warrants have been exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2018, the Company entered into an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with an Investor and its affiliates (the &#x201c;Exchanging Stockholders&#x201d;), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company&#x2019;s common stock, par value $0.00001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#x201c;Exchange Warrants&#x201d;) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company&#x2019;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,&lt;i style="font-style:italic;"&gt; Equity&lt;/i&gt;, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480&lt;i style="font-style:italic;"&gt;,&lt;/i&gt; and fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September 30, 2021, 400,000 of the Exchange Warrants remain unexercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company filed a registration statement on Form S-3 (File No. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $250.0 million of its common stock, preferred stock, debt securities and warrants (the &#x201c;2019 Form S-3&#x201d;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, 2019 (the &#x201c;2019 Sales Agreement&#x201d;). In May 2020, the Company completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share and issued an additional 1,050,000 shares of its common stock at a price of $14.00 per share following the underwriters&#x2019; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $105.3 million. As of September 30, 2021, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"&gt;In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which it completed an underwritten public offering of 4,761,904 shares of the Company&#x2019;s common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of common stock at a price of $21.00 per share following the underwriters&#x2019; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $107.6 million. In June 2021, pursuant to Registration Statement No. 33-251254, the Company completed an underwritten public offering of 3,046,358 shares of its common stock at a public offering price of $37.75 per share and issued an additional 456,953 shares of common stock at a price of $37.75 per share following the underwriters&#x2019; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $123.8 million. The Form S-3ASR expires in December 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw"
      decimals="INF"
      id="Narr_8p4IY5txmkqga8vJ3P2Zkg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">2750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9KOXTrTqMUiTDI99y3z_ig"
      decimals="2"
      id="Narr_3lWadvsahke6nmb48iLqbA"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">8.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw"
      decimals="-5"
      id="Narr_QKnBIEfHH0SAjcPVE9tDTA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">21700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_M6ZuWy-_Aky-LJndvpy4bA"
      decimals="INF"
      id="Narr_VSnChRrS30iU0rwHvoaXYQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_OGp3vb8bZkeXhykCazB_Vw"
      id="Narr_wVRnXKW3vkq4XxkBdnmPBw">2023-08-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A"
      decimals="INF"
      id="Narr_fcKYxkGVlEGlX-uyDbMWug"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1375000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Sho3yQXZa0eSCJcWq-gW8A"
      decimals="2"
      id="Narr_uxZ9VeLU80C2mEWJW4qmaw"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w"
      decimals="INF"
      id="Narr_ZzHekoC5p0C6GhCu9OH2HA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1375000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_kyi3WIXJuESMGykrSY0s6w"
      decimals="2"
      id="Narr_uO8beZgCr0avgT5A18AOYg"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptgx:NumberOfWarrantsExercised
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_JyX857Du9kCccikwVOJK1A"
      decimals="-3"
      id="Narr_sdy3SpuLX0iQK51IR2cQwA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">0</ptgx:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ"
      decimals="INF"
      id="Narr_m17xHVihGU2-hPeBfc6csQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ"
      decimals="INF"
      id="Narr_3TWsI55cOU6BQHtue_29hQ"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ptgx:StockExchangedForPreFundedWarrants
      contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA"
      decimals="INF"
      id="Narr_7BhUSK2wXkSzqbzYD9LEfg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1000000</ptgx:StockExchangedForPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ"
      decimals="INF"
      id="Narr_UHGI_KO6dUOg3WhLM2gzVg"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptgx:ClassOfWarrantOrRightTermOfWarrants
      contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_kbMsuScZ10KSpuxzyZfbeA"
      id="Narr_JyJ0ojtW5UihwdCDMPq9gw">P10Y</ptgx:ClassOfWarrantOrRightTermOfWarrants>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_qLVXaZjr_0S9hMiczjsSCQ"
      decimals="4"
      id="Narr_8xDA2VQi1EWNKwkVgZePOw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_YTpXeQgJJUeKa5oZr8AiAg"
      decimals="INF"
      id="Narr_GoMlPkRGGEO52bNtLHYOUQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_uyHNYHVIIUOFt7eISFZ0iA"
      decimals="-5"
      id="Narr_nyS-tZTR20uJkphSeZk53w"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">250000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_3MZvEqMKLkqJJimay3c3Rg"
      decimals="-5"
      id="Narr_oMgs9-oveEmjEmWVAGkzKw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">75000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_11_27_2019_To_11_27_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_xRIStPOlqkO3ZRkjqtTj2g"
      decimals="-5"
      id="Narr_lFGPYkqRHE-qNfSR5-yDOA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">250000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g"
      decimals="INF"
      id="Narr_mpMIa_s68kCkGIQq4ZMeRA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_ChADps65pUSE5xPbZYa91Q"
      decimals="2"
      id="Narr_jPUPcPkzx0aM-DvuF_CKxQ"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_URkiGm8zuEaVvS65J30DTQ"
      decimals="INF"
      id="Narr_KSujYu6tK0O3VhELyM81Ng"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8zEeV8gTA0OQG69UlVTpzA"
      decimals="2"
      id="Narr_h-PpZtoXJUKDEkcJNByiDA"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_P2U8xNSo80WUYrcfk7En6g"
      decimals="-5"
      id="Narr_Br5LFMTTFEWueNxEL4-jrQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">105300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_zKmsy6v6FUaz1H9GRlgxZw"
      decimals="-5"
      id="Narr_LD2y1VwFd0Cgni3iozrJSg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">94200000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_FinancingFacilitySalesAgreementMember_9Z964QKwJE2qr29wKQspDw"
      decimals="-5"
      id="Narr_RjmeMTMJS0u-aA-opReJxw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">31900000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg"
      decimals="INF"
      id="Narr_s9h4ANeN-EWT5OZrqM39mg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">4761904</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_59vPe4YVMUWB01DLx1U1Ew"
      decimals="INF"
      id="Narr_ac6mZRjQgEeMtjEB_i6UOA"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">21.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4dru7UabbEO8vq8Kk60BLA"
      decimals="INF"
      id="Narr_TehSuQznWkuK--IYlosbrg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">714285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ZWhhGQPBKUuEzunwWJ1GhQ"
      decimals="INF"
      id="Narr_V5DKjoBBK0-ZSZJVlzQQCA"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">21.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1vZLGchaBkSAfPJ2PEvfjg"
      decimals="-5"
      id="Narr_jOeM5D1Y8UudLVfSrpwpOA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">107600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ"
      decimals="INF"
      id="Narr_EoboCxcPXUaHRPb_kL9d5Q"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">3046358</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_sPnFRiazY0WPCIV18TjFyg"
      decimals="INF"
      id="Narr_CjCaA3v-3ESxnwqzGsEw_g"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">37.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_T3JUh_bQFUWzNCgqWLw-SA"
      decimals="INF"
      id="Narr_Pp_xPPHMakSsFSJ-DllAzQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">456953</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2VW_uzB5fkeRI3qxZyicNA"
      decimals="INF"
      id="Narr_G0sfsuJsLEKCW5-QJ6_qxg"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">37.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_UnderwrittenPublicOfferingMember_r4eOj03kU0CTGwbpOrnNOQ"
      decimals="-5"
      id="Narr_9_Rqj5ctUES5Q-LwTen4jw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">123800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_jDM9HwKEM0mcm45Sz-iJ2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;13. Equity Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;2016, the Company&#x2019;s board of directors and stockholders approved the Company&#x2019;s 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) to replace the 2007 Stock Option Plan. The 2016 Plan is administered by the board of directors, or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2016 Plan expire no later than ten&#160;years from the date of grant. As of September 30, 2021, 524,762 shares were available for issuance under the 2016 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2018, the Company&#x2019;s board of directors approved the 2018 Inducement Plan, as subsequently amended. The 2018 Inducement Plan is a non-stockholder approved stock plan, under which the Company awards options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than ten years from the date of grant. As of September 30, 2021, 243,125 shares were available for issuance under the Amended and Restated 2018 Inducement Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock option activity under the Company&#x2019;s equity incentive and inducement plans is set forth below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,920,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (308,125)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (176,580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercisable &#x2013; September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,121,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and expected to vest &#x2013; September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on September 30, 2021. The calculation excludes options with an exercise price higher than the closing price of the Company&#x2019;s common stock on September 30, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated weighted-average grant-date fair value of common stock underlying options granted to employees during the nine months ended September 30, 2021 was $21.92 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options Valuation Assumptions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of employee stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.02 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27- 6.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;87.4% - 88.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;84.5% - 85.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;87.4% - 90.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.1% - 85.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.85% - 1.16%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 0.40%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.11% - 1.16%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires judgment to determine.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;The Company&#x2019;s expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#x2014;For the year ended December 31, 2020, the Company&#x2019;s expected volatility was estimated based upon a mix of 75% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and 25% of the volatility of the Company&#x2019;s stock price since its initial public offering in August 2016. Beginning January 1, 2021, the Company&#x2019;s expected volatility is estimated based upon a mix of 50% of the average volatility for comparable publicly traded biopharmaceutical &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;companies over a period equal to the expected term of the stock option grants and 50% of the volatility of the Company&#x2019;s stock price since its initial public offering in August 2016.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans is set forth below: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested RSUs at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 302,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested RSUs at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 418,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:6pt 0pt 6pt 0pt;"&gt;Performance stock unit activity under the Company&#x2019;s equity incentive plans is set forth below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs at December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;                 &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 105,500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt;"&gt;During the first quarter of 2021, the Company granted 110,500 PSUs to certain executives of the Company pursuant to the terms of the 2016 Plan. The grant date fair value of the PSUs was $23.57 per share. The terms of the PSUs provide for 100% of shares to be earned based on the achievement of certain pre-determined performance objectives, subject to the participant&#x2019;s continued employment. The PSUs will expire five years from the grant date if the performance objectives are not achieved. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company&#x2019;s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing price of the Company&#x2019;s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest when the achievement of the related performance objective becomes probable. The total fair value of the PSUs granted in February 2021 was $2.6 million. As of September 30, 2021, the achievement of the related performance objective was deemed not probable and, accordingly, no stock-based compensation for the PSUs has been recognized as expense as of September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;) allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation. At the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;end of each offering period, eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the nine months ended September 30, 2021, a total of 43,648 shares of common stock were issued under the 2016 ESPP, and 1,013,999 shares remain available for issuance as of September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,611&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,006&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,098&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,775&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,888&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2021, total unrecognized stock-based compensation expense was approximately $51.5 million, which the Company expects to recognize over a weighted-average period of approximately &lt;span style="white-space:pre-wrap;"&gt;2.9&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_VXWpZKcTTkKp8eVZQhziGw"
      id="Narr_xl6r0NZgQUGOY5eYuVVHzQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_RdllORFsOUWkT56_8WgrPg"
      decimals="INF"
      id="Narr_0VcYX_iFwEik_PZ2RylqYQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">524762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_tOd2A-ZoskaNnweabNr7Ig"
      id="Narr_dx8u4exlTEmMWg89N1KcDA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_MLttZWHz2UiEm3p_zIvcnA"
      decimals="INF"
      id="Narr_pHSsGEivlUuZeGTe-8drtA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">243125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_w0JcREucJUSTKNE1QVbszw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,920,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (308,125)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (176,580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercisable &#x2013; September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,121,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and expected to vest &#x2013; September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on September 30, 2021. The calculation excludes options with an exercise price higher than the closing price of the Company&#x2019;s common stock on September 30, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="INF"
      id="Tc_AAlMzepgEEauKJ9L_Sa8dQ_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">4648120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="2"
      id="Tc_nxKsMPlDp0uVcLjMXqHCGQ_8_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      id="Tc_C1zAudG900ugOvd1DcyFrg_8_7">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A"
      decimals="-5"
      id="Tc_SZA_HdFcBk6tmPWs9oohOw_8_10"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">40000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Tc_NFHZzN79akKcrEtlJQGZbg_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1920540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Tc_7-iK8ffqKUSJtnWztJ8Vnw_9_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">29.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Tc_Al8z0pdx2U2BwVUAlfRGow_10_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">308125</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Tc_2hXWMsXgkEuDSUEEqCQaYw_10_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">9.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Tc_pErEPlZ11UKuRBps72FsKg_11_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">176580</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Tc_LxrT3laa7UCiwM_gBxlbCQ_11_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">16.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Tc_dmiGqPvfGEyNBjWzdV9NOQ_12_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">6083955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="2"
      id="Tc_wC-m7Ed2f0OMuUhiD6agcg_12_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">17.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_NrcbkYWX00i08WopzHVxSg_12_7">P7Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Tc_kEzDuPiAvES2-ixVAEcwsw_12_10"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Tc_eIZ6DGj0vkqvz20shK4VNw_13_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">3121045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="2"
      id="Tc_bTnojJ1U6EarXnXF63s7JA_13_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">12.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_T03xXGs05kW9l0Psqk8XsQ_13_7">P6Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Tc_mW9pwDsrnkuASjaZh8KtrQ_13_10"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">18700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="INF"
      id="Tc_e2JIXmDTmUWJjIYzkD9t5A_14_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">6083955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="2"
      id="Tc_jvvR9SeBPk62z1TALZrXzQ_14_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">17.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tc_NmUatdeAtEG9rtYaxE2Qnw_14_7">P7Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Tc_4u3BGa6HeEGQLQO12DmOpg_14_10"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">27600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Narr_QmeCdPBnLUqI2tg9JykJsw"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">21.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      id="Tb_yUvznez_Xkif5hSUDvrFhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6.02 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27- 6.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;87.4% - 88.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;84.5% - 85.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;87.4% - 90.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.1% - 85.1%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.85% - 1.16%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 0.40%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.11% - 1.16%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NQqJPEuYYU24niCb9tj5og"
      id="Narr_qJ4Xip228kG2uWcPfvpG8g">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEkXG0l4dU-MPpEChb8m2Q"
      id="Narr_LcuHDHnm4km3et_SU65mKA">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OQZenvrZlk6VJmwZFGIrag"
      id="Narr_1RgZvknKwkSwfdeP_9ziPg">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_HO9dXCVgUUKyFTdCLwfdHQ"
      id="Narr_zhIbV8UBskS4_SDx7e_JPA">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MdN54EnQNUy4goQYips2hQ"
      id="Narr_306hDEZ4j0Oo4Ucd6m_Afg">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_rFCznfZHPUidpHv3XziwjA"
      id="Narr_YZZj7UIK6ECENQjacfMgWw">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3v_HJaV_TEawCCjJ-8U_bg"
      id="Narr_73x_z9mg50ib2kXCLDqlJw">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8bkYSfa3AECmsmdja2QoLA"
      id="Narr_W175tND6AUyqn5RBnQgOkQ">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"
      decimals="3"
      id="Narr_vQC4uhSdzkSix-FucAtqVw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"
      decimals="3"
      id="Narr_l34TQ83BUkyw4ZddacWamA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"
      decimals="3"
      id="Narr_LxK6IO4ezU-owLO4_KY7Mw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"
      decimals="3"
      id="Narr_1ElR5kulkkicWmpIWJMyMA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      decimals="3"
      id="Narr_mGYtTFC3aUmMHdBpcTl8YQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      decimals="3"
      id="Narr_2i490yxFQUO4xPheOmw_gg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"
      decimals="3"
      id="Narr_1DTtHP1_RkiITYLcr1_Zrw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"
      decimals="3"
      id="Narr_T1IYapYnrk2_Tsu0cIr-OA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"
      decimals="4"
      id="Narr_YnK00bNQJ06O0Vv4XPTznw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"
      decimals="4"
      id="Narr_FA_OJmCMbUmeZX--00ernw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"
      decimals="4"
      id="Narr_uTIDPFtgTUWUkAWwZ79mJw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"
      decimals="4"
      id="Narr_HpTz4Ial-U-rI3rYxgSCxQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      decimals="4"
      id="Narr_pbCIZZKVNECyaKsABlw_eQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      decimals="4"
      id="Narr_tIvRjKFOckKgcowANKTO2w"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"
      decimals="4"
      id="Narr_aAl333qx9USU6FP9-JXiGQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"
      decimals="4"
      id="Narr_eEw-DQLsZUiIMDuta5nGKg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg"
      decimals="INF"
      id="Tc_Z-6yXHmVkkCSSKxBc4Ecaw_7_2"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hKrk3LkRuE2geqIn9_-_vQ"
      decimals="INF"
      id="Tc_VPvdmohqAE-STU7VOr_gBQ_7_4"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oCx_LC_5N0yUfiYoS9ufdg"
      decimals="INF"
      id="Tc_wHopSw9FIU20kWgp22k7_w_7_6"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MVX0PjxdO0KWY3vFPjov8Q"
      decimals="INF"
      id="Tc_LLtErILH-kqV9v8yzl6I0A_7_8"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      decimals="2"
      id="Narr_Ciuw1SgWd0u-Q7V0Q9G9-A"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.75</ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants>
    <ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
      contextRef="Duration_1_1_2020_To_12_31_2020_q86YZblaSEqm_eisvoAyTw"
      decimals="2"
      id="Narr_L7vjfN4lvka6oZ4yhdLVIw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.25</ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo>
    <ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
      contextRef="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw"
      decimals="2"
      id="Narr_Egi-wMvp3Ee-bx6H6qKCIw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants>
    <ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
      contextRef="Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw"
      decimals="2"
      id="Narr_-B44rNlWo02qw5S8im7JNA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      id="Tb_y8B4shYqG0KDDCa-cxtLoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested RSUs at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 302,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested RSUs at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 418,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ"
      decimals="INF"
      id="Tc_-Lj96MGmiU-xIJUPNaa1Ng_5_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">244545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ"
      decimals="2"
      id="Tc_H2Cjelg8HUabGBL8DHaNvg_5_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">9.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="INF"
      id="Tc_CuGElhMTK0uVAgRoCK5Hzg_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">302250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="2"
      id="Tc_oXyt2yv59kqbtW1t7PfSYA_6_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">24.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="INF"
      id="Tc_GRIBE5ltKkudQSIU_Rcj3Q_7_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">78165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="2"
      id="Tc_QzbAL3ENFU-cVcK1JWtv2g_7_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">10.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="INF"
      id="Tc_995Nl2esa0uh1_NRXLWqhQ_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">49970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA"
      decimals="2"
      id="Tc_vQijrE02Z0y3VF4liAtvpA_8_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">18.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A"
      decimals="INF"
      id="Tc_voN695BjME6BvBOKH2rRfQ_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">418660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_AAQtjJxDb0WpJxd15cqG_A"
      decimals="2"
      id="Tc_8f8wayk88kub4oH3C0_B1Q_9_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">20.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"
      id="Tb_e9x5b02NX0ON6Zwv-e34kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs at December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;                 &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs at September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 105,500&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"
      decimals="INF"
      id="Tc_WVcHtbyv7UerN80ORwOdfQ_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">110500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"
      decimals="2"
      id="Tc_8oTF9gEv1UiZkZ7sa1KM3w_6_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"
      decimals="INF"
      id="Tc_kqF4Z8Z2gEioyNRv2-TNzQ_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g"
      decimals="INF"
      id="Tc_Z9S9lSPkp0aOsLFcFVY6NQ_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">105500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_qpECmod3qEGyD4iKbusL5g"
      decimals="2"
      id="Tc_sTJZn5R64UCThtfe-GZMjg_9_5"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ"
      decimals="INF"
      id="Narr_3V3wGGeatE6hQ_xIesPIQg"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">110500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ"
      decimals="2"
      id="Narr_3EoQwVF0hUqUNPEsfOkSXg"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">23.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ"
      decimals="2"
      id="Narr_4y7lpIYSJkCxrKL17xCOFw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ"
      id="Narr_oiYadHMCIE-rGEdrnhjYAw">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_F2fAANpPG0qxaN1I2cAc1Q"
      decimals="-5"
      id="Narr_AGj38ifyvkSMxbyv_7BIPA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_ehGT5VHYrkSCX0fpmmrPhA"
      decimals="0"
      id="Narr_wg5kzDrW9USA4m2p9Huavg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw"
      decimals="2"
      id="Narr_w72ijA7Uck6KCJ9L-6oKGA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig"
      decimals="2"
      id="Narr_jtOYGLBf0UOrXV1bFgtMow"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_gNw5tcWvRkCfjKjQF-ryig"
      decimals="INF"
      id="Narr_sbWSMS82p0elvDScXk6TqQ"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">43648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw"
      decimals="INF"
      id="Narr_5Ot0oGHC8EqfxenMzse-SA"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">1013999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_rPxn-Ro7YUKA-vRgstK-XQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,611&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,006&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,098&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,775&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,888&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,371&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T0H8ABLR8UW5UTiO70X3Lw"
      decimals="-3"
      id="Tc_TI4EFht7Ok-qSajA6nuEDA_4_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2611000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_a0FuumrKYUO7tJOSkOvu3Q"
      decimals="-3"
      id="Tc_W6GmQbQsZkOa8hreanHOyw_4_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1006000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2I_k75JCq0eeHRkxbMxQXA"
      decimals="-3"
      id="Tc_4CgX2xRsbEew5WXyuOu6Fg_4_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">6241000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l6HbK0TvKE283tUIhVWh1g"
      decimals="-3"
      id="Tc_UiuCpXROBEu8SyU2PubttA_4_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3098000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_AcXFvIPtgkyUmawuHCqSow"
      decimals="-3"
      id="Tc_OgM8RCHW_UyAKPbM8myJtA_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9O0ysWYJAk2T3ppTE9BJ4A"
      decimals="-3"
      id="Tc_2QiirjP2NE2r5sRENAIzXw_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_t-wbdQnITUaC7MfBqxrb9Q"
      decimals="-3"
      id="Tc_6CRLFCaE-0SwWLZ8BCX3jw_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RLO4WIMRGkC7XbCfwot3cw"
      decimals="-3"
      id="Tc_wqIsmyqJVUeF0HiNHx-d1Q_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">2834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_0DEyI0365kOcalzxntSEhw_6_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">4775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_4cs9hb1RWUKY8pOxdsa57g_6_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1888000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_yhEXqGttOkC9hlDz-2wOgw_6_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">11371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_XBGYafnWRk--XMXGTunCog_6_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">5932000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA"
      decimals="-5"
      id="Narr_7RBcB1neEUqjmL0enMODEg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">51500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Narr_Og_mOMmH8kqhs8DSVS0ruw">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_iksScfRBi0WG8QXUtx-Dow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 14. 401(k) Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (&#x201c;401(k)&#160;Plan&#x201d;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company may make contributions to this plan at its discretion. For the three and nine months ended September 30, 2021, the Company plans to match 50%&lt;span style="white-space:pre-wrap;"&gt; of each employee&#x2019;s contribution up to a maximum of $3,500, and recognized expense of approximately $0.1 million and $0.3 million, respectively, relating to these contributions. No contributions were made to the plan by the Company for the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Narr_qtj4OoArD0ulZQ1GueuQ3w"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="2"
      id="Narr_CZ2sZxPaQUe4rbGW3ksFiA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="0"
      id="Narr_wF67uOoOB0qN6yNxuUyVpQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="0"
      id="Narr_KJDfr17BnU2_yxDurTp7SQ"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">3500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-5"
      id="Narr_8a_jXlTjjkK5e62uKhqaUg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-5"
      id="Narr_XKoXZmXUgEKJCsJ629V55A"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="0"
      id="Narr_EdfAsY0se02URu5SO3p36g"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="0"
      id="Narr_qqsOflBaPk6larXbJfKiHA"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_IYHVyED28UyJDlMX6gFz4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;15. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No income tax expense was recorded by the Company during the three and nine months ended September 30, 2021. The Company recorded income tax expense of $1.3 million for the nine months ended September 30, 2020, representing an effective income tax rate of 2.8%. During the second quarter of 2020, the Company&#x2019;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a valuation allowance is necessary for its Australia subsidiary. Income tax expense for the nine months ended September 30, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain tax position liabilities. The Company&#x2019;s effective income tax rate differed from the Company&#x2019;s federal statutory rate of 21%, primarily because its U.S. loss cannot be benefited due to the full valuation allowance position and reduced by foreign taxes. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="0"
      id="Narr_Ljtwvi0EDUSuJj_Coo3sKw"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="0"
      id="Narr_3h4Dahl2zUWjT_IxiD-45w"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-5"
      id="Narr_HVz670uwlUOtg1lRIP07Lg"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">1300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="3"
      id="Narr_pKokhmkwqEunbZi-7ePg7g"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.028</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="INF"
      id="Narr_HN41UxW970-KZBLdYjLgYQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="INF"
      id="Narr_5oCoMYL7Ak2e55M2rknuHQ"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Narr_0y2_Uc07qkWl7AOJBicZkw"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="INF"
      id="Narr_qrxB8KSKC0CYVPAP_pMxPg"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_x_nrzoE22ECZiUrUDrfVZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;16. Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company had net losses for the three and nine months ended September 30, 2021 and 2020, all potential dilutive common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,804)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,987,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,386,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,705,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 32,647,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.70)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.94)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.45)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share computations for the periods presented because their inclusion would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,596,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 418,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 262,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESPP shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,376,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,638,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_vNXqncqtU0Gl39OG6C6daw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,804)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 47,987,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,386,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 45,705,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 32,647,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.70)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.94)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.45)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="-3"
      id="Tc_h5Kw961_X0S7SfTJRwyfMg_5_3"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-33804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-3"
      id="Tc_gLhAegJzy0COO95MoZBrRw_5_6"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-7763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="-3"
      id="Tc_Np7e__s3g06ocw-ZgCf-6Q_5_9"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-88644000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="-3"
      id="Tc_sk4NRceG9k63NHbxWTCWJw_5_12"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">-47264000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="INF"
      id="Tc_qUJqw9u_tkGhxuK_PH-ikg_7_3"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">47987184</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="INF"
      id="Tc_5mETal8IHESrce0yY_NY1A_7_6"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">37386881</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Tc_Dg5fVpomLUuA0ea-tTQ7CQ_7_9"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">45705782</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="INF"
      id="Tc_rC_60f88u06qbbEjIdcLiw_7_12"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">32647524</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg"
      decimals="2"
      id="Tc_W73O8A8d9EKB3NijtoY-7w_8_3"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="2"
      id="Tc_J0mldnjxnEO_vV2xZjDAOw_8_6"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="2"
      id="Tc_X_1vKbYXHUSAOYdqIdFGVQ_8_9"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-1.94</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="2"
      id="Tc_D-ySwlo2YEOhvNDDgTDjcQ_8_12"
      unitRef="Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ">-1.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_zZUFD2o3rEOO6LpLMwaVvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,083,955&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,596,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 418,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 262,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESPP shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,660&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,376,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,638,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbxkG_gzsk-x_bM6qbI8_g"
      decimals="INF"
      id="Tc_AG5xZmpMREiBXNWCdUvoxg_4_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">6083955</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2SpzSmd-Mk2osYBgelFKpg"
      decimals="INF"
      id="Tc_KGMQc-lKU0eWUTTP3QBvOw_4_4"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">4596819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_nTdQkTXU-0S6ergKcYz3vA"
      decimals="INF"
      id="Tc_sB2GCAQe-UGOCMb5OLkeXA_5_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">2750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptgx_CommonStockWarrantsMember_tLWEwGzi6E-KqzZmPdOOrw"
      decimals="INF"
      id="Tc_g-to4f8XPE-FC1ezqOX-dQ_5_4"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">2750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_r1RtIdBqNkaMdBGIaOjSHA"
      decimals="INF"
      id="Tc_L4_aNlFFtEC856hisNKIlA_6_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">418660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_n0Ta9bA0r0Kq2dDdfjjplg"
      decimals="INF"
      id="Tc_vu6nOPP9d0yoN9U-8hKl0w_6_4"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">262608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_1dBmY6pAUU6RcuwSZPcgtQ"
      decimals="INF"
      id="Tc_gC4EgAXO8U6yp9k5DDNpKg_7_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">105500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_YzrwOrK_Z0OF0-Mj3NtBLA"
      decimals="INF"
      id="Tc_WLlLjucglUmCeA6MYXb_6Q_8_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">18660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_GzDm5mfuBEe6F8PeGg2E1g"
      decimals="INF"
      id="Tc_y_XU-L0e6E-85UwER7DKxA_8_4"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">28618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      decimals="INF"
      id="Tc_Q2qG5Z_Wm0ChjxvVoxWLzA_9_2"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">9376775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg"
      decimals="INF"
      id="Tc_67OOgxBEckerjm132I8gCQ_9_4"
      unitRef="Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ">7638045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg"
      id="Tb_DYMDRy1U20mVKnU7jnDodA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 17. Restructuring &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately 12% of the Company&#x2019;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $0.3 million, substantially all of which were related to employee severance and benefits costs.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan
      contextRef="Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ"
      decimals="2"
      id="Narr_Mazj4_1jOEK5wFgY_celEA"
      unitRef="Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw">0.12</ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan>
    <us-gaap:RestructuringCharges
      contextRef="Duration_7_1_2020_To_9_30_2020_-MNWwoX7RkWM7WsdpsNOzg"
      decimals="-5"
      id="Narr_CSF1bGw2MEiBGwGgwGRf1Q"
      unitRef="Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw">300000</us-gaap:RestructuringCharges>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492534952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTAGONIST THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0505495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7707 Gateway Boulevard, Suite&#160;140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94560-1160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">474-0170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTGX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,728,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001377121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810491835080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,542<span></span>
</td>
<td class="nump">$ 117,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">193,759<span></span>
</td>
<td class="nump">188,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from collaboration partner and contract asset - related party</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">2,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,877<span></span>
</td>
<td class="nump">6,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">327,687<span></span>
</td>
<td class="nump">315,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities - noncurrent</a></td>
<td class="nump">38,169<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">373,175<span></span>
</td>
<td class="nump">324,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to collaboration partner - related party</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">33,061<span></span>
</td>
<td class="nump">18,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - related party</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">14,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,156<span></span>
</td>
<td class="nump">40,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - noncurrent</a></td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,515<span></span>
</td>
<td class="nump">44,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value, 90,000,000 shares authorized; 47,671,654 and 43,745,465 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">702,319<span></span>
</td>
<td class="nump">563,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) gain</a></td>
<td class="num">(204)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(372,455)<span></span>
</td>
<td class="num">(283,811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">329,660<span></span>
</td>
<td class="nump">279,606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 373,175<span></span>
</td>
<td class="nump">$ 324,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487806840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">47,671,654<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">47,671,654<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488833464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and collaboration revenue - related party</a></td>
<td class="nump">$ 10,286,000<span></span>
</td>
<td class="nump">$ 13,114,000<span></span>
</td>
<td class="nump">$ 18,740,000<span></span>
</td>
<td class="nump">$ 22,978,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">usgaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">usgaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">usgaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">usgaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 36,956,000<span></span>
</td>
<td class="nump">$ 15,995,000<span></span>
</td>
<td class="nump">$ 87,633,000<span></span>
</td>
<td class="nump">$ 55,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,256,000<span></span>
</td>
<td class="nump">4,891,000<span></span>
</td>
<td class="nump">19,936,000<span></span>
</td>
<td class="nump">13,644,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,212,000<span></span>
</td>
<td class="nump">20,886,000<span></span>
</td>
<td class="nump">107,569,000<span></span>
</td>
<td class="nump">68,664,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,926,000)<span></span>
</td>
<td class="num">(7,772,000)<span></span>
</td>
<td class="num">(88,829,000)<span></span>
</td>
<td class="num">(45,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(471,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(585,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(33,804,000)<span></span>
</td>
<td class="num">(7,763,000)<span></span>
</td>
<td class="num">(88,644,000)<span></span>
</td>
<td class="num">(45,959,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,305,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,804,000)<span></span>
</td>
<td class="num">$ (7,763,000)<span></span>
</td>
<td class="num">$ (88,644,000)<span></span>
</td>
<td class="num">$ (47,264,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">47,987,184<span></span>
</td>
<td class="nump">37,386,881<span></span>
</td>
<td class="nump">45,705,782<span></span>
</td>
<td class="nump">32,647,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810574019992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,804)<span></span>
</td>
<td class="num">$ (7,763)<span></span>
</td>
<td class="num">$ (88,644)<span></span>
</td>
<td class="num">$ (47,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">(Loss) gain on translation of foreign operations</a></td>
<td class="num">(140)<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (33,949)<span></span>
</td>
<td class="num">$ (7,643)<span></span>
</td>
<td class="num">$ (88,876)<span></span>
</td>
<td class="num">$ (47,131)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487710856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>At-the-market offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,846<span></span>
</td>
<td class="num">$ (221)<span></span>
</td>
<td class="num">$ (217,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,011<span></span>
</td>
<td class="nump">105,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,011<span></span>
</td>
<td class="nump">105,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">1,565,840<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,264)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,603<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(264,925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,590<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,846<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="num">(217,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,761,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563,389<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(283,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,606<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,855<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="num">(257,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,802,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">333,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,763)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,603<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(264,925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,590<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563,389<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(283,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,606<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,503,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits', window );">Shares withheld for net settlement of tax withholding upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares', window );">Shares withheld for net settlement of tax withholding upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,319<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="num">(372,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,660<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,671,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,671,654<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,157<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(338,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,447<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,525,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,804)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,319<span></span>
</td>
<td class="num">$ (204)<span></span>
</td>
<td class="num">$ (372,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,660<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,671,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,671,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492123624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (88,644)<span></span>
</td>
<td class="num">$ (47,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,371<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_OperatingLeaseRightOfUseAssetAmortization', window );">Operating lease right-of-use asset amortization</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium (accretion of discount) on marketable securities</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee', window );">Amortization of debt issuance costs and accretion of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Change in deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Receivable from collaboration partner - related party</a></td>
<td class="num">(212)<span></span>
</td>
<td class="nump">3,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,632)<span></span>
</td>
<td class="num">(1,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(2,285)<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Payable to collaboration partner - related party</a></td>
<td class="num">(1,611)<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">14,393<span></span>
</td>
<td class="nump">3,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue - related party</a></td>
<td class="num">(12,236)<span></span>
</td>
<td class="num">(20,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liability</a></td>
<td class="num">(1,493)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(80,926)<span></span>
</td>
<td class="num">(53,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(255,902)<span></span>
</td>
<td class="num">(147,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">213,080<span></span>
</td>
<td class="nump">131,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(905)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(43,727)<span></span>
</td>
<td class="num">(16,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">123,995<span></span>
</td>
<td class="nump">105,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits', window );">Tax withholding payments related to net settlement of restricted stock units</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs related to long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Early repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">127,750<span></span>
</td>
<td class="nump">120,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(148)<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">50,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">33,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">120,767<span></span>
</td>
<td class="nump">84,085<span></span>
</td>
<td class="nump">$ 33,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering | Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock offering</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering | Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember', window );">At-the-market offering | Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember', window );">At-the-market offering | Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing and Investing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ptgx_AccruedLiabilitiesAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ptgx_AccruedLiabilitiesAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487392024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;1.</b></span>Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Protagonist Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) is headquartered in Newark, California. The Company <span style="background-color:#ffffff;">is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform. </span>Protagonist Pty Limited (&#8220;Protagonist Australia&#8221;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. The Company manages its operations as a <span style="-sec-ix-hidden:Hidden_u4SjkEALd06OJORFVCaVuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">single</span></span> operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash, cash equivalents and marketable securities of $352.5 million. The Company has incurred net losses from operations since inception and has an accumulated deficit of $372.5 million as of September&#160;30,&#160;2021. The Company&#8217;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#8217;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under license and collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the&#160;ongoing COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities remains uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#8217;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#8217;s clinical trial sites are located; the development and spread of COVID-19 variants, the timing, extent, effectiveness and durability of COVID-19 vaccine programs or other treatments; and new or continuing travel and other restrictions and public health measures,&#160;such as social distancing, business closures or disruptions. Accordingly, the extent and severity of the impact on the Company's existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company's future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these condensed consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company's future financial condition, liquidity or results of operations remains uncertain.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487282072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;2. </b></span>Summary of Significant Accounting Policies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) and applicable rules&#160;and regulations of the SEC regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the condensed consolidated balance sheet as of&#160;December 31, 2020&#160;has been derived from the Company&#8217;s audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair presentation of the Company&#8217;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2021&#160;are not necessarily indicative of the results to be expected for the&#160;year ending&#160;December 31, 2021&#160;or for any other interim period or for any other future&#160;year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the&#160;year ended&#160;December&#160;31, 2020&#160;included in the Company&#8217;s Annual Report on Form&#160;10-K, filed with the SEC on March&#160;10, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by two financial institutions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that management believes are of high credit quality. Such financial instruments regularly exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March&#160;2017. The letter of credit balance decreased from $0.5 million at December 31, 2020 to $0.2 million at September 30, 2021 pursuant to the terms of the Company&#8217;s May 2017 facility lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Condensed Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,625</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash reported on condensed consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,085</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three&#160;months but no longer than 365&#160;days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive gain or loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, and that expectation is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant </span><span style="background-color:#ffffff;">financing component</span><span style="background-color:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the condensed consolidated balance sheets and within research and development expense in the condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number of locations of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. federal income tax credit on qualifying clinical study expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Tax Incentive</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available.<span style="white-space:pre-wrap;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company granted performance share units (&#8220;PSUs&#8221;) to certain executives of the Company. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes compensation expense over the vesting periods of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260,<i style="font-style:italic;"> Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible, and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholder&#8217;s Equity for additional information regarding the Exchange Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company adopted this guidance effective January 1, 2021 and there was no impact on its condensed consolidated financial statements and disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its condensed consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486704856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member', window );">License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Note&#160;3. License and Collaboration Agreement</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Agreement Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 27, 2021, the Company entered into an amended and restated License and Collaboration Agreement (&#8220;Restated Agreement&#8221;) with Janssen Biotech, Inc., a Pennsylvania corporation (&#8220;Janssen&#8221;). The Restated Agreement amends and restates the License and Collaboration Agreement, dated May 26, 2017, by and between the Company and Janssen (as amended by the First Amendment thereto, effective May 7, 2019, the &#8220;Original Agreement&#8221;). Janssen is a related party to the Company as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp; Johnson. The Original Agreement became effective on July 13, 2017. Upon the effectiveness of the Original Agreement, the Company received a non-refundable, upfront cash payment of $50.0 million from Janssen. Upon the effectiveness of the First Amendment, the Company received a $25.0 million payment from Janssen in 2019. The Company also received a $5.0 million payment triggered by the successful nomination of a second-generation oral Interleukin (&#8220;IL&#8221;)-23 receptor antagonist development compound (&#8220;second-generation compounds&#8221;) during the first quarter of 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement relates to the development, manufacture and commercialization of oral IL-23 receptor antagonist drug candidates. The candidates currently in development as of the balance sheet date pursuant to the Restated Agreement include PTG-200, PN-232 and PN-235. PTG-200 is an oral IL-23 receptor antagonist in that was in Phase 2a development for the treatment of Crohn&#8217;s disease (&#8220;CD&#8221;). PN-232 and PN-235 are second-generation products currently in Phase 1 studies. Janssen is primarily responsible for the conduct of the PTG-200 Phase 2a trial and the Company is primarily responsible for the conduct of the PN-232 and PN-235 Phase 1 studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restated Agreement, the parties have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">amended development milestones to reflect Janssen&#8217;s expected development of collaboration compounds for multiple indications in the IL-23 pathway;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limited the Company&#8217;s further development and related expense obligations under the Restated Agreement to the PTG-200 Phase 2a study, and the ongoing Phase 1 studies in PN-232 and PN-235; Janssen is responsible for all other future development and related expenses under the Restated Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">concluded the parties&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> research collaboration, while enabling Janssen to continue conducting additional research through July 2024 on compounds developed pursuant to the Original Agreement.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement enables Janssen to develop collaboration compounds for multiple indications. Under the Restated Agreement, Janssen is required to use commercially reasonable efforts to develop at least one collaboration compound for at least two indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s development cost obligations in the Original Agreement for the period following the effective date of the Original Agreement were as follows: (a) up to $20.0 million of costs related to up to three Phase 1 studies of second-generation compounds; (b) up to $20.0 million of costs related to Phase 2a and 2b costs for PTG-200 (i.e., 20% of the first $100.0 million in costs); (c) up to $25.0 million in costs related to up to two Phase 2 studies evaluating second-generation compounds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s continuing development expense obligations under the Restated Agreement are as follows: (a) the Company will continue to fund 20% of the costs related to the Phase 2a study evaluating PTG-200 for the treatment of CD (subject to a $20.0 million cap); (b) the Company is responsible for 50% of agreed-upon costs related to the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ongoing Phase 1 study evaluating PN-235 incurred through January 4, 2021; (c) the Company is responsible for 100% of agreed-upon costs related to the ongoing Phase 1 study evaluating PN-232. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s previous development expense obligations under the Original Agreement have been limited or eliminated as follows: (a) the Company&#8217;s previous $25.0 million obligation for 20% of costs related to Phase 2 studies for second-generation products has been eliminated; (b) the Company&#8217;s previous $5.0 million obligation for 50% of the costs of a potential third Phase 1 study evaluating a second-generation compound has been eliminated; and (c) the Company has no obligation to fund any portion of any Phase 2b or other study evaluating PTG-200 beyond the Phase 2a study in CD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One milestone for second-generation Phase 2 development was reduced from $50.0 million to $25.0 million in the Restated Agreement; otherwise, t<span style="white-space:pre-wrap;">he various milestone payment amounts in the Restated Agreement remain substantially the same as in the Original Agreement. To reflect parallel development of multiple indications in the IL-23 pathway, milestone payments under the Restated Agreement generally now correspond to the achievement of specified milestones in: (a) any initial indication (rather than CD, as in the Original Agreement); (b) any second indication (rather than ulcerative colitis (&#8220;UC&#8221;), as in the Original Agreement); and (c) any third indication. With respect to second-generation compounds, milestone payments for second and third indications may be triggered by any second-generation compound (i.e., not necessarily the second-generation compound that triggered the initial payment for any indication, or the payment for a second indication).  In addition, the opt-in payments contemplated by the Original Agreement related to the scope of Janssen&#8217;s license rights have been converted into development milestones in the Restated Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upcoming potential development milestones for second-generation compounds include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for completion of the first Phase 1 clinical trial of a second-generation compound; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication (i.e., an indication different than the indication which triggered the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million milestone described above); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$50.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$15.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for a second indication; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:56.25pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$115.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> million for a Phase 3 clinical trial for a second-generation compound for any indication meeting its primary clinical endpoint.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Development milestones for PTG-200 were unchanged under the Restated Amendment, except that milestone achievement is generally no longer indication-specific. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Restated Agreement, the Company remains eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to ten percent. The sales milestone payments in the Original Agreement also remain the same in the Restated Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to both the Original and Restated Agreements, payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Janssen retains exclusive, worldwide rights to develop and commercialize IL-23 receptor antagonist compounds derived from the research collaboration conducted under the Original Agreement, or Janssen&#8217;s further research under the Restated Agreement. Any further research and development will be conducted by Janssen. The Company will have the right to co-detail (for CD and UC indications) up to two of the IL-23 receptor antagonist compounds under the collaboration in the U.S. market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Restated Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Revenue Recognition</b><span style="font-style:normal;font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Restated Agreement contains a single performance obligation for the development license; Phase 1 development services for PTG-200, PN-232 and PN-235; the Company&#8217;s services associated with Phase 2a development for PTG-200 in CD; the initial year of second-generation compound research services; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200 through Phase 2a and PN-232 and PN-235 through Phase 1. Under the Restated Agreement, development services performed by the Company for PTG-200 beyond Phase 2a and PN-232 and PN-235 beyond Phase 1 are no longer required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the license was not distinct from the revised development services within the context of the agreement because the revised development services did not change the utility of the intellectual property. The Company also concluded that the remaining development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the Restated Agreement of the development license and PTG-200, PN-232 and PN-235 services, including compound supply and other services. Therefore, the Restated Agreement is treated as if it were part of the Original Agreement. The Restated Agreement will be accounted for as if it were a modification of services under the Original Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the Restated Agreement, the Company calculated the adjusted cumulative revenue under the Restated Agreement with primary updates to the transaction price, including the release of and update of prior constraints and fewer remaining services to be provided, resulting in a cumulative adjustment that increased revenue by $8.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the duration of the Restated Agreement began on the Original Agreement effective date of July 13, 2017 and ends upon the later of the end of Phase 2a for PTG-200 in CD or the completion of a Phase 1 clinical trial for either PN-232 or PN-235.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the effective date of the Restated Agreement consists of future milestone payments and cost sharing payments for agreed upon services offset by development costs reimbursable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract are included in the transaction price at the Company&#8217;s share of the estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen related to agreed-upon services for activities that Janssen performs within the duration of the contract are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The transaction price of the initial performance obligation under the Restated Agreement was $105.7 million as of September 30, 2021, an increase of $9.9 million from the transaction price of $95.8 million as of June 30, 2021, under the Original Agreement. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. The transaction price as of September 30, 2021 includes the $80.0 million of nonrefundable payments received to date, $17.9 million of reimbursement from Janssen for services performed for IL-23 receptor antagonist compound research costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">completion of the clinical data collection for Phase 1 activities for PN-235 and $8.4 million of development cost reimbursement receivable from Janssen, partially offset by $8.1 million of net cost reimbursement due to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of September 30, 2021 is not probable. The Company concluded that the variable consideration constraint is appropriately reflected in the estimated transaction price as of September 30, 2021. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation, revenue is recognized as these services are performed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input methods of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $8.0 million, and also recorded $2.3 million of license and collaboration revenue following the contract modification for the Restated Agreement. For the three months ended September 30, 2020, the Company recognized license and collaboration revenue of $12.6 million. In addition, the Company recorded zero and $0.5 million in revenue for the three months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2021, the Company recorded a cumulative catch-up adjustment increasing license and collaboration revenue by $8.0 million, and also recorded $9.9 million of license and collaboration revenue following the contract modification for the Restated Agreement. For the nine months ended September 30, 2020, the Company recognized license and collaboration revenue of $22.0 million. In addition, the Company recorded $0.8 million and $1.0 million in revenue for the nine months ended September 30, 2021 and 2020, respectively, related to additional services provided by the Company under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables present changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,520)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,638</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,477</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,951)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,241</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,450)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,789</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,877</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,299)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,077</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2021, the Company recognized revenue of $0.2 million and $1.7 million, respectively, from amounts included in the deferred revenue contract liability balance at the beginning of each period. During the three and nine months ended September 30, 2020, the Company recognized revenue of $8.5 million and $11.8 million, respectively, for each period from amounts included in the deferred revenue contract liability balance at the beginning of each period. None of the costs to obtain or fulfill the contract were capitalized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810491514216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;4. Fair Value Measurements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 1</i>&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 2&#8212;</i>Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Level 3</i>&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 290,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,863</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 276,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s commercial paper, U.S. Treasury and agency securities, corporate debt securities, U.S. Treasury and agency securities, including U.S. Treasury bills, and supranational and sovereign government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487218376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 5. Cash Equivalents and Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,413</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 348,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 116,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,759</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,169</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,481</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,592</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,590</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,210</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,142</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,144</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,693</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 188,451</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Marketable securities &#8211; current of $193.8 million and $188.5 million held at September 30, 2021 and December&#160;31, 2020, respectively, had contractual maturities of less than <span style="white-space:pre-wrap;">one&#160;year</span><span style="white-space:pre-wrap;">. Marketable securities &#8211; noncurrent of $38.2 million and $2.0 million held at September 30, 2021 and December 31, 2020 had contractual maturities of at least </span><span style="white-space:pre-wrap;">one year</span><span style="white-space:pre-wrap;"> but less than </span><span style="white-space:pre-wrap;">two years</span><span style="white-space:pre-wrap;">. The Company does not intend to sell its securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell its securities before recovery of their amortized cost basis, which may be at maturity. There were no realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485394856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Payables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock', window );">Accrued Expenses and Other Payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Note&#160;6. </b></span>Accrued Expenses and Other Payables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,335</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,413</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,566</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued collaboration payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,498</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of accrued liabilities and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486771384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and Zealand Pharma A/S (&#8220;Zealand&#8221;) entered into a collaboration agreement in June 2012. In October 2013, Zealand abandoned the collaboration, and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#8217;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company previously determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made three development milestone payments for an aggregate amount of $1.0 million under the agreement. However, upon reevaluation, the Company concluded in 2019 that rusfertide is not a compound requiring post-termination payments under the agreement and initiated an </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">arbitration proceeding in January 2020. On August 4, 2021, the Company and Zealand agreed to resolve the dispute and entered into an Arbitration Resolution Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 11. Commitments and Contingencies &#8211; Legal Proceedings for additional information on the results of arbitration proceedings related to this research and collaboration agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. $4.0 million in research and development expense was recorded under the agreement for the three and nine months ended September 30, 2021. No research and development expense was recorded under the Zealand collaboration agreement for the three and nine months ended September 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485295800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Programs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsAbstract', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsDisclosureTextBlock', window );">Government Programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8. Government Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Tax Incentive</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2021, the Company recognized AUD 0.6 million ($0.5 million) and AUD 2.9 million ($2.2 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the three and nine months ended September 30, 2020, the Company recognized AUD 0.4 million ($0.3 million) and AUD 0.8 million ($0.5 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. As of September 30, 2021 and December 31, 2020, the research and development cash tax incentive receivable was AUD 2.6 million ($1.9 million) and AUD 1.4 million ($1.1 million), respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received SBIR grants from the National Institutes of Health (&#8220;NIH&#8221;) in support of research aimed at its product candidates. The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $0.1 million as a reduction of research and development expenses for the nine months ended September 30, 2021. The Company recorded $0.3 million as a reduction of research and development expenses for the nine months ended September 30, 2020. No such amounts were recorded during the three months ended September 30, 2021 and 2020. The Company records a receivable to reflect the eligible costs incurred under the grants that are contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the condensed consolidated balance sheets. There was no such receivable as of September 30, 2021 or December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the government programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485338456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Facility</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 9.   Term Loan Facility </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#8220;Closing Date&#8221;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#8220;Agent&#8221;) (such agreement, the &#8220;Term Loan Credit Agreement&#8221;), which provided for a $50.0 million term loan facility. The Term Loan Credit Agreement provided for (i) on the Closing Date, $10.0 million aggregate principal amount of term loans, (ii) at the Company&#8217;s option, until December 31, 2020, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#8217;s option, until September 30, 2021, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#8220;Term Loans&#8221;). The Company used proceeds from drawdowns on the Term Loans for general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Term Loans were subject to an origination fee of 0.25% for each funded tranche under the Term Loan Credit Agreement and bore interest at an annual rate based on prime rate plus 2.91%, subject to a prime rate floor of 4.94%. At the Company&#8217;s option, the Company could prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of 3.0% of any amount prepaid if the prepayment occurred through and including the first anniversary of the Closing Date, 2.0% of the amount prepaid if the prepayment occurred after the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">first anniversary of the closing date through and including the second anniversary of the closing date, and 1.0% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of 2.85% of the amount of Term Loans advanced by the Lenders was due upon prepayment or repayment of the Term Loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Term Loan Credit Agreement required the Company to maintain cash and cash equivalents of at least 35% of the outstanding Term Loans at all times and was secured by a perfected security interest in all of the Company's assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contained other covenants that limit the Company&#8217;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balance above a certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants would result in default for the Company. The Term Loan Credit Agreement included a clause which allowed lenders to accelerate repayment upon the occurrence of certain events of default. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company prepaid the outstanding $10.0 million balance on the term loan as well as $0.6 million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $0.1 million related to capitalized and unamortized debt issuance costs, which is included as part of the $0.6 million loss on early repayment of debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company executed a payoff letter to release all obligations under the Term Loan Credit Agreement. As a result, the Company had no outstanding balance and no obligations related to the Term Loan Credit Agreement as of September 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486686680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC 842, to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company has elected to account for each separate lease component and non-lease components as one single component for all lease assets. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has one operating lease agreement entered into in March 2017 for approximately 42,900 square feet of laboratory and office space located in Newark, California. The Company provided the landlord with a $450,000 letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. The security deposit for the lease was later reduced to $225,000 in March 2021. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 2, 2021, the Company entered into an amendment (the &#8220;Second Amendment&#8221;) to its facility lease agreement dated as of March 2017, as amended, to lease approximately 15,000 square feet of additional office space in Newark, California. The Company commenced operations in the additional space in September 2021. Under the Second Amendment, the Company will pay additional base rent of approximately $1.5 million over the lease term, which expires in May 2024. As a result of this amendment, the Company recorded an additional right-of-use asset and the related <span style="-sec-ix-hidden:Hidden_W9bIUIMLtUuXqk-5ssyS9Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">liability</span></span><span style="white-space:pre-wrap;"> of $1.4 million as of September 30, 2021. The Company will be responsible for its proportional share of operating expenses and tax obligations. No additional security deposit was required pursuant to the Second Amendment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides balance sheet information related to operating leases is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_If59OPpEK02lxvyiRk3sOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,950</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VdeOmiqn-EmGbvHLuN1aAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,027</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,459</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_K67XINXtckW2yeWVvsxsDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b6WSSFcN8kyrZANs0pC1gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,265</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,959</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.4</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.6%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Other information related to the Company&#8217;s operating leases is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,331</p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,310</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental cash flow information is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,493</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New operating lease asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Future lease payments required under lease obligations as of September&#160;30, 2021 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 556</p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,660</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,744</p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,160</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,120</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (855)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,265</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486674232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Legal Proceedings </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accruals for legal actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand related to a collaboration agreement the Company and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 4, 2021, the Company and Zealand agreed to resolve the dispute and reached an Arbitration Resolution Agreement. Under the Arbitration Resolution Agreement, (1) the Company is required to make an additional payment of $1.5 million to Zealand in August 2022 with respect to rusfertide, (2) all development milestones with respect of rusfertide have been reduced by 50%, except that the Company agreed to pay in full within two (2) business days after the effective date of the Agreement (and timely paid): (i) a $1.0 million milestone for initiation of a Phase 2b clinical trial; and (ii) a $1.5 million milestone for initiation of a Phase 3 clinical trial; (3) the royalty rate payable by the Company on net sales of rusfertide has been reduced by 50%; (4) all sales milestone payments on net sales of rusfertide have been reduced by 50%; (5) the parties agreed that each party will retain all payments previously made by the other party in connection with the original collaboration agreement; and (6) the parties have released claims related to the original collaboration agreement, the abandonment agreement and the arbitration. In addition to the payments specified in items (1) and (2) above, the Company may also be required to pay Zealand up to $2.75 million in future development milestone payments relating to rusfertide. Those payments include up to $1.0 million in the aggregate for registrational proposals and up to $1.75 million in the aggregate for commercial launch in the three geographic territories specified in the original collaboration agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company considered the outcome of these arbitration proceedings as being related to its research and development project; therefore, payments or milestone payments were recorded as research and development expenses. As a result, no related legal accruals were recognized as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485363640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company sold an aggregate of 2,750,000 shares of its common stock at a price of $8.00 per share, for aggregate net proceeds of $21.7 million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of 2,750,000 shares of its common stock (each, a &#8220;Warrant&#8221; and, collectively, the &#8220;Warrants&#8221;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase 1,375,000 shares of the Company&#8217;s common stock have an exercise price of $10.00 per share and Warrants to purchase 1,375,000 shares of the Company&#8217;s common stock have an exercise price of $15.00 per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480<i style="font-style:italic;">, </i>Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;), and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of September 30, 2021, none of the Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2018, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with an Investor and its affiliates (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company&#8217;s common stock, par value $0.00001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company&#8217;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,<i style="font-style:italic;"> Equity</i>, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480<i style="font-style:italic;">,</i> and fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September 30, 2021, 400,000 of the Exchange Warrants remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company filed a registration statement on Form S-3 (File No. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $250.0 million of its common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, 2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, the Company completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share and issued an additional 1,050,000 shares of its common stock at a price of $14.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $105.3 million. As of September 30, 2021, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;">In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which it completed an underwritten public offering of 4,761,904 shares of the Company&#8217;s common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of common stock at a price of $21.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $107.6 million. In June 2021, pursuant to Registration Statement No. 33-251254, the Company completed an underwritten public offering of 3,046,358 shares of its common stock at a public offering price of $37.75 per share and issued an additional 456,953 shares of common stock at a price of $37.75 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $123.8 million. The Form S-3ASR expires in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488163960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;13. Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) to replace the 2007 Stock Option Plan. The 2016 Plan is administered by the board of directors, or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2016 Plan expire no later than ten&#160;years from the date of grant. As of September 30, 2021, 524,762 shares were available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2018, the Company&#8217;s board of directors approved the 2018 Inducement Plan, as subsequently amended. The 2018 Inducement Plan is a non-stockholder approved stock plan, under which the Company awards options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than ten years from the date of grant. As of September 30, 2021, 243,125 shares were available for issuance under the Amended and Restated 2018 Inducement Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option activity under the Company&#8217;s equity incentive and inducement plans is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40.0</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,920,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (308,125)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (176,580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17.54</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.58</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27.6</p></td></tr><tr><td style="vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable &#8211; September&#160;30,&#160;2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,121,045</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.89</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18.7</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest &#8211; September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17.54</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.58</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27.6</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on September 30, 2021. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on September 30, 2021.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated weighted-average grant-date fair value of common stock underlying options granted to employees during the nine months ended September 30, 2021 was $21.92 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options Valuation Assumptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of employee stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.02 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27- 6.08</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">87.4% - 88.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">84.5% - 85.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">87.4% - 90.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.1% - 85.1%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.85% - 1.16%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 0.40%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.11% - 1.16%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 1.44%</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8212;For the year ended December 31, 2020, the Company&#8217;s expected volatility was estimated based upon a mix of 75% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and 25% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016. Beginning January 1, 2021, the Company&#8217;s expected volatility is estimated based upon a mix of 50% of the average volatility for comparable publicly traded biopharmaceutical </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">companies over a period equal to the expected term of the stock option grants and 50% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans is set forth below: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 244,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.31</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24.40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,165)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.13</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.86</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 418,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.07</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Performance Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:6pt 0pt 6pt 0pt;">Performance stock unit activity under the Company&#8217;s equity incentive plans is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">                 &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23.57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23.57</p></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.7pt;margin:0pt;">During the first quarter of 2021, the Company granted 110,500 PSUs to certain executives of the Company pursuant to the terms of the 2016 Plan. The grant date fair value of the PSUs was $23.57 per share. The terms of the PSUs provide for 100% of shares to be earned based on the achievement of certain pre-determined performance objectives, subject to the participant&#8217;s continued employment. The PSUs will expire five years from the grant date if the performance objectives are not achieved. The PSUs will vest, if at all, upon certification by the Compensation Committee of the Company&#8217;s Board of Directors of the actual achievement of the performance objectives, subject to specified change of control exceptions. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest when the achievement of the related performance objective becomes probable. The total fair value of the PSUs granted in February 2021 was $2.6 million. As of September 30, 2021, the achievement of the related performance objective was deemed not probable and, accordingly, no stock-based compensation for the PSUs has been recognized as expense as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation. At the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">end of each offering period, eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the nine months ended September 30, 2021, a total of 43,648 shares of common stock were issued under the 2016 ESPP, and 1,013,999 shares remain available for issuance as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total stock-based compensation expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,006</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,098</p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,834</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,775</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,888</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,932</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, total unrecognized stock-based compensation expense was approximately $51.5 million, which the Company expects to recognize over a weighted-average period of approximately <span style="white-space:pre-wrap;">2.9</span><span style="white-space:pre-wrap;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486666424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14. 401(k) Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (&#8220;401(k)&#160;Plan&#8221;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company may make contributions to this plan at its discretion. For the three and nine months ended September 30, 2021, the Company plans to match 50%<span style="white-space:pre-wrap;"> of each employee&#8217;s contribution up to a maximum of $3,500, and recognized expense of approximately $0.1 million and $0.3 million, respectively, relating to these contributions. No contributions were made to the plan by the Company for the three and nine months ended September 30, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486774856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;15. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No income tax expense was recorded by the Company during the three and nine months ended September 30, 2021. The Company recorded income tax expense of $1.3 million for the nine months ended September 30, 2020, representing an effective income tax rate of 2.8%. During the second quarter of 2020, the Company&#8217;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a valuation allowance is necessary for its Australia subsidiary. Income tax expense for the nine months ended September 30, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain tax position liabilities. The Company&#8217;s effective income tax rate differed from the Company&#8217;s federal statutory rate of 21%, primarily because its U.S. loss cannot be benefited due to the full valuation allowance position and reduced by foreign taxes. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486508456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;16. Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As the Company had net losses for the three and nine months ended September 30, 2021 and 2020, all potential dilutive common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,804)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,264)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,987,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,386,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,705,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 32,647,524</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.70)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.94)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.45)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share computations for the periods presented because their inclusion would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,596,819</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,750,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262,608</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESPP shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,618</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,376,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,638,045</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487210568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17. Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately 12% of the Company&#8217;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $0.3 million, substantially all of which were related to employee severance and benefits costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485095496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) and applicable rules&#160;and regulations of the SEC regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the condensed consolidated balance sheet as of&#160;December 31, 2020&#160;has been derived from the Company&#8217;s audited consolidated financial statements at that date but does not include all of the information required by GAAP for complete consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair presentation of the Company&#8217;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2021&#160;are not necessarily indicative of the results to be expected for the&#160;year ending&#160;December 31, 2021&#160;or for any other interim period or for any other future&#160;year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the&#160;year ended&#160;December&#160;31, 2020&#160;included in the Company&#8217;s Annual Report on Form&#160;10-K, filed with the SEC on March&#160;10, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by two financial institutions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that management believes are of high credit quality. Such financial instruments regularly exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S. portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March&#160;2017. The letter of credit balance decreased from $0.5 million at December 31, 2020 to $0.2 million at September 30, 2021 pursuant to the terms of the Company&#8217;s May 2017 facility lease. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash as Reported in Condensed Consolidated Statements of Cash Flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Condensed Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,625</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash reported on condensed consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,085</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three&#160;months but no longer than 365&#160;days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive gain or loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, and that expectation is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant </span><span style="background-color:#ffffff;">financing component</span><span style="background-color:#ffffff;">. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the condensed consolidated balance sheets and within research and development expense in the condensed consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number of locations of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. federal income tax credit on qualifying clinical study expenditures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock', window );">Research and Development Tax Incentive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Tax Incentive</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available.<span style="white-space:pre-wrap;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company granted performance share units (&#8220;PSUs&#8221;) to certain executives of the Company. Stock-based compensation expense associated with PSUs is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes compensation expense over the vesting periods of the awards that are ultimately expected to vest when the achievement of the related performance obligation becomes probable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260,<i style="font-style:italic;"> Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible, and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholder&#8217;s Equity for additional information regarding the Exchange Warrants. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company adopted this guidance effective January 1, 2021 and there was no impact on its condensed consolidated financial statements and disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its condensed consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and development incentive grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485414952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash as reported in the consolidated statements of cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the condensed consolidated statements of cash flows consists of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,625</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash reported on condensed consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,085</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810583476824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementDisclosureAbstract', window );"><strong>License and Collaboration Agreement.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of changes in contract assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables present changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,520)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,638</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,477</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,715</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,951)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,241</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,284</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,450)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,789</p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,877</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,299)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,077</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487230136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 290,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,863</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 276,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 304,144</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810485376856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,077</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 161,312</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,413</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,392</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42,187</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supranational and sovereign government securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,028</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 348,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 116,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,759</p></td></tr><tr><td style="vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,169</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 347,996</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,481</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,592</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,590</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,210</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,142</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,144</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,693</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 188,451</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:49.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,144</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486682216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,335</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,413</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,566</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued collaboration payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;width:65.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,498</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486715912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LeaseBalanceSheetDisclosureTableTextBlock', window );">Schedule of balance sheet information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_If59OPpEK02lxvyiRk3sOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,950</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VdeOmiqn-EmGbvHLuN1aAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,027</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,459</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_K67XINXtckW2yeWVvsxsDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b6WSSFcN8kyrZANs0pC1gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,265</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,959</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.4</p></td></tr><tr><td style="vertical-align:bottom;width:65.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.6%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11.0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,331</p></td></tr><tr><td style="vertical-align:bottom;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:65.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,310</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,309</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LeaseCashFlowInformationDisclosureTableTextBlock', window );">Schedule of cash flow information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,493</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New operating lease asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> -</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum lease payments and lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 556</p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,660</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,744</p></td></tr><tr><td style="vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,160</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,120</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (855)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:80.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,265</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LeaseBalanceSheetDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LeaseBalanceSheetDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LeaseCashFlowInformationDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LeaseCashFlowInformationDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488856440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of activity under equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40.0</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,920,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (308,125)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (176,580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17.54</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.58</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27.6</p></td></tr><tr><td style="vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable &#8211; September&#160;30,&#160;2021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,121,045</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.89</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18.7</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest &#8211; September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17.54</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.58</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27.6</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on September 30, 2021. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on September 30, 2021.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total stock-based compensation expense was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,006</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,098</p></td></tr><tr><td style="vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,834</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,775</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,888</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,932</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes option-pricing model assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6.02 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27- 6.08</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">87.4% - 88.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">84.5% - 85.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">87.4% - 90.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.1% - 85.1%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.85% - 1.16%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 0.40%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.11% - 1.16%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 1.44%</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of activity under equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 244,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.31</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24.40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,165)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.13</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.86</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested RSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 418,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20.07</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of performance stock unit activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">                 &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23.57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested PSUs at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23.57</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486691384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of the basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,804)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,264)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,987,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,386,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,705,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 32,647,524</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.70)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.94)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.45)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from diluted net loss per share calculations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,083,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,596,819</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,750,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262,608</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESPP shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,660</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,618</p></td></tr><tr><td style="vertical-align:bottom;width:69.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,376,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,638,045</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810489253592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Liquidity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsNoteDisclosureAbstract', window );"><strong>Net losses from operations since inception</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 352,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (372,455)<span></span>
</td>
<td class="num">$ (283,811)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486745512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Institution</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashNumberOfFinancialInstitutions', window );">Number of financial institutions at which cash is held</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashNumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of financial institutions that hold the entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashNumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488036248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Aggregate amounts of cash and cash equivalents and the restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,542<span></span>
</td>
<td class="nump">$ 117,358<span></span>
</td>
<td class="nump">$ 83,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash reported on condensed consolidated statements of cash flows</a></td>
<td class="nump">120,767<span></span>
</td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">$ 84,085<span></span>
</td>
<td class="nump">$ 33,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Aggregate amounts of cash and cash equivalents and the restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486704856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice', window );">Number of performance obligation</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientAbstract', window );"><strong>Revenue, Practical Expedient [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientFinancingComponent', window );">Financing component</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold number of performance obligation to allocate transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientFinancingComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130569-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientFinancingComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486598120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>AUD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit', window );">Potential Federal income tax credit discount</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Australian</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria', window );">Revenue for availability of research and development tax incentive</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the potential Federal income tax credit discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The revenue criteria for availability of a research and development tax incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810482384824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Jul. 13, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Recognized revenue from deferred revenue contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase (decrease) in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | License and Collaboration Agreement | Phase 3 clinical trial for a second-generation compound for any indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | License and Collaboration Agreement | Completion of clinical data collection for Phase 1 activities for the first of either PN-232 or PN-235</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DurationOfResearchCollaborationAgreement', window );">Duration of the parties' research collaboration agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Three phase 1 studies of second-generation compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DevelopmentCostsEliminated', window );">Expense obligations eliminated</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated', window );">Percentage of development cost eliminated</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Phase 2a and 2b costs for PTG-200</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost incurred, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Phase 2 studies for second-generation products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated', window );">Percentage of development cost eliminated</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Three phase 1 studies of second-generation compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Phase 2a and 2b costs for PTG-200</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Phase 2 studies for second-generation products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DevelopmentCostsEliminated', window );">Expense obligations eliminated</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Original Agreement | Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ReimbursementForServicesPerformed', window );">Reimbursement for services performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PercentagesRoyaltiesOnNetProductSales', window );">Maximum percentages royalties on net product sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase (decrease) in transaction price</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | Second-generation Oral Interleukin ("IL")-23 Receptor Antagonist Development Compound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementEligibleAmountReceived', window );">Eligible amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | Phase 2a study evaluating PTG-200 for the treatment of CD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost incurred, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | Services performed for IL-23 receptor antagonist compound research costs and other services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ReimbursementForServicesPerformed', window );">Reimbursement for services performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | Additional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementEligibleAmountReceived', window );">Eligible amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Collaboration revenue recorded following the contract modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Phase 1 studies of second-generation compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated', window );">Percentage of development cost eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_UpcomingPotentialDevelopmentMilestonesPayment', window );">Upcoming potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Phase 2 studies for second-generation products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_UpcomingPotentialDevelopmentMilestonesPayment', window );">Upcoming potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_UpcomingPotentialDevelopmentMilestonesPayment', window );">Upcoming potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Phase 2a study evaluating PTG-200 for the treatment of CD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost incurred, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_UpcomingPotentialDevelopmentMilestonesPayment', window );">Upcoming potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Dosing Of Third Patient In Phase 3 Clinical Trial For Second Generation Compound For A Second Indication [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | Restated Agreement | License and Collaboration Agreement | Maximum | Phase 2a study evaluating PTG-200 for the treatment of CD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable', window );">Development cost payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment based on the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementEligibleAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount received from a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementEligibleAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of development cost incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of development cost eliminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DevelopmentCostsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development costs that have been eliminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DevelopmentCostsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DurationOfResearchCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of the parties' research collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DurationOfResearchCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PercentagesRoyaltiesOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentages on net product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PercentagesRoyaltiesOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ReimbursementForServicesPerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reimbursement for services performed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ReimbursementForServicesPerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of development cost payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payable under the research and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_UpcomingPotentialDevelopmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upcoming potential development milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_UpcomingPotentialDevelopmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForAnyIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForAnyIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_OriginalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_OriginalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aEvaluatingPtg200Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aEvaluatingPtg200Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_Ptg200PhaseAndSecondGenerationCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_Ptg200PhaseAndSecondGenerationCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_FinancialServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_FinancialServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseTwoClinicalTrialSecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseTwoClinicalTrialSecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810573679720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityNetRollForward', window );"><strong>Deferred revenue - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">$ 14,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at End of Period</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract', window );"><strong>Payable to collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at End of Period</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetNetRollForward', window );"><strong>Receivable from collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at Beginning of Period</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">$ 5,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">5,732<span></span>
</td>
<td class="nump">5,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetDeduction', window );">Deductions</a></td>
<td class="num">(5,520)<span></span>
</td>
<td class="num">(8,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at End of Period</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract asset - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract asset - related party, Balance at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetRelatedPartyAdditions', window );">Contract asset - related party, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetRelatedPartyDeduction', window );">Contract asset - related party, Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityNetRollForward', window );"><strong>Deferred revenue - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">14,477<span></span>
</td>
<td class="nump">41,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">16,715<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityDeduction', window );">Deductions</a></td>
<td class="num">(28,951)<span></span>
</td>
<td class="num">(24,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at End of Period</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">20,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract', window );"><strong>Payable to collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DueToRelatedPartyAdditions', window );">Additions</a></td>
<td class="nump">9,785<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DueToRelatedPartyDeductions', window );">Deductions</a></td>
<td class="num">(11,396)<span></span>
</td>
<td class="num">(1,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at End of Period</a></td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetRelatedPartyAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetRelatedPartyAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetRelatedPartyDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetRelatedPartyDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DueToRelatedPartyAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional amount of payable due to a related party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DueToRelatedPartyAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DueToRelatedPartyDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction from obligation to transfer good or service to related party for payable amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DueToRelatedPartyDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PayableToCollaborationPartnerRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492332216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 347,996<span></span>
</td>
<td class="nump">$ 304,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">57,077<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">161,312<span></span>
</td>
<td class="nump">65,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,187<span></span>
</td>
<td class="nump">183,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">81,392<span></span>
</td>
<td class="nump">27,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Supranational and sovereign government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">57,077<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">57,077<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">290,919<span></span>
</td>
<td class="nump">276,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">161,312<span></span>
</td>
<td class="nump">65,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,187<span></span>
</td>
<td class="nump">183,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">81,392<span></span>
</td>
<td class="nump">$ 27,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Supranational and sovereign government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 6,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_SupranationalAndSovereignGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_SupranationalAndSovereignGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492608280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">$ 348,019<span></span>
</td>
<td class="nump">$ 304,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">347,996<span></span>
</td>
<td class="nump">304,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">42,186<span></span>
</td>
<td class="nump">183,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">42,187<span></span>
</td>
<td class="nump">183,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">81,413<span></span>
</td>
<td class="nump">27,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">81,392<span></span>
</td>
<td class="nump">27,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=ptgx_SupranationalAndSovereignGovernmentSecuritiesMember', window );">Supranational and sovereign government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">6,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">6,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">57,077<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">57,077<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">161,315<span></span>
</td>
<td class="nump">65,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">$ 161,312<span></span>
</td>
<td class="nump">$ 65,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_SupranationalAndSovereignGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_SupranationalAndSovereignGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810491398056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 116,068<span></span>
</td>
<td class="nump">$ 113,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities - current</a></td>
<td class="nump">193,759<span></span>
</td>
<td class="nump">188,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities - noncurrent</a></td>
<td class="nump">38,169<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 347,996<span></span>
</td>
<td class="nump">$ 304,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Contractual maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CurrentContractualMaturitiesMaximumPeriod', window );">Maximum period of current contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NoncurrentContractualMaturitiesMinimumPeriod', window );">Minimum period of noncurrent contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NoncurrentContractualMaturitiesMaximumPeriod', window );">Maximum period of Noncurrent contractual maturities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CurrentContractualMaturitiesMaximumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of current contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CurrentContractualMaturitiesMaximumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NoncurrentContractualMaturitiesMaximumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NoncurrentContractualMaturitiesMaximumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NoncurrentContractualMaturitiesMinimumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period of noncurrent contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NoncurrentContractualMaturitiesMinimumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810600010504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent', window );">Accrued clinical and research related expenses</a></td>
<td class="nump">$ 24,482<span></span>
</td>
<td class="nump">$ 11,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee related expenses</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="nump">6,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional service fees</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AccruedMilestonePaymentToFormerCollaborationPartner', window );">Accrued milestone payment to former collaboration partner</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other payables</a></td>
<td class="nump">$ 33,061<span></span>
</td>
<td class="nump">$ 18,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of accrued clinical and research related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AccruedMilestonePaymentToFormerCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of accrued milestone payment to former collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AccruedMilestonePaymentToFormerCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486418856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfDevelopmentMilestonePayments', window );">Number of development milestone payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AggregateAmountOfDevelopmentMilestonePayment', window );">Aggregate development milestone payment | $</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AggregateAmountOfDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of development milestone payment made by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AggregateAmountOfDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of development milestone payments in collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810573602872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Programs (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember', window );">SBIR Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentExpensesReduction', window );">Reduction to research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentExpensesReduction', window );">Reduction to research and development expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember', window );">Overseas Findings | Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentExpensesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reduction of research and development expense in connection with the research and development tax incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentExpensesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492546216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan facility for general corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentTrancheInstallmentAmount', window );">Tranche Installment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance', window );">Cash and cash equivalents ( In percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentLoanOriginationFeePercentage', window );">Loan Origination Fee (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage', window );">Additional Prepayment (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance paid</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Prepayment and exit fees</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Accelerated capitalized and unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">prime rate (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentFloorRate', window );">Floor rate (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember', window );">Debt Instrument Repayment On Or Before First Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember', window );">Debt Instrument Repayment Between First And Second Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember', window );">Debt Instrument Repayment After Second Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the floor rate of the debt instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentLoanOriginationFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of loan origination fee under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentLoanOriginationFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of prepayment premium under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentTrancheInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the tranche installment amount under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentTrancheInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492342360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,959,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Newark, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfOperatingLeaseAgreement', window );">Number of operating lease agreement | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Newark, California | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Additional base rent over the lease term</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AdditionalSecurityDeposit', window );">Additional security deposit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AdditionalSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional security deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AdditionalSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfOperatingLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of operating lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfOperatingLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_FacilityLeaseAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_FacilityLeaseAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810489176424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental balance sheet information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">Operating lease right-of-use asset<span></span>
</td>
<td class="text">Operating lease right-of-use asset<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">$ 2,027<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">Operating lease liability - current<span></span>
</td>
<td class="text">Operating lease liability - current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - noncurrent</a></td>
<td class="nump">$ 4,238<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">Operating lease liability - noncurrent<span></span>
</td>
<td class="text">Operating lease liability - noncurrent<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 6,265<span></span>
</td>
<td class="nump">$ 5,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486587704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted average lease term and discount rate (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810486548376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease cost information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,378<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Less: sublease income</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 1,310<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810598523304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash flow information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow used by operating leases</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">New operating lease asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810484215800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future lease payments required under lease obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 6,265<span></span>
</td>
<td class="nump">$ 5,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810581316824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfBusinessDays', window );">Number Of Business Days</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember', window );">Zealand Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember', window );">Zealand Pharma | Arbitration Resolution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable', window );">Additional milestone payment</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage', window );">Litigation Settlement, Collaborative Arrangement Milestone Payment Reduction Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_RoyaltiesOnNetProductSalesPercentagesReduction', window );">Percentage of reduction in royalty payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage', window );">Percentage of sales milestone reductions</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable', window );">Future development milestone payable</a></td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable', window );">Registration proposal payable</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable', window );">Commercial launch expenses</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfGeographicTerritories', window );">Number of geographic territories | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember', window );">Zealand Pharma | Arbitration Resolution Agreement | Phase 2 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember', window );">Zealand Pharma | Arbitration Resolution Agreement | Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable', window );">Milestone payment</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future development milestone including commercial launch expenses for launch in the three geographic territories payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future development milestone payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future development milestone including registration proposal payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfGeographicTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of geographic territories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfGeographicTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Collaboration Agreement Development Additional Milestone Payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payable under the research and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_RoyaltiesOnNetProductSalesPercentagesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in royalty payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_RoyaltiesOnNetProductSalesPercentagesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ptgx_ArbitrationResolutionAgreementWithZealandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ptgx_ArbitrationResolutionAgreementWithZealandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810490268504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,995<span></span>
</td>
<td class="nump">$ 105,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember', window );">2019 Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_FinancingFacilitySalesAgreementMember', window );">2019 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_UnderwrittenPublicOfferingMember', window );">Underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,800<span></span>
</td>
<td class="nump">$ 105,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,046,358<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.75<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">underwritten public offering, Additional offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,953<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.75<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,503,311<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="nump">4,761,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | underwritten public offering, Additional offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember', window );">Investors | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock sold, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  08,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember', window );">Exchange Agreement | Exchanging Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockExchangedForPreFundedWarrants', window );">Common stock exchanged for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ClassOfWarrantOrRightTermOfWarrants', window );">Duration of warrants from date of issuance (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember', window );">Exchange Agreement | Exchanging Stockholders | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Remaining number of Exchange Warrants unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember', window );">$10.00 per share | Investors | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember', window );">$15.00 per share | Investors | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ClassOfWarrantOrRightTermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of warrants from date of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ClassOfWarrantOrRightTermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SaleOfStockValueOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of shares permits the offering, issuance, and sale by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SaleOfStockValueOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockExchangedForPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares exchanged for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockExchangedForPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_FinancingFacilitySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_FinancingFacilitySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_BiotechnologyValueFundL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_BiotechnologyValueFundL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810573596264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants', window );">Average volatility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo', window );">Percentage of volatility of stock options since IPO</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember', window );">2018 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810574290440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="nump">4,648,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Options granted</a></td>
<td class="nump">1,920,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Options exercised</a></td>
<td class="num">(308,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Options Outstanding, Options forfeited</a></td>
<td class="num">(176,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">6,083,955<span></span>
</td>
<td class="nump">4,648,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable</a></td>
<td class="nump">3,121,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Options vested and expected to vest</a></td>
<td class="nump">6,083,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Beginning balance</a></td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options granted</a></td>
<td class="nump">29.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="nump">9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options forfeited</a></td>
<td class="nump">16.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Ending balance</a></td>
<td class="nump">17.54<span></span>
</td>
<td class="nump">$ 11.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercisable</a></td>
<td class="nump">12.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options vested and expected to vest</a></td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (years), Options exercisable</a></td>
<td class="text">6 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest</a></td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options Outstanding</a></td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest</a></td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, weighted-average grant-date fair value</a></td>
<td class="nump">$ 21.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810492684008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Stock Options Valuation Assumptions (Details) - Options to purchase common stock<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">84.50%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">72.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">88.40%<span></span>
</td>
<td class="nump">85.10%<span></span>
</td>
<td class="nump">90.20%<span></span>
</td>
<td class="nump">85.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.85%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.16%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in year)</a></td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in year)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810574228872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Restricted Stock Units - (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, Beginning balance</a></td>
<td class="nump">244,545<span></span>
</td>
<td class="nump">244,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, Beginning balance</a></td>
<td class="nump">$ 9.31<span></span>
</td>
<td class="nump">$ 9.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">110,500<span></span>
</td>
<td class="nump">110,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810583603752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Performance Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,371,000<span></span>
</td>
<td class="nump">$ 5,932,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,500<span></span>
</td>
<td class="nump">110,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Grant date fair value, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage of requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of stock units</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487280680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 11,371<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member', window );">2016 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum payroll deduction for share purchases (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of stock (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period</a></td>
<td class="nump">43,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">1,013,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810491642024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,775<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 11,371<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation costs related to stock options</a></td>
<td class="nump">51,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized stock-based compensation costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">$ 6,241<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,164<span></span>
</td>
<td class="nump">$ 882<span></span>
</td>
<td class="nump">$ 5,130<span></span>
</td>
<td class="nump">$ 2,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488053912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Company match contribution, maximum</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions expense recognized</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810487084136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective tax rate of provision for income taxes difference from federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810488035064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,804)<span></span>
</td>
<td class="num">$ (7,763)<span></span>
</td>
<td class="num">$ (88,644)<span></span>
</td>
<td class="num">$ (47,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per common share, basic and diluted</a></td>
<td class="nump">47,987,184<span></span>
</td>
<td class="nump">37,386,881<span></span>
</td>
<td class="nump">45,705,782<span></span>
</td>
<td class="nump">32,647,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per shares, basic and diluted</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810574011544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">9,376,775<span></span>
</td>
<td class="nump">7,638,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,083,955<span></span>
</td>
<td class="nump">4,596,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptgx_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">418,660<span></span>
</td>
<td class="nump">262,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">18,660<span></span>
</td>
<td class="nump">28,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptgx_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptgx_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139810489027752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan', window );">Percentage of employee base impacted by the restructuring plan</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total cash expenditures for the reduction in force plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of employee base impacted by the restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M.IK?CK#I&JT[ 6W5"<:Y4F9"4LZ,BG2!,>36F7R#XM>W\_\?R>H.0%MU@(F
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M 6I;*"8]H2/4\P/JN1?U=Z%9\0: <^O=E"1Q.H3H$,-1'(PD!@ZZOA^\ORE
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MC0!\OQ)"[V_,P?[AAYS%?U!+ P04    "  KB6-3;Z5X>Y@"   <"0  &
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MC"3HKFPNS9H7+:KZ5F@A-!Q Z\<-9RF7!@"_KX30+R^F@>[J<O(=4$L#!!0
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M*?*:E0^8AK:QI<QE%%==/.Q23_T[8&70)/?'YYA\1G,!'&Q#)2F!#%YN>,Z
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MG"(?P/-5P#[:7["!X4O=]>]02P,$%     @ *XEC4W$BG7^B&P  RE8  !@
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M0$!*^*-W.WY;Z=+UO=OR1Q3,3(<'Z'>\C3'\@07BZVN_^S]02P,$%     @
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MJ=VP][S26E3LC02>\DW&WE7Y)&.<?1!5I??E/:\D9[EJ:G>&V]FN=-M-V _
MQ^%QA@4=<Z")Y4=PD;&"-ON&@[Q>H+QF(+7EGM8L1;L30'DL/GS?<?2,:R\^
M6(*/?24;#1K!-XDT>*\1K<J86*T$!4 ZBC0SNS&:L=Q^U\BUK'AY*,>)/U'"
M@<!C2337O&GA5)72I]E[M:DT,/EWOJUO_:MW5:7N#?=G[/W[MW=!$5JN*[F2
M.0>"(>#EGS:J+$3#U"K>.DMXYXU@2P7JU=U2RT+R1H+48<7@Z49UAQR"B'.0
M8"0=98UW=F&4,6$_ULJHP#]4":T=<8=[IN;>B%S $K!O5JGJ#%).5Q5\68J,
M=?6J@3#)<JXW(,P]$03;GBZFDRG$^K)$8<$S6\?U0\3TM#]*R>E\$9W@CHY/
M O<D"S&"\\HMM4KV&=JF!8FLR<6M3>HNSX'(55>""""%&2, DD'S(E=5<;8&
M+JQG@(>48!@0(TK1?9+!&=]][<SQ;'Y!1-2M:L F6KY6E02^"W$/&*,F(G*@
M6(&D_?+#D]PCVH>+HFMDM2::5R3)GSLP<6.($,BFHP' >(1VOA 1DD&NKKH5
M8(^N,8$ CMV*)I>\E+]X21BNOQ[EK.G68"95(3%::$-'> TXH6G@,#!;$%@L
M!NY-8\E+7N6@#$)ZN(S57:,[]#E+]@!CLLK+KA#LPP__/ .8E[$/WP*-<V*$
M_EQ,W&<4&ZJ'.)%HO;QE.Z ,_OZP 4#%YCPA&I FT=,"R&R=4]PUX,FHJ=G5
MK6:%U )7.NW>O0VQZH!$BA6'^J\;571YVY.>H6@&<:@K)(HZ"GUU(P&XRA)]
M28,C:@E^[,G%_6$_)W G%L\B^ 6(!LF*O?+)VQYP=T#QAP?U:@(#QF\,FAM^
M+[Z +'#SXNKFUB>46"/@XK"'JHR)0PQ#3,VB]$A*$9]K>+NW%,C.D]3GW8XX
MW )XEC6P*\&8<WI"&R,1UHIJWFYV?'_K"2SE5N(ID10]":NNP8R7^@"E99.R
MD$3,R&I9RK4]#6@1S9@#6!$>*!.%;3,2?JZJM<+0T=,%&51?8;>Q2?4USLN2
M*6)AU5'(>("3X^3?TA(G.+ D\N8BUKX5'6MWZFPO>(,4P7_Y)E5;QG8;, )
M;Y"[D%/' P@(]FUEU7E3Q8]Y44A<!Q;O-VPWC>K6&PL.I_-+EIB#Y12!1<^
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MVF'I"0$?QC6RLP% ,5VQ%A3P_+P?'L"TY:F.HU6XFH6)O$&_675E>0;;P:X
M6>YY:5T(,5L8$9B[L9X5.FU,X$$E<?,\'@@GLN[+UZU]LFP1/?" '^PAZ:8D
M[Y5H^OV6@X2<N@;PUK,VNA[8SZ3<C +C*G/ _7X8U+L'6'8&,ER4'$]B0,+I
M;+J87/D6IKDP^3U4R6*[A)7N.P>VX6RR!EW2O9G<I'=TA\V3'EU,KGLGO._
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MX$VX_]Z(AW\1/DBS :$BIS54Q\/%P0!]F;^9AX'3E;\-K[3#W=J_9B31T[$
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MZVT9<'XI\=C<OE@#W4W8Y;]02P,$%     @ *XEC4TZ1!G6T @  Y@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK57);MLP$/T50BV*%A"LU8J3
MV ;B)$5[2&LD7<ZT-+*(4*1*TK'S]QU2BQ4T"7K(1>0,Y[W9Q.%\+]6]K@ ,
M.=1<Z(57&=.<!8'.*ZBIGL@&!)Z44M74H*BV@6X4T,*!:A[$89@%-67"6\Z=
M;JV6<[DSG E8*Z)W=4W5XPJXW"^\R.L5MVQ;&:L(EO.&;N$.S,]FK5 *!I:"
MU2 TDX(H*!?>172V2JV],_C%8*]'>V(SV4AY;X6OQ<(+;4# (3>6@>+R )?
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MXPWH^TK3G-!N?(!N:I_^!5!+ P04    "  KB6-382C=+!H'  #3$@  &0
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M;=<.W#'$Y6BW/>G%0K(%&MGV8GO4]OY6V_\M'+ =>0-83\+AMQ"![-A[&.(
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MA :7"9Z[:KIELS"R<@UG)0VV+S<M\ <#R@;@^[649K>P MTO:_H;4$L#!!0
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M:$.#7Z^-X7,1KM;ECZ'\!5!+ P04    "  KB6-33H;E(Q4#  #V"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6S%5EUOVC 4_2M6U(=6VIKO !4@
MM<"T29N$H-V>W>226$WLU#;0_?O93H@@"8A)D_9"[/B<ZW/NO<0>[QE_$QF
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MP[9R+R1HG^#^%XCV%'B"_LW-_@!02P,$%     @ *XEC4Q'[,<6+ @  (@8
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ME[#D0E !S"2T1-B%#=.&W+PF%[]![B,LE;2%@4\RP^Q/_Y 2;;.-S]G.XT[
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ME2B<G$RQ2-#]6T'6. 4J!<(T1@^8OX+$BQ30'**"$TE H.]HFF(AR))$6*>
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M#K:!_N\SDQ63^L&GS/N]01@&!_(-84[/[?7,!H:-@6'W+Z%^>*YNCT+94->
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M H)S 6$+",\%1"T@.A<P: &#MX";$X!A"QC:W#?)LIE.L<))+/@."6.MV<S
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MC$6OBO.EHF-DFI^'W$EC9)(WU\ B4/8%?+Z4TCQUK(/JE&_\'U!+ P04
M"  KB6-3L;$ZL(X#   X#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6RE5VN/HS84_2L6K:I=:6? A$>R32+EL4]MV]%&VWYV@I-88S"US617ZH^O
M;3R$!/"FW2\)!I_CXWNO#Y?IB?%'<<18@J\Y+<3,.TI9OO9]L3OB'(E[5N)"
M/=DSGB.IAOS@BY)CE!E03OTP"!(_1Z3PYE-S[X'/IZR2E!3X@0-1Y3GBWY:8
MLM/,@][SC<_D<)3ZAC^?ENB -UA^*1^X&OD-2T9R7 C""L#Q?N8MX.MW,-4
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M\TS)+5$V&MGLP'GCT%@-$_84%T;A+D.<R>\!/=#DDK@!*:0VA G_=5B;S^_
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M9H&>SSE7'QU38KL7-?T#4$L#!!0    ( "N)8U-"QH/6T0,   T.   9
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MKQIJX,4"]7[+F'R=% [J%GWQ"U!+ P04    "  KB6-3/T =N3$#  "*"@
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M2025$8E0U*]>P1E10*! F2#7YZ>"W'Y:V.L$P=<6V<-&]K"5J$G$0M($06Q
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MR\5AXF#G>>(^VZ;:3+C3\8YNV8KI;[NEA)%;LR19P;C*!$>2;2;.#;Y>8&(
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M!-Y&',$<@ <,B:)J']S;C\+-/A6VOX&-?P-02P,$%     @ *XEC4Y>*NQS
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M\0)02P$"% ,4    "  KB6-3!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "N)8U-(>GQ;[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( "N)8U.97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ *XEC4P\I'LU3!0  )!8  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( "N)8U-!LS543P8  -09   8              " @94-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  KB6-3;Z5X>Y@"   <"0
M&               @($:%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ *XEC4SI S XI!0  QA0  !@              ("!Z!8  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "N)8U,DM>_;$ ,
M -4)   8              " @4<<  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  KB6-3MS2(-#H(   ^,   &               @(&-
M'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ *XEC4S[B
M&/U^"   CB8  !@              ("!_2<  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( "N)8U,OJ@$)\0<  +43   8
M  " @;$P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  K
MB6-3<2*=?Z(;  #*5@  &               @('8.   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ *XEC4YML![!&%0  0%   !D
M         ("!L%0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  KB6-3',8B-L\%   J$0  &0              @($M:@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "N)8U/8"KI_;04  !43
M   9              " @3-P  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ *XEC4TZ1!G6T @  Y@8  !D              ("!UW4
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  KB6-3O-Z/
M_ 4%  !V#0  &0              @('">   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( "N)8U/HH<M_' 0  ,$+   9
M  " @?Y]  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M*XEC4V$HW2P:!P  TQ(  !D              ("!48(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  KB6-3D8M7Y[(&  "\$P  &0
M            @(&BB0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( "N)8U.FY^=%*08  *(/   9              " @8N0  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ *XEC4WI^XK3B!P
M=AD  !D              ("!ZY8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  KB6-3-%='"N0+  !))P  &0              @($$
MGP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "N)8U-C
M(,P2* ,  !X'   9              " @1^K  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ *XEC4U44%('8 P  ^@@  !D
M     ("!?JX  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N)8U.3T*A#> ,  .L,   9              "
M@5'9  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ *XEC
M4ZCDE#!J P  Z@H  !D              ("! -T  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  KB6-3MYC6W>,#  "6#@  &0
M        @(&AX   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( "N)8U/AV+,$NP(  .L&   9              " @;OD  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ *XEC4]*.PW_S P  $@T
M !D              ("!K><  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  KB6-32G9=0"$&  #*%0  &0              @('7ZP
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "N)8U,S]B^B
MCP,  "D*   9              " @2_R  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ *XEC4P-,Q%.V @  O@8  !D
M ("!]?4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  K
MB6-3>AK5*OL!   D!   &0              @('B^   >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "N)8U-.AN4C%0,  /8)   9
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M970T,"YX;6Q02P$"% ,4    "  KB6-3MO%Z;54$  !R&   &0
M    @(%<$@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M "N)8U,<>,Y&700  !H8   9              " @>@6 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ *XEC4YZ:O\T= P  K H  !D
M             ("!?!L! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  KB6-3IQ&.B<0"  #9!P  &0              @('0'@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "N)8U,DRW%(JP(
M $8(   9              " @<LA 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ *XEC4Q,=A9O% P  @1   !D              ("!
MK20! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  KB6-3
MY<":2KP$  #Q$P  &0              @(&I* $ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( "N)8U.QL3JPC@,  #@-   9
M      " @9PM 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ *XEC4U 3J"SB @  \PH  !D              ("!83$! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  KB6-3I9T1U2("  "*!0
M&0              @(%Z- $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( "N)8U.DR7;L:0(  #T&   9              " @=,V 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ *XEC4P$+VE5E
M @  R 4  !D              ("!<SD! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  KB6-33"^9%:<"  !=!P  &0
M@($// $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( "N)
M8U-"QH/6T0,   T.   9              " @>T^ 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ *XEC4P>/ :4;!P  YR0  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( "N)8U,_0!VY,0,  (H*   9
M  " @8I: 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M*XEC4Q9>IEGQ @  '0@  !D              ("!\ET! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  KB6-3*XUH(IH#  "N#   &0
M            @($:80$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( "N)8U/5Y:ABI (  #,(   9              " @>MD 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ *XEC4R;_Q[6P @
M>0@  !D              ("!QF<! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  KB6-3+M!8C @#   >"0  &0              @(&M
M:@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "N)8U-2
MA+1=70,  ,\-   9              " @>QM 0!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ *XEC4X!33"PO @   @4  !D
M     ("!@'$! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
M"  KB6-3X323'2<#   0$P  #0              @ 'F<P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( "N)8U.7BKL<P    !,"   +              "
M 3AW 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "N)8U,D]A89:P4  #@L   /
M              "  2%X 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  K
MB6-3R%S!4B "  #0)P  &@              @ &Y?0$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  KB6-3XB$R0O$!   9)P  $P
M            @ $1@ $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2P!+
+ (04   S@@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>249</ContextCount>
  <ElementCount>403</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - License and Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement</Role>
      <ShortName>License and Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables</Role>
      <ShortName>Accrued Expenses and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Government Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms</Role>
      <ShortName>Government Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Term Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureTermLoanFacility</Role>
      <ShortName>Term Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Equity Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlans</Role>
      <ShortName>Equity Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30303 - Disclosure - License and Collaboration Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables</Role>
      <ShortName>License and Collaboration Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables</Role>
      <ShortName>Accrued Expenses and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Equity Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansTables</Role>
      <ShortName>Equity Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureEquityPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Description of Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails</Role>
      <ShortName>Organization and Description of Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40301 - Disclosure - License and Collaboration Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails</Role>
      <ShortName>License and Collaboration Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>License and Collaboration Agreement - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails</Role>
      <ShortName>Accrued Expenses and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Government Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails</Role>
      <ShortName>Government Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Term Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails</Role>
      <ShortName>Term Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureTermLoanFacility</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Leases - Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails</Role>
      <ShortName>Leases - Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Leases - Supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Leases - Weighted average lease term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Weighted average lease term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Leases - Lease cost information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails</Role>
      <ShortName>Leases - Lease cost information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Leases - Cash flow information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails</Role>
      <ShortName>Leases - Cash flow information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails</Role>
      <ShortName>Leases - Future lease payments required under lease obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Equity Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails</Role>
      <ShortName>Equity Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Equity Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails</Role>
      <ShortName>Equity Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Equity Plans - Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Equity Plans - Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Plans - Restricted Stock Units - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41305 - Disclosure - Equity Plans - Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails</Role>
      <ShortName>Equity Plans - Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41306 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Plans - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41307 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41401 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/Disclosure401KPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/Disclosure401KPlan</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Net Loss per Share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss per Share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ptgx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureRestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureRestructuring</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ptgx-20210930x10q.htm">ptgx-20210930x10q.htm</File>
    <File>ptgx-20210930.xsd</File>
    <File>ptgx-20210930_cal.xml</File>
    <File>ptgx-20210930_def.xml</File>
    <File>ptgx-20210930_lab.xml</File>
    <File>ptgx-20210930_pre.xml</File>
    <File>ptgx-20210930xex10d1.htm</File>
    <File>ptgx-20210930xex10d2.htm</File>
    <File>ptgx-20210930xex10d3.htm</File>
    <File>ptgx-20210930xex31d1.htm</File>
    <File>ptgx-20210930xex31d2.htm</File>
    <File>ptgx-20210930xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ptgx-20210930x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptgx-20210930x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 25,
   "contextCount": 249,
   "dts": {
    "calculationLink": {
     "local": [
      "ptgx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgx-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ptgx-20210930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptgx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ptgx-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 554,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 24,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 29
   },
   "keyCustom": 70,
   "keyStandard": 333,
   "memberCustom": 46,
   "memberStandard": 28,
   "nsprefix": "ptgx",
   "nsuri": "http://www.protagonist-inc.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - License and Collaboration Agreement",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
     "shortName": "License and Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_6OY5GB4KbkSfc3z78Prigg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Cash Equivalents and Marketable Securities",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Expenses and Other Payables",
     "role": "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables",
     "shortName": "Accrued Expenses and Other Payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Research Collaboration and License Agreement",
     "role": "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
     "shortName": "Research Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_308Ct_3m0EGCDu5rHdSB7Q",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:GovernmentProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Government Programs",
     "role": "http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms",
     "shortName": "Government Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:GovernmentProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Term Loan Facility",
     "role": "http://www.protagonist-inc.com/role/DisclosureTermLoanFacility",
     "shortName": "Term Loan Facility",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Leases",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Commitments and Contingencies",
     "role": "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Stockholders' Equity",
     "role": "http://www.protagonist-inc.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "role": "http://www.protagonist-inc.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Equity Plans",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlans",
     "shortName": "Equity Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - 401(k) Plan",
     "role": "http://www.protagonist-inc.com/role/Disclosure401KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Income Taxes",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Net Loss per Share",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Restructuring",
     "role": "http://www.protagonist-inc.com/role/DisclosureRestructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - License and Collaboration Agreement (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables",
     "shortName": "License and Collaboration Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Expenses and Other Payables (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables",
     "shortName": "Accrued Expenses and Other Payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:LeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Leases (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:LeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Equity Plans (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
     "shortName": "Equity Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31603 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Description of Business - Liquidity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails",
     "shortName": "Organization and Description of Business - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:CashNumberOfFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:CashNumberOfFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Institution_shXDCLz5nky9dOS1WLJZVA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2020_jk87RPM6Vk-cunjsCAvc5A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_8BRe1P6w6kScgLtTSSdtLg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails",
     "shortName": "Summary of Significant Accounting Policies - Research and Development Tax Incentive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - License and Collaboration Agreement - Narrative (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
     "shortName": "License and Collaboration Agreement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations",
     "role": "http://www.protagonist-inc.com/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
     "shortName": "License and Collaboration Agreement - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_dDYRBHtX4kywnb0ImA8z2w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9qWORH9HukCvrBN22NGemA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Expenses and Other Payables (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails",
     "shortName": "Accrued Expenses and Other Payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgx:AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfDevelopmentMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Research Collaboration and License Agreement (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2014_To_12_31_2014_KzCscwYm80-2La7sYuS1Hw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfDevelopmentMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_payment_T7gXHJKAmU2BD0GtiLnY1w",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Government Programs (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
     "shortName": "Government Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ptgx:ResearchAndDevelopmentExpensesReduction",
       "p",
       "ptgx:GovernmentProgramsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_OrLsItNoVUWmXfX_oVcZTA",
      "decimals": "-5",
      "lang": null,
      "name": "ptgx:ResearchAndDevelopmentExpensesReduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Term Loan Facility (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails",
     "shortName": "Term Loan Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_EbKZ2nex5EKy9efnCxOy3Q",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Leases - Agreement (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
     "shortName": "Leases - Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA_nJ2YdyBimE6P9t5VGQxkZA",
      "decimals": "INF",
      "lang": null,
      "name": "ptgx:NumberOfOperatingLeaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_lease_l-KtIo8rkUevq1Vg6RPLug",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Leases - Supplemental balance sheet information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental balance sheet information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Comprehensive Loss",
     "role": "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseBalanceSheetDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Leases - Weighted average lease term and discount rate (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails",
     "shortName": "Leases - Weighted average lease term and discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseBalanceSheetDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Leases - Lease cost information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails",
     "shortName": "Leases - Lease cost information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Leases - Cash flow information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails",
     "shortName": "Leases - Cash flow information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseCashFlowInformationDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Leases - Future lease payments required under lease obligations (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails",
     "shortName": "Leases - Future lease payments required under lease obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_q-TA0t5Qn0yFxXydp_QPQA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfBusinessDays",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_8_4_2021_To_8_4_2021_y8wqQ3yTvUKfZ13bSCwzcg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfBusinessDays",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_zKmsy6v6FUaz1H9GRlgxZw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Equity Plans - Narrative (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
     "shortName": "Equity Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_1_1_2021_zjvz7zGDdE6xjGb59pq1gw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_5BRe0n3ymUS8fsO0SC-D0A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Equity Plans - Stock Option Activity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails",
     "shortName": "Equity Plans - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Equity Plans - Stock Options Valuation Assumptions (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
     "shortName": "Equity Plans - Stock Options Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eJLHuhmOH0-QEOu6EIHFjg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IBSpr1aeukqGtrasp--WdQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
     "shortName": "Equity Plans - Restricted Stock Units - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_aKH-RdBDJEyGQNI2GyAKiA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ShsA1tWpGUmhQJqfvR21Pg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Stockholders' Equity",
     "role": "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_eu303YctzUm4oyVCdG6opQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41305 - Disclosure - Equity Plans - Performance Stock Units (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
     "shortName": "Equity Plans - Performance Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_FOt_zm0wAEeChHXp65bguQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Oc5ejUy-cUGFzF_CqBiuxQ",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41306 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Plans - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_tFQ4rXAvEE-kFtJMRReIyw",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41307 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails",
     "shortName": "Equity Plans - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - 401(k) Plan (Details)",
     "role": "http://www.protagonist-inc.com/role/Disclosure401KPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Income Taxes (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_wZ6ykYXsP0iNtGgqfZQPrg",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_jIdoM8q1B0yEq2i7xedVdg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Net Loss per Share - Computation (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
     "shortName": "Net Loss per Share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss per Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_3sicqthZ7kOf_9VPPWwoeQ",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Restructuring (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails",
     "shortName": "Restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_5_7_2020_To_5_7_2020_584PuXeIL0OizpRsBvb4QQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_UZzxNoTjrU6agkS5JMOENw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Statements of Cash Flows",
     "role": "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_8WAQ-meu2kSWBb7jv4WDkw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Description of Business",
     "role": "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_PifB0UjhBkGIJFlyu6Mdgg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of accrued clinical and research related expenses.",
        "label": "Accrued Clinical and Research Related Expenses Current",
        "terseLabel": "Accrued clinical and research related expenses"
       }
      }
     },
     "localname": "AccruedClinicalAndResearchRelatedExpensesCurrent",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AccruedLiabilitiesAndOtherPayablesCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of accrued liabilities and other payables.",
        "label": "Accrued Liabilities And Other Payables Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherPayablesCurrentTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_AccruedLiabilitiesAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the information pertaining to the accrued liabilities and other payables.",
        "label": "Accrued Liabilities And Other Payables [Member]",
        "terseLabel": "Accrued liabilities and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherPayablesMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AccruedMilestonePaymentToFormerCollaborationPartner": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of accrued milestone payment to former collaboration partner.",
        "label": "Accrued Milestone Payment to Former Collaboration Partner",
        "terseLabel": "Accrued milestone payment to former collaboration partner"
       }
      }
     },
     "localname": "AccruedMilestonePaymentToFormerCollaborationPartner",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AdditionalSecurityDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional security deposit.",
        "label": "Additional Security Deposit",
        "terseLabel": "Additional security deposit"
       }
      }
     },
     "localname": "AdditionalSecurityDeposit",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AggregateAmountOfDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of development milestone payment made by the entity.",
        "label": "Aggregate Amount Of Development Milestone Payment",
        "terseLabel": "Aggregate development milestone payment"
       }
      }
     },
     "localname": "AggregateAmountOfDevelopmentMilestonePayment",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.",
        "label": "Amortization Of Debt Issuance Costs And Debt Instrument, Accretion Of Final Payment Fee",
        "terseLabel": "Amortization of debt issuance costs and accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ArbitrationResolutionAgreementWithZealandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to arbitration resolution agreement with Zealand.",
        "label": "Arbitration Resolution Agreement With Zealand [Member]",
        "terseLabel": "Arbitration Resolution Agreement"
       }
      }
     },
     "localname": "ArbitrationResolutionAgreementWithZealandMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AtMarketingOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sale of stock by a private company to public at market offer price.",
        "label": "At Marketing Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtMarketingOfferingMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_BiotechnologyValueFundL.pMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exchange Agreement with Biotechnology Value Fund, L.P",
        "label": "Biotechnology Value Fund L.p [Member]",
        "terseLabel": "Exchanging Stockholders"
       }
      }
     },
     "localname": "BiotechnologyValueFundL.pMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CashCashEquivalentsAndMarketableSecuritiesCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of cash, cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Marketable Securities, Carrying Value",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesCarryingValue",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash Equivalents and Available for Sale Securities [Line Items]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Cash Equivalents And Marketable Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and marketable securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAmortizedCost",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.",
        "label": "Cash Equivalents And Marketable Securities Fair Value",
        "terseLabel": "Total cash equivalents and marketable securities, Fair Value",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesFairValue",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities Gross Unrealized Gain",
        "terseLabel": "Total cash equivalents and marketable securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities Gross Unrealized Loss",
        "negatedLabel": "Total cash equivalents and marketable securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashNumberOfFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of financial institutions that hold the entity's cash.",
        "label": "Cash, Number of Financial Institutions",
        "terseLabel": "Number of financial institutions at which cash is held"
       }
      }
     },
     "localname": "CashNumberOfFinancialInstitutions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_ClassOfWarrantOrRightTermOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of warrants from date of issuance.",
        "label": "Class of Warrant or Right, Term of Warrants",
        "terseLabel": "Duration of warrants from date of issuance (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrants",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents",
        "label": "Clinical Data Collection For Phase1 Activities Pn232 And Pn235 [Member]",
        "terseLabel": "Completion of clinical data collection for Phase 1 activities for the first of either PN-232 or PN-235"
       }
      }
     },
     "localname": "ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CollaborativeAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment based on the agreement.",
        "label": "Collaborative Agreement Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementUpfrontPayment",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of future development milestone including commercial launch expenses for launch in the three geographic territories payable under the collaboration agreement.",
        "label": "Collaborative Arrangement, Commercial Launch Expenses Payable",
        "terseLabel": "Commercial launch expenses"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercialLaunchExpensesPayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Collaboration Agreement."
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "ptgx_CollaborativeArrangementEligibleAmountReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount received from a collaborative arrangement.",
        "label": "Collaborative Arrangement, Eligible Amount Received",
        "terseLabel": "Eligible amount received"
       }
      }
     },
     "localname": "CollaborativeArrangementEligibleAmountReceived",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of future development milestone payable under the collaboration agreement.",
        "label": "Collaborative Arrangement Future Development Milestone Payable",
        "terseLabel": "Future development milestone payable"
       }
      }
     },
     "localname": "CollaborativeArrangementFutureDevelopmentMilestonePayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of development cost incurred.",
        "label": "Collaborative Arrangement Percentage of Development Costs Incurred",
        "terseLabel": "Development cost incurred, percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfDevelopmentCostsIncurred",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of development cost eliminated.",
        "label": "Collaborative Arrangement Percentage Of Development Costs Incurred Eliminated",
        "terseLabel": "Percentage of development cost eliminated"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of future development milestone including registration proposal payable under the collaboration agreement.",
        "label": "Collaborative Arrangement, Registration Proposal Expenses Payable",
        "terseLabel": "Registration proposal payable"
       }
      }
     },
     "localname": "CollaborativeArrangementRegistrationProposalExpensesPayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock, preferred stock, debt securities and warrants (the \"2019 Form S-3\").",
        "label": "Common Stock Preferred Stock Debt Securities And Warrants [Member]",
        "terseLabel": "2019 Form S-3"
       }
      }
     },
     "localname": "CommonStockPreferredStockDebtSecuritiesAndWarrantsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ContractWithCustomerAssetAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdditions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeduction",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Asset, Net [Roll forward]",
        "terseLabel": "Receivable from collaboration partner - related party"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetRollForward",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_ContractWithCustomerAssetRelatedPartyAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Related Party Additions",
        "terseLabel": "Contract asset - related party, Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRelatedPartyAdditions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetRelatedPartyDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Related Party Deduction",
        "terseLabel": "Contract asset - related party, Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRelatedPartyDeduction",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityDeduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeduction",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Liability, Net [Roll forward]",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNetRollForward",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_CurrentContractualMaturitiesMaximumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of current contractual maturities.",
        "label": "Current Contractual Maturities, Maximum Period",
        "terseLabel": "Maximum period of current contractual maturities"
       }
      }
     },
     "localname": "CurrentContractualMaturitiesMaximumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.",
        "label": "Debt Instrument, Additional Prepayment Or Repayment Premium Percentage",
        "terseLabel": "Additional Prepayment (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the floor rate of the debt instrument",
        "label": "Debt Instrument, Floor Rate",
        "terseLabel": "Floor rate (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentFloorRate",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentLoanOriginationFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of loan origination fee under the debt instrument.",
        "label": "Debt Instrument, Loan Origination Fee Percentage",
        "terseLabel": "Loan Origination Fee (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentLoanOriginationFeePercentage",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of prepayment premium under the debt instrument.",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Prepayment premium (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring after second anniversary of the closing date.",
        "label": "Debt Instrument Repayment After Second Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment After Second Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentAfterSecondAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring after first anniversary and through and including the second anniversary of the closing date.",
        "label": "Debt Instrument Repayment Between First And Second Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment Between First And Second Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring through and including the first anniversary of the closing date.",
        "label": "Debt Instrument Repayment On Or Before First Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment On Or Before First Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.",
        "label": "Debt Instrument, Threshold Percentage On Outstanding Debt To Be Maintained As Cash And Cash Equivalents Balance",
        "terseLabel": "Cash and cash equivalents ( In percentage)"
       }
      }
     },
     "localname": "DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentTrancheInstallmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tranche installment amount under the debt instrument.",
        "label": "Debt Instrument, Tranche Installment Amount",
        "terseLabel": "Tranche Installment Amount"
       }
      }
     },
     "localname": "DebtInstrumentTrancheInstallmentAmount",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DevelopmentCostsEliminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the development costs that have been eliminated.",
        "label": "Development Costs Eliminated",
        "terseLabel": "Expense obligations eliminated"
       }
      }
     },
     "localname": "DevelopmentCostsEliminated",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication.",
        "label": "Dosing Of Third Patient In Phase3 Clinical Trial For Second Generation Compound For Any Indication [Member]",
        "terseLabel": "Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication"
       }
      }
     },
     "localname": "DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for a second indication.",
        "label": "Dosing Of Third Patient In Phase3 Clinical Trial For Second Generation Compound For Second Indication [Member]",
        "terseLabel": "Dosing Of Third Patient In Phase 3 Clinical Trial For Second Generation Compound For A Second Indication [Member]"
       }
      }
     },
     "localname": "DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DueToRelatedPartyAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount of payable due to a related party",
        "label": "Due To Related Party Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "DueToRelatedPartyAdditions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DueToRelatedPartyDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction from obligation to transfer good or service to related party for payable amounts.",
        "label": "Due To Related Party Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "DueToRelatedPartyDeductions",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DurationOfResearchCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of the parties' research collaboration agreement.",
        "label": "Duration Of Research Collaboration Agreement",
        "terseLabel": "Duration of the parties' research collaboration agreement"
       }
      }
     },
     "localname": "DurationOfResearchCollaborationAgreement",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants And Directors Stock Options [Member]",
        "terseLabel": "Stock options - employees, consultants, directors"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EmployeeStockPurchasePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 Employee Stock Purchase Plan approved by the board of directors and stockholders in July 2016.",
        "label": "Employee Stock Purchase Plan2016 [Member]",
        "terseLabel": "2016 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2016Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 Equity Incentive Plan approved by the entity's board of directors and stockholders in July 2016.",
        "label": "Equity Incentive Plan2016 [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exchange agreement for common stock.",
        "label": "Exchange Agreement [Member]",
        "terseLabel": "Exchange Agreement"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.",
        "label": "Expected Volatility Calculation, Percentage Of Average Volatility Expected Term Of Stock Option Grants",
        "terseLabel": "Average volatility"
       }
      }
     },
     "localname": "ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.",
        "label": "Expected Volatility Calculation, Percentage Of Volatility Of Stock Price Since IPO",
        "terseLabel": "Percentage of volatility of stock options since IPO"
       }
      }
     },
     "localname": "ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_FacilityLeaseAmendmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to facility lease second amendment.",
        "label": "Facility Lease Amendment Agreement [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "FacilityLeaseAmendmentAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_FinancingFacilitySalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2019 Sales Agreement.",
        "label": "Financing Facility Sales Agreement [Member]",
        "terseLabel": "2019 Sales Agreement"
       }
      }
     },
     "localname": "FinancingFacilitySalesAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_GovernmentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "ptgx_GovernmentProgramsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the government programs.",
        "label": "Government Programs Disclosure [Text Block]",
        "terseLabel": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsDisclosureTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_GovernmentProgramsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Government Programs [Line Items]",
        "terseLabel": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsLineItems",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_GovernmentProgramsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of government programs.",
        "label": "Government Programs [Table]",
        "terseLabel": "Government Programs [Table]"
       }
      }
     },
     "localname": "GovernmentProgramsTable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_InducementStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2018 Inducement plan, a non-stockholder approved stock plan in order to award options and restricted stock unit awards to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.",
        "label": "Inducement Stock Plan [Member]",
        "terseLabel": "2018 Inducement Plan"
       }
      }
     },
     "localname": "InducementStockPlanMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the related party Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The license and collaboration agreement with Janssen Biotech, Inc. (Janssen) dated May 26, 2017.",
        "label": "Janssen License And Collaboration Agreement26 May2017 [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "JanssenLicenseAndCollaborationAgreement26May2017Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_LeaseBalanceSheetDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease balance sheet.",
        "label": "Lease Balance Sheet Disclosure [Table Text Block]",
        "terseLabel": "Schedule of balance sheet information"
       }
      }
     },
     "localname": "LeaseBalanceSheetDisclosureTableTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_LeaseCashFlowInformationDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease cash flow information.",
        "label": "Lease Cash Flow Information Disclosure [Table Text Block]",
        "terseLabel": "Schedule of cash flow information"
       }
      }
     },
     "localname": "LeaseCashFlowInformationDisclosureTableTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to amended and restated agreement.",
        "label": "License And Collaborative Agreement Amended And Restated [Member]",
        "terseLabel": "Restated Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborativeAgreementAmendedAndRestatedMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.",
        "label": "Litigation Settlement, Collaborative Arrangement Milestone Payment Reduction Percentage"
       }
      }
     },
     "localname": "LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of sales milestone reductions resulting from dispute resolution agreement.",
        "label": "Litigation Settlement, Collaborative Arrangement Sales Milestone Payment Reduction Percentage",
        "terseLabel": "Percentage of sales milestone reductions"
       }
      }
     },
     "localname": "LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_NoncurrentContractualMaturitiesMaximumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of contractual maturities.",
        "label": "Noncurrent Contractual Maturities, Maximum Period",
        "terseLabel": "Maximum period of Noncurrent contractual maturities"
       }
      }
     },
     "localname": "NoncurrentContractualMaturitiesMaximumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_NoncurrentContractualMaturitiesMinimumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum period of noncurrent contractual maturities.",
        "label": "Noncurrent Contractual Maturities, Minimum Period",
        "terseLabel": "Minimum period of noncurrent contractual maturities"
       }
      }
     },
     "localname": "NoncurrentContractualMaturitiesMinimumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_NumberOfBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Days.",
        "label": "Number Of Business Days"
       }
      }
     },
     "localname": "NumberOfBusinessDays",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfDevelopmentMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of development milestone payments in collaboration agreement.",
        "label": "Number of Development Milestone Payments",
        "terseLabel": "Number of development milestone payments"
       }
      }
     },
     "localname": "NumberOfDevelopmentMilestonePayments",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfGeographicTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of geographic territories.",
        "label": "Number Of Geographic Territories",
        "terseLabel": "Number of geographic territories"
       }
      }
     },
     "localname": "NumberOfGeographicTerritories",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfOperatingLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of operating lease agreement.",
        "label": "Number of Operating Lease Agreement",
        "terseLabel": "Number of operating lease agreement"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseAgreement",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised for the period.",
        "label": "Number of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.",
        "label": "Operating Lease Right of Use Asset Amortization",
        "terseLabel": "Operating lease right-of-use asset amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_OriginalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Original Agreement.",
        "label": "Original Agreement [Member]",
        "terseLabel": "Original Agreement"
       }
      }
     },
     "localname": "OriginalAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_OverseasFindingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for overseas findings.",
        "label": "Overseas Findings [Member]",
        "terseLabel": "Overseas Findings"
       }
      }
     },
     "localname": "OverseasFindingsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PayableToCollaborationPartnerRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Payable to Collaboration Partner - Related Party [Abstract]",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "PayableToCollaborationPartnerRelatedPartyAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of employee base impacted by the restructuring plan.",
        "label": "Percentage of Employee Base Impacted by Restructuring Plan",
        "terseLabel": "Percentage of employee base impacted by the restructuring plan"
       }
      }
     },
     "localname": "PercentageOfEmployeeBaseImpactedByRestructuringPlan",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_PercentagesRoyaltiesOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentages on net product sales.",
        "label": "Percentages Royalties on Net Product Sales",
        "terseLabel": "Maximum percentages royalties on net product sales"
       }
      }
     },
     "localname": "PercentagesRoyaltiesOnNetProductSales",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Phase 1 studies of second-generation compounds.",
        "label": "Phase One Studies Of Second Generation Compounds [Member]",
        "terseLabel": "Phase 1 studies of second-generation compounds"
       }
      }
     },
     "localname": "PhaseOneStudiesOfSecondGenerationCompoundsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseThreeClinicalTrialForAnyIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents phase three clinical trial for any indication.",
        "label": "Phase Three Clinical Trial For Any Indication [Member]",
        "terseLabel": "Phase 3 clinical trial for a second-generation compound for any indication"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialForAnyIndicationMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseThreeClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Phase 3 clinical trial.",
        "label": "Phase Three Clinical Trial [Member]",
        "terseLabel": "Phase 3 clinical trial"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseTwoClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for phase 2 clinical trial, related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners. A collaborative arrangement is a contractual arrangement with a specific party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Phase Two Clinical Trial [Member]",
        "terseLabel": "Phase 2 clinical trial"
       }
      }
     },
     "localname": "PhaseTwoClinicalTrialMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseTwoClinicalTrialSecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents phase two Clinical trial second indication.",
        "label": "Phase Two Clinical Trial Second Indication [Member]",
        "terseLabel": "3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication"
       }
      }
     },
     "localname": "PhaseTwoClinicalTrialSecondIndicationMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PotentialQualifiedDiscountFederalIncomeTaxCredit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the potential Federal income tax credit discount.",
        "label": "Potential Qualified Discount, Federal Income Tax Credit",
        "terseLabel": "Potential Federal income tax credit discount"
       }
      }
     },
     "localname": "PotentialQualifiedDiscountFederalIncomeTaxCredit",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ptgx_Ptg200PhaseAndSecondGenerationCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to PTG 200 phase and second generation compound development related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners.",
        "label": "Ptg200 Phase And Second Generation Compound [Member]",
        "terseLabel": "Services performed for IL-23 receptor antagonist compound research costs and other services"
       }
      }
     },
     "localname": "Ptg200PhaseAndSecondGenerationCompoundMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ReimbursementForServicesPerformed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of reimbursement for services performed.",
        "label": "Reimbursement For Services Performed",
        "terseLabel": "Reimbursement for services performed"
       }
      }
     },
     "localname": "ReimbursementForServicesPerformed",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Collaboration Agreement Development Additional Milestone Payable.",
        "label": "Research And Collaboration Agreement Development Additional Milestone Payable",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of development cost payable under the collaboration agreement.",
        "label": "Research And Collaboration Agreement Development Cost Payable",
        "verboseLabel": "Development cost payable"
       }
      }
     },
     "localname": "ResearchAndCollaborationAgreementDevelopmentCostPayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payable under the research and collaboration agreement.",
        "label": "Research and Collaboration Agreement, Development Milestone Payable",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "ResearchAndCollaborationAgreementDevelopmentMilestonePayable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndDevelopmentExpensesReduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reduction of research and development expense in connection with the research and development tax incentive.",
        "label": "Research And Development Expenses Reduction",
        "terseLabel": "Reduction to research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesReduction",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and development incentive grants.",
        "label": "Research And Development Incentive Grant [Policy Text Block]",
        "terseLabel": "Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveGrantPolicyTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_ResearchAndDevelopmentTaxIncentiveRevenueCriteria": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The revenue criteria for availability of a research and development tax incentive.",
        "label": "Research And Development Tax Incentive, Revenue Criteria",
        "terseLabel": "Revenue for availability of research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveRevenueCriteria",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research collaboration and license agreement abandoned October2013.",
        "label": "Research Collaboration And License Agreement Abandoned October2013 [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementDisclosureAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "ptgx_RevenueSourceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by source of revenue.",
        "label": "Revenue Source [Axis]"
       }
      }
     },
     "localname": "RevenueSourceAxis",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_RevenueSourceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payer source of revenue.",
        "label": "Revenue Source [Domain]",
        "terseLabel": "Revenue Source [Domain]"
       }
      }
     },
     "localname": "RevenueSourceDomain",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_RoyaltiesOnNetProductSalesPercentagesReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reduction in royalty payable.",
        "label": "Royalties On Net Product Sales, Percentages Reduction",
        "terseLabel": "Percentage of reduction in royalty payable"
       }
      }
     },
     "localname": "RoyaltiesOnNetProductSalesPercentagesReduction",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_SaleOfStockValueOfSharesAuthorized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of shares permits the offering, issuance, and sale by the entity.",
        "label": "Sale Of Stock, Value Of Shares Authorized",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesAuthorized",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule cash equivalents and available for sale securities.",
        "label": "Schedule Cash Equivalents and Available for Sale Securities [Table]",
        "terseLabel": "Schedule Cash Equivalents and Available-for-Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents second-generation oral Interleukin (\"IL\")-23 receptor antagonist development compound (second-generation compounds\").",
        "label": "Second Generation Oral Interleukin Il23 Receptor Antagonist Development Compound [Member]",
        "terseLabel": "Second-generation Oral Interleukin (\"IL\")-23 Receptor Antagonist Development Compound"
       }
      }
     },
     "localname": "SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to second generation phase 2 studies.",
        "label": "Second Generation Phase2 Studies Milestone Payment [Member]",
        "terseLabel": "Phase 2 studies for second-generation products"
       }
      }
     },
     "localname": "SecondGenerationPhase2StudiesMilestonePaymentMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to second generation phase 2a and 2b milestone payment for a PTG 200 second generation product.",
        "label": "Second Generation Phase2a And2b Milestone Payment [Member]",
        "terseLabel": "Phase 2a and 2b costs for PTG-200"
       }
      }
     },
     "localname": "SecondGenerationPhase2aAnd2bMilestonePaymentMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationPhase2aEvaluatingPtg200Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to second generation phase 2a evaluating PTG 200.",
        "label": "Second Generation Phase2a Evaluating Ptg200 [Member]",
        "terseLabel": "Phase 2a study evaluating PTG-200 for the treatment of CD"
       }
      }
     },
     "localname": "SecondGenerationPhase2aEvaluatingPtg200Member",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents transactions associated with the Securities Purchase Agreement with certain accredited investors (each, an \"Investor\" and, collectively, the \"Investors\").",
        "label": "Securities Purchase Agreement With Accredited Investors [Member]",
        "terseLabel": "Investors"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementWithAccreditedInvestorsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.",
        "label": "Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units",
        "negatedLabel": "Tax withholding payments related to net settlement of restricted stock units"
       }
      }
     },
     "localname": "SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares withheld for net settlement of tax withholding upon vesting of restricted stock units.",
        "label": "Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units, Shares",
        "terseLabel": "Shares withheld for net settlement of tax withholding upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnitsShares",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units.",
        "label": "Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units",
        "negatedLabel": "Shares withheld for net settlement of tax withholding upon vesting of restricted stock units"
       }
      }
     },
     "localname": "SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_SmallBusinessInnovationResearchGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for small business innovation research grant.",
        "label": "Small Business Innovation Research Grant [Member]",
        "terseLabel": "SBIR Grant"
       }
      }
     },
     "localname": "SmallBusinessInnovationResearchGrantMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_StockExchangedForPreFundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares exchanged for pre-funded warrants.",
        "label": "Stock Exchanged for Pre-funded Warrants",
        "terseLabel": "Common stock exchanged for pre-funded warrants"
       }
      }
     },
     "localname": "StockExchangedForPreFundedWarrants",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_SummaryOfSignificantAccountingPolicyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policy"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyLineItems",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SummaryOfSignificantAccountingPolicyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Table]",
        "terseLabel": "Summary Of Significant Accounting Policy [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyTable",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SupranationalAndSovereignGovernmentSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents supranational and sovereign government securities.",
        "label": "Supranational And Sovereign Government Securities [Member]",
        "terseLabel": "Supranational and sovereign government securities"
       }
      }
     },
     "localname": "SupranationalAndSovereignGovernmentSecuritiesMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_TermLoanCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to term loan credit agreement.",
        "label": "Term Loan Credit Agreement [Member]",
        "terseLabel": "Term Loan Credit Agreement"
       }
      }
     },
     "localname": "TermLoanCreditAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication.",
        "label": "Third Patient In First Phase2 Clinical Trial For Any Second Generation Compound For Any Indication [Member]",
        "terseLabel": "3rd patient in the first Phase 2 clinical trial for any second-generation compound for any indication"
       }
      }
     },
     "localname": "ThirdPatientInFirstPhase2ClinicalTrialForAnySecondGenerationCompoundForAnyIndicationMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents three phase 1 studies of second-generation compounds.",
        "label": "Three Phase One Studies Of Second Generation Compounds [Member]",
        "terseLabel": "Three phase 1 studies of second-generation compounds"
       }
      }
     },
     "localname": "ThreePhaseOneStudiesOfSecondGenerationCompoundsMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold number of performance obligation to allocate transaction price.",
        "label": "Threshold Number Of Performance Obligation To Allocate Transaction Price",
        "terseLabel": "Number of performance obligation"
       }
      }
     },
     "localname": "ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten public offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_UpcomingPotentialDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upcoming potential development milestones payment.",
        "label": "Upcoming Potential Development Milestones Payment",
        "terseLabel": "Upcoming potential development milestones"
       }
      }
     },
     "localname": "UpcomingPotentialDevelopmentMilestonesPayment",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_UpfrontCashPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the upfront cash payment received as part of the license and collaboration agreement.",
        "label": "Upfront Cash Payment [Member]",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPaymentMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_UsTreasuryAndAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and Agency.",
        "label": "Us Treasury And Agency Securities [Member]",
        "terseLabel": "U.S. Treasury and agency securities"
       }
      }
     },
     "localname": "UsTreasuryAndAgencySecuritiesMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_WarrantsPurchaseAmountPerSharePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first group of warrants which may be purchased at a different price than another group of warrants.",
        "label": "Warrants Purchase Amount Per Share Price One [Member]",
        "terseLabel": "$10.00 per share"
       }
      }
     },
     "localname": "WarrantsPurchaseAmountPerSharePriceOneMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second group of warrants which may be purchased at a different price than another group of warrants.",
        "label": "Warrants Purchase Amount Per Share Price Two [Member]",
        "terseLabel": "$15.00 per share"
       }
      }
     },
     "localname": "WarrantsPurchaseAmountPerSharePriceTwoMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ZealandPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Zealand Pharma.",
        "label": "Zealand Pharma [Member]",
        "terseLabel": "Zealand Pharma"
       }
      }
     },
     "localname": "ZealandPharmaMember",
     "nsuri": "http://www.protagonist-inc.com/20210930",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r234",
      "r236",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r234",
      "r236",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r144",
      "r204",
      "r207",
      "r369",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r144",
      "r204",
      "r207",
      "r369",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r215",
      "r234",
      "r236",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r215",
      "r234",
      "r236",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r204",
      "r208",
      "r402",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r204",
      "r208",
      "r402",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r165",
      "r235",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C [A]",
        "terseLabel": "Newark, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premium (accretion of discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued employee related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r50",
      "r51",
      "r52",
      "r389",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) gain"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r99",
      "r100",
      "r101",
      "r311",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r238",
      "r240",
      "r277",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r240",
      "r267",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Potentially dilutive securities have been excluded from diluted net loss per share calculations"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r133",
      "r136",
      "r142",
      "r152",
      "r305",
      "r312",
      "r327",
      "r372",
      "r387"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r46",
      "r92",
      "r152",
      "r305",
      "r312",
      "r327"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities, Fair Value, Rolling Maturity [Abstract]",
        "terseLabel": "Contractual maturities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r242",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r30",
      "r82"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r83",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash as Reported in Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r83",
      "r89",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r82",
      "r87"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash reported on condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Aggregate amounts of cash and cash equivalents and the restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r328"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Asset and Liability [Abstract]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]",
        "terseLabel": "Stock transactions"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants exercisable date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r185",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price (per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrants to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued to purchase common stock, number of shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Remaining number of Exchange Warrants unexercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreement",
        "verboseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Research Collaboration and License Agreement",
        "verboseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r164",
      "r377",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, Ending (in shares)",
        "periodStartLabel": "Balance, Beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.00001 par value, 90,000,000 shares authorized; 47,671,654 and 43,745,465 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r63",
      "r380",
      "r396"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r121",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of changes in contract assets and liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r187",
      "r189",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Net",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r187",
      "r189",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "periodEndLabel": "Contract asset - related party, Balance at End of Period",
        "periodStartLabel": "Contract asset - related party, Balance at Beginning of Period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Net, Current [Abstract]",
        "terseLabel": "Contract asset - related party"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "verboseLabel": "Recognized revenue from deferred revenue contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Increase (decrease) in transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Collaboration revenue recorded following the contract modification"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r187",
      "r188",
      "r205"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "verboseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r216",
      "r230",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacility"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r373",
      "r374",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "prime rate (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Prepayment and exit fees"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r96",
      "r180",
      "r181",
      "r182",
      "r183",
      "r336",
      "r337",
      "r340",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "terseLabel": "Accelerated capitalized and unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Issuance costs related to common stock offering"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions expense recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions made"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Company match contribution, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r80",
      "r154"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Equity Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r3",
      "r12",
      "r21",
      "r94",
      "r357"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Receivable from collaboration partner and contract asset - related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r32",
      "r97",
      "r357"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "positiveLabel": "Net loss per shares, basic and diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective tax rate of provision for income taxes difference from federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r284",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Total unrecognized stock-based compensation costs related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period of unrecognized stock-based compensation costs to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP rights"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r118",
      "r153",
      "r179",
      "r184",
      "r271",
      "r272",
      "r273",
      "r289",
      "r290",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r230",
      "r320",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r319",
      "r320",
      "r322",
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r216",
      "r218",
      "r223",
      "r230",
      "r320",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r216",
      "r218",
      "r223",
      "r230",
      "r320",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r230",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialServiceOtherMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.",
        "label": "Financial Service Other [Member]",
        "terseLabel": "Additional services"
       }
      }
     },
     "localname": "FinancialServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r80",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early repayment of debt",
        "terseLabel": "Loss on early repayment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r370",
      "r378",
      "r382",
      "r397"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentTaxIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Change in deferred tax asset"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r291",
      "r294",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r109",
      "r110",
      "r132",
      "r283",
      "r292",
      "r295",
      "r398"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax expense",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r43",
      "r376",
      "r394"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Receivable from collaboration partner - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r60",
      "r131",
      "r335",
      "r338",
      "r381"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r66",
      "r130"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Classified as:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum lease payments and lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "localname": "LessorDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r92",
      "r137",
      "r152",
      "r306",
      "r312",
      "r313",
      "r327"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r92",
      "r152",
      "r327",
      "r375",
      "r391"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r92",
      "r152",
      "r306",
      "r312",
      "r313",
      "r327"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License And Service [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Loan facility for general corporate"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r33",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r175",
      "r374",
      "r388"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r35"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities - current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities - noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r57",
      "r62",
      "r81",
      "r92",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r152",
      "r327",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss",
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Supplemental Disclosure of Non-Cash Financing and Investing Information:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r347",
      "r355"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Additional base rent over the lease term"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Minimum lease payments:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesFutureLeasePaymentsRequiredUnderLeaseObligationsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r345",
      "r349"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating lease liability",
        "verboseLabel": "Operating cash flow used by operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "positiveLabel": "Operating lease right-of-use asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r36"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r303",
      "r304",
      "r310"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "(Loss) gain on translation of foreign operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r55",
      "r58",
      "r303",
      "r304",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive (loss) gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent.",
        "verboseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "underwritten public offering, Additional offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Issuance costs related to long-term debt"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r70",
      "r149"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Available-for-sale Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r217",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r242",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Balance (in shares)",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r72",
      "r270"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r69",
      "r149"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Available-for-sale Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r57",
      "r76",
      "r92",
      "r102",
      "r109",
      "r110",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r152",
      "r303",
      "r308",
      "r309",
      "r314",
      "r315",
      "r327",
      "r382"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r155",
      "r392"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Outstanding balance paid"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Early repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r280",
      "r437"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r11",
      "r87"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash - current",
        "verboseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r87",
      "r427"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash - noncurrent"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r80",
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Total cash expenditures for the reduction in force plan"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r184",
      "r274",
      "r390",
      "r407",
      "r409"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails",
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r153",
      "r271",
      "r272",
      "r273",
      "r289",
      "r290",
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings Note Disclosure [Abstract]",
        "terseLabel": "Net losses from operations since inception"
       }
      }
     },
     "localname": "RetainedEarningsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r147",
      "r203",
      "r204",
      "r369"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "License and collaboration revenue - related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_RevenuePracticalExpedientAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Practical Expedient [Abstract]"
       }
      }
     },
     "localname": "RevenuePracticalExpedientAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuePracticalExpedientFinancingComponent": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.",
        "label": "Revenue, Practical Expedient, Financing Component [true/false]",
        "terseLabel": "Financing component"
       }
      }
     },
     "localname": "RevenuePracticalExpedientFinancingComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r350",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "New operating lease asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale Of Stock, Value Of Shares Authorized.",
        "terseLabel": "Net proceeds from sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Aggregate shares of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock sold, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureAccruedExpensesAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from diluted net loss per share calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of cash as reported in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of the basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r240",
      "r266",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r240",
      "r266",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of performance stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r252",
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity under equity incentive plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r242",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Black-Scholes option-pricing model assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Grant date fair value, price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Unvested, Ending balance",
        "periodStartLabel": "Number of shares, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested, Ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum payroll deduction for share purchases (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Ending balance",
        "periodStartLabel": "Options Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options Outstanding, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Shares issued in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage of requisite service period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansPerformanceStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r263",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Exercise price as a percentage of the fair market value of common stock on grant date",
        "verboseLabel": "Purchase price of stock (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r118",
      "r153",
      "r179",
      "r184",
      "r271",
      "r272",
      "r273",
      "r289",
      "r290",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r118",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r179",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issued (in shares)",
        "verboseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r19",
      "r20",
      "r179",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Options Outstanding, Options forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r179",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock under equity incentive and employee stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r179",
      "r184",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Outstanding, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r179",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r184",
      "r241",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock under equity incentive and employee stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r92",
      "r148",
      "r152",
      "r327"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, Ending",
        "periodStartLabel": "Balance, Beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r348",
      "r355"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Less: sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureTermLoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Common stock available for sale"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per common share, basic and diluted",
        "verboseLabel": "Weighted-average shares used to compute net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130569-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r441": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r442": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r443": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r444": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001558370-21-014338-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-014338-xbrl.zip
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MB;S=:!S8"]W*G)J+KS.KPB:IE5FEL[JHPTI+XD!1G+0LO7WM< GVG0C\4FE
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M)A0.8X*^]$%G2PJ:22O5!Q)565X2B,NFL6Q+_LK&LC>F!#YS^P*E#D3QQ7]
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MF'!CZ"8XZJL"]8-(00-M6SQ%6"TLN@UZ,1NO;H.EWG'/0.$ ,%%4&UHXS+>
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MT_'J[X:I2O=]*BN5O.)%) 45;>PH?JS8*/WDP?<D*X=ZQZ NV^>.P)B_)31
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M/G\Z$ >R?(II*(8B_'_);=_43BE7^P:50-AE6P:VE GMN]8VRT=X'ZR1Q[T
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M<]-?I^W4Y7O0=(K S=8UG9H)$"#=CHDOVI-9[K"I57DF%:'HOS*Q+<!E0!<
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M)&^P)0SEU$(3 $%R<CJYBKF=B6UZ2> FIY;O^*?X21UC8E890L:&.GM'0_+
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M';FTQ*9:9MY_?.##X;&J__;_ 5!+ P04    "  KB6-3F1 'T7J.  !K' @
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MU(C.MFEVEC-4Y$Y[F6ZI[?!$[%:O$Z7;Z>X*3M:<+:1TDU\R109^SI/-QZ
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M#7C&\B12"25GPV7BL=T-M#<?[6R\??F9=K!D3VE0*W)JV8G)N$5*8MP*@FZ
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MZM=T(\J 6]DJ]1'U4"087:B'LMITI';%@-2=>AB9'85+O@\6[D,]$>$E'O"
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M92/XI<SP)J/E;2GVKUW$^VY:A\V]P.BF:L&:QGA[('TP9R-YRH*D=IR\KW'
M/P&)IU&R.[,=#]"@("4.GT)D=P9ONM]N*7=QOME$!>])UA"QSFY'^!!WC.B.
M9:@0--[&%9T/+F@8S>I"R1J5V45!/5U36QELGB$IM:E2F3$%#Y:3+U$<0UYT
M<V!;_STTI:HQY5!BW>!5AS>H_FXBR7:<8(-7]H=K%AGY[!PGDH::>6^2"C4_
M.=R&?]!U9^H.PTD2Z,B5DP''8Q;?]*L)4&U]:L^PY;E^G V\);GRP41UT+,/
MHDX;?ZR$V"6ERKH-XV@?TET=XO79K7HH<C+KB Z+W3"E* 4(P\B7G#5_,_QK
M5 SN@3N'NG].6"B2%? Z.?2A $[*)>D3M3,! P8?S,**2;VI]((CFX\%;6:3
MDI"0"@MY4^+Y=D48*A]L;0BOYV%(8YKQZXMAL(^*(.9L@C$>)+9% )WG![X@
MA6D^:4NOJ@'9>@^DL*7OF@8Y/:^:O*FB2",(8G<_ QN=QGZ:\;@]_7J),B68
MF\Y^:86&;=X8'O3.?6YL->WM:CC" 4D-B=BO;R@OVF^"V,<VH\%Z>\W<CL;5
MR0.0.M5V2&RUIJU_7;X7[='472?/!O ;/&P(TD,)MB3&"A*7T\+R2>:7]W2?
MYI$NONN,PM%'#;&R4AX-65PSE?-W+YF5HT@Y#$=%'6G=J&E=L U^R_F7UY8U
MO&G&(C6][R.\U>M>-7#Y%O=Z*KK)FW:0L*HNNB/ULW>@7,J?/@2\V0DDSY_+
MXT(1)L#=3U_TO6I;KKN9IQWM@\YWB-=K?3T46>^/Z#!K?@W@@^Z;J!<A?3PO
MR::&_&XDWY0=CIZ#^"#J8EL\3/P>:NT=^B,DTV",9MHFTIO.V;J12&VR^\GI
M>O"Z'8UTWIH?A2M+-[QVY:&A'#<H'$O]L=P1MS2'!^X91(]*7>Q[- AI0Z,D
MM;6?:8U8?CNCF+Z[0R@'$3%J6KW]61"9\-[HF][MC VMUS3/?R%Y17&DI'C!
MC@R,G#1K^GV?/^3\G6\-B_KA2)T6#.2WNBIHQB[?0:&7$'6DE*^D=.AO%012
MKUY'!HX"U?P77W8TM]'C4['>?L[I>9[3XHY%!CPGN]Y>5DTL;V I80O,AZ\%
MV\I%S&JOHUS[XMU4V'W8,8T6CGZ'-1@U\HYL)-WF'1R?X"S=GGV&XPZ88T7J
M62#.K.<AU43DMV8J G,A^81Y)=7PO2_!?/$A]::Q?,IM8B<R!KT/7F2\>"P2
M-<ZX?<GL#"3<(154OWAXHHYD<E&=@"?YQ(QL7F<R; :O_,D8(5FXE"'H??$J
MPVEW<BS--*?N6R84V FXE[F<RLFZDED<R.FYC5F=Q6D[B%?L%OY*8:M&-^?/
M[*^/])9"XZOJQWN:[71=-]S1^&#T]NSJ;=R, ]FD;0DT6W"%B92H2(VKK,F\
M5Q0H8)CJ8)8KP+.@Y#"K.6Q*,,B;%QID.>)MMEYNJ])SZ()0WKT;(C0E&@^-
MMH==:Z-5X/#+:+4$#C#:^@(%(%M5US,]-%M[ICMFNZEX'-I1>0X[O4@M@V@Q
MT =;DTG66Q.,0K:7A@2S1<!8']3=BF:Q[(0*DI<\%N[77G2E[=55/!4U?>79
M]=%4\68B\!X0E"I(U96T"U[A;Y\BK1]$/]4KMN<*GQC5]#+-W&I41V%$:@PP
M7@BM'@+#T2W?;F LK=T[<YT#5E)AA4?B*KS\G8;CZV?(Y;73"^,3_=*]E\9E
MDDHRH;),CH=KZW>QLYP1S6_*W@_O#Z:J)C<4/D1I=FR:TY1J>$\RDGW$F6(^
M(B%A.YZJ'0G#@UX]-0&S'Z.$OY,CC+!J<H)85P45891JW$_%ETC*;. :[27;
MK07QO]/@^"GU*1#BE2*.$\%QL>(P;"CEC&-(59;(4KHZ7H!;YPD5WA6I,8N3
M!<!- #E>:>2DPFBQ!]=$/#=RYKP^T:_%_1<:/]./:5(\Z9X$'([.8P/O8=_9
MO!6X_#1N+:$C31M6:T!,!&8B4'MLV/:"8";VH_^6#'[I_DLZ4B0U%K_M]HC9
M(>9:HO#62EOT36"<@(\99^JW2?9SS4SDIQ.Q1#:Q[CK9 #PG8(TRPX/M$9#X
M;9$-A9/9)*"<Q2J?:?:03FB7/;PSD_F3_Y8Y4@B^V^$8\_/6ZJ8R-JPSG%%<
MBB.>[:$X9)3LE)DD3ZWN<U*=\M/-AZ\A&]K;%W<@+@_MT<2XM7'J$/EEJ?U4
M#C);&241.&=IV6M_6WQJ"?Q"HMW^4/!#&Q8Z4]3R@33/+]CVE_%%DS"B^3T\
MEJ43A&8PDAWVDMXR-.7(Y2VIAPS%.X!,[UNCR6]\?.<L!%%9KJ.$7A5TITT<
M]@!XHC0=%GH5IQZ-KSQ'I%@I$, 0#C1(BS0-D&YISO8'(7\W-XT9VC3CC7OJ
MGJOOZ3.-TWW[18N/4<P\7YI0%@<I?,ZDF!%:*TTKE+H/TS1H<9HV34F[XO1%
M(!=/4LOHFV[$1)I ?A&FGH*4<RS<">IT!(/0:&I6X4B\[FI>R[W5A![RFDWR
MR*F^HT41<[(E9I[I>99!Y0[\7:8<_ON6;@XA@-[T/BLV^10(/G,F,=7.<V+\
M.%YT%B;<7AG/ X96,IBL0INS?^:'F._LX+M"K3_L=.#/:7S@3@>KQ_TR<FMF
M(<TT*]*:B$@SM5TL_TL]6<]+9!,\)_'ND+-H,,_?!R_'X7O/.,2'(U0$=UZ+
MD ?A/A'1I43WZ,!Z2ZK!!$8C/?XPG. I]Q+I2Q!#B=TZ^42+FRP%6[@#?],8
M0UY;B#)><,2 L3<8Q&2S!W "1XKU!]#8;>/;6G7J509JG3.._P5B-8R ?0KN
M:B1DG< K2:3$0SBBE>3]\V9-P C E_V42&$W9VB!V-M^'L\#<%>!#8K";2?Q
M/Q1WX^0_XO$IA><<E//Y!H;F"WCD!45W8ZEH$WIM'2>7_!Q<RO;89)!'($/P
MOZ-9KYWL8$PXGG0DN>J7U>N>_V4%Q49*<K:R?8"(''CI/CC7L)4DQ?*/4XM$
M[^T$QE8.V(?$[]0"N+30@@7<V"U]C.#*&'>_6;I/F5,MGQ_*!S@R*W0>N3('
M]HW.S *77^[,FN Q#BU*POC GTC/I.G(OISOY!S><*%I71[<19-$4V&M7B3+
M/?1ZPZ5PVZ<%"SB\BW2W8U%D!*62AR1\&N'LC*@\<G26;!N=G &/7P[.BMAI
MG%M83T5B/E?5!27G_0_*OT4)]W %%*^31YH^9L'^*0JA5UP6,<V&]-NI.<1A
M0NYQA@U"(C#Z[ B'<J_3%E_*Z5[.PS [!/%Y<1%DV0O[XU_@]3JK<C MK ]%
M=@;&]/5V&D#DTKM>JDQ5>"^DA$:ZAS>6DU#B)%!S,L'1]*^UG[YOW'3?T:4&
M /&PNI>%SJFU<C3N\74/2;IC8;9VJU=8I /M 2RLMZ2!(A(8P@(XQY= ?6HQ
MCS91D+VLLP]_/T3%RT=:/*6;J^29A7:40IYZO;TKTO#W=R_=P=6PONL)TTZ!
M]LSCY&(Z>B1R,OP83TQ.3+SJ@<H2BK!-A( C8A92P:_X^1 8&9^*/+P0)5@U
M'O_B1D.>)*)KP^4-$Q"V@?2QHE9Y%02B$NO)Z5'+8^7KN].Q3% YC"$8])3&
M;,>=_U-I,'CV<1$'>5Y2WCR6F1N:$1JA<"S$DAG91 P@B]N(%3W=/3Y -98A
M :)W$AS&D."#C4CR8/@Q^T1+2&/;56!Z]Q0P'J[R_ #-3>\;,G6.P@D%TO(R
M@,W68N, O_S2XTQ<5R7EQ6=%FOV&0$0$)DB[2KB0UJ7QW)X_/F;\?CC)!7N,
M4<@[IPG)N6WF; 7SPB9OLBB$AQ@XAV:!' U'MS4E^1J[:HW%M"$%(29[X2!0
M/";L!=TP;%BX.%;X%=ES-O:,C5S%!HH%7+#E,=I0<69S2T,:/=/-VFU9LL&!
M;BOVC&H,R(P TZILJ5.;VKHV-9[+YO\M7/?Y@6WBL^@?=#-/.M+%[ ;S"-<$
M]ED:4KK)145O7CH8>5E"WTC]-8#SNF*=\5;X]>I+PT/&^V=?!'%,-^]>RG%Y
M.5"7B1B-%74C-E88BHW:4)18&[EQ].HW>N5XR+EQ@%9 6F,G CWDZ:H):@BD
M'K7SR*7F+A)1>)&2/2/]2;Q2U/B'%4EJ,8G UB^/D1?O6<Q]R8SIKT]1^'3,
M_8>O<)*?]YP$C$7JC[]P%X7)7=AC],);N)+KXBP LUA%OP!NA7<@$GY_/,5H
MF=2,TF8HV: ^Q^?H$3\$-=_EV&D\K0JO/]Y@D$!&Q ]=I%[XA $43QA#P!0=
M*'^<PQ3"J?V#+H(@;Z*D#!T0G]I5LE]Z/\I3&_6/M7/4/9(]$)='OL&6<:,_
M,"'RPP?84>EB]Q7&,DO7C)E[NV#1J7M*$1SQ^:;.XR&:LIR9M\IEZ\<C)>A,
M#+22<;K!RR?>^BGI)MGD8QY?\MF./+02VE')B3<I[<J*SY.-,./UH<B+((%+
M#QH!](/@V(,-&[))](U?W"K,Q.A#)C:JVCQ*4#B6,8"/EG$$ST$4\\TA7*F!
M5+-GP9[9-LQ@'H5P!ALQP?@1F%GHF#X&F]MDAH9:9J;$\W]P,ZU)KM:O%-?>
MX9"4*1<ZJ&Y <W%".EKBQUY5I4-SYG7$JS44PA4*>V;J>Q1F$)S+%+9T*6]$
M[H*O_,&/YF9D683"@I1=5#8"2K=;FC&E6_% )F"27?$5B!\+/KSP,8S"J'A9
M^!+&8-:MCW$1KF0,9NIC]2WK@J+JPXG <X9+5)7+J79[2A?0,QCQ\I26],[%
MJ<Y(W$M3&G*4YMVL$E^.LO%TP\.MLL]7E,Y4L* U75=NFGQIO<Q]T"UR"QCI
M</*['V+*-1J\1A40;"[3[":CEW#E?%,1JO0X%E 8:[0U,\T:;01!6J,MZ3(8
M<;DVTPH1-^%]1L^V'%>M6TLOPT.Y$[7G'UKLW#3L5- 8B_!0EEI;6^.'FK(S
MBFI'<<^BN,9)J1BU L/H>&+/3M/=Q R#U,G$EC"E_6\.98\0>?40G39%D%>'
MY4OW#AG,5L_F'.#E91ZC*\A@OMY;?RI^N/E"@PSS;+-[OQ74>/TE8>)YBO;:
MAL0#X'$28,X,RIDP:^#%4V*.E'4/YQ17CD67GAH'6O/9B7G<"1XCB<>TYG&O
MY7'!0\GPB6X.<;7-?Q>P'0$+(J!OD'B"J.E*E+][:<:477;/F9O9]#8LF X_
MTJ'GU )J'9).A7SY0]5I*>_&YB7^^M[=V0. $WD.N<-7SEL42 .K?M9\)EU[
M@H4.;U^%K!8NE.B3DDY(UZ9V#Q,@1BR]F$0DG1J-45AQBCDF(%E=]6$P'(/=
M7*.WJ9A+.&4T<\/^B'D_'VA_,+/W<,S>AZ_[J&PKRY/-?>*;!C^BEYA20!UG
M,05R')\Q'>73NPZHRZQF(F(J1 <RHZ0D-O=*-D\@R&@W6CBORH<NT^Q72+A,
M[9J-TYU80&(IODG"%,-<IQ.\6#$RAU_J-#\Y;Y7+\=FQBI@6EN:GXW.P=N5@
ME5D]P?#HIKS^4M;8BS,DT3M#9*BF7BTL)CRQ ,I:A)-$5,;93B?$LF1E#M]6
M3=W<A2E/3ZM&-H* $XO$A@JTOC$C;@D$S+\=/<$'Q3K;(,K(+LA^IP5YYF5K
MQ^VBV#\>^9F:ZJ[MHDO#DM*K=6E?Z5)YAU"6XZ"C-LUY.SP)$!9T\Y<T9KS%
M;'=^$<3A(:YB\/*[K;?G3%SL'\VX"E*<*'+>UGN ^E5[2C_C9 AG^[.+KJX(
MF&TFG#J"F=EQ>Q T$'.0YWH2'H8Q7[0/,AZ5[0\/<13&+]!=$JI>'J)TSXQ^
M%X3T4$1A$(O!"5Q]3ADV8:AL4TKHWP_LUR(5I<4E[=!C?%?YP=+7<1Z$O\M7
MY)"+MH#\>95&,@!3(VG(7;A:8NF/5T&1!A&19I3??H;2YW)6>72-@==D5.72
M1,PMMAX8Y1E+"_*\H^@8RT@S0&ZK=Q<Q5WNU3T?)R83:YR7"3BSN"T(_7L_=
MOPWQ;LY><O)U:"4BK1RP$K@J$B51 6\?";??7#YX'5YYD$P=?; TJO:V8F_$
MYR%7-VN?_>T@$=T8]4PL\GFI:0H9G$#.^I)MV_AMGO,\/^P$0Y5<WT?/T88F
MFUNV7YLZTV8_[XEEL5T%.DDZVW;2T\EKNW$T1Q((*"@OX$DTK)K@LR*#W,Z5
MSYCO6'^D>&O67R**V@-\*/\BNI8[ MRF<7R99O#CU,(V3'9B#LY*=)-XM=Z9
M3L>56; QA_]:5PY+FIC\!E.3<NY3JT4:(L@2IJ^UPDFZ*W'F.+^$JWE.WDFU
M!3:3?Q*3G+)KDCE8RBM5Q02SN".1N/V0;!9R2;T"5'@C%E *U_P0Q*HJ@0F%
M<%<$6>&M&-[1QRA)>B1Q.GY:9&VORHJW7[,TG[SNO&^FT_35/4*;TELKICDY
M?ZWE85:/+6:%A*F8%_["9C[-(-)>A$IG5?V1'_ -ZY0QD:N"3*3H_OC^ %EM
MP9 H8),.DK2=<,8@0G(T@UEN^1%G+,N[B8$DSNH%JKDD1S"M!_A9"";AG:+Z
MH[:IY--KXJ/:X2Q@Y+<T+[(($G=\F$COI=F61L4P8S<@]-#HK41@;?R]V/QR
M A:D:GK;E$]5"I3U@BZPKDB#MSSLJW+B%6XO37Z(-'I-?ZMC]W2V(M)S*+.F
MC!3SG.8V1"NP*3<AG4E.;@NBX6")T /FG#5E-/OFPU9X-G&)ZG&FTW%/?V$N
MFV[.DTU= 9?"GY9*=-M/?YK.S%6\4_HXV[E/SO6Y,3:K1Q2D\)['=5E"D?(_
M+Y=AG]U=CA1XKQ=];B1()0G"GT_7JTJ<_I5"CS@F/5$KW'HT!TY/MTN5/%@3
M<IJ>=KC(9SJ*M*3BY+SO4!:7.\RLR*IO+AP].?7;^0/;IP9A<?KU%^.^0 5]
MIA&4]F6E5^>)<;_4*_>YB([VM7I7SUSJJR@<&2!O:P?Z2HM,YA79*16D:+M#
M*H^[YUB*IJ3 T^5H>B$[+4G33>_?LC0U;X.6IO[NI[V5,!@+U/A ?W:I.WA;
M?RIJQDJMKI# =+>.1)RHQQTDZDF=KA,%I^=W![ WK^M5E!^]5N\[A>P'.& ?
MZIW&BJZL^CADN$[8F8P3=<,#Q3VI(W:DX?1<\2 &YW7&$DFOWQU/(_\!#OEU
M5:$AI,&M9_?4_4XKW)GJV$[+V4[)UW(U;Z?I6&>5]?  ][47SB$XVK%$G:;_
MG>93+%MZ]ZJ\]13L>E*F]RH]_"S?9X#C?Y6U?N>;303_".+W41[&:0X;E*K"
M:*8/:ICS--VXE2"G]-*]$YZ<$[;@9E8?V\Q/) ).OMANB%@[KO&6[H*(5S)<
MI F'A"[6U]&6DC?83SUS[A_, GIP+@>IN9:8A@;+/_9]JJ4I.;'73,8+?9)G
M3H:3<3KOGXSE$;$Z3^UO@+83>S)E\F_PAW+-^LR.3FQO9_J @R@Y3=<\0NA3
MNN8!9)R<:Q[,(V+&^+6YYNF^P0#7[&-.>80LG?,T2[OQ*0D\3>\^_2>:TNE/
M1]W)K053L^YK/OJUK1^S?[=1R\K$&6O-4T^C<U2/CQEOW73%^(F2/ K%TP+J
M)/0R4R(\#;60&.LGHV:>#^<IJ468ZAAI\GVP[.M..&Q.FF^O*" U">5K*5@I
M=T3!:H5QNN>*T@K8%L7\USJ/YSO-\T2C &>ZC]Z>[.3.$0V<+)?5-ECR:1P?
MNDI3Z\B:F-2?EU2F21NUY;) !KHSX6FF(LPBG"F??#3;R:4*3*PLEQWVQ\4M
M*4X+'^=/.G?6LCM-L(M6!JBEYS0CP-$?8-F:8 TQ)Q=!CN34D\RK]9;R- +1
MJ3^*A1-_E>6^O2TY^(_OF5#JYUUG^IK.5)RF Q\H[/F>JS*2<'+.>A!_"S]S
MU3D$XT,($":]$GV:?GD:^=?"^U*==@6EJ'@[G[,-B&H+HGH^T:RHZL%LMII]
MI,53NDGC]/%EKCL7+C.?F)MU%^HDKM5^VM-QIZX\S>%"&U]()"IX ";1T7,^
MM)P?X!3?LUG.OT:ZMSF/QN#8EI)0V0I: Q;75\7LW5 =QA 8Q#X]&X;XV8WF
MI6T"TC":;&X8>Y^"'7V?0B7'4$L>-)6G#GZ$V*9I J2?QS\7/I@)M<\F[WI]
M=D[>E4Z['-ARVD0R3C8K@6D)S$M^$S/[>FUN.B%^^/LA*EY*0>BX7LY%?=CM
MX_2%4NG]RH^TYPFDGO$XSL+(@&SQVL&+FZV!DJ[:E./+!Q(%!/E-P"!9C2L/
M5::L2,F>$?/$;(F$Z6['&,D!Q616D&>%9 'LOXZUG_WI;Q^C)-H==DIM5_R^
MK'9K"01M[ORXF/9J9NY\Z7(,DGXZ4GF"906J[5>=Z9[C1H3%A"=65F MPDG*
M"HRSG4Y9@24KR^WX5\W9U@E>#!@JSN8\CPTB;Z*$0#4_]O7=J7))%7=_26.&
M)F81\VU0T-)A+Y',,A#@Z<9X<A'/E@#MG=V_3?3$K*$XQX8> @2MB";^\63+
M/;?(:[D\UT!:D;PN+QI\1?:B%0&OUXNV1;RT%Q6SOTHO*K/FB1<5)+U>+]HK
M<K4758OD1+WH;93_?IE1*!2C[",6"T>BO=._ @]J(=[9_&?/W*?M/8V,+>D[
M@1@"U)"*G%<7@+K+&R#.MB"4J!)*UB>4U^0\EPM >Z=_K<YSH>"S9^Y7Z#RQ
M D^]\WPU<:>[O/7.\V0C3U$7<)7D1<9;5N3KXHEF]T]!4AZ;?DH3<<7@-HWC
M2_'2_=1?9R 1)^9(1XEZ$G<ZB(+3<:HCV)O#M98E-Q(]A!-$"D914XE?$\7^
M>8!C8Y)N!=J<_ :$DI)27XN4EO@<QY)YU9Y6,(OW.:KY7ZU_;0MX8=<J)G^-
M7E7FS">'.HO?W/.K1!^2#;+O[!5ZXS9S[C97Y',MFP_\/BIY"!C$3&_N"!G=
M%4%6G*J4WM''*$EZ!/4:5I[V];C%O]+Q]*]MW5&+=YEEISWW*UIU5(PA+CK'
M]VE?6ZQN)>ZN(^5@)_FFKU$BHM<#FM,\GOZU.4VU>)=QFNVY7Y'35#&&Z#3+
M/C$S.<V?A:03WD %*4RW$GC7;0JPU^@U+ZMGWM$<IX*"U^8[M4)>QGUVIG]%
M'E3#&Z(3K2EZS7[45NS'>6))/*_1F];Y#6-+&R].[]RH?&U>>=3'6CA)[4+B
M*_+N(_CW(^%MU\3K=-\+7O0+=AZUL>J(]L=:5SS^P'_D%<379>,/N5:<W@+Q
MJD],AWXON^7@#WO$NIQ8_X!GLOZMPZ^].?)<'PCCV/>/M"Q[TVIYX,'Q*VW$
MO-!WLUU,_C#GTOXM',[TO;:%8^ 'PCCZ_B,M'(,X]^CP_(^Z<$SSW6P7CE=_
M,G]@G]^_1<.-N->V8@SY-(L>]5M1]HK6"G>V\0L$#OPX_(^Y1DSPO6P7B%==
M;]#>I,W[GN)(8E[;&F C>HS<TJD^HS@!FUYEC3H/!)[OT@/#RWX7\[TVGS[@
M^PB7??1,UXKLLRBD9,\$E:L$=0*-N?G_@:U)E#S>PCJ5,ZF$[%>V4/5]F.GG
M.K%VW#:"FZ03=]]$I].$V\S%'#Y1/%I23DO$O"O2S'QBK;<'"+'B?5\/A!+7
MC#(?F;-8D^0T>RY]F*+\]S5$GNTLSWU:!+$O*>QC8EY;Y&DC>HSD=)N25Q1Y
MFMGT*NW\>M,& S[$91U7\OM<_-6D0Q(5I]BQINQJ5K^W='C(PRSBHH%>:5-_
M#N-T)^98+<4WB>LTS'4ZSM&*D3G<7SDQ:5X\DZ;FO0]/S+L-DV0EAGWPDD'O
ML0W='$(N@FU:[H_K5]1R\B;(25!%I:?X" S_:WZ5YX?Y;J2JYS@Q9]8GJ$D\
MF&J"TW%;>NKG\%5B-B*FF[GGR#/-'M*97)2KU'(2U2RC;W7#)^8:8[K>UAY6
M;,(UTH@Y+>Q?Z^TM#=/')/H'$P9GXB+-B_P^>(BU(=4\<R&YH#D%UW)%<TRT
MO$N:CXNND95SP=:EB8/*W)+.;ZU(,R< -K.6;HGP><EO?&:L"X>O7(K+^;VK
M)$QW]*Y@(23X\>N29GCR7B/[7@@<'V3!A.Q)>H8O[@^,M'3T44"0&H14,.0W
M@/)/E\3KY&[\5S!>Z5.;$0N-DI]PQ]>IW@?E>[1*\[K\,IY^&5Z6LY%;FE.F
MB4_GR>8]?:9QN@<*X?VK)*?*5\2=(''LQ8$IV6HLP!:W'6N:NJ])E)"$@1()
MEI3 2,^83\A8P!C;-+!X1O0K36@6Q(R5\\TN2B)H?E%$S]3&C"QA<0S)B3'9
ME*P %S<F!ZJZQ3T"EEM3&]H3@YJ".;"HH 6-9U33[*2NHX1>L657MWN8?!8<
M0YU)6+))3SS%XL8_"_USI%];8# I^0UF)7Q:).?R2H6WG#<K94,W:M&53EHC
M?5M@'-_CQIKL4NP@%_<4+F1U=+@&UN;BJG@!ZSQE%'N\2D44GI2LA3)K5,V:
M9U%#W52&.XV<\R3_#G[C4UK\.RT:-S;&,0Z;S^-(8HP G6.*(9/Y&5T,YZ3[
M0KE]YK^>5:R1N6J19+.2%UI(YP(>QQD3BE&XLT.2-><A6M\6\A.2C,;<NQ=I
M67Z7BF*^5^CR1.1VF6;EGV#<VZ4_G(:(5^8<>T6]B,=44O!ZW&@/>\O[UE5U
MZ I%;Q)!K\SGNLB\%$BZ=7+&S D_4))I%ZWEG/![NF7;3"8RN"CX<  :;QB#
M?64W_2 X#LZ&#=D=]8U?W'F8B>FH70E"9!@"0/B5$"5I[VC"_E$ 3>^C/(S3
M_)!14U;3$A95Q^P84RA;/R"6UME0I56_$EAH7@/N2>Y*8U?ENI%]#(KP*4H>
M6[^+FNWUEO_H9J\N>+WRDNX"L7"E]DA]\;>N%-L[Y555\):1"GEK4'UK%^((
M/@(GHII+,/PWZ9:N=RZAO-YQGB0'" ^;'^$.<A5GBLX1;J)S0NR54Q@@$@NO
MX(#5%[?@3+*+7ZCN%0GLK1$Y[U%235 U+O'*,8P7#6S%@N2%[+B'"%L^<2>P
M>^<L8,MHS*];PGIE\FK&+*RZ#>B+X:JH<K%-@/?*W*P8:KN0\ES+YU1#%5W
M]B&C\-<@>Y$'#5EWK9%Z98".HG"(P@T8?3%9)W('Q=\MS.V1'BZPX^31=@6[
M8(-YOKW=TA *\T11^7WP%6Y; X51<F![BC7;'? ,:5[^!(XN":,X$B4ZY<-L
MNE3P5-B1CF>F%4[KW&4:U,L?J$Q)=_>DI,).RCL.# EO9D#::)J-.?;3@$O)
MHV""R$ 0Z9;LL_0YRJ.RR4$D),4&T)QL(@:14:;9!%29;.F&%^+F15 <F MY
MX4A.P=V,EK?_3F.<7_#8]*>R;M]-VLAG8YO">'UI0*)F\<@U%9?">=Q5OJ,U
MV$EXCIA],MQ!0C%;M!-:3TQ] ,TC?$!0D'("4L]P#.2EIYA"3)>===M75_*)
M%H*AZS3/#=L!S5@<<^\E7#9@Y<#%3;*'BH[VL+&5I;R!X=^2\T+L.*$& :I<
M;H+,A^C9B:G##M;=-/L%3]F/7F-@)#W0;+T5W7[6AX*9*W]#U6 '[FAP3&0H
MN[+UN.)8W+"&$:A]<*-^J40@@OU:V0Q*PK4B[Z/X *.Q+7 B[M_3)-U%";)Y
M-FUSSEFPO@$1L\7YCH:'+"HBFG_X&L:'#=U<,BV'$R[F#V&)7F\_!!D\T O'
M8YQSN^Y6TTR"W=9J2E&I^UE-,0-B(ZOIR._MO21/0YIY2#612.A(4_&&3>5D
MS;L9OC2N>AU26_!"YSAYO7M1(^AI=#7KC$A71^<78NN^Z7S3+7])=6Y>NC=;
M-::+W>9+S<BG8$=[.WV9P7RRB2X[9L5N8#S1SF."K%4, )$;?TW+T:J?I47[
M?Q59%,)M<+AJ\QG>$KB]^VSJ_-4'@];SR\S(4;<O/0!&GR\3-:I&6"4,X4"$
M0Y%;<D<^XW?W&L..%P];U/?B@)A>@U".1+ZAVB5:>8VT&89WU_.8AIX+F5PO
M<%7;@>R[FQN2\2>X?(N.K./$:\--L^G0^Q1M#1?/A-N-&K<GT=M0PJVC/.<<
MP#5V6ZR9!763%I3-$,3Q"ZD%EC<">PK8?S]0"GUW9-%MRF1U0@L2IWG>/#Y*
MPB .#[$HASA9I]1;R3P1[I-T1_JZYDD0GYHCZJWJG<@+X5XHFEM 9RJW\R9*
MA#?)!]4Q[(O'K^ 8WO[P\T\_<+< ?_E;\TII\XH"M*&XVNT#V!2\>^$;A$-8
M,#J21RCK/A+*<#3+&OM8=L&NA^*8Q80W:<A?..1:-M%'T6X2]XQ"_GQD\42/
M7JREU3X!&H:0J$0.'2-A;"9/0?8,[7>S&*W*H4TLA9L6V_7V")"1*XGM%CY^
MA6-9-S4KVZY?&SG)5M%RP3SG(]7MI]1#$5-J&K([F;2C<3@)-"41ZD13K1KE
M6,0\F1W5HE5=&.1/XC;B)F)0;#6&.P5"X:NG%"-^T0#>ZT;5^OJ]"_$0+@0B
M:0*>N^>,TP"#5'MAPTBKE*(/8/G*"#,UW=25>*VY&8M^RG=$?._1GF8L4D:V
MC_!63E8U</FLK)X*HY8@']'-0OIR&LYHV:6)^;1!,0Y'L[4$RUK=&;2X1FLH
M4/708..\.&,80C)B-F^SX;T=@_@FB#97R46PCUBLTJO$!ABD[)L-(ZVL6A_
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M(BE215(D)5$<2G 0[HH0'KZE:C@2%N,1&ODDEM7FO1YR[H!^W!QH=%+")X*
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M@^^!C1%@]A:NB"L[HR*%DSWY:R[W/$L(DJ04'HB1;;^!+GG4A$E@*!?WT[9
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MS6-FH9V6-=6T@V(K09WM9E4HX! 5HLI$JUJH)G]H:>9([D]0)%_SQR#E^17
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M[C_>0B\?X/27[;>(+="_/N7-/J%??9J<?#J=_/PC<GY*I\@P_D\Y,>@7=>1
M7E_]@O_Z$^3!:/37,/# ,UB,\._^$G]LP-]^BMSUQD-CX=^M0K#XVT^;>/GC
M$^+C^.ITC";U3[>9N//_SGSGLQ^[\<>]OPC"-6;)3R,T_K?G^])<-F$06\O
M=Z,8,M3^V0[6OZ!VO[ -^4O7F;_$$$AH_&O+0\)\60$01YQS)0TB:79/5@A_
MM0*Q:UN>D*GNC2ANWML?HOEBO@$A%EMK]I)&DS/?FV"]"<$*^)'[#AZ"2,BT
M:P:5,_N7.+!_7P6> _7VYW\D<.&(F'[=J)*X;T6K.R_X+H;KN\$ZS_;6C6PO
MB)(0S,.EY;M_8!1"]70+(CMT-^A?\\5U$KD^X,8,[^ "J7E)UFLK_( R=I<^
MW#1M"RI=VPX2J'7]Y5/@N;8+VM/#.KQ BAY<&ZXS +EW$WB>]1:D"F.V# $&
M1FM:F@<62,6=Y89_M[P$? 46^C>&=.NI$T83.%^TUI!J>+<\-#9DTE<K_!W$
MUIL'7H"=A&[<!4>LPPND",(T3(#S^<<&21U]<@[WRO#)^D ?;4]*X[@":7@&
M$;!">U4&K._D4.Z\)M@_()"J+P$\EOAHV*<P6(;6NKTPZH82.--7$*X? LN_
MLVS7X]^,:0.)U)A0*70 =-Y=I#8)UFLW7F=+_2; NP4\?792(;0Q1>ZH74TP
M^E "9YH.^01/!.VY6AI#X-S.QI/_0*.VGMAN (&SNO?AE\"K]:,##DMC")S;
M(XC1R>()A"\K>+!K/;_*.&+WHSA,[!CNU_ZRRZ93'*5W:[@GJUB*=<SVZ==N
M)@[?1WJT_3O2Q3J\['- 1S*H8_9^)NA(#-]'^CL?="2+<73A5F#7%5(:1(ZM
MTG&*-2/)VX4[SI4P6L_>K <7LLR!3+N%R\KUY'JWJA_K??>#9P.HY^/,T3Q?
MW(0 3NC9C7[OR@!AW^^?)U#-HGVOHFVQ,>;:,<!_ZXE!G)/IG5O/X!WX"?R8
M'<!62(S],(;R704\2%U#>*&_ R_8I";2CWN,;O<=],43YGGT:(D^6B'Z37<F
M\'^H1RJ1ER6T['@610 OT ?7>D,.+"@7V80S?5NVI=Z52/J@O=OJ;*VZ$BUE
M+OWSRK.B"&NEU,#1BG?=YM;?*:HK.UB'5W#GTI4T[N](O8'I2@UE1(GW,5UG
M31Q/^+E<&&Q(PPF?\4NR@;W0-RRO&'94B.020PO/AX13^2MPERMXWIA!^%K+
M])<(%<C:A$V1+?ILQ=VMO%8?$TXM_M^;(!(O1.K(PNG((X.$DT$;6#@5=TF<
M_PPW-&P:/@.XBX? ^>8[(,1_F;]Y[C+U)(@AL?57^[D?[FQ ,0PM];:X\ZF8
M/*(<?ZRPHRQU3#ESQ\R:8Q?DS(;?$\!_QM&ETQ.A<V-J%$91LMX(40%M/B6'
MTIVK#T_DF^]V/VVS#B^'HB<0XDT#V2\R2**/+X>FS[!G\ '2#SXE\+B"M@WX
M%X%T-7]#XEK#KU50>#<\<^$5D!TU12^TQN](B+WI2D-E'#F1.%VG63>4O!M!
M),,D%F)R,HPLCXX9-(P<UTO0)BW.?<7W$5F120)<,S6#9;/=A"!"9U4DIP<X
MN6R*: B1;Z2*S  _8@!-<V?[6S=&'QN/QU?CT:=1/E#Q1\MW1NFHH^*PF 1(
MA!?8I2]XZ 5<$);YC8B)(#7XI5H$[)^7P?LO#G#1:[PQ^@$)8_QI/,E>N?T3
M_-5O-\@1-'N+L.\^'\^SWH#WMY]J_OZ+_!GE/'F%X]9,J/CGWZ:G%Q>3\XOQ
MR=7EY/+R_.)J6IAB4?*SL#Q=*[3SL>&/%3"4'_ME+7[9X =<G^R5ZVUENPB#
M=2VGLJ\%C+,.0GB ^-M/DY]&203G$F"C#CT3@U0L0 A/>P\I#XBSQ%.,X2D$
MX):]RNH_$RN$G_8^GL$F".MP1&@Y/ FR$) )\Z0BS#Z73PAM&7PGW2B3_:;#
M$PH3!9E43E5*!>ZT;@#W#^?6BFG:K=2N3,W5='QQJKD\FJ>?">-L6/HNW:+O
M7 \\)NLW$-9(<+_)<(3'-/-,;N<J%E$ZP6>P=!$!*-9B7;>&ZIH-30H,L\\D
M,1WB"D)GP'"37:+B-\0WZ#8E_+@)'+)(J;V&)F%^8C*!7ZA;>BB*RT%!7'DH
M0X,6)+0?FJAXR,B$=*E.2#/'@1R,LO_ (R^8$ 54TW9HPF$E(1/,E7+!W, ?
MY^%K\-UO$LNNY4"%TD! ?N8=*Y<)UK_S\"D,WMTTV1!5,'O-!RH=%BIR$57]
M$GV+Z"F(8LO['W=#-1'J&@]4/,TTY,)1XF= :WL6 HL@CN*?AR. QEGG+%?B
M1$!YS[RG5>"33Y_[38;#>J:9Y^RON@UZ8']V(_(Q.7E[11[]&O;O-QD.^YEF
MGK-?R>G_-;10,L27C_5;X-7POO3WX3"^>=HYUZLG_1Y!__F'O;+\)2#X7.J:
ME8BY&D_'5[K*@'GVN2@4GL%ODA#1F?JY$7 @"Y.(:!#5-Q^.:+BIR$54/8$/
MPB\&/VO9.!+/BJV,;(I#K*[YT(3+044N7(6G>.0?#V_@R6D9A!]4__^VU= $
MTCSY_(*S>G(?P"+[_&-W79A>5!'%6&TZ-%DR4I +5.$Y_V5M>=XNZ29!(J56
M0Q-&\^1S.2@YTF>(68-P"??8+V'P/5ZA*#?+)RNZVM9#DPL[$;E\E)S_,Q"M
M@.<UB:78:&C2:)Q[+@0E7H#,( W6:W1M%]B_X\C):)[$*%&]@U.DD6QQ2J>A
M"8F;EEQH5=^!UB9#9HW>N9%M>?\-K) <NT-J.AS1<E&0"W1@ 0AYB-*.R#OX
MFSJ#@]"RS(P)9,:EIN+D(2"79M6S,2!II@8NFSP+;8<JT282<ID.TA5R U ^
M&>_>=\"/_P!D2V>OW7!DR3[]7(Y5KX?6<IQ!I#H8K9Y59Q25_CX<N35/.P\T
M%N\=^>LO^\]9!#UR(177*3*:^*QE,D;/6K9#P)^S44;9,-Q8RZ&VL*(WS)0D
M^K2TK$V*-^#%4?Z;?>!EO_YM.YOYXL[UX61<J"^#U ]">.["UH5_X70G)LNI
M53_M^D;:K"<>0: EQD&.A#<S&[BCHIL@_'A#G:@S0YQ)XGMMM1$\AR!)TF<A
MS400$!)NQC=6&'[  S9.44< !5-?34'"(N\J5MI3;")V:O//U=XC,O0P"B>\
M=!)?\8E QU0-.LH9>^FXJ&U;YM3)=')V,5Q$L%-(?#LH @L7:K!PFX [R,IG
MX*$RKT]6V*PJ:%V,0@8WH1+>,^X <J8&((5,'<_ !G!G?:M$/5+;&@4)=@J)
M;R0';%8\A6!CN7EFUSRQ:XF?!&0P]#0*)VWIE?">4SEJ6/!A+A*89=[YTB6(
M+4\7F=>9V8^!;W.?07:=-$6%@/-' XU2CR"*K(JG,-B ,$VVAI,IP3,[KA'Q
M",A;"+F+&=C@IE#J@>14A\-IH\X@-3<#$5S4F7CZF,,%8:%@?YSA^!FEXIXO
MOD&+"G&3  EJ'S-PP4^BU..((G"DK*-:E&:(FT*+J .#3L9CH6@0W 6KN;4;
M;L18NVN#C;:WHYT(E6I5J@<.V^4IN4.99Z?3R?FY6L712=A4[+!0;N(E65:V
M+LH*$S4X*&H;ZXP2%K'6;#7L=)J(B=L$O :<ER&$#N9A@Y-6J3O,I:+S"';C
MEM<(5,=9R;,"ATEG$];^YJ&G&^E271VJ(GRR:IF_NO'J)HGB8 W"G \?=+7#
MTM4\"+6F6I!KY!V$;X$^=_=E+P C<NB=S,-,"WJE^DK.=3D:,1^)S,,$(XU&
M^E8"?XG*%]Z"-R(""DUTEKV08W 3K5*-6$6Z@* 2&^]:&ON9CI9V#)!JNJJZ
MET'&?(&[S=@A=BCS[&P**38+-'R4FWB+UWPN)A[_S,-#$ZFBK$^=K Y*@5?B
M 9?8PW2 \))N8LP@]Z4?*]?-@PLGY:*B#75"RU,^=<P+VL.XFI;:X8-3H'5Q
M9&Q$FGB!4TA)1'T@N=?,/! P42CH=$ORBZJ*"W(<-R7DR7*=>__&VKC0&"IP
MA'3)V]C1/)RTI-G$^YB9;2?K!%]OXD,;2C\7@A7P(_<]JUB,"N4^@GB^>+5^
MD",%>$8Q$%$"&"#U%*P(7L^H*+$/G,]6Z$.+/BKPZ18L7-LEQS@W=2SS\'PZ
MOI@,'$0M:3;QU5V5E\QG(/-PP4BCD5<W#>?&EN&PVF%$GK^-G7YB!3^A^.DY
MD]<39OT*Q*YM;8NG-*;U.J>F]1K]J33JGX]IOH3Z,B!SYR&>K(-/<4\@Q)EV
MF=P;I,[:K/BV@>\=R#31YU%F1YJ)>9;$*SBK/W9+F@J5_4Y%WL&O3L=G \L<
MUX(\$U]$U+'A/HH2+EBD'8R$!(4T$ST<=2P@)ZUG[&4D,)KH,_&:ON#SX[0[
M&'H.'B5M:331)5$I_-!H;E!ZF(0,'D/#J O["@^H5@:AM7E(:+8OC+J(YZB(
MP]+%/#PPFA4BBS4H\3MM?XCFBRQJ-O!94\F?5%+)[X8;!8M184!E"1&W,R(X
MF(BMU-P\O0,_3699]X0*SM5+$"11G@GX_QWRY6:+D<HX/YV.IV=J%G&#X,JW
M3V+(E.!MTA _3V'@)#;*6/4"PG?7!I_1RH[<-P\\0!71#DH-@VJ#*M&0X09C
M&T91<*G8@M@^L<A29S85O""VUP8@'&J'CQ@)_DI%"=\ Y"+*WG\+D>X%..5=
MQ@&B[J#TT4;R[<1:IP!XJ37QEN,+\"$;/90RP%F[R/9$3'T'=*0T]#(.*VWH
M-?'BH\)'UOW#.$2P42CJMD.G@)DMY;N@PR84[%IJ@X,V]D,#&1*$K:8TP3N(
M\$.IE-Y['ZH@0#QPD)H/4=)<M$BXJU(C[I1&^H:_UVJ8PFTFH>NMTE4J4Q\L
MT2V60JE^L5P_0IH*1',?'EVA]DK<:)4Z6RE9*AK[#5'R[8B2<)^D+*? 8^ '
MY5V,OMSIG8:(@184";I**C_C4E=L""V W-OE^@EDP<[C?PT600@*97C@*@DM
MR #7M\*/>\A>G& !^<D"S\/<:S *I'UQB.#KFQT2XJR5%LG*5NDU/(4OB.]Y
M"*W+##H[O[I4E(^:&R]LI&2R;EW O&RRO"K>K1Y!W'BL++49HGB;"<@]C9W+
MG"M>P?D[LSR4Z]J*7!LY7%TOB8EQ+ V]ABCR-B3E(!CZ/>>O %72 ,X,6D+6
M$CPFZS<0SA>8#X7(#39LM!MLB) 12&F.)+$9"51$O91>/1?WB(;@E].&X)?2
MN",\L-HG5RE0<*:BRCOOYM=7;+V/&WS+:#4>X;3;^(VZ-&)(5P#W13=P;E:6
MOR3!N^MP)@%)* ^,O*@D,.@.GK+=I9_F)[8_7D/+CR!?D-!]!__+2R'@_&^2
MW@1LV1F$^ ]Q'+IO":XU^1JDKW0Y@2IE#MJ@6PI$V5= ?\P])%7]S0^!Y:&G
M%_\6>,CJ1"YU),FYORNX.@O="/[I%O[37Z:B;4CJ(^MSQ\4@D8^2LYM-E;VQ
MV.=> W@I/;3!GP!3@Y?,?D)>^CUUDK/"-!P[SQJ.G<6!_WF4#:WVX,F<(Y:Q
MCYK<3MG47M$N3EB_Y48Z+MEF491S.#728Z+)LB4[Y1!25X&/UM?LATMR,%#[
M:(,$#L%2T,!,HKZO%PKO_;X"Y 4E[\CE=OJ*DEDJM1LR Y6&O)$BY%&EPH#:
MI\RL\^E8?6+0[I#@I]B05RX,25'I4&'M;R9L.E$O(9./#OECJ7BI;VPD.#A(
M-202>H]9M\$:,H 4HE#7UD@<L%,J(26/D@-%\A:YCFN%'R^6![)3&.TP06JO
M+QRX#A)<Y%'LBM:'B$V\_(&$-1E?G8ZQJ-!O?IO%7ZWP=X!B>><+B"_XWUK=
M36^LGY"X^+V35PLR#3DC%/CT:*WACX5+'ZH2;^YH##HZDFS(<6&K !^@98.#
MJIL<1-N&^B&ADU>(3I>)23KA>29$]45O0?K?>[_J7GT./.\N"+];(2G\D',4
M?5%#!T 5.2((E^I^5E3U5U 9"2W (4+&=3J'B7!!X-C@"VP(\S"N0.14N?M:
M?/H^8V'#S0)!-@H-0(HR"&,FI#DOBU$:.$GN(_B._T*V9!CZ'@BDVO-"JD&D
M2"T1N)$NMI:PVNNL':[:(X 932PL$+37D4*H] (49F[^Z G@\", CYR(Y!8Z
MJWX@[8#6OP+C8(S4+/LJ[7#2:A2!/MI(92Y/IY/)B;YZC@,HG$J/@SDF'@5W
M(>71:T"XDL<L>MMGT3. "B%R8Y#E&DV9^@SL8.GC46A%EV5_5CMPR]&M2M@H
MM8J%HDAJIEAW88]I&$<]$!#+X)+4NAK<JIIP&9AN0"B!\PIX#F0:I/8%Q+&7
MAW!#PO%?TW<0WS9P58(HO2=[AC^$KAUGE8J^P46[?^R1\@W#,=D?S[HF:JK-
MVM;A.-4*H]RL2(?C!VK+#VF#UOYPQ85ED6PU,4Z_X\-_X]0C.\U2J]>H=&F+
MN#8S%A>,A'=-_U6Z]?CL"]C]!G!I9BQHN%D@*M$8&3];!=-SHB K6MUYP7?6
M!$'G30F"X'BC=$"U[S.WA#4_RZQI.LC7F!?3\9FBY<K">-9'F!D9^KZSDQ3Y
MK%!\'&*ID247>1J+M:_X6!T$S26S&IFW(]F02.K[ISGU^=/V[_K)O9W<:N(<
MJ20JEW./;R%,D&H+>@T)=;^V/,NWP<L*@/@!?09)C;R5DYKK!XDV.SD7=3*>
M,,F3*74#)W?03JY<(F*3L,[[-4F/VW:8P(^[UIOKI=FY_/1M]I/U@0!?_SR9
MJ^\@1,^AW;N0K1P'8A3#4P@VENML2]EE#$B3(,:H-FY,?]?./H YZ!%$NR'V
M@K"G<1I HMUIGXTN2B2X^@LVY*)Z"H-WUP'.]<>W"#CW_K9ZX0R:S>^I@J0G
M6.8?2%\$T(59>QLG@G;) =Z* APA5Q9N3+F_W370#A&"!%NW?5!IEGJ5KRC"
MKQ0JB>(<?=OU0.DB^S40HXMD?.IPL-D;]TQ,(<_W:( A]%T#I/4&B!K[BIU#
M4G6FJ&B^+4<>T/7],ZK5,U] 9N$#PVR-@FS_J$,,7^<R?RXOSL^G!X<@ 1R3
MJI\F:O33+8"3MUV:5BHV.2*)@R^"WON2['=%07?(50:PA OK9;ZX=2,[2%!6
M.-]Y"L':3=;1KA(ZR=9O-]@1A5(XV/5%9T,$_*711<P/&X7MF-7UX5H#X(3E
M""RO+$@->KN*_,4W0817&/Z=#SF6X'J,^9*<+^Y<_/KO _WZ#NR'K0D>_0C(
M?E@J]2V;(CMP6RSZ!D[?Q3PJ2(\4R4/M=(1C)TYU?8]&19FBO;@:K[YE;?8X
MNL&3QSZ =NB3YI_KR)/#2-.X78 @@BL?N.^4*'+&WMHAK",06)#%SHBN[C?1
MMITL8$'; 9^S=NQX!K@8PI,5HL7,C+&F@0X1;JUXTM5-UX \16Z7*G.RD)/;
MC*@L]"2//$E#3IC1QS+8(2*P-5^Z;JM#TW]9G-QK:#GL^VI=YT-$&3,?I"9=
MTT:S[;&CXX9:.\H191Q;J9S,4MK +57E9>:@ WHE)IC]4,HZXB'"L!MSI#K?
MM-E5;P(?,QFE@KE)HA@>NL*<,Z0D%YRC'"+T^!DBU0NG2 .6HR R9S=)N=4W
M-A\\''1W3:W38.HKBL\D*.X=7]KNBW4CE/@Z&9]?3L\-PU-79@A*T:.5(F)W
MB7=^9* =P*1=!W3DB:@39@"7B"[V%8$E:3R,@$<ME(&TPYWH1RV\M L*HM3M
M44MF'[P&,_L?B1N"V;OE>NAD<Q>$* '!"["3$'.'$G+$.8IVV!($D2KV1#!&
M\H64H@QWD-<V $YT!P6!& $/TE^M&/'B8[X@<XG\]*K-: <$1($,DAI.KLBB
MJRQ4R#!H>,0?3Y[EQY!;*"?A!C5A58'$ 0X(=-UX8N9-%#NW.]MRAX.TCCPY
MH+,#BA/U;0%G!\I VN%.]-F!EW;)#VK4/8C?VA1YG/)\44C"RV"LU?8K\W R
MA?+14F_QPH!NEK&SPL3R4?6<2-,X?_,AO??P%SYD,S)=ZU_3(JLB@LV\!"5\
MQNR;8]:PG!J$?_/002R3C5)/(!=Z%CRI>X(C^!/F0[8WKDD^NW!C5.PIN>9M
M4L.QN*:'^6AKRP3)[UE5@:>P32 ^X(IL3!AJ['A 4&K'"Q/CX9[!9KNN'@)_
M^0K"->6.@M3\<+##Q8&NX6H-.DC1*8.=MYV=(66NGAB,JXX\$16I5NM\4_1>
M]/-B 6RHF3__L%>6OP3/<!',?<0E]'_([?UN>0 _$,H-2O0'>#XJ_Z+0D@!(
M"5_2#KFMW7=],4?JZP95)<BZ<"DM ET-'<L.^$5YI#(BH+O?29@#? WX)LKD
MK%7K0UP3,B!^1&RC4N[ZX"*M[0?I"F-=K-@AP'!RQ&'.!T$&+KG(I*K#5.#;
MD/[=);OO;&U^S/*FBV76_N9HN6XD"RJ%K-DU<O8L ;]0=]PX@>*$M@:J/^%<
M)_%C$/\WB)\LUR$J+K;N98Z>3L=7JH-A.F&A3G-U8(2)5\H59WO.CML$54'+
M^#\/\4-BR\O^72BR1D!<YW&-AZ(<#O43=RJM4#/*;.H%$5R7\W!I^5F:/YS3
M+[)#=Y/F\;M.(KBG[&I,4 LW3\;P_XT^C79#PW\41Q]9OC,JC(]J.6^_H.(%
M9V%N-X$?!9[KY&QX*C XS6<(\6=YNT+4!'-"T)A*'K1VF?I.Z*\0'M<>.>!*
M]&>TT5]"X51Z1-L'QZ3NN2<]ZK.79+VVPH_YXL5=^N["M2V<FA3E28#:_@DR
MSR[<J#1HM).J1LO&1\JK\(71[A.C[3?4Y!7?HY2@J&@-E93XH$FK2:>P=2[C
M_FPZ.3]5HRF:A52JUM&>.&,6]8-K9QG#;@(/"C\(4SDM0P"*[V :EO-I=3EG
M(V/;I#3V:#>XB "\PMCO8!:&R&F-!M]-AK!0N7LK6;WV"CB)A\.%ZV>*DO4B
MTYKPYX*Y';U2LHJ*_Y V6J$E3$JJHA_N4-2*XCN15_B!^:) $*7.=FU;;=#0
MLTBK6&)G#P,<%#T[JG+)JF<,M2(OYRC:08A=DE44B*!=>65GPI;\[W#V4!9-
MML7)]*OU 0\"%^1ZW^U&T@XH(H2]@Y!HSBB'D: ;ANYJ_*&A+K3(3V@'4F4;
MHG2N2D[JHB@RNMFB;3K=<XR@'5JE@X8=IZSLDNHTN.S1:7!GN>'?+2\!7X&%
M_EU*T-C@*3BK>@K0<",\WJ@TH((UM:5L-T&2GX_>5(5"J)M1DPJ@]M%FT;.(
MI;A2^:DRQJ&W%ZN$,P"%OX,8[<?5!$L-B_6\NEC1^*/"![!_;_>)4>$;0KQ[
M3.10/7R<(V@2ZD>89^.6SC]2>3V<3\=GBN*N.@B\(;:O%0OZ"9;I025DJ<NS
MXB!17ATDRVW.J@NF55V0#3S*1\:Z (\]V@ZNJ 1P.55[3G+Q5_2H1<XQQ!3R
M)'XSY^8-"J^!1BQ!";0<11L%T$F N_*:8A@@=?E/>ES^SW DR/M5V4'D.[GK
MB/.J[Z*J!_(O[-WS(6V0WP**O?-C)8GM#K#+:,<[P0X>(=6V1G<8]7E'V*R7
M%%\*";XCU& CZDFDK>X(M8>#!G>$&D"(79*"[PCEF3%"C%U6W3M[@V9$X -G
M;L<!)/)D/#DEWQ=V'U4[ (D P9Z%+(E+RJ%VO$?4 ;#*-DWI7)7Z-$51#A.%
MMX@:8%4Z9 3>(HK5LJ3+[&F/GHDO 9R%CXA_"H-E:*U9?9&751_$;JS1=C 1
M=DIUCC17 JVU$+.I^H'FA<K>L0RXZ?3D_%+A\;R9]5N+ICUU4MU\ISTN)I3G
M[2&P_#O++I7A;%A*5]6EA$8:H:%&V[$4O>MM]-\U-5;U()E]]R2TUF8ELHEC
M_UGPP:T^7(:3<?N:C&M>RZ3]%< U_7+#^MIOI&)=/8 H J!<^+3Q/IS>2;M5
M5B^,XNIJ09#41=;GBWI4,<&-<_L<54N&'  ^^[/32<U#^L*@V5NUXK!*3F1$
M*AOW0\Z^:@Z<#%-L/G/R#*+-,F\EVO+AL3/=QD2ZX=S\*'T_G F*]6$U>2=U
M;\\+8_WS*!M-Q=5NA:;'(&XR?ILZ*;FCKIT3^P)G[E_&^,5T<G*E.FL8BPA+
M%\>=:)7L#^K3B$Z)QU5B&)=RS;OS=)!1.HJ*X]\N ="B6/SF&7@H1SI.E(1K
MD[RA\CAYT0C"$N\ZF)+S+^N<KXMS;CPG=QM5&S4A!AZE\[8$SAAC))R-)_^!
M5 &C/JEYG0)_]:??_XSUB:+3P%:B."EI[(9LL6U</964BH&S2^>61F="H(;;
M25X#'RQ<GOQ7;8?31C6T$'6I:(Q(^HU1 /<^_"5XM7XP^PAJ'KVD@XS2412L
ME"T1C8N>VE+%(J^94--"IG4I@_5R.CX_4[-8&4127)S<-!FS !]!_!!$J-P
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M"''/FNQ,^X!!\?H]Z 2*;?\#! 6==D.BY03'SVL # 6V!#MC>GM,-<2H>PW
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MZ/F5<'$QGHZG%\<EKM,2%R'/X];=W@FGWPKGG-]QA6N^PD7(4^H[;^-6>.8
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M0_<ZM%*RXY.\.!HQ;&8^RU0U LG5XCN%QM'67134QR_]-DEZGQ4.N-3D#2<
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MEOV+O,-L[V]H.I,3$/6 (7=H&GZU\U;XL+U]5($33%(1#54/?OVW [UT-]$
MBT3;,D3SOW^MOX'_NG!:4O[[=]3:55< =A2^)GKO+_AG(OQ_8OUOV+^8F#A
M^??'?SHL#3^ZMFB>Y(WKCV%'OTS+,41]_<UB3>OFJW#&3(JZ.C9_A8R%X^F$
M1;P3EI((3_N$X=E_?H9#@@(2X?_;>P0E06 [OT:6-_G[J<R>"6.'VRAZEUYS
MX#0<CDA1S= U^?68XW_O8^OZP?MV23A^SS)^H=BV*QE(UMK?@N"%$-55$_P]
M5UUU%*VW?DU4&;X+]OT__\E@"/[W/9_L1]S9@C1$''J'V,N_1Y8#NXN^P.]"
M,+B6KLJ)_R#1_T['D$=OWL.@G7&@>\9Q#/]2^_EW))?$R.8(X@B31Q) !9'
MTT)*5$9")IU1A'2*P,A,%B5'*/BQP5^$O=.P9U<;1I8N[^J"!,+LP2<L&.W!
M#[&OHQ^_^4:YP^037(?J,-P_/T=K>N,_;HZA^7:Y4V:X!-7()Y@^7:(:129!
ML_5ZF>/*;./$Q#P?^V$UC@QGZL%P[J,+W4]73W0G4!4\R_PKD;^C[Q(8DDYE
M[VG94=?W4W.'/%,&Y/'\@MZA66#LL8J/)YR=T8Q$21L[X4'(I&3IEO-KJYS;
M'D,U?]9=J-'('0%?M>X82]_!GM?J#@T_-&-;IB9$W[/"=ZX5ZU3JM1==!V&:
M>B;: MNN_\]_4 +Y^Q_H(< 11VLG54ILUGCM<+Y\WVHX88KA6E<&ZJ^\)?G;
M_:H?D2EJB(XC6 XZK>K]+LECQ3F[Z/GIR9R&#@]<Q+<BC^5A/)^ G@=WY;N"
MZ;US^TGFIJQ$XI(D9014@IA*R>$L-9*!(!,D2&,9/).2L,W<M'ZB(PE3TTIG
M9J:\THJ$MN"MG)R3TN,0IIN67N1B;:6RGH6E\'"/[8)?VS^>ZM-&2*&'):T]
ML\<N\>Z,OW:(D6>NK.=LW[HC\O![>?O]'#A>&,#>*"H4_J:+]%TF]7]W^;YY
M5V28L8T&X^ON=C"W\YXPTTK1K<66[=O/R84CVK]&#A"UY (RXU47_OYW<10=
MW=M@].R.^\MNY)&XVM6-GYY\%.^S*;@NN3'_#,S_Z3FA5IQ< TY*_;9OY,'U
M>3PKAJ481._?'RHTDBZ0X'1KZ2-1URUO9"U_G&?2;/FB$Y9S"-K MASOQ];X
MC3W@@4QZU>(Q1UY0J0 :7XV"+T->6MMR8&R!!%].<($!G85=3F0CBO_G/UDR
M13P(<\\T?!9M.HL@L7?YL"V>:G>8=FV0:#--MMU)-/DVQU.-3J+#)J#CWH'>
M^=II0O$$VTZ@Z3_D/]=?L(5$I\0D=KS[>\^>HCL)^#.:Q5/W[O"#:OR,IJI+
M./O/F?.8&P7+27@3D)AM<9A8;P<DHM.PB8B6@UKR2P[W;&&G$UD, B ZP#R3
MFC2C03'KG8L=)[.,,,OBJI!U>3%=&G?99&XJ(>-7:.: [:WWB''DKT0XDK7(
M]BA#_ 1F.??XVOA6")XB<4(:02<KC0LI!4D+(W$D"BA* E(A@#+"T:>^%5 "
M4%M,ZCG>&,X]0L_2DZ74NG[?ZC:]7]"WNCFV,?"M8C,E7]ZWZCBBN4;"$^=J
M.F.4U7#(MQ'?2S6KKMPS/'U\&N<J=3+GZK)>\ON<JTZ;:G#ET(6Z6N_JV)C(
MD?H<M_CN?O?/NU>5K?^G.):Q=O\./W]X?^?)+T\"92&C0HE_YG]?(64[I(1G
MQ38T_WB\X0$/U0T3'!,%%?IJ#>MNA](SQGN9*$4I?"?L'GK1.^YXQU#A$%-4
MP(M]D@:-TE)$FXM7"$$0-(F3F31VT L_5V0X]3U#P=B;M[^>XO+LZ&J#L>J&
M1LD+JX[L(&R@-X)LN]=AF60^XPV$,5Y"#;C@:[;9#E5D&V6N$\XB;:K)\)TR
MS?VUUHER@[X[SP(O>T85_X-9BI(7,2?,)'#NF9(0W81K RG,'903JIE0/3<A
M3:(E_)]GWXZ['K79K)!3A$QF25$4%(D<"2E<E 21)+-"*H-A(R*-23B9>KI"
MU@UF4<R9^0I/4SDI9?HCS^\O-C[BHY9#>T@VS1YM:ISDU5F7="BD%X;JGNUH
MK.15)UU0FH$&.(+KHOBHE:<6 OZ\3T&H#(UI'FMH51TC.W*ZA[;D%FSYO,^*
MDN);_I+7X)L-KVFIV0S3$E+/^R1LU@X0#9\CW("DI$DW/2XBB[#NXJ.L@/5_
M3[7^WR G6OY'4ME\L5[^1]\<'2+(;",$1[G0J<P=1AQTH?%SN-#O-Z%/ET=1
M!3K;L>:A[I\\JK:VL653VAP"AGU%QR^B:D].0%LRN%\K"4AOX7 J6"#L7.2;
MDKLJ8]6%@$3XVK,RR.Q?&.2A%B_$,!_RP!S_\LIH;7FVBG^710\*%CGCVNBY
M& ][FV]8[$&D9@X3%#.DG@&('7%9WF3"2U%_NWXEA& UWVVK?;:!:45[,LVK
M.-G)#,<0@MB;()C-))%TF*^2?AF$KP=<'J'Q<^T,^8KP7G4I(D5/P&6?%58<
M3TQ]1W5E58J6?I;RS\A)_/RM[EJ&J*TS%DUU%7W^\_$*//XJ^W09?VP@[GCJ
M/E>!/PR!\EW[CMLL%AG#UJT .&O!/U;#<$GYYYYX2UQUX^CP#?&&<.QU8OS<
MM%Y@RCH'L?&'<ZPF:DJ6'>"ZFW]JJ@G0G:7YV&,ZS:&V:FA!T:UHS22>JE2H
M-TW1)(F0B2*<H!9BD,A9O@[FHB/_E>!\U0.;L'$*V3M]'_^2M:G[G"C9AE4T
M_)-U.M;"W.'7A)@IV(0U@3:3E51A/)SQA=GSO>N72($X$AWM@_SXZY5=_D];
MD&R8%7DHK-.$+X..R&[P9X0TQ+188%H,792[EI8$"%E]&\=HJ$N0-E,5/\BU
M?4P['T^:%A2 /E3MA[796N<L+=?J&>J,Y[3D!'-+6I^?MM[F%J?2!))$H6Y]
ML;79EW+ZWCP9' ^ /\Z-Y-#Z40X0GV!W+N47HZ"AJPS7,B>M'BTN<M3;YHLT
M^M')X,^SZW'-@@!J3BSS^79)*Y=/U3OS0A-AZRFDD7,=U9/?9L]29%CCA'Q%
M=V/MYWQX/;.QD7\EX'2A^^$X$RO5AE*4P5^/X^:AQJ/DWV["=F!;U1;U!%@"
MR0_CR[ E7/@ ][:^O?;U;0?HP X5+F%&&K<+#!':H1,AXPRY!^'>>7)G$^3$
MN45GW1#Z]B=L,J_C]J%@WP9ZP %RPO8=UP]W]3PK 5M$H1<4^V/T9PC1,#N#
MDKQ?9\U(.''.R_VVFT+B> H3L(R$""D<4X01.B(%@. 8DB5(DL">)::NDHZY
ME++XA"=P8Y4:9KU2LT7MVW;+CHL3=Z+ENQHG3].3A=^O3\!N"NM]2SBOXFFR
M/1$8&A\%2KXJ6-IB[P:=8^?"A>O(8F:RNBA[,A;XJY: /7_[#)$J1K,KCC2Z
MHT^#@91U^LM%6.7KQ FTI]U NT,R'\VRQ?$[_&!J6HRR.]^3Q1K2=G"B^P*T
M7:7<-L[KD[%EUC4FWH39C1INCS':RR=']3>_1WIT\%=GPYH#/Z^K!#S]\3#7
M/VS2B0^Z2QW56Q>J *(T24BZZ+I'>L#/].;&WWW\=<3(\UQG#?]Q]/KBAMYC
MN-O8Y$9%X 6;6Z$2T(%:3%3XS8.7M7<?ZXE-(>[PFTTYVDT\8\QDXR<'*#:*
MS--.S$3!ATHP%_(*;TS5#IE,<<62-7YQ1VB=*PLQP7F6I!U*SW_I^;\2MN@D
MYN$E9XG_ YVHL)3?\6OI[V$G+XV9C9U=F]G[W!$7Y0<K8U4<\4F[-.AD="O/
M%L?03T=?@4RS4^R?XB3'MS<3+S&Y Q>W6R:_O/\4FO:S;#UM3<WV1L$G^<92
MTP_P>;\X8%2.7XW);-WOC%\S-PW1E<79>PS-VD0EUE>M_)6HU>C]>]:?=>3E
M\P^Y;)*F<>+HK9VGQ[#*IAPFL(#$*$A($P#9"?O1H$, HHRG,*"RDTG]![HY
M?C01W82BZD!.B+H.6X0GQL(PS<Q7PR"-9R5&8-, =KR)T]P?9;*<W:-,F[C-
M3KAG"Z\PEA/Z*^%1IH0,?X6>8=C4=H $(C\1Q=9]1.>JW<0?L&>H# G7A^Z,
M.['"%._M&1UO(GI/Z5F(CP<=CGC]\(:D/_]*B*:<^ /;H7L$]0HV&DTA5>%#
M47OX9#B>36?A@3HW&DDT7-'U$EEDW8,L!NY=XG'ZXSZ=/L/V*.T[#AS8^GQ?
M:/T]T?/='?U%NU- )WN]%</:"".G6^UZ87)8?]<(&@#W;<J[/?_WG -'ER'<
M<YHPD\UF#W=TX,6[_VU8IQY2EL2^C.:'P(>8-U3/@ZH"=(A]QS+#25P/$@!.
MZ$&B',YGHA1M N1%3UR?M'IB$Q[ZV WDMGU]D[&20M*AQK?!V-?7>75<LI/X
M(_R1_!O#L;M- V^B1H<X[/ 0QZ?8AO7([[4=N']>2(UW^!RR>:/5.VKL"AS=
MK6E9H%4]H=+5[#Z5CPZ6W=0X'FJ<?9,6OTU1H5J("1WV!1*B)$%%#>\MDR/$
M.N%DMO?;!!1W<N\/K@$U'+[%V4X:$-$&Y$3P5SB+P^[@7!>.>YP8.];"FVQ_
MOH/S.8C&)@-%-:-@IALJ;N@08<C?AT88_8S^O6WV:H/#X]LV#.?O_YGYEO?W
M@:&N?PP/ACV8(;B63F+;':5==V1WRR8CR:0DHRD!QY24D,)362$K9=("R(JC
M= ;!Q0Q"/MT*F<YXM4]S",$'(XO52TLO4":+?9LF/-,H,HJ.X@R6SO6]WJK:
M%V?;Q=CC^B3 R5ARM> @W*3)<LF&I3H:M;.]\K!A1 Z4N5-0#*1'+Y 4-AFT
MJO7P[?C3EE*6ELLJ4_8UCA][*>"4%JOFWC-5(M?(J(VQP3"BFUO6>Z;@UX>4
MD'H^SI%=UH;=OMSG117X04].5M/&[IFJ:ZRC@A)W&'X%.P774;_CN!@!>3#?
MYL;PTS,<.U@EY<;M&[=CS.W=1#XX>X0M__V!_7C]B&'V+IMY20KQ)'\#L+=0
MFD:ND\RWE'EZ=8(^N3O_C.I:Z.RN'<L=AW;]1>35OC5(_O($>'Z"WK">VKN"
M.HTQ/#^=U,>E=6D23B*J>.G;:U&PER-?[R_/'1\%?7=]\L]AP"=@_G&FZ#H(
ML%;1^TC ^N-FD1^G\>^9%B]7_V\=4XPXF/-=U02N>[\?G&QE/472> (1'6*9
M+61LIEX/@P#X2W;E9'658VYUWBK%]6V%T0P2AO/&EA.<Z6Q@&'AWZ,T['J29
MSU*+Z9"8::I05XO#1DXS*HM-\9N70JV-?<'!$VWWQ]>3>0;CY\"-CTEYE4YF
M?^PS3C1\6,'.;R:W7"Q&3*37/+Q7,*7F3KK5,9+41*I2[I#F/*!R823T$\WE
MN7(=GI8YW6\OR.-]B7/787UQZU-Y8><B/ "U=\-%5?9MBD9;H= HFE:TD^F[
MZUT/"+QU4?@]Q4(M)WJ7'H0O7ZCPU?"U"1,2;84;&9"!D9$U15-213W<) E+
M386-W<TMB>')*RN\;77O>9AMGL4?XN,,B]U]C+N7"X >F6CT"1JW?"A,O*YK
MOYO>.#0\JSR8#GE,+/8[=-I!9Q/JW,KVU2OGOF=1]:Y=2G<"='VK=HD_H#)%
M>X7K(HV/]^)>WQ%>3%0/).'O$OAE.R *?<)A[=W$V^84_7F7@/];OV4 W-=W
M\R_@F(<\>C311,@W\F22;5AZ7B/Z))U?3;L:&+<^COS#!;D_82_^S<IY>=Q_
MEG:^+6. BG;:6<FSPGL[L.SZWHZ_0CUP0&(1_F<#[$*42 +GIO"JW BW;[DK
M^]'U)J9OR)8G TF%:\D?"1=ZD)!@Y+%64*X >T"A$F37>D#UAE/>[M$T(Z:(
ME:H&.+&48<^;?MQ_?Y0;A3VI;%&.>I3_R45#9'TOFASA++FK)I(]Z.9DX#-^
MCY+F9:+",*E%6 C@+Q++_(5AY!;G6T;\3JQ)WIJ-/8>>=_/C]^6ZA_/\NI>_
M$M;#L.X.7=*Z#<3LWM.Z^>Y3KFJ]3[/VGB9>O_."UC?OV=S3(ZNNK8O!^@#R
MVXC;/0U^[/R*O&MSZ7__KZ..7^_<4+R]ZCEB^A@DUSMRHN(!YY>H+\3 W=YD
M %E.W!_#ON<V'JEW>-5TXN'/A^-_1]Y?C2)W>/KI!=;;+X^_P1I#[R+C\W!F
M/87>D9]TA36./'CXW^H.ZQ_W64<D(<KI$88+*30+A!0&$"&+CP@AE47P46HD
M8JB2WN337.;NWX/5Q1/KPN(7NY0XO.$UL;Y1]3Z):XV=RS&K0^5J3'A=!\TV
M.DRCPR4N6;M@=^!'&L8X'MU_=UK7HT(NT#2BV0LF8^S<R/L\+^/L^1CE-V:P
M/&)=!KT:UKV7PKO7:S[%G]8WEKIZ52-."9&W"N.U0X/'">MS#.]+A[2;T$/\
M4!WA:Y#26T]?OGT_\"4F)+!S"/VQB.^]TR;5[I0+Y0;5H,M4#:YFH1="A3=[
M"22&I,CG-P.<QV]]ZHQLO-9P=)M;7]:@$W^_:4_H18#<^'S/Y_N!)79&]@:.
M'SOYG,6&1?[5B8KH7942G\)!OAI-.C^Q-Q!?U$*6.TP=%3)D&LEF8A P*7O
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M^= HK,^_A&W:P/7U+[SPS7X%:X"W>*K1*7>H3KG+0"#"C[7-IQ"@-9;CVS%
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M1_O3YB [@-9O#[+(*85[=A(,&#_I2OAB65PZ?4C6'F0ET\N%YA0*#D/7E)I
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M)5,(O$WN#KW-3Z[<$7=KLLA9Y+;49 5\@QL&T5X)&SS0+Y))T@R6I"DRNDC
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M[J9/K%Z6%^%#33\ DJMA?42E-^)(4(5LKBF@;9HHK40B[(= X%R2IH^51(>
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M@[F"(T8JR7$?ZPT%H0!" 82"N!U(?@X*2O.>-ZOXU)J7YN:D,!NJ7HY=!5#
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MP8F4-ZC69!U=9-IX:X%5LV9I!?:8\,R7B89B[N3 -TQ[#OBI2HZY23CJ7-H
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MC1,PG#_ATD-5N5F8?OE)WA<-'8KI39#*EY_DXS/-9_59K_/.":$EE'IZ;2Z
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M[*::!<;C-+TGB3SC2<GR).6WW9MMC'P/.3)^-"-;AB'-'?!K_\,QM$0O$TT
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MG^]G++X)]_/";KPT%WE0U0M#N\_R^5D^(VV&N=&66B%S@6B>1WB59<_Q^.N
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M1"'@UN .H'U' [&UD;<[Z$?CE_W<CLC8L$8HKO!'(&/[X3C8:[<]^/7#'V!
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MPC3X%5^J4.SEV7[X]-3VWT?"A^E 9.?1FDH15=)0&/-DB5X<WS_Q(N]:]=]
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M^H]+N&2$\,Y1?%R+C5C+P5K4P:170IV@6 *+"Q*HX +!-(I?0$=O$Y("I[1
M;F=B+2QZ/^A*)_,HLCGI#&WB82,,B0X5WQ_/;8=/)>=")*+*NI^$YNQGJ\)U
MM!W2,"3Q-9I;.= /:$\4@L"L00=^Z_;;O3.;_8)B/_CJS(/";[IRM!./A2;
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M\RF$"9@.[1*8!PJ(4HRO&L?>.4;T8/+:=6Q+TCF$-US*MU2%)D.1*"D(:)I
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MCVS7Y=B+5-'UHOO?Z6NL1S+F^:/-N'&^B%U:C%[[OS]D\&EZ%(N/X$0X'ZJ
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MEHXKTOQS9HC?Q<G;#AQV$2!N*>_TB0Y<=.TV)M/4F8:S0?8Y/Q9?A^+A7Z\
M.Y0ON(D_/@)ML?#,24YO'T_^/"/Z84+R^7+R0=H+31/V"']*0*]I2Y<>L6DG
MXN/^<'Z^D&,^LLKC>'Q;[>5YKL+$FKV8-FC<*AO_Y"%D^01-'K(!T9S:9GEP
MX,IC.K*M6T:KJIU8B>\F8YJQ&][DTKDSP ESHT4AH/F29GQ?L3]O-S /C'&&
MB@)M6Z'G$&*_-F.ELX8A6F=KZS@>ZZ9<.R^DP]1HV(5A$Y$]586R7W#9'ZC3
M?N_U]7%.&YRL@-4))U'B7$QG#$WT30\P*11>K=!YA^T%F1][@A GNPGV+#G7
M*,=6F)/<)D[1QT@_(GM7R'A5T (3]U@-WB*1K?8ZF(OHW>67%^NY5O1!U[R@
ML=X!H1BG5S=I=NM.0-_SG.]U!@YX"^D<;=#'868Z_P^=GWQA<97GI,9+B]S?
MT>$*@^I$K!XV5;%+U,/F]- -:[M5C3\7;REYUFD6'JUQB:^-Y&F[OHL_RF_T
MY'O@$"SD]CS#!D2%@%B#B^SOVC5S&>\G2LU6/UF<</>I3/O9(GML31KF7F]^
M>[0WVH-/\88BL>->S7\C/\<A:G]4+ '?!<NC-[-C9VKFNX4V2[5F0IC$<UEY
MD,Q4>M%XHM67_[QMQ!_CM93MW#*)IFC*@[NQM#.UP7(5>Q->.T8FV'OLV-,^
MU39#?TK7XO759_=6^R+5_F(Q=9N7$FFMG4R6!D^MOMK?:JEU<X\#LW\:MT('
MABQA?H;V=H"K1I76'CC8&F4]Z,JK&;[78,6[TF*>[4>YCC+="!A= QK349V!
M!'X^AF&&:/96-!O=5]9R[<%DY562:;4G?"._-,Z (=:GQ61Y<5=N,/R=WER5
MUGV$_6V8"W>2(^)Q/@A]_T%">O*Q0OK+<.YLA#151-\?*8VM%%7Z_?L6(^96
M*@)H)Q?3ST#[+-VN^@^U ILMB7HS/1IEYGPM_FQ"B8V3 =KGQI'7CN[I2>(^
MH8-^5L#\B*5)_2.XHBV@:=2+'>1\@,WHC:;BV9>.,P9!#)+X0LWEG41*R4&U
MECE#FN%G9(BQN6A^VTOK3$7J<$--T$JC]KEH-:GES7B\%C:]4G/(U'GUOL<F
M\YO36HV/LG' 9R_0XR5I6P</SHDH1GX:UO@1-ZC6/BRA+!1<7X'Y8FR6R);G
M=VEY,;W?M04KT<@BY/IRF38>=VNCQB13DQ=/N]HPOUOFNXO-<Y;GA%_^0_P@
M!\DOAR')B^#5WQKQUDKA?MENW\TYD7F0[]EN='B[/A>6FUS?=1<+MC25K9;P
M,*Q*-^5!%6=Y![-</"Q"B.*1'8&L-[A6]\(J<^-A96Y8F7O.E;FGJQ=?4>OX
M?E.LCX?*@M)K]I4RDGCIM-MPHKJTETV"E-,1E\)WD'?G9)M\1%3KS;)RH;!U
M5MI,)TQM>2M5GRK;=<'Z?%E9@BPUF!IW1&JN[B;->K??8CA^W2EUU&R\EZW,
ML'/LC6+S933"?E6>?H'VX3K2E'6IBVM)LXQ7.","(MBXH3KN:&TG"<((-><J
M3CDJ_#OYJ,#@%V5*G8WI]F$^Q^1=)9,7,EI+KI2>!DJ*Y:+J^(WVV2%=!]#S
M7E";&8D[4V<M.3IN%)ZB"JL/Y/9S;D5/!]\/%3SGE:IWN0C6J@X[:7:>,3B)
MNV^Q4F&DR+7-V<F6AMF9%>*WM8G<C YV#\W!*%/8G@CM'0M .PYMW,GI>+6.
M,T; Y;0^Q\*W9Z_?(65HFEI7A.4Z+<A2L3:+&?G.35-[8R3QE0QTE7V:JM5Q
MIR3SB7N6X6M2*[::/5-5&?+/2\.PPKU>&N]2%:G$*X\]I1*OW!GYW-EQT%ZK
M.\ZD;]@ZPP_KW*;[J+7CQN:X3\L-(^#*7:?3-)E\>EPE#RKR=5)6 ]DJI 0=
MVK!DT*F7&NPP&_P5M\RC-<7H1\K;Q\Y<ZN,1CK&XTVA]RT$X!.GQA>)761((
M53T3H(-EDRW!O-;$!@_A1'0'[;&@,\ WR_R[?/U*'/<[+;.ISF2KQD\[T5V9
M*0X_(6G >Y*C49:XF3,FRX2P9'9YT[J)+BJKSBCW7#>3#TPP_3YBZ(/0[,T^
MI%YRIJ5[F=2C7+D99)JSB9!,YMMG@H>/];FY&;09C;/B]71JDXHF#>E94Y/6
M#@25"&(IL)$,\2IBOF3L%$R[X76LP[MLV&YPP>,&&L;Q[T';=O #0>\ID[?G
M,7C'/1PM<[B.]-P:9(3JT!16.:PY?G%=\95_]\^DNA#Y MM5M0UT/2.>8\<#
M=S"WAXX,A G<;A4U$FG8\T2F1TA827!W&OF)D&..=\"#B+TZ"0\:OH57$0EX
M]$V6,A$)\D-]#/JJ._Z)*]A]&I[]F*U[P >)8N-^[SHR@(9Q !&:^W B]2D0
M]*X@IU6U^Q\P\(RYL;C?0L4]>Z *1?.D832?*D*?%=+4 6/;\:=P.PSW,[@1
M)[TJI[,0[J&Q\^SO*F+7X'B7^"_FG^L('AQ#2]%("P9M"<J/"PO,[A=+9V[.
M$7?G@0?8F&A+'$HZK,]7:#,]'+HS/%Y2]!TH?+5;"AZI_#]*R]=?.LV"6TZ@
M8\[,HVX?.4"PCNB6K]&>*K\B8?>+O[8L^ILE:GWW,-_3<B,,,F6]SK&[5I,3
M-Y:DQ=[HJK(92<OF(T$JF7&JTV'SIA&K/I;FABP:^7JA\WAW7U(W/WZGKY,^
ME<SFF5^-\&[#1<0=\<!BT?83N+4>MN=BHB )"&VO2<ND(_W);([J]A$X@YX3
M(7<-N>L%<-<>Z+LM1$?HJ:J*&YL2,[A 2:\'E%>&=HR[8XR7_+7JZ)J?P(?K
MF5UY7FUV$]Q@>J<R4718H?#&F.N?\V&AFUNP4>9QQ'1US9Q9U>B\(1RSC<^2
M$0MD@"UEPG$=6D5CG'#F97OX,GO(EVVSY(1QX[=<0FX=<NN06[]!%^YMM#WF
M3-CRI[)?.1U-2J6UU)=Y3MNU=FIMG.'?Z#'_<_8[XT2^U^&L#=.L-G;FK,]W
MFD^XXC-DOU[V&^2N(YXJ7O7^4I"F4Q$:H1(O'G%$.7\ET[GV_53G M20@UQ:
MS..F,;R;6(T[12XDE-A].[OHS)*?$/-XKKA)UT;"4V&XU+C49M2^*7+S?I2=
M78I*Y_JY!=&8Z-(8DE#'VEK\)]2Z0JTKY)FOXYE%+)V;TWU;&7/.^*&9?$8V
M<BF^&B7O8]LM,\A6;YAJ4>L_5+_,5SDHWF]KXE/Y3HY6#'T^9MD87SN6QW!V
M#/59)8VGRED\4#D++>.01X<\^@)X]!?8TLG-0JOU.VR18Z>#V.V@$G\H)3ZA
MO/]%63^Q]NRQVE'K=:Z2&]XG9'9>8&&65NPBU."/YMI^@SKL?!XR[Y!YO\VM
M"44! 5$G'S,N=C(/QC F)TJU0;E;'C[-M&SV7!AF.C5YV(P;\R=Y(&5O1O/*
M]$8O \.\'([YGJIL9"&*.+D?9D:3\48[][5((BXUZ?(ZF!>/YWO910RXJ;6E
M3N9 #4)@@N?"&1\I;F$^%DD =%TWWKQ.R=A+ XTH&GJM[@%TE*9]3KZJ/.*E
M8Y_<,9F0CVM E0D>@4<&_> !>!$DG\&SK&L[7L$SHA BJ:)IE_Y%#!X:Q2-@
M+9VB&R,"? <P#==8+"0A"G(?O5= [R>-VR^C4.LC=<W1?3FSX^K92DD:Y-<C
MN9HQ<OR).B@\B )QSZ!!%&[!D]&Q+ZJI-D232I4N7%)PG9-A->3.;4^S.'YQ
MVUI7BE&I-$=,TA15?RHYO6,RZH[<?$ :[_$F]736)L[^=O*]C^>6G@'YX"')
M>Z>!S&3_7HTK]_P',YV!%3FS)N!I;XJJ0>2Y@9LHNFQEC&0 G>H-JB@9K<4;
M^\N71)23%@<\0F"3_%Y =+P&JKVB::U BNX.8!" A$D9#R2BZ5WNO_=+IMSE
M[M0]V)WA.R-0MC&'#=A3\0)>1TKD>,,=7@0/.$U;QCMW[F_=CUFPUAW5"FV0
M\(?L)&@/_\<]*0G3%J[=?E+>-CB7UU$J$7:4"CM*O42'/,..4NRK.DK%WY?
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M%<,6A.O=L6?3??V@. 0'PCQ%P;U%N[QS@_N F#"*':E:2))XU(NU9(A'C$]
M3"HEJ5/%%@2\0V=C<<+#5+YG7R9( MX#\;?A]1829Q)(L2E%:Z3N@5%K03VM
M#MS9W.UK#]A3X)U3ZN DR,K#D05[9G'P^?&44VQ;.^8Q$,\8PQ'M82&1B8-+
M'9_,U25<"* _ 0LYYE.S3Q? 7PB:'>4@SOZ]!KM#V4!PRH[(,4+)=#6&&#([
M-%V\.K8GR2#=Z8G[ ,E,B0[Y W@<'P1(+B/@?;;^QT\FV)M&'<U[K^8C"TT
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MG!G>WY3FD^4G#)M_4<[_4ZY43<]B\W:)7[6BO+YF,]M&.[@-7T")OMVYU3/
M]YOD#B;#W,$P=_!"<P?CK\H=3'S"-,J7-$GW-]1TG.U("^/MQ&X[-<7).W"]
M?5/'^8X%X7G*M4M1Q]^F-4WEZ6(TEI.)4G/#R9E9?Y54K0U$S1(GE:9#R^U
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M$KR0&?%C41RELJG8=!Q/C/EDZ@?Y*GFB-QGU1<&<U+)<28Z:HO&D\1UNP<Q
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MLI21 F1,M'Y'D=6HX.R[EJW>$#ANT/".Z#RB\XC.(SJ/Z#RB\XC.;R:1_)^
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M; QB0Q.(:DP<P3?_%C577%O!,9.I1YH,.?;WEC,1(#"">,2I?V'^S_@CE?
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M11V7G]R5=[:]K)_--6,-P)L,D1\ADFY?\GQ>5>W/D#*?;D*$&3P!$W$!#V6
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M\/J*8_ AXW.2HD/Z9NPSZP2TC+A^CS;4Z Q+/KY48AAB -M#@6?U!DC MEC
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MGUXDXM"4!S__+/"SQ-VV5B]1_C[:3F'CH$O]>4\F\% N[X.*YE"QP\P[TY
M0,3E6=TBW"DT?% 0XA&KZ1CCC!W+QN+^[)J'(SME:XHCD>(9.-#.-;2E/\X
MM:!V[&".P9[I#Y^\LXDF\#J=H1^99X%Y'>^F!0#F^6B0R]!19XH]VPXA9SUD
MCH$N[8Z+*D,-HV'U+20#;2K[ECK\DZ+[V@H=T/"-/0@F1[/]X3XGT7'@'"C6
M<Q\*WSP^:1I=!V:58WO"<W/V4SP]T]@*;#T)"4Q(-P?'VK52ME<^@7_C3]YX
M'C41_!VI0\4?UR(_7MI8>6OW\*O8*L*L%)?B\TX>C_7$7FE0$>)6ZWF.SJ>#
M)'D2)-.B;%12"R*#K[D%J2170.[(UP+)W&@PQ8PVZG(+H[4H%1+P"\KXUY_X
M"?/M97M.T5^E4B^>L"7K4[96Z(-Z]KGW&!UZ5-@,0G9B0?&(OG<\+NSQLV/-
M)R<GA=C#!7= K]5^SZKC2M7.CQ>C0:-NGL/>.=_F'Z-/X^.S6*N]ZJHQ*DUS
MG>2&F33'%Z?H YC$*M6N:_223;5;278M>6Y5:YNKP<19FZ5Z9DWP*OTT=A9Z
M*F^/9!<%%M] T1\EXU#/O^21OX^X??/BA4$^EYSYD4<-6KWX%=368U.<6><"
MSD-RE$[%+#:-D_9P4BXD*REF>JEY#>\,(?O1XM0C]GPD+#S39UI.[[K)\ QP
MQ88VMG1\GE]_FKO$MT/V6%M<844=.7;0;O[2T<:'AX(DADSA]\OI?=,8<=!8
M]P98,7SVK2(<+A42;%4&J_PHH<XRB[3<6%-+*LZ\2P&']SP0HL8,0-@RCCTQ
MT+BM*N0$[[(G7,) X]Z$Z!)UN,Q[9FTT4B00W.4X9">=FN>J;15DN:FM@GDA
MWWG_\$V/]4+D,[J\@_JPN4L3R(X'F].CA66-'"K%W$@MV:GB>$'Q"E-I_/J#
M/Q[706Z5]E\7,P5_"MAS);9E=M>VS(DD32Z)7IQNMSRPOSS/^=\>QUR2Z,]?
M;OYSZ%MD HA/70>:C-W"W)$K1K>2^:#]^D^@GYDW&U9J1?=5EFVUQKBQB<4X
M!LV=35^#Z'\*V"U*S^2:)7'$UY9.3;<H2EII#03VET<A__MP'KF(;D7,\#W(
MR7^3EPL!KP/_*]Z=81 H./U%2;3@"J@YE5!S8B/3F'E?8MJU1^RCN@R_IBX[
M,+T_C[X:EN4"HRZ1_%K**DE.+BA-J_'U],76,D*QKF1B?"O%IP1I6=U851<)
MU?@5==FW!SMI5Y@!GNS2>)<FF(K54Y=IFD%@/^X?\^6Z[&+0)X2*FM#2O2G7
MS3XM"NI< USE"M#/#Q@F59K.1(Y,KXKU;JZG\8I'],?99%^GR[X]V/'N(D;F
M"5#GUV9YFJ$*HD9J[BL&W$WJ,L:+E!^[78$K*06?$KL*[#UO@TH.*$OO.@A%
M0"[ \X<YVB]3VW,Z7@VZ]O ,5@XZK^A*(/0//HU0I]-X:?"D6AR^KB3<H4(D
MJVGN_497F-6WW1 BS!"@)RFSAS<G2I9B7*YFI&LQ/#NKVT//ROI*CR["R2Y.
MY'5?;K,+8:RV*)Y<)P%>S"U<E.KPLL-Q,15YE!)]$[BI3\'JB4FN!URK&M/[
MZ_2@5!2_ C=QG(]7L^L6X/*9A%.JC:L9G??24+[2:HR0LI\;]!1KI%@ZQW!=
M\ZFOQ_M]26<]ACDN<GE!O7[J+?<;@K!G[KTA*#0LXUC00;0LK*CKQG)[.^_K
MT3"KMY4I-K<IO7E3#!OW7#43>>)?7$!\(9\6[A ;>SM[-B2J8G =7]0M6[$=
M&WA&10&(FOU\N&JQL#T;-&,L9SXW3'O?[('[ES'1QA3X^+EI(-,(&A60O&41
M/G0_"W;K/N^;47ZFQ"MFE#L!^O-O!\G"P?$F(C1?ABB'-+P$WZ8^>RNP49!H
MBJC:XV9$D@Y$]AJ3G<#.@H<^WK5W!?3%\:2@"F$)= >T#,>4P+,@\2@T)-!G
M^@S)TR/$0"2,"K8B%3:4SM5*6E)6^\GR4^(*$=3%0!R,K2I)J:V9X1A/B_+&
MIL;( ']90GS(X [OW]YVI7P53!]X6Y^$:3'?I*JZ@!L\"[7&N :LGMR[ J8+
M2U/5Z 4_Q1=$,3]?Q[E-=N:>CR]<&M/XY9('3H>-/@FGW83 S5:2IJN+)2@F
MV&FQ1[OGW.=S]^W_!*E.>6#+4Z$]Q==]H]]+C :NJKM?G5#S25"MF66K:%>-
M#M^=]48]P>A(@_8Y3KD45 ?V_"DWSR0,?@&E8BQ)4W7O-N]-"0Q>_82?FP[U
M(]C-)9,/X]VOR$&/QWPV.1:(/F=N@P*>NAYI7@$/2CW3E+&"/I<,RWY./]M)
MF BTLY>LAC+>CA5OH,:#UZ(]*-;N*_VTMFTF^-P$<U$YV0A!\HLYH3BQ $HI
M#,N!D UE^45#7K<.SWH8HD0."6#6!,#%WM%-/^AQ8>?ZD\BX6NZ6B D->)XM
M$RU6)]A&TOU ,DYH[OOVZRN6/EMB;("[O,8I7$HR:'E03W*?+PB._*M/@EF*
M7.!ZNV.U>#8U[ TJS0TMEC_ ^N^"F2#,&(DKK%1\D0&\F"PZG!N'MH_^9C;?
M80;QI?@?U(9'X;_'DU4,%\HK"F&2!<.SU:O3*C5)F/FV@<>2+-L@%B4V232.
MJU=/K[N5ZM4SLP!WZ_NAL/)&8(?UKNE'#,/:P)QA94/4L9PH>77.V'9RX)>[
MCK7GHE*?EHCT_K7G0:DJ"W]6_(*9%H "%^U^FZO^@/FRU:?2P^=B?Z'G!NXE
M"^D#::FLB'*X C]S&!3]084UWMW$ U919%:<8SE%AT);@;YKVW0L.PC*:TBS
MF0]8"P(3T@?6@0(!K+&,J*L'*[R:2T]7^)]8?F$A^MP$J #3\Y$A;#VMA/Y%
M^SGW<GFFZ(IE^P7<F#@.JXF\!$$(.=2ZQ_LP]*L9]-OVQ'_Y>OP9@#L@>J:3
M .A;.(=??PB*#(.Z3[_N4/QT#R80QWA0F9;>!J00KZ,@@NGLE\^CG:.-^_O>
M;CN0PMRP-"!UL$IPI74:C'1V55M3[[\5"@5.&0K^VLA_5<A0%7&ES)Q9QC!-
MKX(7H@_^Q5Z?%-!#.B$D^MI&Q)5)IPB<^CP?&T$[+(&?JVU#M668AK S"E[J
MFT\O8VT?37\I_PXME%U>>/AIV(.LCEZ(-G,2.R-E.+5K<A?G8ZM%7]JLU(P]
M1L'%L]AYKM^<0V-84N:(#[>5G%O<60\0#Q 1025%(&ZV==[&W"]+A%]3M%/7
M:ZA2]+F\Y6=@SO-[]G?0AG:0- 'H RAZO3UYL#Z)4#I5 (U&;"IRB[E1'SFY
M@4Z.43[7.]D-VD;#:=!) "'/@B+8&HG;$$)8U/[<*N A<"00KVTGVS[7 .\4
MQ?MM$R!IO)4V3B7"1L3Q?N)@:T0I8U@%EXLY!5)M9L5,O^'>&G'\A;3[<V;
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M9>'84%6/A&B:#E-T-$I&_W:E=8E#"A"FD&#MBBJYUY>J^L(+VU,X^3"!T<%
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M&,)%AD:.[9C!;JF"#=_H=4@U=,L.^Y-U^P>ZK(0WPGW3$$R$A:R;"#U#,J3
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MDNCMV\4_T4Y^_?5III+(+TM<A9B)LVBLM0G+16H\0$/I<R&;WQ( 2CK0<$P
M0#\,_O\(F+M8P<,Q PP%"S#X'+'$H)5UD?CP9UE1X^HR9HO=15-)CZ:E:2,;
M-M?RQXY?WQ,LW,X.Q89JHS0V7-UYN_'BXW;4U*X]YLJI$<'7S%Z''&;'=D5?
M_OK#/F]'A:!9[9[P;<-<D#,48+\AVB6X%M<00(;2$+-X7WK"/"'H&7I#@RPF
M& 9TM3 #;;G'_4(D%#B1A \&(?A.>V*AKT-'\EC\0/!"2?#A7Y:F>R[.N]#Y
MI!N,*%B6\WQ"+N8V:]AM55HL91! 761:8D]AVO/&KS]1^H&)LD="!EOG;(][
M(/N!D(Q?%VC/L?4 'U 8YX))8.?ROBY$/3?%JS9RJ9A<"+**1"NKF_C0\"@A
M8S6;T'/Y-,O-1RN@5386"+>0^_5 D/1#(I%XEI8FF*&S(\%_#8[^(%KB"-TE
MPCLGQ&SVXA#N<0#>MKUSC%N+V;R[_TQ='J4(?CI)*;E",:NN':8BC<?/=Y+9
M<C\P%[(7JCQD3%75W3.BVJBY#?6YV)'6+=LZ;#)CUE=:N*G''_E2,KQHCBV[
M%.XUSM1DYI78%%89ST8T_6@E"C/#_XUT-Q3UEXR.0'3'@MAC_?W[UACHL_KB
M>#/ 'K[@V+K_@>O>XT\NW#HGRD1B[+T<_RZB_76-0NY4N (JD!'Z3H=KH ,1
M(>YM0JZ!$G=<N@8JD!'JWN'N*@@!@>G>T>LJ*!%)W$7B.@AQQZ;K( 2!SX?O
ME/AZ2MRQZ5H(<<>FZR#$W6[Z7$J\L:33JX&^R_:VN$S#BNM9[\%!RWN[N,3>
MV\B BD;BY]V0CS8J:$], $(5]]B:P\?6G]7,XQ5U_ -Y@3GOAGRXI1/*8'B!
M%>[H=T>_=Z#?#;=Q>:X0U!TBSPF1WYYA[D#ZQ4!ZO9VO2'P%X88EX*4:>7<>
M^#$\\&R_KVM3D5?-!O2ML\%G0<'/9H/OA@:?54CV*PRC)K" 8*)K 9H4DL "
MJ+J!DIO/6FWR)]>:?/%P[>9J3;Z68G6!6I/OJE[[YHH3\1>OH!0T5&4%/MW&
MEP7*7G+V7OT)7]*2FI39R1GG)CM[UQK:1)Y-ILI-EN_&^+9<BQ,]NKQWK2%,
MO^%6@Y<F#J3C6>3>N[=W%.AMP<AV(<IE)W:\IH3G+6&:9#2'RR0'T0$-\>^!
M(<G+5J?]R7CQ\MGC+0+&!4H-7P]@$$' (#X=, 0BZS@SL_3(U^)VL=92:@N'
M;EP>,+I,;M88-JR^4A/8B0D$+5];+R%@,/A:$W%8G>B\4O.U@<@[9GPV9ES
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M-E)30EUA5,'L#8NCDIQ/(N_E=:Q\8@;C[J8S00*^X8WM8<_ ]NW8T7ML8>+
M10TZNF=V4-U4LK:P>LD)+3SF.VLN0['\NIA1*SUFG-U$/5Z!KC20DO8+XW"_
M:_(Z7%;7]R)CD9"[\!!<.;"^QG&]-H7Q)F'=\HT72/9B&4>EL#RUEPN9X#)\
MRRE.!VE=IZW2Z:[+%]EWG[@!]"2:$28JM>&[T_:@L)(SX6AL>2(,R2ZCHAA
M, 2,C#@3X<D3"))VG;;?YI'O!P.VCS_R^@NX,6\_&WF+M?,:[8+V3;ZS8>*$
MLU3YFCTFU6:A3L3+4-62+]@W6SUP"OHC\P>ZEI#%L D$E0H8C5S;*+CY<'_
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M']^#1(MZU.P3)!LW&[-NI8!1)XFH(2C:$K9O>\/(I9:E01)J'=<'.\-%VR]
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M:D!2I /.4A B]]BQUK>'&F]DC(P OR C"#&D8]OCM* RP)][+OA(?'[@NQ;
M$=83RO[+X#6'\!MOL8SQCDZ"_NS$\:*Q <$#A@=1E,$O+CAE;N9+3T=J67L/
M>C3H,W2C&<PQ!,'L@&YUD>+ EYI%$#@Z"_L1N(O@&-JI,$/'T7$'\%RD"Q3(
MGUK,PR6/?>^@*AC]$GQ<BMN,/8W>OA./?0U+9;"-\1]<M*[:8U\#]D:_POC
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M[$Y.(S:734#2#B)5TA#=-X V?4+A8QOO'>C9&-2#[UT?*0L1$@<ZSADR%$0
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M0H?AVD;@" OPA@!\5'FVAC5*V2!?TS'$N^ QAR.59D:3EHO)LK9+B@U&"AS
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M*O&Q,A^;S&/Q0*?#\Y;R#BN1*@^R)@?IXB4XL)<)QB0HT9ANO@ *#M#)X)5
MR>P;'L.0N2V<'R47!K)COG?11);+W5QG6Y$S"D=.NZ</Y&'+J,%M63NT!TCP
MHLZ"HP3-B:"/*\G2AH0F?K8ADS_8+$!<158XJS!YIUG90;JBGLWA&+JM1)CP
MZ6D9L0J'+,Z(9W#/45"G/X!P#).!2$)A2P):I)WV$T7UR,(H:V-3)+^R=A8
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MNS=N[,)TX(7# #C67[8?1<S7/KH.9<MPCL-"R=T!+%SDSN2HN(D)9YY@7S\
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ME2M C86J&O_+#14&@C7!I?))W2#D%@,.;]_8KD>PA%GA=\!:>8Y66(X]W!@
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M2&+1-<"_:?ZB\P[A+PVK;*2$5* -;3995#30@B]!A5M/>MTH:]\8K-4)NC[
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M>0G4V;-OD)$!UN!?$*T#49,("0$,MD-[!S0!AP$N\ <7-VA[!>;+&"T'QR^
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M9T83_CDZ.>8,)V<7-<J3K*Y57R"^E#@'MZE6O=6%U/4T]:8UWVMP%2,H1MA
M1K#TVMZ>8H3GYRM631W+8H0UV.HB&*&FFTUSFQKE;%&VXZDXW1O7\-N1$6G0
M'!=!C)=(CA7DJ!C24@.PJY:&JXT9;+%I5*GKU=IX8$$QE6(JQ51/-;,:>JTV
MR]]0/+6P9,>JZ6GE/+4&,%A(#J2A-RM5E0/9]1Q(?:-S('R*CT$4\8N$A5\3
M^!/]F5W4!AM7'C+G^.M:%5P^[,Q/HZ$WS.:L,V**D!4A;P A[U7U6J.F"'G#
M#S;,.1&PB81LZ<:>-5="7E^C>&=LW^9X2&$K(OU\BO?8-8M%L>;Z3M!G*FRR
M,P76RPHU;B+/6]CM5\41=XLAU@@8F\LY#77<8/>.&RPKPKZ)/D%S9HA&A<\W
MR85X(@W4C&WHSI-Z"J(62 5J-C3BN(LM4IYJSB H#'-[>X8KDM]:DG^JP5*?
MH*T4N6^4/;Z+/8:>7,A=GQ7JV2(S?%>L;:-2>9"YO:D1>RIC"7R-V:$WU$(V
ML(?4JRCH:&W6BE78104L5<!RGA:^XA[%/=O./4_4M=5&=3G13<4YV^5>;$]>
MX,DEU0U55K_C>8&'>BIK[I"<QCT6RJR KOELH@^RBR)_ZXXGKBJ.NFJ8+(+Y
M+57RK-A%L<L#V<6J*V[9\DY"J\I:K!HF"^"6V45'&^=#+)\R5N]3//D>Q=KX
M)8K;EOUHL4X0,G%D08OMNUDU22H(I<*W*GP[[0AQ;6]/17 5\RCF><JQY69U
M2<7=BGE4^F,]TQ]/91Y3KRTK=[@%WLOVI$J>? I[_"*.S<N4O'^0P[*+VD&%
M?G<@]*L.82B662N8K#_+/-&\,G2K,M.Z4@RC$B9;F3!Y<D=NY!B5,]GLG,E3
MI>66GQ@Y8;'F!9&ZO&&5?>8M$)/M(&EY;"UTQ\ME]YA?P?Y5QD0QE&*H]6:H
MO;INUA1#K<.M#3O&4.NP_T4P%'@RC0GV[#9F5G;A;,F3&_%-*0/[+;:!PO_X
MO>W>/'_MY0Q#DHOH&_@H+XTN&TW6?ST((A<O7-@/F4>W3DL:PCNE7Q16,XXZ
MP8QR1,3"V'!T+W6YQJ3;95;+%<G@@%*?I3#5["0.M(I6P7E_@XGEOP28=!5<
M-, */'L0L7WYQ^LY$',!5/P;>:TVK:'DV<,@B?<[[AUKYP$EMB.HH.B<SEQ7
M;AW\7N\)UW=/Y_/&&-V_PAXQ18X;88P\B3X+9/PC#@2K"ONVQ[^YY<0@OLHQ
MD,<Z(M7F)6V8Z66M;&DPM0?D0K>?O[3*1OI%T-& .$J.'?5@M8%S76K9$6MK
M3M#'_!Q=$B)S=5HG"+6XQS3?]1D7/7U82B_2F-^&=\[9(&;]%@LUJZ)K9L4T
M:#[X SZ&+!HP!TG5&Y93SASC2D6##Z=!<W-HL)HC.:)!L]Q86QJ<M]Y^HN4[
MGV7D4.?&@!VG@+I6X+5'+0S#S(J-78> CB \1.8#XN?H^,)NF)\P;8XK)?IQ
M 8M^O&_5QBV?W+H>8@#DU^X4UAZ*M;>9$S*BM)=[95.2HZX!A1F-7W1^5=)+
MTRI74E+-4Y\VF_ J&FC9ET:C7'_*VX:NP;Z<GG9K1]H@= $6+G6[ 74/S\/0
M=KI^S058L/ &-HS/!C<N#@GV ^/3_67[4<1\;3HV#[HA8]1$)V1.T/4!)VV-
M,R'\"D,.@A ?M#UMP,(.\KOO,&U@P[>V!^L*.IV(Q5IK"(-K+QLYB#E)/^$F
MBN;8L=,K)0/-[H-U4YBKG81XR^[#@=.!]0>W\AT;UMZ638"")!Q!N)UN3V*@
M#23@!0/YRON/IO5%LP%*<:3=NG%/PJRL7?3<:.(FBHC!04&\)!Z-!T"PP=[V
MQ"U;Z:JR8?)@1#GGL3C%&3X:M$"0TLO3]PI$@%\4]\JI)F3MQ$$ZH67U;=?'
MUU,BB7MVK-W"6"&M>A#X()% [\*(@GZTE,,?1?(NE_AM#4&0#-I K$B=?-V(
M] C'8R#J.2XZ29S &M*%96N%I;12,#V5G"43.4'(MXG:$; %RQ2<3[ &10Q4
M/((>&#RVNPQQ)Q"4PV0>?1FJ\F0<]]RPK?U,@$40I1VA@IP@@:':G,@<@*8+
M,&X7QL/]M)D'RPB1L3+@9" (_&Z $ST"%&7M&\>WSVQ:Y/BF)A$*QX*4*?!1
M3IDMID!_.J*;Y((#L QU#<RL'CUVUD-196AQ""(CPL?.3DJF5=7^S^X/7O,/
MID08+A0UOB.$72O/)8*@.K!F&+L(8J[N(Y L?@9]^-X<T?[:_#7M#/WU0)4%
M&.K9-RB=8-7@0Q(# Z<2/84 >-LA?('8<8@P\0? & KA:229X>D+BV)2'H_1
M!RCE7AJ5:DZ+P3<P]22A#!N4G(6/O*SGK#Y2IE,W\K+9*-=&9CABCIC $-(E
MV\MIZ )H8=<Y^GX/A!S2 T$&P<E3ZBC\V(WM)0009'[112X:)3L05@Q(IJ"B
MX,]4KG,.\&$*)Z;>#[P/7:9>G""*4;"Y_5821ARJ(W/ W+80OZG>^?90,G"E
MD0UZMY)3O-RJ#ED'H$:CISM,MX2  @#H@.%ZN9E_L[A<PIVD&A3;F;61RF?\
M^OW'$NE1%)R![T8Q,2U&,I#Y0.Z0*$9P(,D%U#9##J73=T"BH%$1,C<@I6C9
M#BJGMM2D] D> DR@GD4:JZ8+A__"  %@76Y6BY+6#P!UIBOS0H^^\8"!P E#
M2-@DRQB'KI17".P;8#%&JDL*+7)B&N6]/-!&L3X"10YVVE,>H/I$,PK&+CKI
M;.*8[21/-5-P@T8,RS@3Q><8%=&*,H[+F; 3/"H4"CASSOP)-*=G^UU2X:F)
MBO ]YZ+X8-1J*03G*/R4"X$Y'A +QB9[(]ZZA<*T&#F;>P02%3\+I?0V]V3@
M-?4^K&9NU?3O__[/@P)XN6V)6)Y)7GV7E5J F^N2W8&9]VWOUAY&8IMU$(QF
M%G60R[+((S+*%>L7C?]=*5O57[*07FX]??NNE(.9"!*4T$G?%Z_)[T(>8:1Q
M)P097XR,FX9-3*-<*\8]K5JYOB!<C?B%5H:9WVVM!Q+OOR_^<W%ZN 8!D OB
M=F#?0W@:96]*]?9#*+^(MC%LY*/,!D64%@7B1[K>CS5+X4VIC*<H.6:34T-N
M*(A^$&UNT*9Q;;2+'1;&8+IJZ+*@=N%N3>"AD@.1R#6-%%#PG..&8.R#.>2C
MH P<)PD781$^*_;R16I,W.513K4<\TA8Q&,OCPB8\H4AGPJJ00IS.&46I4(N
MT2-$PKC<C4,Y:RXO\>(9Y7-5LVS-S*?EV"0W)7IO'?"/92Q-?B9BW.=R]1;@
M<J\XRP6$TT?M%E!1$H]F:Y:<*L^]AV'C!R;.<YF=Y]4UFN5*7>%E_?!BE V%
MES7$2[.\UU1X63^\&.7FS$)DA9=5X<54>G\-\=(L5V?6_BB\*#FF\%*PQQH*
M+^N'%Y!C"BWKAQ;%+NN)ET;94GA9'%X>WK7ER8&RC3C),><@U'KOV0D\_/*_
M+ZHOGKI_ZQZV?#8 &K/28),ATBK,F8]KO_CC!+/OGWB]T#'5"_W^6VM.O1A6
M?)YX+I1@/I42C$JY-C.^M.",Z&,$94-F0?*TL:3N%;.MB_6FDL5H[FTB#*5&
ME1I]NAI=80>7.:O9M#R''X:P*KH\%*B4[48HVSG3PQ&F_,.Y85\IT75'^"]%
M7"N]N*%ZD8OM\7\7(-#J:]7"[+D,@"6I2MO-BSCJS6TCCHHBCGF:0MMC.A]2
M0:@RE9YI*FTW00A[:B3C49F2 "APFI&QVLC&E:6VR9;:7,1PXZEBV*J6FQOE
MH+SB+FG$SVT&263[[>A7)7;7UT-=W)[GT%1VC87AH3Q+R(]P9T<V9/,2T<A?
M"Y.H@[MK,^W5V<6[DD4->!?7Q6NS9>:<@7%?V?SF=_9;;G9P;AW;K+INF.-=
MVQ;2"7.#/;FY V-V]?7&L\/L(N;U90?3U!L-0['#TK7#BHVK1;/#9G*#L:>;
M>_6=(( UXH:E5Y3,C5YJYG:6C#S8QS@[*37WK)T/N#PYK+!S>]Y<Q\&LZ59S
M;ZZW?6V^0;1Q;L J*'Y3?0.CKC=JLZPA1?&[8>CMBOG?T*OF7.E]]W"_N;;\
MWI2K'%0B@7<C5*F#G4D=K!$P-M=?L/1ZLZD"J[N69U@C8&RNYW'_7?2*>U14
M>N'<LYG,LSS%HZAEO?V>_[?#:0G3,E5:0J4EMM[-:-0K*D*K<A+*,U DOUN6
MVZZ8\W,6\+N'^0TTS7<RRW#QKF16*BK-H-(,*LWP</5@6"I*JG(,*L?P>,;1
MC8HZ!Z0R##N<89@-G&F,\\K0*\WJKXI:=BW#\$1R:3;':67'TA'@VAB379M=
M]&!VT5'9&7_$LF895;MH.^VB>[$S7H1540<D5$1ZTPS_)U/[K$X!"O$;8,,_
M.5HRGH3:[KS%6<B<@GWO1@Y>-S3$2[_YG=G"S%<9"Y6Q4!F+1XB2NF[55<L9
ME;5068NGI/OT6K.JF$>E+78W;?'T@Q&U>DU1RZZE+9[<\&4\LK,5:8M/KL>B
M./"9-K"'E*\(6K!V&R]!U>) ZP1AGX781-JS6T'(OQ_88>RS4*4P_C][;]H<
MMY&E"W]_(][_@/"X)^R((IO%5;)F)H*FI+9Z+$M7DML1]XL#!615P4(!92RD
MJW_]/6LN6(JD-E)2S2)+))#(Y>39SW-V(8POWD YGAP<[(HJ=D&,K\:HV!55
M[/S97U<@XX.S^*_O[.^E8O_5E%7\HXJ+IJ;(1!/_%64%-E#)+F%\33ZJ3+::
MM55M4,6?1(5I=H&*3QJHN.L&=]LV:Z#KXT>)3]SU'GR$=,;#R>&#@T^3_?H%
M*%$?-GQQU^1TUU<*#8R[WH./<*4>'#W87:@["6G<-3'=^86Z^RWX* 4:Q\>'
MNP*-7:3CQAD97V@?BS=E$^<N86ND3J/>137>(ZH1\L\CX)]IV<YR<R]DR&";
MHP]@R=S!,C\.MLCD]&A; ?G7J&%] ,ODB[P%?>/C"[D%)R>3@\-=P.\#>,#O
MG#P^P2VX!ZO\*,E1AY/3K5@B7Z-I\-58 "=]P& R /[>Q$#8__-?:7;Y_G/?
M=R>FEX=^ O]<<C-W()J'9O5H7=899AW]4)D\QJB&TM3!P=]P1=YL^L:;W$$=
M$4^A-UQ3KG\XV#^%3XGV?K)_H/<:CK0P=D^CN&W*Z" ZP._^'3ZL?WYH^L7@
MU4M381@G7IBH*)MH9>("J&?>YG0J'Y!ZL@)N0//#T6EW"@&QA$<U/80G;GB-
M/L547UUGU6%0K#)Q;=+HVZ/#_=,(9I$#&4RBL@*"_]LDFE?E*OKV! Y??X?)
M;U&SA/W/"L,.J!5,:EE'!N:11J_-NC&KF:FBHX-)= AJ V;,??O@S U_ZR&F
M^]$;>%QG&UW%=;2N,E@L[%J4M@8_ :=B'RCGT;?3X_U#^\6L\)N]V[*EILH&
MP F2LL; 84US#)^MHV5\:6">59GG,%5\=5V5"S"@81<G.(.\189&[Y;%HL2_
MOUSBI YU")C,RW]-(N T<#8SLZ"91X]-PHL^/)@^Y+ E##'/JKJ)_FSCJH%?
MP;IP.R9HL*]-@C<UWTSHX9]^ZHT(AP_;@T? CP356@GL>!4G<(?BHIW#7]H*
MIQKCH, +F#C:JH)%PE#X5?PO<,1U+ F/>HHCJ\2/Q-$ZCXL"QECDY0R^S,\<
M=4\ UN4=#^W/(Z"9_1/_ +F3YLT.;P['4U[I.< +3<:3AB_A3X*YXN"_7@ =
M5?I";6![TLZV']"WB$.:=]D_6-&Q=X]@4'L/=5 @XU4W]Y1WTB6@UA&P<L-;
M_W]-G.-OSX$ *8I-A^)MY;JMZC:&G\/(^ +039FWNA/ZV;B:90V?*DSR:/^!
M/TG>JNE-][V29DA(AEF!W+E#W$R-X5T]VC_S3WK=K2RLVL66\L*:R?O;@_V'
M[S_Q0Z46/KCG\<9QH-KQH#JZ,I6AI%\8%*Y9.9_7IHEF&R#Z;Z?[Q]YZ9*$P
MV@)S$OAF)$G5&B2G.1PGJA!1$M?+;JH"7Z+4^'QM?QK<"@:%O&Z5EM0<\?PS
M+H!I%='/64+I$/C*19#2[,A*>&S95C!JGM$QP&3J=E8WL"3> O@CBO&5=*]=
MP^L@LRYA[-IR"IVKWKYPSOL[&=Z?ZF\&)$X:/3RDXSDYBT#7R?<:&#$R?[;9
M99SC\8S[;U?KO-P80^(,#JPO6ND5OI6^4-F/KM<>?#$>72/!13+2I=(;Q#<_
MH&;@?,G;O1FI)$FYP@\Q*6K.#EUT_R48I(1)5-':5'4)LB;?4[9F)XHCQ17S
MUQM.^.#346-TK\B1_XD#_9 U8$,E_),K-A9F99YV34J<H^9<F<)4PGW.4S!;
MLIKD"JA,3_Q(PJ?85G\N<3B7(?WW=/\H4'^/3ZWZ.SUZ#]V5U=_I0T\VW5K]
MO5[9/0I5)7L7/!'9$4JHP-1MWJ" ]AXZ""4Q?/6M:;9(W."S(+:K-@N&Q,G6
M[7I=5@VM&2S1JV9)MQ9D20D39:5F(J(.ACP<%)TY:+5Y- =6UC$&!I<[;"*$
MK.?0G?C-6<\T-"JNP!)E*5V#)E9E.+N=&!L58X?'M%=@WPR*L<66*_ON@HP=
M-N22\-PB20X4C?ZJ9<?A<H0S#KTI']PKA?J=J72+#H_5.6<9Z?&!-VOZ\___
M_V[DU/&6)?Z=0_*R+<S>#&C_[5X\AR__$.=7\::699X]V#^UD8L?K'/VB)C[
M=/_@Z&\1__U@_^CD;\[-X\UG%?^UY^V9>/7V<C-O?I#7]&<5>YUHW ''TS>=
M<>EHT!L%.OAIZ L[.MT_^TAGU1%Q1^YD_BN.EJ"T__<W__'FQ47G#GXHP5N4
MU2K. \$K/_)H"/<6 _AD.\"-N("GT5RT5SO^GQM0?GAL0Z?QX=E#SZW7W\2;
M*"#W@]>]]V*^^9]GR S Z(^>%2!XS#V?[WW:_+Z@L7N9T5Y:TSE45DC#.YU:
M#>_ <WG<PJIAW>[ TR-N8Q*A'I/5SKA'E045%:>V6*=-PD9> APZRLLK6)RL
M$J0C>B,OLZHLR#AC+2I9QL6"5"-\?Y7]A0R"=3EB%[5)VHJ]5%W;"+X.:]@
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M]ZA>9FO7+4APZVPY (&5+<L<F)I+]4^!4!I,/;?14Z^TOPZJ \@?R56L44Y
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M'7M@;+!95<;IQ,;30LPU5UF"C?HH6=B2K(>BW[M*'RN?^N,Z.GZT*?-P:,]
M1:F;:G-3W\7-$J_#Q'4% [/VG)3#$*R]L*@9&YY%F9<+SAU;$UYS8EJ2PY@Z
M0A.]E0MD%XK_VG6;CYD)-98",I '=5\2LK 8+D@=H,:M#:?-<"LG4@VNO8Y\
M?<DE>8^,B=V-NVL"0P&C:>:<ZV=+F:2K*)4Z-&1;8"HD*96D:)2@4J"F\&>+
M[8LR:H@J8$]!2U3@\V51F)TC9D=XH1F+JBI&3ZO,H"%JBVLRMH0(>4TQ A95
M>84)A%(OYVF].[+:D56OI.9:;YS7+B+R)&>]J1NS(DMHQETPV,; W&>!F=[L
M"&Y'<([@$+MRA;7![#N>;8(FE%1^['+HU4E''>!<8;LT.5[$_ N$:@ V&"M,
M.QC@*6(ZO NDRWTBUIWK^!XH>TL3IP*U4V,!F**1%]C.Y"VLL\#^I\T2GGF+
M8!Q8[/KOLMAN.'QI_F#<*(37S+$)$[:$>2E-N&^56W*MWS#S/V'[?)-W$$XF
MP2(:BC250]6@0;.+FZ:8[')+=JQAD#5XP81N!(%JJ]"]T(P0+.4I]QR*0UY=
M:L$FRE:&PE'0V3H.:W9RF,!Q+9"Q[%2^5V)M1[QW3;R_*<8?:E(,+P?DDL=7
M=8OXW$!12L E(@6#YI^XEB,]>E;4!U:W9L9514\86Y#TLY7&88+@VR[M9$>A
M0Q3Z,FZD Q*L6:&(!CBDI;DYM:0&<H9AJ'BU+81PO[#RG0>[\IU=^<Y-KM"7
M5[ZSLX?OFJ3\_"G&_P7Z&E9RLV*.C)L[@:"VH< 1U.V)( XTM\I!Q1%PW !Z
MV5=D25\58(=*PQ-J"\*PFJ^Q<N7]DQAZ  -7A4I7'[]S5X?Q<=G&X9VQC;Y^
M,*?_>;\=?Y]@*N'%,I(L0E92ZQ/N%97GVES$AP< 6@:;!:10;FP"EP#-8KQU
M$5=I[KE]'$*WESN\,S9V8BT,22@P%Z6<@D2+%9\]-7^V<;)10><WLN$"BAZH
M;B:@TOC8')&O$Z/>&$T* [KE'FM2V\,LE;N>#L IWR=RO8=*V(Z;$AF_1H!<
MZN=6,Z*W$-*2^P2D9=*N;"OCQZ!R4 ,%^(\'M YL=J^)WQIJT:2P4AZ"-*EJ
M;858=; +<?)GFPDF$7RMK2F<)TH"9;2^-2$,Z+W)$RNKH!B8R]'7.::/K:@C
MEHL;E"!1**B=5490PON+N%>4L'\G,WR'=,&[U.??$3G^9MC>T4=#DM_:M^(&
MIT%]YOK@X?<0+OQ.P=YO8F:]H5[-#:$AEN($Y_X,O ?]3>YC7?5W%$.9#CV4
M^\(7$O"!CV,]"Q:3!&#OU"?K[%%MQRL&ZE(XK0)_%X.J466&.T[/-;_"'20U
MF<E6!-7("YQT.JO2D8$<D)1'&.8R3A+XF+:8]LIP&NS'0Y)G$A5P5JP9X1;0
MMRH0/+F7_ZCHD23#B%3:68X$:N(<+-:5B6MJFLD=3P@$$4B7S-H<R0BKM&CF
M=O72RY*F! ]4[=IK<M"M[Z9*#]CGF'B^/4+<L%BQ]?IM9F.9+\K.8K@LR:T0
MKACHCZZ($@\:36R39V7%T&C&GN2<9XE[R'/-:H9EY%(#T$TJ(II&#W^"!(3T
MLC$-)RA@P^VBI3:/,%Q0%>6?^@6FI995@=W5[5R#IP<7-A'5H:$]*A%%DJ[E
MS"Q:+*?: PN,G0P%MXFL3--6!?_-.VIM,!YS::=V!Z=?(-G8HTCPI["F>K@-
M@KU?'"YE?N:E37K((1XQ$*:F?#)U'=AM'YJ;,L$OL"3#-B#9&9,WT+VD806Q
MFC _UQ1@,^;DB8B;C#3Q;*2#@R<H/;C\SJ\?W2.K<$=W]Y?N7%D^K!E^ -R/
M\GA]WM]]![2SJLV:@"CE=2_U,JR%IM^#^)W/Q?AC-PJS?B9PK]\4\%4!, 89
MLB/E'2E[I)RAK!6G JM]"3>=KH$;8@.U^ I$LNV$9'$HYGVH[%"I#4<N:P(.
M ^715-3=/JX'\+:90HG4]0VF<J#?M>NWO6T:._+>D;<C;W(CB]Z)Q/+6;+HD
MA^;$)4'"3R*U< :HTH.7GX Y9KA-ZPI(5'3:0LTK4%I+5&P)>IXJRJG_^PQN
MD4FQ=CDBAQ@:'PLTPPNQUR0OO_+,%U&5PS5T)R?E).B*%(<C8L)LN$U&2O:;
M[15D56I-\5U48E/J,%1.$LH:&@T6L0:YTNPNV.Z">1?,OP*DRXC8Z/JJO*(3
M!B,G4]$UIJ"TLJ2E>U-T67S@7Q%\$.EJ3!G ([XO;KQ@?ZK.KK##!:-8X@7(
MDK=L8+*;HLXX1!5?EAD[Z?#>4"0_!XJCLK]V31Z)M2G7N?2:\*QL6,@*+OA*
MIAESBKRD((/MS?X<+S2%8SF6L*>,1)(;ZJ7)@1/L :V3\UPS#Y";P"G I&!7
MJ[?2(-E.8W=?=_=U6"#6-C_(>H3\)K4"4K+_>C]Z6I8IA[(PA^@\7<&5JK65
MMB([/GU\;E$=K4-RN/G*@$"JS&4&BR?(,L4"0N<6YAILH^'/+:?TX2ZG=)=3
M^G7FE.ZX_UW3E&/V#GB/#!I0DTQVJ=8U&MLYL6FMY!6[ FUW] D4QJ0<D54M
M[;JXHRI?.VUD1X^.'I-E7"S4"TJ* OLK:TI\IH <4LZZ1(#G;OS?17JM+J%=
M#KB]&H].+UT)V?.C XW>J+Q0B-FDDV!,4LTS[#/)_130U"AKQJ0+OTB1=0_,
MNNMJL.W='M$%N4=WX2.DFNVNPKNQYL*@G1A7&_;\:+B;+$^K3J._J $:K5VO
M0S_LC:9CA2@-$2B(16(!@DN+\3#DP\+ F=CIG@.84*ZKO&P7RSJT4#6]@(?T
MT)3N1=+1+3)0GA4V5#V1?FK/45I%AP>'!Y/H/(]7)HU!$VL+K,%TT7MD%$:P
M:P/T DKW8_B"B<NU]J!?-(!_C7$?L$4XP46;I02-VT5Y%6:X'_VVQ&QM_-FU
M?@/*QJ., O@]Z-\T(,++X%S72PK/P^4'OH45"8H4#9^V:09S'S0:R&?K3G$E
M;">_W-N2)(;[C"Z17EJ*Y*,PM"@U2K6>5<6B1J<24+HD3.I'TGZR"HU2F579
M&/*73/@*")Z[!RSF<B<P#\E*FQP36&PBRB6"[A F@^"_HZ4KOAV\=>*FRG'&
M*ZI8AZTC"%+5B#P'M&1_VA0D*X]DOCG6_^(IL)UDT.DE^Z&I.N2X6A0"Z O2
M9T5(IDG2KF/)Q  A1CDZLA'P!8.NZZ)>9;7&:ZR0Q<])Y!PWBPB(UUN4Q9ZW
M9NO@ UK*Z7#:AC)5P"BI&Y+G>VC/#YC^MGMS4$5 /@A,C462(P00)%*:-)$C
M_FL_"FZN4)AFMW D'^7WBE!I2OX7D]:E\8D ?@D,6'EB>*'>+ WUN7'Y*YI*
MX";*F2^%6<0*"3"4N>+J(UBI8.)V34?QO#/!#;N+1+RGW'/6;B26,GGXT)*Z
M19.&]>7LV?2[ X4A@W699U;TN&A$0*+ F]:V EY>0]1[!!_"K T;>'3985G5
MA@XD+IR*6FI6A-2WPLP]3)#CF,A$3]KK$(Q>6\T,Z476,1*TS-9KBM9[J..2
MELRI5?9U.%)*O0-MLS<,%<WHU42XXX)N'M]S"VQ.(1?I(L'ZY;JMZC8N+**P
MC>@T)3RDLKP&IH9'0#QA@3XZ.^::] 84W^J>^\?%RUK]<_O12YW]U1+Y1%U'
M=;*$\\D-^=\PTB-A*0;6]4)062'3$;!VL!4WKLTTS0N(AO*_;$J74Z+AM$JD
M'3@.6C?UF/;Z1J9DD<)UY6]TO./^S8Q6;<W0'%0W0B@'FGAOV%WY!SS!\(^8
MWIDD(/)(>-*&/7U\;L6IWG*/F/TNOWH;7'(]G,N\S>=9GMO"*+?&N+_,VC0A
M=D.?5[AS%N[PT5#,KV$#3H.0C%O9>)<F.6R'=3-A0^:F+,]/N07J\D2UL GD
M[J:;BII4<)5K&Z =RT8< B'3G1Y)V)T,,6"^N3U^_2'Y\H?*B;_0*__8RZR]
MQRGQ@H(86UX%;Z#*-LO*05S@#=_6HG0([A84'@\)?K',L 9,^%X #>_DQ%M4
M4)OP!L>HMM9^VA^\7J]-TI/,[OSO,$_^'7<N9@77^/3,.R;LE6\:2K4J3LFY
M06_O8P>OSL!6$'JTEN$82SAB;'D/F]>RBQEN>8JW_*WJW()_@T_[72A3LZ@,
M.;HM6U"5VE.P4/W C FZW&2?Z**<8J*Q9H>9.0DF,=HWYR6:.M'4^_MA/Y@L
MS06R-86DNM!1HJH+KV#%'FL.\%RS^<87+'UH%;^3 N>2!UW*9'G$(7N7P&^,
MD&[KN%Q6W=YG:EP !627)7>V7[BX'ONLJ!]'84LEAR9_H1*_046 *CD]>&8P
M/2H6SOWKUE>(2T]^N,N(G-\!C6.K"-3E+06@YL4-')8Q+H<D2#5 [FC@]9B(
MY!LP>M<GTKP?!>U944NB7>D+HF$YQ$4F\[Q%((C&=#:'#Q^F5-+MD+^);3-<
MC[*2_AG,+9'+S,RFE)1H*<'M)OAU,/^T&&6"%>)2%CG;^ '@69E24"$LX)AM
M+'!\Z><^Z>3T#HD6UY">A@@+^L!^=$Z:'<Q+Z8]*V;,E:L0R.YVLZHP&"X#I
MRB :%\HG?)*VP37,298Q*.3DH2:L4ZQ+F5'W\@ZT0QS=(")W[V+1)P>[6/0N
M%GTO8M$?6TV]J<8TQ F]KCT!-R1S!7U;PI2#E#?+L<NJKT:B>X&-0/;S88]>
M3GRCPE"$989):;ZGY\?Z=";(NZKU8*Y=9J2S**ZTB->^M!AH,.9<(DZ_Y(UV
M+9Y8 %CIC6 2[*W%"+89["F&8K]BY6J\_6O:[2^F<'==T F3WKD9X+S*VG]K
M6R<OCJY:Q8XW1%6^@:3)7K<LMT^D2_*)*#RJ01^M=0V*&D7\0GOU11U5)]3_
M*:W?M3L3&"KZ!)4&@A[$!:7.%_Q7$\UA9S? 8EP?.)A"Z4&\:G[H&-1KO]6P
MM 09ULX]I[QXJZW6-O %FM-VBJ268[K+D[ M;(\TN1+6); VAAK03KII''D\
M0^L$_J9?FLB)A?W9,!I29;/6W_BQ980Q&O((U=ZR<(39YCU2!?UJY*%<P1M7
M^':" 6@)A7O,J\R\(%"VFK5PM5?L1.TM=L[^<#\W$2/\;5V[B.PZWI .*OP/
MB62-P;2F"9HJ>KWLW X/+PV6 RR-5"B/8# 5 DMSR>D:8WY.$N[I+]Z>6J\Y
M;/2$:PAH!G"U@&D77E6T?$P_0\IXQ2D7*1L<0V="RZ4-PTP@/P^(4J.!N,E
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MP5$YO 18_'"%CB;0\Q29@F*_?A5GN F87C*<E^<[G6]YROO1*SU?VZX@*(Q
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M6)$N V'&91NT>Y#S?B=MO]&P)X']RM2>0-PV-]FI$,6;(U3V80J+!9)\(J
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MP> L^R8";\! ?KE$5^4@/04\<,3R"=(,6KY2M(F*,F!AF;"E4V%!B=RG:XT
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M\XL /(5SY<AB8[UDJ)#),\[ U,<PCJ2JD_<+CYQ18G1M>8S=O6R;J0 =QN]
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M*%="C?O9&G]5$<7>"4-L%?^"->LQ]D>NN;^S5>6BY"" O)@ AG,%!&(^)ZC
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M9CP6SE3YATVL#M+HKMW52I*IB?:!N>780M]Y(0FK",B2!C77V="U(8PA]<J
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MF.'XC[US3R5V3D%K&X!^.<$3N<NEHUHN@YP ZK2IR*B:(&"Z=$9V0[")R>\
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M&'T;G>Q.,8;*_72D)235ZI\+B5R[5<Z-%HF4)J02!H,_5_0^2FX&O@@5BP@
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MF%U32#+LJ5S.J(@9,"'$U.E+3$R2 EB6GH40?"J6?PJ]9L]QH#_#GK=>5$>
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MX>&S[EP9,9%@]^9&R&=N!^C_GO>.YBS E&;PCL]W\"?!+/S+NC6P?JY]PU'
M'Q@O%O%H8H<3 ^4UOCNS6/>[/3NDV/J[HU$^LS,#K-@XQG]?QH5U>J>KZ*.!
M\4?V.:_S8L8D@+L[_QZEY"HGH/*>H/^<;%J<)W^1V8?=4:7B!IY!1\?],I_-
MTA(SK/!S_B*[RX?@N(_RPKX1ZD8.5U%AQG;# 66,=>ES^_D5O(J=3+M<V[W.
M6G%)&BM*J-O3:R.'RCM[UO !,1B"OJ5).E%>^VB%:7R[%_-TY/+@RXFQ#RZB
M69Q _&&WIX$OB\<+?CN0TQ22Q'"Y.E%:%*:<&PIC[&=@JLY-9@<\W>Y]_-3#
MRDSM>)802HWLYV,;VR00+I7+T807X(;.QPW='V@2E5D>36V ![?CI&+_!VA)
M FM^RYIJ_;WY(MKU_[5?>;BGWAK_]W__KZTN%34LOE_Z:%_.S<[0VKDO.[A7
MGL?3RWA5\C /C[H'?7>Y[,IKP41$UF??'?PQHG_>[0[V_^BO&?4^L_CKCIJS
MT)[1G\G/"KKU\+D-%]^3RG/=1=SO=0_"NWAPT#V\I;7R^PT79>!7YL\QT\?^
MX=/[ETW7T0^FBOT$WA 2LMI/VVU5UAA0-^[\<-F:5B..TN1?GYP9LW=XM+^7
MG.V.>N9LSYJ5LV?/C@[/AH>]P]V#87QPV$N>T+?27YR^^>N[XT^?/YZ<GAWN
M[QWN'O)O;V:!]-P,\VFR4;$0U[#7=VOH7RVZ01NEK^S!07T3J1?XH#ANP50S
M32\X(66TK4X%_>&YO;; 6T'G)5G:"QNS4@E=XP5=WG1UEG9R["^L[8:4U=!,
MXND8KE!X$%YP] %\<F&6<)WB ZV#.<D+.\Z$3#HZX,X2H=4 *S2-YZ5Y+O^@
M9P<F@\\L[+@1[=302JC0@TU$W0Y?G1NFX'30[3^8F,:.QTX9_/!?G_2?7!'$
M48+5FKVU<6G4#^Z1VQCJAX_O/QW_]?V[-Z>?HD]_._EX_.'D\Z<W+T_%7WKW
MLGN=G'XPMH>V=-LL5[?WR ;4[QX\F"&U^Z_=?_=[_VUY;_T P_[*!H_/=3+A
M77X!I:PBLO$M""7<X-;[ </Y;?7\&[<6^S0<$/;F7Z,RGZ9))$'6#]UZ3\NG
MT2L;7I>3Z#^ZT0>[1M-.]&'2?76M6_9NO:/_UQJM8&=!/'O'V^JA;ZGVUKS_
MMR; 8S'-WMDH8//*AKZC15ZTFZ_=?#<XI#1,:&-F+5W8MQO9W_[RH4BS43J/
MI_5-^>N?GZ:WX<(]T+5K-^,-#ZF^'^\DHKC-*"*Z]0"B#1JN#!KR+/JW>/HE
M'YOLX6R?UIH]],"BW78_S[;[L2CO9J'+=I.UF^P.P@:_#R&&/1Z-\F6V -S1
MABA"L(OW9"GNR6L\-&S._HUB<WB$&BK#/PJ0,@H),Z"34(7T7.1IL@;1XY&A
MPSQ9V?^;+&;3O_Q_4$L#!!0    ( "N)8U-D@(3&\78  (6&   8    <'1G
M>"TR,#(Q,#DS,'@Q,'$P,#<N:G!GS+IE7)U)MR_X8$&#!7<-! ON3G!WE^ 2
MW FPD1#< P2WX.X0/+ANW-V=X+X9NM]^S^D^<^?.O>?.AWGVKSY5U5K_I;56
M[7J>>UX#T&4DI"4 *&@ @'KY <^+@!B \.H5_"LX!'AX>$1$!"04K-<HR,@H
M^)AOT+"("4A)B F(B,BHF&C(*!@HB8AHN=XQ,+.PL[.3TO (<+/R,[&QL_Y!
M! H1$1$%&07O]6L\5G(B<M;_[>^Y \! @"*"]H>!H@"@,:!@,*">NP'2%YQP
M4']^P%\?%#0,+-PK> 1$).27!77H #04# PT+ P<'"SLRZS/RSP BP&'2<XB
M\NJ-\D=X"D<L5O_8; 1*T:I.;)7QWU1LQDX!B$@XN'CX!-1O:6C?T;%S<')Q
M\_"*?1"7D)22EE%54]?0U-+6,3$U,[>PM+)V=G%U<_?P] K\$O0U."0T+"[^
M6T)BTO?DE)S<'WGY!85%Q=4UM77U#8U-/W]U=??T]O4/#$Y,3DW/S,[-+ZQO
M;&YM[^SN[1^<G5]<7EW?W-[=_R$7%  #]>_O?R@7QHM<T+"P,+#P?\@%!>W^
MQP(,6#AREE>8(LKP'QW?4+#Z(V")QF97=2)2LJG\QC9V&D?"H6)?IS[[0[0_
M)?M?$RS@OR79?PCVGW(M "@P4"_&@\$ A("QZ=,*7)UV]98F=5Q, '88((QN
M586,M3T#F8L5#X^KF[J\!<$<H74V\R:5L;F>RPG^!B(FI^I"Z[@SS\ >,<W3
M9?NFOG0)4:3,YF6JOJ&VI\JB4K*<B*Q]BN(&-S';,S!34I9M<TBD^)33-TS?
MMV"*!_LF+0,!P'10H"O5P0TQ:LA *#532Z.-@6[BYB':C;+>T/6H9\'3M6+!
M 3.@!]MUUIIDBHI<$5MQS4<R[961I)9(%5$<(E][<H;L/JBE4E'%8#FF/1;P
MP. 52/\XC-46<[Z^TY)1HF,X-SWADT 3 QLIENE$O<<5H_4XN@:PJ(RY?[UE
M%5'?0Z.)/;#">8];\HIS@D4_3[:8.,_Y*]'O59:=\*B5'^^R;P.D"\+X;IQ1
MJGIEEMH(01+P/R]&-%NJ9A@^;3<EJ3C%#H^A)Z%*DZT]^'IOIFF$H>'W-J(/
M:I5/'*%7X5'&9WB\+0&;;*2&6ZW%#=0K0$R;E:%,TI=B1]E&:=NS= >^&R[@
MKEX\N#X#H-1'R[\K7+/][[J5?*2X7WV"^?$,M"4]6E=@,E)$7P?=/#X#^J#5
MG6> 8.+A;5FX*V327M"$A!$R!3%"NY$F^;X;E7X@="M^U7X/+_L,^+R_G4G3
M@# &<,?QL:(8P8&8!&X!_PO7M3?1,O+E@=)7Y-'BL]N)'IMML2W)B30?G;:\
MN\B#B]>B?/8@_3/A6/*:GRF^QFKLR/5]6V'+5$*3F_ZFB->[MX'H7D3*@R#[
M4>:QC_^W([B./+RG#Z]FP>W8N*H7.;)9XE0/]9672GNVAGZRUCXO>#%N1D!S
MF'J%*]8NC>&3'\[KC'3)7>6Y_?NR:W579ZP<4,WWO SASKN.-8Q'FO.2T0QF
M"W==\Z!5OA2L2$2J $7BT5>*=:*)@G11Q^6) U_ W(TF=<RF@)]CYG7TKOBO
M%0GU!VM>G_&&)*4F"R34#W'O#<T[G^@:_E 79/E?VIK^.5;W,- R[S)2%N%[
MK R_]5KD&4!H:W@&A/>%3O->5ECEZ)A)5;S?2>%.O-]UKA1)7BSBOBJS8D^W
M@JFV;C.FO#.;V>] :R$W<!RKO.[1B.[R.E+Y$5HP2(S'FE8!2Q1UE<M PICD
MP:FK/JJ-R?TKOI'3<9+*/U.'4/]5DE/MO7F%]43HE2-F[R*,M#-%L&US?414
MXU7'EA)[JUEU>%%B,L JRF3H8EIDIGHB+, &QK;*/K-)7#:+]<.64X[Y#@N=
M>ZN N*6J,]L30?X,?' 8Y^5V54,93GMG,EUU*K/9$(ML13"A\Y1]Q8/M >>]
M+ZTBFH;Y"NHN6%4Q570VITGW8Q%.<@.V8FW_CV,R3BX3_[3=?*A>1\6']V%A
M4A5&5*OT<G*QO=U\)E28'GM"=*8ORDZQW(D;7Y!Z'"D5-84?79\MH(&I]\B!
M6#)N&4M__DQ4'JC<Z% J[)+^>^Z$9U_^'XX<''15R?*4_G[G_^[&MO]RXW_;
M97+BJ"[2 '^[88I:&9DNYF)@@"QVDIN(1 %._+_8)YG]/8:D!6..UF#EX,$)
ME%X<%$S:0XI\N5_\03AHCO=Z3_(ZWEPD]F'?XX[KWGL);1W,(6[KJNKLB#&5
M'T7O^%,WE#K!Q""0*&*7"L6X5H44E]*.,V)NCQC#[XZ3"-IC\+>/-7O5F9PS
M7UXHPN;K5U,L))F=Z:W^^S(0,]W^?$8.$U<;NY_Q-7I)&-7Z+*J5,0H^W!ME
M;4$;>-.AK?%08N_OQ1XWK>R$&'RLE>'#.C4XD28HV:@B4<R^55&M71-=YK'<
M=O2>/67(ETM3(G;2-T1Y;#Y:ON2#J?P4N[*W68G*UH=4!;Y/#?8A8;_%O)R$
MX;,Y1+>O^*36K.SM)--*.[UO^KNPR2YFR6;FPWOQS67-0^>(P9@2$4XB5+%+
M,:R?-[);)A_E?1"C-N4UMM(W:+M0ZC>_'K!*/^[)R>/]-U/.?[&54.W[]MWK
M0\@SP'4[??JO)"/]9Y(9_R^V>H]>&SYSS]3L;&'OC)--KCW%6I0A[ D;-4>S
MS0]M#9-_.$0T.NN.]+%!]ZM$>M='?SX'4 @<5;1UH@!;]YF\/9UV/\'">[KW
MS4%Z&),"GOS3(=EG7UC$L=S.BR6R':"]UU" I<<NDCJN"_'%@83CRTB[#3X+
M?>F.#$I6"$0L""#IV+H8,R\*J5.E/G@M87C)_O[M8;!*!\A5 ?&Q1 6!7]O6
MG@ACSA_SG?Y7[GXC"4%[ ^YBT%P&^1M%NOWA,EYV.RPR0MU"&'Z7'(AQ0VS\
M4[;/,R#48'ASU]X;?8Q\>O?T\QEH'X%P?(9@^-A#_"= J[(0=M"O]V7/P!BO
MXL,^J+?X[.T$[3-@:0@"'\\^0>S/<A]$'R @N_;3"U"DP3/PQ5#W&<ARR;R9
M> 8B27^''X(N4>,A]X9G.6?(4EFNA&-LUW\=PI-[!F1?63>NK:0BVOIW8JHZ
MX &3G?5@N;#L/W4> ;*0O:NXG9YG7\62%N@>L7J?[(B;0 XG.=0'DR&XMR]=
M-_XM_B#L1H-@.;UNZ=Q@I'Y&A-#?X8X&A@I-I$GDAN.3)>_I]SU7KD&*9ML4
MC;4T% !1@#=*X$ Z^\S[3!HK\1SOAX9F!"S2_($4V !><.HI@^G\L<:XC&2Y
M3?NK0*MSFM=.PA.\_5N3+I("SDQGCY34XP8:)\)$5&$R4S2YV%G\XK\[GXV9
M2R9&WI<9,3D2.? .]_DD7VN4$\M"\3^4EV*9F"SY-WTI_ PZZ7D&Y)OVGP&!
MU$=KT-]=;VIH/=V4EM0HOJ#X195N:]ORTA?L'O,CO!-YI.:I[ON^/4)_FJSI
MQ61E+U;ZTR3@IR?[LY+,WY$V0A?K-']F*4H=\..M](LJ9[./:6\,_2_:-7M!
M5&T[_RZ),A_N5S<E_PR'I6=@]25H"%Y((LS4/ ."F+XV?]B?H_09 '_)3'G!
M03(1[7H+/WV6.?"^Z=LS\&?@[$(@#;?C?SF3T,U5>V_Y/_:0_@U.;>ZR+]25
MM\6Y[(F9UJG]5@*E[F)$#1Q^<C.$H]9%WY4I8T%>9$)-C/)]*B5Q<WV@'^+6
MY?5E\;OU$6L>[)E>^4$Q5,W"1QMYXS,E)IW)X15=]V0"KA6C;N=%2N[28K7H
MN6\@F)P@I% A&\3'>+9RHVG&3Y&+UG)C)W-Y%MXUI@&-_%LF- (A5R64,C,Z
M+!36'\?RU<J&T$? @P(0U>,^G3!;0L,,#.2YR@BIB2"EK%>?+++W.S;*\5I4
M+VRKU9?Q(H[#6#KP2$-@_7Q&:#ALJ4D[&L>2V'8*^*S&'P?CM*S/>DT)OKNB
MXT-D\WF -?\#W[3/DXS''%;'WA=%>-^X-;3MM+6A3GS@#WSHAF<$J3(464I%
M&^*,!BG>#T281%M[NZW01'&/S=]EZ&586BD3-Z!N9<B_MRP[D_Q-6NF]"GN\
M-WBV_W.I 3=&\C-E:[;PNH5]JN,FZ2QWSC.@,..RZ&F>JN14Q3E9[4YSBKUY
MALV/TT93WYCAP8CBI."TK0Z,(NPO%A41"&'U1\3-,Q1VP9F&<<*G70KN1%M5
M]!!B'PG,GJBUM9*FMXN^FG#-2UF@+&R[Z]U^.LJ":G#7,TISP^<@XB3XL6(D
MKV<OW1+WU1-J>>"RE_D'!/OC<8LL5974O?>G,Q3HC]&QD8V"+:J"/1N.#A?A
MGORSWQ5TMQ_6,.Z,8L-X+F]S;Q''W2?2CO>NGP&^4-38<KU>ZOHIE''B(%/9
MX*Y7QDWXNP&H'C_BI6=R.0==<98=.E5O)@"VC+((M_VT!_6@Z!['_FCL&O'*
M(O%(#'6W70"J5] D4V_2M.&,O4WC =8$A[,JC-6!CU1YA,D=%,9)/U<"0LU[
MPH]T%\PV<Z5N7E4 XW?2TV]>=1:"_M.#9])7PBM6]>IZ>N)K(P J6P!@?@5U
M62BT3C #VOVE. +J;8B4T="TAA1N9)!B#]]]I'<9_V^$@.*"\DD[M&]%!$3:
M9[C@[UNB_Q;/',X0C#(+B#?5X^RCY4M:M=%^B55$(8Z7Z!3((SG\C5:R*11G
MZ/SNKU3\9]SGZ8O>./R13@Y?THGNH_7J?\;^1,77NIBN)VB%MA((^V<9@=DU
MTG]E@<^XF^),K[$O:/:^BOE<WZ?(M#"(O5[YB+^;1SJ_"?'*' R/ZB&@N[GV
M> 8R"LYS'_A!8-4[98<JB;#6IPRAW:+'0@B8]&(*HJ;'H)Q3 ;*(OCL T0G5
M]#U>"27@(F-9EJS^BTSTT=D+*,5M\5\OY [FH-EV2!KW9?\BT:B5*V[P%YV_
M2##AT(YKMO^+SK^1!(6QJY_^14>* 0I\B@9/3-NHE?>_NU?R+VERUHTCL3__
M2R05#C\]W]_GCA,O*]7^IRN5_P/T#]ZP#;M'Z=(N&_J0S4C-XU3J7^D07;]V
M)NZ.JT.#X'_K9]3P;@]$KK!1M7-C\'::86)DHS'L6$^&&B-DJ\N[A)066/^.
M*4 WFKJA+Z'-WN44='S-X#Y1RJU,'X>;N=Z+&WW=6M).X!05_0Q$A0G5S$*\
M2!]VPK.J?HT4'K@U:+X3+*:LC[JSU5D_CD?/CA#<7*1*;SD;D?YQ&Z7-])AZ
MMTY8=J.[[=U>V_#] %\$\EM]<Z79_NCJ1:S@<ZQ,(Y6Y%0^86\N?R"3>&913
MOJ/$3#GI&=AQ:^'>((NJF'<H\#1 5>?N-E@F1<!&/7&$NKXQRLA>/B9.Z]NK
MY<@XZ!^!M;O<:Q#LE?^P_*S_#NG@"[R>VWB#3/$I]KTX/5%?FSAC%'UWJ/.H
MW7+1RWX!.E+,PX9[N_S8!45,\6ME9DG$9$)?9K8AQWD'FY\0\!_Z^H-2Q?<7
M6P8,;X#6*=TF[,*611NJEFL_(6UG!0\O[F"=!NUD\5ZMWC=,?_PZ)LT<K<JY
M5OH@FJ#$Z\K RGN\T;QZM$UT%PRYPP)9E+/L$'D9OX#JU/8(5,Y4#J).84_.
M\R=4./]Z'(UGX?VT7AOGN5DG>*K?&JS5$D#?/Y_3=!X''B1L::=WC!?P$ JV
M/FFOF>6Y0/5QH/T7OM,4IH ^@%^RB'J*OI7&BOV,5;</G6IHVYXO> 7(^&+J
MMC9):CC5'\7'M]I0,H# A7/=CX>CR8@'OTUE"Y\AX>!9(<))Q@KY?=$G8_B7
M-7+V&#R7#"BG=/L9?>#3KSV(&1.I1X;X@[1]1 "4S>P15E+T@XE%N2%/0L7K
MH%#RB _Z(JD6RQUDFP]]1+.YSX!%N?,.Z<.6\E-:^^HST">.*V("SCM#S7N5
M;.)(/4C/T5W$BI<T2E<*Z*=SH1X4\ >PZ>?I_TL:\O^)HQ?IN?UG.%'\$;FD
M@W\%R=5?24$ ]-^,XO]Y?/W_D9R2RQ6,X,<_R#6)B^TTU&%]E26]K[M7+:IZ
M!DH,\WC]D&AS_C$(,MW/A$:+1DJM9FY IBG7L(UW()=1&.\^F&BOQC_GJDYK
MD3\7V>?9%%'$[74L?EV-Z7;Z85$A6#O],U*WR.JJE8GG@R+(CHKZV[L8"SHI
MRM]DT;]*K""T$ZZ$'OFR">$C2\IOC4H'FP9ZO1Q =#D9F/51!ROK=>\BJF0F
MV3YBIR6]GT+QCY_,D^!',S(@O2S"ZP*^;*MEP-CR],'O"/"NJ2\0#]8B'VZ,
MD.CVU 7L6\36&_6*J+;61V!Z/@.'4R4;MN3E%E\,NC\@$$B+O0YDT+3S<>)5
MU_:FMZ6:&;D>4"<+0UA@QD6EH"KB-W45H$N])1G?5/,1=4,(27Q(0$LLU/*?
MW'GH=A;/PO&?EJ20)QAX4]*[AFW& ^L5I@9Y?U.,C,Q=^X# ^-+\JR/!&@!K
M/MQ%D[=M=<DPA3EA .U?XUW%H] IDNO+^1=\*(R:$T8+_'WD1U\%[[V;&H=4
M/L$!O&&T6=!_&Z\:5A6+"E1U3RMFTH7AL)3_<Y@?,LLZKS^)(KLRLL=(%6:M
M)9*M:22(4.4C:YMAM 3!</;W:E=E %?Y#7!-?0/KX<=TG1S$0F\.E%J<&'_2
MAB(@J2?A]TI]BL]P"]MCIX>?M,VM=>9C=WA[;8SR:2NNVWV :E=P.M>*YV=M
MF#-*93(Z5Q+=^J1 R)%-1O,L!]YF2U-#"#NSW%YVSIU,82=?S:RO,,PS4*'I
M*2MZLIT].:YWF3)RV!N*]('I2R1&,-QP>;-S8"^ZZ7:T*-]-IN;L,U!#'<?1
M@*I!L9Y\'3!'8S_KYS@+[V?MJ=6D72=NE(F!Y_W=M'[5Z?P[<_1Y$J$(649X
M:ST$:P@-0V $//^C@<2E.I-<N9'EJYDYS9@MC< Y'%$IC_;8"]L,BCC"U"L;
M4\NRF^J86VIT6A.P:N,:FEV=C=(,I,MQF[%$-B@BCA#/PKBXL5,@5-!/>;!G
M<,2+/M,>JS=51U92ZIJ-#:=C\*0?_\"AJ;.3+ *U5L\CK8LAEC&<KQLJ!E&X
M\XZ;I, YZ#Y0DI*4GA>)'AKM#>+)2&-UO),,>:S_$A2#&KKPEO>/C#2OF?P,
M^Y2YERJ'@9YSLYOJ>#&#]Z:'!J?AC;R=;D[8.P3:O_G(?_@*VK*0C([8C>*$
M'[VR.%9'U3\B-.8?+O R7BLVWV;NZAGDYBX=I#P-^VH-KO20>U*B!I"2^]WI
M?KV[<3QPUL_Q6>U^!GA=U<R&*C?IB7ZTO0EX5RN5VR ;<AP18)4G3@-':"?I
M@!>!NJ1N2RD]_<F>,<)+OU2UQVY?8*DLGB'XMH'>+)#$82AVX>=A<W3U/-BQ
M!I1 *#@F//K*,;ZCE!Z$T\/D[UPD4#] !F(LZ\Y*>VP<(#,Y13GK4?F6PLC#
M;FKM15+D7K@$)DD) >,L!L2_3A+SXL3-A@TR(V^$*5!57O3XK!*N5)^B*Q 3
MBB,U$ L:V\#D8_<FV1OD[C\>TS0K,'BJG^,KE::E8G<<IH*!)Y9\!G3*E8\)
MQG@6QOI^_QS.(*C2#J3_Q"=VA1A?27J+2C_,+UMHP^IQ<*%8-66WR:I'Y2C1
M@%*,J-[GR\-Q=+6>0=," =]&NGM@Z)>=Q E_6>/$5J#;.WP[E%?Z70\-1[=6
MA(-OJ((C'6M!G[^=U6?-<53"&M'.6Q6[K+7+\$""Y_S-IQ,I\K"/P<9:Z/!>
M4>^Q]5-+BM[KR/;;*?6.\Q_EX7HX8 =3Q@C6%<!'R2[+NKMB,H2C!'!OZ@^>
MLZ>.1RD.U6[.<HQ;,7V=\8F8:3U3$36S23?ZP&4V-.#?<.I\')B9I]\0V.O.
M";*..E3%0._&3>\T*B;T/T$C:2T6$.IA#F\5.,TQ>^!E<):) N_T9G^=)!'=
M#D373;$Z^S;R>H.C.BE]UW(+,^'\2\@;P+T#AE2&P"< 7*6W>IOW(:^\+@B]
M4IOUW/O+)?S8N1!OZLB9U\_2^$,6Z,'F'Y[J(B;^\8LIU1#^GY\U_70EF@!Z
M1$48ZW=@HEV+]8S+S-_I2SZY(YR%$F9\*"/1&>KQEXO1>3A)1K-5HIO*9QRE
M\@P-]SF_RDTNO.<Y<6 C8,8N.6S[PK%&7^5Z060^[)I-<I[1+,U'MR@*"+P6
M+[RM/2!@_^E8%48=VQUQ2,X?S)AF\E3J6C#O,7,P.*OH;Q0:E&5FSG@ATZRM
M]F;1TB2,D?X3CD](XF%/.:+T53X21+M+N@OD?G@L#7<:FM^<.&7-^\59C%":
M8LAAOTK--#Z^[QG04SN_';4Z*<M/F:;2HHX3CGQWUT F$A^5A8HJA!3Y*)?D
M-9KMXXSVK2%18JZ8>%%A#.LBZH#M*@=<J7W]OC4Z GT85S-1PJ]ZL&JU!LLH
MKS[VT$^*9%IT8[/[^J>3H6SQBB=#;!O<(HZZ]Q&51<2Q4)ZXX\:RZ*9^M(IG
MYB?5T-PZUG@"QX#<N8CHWO!5=.JKC&(2@7A#:4!K]D0<RV@-Y@YM]$NF&J)@
MX5147\]Y@E9=J($HI0G!:OT6*FM0\*=I&_$SU\T6FT)#,;HUA!.F%"XG$3):
M&JJ8U\+\'[TY9/FJAXWJM'XM>/8-4:O:^;;NVSZJ$REE)2EJ6\B*F#=0K)6&
M)1M+<7/3N*'5O=BIMOF-U>KO;]:) P+U-8(D&E_9X^X2MAR:PPIIX@.5=)<\
MRG=D7:).U90=,]^M6*@9O9)>4F &J%)R45M=;7) YCK#UWOF5@92/^CT6(,6
M'!>C9^IP>VM^6)98H&I1+)E+T-.5FC,#$+1O:9NMKP4[+>9*/A?97&-*Q-DD
M89:&4$D&7/:7MBOY%%<\4A',/L&=/@._R=M[2PST%A2I0*8ULE+CT,>8N R@
MENXK(;_BQ:0I]<+R'JK(][=2'!7WR"_%X9H8Z*4EC;$QO,1M?P8ZOKYTE2-+
M N*$P86Y"6[$L7G/ .*KNF= Y/,S\(A@?Y8+P7QM PFX>09NT5<WM9M?ECE<
M83F5=YI:@7Z)E('&#)Z!9P":\,].-5#G&<AJ?08@L%RW,W;K![0OA(E**K4)
M#/_)4&B=;*9][SWH&?!_#>%(;?0*XT)3EJ0[PI%(^H=8T?] ;7YBJ"SQ0G1;
M/Z!_XK]P&_\OL$N7NZ:47^CR:!I5L[?_G1W[/V';<+V(8T>2$Z4^Q_ /+;UT
M[EX6_H\./XOSDXNE<)XD*+_]IB%]U+RH('^1RDO1[Q'%U-(U78>U$.&SC=M:
M_/SB/5IO=0F>TX&%NF22ZI15T0WHS>/^-$HL_K%9B-09+DKS)K?9J"?\3&,4
MJW7.Y'[LSLA6G5+!6TPUP/=&\05/F5:=W\*"&%2*=H0E[LBW[57B@1,;I,VN
MR66K62NJ;K CWU -Z&0JWL\#G^JM$(9:W &'B8I6;>%6F)7*.)7S0X-15IR"
MA^!N2N+&1$^XO#-<$P,T6W]NVF\HFL/HWJJH2-?83\81\^Q1AI\RN2-B0SHI
M@\A%/I$H[LJ66/$&'3]((TNH>O%_.J^<KWW38$F\:@6^5:T^X?-, 7\L".8[
MMFT8.4_+V7[87,T'H8R_2K:R=;&C"%7N]E6! ^B8G$3])VGB]0YN/ZNLZ(<1
M-S_&F//(%3-YD'KX/=[':FY,7"%<NC:X:X+J\ W(R:%REZ2$'?OPK@_XQF:_
M+UQPI/P:F6/3^:4E]!U1Y*;5MP5M,"&[-GTG<O.K!+GW--D;R"@HSWE3=$H#
MQR*!^MM/OS8;6ZT.&DNP;3>JE_\'+XULJVQYV.24\^V-R P>5#>@V&E9$JKI
M.(6A.:AE9+- *S[>XI7;T3.@(7C"$IW_;GQ.NQN(FL$&=D,Z=OG:,X5T=A>%
MI_#?VO/!_OR>BYE&8<^PAS8)(Z3<D2^=;;VM).Y"Z1I2&#]J4IG>A]S125BU
M9(3*"H=S@>R93C"W0!5*H2M:'HC4"5#NWV4.3PT>K"48=6"BHCI(6N\H!(*H
M/N7KAP=N%R:WNPT/(N+UB:OXEEI#95F/2R()C_4U[)CL9+;(LKF=R$"(+;?U
M?PTUS5 5D=T1:YGP$YU!Q 6;N%L$"GMPXPESNK9#-D78H*"0LJ28>?A9^HIN
MRI!?TUTO>#(9J+/QOTYK1C>U8.R_A+'$N_FQT1R:M[1@H;: [[?DP.J5*1-4
M8:OA#-48(L.,9(^/?UT.4AB[@IVRW6UE:5$6_-WVT1A/LL%=09JZ]5YM5VX*
MVEI$!'.9OS1R]S&0OLZI\1(ZD^X$1W^DO;:S3DN19$:,(GT33H*U:S$6W/KJ
M8$D7.9[?5T3IEWR7%7SVB)'\^L#"/D68$\/C%__D56=8V$0EA%Y"!+1*#C/V
MAP=Y:'I:S!7IS7BDT_$WCN1^E(1^O?#"OM]*FX.2G%6/ZU-C?2=1=_7[N:*_
M>T7;O:8ST!E"2.3[KL/:"1,,:W?$=MA?_AF"\?!=?0+OH\O*6_44N1,*UAS.
MS?R-8<6FS93:GY1#Q+ER(>:Z58YL3? Y:[: $5H"0.QWJC#4J(WM+;[9^KY+
M)T[+0,23:@0]E;GW!QR5_\!'\*"5M]!F.E>W5_2<K6V%\;=?D^\RR(H'$50#
M$$_$G830&;9!!#T.]XPSN3;7L'*B%7Z=2T_;\!G)),%G^=Y"X9J9?9@&!SB:
MS!(,!ARK,)($KP?J<"D!(R(TZ^/[5M*2S[(/*R6M]4L7;56:AX*C*Z>YQZLF
M,R]%Z\7H[Q]"+D_OK/ZH78$R<2Q5Z&[0P>R^0GX?I,SWVX$PEK(X\/?!(7BZ
M 4KG3?FSA4P71AC$EZF$D^J$S\;69E_$&Z/0UBT&!K&-E9B7)16>#J:QH& Y
MW>KGSAFSPY$K/2UQD=,VH^:+]EYZU"\BR#4X8:S.4X5%146/ACJ Q7S62]N+
M\0RL0D?7B#P#_)3/0!N<K#@@?FTIM/L%=-.1>S0& B,\ Z?^*N/"&#XI:'?K
MI$^_:1_822]^"3VLJ=4JP1J:!T(\7DI,;R0;W0Y.R 93^Q*VP!_=VP$M5.9_
MS F.P#_^CH;<8C-B0>'^?\O6LC[0\ZG;!_XW4D:*T QI5M:K_Y<-_P=8T#EJ
MH9)N_ER>_N\%!2]=9QFO'\6_F2G_>Z+(,@NA[2]>6/_&1*=#"_W^3TX4_^*$
M!:B]4:BOCU<X.*JBYU'3'Q8>6$,M6"C(+UA^5+S(0B@]B;L>)"R<^" =PZVM
M5 )(.(CLV;RR?S-D6Z!C(/L)WS3#8TL*<CUWLVFGJ%KI>E6>6,-4R\AYS$3I
MH4ZPKL5'WGG7=D;L+S#*DX7$94##$KH1, *9AJ%-)OY*"??-@NRBRR+LJR%>
M!Q,F]_&BI??@D02LEI.62=$=KT:SI9<)';UVMRAQEX!T/W_&HY_G)59HMI5E
M9^(@F02SXR1^!\E2!J^3U1X%LCV&KI[5+%>&7&'] 7Y"53\E)3SW]6%G82T8
M V1M;;Y";RZE0F-A(<3L:MO8E\\S8EF>8)08IQ-N^1C*3(Q&=N^KA7>9LRI;
M59,T$C!/&;\S%%7@"+MU,P#MQYISIH<:.T"=WNW(2QELG$;_E7[U*?!R(TX(
M9U&:KI<L==C\O-N#E(TXU<$Y@I39^0A$+):[WTN.4?.E%UOMG0%STX+0Z[Z+
MXLVN%.,E_ \P<$C5;B;GC]U7_7.-/)M8E@1!7YM)LAWYE1=EVBWDAH<EL*N[
M[ T4U"XFBMY',":2LU^[HW=5Z34M.. C5P#W[Y[HK5<5:VM1R!JBF <QZJ.R
M+/ ?P;O*D30*4)I',>NB:]C]OXK4'_TISW)%DM_<EGJ^*:M+BW1%LG=Q@BY^
M;-GE?SI9^9H?WCW._T:.T=PCB^%MC*W2%PL8N%9@=\D75U=TDH0YTH(0<!Z5
M%N#-V/3OO"3Y)AB4-W!S]-%(!!9[;5>@U=<$W$J K!*5N:%U>KH3\L$D (]$
M&AFFD;42_H#96>&E6DJ E:746BJT?-T_8'A%!FU8\2 659=KDZ<U/WB^N"@1
MQTV^Y*3+GQ8_RUWX-2@O"(G!N(.'R&T_NJ!!T9H=ALD>&S?H=5ZN79QP5>T/
M6_J=NT]S\/PD@1$[F:3A9=1:@XO@4,"5&^_\FNWD<"\XJI5>RTKC);G$O@Y^
MUR?6#(($@6?B&&D4_1-R:T-ETBKP^V"-O% P6293V&&H/'[-?[.M:3+9KOWA
MW4*FU+W+G^9V5;1UQH#16QVN':$R^/&K7"$F,Q7&;%1P19X>@6 2'N513$3)
M>Z%E2E@?9I8PU=S]T=%GP#3:.;TG&):DB20S6(<=NN:P"H_]SD0EU+5I;A#A
M?%.<H3O:@.5V^C57=P-!76=# )^'WA 3_J*'UA@Y/A#]_93((H)49LF'=RE<
M*7P;66,99Y2E$]8'@4K5;(+]+G9&5JK?G94+;P@CP..*R(=V#,E$(T4>[7B^
MP:_W))X]V8P0KV@!GC'N%7Q[!;8"(T@I)O]0B]PB_FB'1VN'AS^3.5%HF2C"
M1/"JF%V?XY-1#<X@XYK/[_S-+W8.DORNW)<Y^F_D,D&I%H2GT4/&\WQ)>+N_
M-P4<>PB@,G&:O,;FAJXM4^C#N^#3X[)S=VV*,SS[*A0\^\L$6,\J;+=8:;4_
M)J_'O)<KZI6LPA.*E*K'*2%RO!,NM:,2[JZ?(488D432L<+))G&-Q)]/D4Z#
M/NF.D[[BG\!WBWF:O"PD;ZUM<HK1%Z.'BBLB,XG^5?!R'-%"UV$IRR%C_.OF
MI.9*MXF!G7"HT>TNIF.T^:N$,)@CEBNTH&%Z8?QH=3>,#>L3LRP&N;',R29B
M'U8IO**XTV8ORYV@9Y5KZ-:YR7"@HT_Q4O0Z*2=;_.22RI)'CF7YR:?$:=]I
M(KEUN:'MR.R!.[\7 SHXWAJG!^R^[*X79(@S$ENPQ_C^. \3U'N#P%G.L[5;
M(:,OUNWNIE-?8%[5_8M;\R@9/MEMZ^L5WNY>?CC2KNK+O@RZ%*U<4A/,]G[B
ME@X_'%<1_\!>72%%'6WOC]_SSS^E>DM_I0Y5]^:$ATD8O.KGOSP4#WC9Y^SF
M2Y5H[B%?W#).U]+>IJ:$H/A3T4"W3; E;'+"5?&8>YL1+9;A$TQW]XF<G\2:
M<)^AXYX\>=+D"83F;D8BV\JI8< ASD#>EKR[_FP@PHBXV1,6VNMB?Z'NSQ53
M[IJ(%E:,W7[?0I%C>--4Y:R^DRC\;#.*S)>CQ!XJ30OBQA?\\9[[Q$KL<)"H
M6K8Q QIV >MF-[TK@]=(K=HC!T^NS:PV<(#:5*DCIB/M\C!*B$71_HUP,XN5
MPV+\"*&PR?;9!3H:L21\2NMGW(J/,7VETGF!/"E\152B#_A.Q<6('?L#L+X<
M^N"0!69FN6)$T,\W9-#-G]/6=OF=X&6:4=MW0E./HK!UJ$+L\&/33#^C(@BE
MRQ8<QEJS]1$YR)10L-'7,[L=]Z]=+[VRG';!:0UE]SB)6]!L]DS>2DZ&[;93
MVWN%ZS_)[S7[S:-$:R;W+.\J(3'/(\Q"+8QVAXY5W0$8A7_;FM/ROD>3WNH,
M]7PM\A=AX18=*EOMN[Y]33%MUKW#M^),V1N%MJ9-MBJWG?@+Y]0K:P5D&)T'
MB*3?"Q<USD3UNZP7,G)H4NVZN5Z/'MF>G@CQ!JP:F+4MNP38X+#"U^D7XAM6
MB$3\;GE00RP&=>\PRMB.'CK0N/3#?!W%G?0/VV^(';>G%-57[5&RN^ @EI>1
M&V.].Y)RQ:>/V,W3?$F/P=W\H.Y%E>-G@#&CHB \H30%\=A=:K%+H90K@<\-
M0D:K=X/UT@/+=38DO/Y^8>B):4_Z;H ES>3676B6O?0!"5QE\%JR1Q.]CT$G
M[X(A[XO)L8<%_4U]@).CR!2_1H/BI_O$K+B^R,Z3,/\X8"O-E?*B&+ET #7)
MRLH^9,L_3] .*[Z=&!&?"&9RIM;LC#IO9!+L;$6?D+[; ->%,%=,VR\@O*#
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M4@(&7H>(R%FV]1:WX4!:#,:+[O ]CGPOR?+A9M5ABP6($^Z*NRBUST<I60
M&]J+?\'O/_<OE#(WB?V 5X,EFR2>T#&Q_WZ(DFIZ (4#<<0&2=YD_C/P,WL
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M%<!T,P;@:\"++AX56/6.\)"65K/GS_-/?M.2+.Y?=&#:.,!&&KFI'U_V;;$
MC- Z41]5+B<07Y/97*\*!_]&+9?6;5=S(:RERKC%NW(7A9D%"H/M(;6 BH)2
M2H2-ET6T;]A:C@!6%:?#]@JSLVX$06#;;/%P^%WHN^#Q>MAWM.N=TN9KG)HZ
M'9C)NWIG:8YVV=<'*A>@42G&)>0!1PDTC%OSL$K5S;X; [WWX>FQEA[T3DA4
MGU;:E3#"0 ('W3:VR!R3IA"@UE3"V<BKI%]_I4ES2* 2F>P@Z</'7%,%GH*N
M3&2]YO]D;:]%V50VL=Y06^H!^UW/TAA%=_%5"]7I#!R"D)!#)CYMO;@J[7+;
MFTK1H9KO9B/G(L+]KTHA<9KED[^B-R8C362((MO<M/<V0#$R@%@W&)^?!7M8
M,,CWK0TXJMDY?WCC*&?D9@7*\3C=[73"4[OUW(?>%5?!2^$D<0Q3F<C;6Z-%
MBI#&>!'Q00,\HV:PK@I['[2YAWRN6>K=CJE;66(_M5J(HZ"A"$3,6D_7JQ\C
MOL_C,K>'N/*G%U)5A8*?-!#9]Y1E]?VBQA)VP$ 9^77#JI:"W@?)30,TE*(>
M7H)*&FUQ>:7''(XEOPB75MVF7+]VXU6@,/Y-CII#J9;&7GB'621SH3E9>6:&
MS9I*WLBU%%]/69'/24BP60EZ3K1 /G#/GD_@HA?L\VG.\T1*H[?1\?K*!5]#
MME*DY8"^ W0_Q8G66SY!&W-)Q'0=8WJ VD_FEK%4TE,*QF<9<6@T=/DR??ZQ
MT^FPR*>ZK/ =I:[5 >N[MZ2T0FPD.%*8VUF&B)!&JV\6& M]_6UK+1X\$%18
MI $(TL8Q+N^,KFJ/@+W9#E>'=A%AE/29P:OA'*A1SZ.I2M]EUO]F+OD?3V3_
M;V(:/=/W_$3;Y>FA)W@F ,D1?#>D[40I1E1OM#Y![JR :%5:%B M<,-&D$P5
MSQ%R@;( S_-#/2:6;7JS&*DT4"CB-=LZ)/A9$P2DV'[&KX4YP+*@9$]9K:NI
MN%O%;92Q#TO>8U.L=!L0C&_A#E/E[&R-?K@6*Q[!9(\<9$ADFO:C_2P#C)VT
ME'TW=/+RE',QLVQA_H<YJ<AW]4&J6$I6"JS>-E*[]>G\W?FEP\VE0G/;*H-0
M4AUDZ]BOCJ:UO=M<%^M9#"C,W1EO?'7>#T^(YE::^U&H\3*T@JT3ZB"XQ:@M
M:$P5M;?J4B^;N$1Y#>8,]L0TW/C+)[7B>G'"30<GQ"QB8\;KQR>+RF;$CUF0
M& EX.("22><X9;O(NI+/?7L/9WR$ZTL6]&87K82W4PS.U9(/>:C$^/N'0&67
M5TH&(D&")(X2_6D54;V[;5<%L(5[EBLC)B1"GJ1$;PSQ?'*@SW+!5A\Z3U.V
M90DP-5QCA>^9ZQD%)KY&2A"!@'[I!=*Z$R7:Y:2@:<6;VBVT!<4G8W:?=Y.)
MG"VZ5R6_]50;Z>08M"M-J[F7"'J5R(ATEN0;!(<_R+*.%T;XH^8")Z\XY%[<
MBA;9[%4/<9K@PF9:*^1B2@^SN7BCR2,/YU=!8>J=-BDAQ<!$9TOEMX"_K@5M
MB7S1418%5F,26  >%JVK$]=I<.]I7WN/B(';< 3J1, 40,H574LY,.7OW,[W
MS[*QL;==I-KC24K_> (X)6FXY:SOTY KU)5%]F\N8[094'FW\C1?ROID'J(8
ML'6HXOFBMS_W\9&)E]M#[6]+7HZ5P_)*/P%2;5>V6M:5#RCMWEU=W"=-_=ML
MPJ5YL]Q-/-NV@A8M)Q473X [2$W@S\L4?Z-XAD(TEZY;DM>^<5]&[_@+W#A!
MP+QCSX-X\0W[WC_A[/\3.%D-N@?J1UZ@YXS[K[OG?B-PADGR7I@XLE=0AOVK
MO+]3X+?GZ/P/5/RYOE=&_,M'T><W3NFEE(/]YF__C\MOL>+*DYVD0723E!.)
M>&6[@K\/9&KY/^'IWC[Z#Y8SJIDF& E+7DMSS0HG_6YGK&GX58PY; 65"L;M
M4GUQ.^F!WGR_SG3FR$.X5%3"+ZZB=@%X C?=JR_!*KRV[(/T37GG74(:FE6K
M::?T(AE2)G;E=SFFEA;8XS-,KXHL\E_CBR(H&UWNWGI+M=>-C6G$9)<5EN]&
MEI,L+-T2+>M#O:<G]>FV8M@_5#IBQI.M*F@P86C2B41"ZF8QU8&-_;*!JQ_L
M+/MQ<2>W6(P766LDJUM<$'X[ BTPM_ECK1%:C"*NSJ:4TZK]L7(5S7N9P+O^
M:9H!TNIRL7TXW?=-=@!VDK!OP&@59=:=8CEW=$WU.0+&8>9:G/1/B'5R'Q8:
M8PZ\+=E'^!>8"VNBYCM<ZPV/-VL$;4,)D6^QVK9QU\.,E; *!*UE;V*5)Y&Y
MOB6 ;G:OJ7H+DXCU6L?@T;.UYN)TQ;U&;J,)24 _]S''$3]O.9H[R<#O2!E/
M\K4N3,_==0HTKO;;0R.&L")V>0(4RG8?FUG?*NZ]_U<'RS^>EUN!8E]V"E)A
M)F4%Z:F%?YZN_O+SJ'4F)&?1/DW6'A)9(T6_]T@C,7&7+O5K+P[\HJ@Y>'E3
M4\(F1G65#Y&+BV",C?'PV&)$>A.;JZ\@I=7V)!NI]=]0],78]8J%)3H1R/8]
M[/$>W-,$INA[ZP93G'5#LJ^?;N]+"(&YT87:WW,I@?7+B&,ZLF2\Z78Y(GE,
MR6EFS^2A]ED@W<\Q(.WO9 V.P[%"Q(6K@5Q85*J:^7JQD O'^RF45"_V3(;V
M"*IM?7'*9X*:!-0@$71#8206FI+!,^4+8J]LJK&ULE-5T5@"5F6U30W--GBX
M_^A1A$I2!BE>DD@/UX\B-0?/8 ])(RB/)2[9X9 S"@1TQ[;;4/YMP!5SW9OO
M>K0N YQV?7V#?!MGKMPC6X; X;+S#RUZ->>@9O";P=LSO![IJZH $ \ _F2E
MK(B>_,NIMG&1K'1;/+'PMS_?)G)!1R9:H]P_JG5O^B[XD\3KS6$&H+?IPGC6
M?<WK*U"J1ZAGPI/JWVD=L>8J9W__]3N177GBZF=SPC#9+KM)I>'&Y6WB-CEU
M;1-\U]=^C1\B=G-,2V+,7<P$6^)+A>/(PQEK05,A@Y.KFM:2:+>E&R<-8KLY
MV3Y3*)%:K-"#,6#V]#MT"SEMU7.\%:O,+.R1AH:QDI/<!2K!G"Y9ZKC[5Y"-
MRIO-6 ;8X\)GTEIK=6E U*S"%JFK-32' J'&/X.1"(GB@NP?*GZ-UB,?/% B
M9HQ6IJP+P_<V0@_IUU+/9&6O,QRHH<(^@)H=X8\*4Q-I)#(@NSCANHX@?;^Y
MB%298<?5U>TF]1#Z:#SS0'F_<@?]XN+/_ND'4M9Z HQ*K0 ?66]FA"O#SA.!
MP]J]\N4GQ4FVMN@M\\6\Z\OLF=%H\[")<'"?07$?A<4B32%%L0T*(DBI"+U8
M4PB3#H8QPR20&+D9Q@O=VTN:GL>@%P_]R]TLZ*[7CV O+OH)]Q#\<=YA_&=H
M&1Z,4G7U*U.!]\S?9M?0T%5?F;&O'VT<XG'@-U$6^?K(&5J,0'R'OPC;=LW;
MB$ZKF>>10>#38N\;=E(:^2^R+_]#]HFK4N!'Y[<7 4J(\"KOJT7)')7[=+,%
MTLC?H-QGM VC>2"XWTWIKG?<J<TO,LFZG=%QVL3?*B-3470[;)P>)]C_%1JQ
M W8L[";^SU>M9]F5*R*U0:)<UQ;$N?7$JD4W#6DWH;8T(.Y;43U'<4_O4)5"
M(PQ(RS2#F$*[:(Z:1]M"9S>4+#S.)UUJ\?;V'NB;A>#JLVH)O:!":A^-QA^8
M)C_';\4I>F[840_JLI->[[\4/>R<]*T8798Z;9Z)&9._NK1S;GK@@82]5# [
MV\C0##M #S/?20);LCK)T3*W![</_JP=LWM8E7X.!A0.-;3Q1_7JC6F>ND0%
M?T$';MZUIMZ7T$5KV>=9YO<JF1>8WD+\S+D2=T;)$I"]Z)JL3J6*+PO?Z#>5
M!4)VCN4':PNF@^*:SWOPR,.+-@)6;8*+-,<57!Q2VIL7N9>Y42P,RC7U!+A1
MO%ZY0'W9VS%]F9 *CEMVR%\V;;X_&%Z% W6NK('R/'@D(M-!TI_&.[!C AZJ
M8,J2?"H+"T6A(X(_SR04Y1N=JN\63M?;T!D2^4;)H"0-'D <W9A9L:P'*_7\
MNUI6)$SII#/@="'3).]0LXDPBE.&9PJR[(RH )?K4O%H&B&9V0_4YT&N"<_H
MLV2RJ/5)([/JB@FBN 8#OTMH> + U%\#O7YN4+W<WJ-X7==SE=12<O=G'?-^
MIMN@U+ZQEU0)[I]0"Q(7V:SS]:>U?]M3_6/U[>&0%?H.[,FVHKAPE>8G]!H[
MA#'_!3AA <?<EC7E%?<_))P2JL0X>Z/PZ2J@759SY5F5X[^H\L]\SDZN?5?H
MG+ADZ$LO==3\=]UF.<7B?Y:-P.]UJN=CCOG((Z/Y:=83P%?;]0G _[*-MK(N
M7).SR.TKU0,M:._^EVK[FVSJR2@-4S2VL\IB[ZEZ+4D_/ 0G#3CI3=?\KO&,
MT=H(@MJ-W4!_T'4<XF %\@ !_PYW/J7R5YK8[.C2\ZV&T3F\MX;IC>>C,#H&
MH6\^Z^37D49Y@/.D.>C65D="9Z@2AS-RT/?J6$$Q ;JJRY.((SYZ"4(.AGAY
M@9!S>EYS;56D3]GLF!T3.VN7H^F01PH*P@TRLD-2B_0]["O-S\-R&A85I8ND
M!@B0&M*C"_.!?Y).#6"&-D^O=RC&5HR1&FT3">X60M3P,@29X:@.@V_($ <K
M,*^\9?#H<M(#7:!T+:=4L=6DV32-8QF@*M[&F6$#Y8HX@+Z#Z?%NZR]MJHR3
MH(G4O-I)-7 3U"CK(=_D<IYL.?FJQAP=6V+]3ICDB%2'X/)+RCV+.XP3U#B)
M4,+$H42L--A[\V^]M1*686:U/4W"$%69DMA241^R[#.=/> ]1-BNR!PNNYB9
MH*:[1;BNSK5L:L\5^3J*EW+P>OHYIGAO/D1DAZK295F1H;+(N!X>/#CI5_."
M\&&SQ-4+'D0,0->\6_J  \YG)U?7=CQ115$[=AAI(G-EF7Y*+8:&X-"&=P^3
M]7G-IZJYLHXU4L2TK)(1P9(@+O@*<SOT@M>W:'"\EZSWL[U@!"@8[=K"):X>
MF SH<-K:R;A ^Y@<(7(0L0\@9!WL$@\1;X_?,K6W(3UV2(UTO@139BQ4&7;1
M2J3U6%&]/:(WHC#N&@7,)CP.)#Y>V9Q\!US<<BUWB[)]3Y!85+][S+N9;X/
MC$'(0_QS_LYT^'=.9_\,KRDDT)0X.&A,[ANPJ9)#9Y+<+ITHJD413-_WX0!
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MO_S&X-<Z;?)7F0+VC(F%/&45%6Q@Z-].RH"\!-;]]H J*D*@\V$- [HX BE
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M=<N!W)=5&\K:DPG*=0D [Y:W!*4+9^/U\@[CETY(N@SUJ;>MLXEM.8$A.(D
M7LZES7W)?#4HM"I*DNT,[J3*)8;!!UXV[Q,@9"4,6PFR)Y[[L+>?'>RG^030
MU:8+ *%DV29)D6YTNIL0'?U!!A=+:6$%F\NU>GYYZR[6[,3;;W!0IG0SIJ7I
M.(\%WI1W'A&#X[B*X1H4ZK,-!D1OO1EW=5KO8552T\JP11$T1;VU7,*,X1]6
MQR*0<Z4:TW?%('\?I!2)A4*/!*&ONZ;LV7L;MJ_1$N!"MS9DKH(=,ES$*,EQ
MRZ\3 9,4*(KK[>V]KR93((2.EF@SD]6E%.(H;_)=D\7N$>[X:X)O)Y"RN8JC
M:RO-'.\;9TY$O/@1( ;LA!/A<G>JY\:Z_8[ U[S8[/!2*/(]IA\_5Y]/7^\P
MH(W4OCCOZ###]Y.S?^R;^^+A5REIA9;O?/;JY-7<6SGH1Q/?YDXN)@1F6!?L
M3@>02#I"G?4B@'HI1 )Z<2])SG.2I(;DW_R@MXN%TK1'@L8"Y>DN9:494_3+
MT%6<U5*/"5[KC;'(86O;#C4FG6;:CM1_'>X-2UE'"QB [X!,ZTV%G534/L21
MKBGRC\=>+6#I8B>D??=<UAQ3=M,'$:42R5I/ .I^$DZTH[D!F_M%&8@8]!33
M0C5-25S9BC F K(Y*%7+&:/C_8L-2\DXC0HOI4!I=FTR&<QOCIGT<J@SD9#K
MNWS8"DK*#Z08F,&QT21)#8,T'HL/.6%-9Q%AP"I)\X)Y#:E24&(QE>P^I#SX
M2A;$-$HKGJ_C'G1C?QPZE'LY$E+Y,N\"_I-S(3 "H&\ATS"STCW>PM-.JJJK
M@9F_F8O(P D#EQ+FW@,_N8K'JRPEJQ6,B0]ZVT%[E":M"#FJE(5NG#D]V#>:
M>1UX8$#W]4"!#RH^%NF57XQ_*Z&'D"/ 0U ZQ\CN3HU#O7)!9:,P$@-K6'2[
M;D@K_:N<J6J9D"]%%477&Z_&=<V3YAK['U0%"YP6,KW8K"BY[ #KODOTG8O)
ME[]V[2C'8+%_Z,'RR@GR\A6:2KK@RG,A^*$R$%TSKWVL:[.=>#Z2"_'UY&N
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MM'<#.=15$NF&@A_,LNCV#?,\=+ 'O^170OK#8#=N_N+B0%HJS'HWS\<41[@
M"VQ,)1E_O0ZWDSSV+^<AC98K\ZE5HV:RIFFQ/UBJJNS>PA+I;-096/'C>EAZ
MAR/R?-LQS+*<[:@9/=*IF_!L4:4^ $%NU^UP'<\7!^T#K.=P.XW1>C-=RVL,
M.80Q1&B]9B!8 M?I]S#K7F;?D7(ZH;(*I(6 TR*H]3-<,H_HY)\G<V!$4:96
MXP.ULIK%VF$[DJ3F(!UC3N#*HXNS,LM. =<2AE+X'-4W4@K0@5E*#_*0_9MQ
M]FGN_P-02P,$%     @ *XEC4Y^,OVR5< $ ][<- !@   !P=&=X+3(P,C$P
M.3,P>&5X,3!D,2YH=&WL?7M7VTJVYU?1Y*YS+\P8!QO(@YR;M8@A.70GA '2
M/;UFS1]EJ6SK1)9\] #<GW[VHZI4DF5C&^R K5ZK3XPMU7/7KOW\[=__Q][>
M63@0H2L]YX^;;U\=+W*SH0Q3QXVE2.';.S\=.#?1:"1"YYN,8S\(G$^Q[_6E
MX[QOMEK-_>:[H[V]C[]#4QWU3A0>.ZW6ZX/7[?UVR]E_?[Q_=-QN.Y??G)T?
M-YU=>OKT>^?F7Y=GW.OECT]?SSO.J[W7K_]YT'G]^O3FE'\X;.ZWG)M8A(F?
M^E$H@M>OSRY>.:\&:3HZ?OWZ[NZN>7?0C.+^ZYNKUX-T&!R^#J(HD4TO]5Y]
M_!V_@?]*X7W\?2A3X;@#$2<R_>]7/VX^[[V#)U(_#>3'WU_K?_G9;N2-/_[N
M^;=.DHX#^=^OAB+N^^%>&HV.#_9'Z0=X\S7\7'KF?N_.]]+!<6M__[</(^%Y
M?MC?"V0O/3YJOGN7?Q7[_8'Y+N*I'<<R$*E_*['M&3U;/<"#(_U8+PK3O9X8
M^L'X^+]N_*%,G MYYUQ%0Q'^5X._@7\3&?N]__I 3R?^OR4T!&VF\C[=$X'?
MAU'@T#YPI\=JIMU")_Q:&WZB/^\D3:8;!1X\>W8_\+M^ZK3VFZW?7W=AE49K
M&B0^/66<MWX"@PK\='P\\#U/AO#\?_['N_;^P8??7^.SSV.8L'K_YZSSX^;\
M^X73^7[YK^<TMK4NX0(K]G^=_^G\/^>_G8Z,4^&'CAN%/1^&E_HB</RP%\5#
M@:<+?\ '@#G!4^G 3PRG:SC0WT_XH3MVNK%P?\HT:3@#D3A=*4,G&OHI\C01
M>D[/#^!3(D<B!CX7C)DYI@/I7$LWB^$<PSSQP;-[8#0AL,A.-!SZ28(C&&5Q
MD@F82QHY5UD@G?9A=Z_M1+UR R=NBM^VWA\<-AP8AH!1>M)K_L*%GG/[)UBB
M&T@1 V](!Q_*W+&*[3TYE;NPOS*VYNG@_W%*SN*\[>3;V<7IV:ES<G'J7)U=
MWYS<G)VNCL<]Z=#A<CV[N#ZCH7>^?_UZ\NG[U0DQFI,O5V=G,+&;%S*33_^B
M27PZN_GGV=G%"QGTWTXNKJ_/+IQ/Y]]OSCI_-)SSBT[SA8P=5ON%C/3RZOO-
MR9?O%^?7-\[-'V=7)Y=G<)EVKG_]<C_AQ>KYR2@0X^,P"N6' "ZTO0$OPAS\
M?(FY[B_*_/F_@UAWW(4+M1]'6>CMN5$0Q<?_L4__^V!=#<4?U'QP<0KS4[/;
M@U?2:,C"L/K*$K'5-[:$79:@1Z(O][J@JOS<$SW8N6,1W(EQHB3K=^^:[</?
M/G2CV).QNK'V)V3RERKI;]^-OR 3N3GY]/7,^?X9KLF+&[@6K]?(-YYF2VA'
M4M$%"5.?0:9E.&:!&"7R6'^PQ_8&.E G#?<-Q6487N& B2R-BN>+OBE0/Y\O
MF_;+E.S0Y(%0:/:H@<?P?T^/]18$>=\5@5HC. SZ[8/FP>%O]FJI?O3*/=,#
MDGIS3>_=_N;.[4WSS9'AJ(I]MT;W3A(%ON=HOK_JV3\AD[B$&\3P!5J%UT3%
M-25O$R7C1?U+R7@U-IP73\^@LUR!W _7>.O%T^^KCZ=GG\\OSE%7OUZ>8I\O
M4;[Z.+E)+YGX:F:Z,:2Y??RR_>))]-7'+]__<79U<7+1.=M$FGSUL3VY22^9
M^&I^N3&TN7W\\N#%DRC,I7-S_@^0+\^NG=,?5^<77YS3LW^<??U^B4XAY^;L
MZMLFTBKPT<.-(LJ:CVX,;6X?'YT\BB^-1%]]O#J[/CNYZOSAY QU$XGSU<>#
M=QM%A37CW!C:W#[&>?3B2;1* -712ILK?![61L^70J U#]UP'OKFQ9-H'M_Y
MY>J$0E8VCRZ!9]9RYTLAR)IG;CC/?/OB2?35Q\_GZ"4Z/_E*<N:&,LVC6M!\
M*119,\T-9YJ3\LM+(]%7'\\O;LZ^?CWKW/P OGEY]?WR[.KF7YM(GJ\^OIDT
MKKQD.JQ9Y\;0YO:QSO<OGD1??>Q\O_A\?GIV<0,BY_G-OSXHT(/S3>6?;R>5
MA)=,C#7_W!C:W#[^V=I_\32*'O9+=+)?W%#F^C7E@?_SY I-GAOK;']71WN^
M% *MF>BF,]%-2"<ZOS@]^W9Q_OF\H_ _@(F>7US_N-K<B/EWM>/HI=!GS4,W
MG8=N0HH1^HN(<>*'\PMBI)M(GJ\^OI_4&UXR'=:L<V-H<PM9YR9D&YV>7U_^
MN#E#_+SO7W]L,..LC9\OA2AKQKGIC',3THN^G5]WSKY^/;DX^_YC0VV=K?TI
MTN9K0C/[J,#FGF:@!=2R]V;H?HC@P<=[[U?!0EX,B.,T/#\<6 %_<<5@Y$6<
MKO:A@M;<GPM9\]5'OX:GK.$I-PN>LL:@7FXF?V9)ZO?&LZ8RV^2#B/%5B^_,
M,2UGAP#GD3[;^X8^%]GU?BPE8M73 LT<*'72^K#K0(=#X4F"HY>]GG21IA%.
M/NHY?\N"L=-^VW"H/L<.XL\O/[@KF:0BI>$Y9Z:C4_AJ_M$V$'P?1]J5Z1VB
M[O]-A$D"_W[RHU2Z@X9S'KK-AB.<2QF&R3BX%:$O'#>*1U', /\[R\] =;;
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M:>E1;S\<'+0:SL'! ?SG"/_SKK7+/9/%!/JD)L]"D+M=9A"FT??MR48/#HY
M)7,D++O\JPE-X:_:FXUO[AP<%=]H60]_EABE%3B?10"<JA,('[@VOU7NYVW[
MO?6BUJM.@#OL_=UW?Z)WP[GF371V#MNE/@_:^V+O;==N ?<_#Z9DA08O.M3>
MX%]8E*C/L34JB'6L*:! %:QU@%[AD^[5ST"IP0\8R)8%?5)PL!5)MTS-<%;
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M1\.1@72!N88(?A7%7)M1)2.*L.]W56WST/S%\,YP2])5229,E&X93,C4DVV
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ME&4LPK[&0=3%'K'N$ .,FJ4Q8Z=+FJ^T"ISNJ4YY<F1J_(;<PT'.R+Q;;8.
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MJ.+%WT'6V_LCNE,U12EQB!^W3H01PRI""VNZ707=KBVHV**)\Z_M R V%[0
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M32'BUG[SJ'FX)53\=]_]B=']-0UO'@VCBK<=TC"B6R(HIY].BD\U#;]0&CX
M$F[M^%M OY]$^!-E"7?L="*O)N&-(>%6NWFX)9:V3U]/:KK=&+IM'FR! /PI
M1A &PFG@W)":?#>$?&&0S=;F$W#GY+)FNAM#M2SO]K= 5NA$>Z<(%$>EYVI7
MQL91\E'S#4B]<MLH^?N(HZAJ,MXD,NY.(>/7%.2JP3-6'8P[Y_H_DV%L%D#.
M^QH@IP;(>11 SD8'Q3]O)EYQ0SMG]PC?EDCG(H*9U?;6#;NQW:T0/ -5CQX)
MVL8#K*EY4Z@9KNBML&(52/F*RP_55+PI5(QFK8.M<(%U*%V>_ D,FU,3\:80
M\9OFVRWQXW:B$$FW]HIM' VS?V$[:#A):T%BT^CW+?#@;1"'+Z^<;]+SE687
M1Z[TLK@V4FP,';<.MD2O T*^R@)9L^!-(MWM"*RY.CNY.7-.:A5N<VCW'9#N
MVRT@782WUR6.:]K=#-K=EH!&]M35=+LI=,O^N"W)0K/!1= "4<N]&T/';T%C
MVX*$B%,_9I#8-.+RJ#4%;PH%LP-C&R(C3KE:>.W V#@:?M]L;840[">CK$YD
MWQRZ;6V%[G9VCS6'G%H*WE@Z1BGXS=1\B VCY2#S0!"^DHD4L3MP_AY&=WM_
M1'<U-6\*-8,L\7Y+*+E0E;NFX$VA8-;IMH,?^TE:)PMO)!5?21?K\4S*B9M+
MQ;K89DW$FT+$6&YH?XLH^#*.4M&/L(18+1IO'C7O-P^VP=]12<ZJ]G$M:FPH
M7;>WE*XY1[0VQVT6-6^!8?G\TZESSA40:WB=#:)?$QS4W@(+QGE86Y0WG:"W
MPZ(,E)P-NU1!*Q)Q;</8)/+=!FDB].0P]'L^\.(Z/FBS"+BU#<J=)N!Q'>%6
M4_ +I6 _]47@%*#9Z@JSFT3(K-MY6Z'8:6*N?7J;1<.MYM%[9QL(.(F"6QFZ
M8^?LMG9W;!(!8_6A;5#IKC[51+LI1,LH5=N0J/0W$2:)K(7>C2'=[:G@K4C7
M*4*WUAZ-3:-H1"#>#MC+:HJN<;4WE:JW PA34_59P'G]D_% 3-MU5- &$?=!
M\V K+&^:N&N/WL82<ZO5W J/B$W*(PG_0<:L X5.W!3S]_P:2'-S"/MP.T(W
M9]+UC8R'-477%/VR*/I;IZ;93:'9-DH7VZ$(1C[AL=3&C4VG:39N;(7_Y*IF
MQ1M#MLR*MP'+XF_7-=EN%-ENARGY:P2:7&V!V!C*)=/:%BALWT28]82;9G$=
M+[]Q1,S!0H,M8+_?_$ F:13*.DASLTCX[72[V>M4= ,)_WK^[5,-=OK(YES\
M9S(,7A/XCW[/#:2(C[M1.E"-[\'G-!H>'V G3!"M_?W?5K+O+AQ)&>M9M0]'
MJ;.?__]A*7)_<FK\WT&L7^H*]V<_Q@R#/3<*HOCX/_;I?Q^LB1=_&$BT[!QC
M%X$?RCWU]W[5^JBO ME+CX\L=K@7TSN%K^" \4LCT9=[W5B*GWNB!_,_%L&=
M&"=JL=^]:[8/?_O0C6)/QGO\W3XNA;5I0W&_9VV-.I[V,/17]CA&4>*C!>LX
MEH%(_5LYT6IQG*O8_"?G:3/IN;A*4Z8//!'YA2$87G@7;7ZC1![K#_9,WL
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MX_\.C,K?%>[/?HSI!GMN%$3Q\7_LT_\^6!,O_J",!-A%X(=R3_V]7[4^ZJM
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M_J")3Y2$2.=SW\D*6!+=_IKX#W_Q1VO%AZX'L@ Q134'DX/:@9'5B$X155K
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M6(8YNS9XF+%T=V(=<>H7O6' !ZMVO8_5K9[)3YC-*H(8*&4MZRXFI!DJXE<
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MC[E8D O.>^.OV*MW*%*1]6-YQ#KX72C*--J03-G40YN, T-J?AP@-0.DYO%
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MC^[:UMGT'LQE=3Z%=5"D>N!VZIL)7QP1]XFW,EUER\F;*.59 _;8A.;2S9B
MC*$44F:#.[*#L,J?D4MU@KF+1/X"'@N_R.9S)H,+BC!1GZ5?2O01_SI>8&A
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M?-$M*PP=IWS$&*'^?V"Y8FZ)H.)A'L&OEEF"<1$N6+FI8L1@IG3,8P(A)>0
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M*A2"AAAT[H+5-,J  ==WWW8B939EW<2-Z8(])A(N8*HS?UK5J"'2*LR2JL
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M)$4O=>I)-. _VJU9<NE:%:%#VX&4G$ZQM&-CT).<PQI0>U?==] ]X37V?Q4
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MVDFZEF35@YXBM05XCF /, TVY#L?Q IJY$(VW8\AJK2?J-*K(<!W*EOQ>H<
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M\ZDZ!7S_FQ_/?KS8"-]_?O;JQQ/T!0[7!?IA0/W8"L<^#_\QS?]B'0GGK#4
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MLB;@GTOX!^'_BB+&),L,1@Z3+,$[RO\49"AJ[* 6B +L'4Q^VG\IRBI" .%
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M&-G"!LZEL#N^MZ1,^"ZCJ\-J%=OZGA&"7N%2V(D/JVV9-LBJ:H0M<@O.Y 5
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M!#VHV"!!LH>9@*A!C.CHW;'J8.6QD37@G2 E>%(VB\E,ZXHBM%.T3Q0%-<L
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MR"/-44L^F*A.9#_U0>I.(8GZ]V:7GAJT.G6*[F57G[(GUADK$M8+A"O2BJ[
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MV+CP3!8H["N@K&3[N*CU0,TCJ3Z:)(@ CI#EJ.?ED]A\%',(?<[HI1+29OM
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MF_ZLY?ZP_ 2S<CD5R'!'+O;O<U&G&Z[@;X4F4V"6A5;)K%I#-2?3=\/>XG5
MI@!,E,ISK'U/:6RJ*$+Z$6/ANIU8W#8<.)"I:X;"%-H1TTWPC) G(_@C2[
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M&N%!&(=M@<3J($>%>*=[S,-%5%P1]-#EAQV#'7TD8T<B6(MD[-8 @1>N-T!
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M35(1&9,#$:EZN'+.9RXUH_N6&BILMH1\2R%NUA$\!!3,<NVUX2\-Z"([JPQ
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M/G5(IWZK<;UT4<%6@I67L>54 BX9C>"\,=WL*U<)@E&3L%[K@(Y1KR]8A Z
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MU8(%*B"LMT.C4K2LL[03A]HU4-O<0=1FZ?.<HCG R3)O1LK%/(Q)Y0',T7F
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M'Z$ER?"G"_0)B%'U7Y@H& ;\!-ZVD!&;P$<,!*!#/ IV"/^8/CU.)<]2AG2
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M.G.*Y_LS, VA4UTF X9 1V,"5@896-\R[1A:&]![K [*/!EAMR092:"GB4,
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M6S9-IVCK*-J?,/(ZWM[(ZUO#K'O!_<>BK'I?^!/X,TK"X,/_ U!+ P04
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M&-8IQH.54$<:PY=PB7LU%T,W#,N9$OLQ^[<2667J\2<7CIQC]E2D"7R=5V)
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M#07H2![)7-H%<?Y#VQ)LG4V=N3SB-H:NI0&.\FZ: U6U1O$&\U&,BF.E$R>
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M**@7(05RH9%GR8XNX2G0)<84[4[KEBB:C%'-&4Z+6;AHFV%[G#EXN3.!):)
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M94I<@15)2CY:!AR?W B6-$'GY;$]6*7>NLDU5VOJ^S?F0L_IOU!+ 0(4 Q0
M   ( "N)8U,4,>-G;!<  (T* 0 1              "  0    !P=&=X+3(P
M,C$P.3,P+GAS9%!+ 0(4 Q0    ( "N)8U,,1)@$F0\   OA   5
M      "  9L7  !P=&=X+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4    "  K
MB6-3,_U;>H<S  !G?@, %0              @ %G)P  <'1G>"TR,#(Q,#DS
M,%]D968N>&UL4$L! A0#%     @ *XEC4YD0!]%ZC@  :QP( !4
M     ( !(5L  '!T9W@M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( "N)
M8U/9'&_M*UD  !>>!@ 5              "  <[I  !P=&=X+3(P,C$P.3,P
M7W!R92YX;6Q02P$"% ,4    "  KB6-3YT9"9W$P P"O9"$ %0
M    @ $L0P$ <'1G>"TR,#(Q,#DS,'@Q,'$N:'1M4$L! A0#%     @ *XEC
M4V2 A,;Q=@  A88  !@              ( !T',$ '!T9W@M,C R,3 Y,S!X
M,3!Q,# W+FIP9U!+ 0(4 Q0    ( "N)8U.?C+]LE7 ! />W#0 8
M      "  ??J! !P=&=X+3(P,C$P.3,P>&5X,3!D,2YH=&U02P$"% ,4
M"  KB6-3H0[T,<X:  "=!@$ &               @ '"6P8 <'1G>"TR,#(Q
M,#DS,'AE>#$P9#(N:'1M4$L! A0#%     @ *XEC4Y1.7/+[.@  WF4" !@
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M '!T9W@M,C R,3 Y,S!X97@S,F0Q+FAT;5!+!08     #0 - '@#  "^R08
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
